PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Smith, C				Smith, C			Drug target validation: Hitting the target	NATURE			English	Article																			0	59	70	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					341	+		10.1038/422341a	http://dx.doi.org/10.1038/422341a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646929	Bronze			2022-12-28	WOS:000181637300045
J	Plath, K; Fang, J; Mlynarczyk-Evans, SK; Cao, R; Worringer, KA; Wang, HB; de la Cruz, CC; Otte, AP; Panning, B; Zhang, Y				Plath, K; Fang, J; Mlynarczyk-Evans, SK; Cao, R; Worringer, KA; Wang, HB; de la Cruz, CC; Otte, AP; Panning, B; Zhang, Y			Role of histone H3 lysine 27 methylation in X inactivation	SCIENCE			English	Article							METHYLTRANSFERASE ACTIVITY; CHROMOSOME INACTIVATION; PROTEINS; ENHANCER; COMPLEX	The Polycomb group (PcG) protein Eed is implicated in regulation of imprinted X-chromosome inactivation in extraembryonic cells but not of random X inactivation in embryonic cells. The Drosophila homolog of the Eed-Ezh2 PcG protein complex achieves gene silencing through methylation of histone H3 on lysine 27 (H3-K27), which suggests a role for H3-K27 methylation in imprinted X inactivation. Here we demonstrate that transient recruitment of the Eed-Ezh2 complex to the inactive X chromosome (Xi) occurs during initiation of X inactivation in both extraembryonic and embryonic cells and is accompanied by H3-K27 methylation. Recruitment of the complex and methylation on the Xi depend on Xist RNA but are independent of its silencing function. Together, our results suggest a role for Eed-Ezh2-mediated H3-K27 methylation during initiation of both imprinted and random X inactivation and demonstrate that H3-K27 methylation is not sufficient for silencing of the Xi.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ Amsterdam, Bioctr Amsterdam, Swammerdam Inst Life Sci, NL-1018 TV Amsterdam, Netherlands	University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill; University of Amsterdam	Panning, B (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	bpanning@biochem.ucsf.edu; yi_zhang@med.unc.edu		Wang, Hengbin/0000-0003-2414-0609; Zhang, Yi/0000-0002-2789-0811; Plath, Kathrin/0000-0001-7796-3372; Fang, Jia/0000-0001-8583-1652; Worringer, Kathleen/0000-0001-7807-2344	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063671] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM063671] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avner P, 2001, NAT REV GENET, V2, P59, DOI 10.1038/35047580; Boumil RM, 2001, HUM MOL GENET, V10, P2225; Brockdorff N, 2002, TRENDS GENET, V18, P352, DOI 10.1016/S0168-9525(02)02717-8; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; CAO R, UNPUB; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Mak W, 2002, CURR BIOL, V12, P1016, DOI 10.1016/S0960-9822(02)00892-8; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; PANNING B, UNPUB; Plath K, 2002, ANNU REV GENET, V36, P233, DOI 10.1146/annurev.genet.36.042902.092433; PLATH K, UNPUB; Schumacher A, 1996, NATURE, V384, P648, DOI 10.1038/384648a0; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574; WORRINGER KA, UNPUB; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8; Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	21	909	964	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					131	135		10.1126/science.1084274	http://dx.doi.org/10.1126/science.1084274			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12649488				2022-12-28	WOS:000181988900049
J	Chang, S; Sievert, DM; Hageman, JC; Boulton, ML; Tenover, FC; Downes, FP; Shah, S; Rudrik, JT; Pupp, GR; Brown, WJ; Cardo, D; Fridkin, SK				Chang, S; Sievert, DM; Hageman, JC; Boulton, ML; Tenover, FC; Downes, FP; Shah, S; Rudrik, JT; Pupp, GR; Brown, WJ; Cardo, D; Fridkin, SK		Vancomycin-Resistant Staphylococcus	Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENTEROCOCCUS-FAECIUM; INTERMEDIATE		Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA 30333 USA; Michigan Dept Community Hlth, Bur Epidemiol, Lansing, MI USA; Michigan Dept Community Hlth, Bur Labs, Lansing, MI USA; Lakeview Podiatry Associates, Dearborn, MI USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Detroit Med Ctr Univ Labs, Detroit, MI USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; MDHHS - Michigan Department of Health & Human Services; MDHHS - Michigan Department of Health & Human Services; Wayne State University; Detroit Medical Center	Fridkin, SK (corresponding author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Infect Dis, 1600 Clifton Rd,Mailstop A-35, Atlanta, GA 30333 USA.	sfridkin@cdc.gov		Boulton, Matthew/0000-0002-0565-9010				Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; ARTHUR M, 1993, J BACTERIOL, V175, P117, DOI 10.1128/JB.175.1.117-127.1993; BANNERMAN TL, 1995, J CLIN MICROBIOL, V33, P551, DOI 10.1128/JCM.33.3.551-555.1995; CLARK NC, 1993, ANTIMICROB AGENTS CH, V37, P2311, DOI 10.1128/AAC.37.11.2311; Fridkin SK, 2001, CLIN INFECT DIS, V32, P108, DOI 10.1086/317542; Garner JS, 1996, AM J INFECT CONTROL, V24, P24; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; Hageman JC, 2001, EMERG INFECT DIS, V7, P1023, DOI 10.3201/eid0706.010618; KLOOS WE, 1999, MANUAL CLIN MICROBIO, P264; Maslow Joel N., 1993, P563; *NAT COMM CLIN LAB, 2000, METH DIL ANT SUSC TE, V17; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; Ostrowsky BE, 1999, J INFECT DIS, V180, P1177, DOI 10.1086/315030; Rotun SS, 1999, EMERG INFECT DIS, V5, P147, DOI 10.3201/eid0501.990118; Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701; VANNUFFEL P, 1995, J CLIN MICROBIOL, V33, P2864, DOI 10.1128/JCM.33.11.2864-2867.1995; Weigel LM, 2001, ANTIMICROB AGENTS CH, V45, P3517, DOI 10.1128/AAC.45.12.3517-3523.2001; 1997, MMWR MORB MORTAL WKL, V46, P635; 2002, MMWR MORB MORTAL WKL, V51, P565; 1997, MMWR MORB MORTAL WKL, V46, P624; 1997, MMWR MORB MORTAL WKL, V46, P626; 2002, MMWR MORB MORTAL WKL, V48, P1165	22	779	856	2	71	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1342	1347		10.1056/NEJMoa025025	http://dx.doi.org/10.1056/NEJMoa025025			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672861				2022-12-28	WOS:000181949100005
J	Reisberg, B; Doody, R; Stoffler, A; Schmitt, F; Ferris, S; Mobius, HJ				Reisberg, B; Doody, R; Stoffler, A; Schmitt, F; Ferris, S; Mobius, HJ		Memantine Study Grp	Memantine in moderate-to-severe Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE IMPAIRMENT BATTERY; DEMENTED PATIENTS; GLUTAMATE; INVENTORY; DISORDERS	BACKGROUND: Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of Alzheimer's disease. METHODS: Patients with moderate-to-severe Alzheimer's disease were randomly assigned to receive placebo or 20 mg of memantine daily for 28 weeks. The primary efficacy variables were the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) and the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADLsev). The secondary efficacy end points included the Severe Impairment Battery and other measures of cognition, function, and behavior. Treatment differences between base line and the end point were assessed. Missing observations were imputed by using the most recent previous observation (the last observation carried forward). The results were also analyzed with only the observed values included, without replacing the missing values (observed-cases analysis). RESULTS: Two hundred fifty-two patients (67 percent women; mean age, 76 years) from 32 U.S. centers were enrolled. Of these, 181 (72 percent) completed the study and were evaluated at week 28. Seventy-one patients discontinued treatment prematurely (42 taking placebo and 29 taking memantine). Patients receiving memantine had a better outcome than those receiving placebo, according to the results of the CIBIC-Plus (P=0.06 with the last observation carried forward, P=0.03 for observed cases), the ADCS-ADLsev (P=0.02 with the last observation carried forward, P=0.003 for observed cases), and the Severe Impairment Battery (P<0.001 with the last observation carried forward, P=0.002 for observed cases). Memantine was not associated with a significant frequency of adverse events. CONCLUSIONS: Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available.	NYU, Sch Med, William & Sylvia Silberstein Aging & Dementia Res, Dept Psychiat, New York, NY 10016 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; Merz Pharmaceut, Frankfurt, Germany; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; Univ Kentucky, Dept Psychiat, Lexington, KY USA	New York University; Baylor College of Medicine; Merz Pharmaceuticals GmbH; University of Kentucky; University of Kentucky	Reisberg, B (corresponding author), NYU, Sch Med, William & Sylvia Silberstein Aging & Dementia Res, Dept Psychiat, 550 1st Ave, New York, NY 10016 USA.	barry.reisberg@med.nyu.edu		Ferris, Steven/0000-0001-8641-6223; Reisberg, Barry/0000-0002-9104-7423	NIA NIH HHS [1-U01 AG-10483, AG-03051, AG-08051] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [U01AG010483, P30AG008051, R01AG003051] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackerley S, 2000, J CELL BIOL, V150, P165, DOI 10.1083/jcb.150.1.165; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Danysz W, 2000, NEUROTOX RES, V2, P85, DOI 10.1007/BF03033787; Farber NB, 1998, PROG BRAIN RES, V116, P421, DOI 10.1016/S0079-6123(08)60453-7; Feldman H, 2001, NEUROLOGY, V57, P613, DOI 10.1212/WNL.57.4.613; Feldman H, 2001, NEUROLOGY, V57, P2153; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; Galasko DR, 2000, NEUROBIOL AGING S1, V21, pS168; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; Khachaturian ZS, 1997, SCIENCES, V37, P20, DOI 10.1002/j.2326-1951.1997.tb03323.x; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; *MED EC, 2002, PHYS DESK REF; ORREGO F, 1993, NEUROSCIENCE, V56, P539, DOI 10.1016/0306-4522(93)90355-J; PANISSET M, 1994, ARCH NEUROL-CHICAGO, V51, P41, DOI 10.1001/archneur.1994.00540130067012; Reisberg B, 1997, ALZ DIS ASSOC DIS, V11, P8; Reisberg B, 1997, Int Psychogeriatr, V9 Suppl 1, P11, DOI 10.1017/S1041610297004675; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; Sartorius, 2002, DEMENTIA, P1; Schmitt FA, 1997, ALZ DIS ASSOC DIS, V11, pS51; Sclan S G, 1992, Int Psychogeriatr, V4 Suppl 1, P55; Shimizu E, 2001, SCIENCE, V291, P1902; Wimo A., 1998, HLTH EC DEMENTIA, DOI DOI 10.1186/S12913-017-2422-X; Winblad B, 1999, INT J GERIATR PSYCH, V14, P135, DOI 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0	28	1282	1363	3	179	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1333	1341		10.1056/NEJMoa013128	http://dx.doi.org/10.1056/NEJMoa013128			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672860	Bronze			2022-12-28	WOS:000181949100004
J	Schultz, CH; Koenig, KL; Lewis, RJ				Schultz, CH; Koenig, KL; Lewis, RJ			Implications of hospital evacuation after the Northridge, California, earthquake	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND: On January 17, 1994, an earthquake with a moment magnitude (total energy release) of 6.7 occurred in Northridge, California, leading to the evacuation of patients from several hospitals. We examined the reasons for and methods of evacuation and the emergency-management strategies used. The experience in California may have implications for hospital strategies for responding to any major disaster, including an act of terrorism. METHODS: From September 1995 to September 1996, we surveyed all acute care hospitals in Los Angeles County that reported having evacuated patients after the Northridge earthquake. Physicians, nurses, hospital administrators, and staff on duty at the hospitals during the evacuation responded to a 58-item structured questionnaire. RESULTS: Eight of 91 acute care hospitals (9 percent) were evacuated. Six hospitals evacuated patients within 24 hours (the immediate-evacuation group), four completely and two partially. All six cited nonstructural damage such as water damage and loss of electrical power as a major reason for evacuation. Five hospitals evacuated the most seriously ill patients first, and one hospital evacuated the healthiest patients first. All hospitals used available equipment to transport patients (blankets, backboards, and gurneys) rather than specialized devices. No deaths resulted from evacuation. One hospital evacuated patients after 3 days and another after 14 days because of structural damage, even though initial inspections had shown no damage (the delayed-evacuation group). Both hospitals required demolition. Some hospitals identified destinations for their evacuated patients independently, whereas others sought the assistance of the Los Angeles County Emergency Operations Center; the two strategies were equally effective. CONCLUSIONS: After even a moderate earthquake, hospitals are at risk for both immediate nonstructural damage that may force them to evacuate patients and the delayed discovery of structural damage resulting in permanent closure. Evacuation of large numbers of inpatients from multiple hospitals can be accomplished quickly and safely with the use of available resources and personnel.	Univ Calif Irvine, Irvine Med Ctr, Emergency Dept, Orange, CA 92668 USA; Univ Calif Irvine, Coll Med, Irvine, CA 92717 USA; George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; Dept Vet Affairs, Vet Hlth Adm, Hlth Sci & Emergency Management Strateg Healthcar, Washington, DC USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; George Washington University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Schultz, CH (corresponding author), Univ Calif Irvine, Irvine Med Ctr, Emergency Dept, Rte 128,101 City Dr, Orange, CA 92668 USA.	schultzc@uci.edu						ARNOLD C, 1983, HOSP SAN FERNANDO EA; BLASER M J, 1985, Journal of Emergency Medicine, V3, P387, DOI 10.1016/0736-4679(85)90323-3; Chavez C W, 1996, J Emerg Med, V14, P445, DOI 10.1016/0736-4679(96)00083-2; De Lorenzo R A, 1996, Prehosp Disaster Med, V11, P270; FISHER HL, 1986, MIL MED, V151, P154, DOI 10.1093/milmed/151.3.154; Gretenkort Peter, 2002, Prehosp Disaster Med, V17, P42; JONES L, 1994, SCIENCE, V266, P389, DOI 10.1126/science.266.5184.398; KOBAYASHI H, 1996, JPN J DISASTER MED, V1, P73; *OFF STAT HLTH PLA, 2001, SUMM HOSP SEISM PERF; Schultz CH, 1996, NEW ENGL J MED, V334, P438, DOI 10.1056/NEJM199602153340706; Tanaka H, 1998, J Emerg Med, V16, P439, DOI 10.1016/S0736-4679(98)00014-6; TSUBOI S, 1996, JPN J DISASTER MED, V1, P36; Ukai T, 1997, RENAL FAILURE, V19, P633, DOI 10.3109/08860229709109029; *US ARM SOLD BIOL, 2002, MASS CAS CAR STRAT B	14	105	105	1	26	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1349	1355		10.1056/NEJMsa021807	http://dx.doi.org/10.1056/NEJMsa021807			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672863				2022-12-28	WOS:000181949100007
J	Anker, SD; Negassa, A; Coats, AJS; Afzal, R; Poole-Wilson, PA; Cohn, JN; Yusuf, S				Anker, SD; Negassa, A; Coats, AJS; Afzal, R; Poole-Wilson, PA; Cohn, JN; Yusuf, S			Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study	LANCET			English	Article							CYTOKINES; MORTALITY; CACHEXIA; SURVIVAL; CARVEDILOL; ENALAPRIL; RECEPTORS; TRIAL; MASS	Background Weight loss in chronic heart failure is linked to impaired survival. We aimed to assess the frequency of weight loss in patients with this disease, whether the degree of weight loss predicts mortality, and whether weight loss can be prevented by angiotensin-converting-enzyme (ACE) inhibitors. Methods We investigated weight changes in 1929 patients from the SOLVD trial who had chronic heart failure, were free of oedema at baseline, and survived for at least 4 months after trial entry. Mean follow-up was 35 months (SD 13). We analysed the effect of weight loss at cutpoints of 5%, 7.5%, 10%, 15% (a priori), and 6% (post hoc) to identify which one best predicted outcome. To validate results, we analysed data for 619 patients in the V-HeFT II trial. Findings 817 (42%) patients in the SOLVD trial had weight loss from baseline of 5% or more. At 8 months follow-up, all cutpoints for weight loss were significantly associated with, impaired survival after adjustment for age, sex, New York Heart Association class, left ventricular ejection fraction, and treatment allocation. Weight loss of 6% or more at any time during follow-up was the strongest predictor of impaired survival (adjusted hazard ratio 2.10, 95% CI 1.77-2.49; p<0.0001). Patients on the ACE inhibitor enalapril had a lower hazard of 6% or more weight loss than did those not taking the drug (adjusted reduction 19%, p=0.0054). Results from analyses of V-HeFr II data lent support to our findings. Interpretation Weight loss occurs frequently in patients with chronic heart disease, its reversal is rare, and when present, it is independently linked to impaired survival. Weight loss of more than 6% should be used to define the presence of cachexia in patients with chronic heart failure. In chronic heart failure, treatment with an ACE inhibitor reduces the risk of weight loss.	Natl Heart & Lung Inst, Imperial Coll, Dept Clin Cardiol, London SW3 6LY, England; Natl Heart & Lung Inst, Imperial Coll, Dept Cardiac Med, London, England; Charite, Dept Cardiol, Berlin, Germany; McMaster Univ, Div Cardiol, Hamilton, ON, Canada; Univ Minnesota, Sch Med, Div Cardiovasc, Minneapolis, MN 55455 USA	Imperial College London; Imperial College London; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; McMaster University; University of Minnesota System; University of Minnesota Twin Cities	Anker, SD (corresponding author), Natl Heart & Lung Inst, Imperial Coll, Dept Clin Cardiol, Dovehouse St, London SW3 6LY, England.	s.anker@imperial.ac.uk	Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260; Yusuf, Salim/0000-0003-4776-5601				Anker SD, 1997, EUR HEART J, V18, P259; Anker SD, 1999, EUR HEART J, V20, P683, DOI 10.1053/euhj.1998.1446; Anker SD, 2002, INT J CARDIOL, V86, P123, DOI 10.1016/S0167-5273(02)00470-9; Anker SD, 2002, INT J CARDIOL, V85, P51, DOI 10.1016/S0167-5273(02)00233-4; Anker SD, 1997, AM J CARDIOL, V79, P1426, DOI 10.1016/S0002-9149(97)00159-8; Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Anker SD, 1997, CIRCULATION, V96, P526; Anker SD, 2001, J AM COLL CARDIOL, V38, P443, DOI 10.1016/S0735-1097(01)01385-7; Anker SD, 2001, J AM COLL CARDIOL, V37, p203A; Clark AL, 2001, EUR HEART J, V22, P2275, DOI 10.1053/euhj.2001.2693; Coats AJ, 2001, CIRCULATION, V104, P437; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Davos CH, 2003, J CARD FAIL, V9, P29, DOI 10.1054/jcaf.2003.4; Deswal A, 2001, CIRCULATION, V103, P2055; Doehner W, 2001, AM HEART J, V141, P792, DOI 10.1067/mhj.2001.114367; ERIKSSON SV, 1997, CIRCULATION S1, V96, P322; Florea VG, 2002, AM HEART J, V144, P45, DOI 10.1067/mhj.2002.123314; FRANCIS GS, 1993, CIRCULATION, V87, P40; Gennari R, 1996, SHOCK, V6, P95, DOI 10.1097/00024382-199608000-00003; Hornig B, 1998, EUR HEART J, V19, pG48; Horwich TB, 2001, J AM COLL CARDIOL, V38, P789, DOI 10.1016/S0735-1097(01)01448-6; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Niebauer J, 1999, LANCET, V353, P1838, DOI 10.1016/S0140-6736(98)09286-1; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; PACKER M, 1992, J AM COLL CARDIOL, V20, P248, DOI 10.1016/0735-1097(92)90167-L; Pitt B, 2000, LANCET, V355, P1582, DOI 10.1016/S0140-6736(00)02213-3; POEHLMAN ET, 1994, ANN INTERN MED, V121, P860, DOI 10.7326/0003-4819-121-11-199412010-00006; Rauchhaus M, 2000, CIRCULATION, V102, P3060; Sharma R, 2002, INT J CARDIOL, V85, P161, DOI 10.1016/S0167-5273(02)00244-9; SWEDBERG K, 1990, CIRCULATION, V82, P1730, DOI 10.1161/01.CIR.82.5.1730; Witte KKA, 2002, INT J CARDIOL, V85, P23, DOI 10.1016/S0167-5273(02)00231-0; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	32	518	543	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 29	2003	361	9363					1077	1083		10.1016/S0140-6736(03)12892-9	http://dx.doi.org/10.1016/S0140-6736(03)12892-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672310				2022-12-28	WOS:000181865200008
J	Esmail, A; Abel, P; Everington, S				Esmail, A; Abel, P; Everington, S			Discrimination in the discretionary points award scheme: comparison of white with non-white consultants and men with women	BRITISH MEDICAL JOURNAL			English	Article							DISTINCTION AWARDS		MSF Ctr, Practitioners Union, London EC1V 8HA, England; Univ Manchester, Sch Primary Care, Rusholme Hlth Ctr, Manchester M14 5NP, Lancs, England	Doctors Without Borders; University of Manchester	Esmail, A (corresponding author), MSF Ctr, Practitioners Union, London EC1V 8HA, England.	aneez.esmail@man.ac.uk	Esmail, Aneez/I-6903-2013					BEECHAM L, 1994, BRIT MED J, V308, P1106; BRUGGEN P, 1982, BRIT MED J, V284, P1577, DOI 10.1136/bmj.284.6328.1577; *DEP HLTH, 1995, CONS DISCR POINTS; Esmail A, 1998, BRIT MED J, V316, P193; Wise J, 2000, BRIT MED J, V320, P269	5	17	17	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 29	2003	326	7391					687	688		10.1136/bmj.326.7391.687	http://dx.doi.org/10.1136/bmj.326.7391.687			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663WL	12663405	Green Published, Bronze			2022-12-28	WOS:000182029500016
J	Vermeer, SE; Prins, ND; den Heijer, T; Hofman, A; Koudstaal, PJ; Breteler, MMB				Vermeer, SE; Prins, ND; den Heijer, T; Hofman, A; Koudstaal, PJ; Breteler, MMB			Silent brain infarcts and the risk of dementia and cognitive decline	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WHITE-MATTER LESIONS; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; NEUROFIBRILLARY TANGLES; CLINICAL DETERMINANTS; VASCULAR DEMENTIA; ELDERLY-PEOPLE; PREVALENCE; EXPRESSION	BACKGROUND: Silent brain infarcts are frequently seen on magnetic resonance imaging (MRI) in healthy elderly people and may be associated with dementia and cognitive decline. METHODS: We studied the association between silent brain infarcts and the risk of dementia and cognitive decline in 1015 participants of the prospective, population-based Rotterdam Scan Study, who were 60 to 90 years of age and free of dementia and stroke at base line. Participants underwent neuropsychological testing and cerebral MRI at base line in 1995 to 1996 and again in 1999 to 2000 and were monitored for dementia throughout the study period. We performed Cox proportional-hazards and multiple linear-regression analyses, adjusted for age, sex, and level of education and for the presence or absence of subcortical atrophy and white-matter lesions. RESULTS: During 3697 person-years of follow-up (mean per person, 3.6 years), dementia developed in 30 of the 1015 participants. The presence of silent brain infarcts at base line more than doubled the risk of dementia (hazard ratio, 2.26; 95 percent confidence interval, 1.09 to 4.70). The presence of silent brain infarcts on the base-line MRI was associated with worse performance on neuropsychological tests and a steeper decline in global cognitive function. Silent thalamic infarcts were associated with a decline in memory performance, and nonthalamic infarcts with a decline in psychomotor speed. When participants with silent brain infarcts at base line were subdivided into those with and those without additional infarcts at follow-up, the decline in cognitive function was restricted to those with additional silent infarcts. CONCLUSIONS: Elderly people with silent brain infarcts have an increased risk of dementia and a steeper decline in cognitive function than those without such lesions.	Erasmus MC, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Neurol, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Breteler, MMB (corresponding author), Erasmus MC, Dept Epidemiol & Biostat, POB 1738, NL-3000 DR Rotterdam, Netherlands.	m.breteler@erasmusmc.nl	Zito, Giancarlo/F-9008-2010; Breteler, Monique M.B./J-5058-2014	Breteler, Monique M.B./0000-0002-0626-9305; Prins, Niels/0000-0002-6297-7592				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Barber R, 1999, J NEUROL NEUROSUR PS, V67, P66, DOI 10.1136/jnnp.67.1.66; Berg L, 1998, ARCH NEUROL-CHICAGO, V55, P326, DOI 10.1001/archneur.55.3.326; Bernick C, 2001, NEUROLOGY, V57, P1222, DOI 10.1212/WNL.57.7.1222; BOGOUSSLAVSKY J, 1988, NEUROLOGY, V38, P837, DOI 10.1212/WNL.38.6.837; BOGOUSSLAVSKY J, 1988, NEUROLOGY, V38, P1335; Breteler MMB, 2000, NEUROBIOL AGING, V21, P153, DOI 10.1016/S0197-4580(99)00110-4; de Groot JC, 2000, ANN NEUROL, V47, P145; de Groot JC, 2002, ANN NEUROL, V52, P335, DOI 10.1002/ana.10294; de la Monte SM, 2000, NEUROBIOL AGING, V21, P309, DOI 10.1016/S0197-4580(99)00108-6; de Leeuw FE, 2001, J NEUROL NEUROSUR PS, V70, P9, DOI 10.1136/jnnp.70.1.9; den Heijer T, 2002, NEUROLOGY, V59, P746, DOI 10.1212/WNL.59.5.746; Desmond DW, 2000, NEUROLOGY, V54, P1124, DOI 10.1212/WNL.54.5.1124; Esiri MM, 2001, LANCET, V357, P169; Henon H, 2001, NEUROLOGY, V57, P1216, DOI 10.1212/WNL.57.7.1216; Heyman A, 1998, NEUROLOGY, V51, P159, DOI 10.1212/WNL.51.1.159; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; HOFMAN A, 1983, NEW ENGL J MED, V309, P1248; Howard G, 1998, STROKE, V29, P913, DOI 10.1161/01.STR.29.5.913; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; Longstreth WT, 1998, ARCH NEUROL-CHICAGO, V55, P1217, DOI 10.1001/archneur.55.9.1217; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Ott A, 1998, AM J EPIDEMIOL, V147, P574; Petrovitch H, 2000, NEUROBIOL AGING, V21, P57, DOI 10.1016/S0197-4580(00)82479-3; Pohjasvaara T, 1998, STROKE, V29, P75, DOI 10.1161/01.STR.29.1.75; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Small SA, 1999, NEUROLOGY, V52, P1392, DOI 10.1212/WNL.52.7.1392; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; SPARKS DL, 1995, J NEUROL SCI, V131, P162, DOI 10.1016/0022-510X(95)00105-B; TATEMICHI TK, 1992, ANN NEUROL, V32, P162, DOI 10.1002/ana.410320207; Vermeer SE, 2002, STROKE, V33, P21, DOI 10.1161/hs0102.101629; Vermeer SE, 2002, ANN NEUROL, V51, P285, DOI 10.1002/ana.10111	33	1618	1693	4	105	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2003	348	13					1215	1222		10.1056/NEJMoa022066	http://dx.doi.org/10.1056/NEJMoa022066			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659RG	12660385	Bronze, Green Published			2022-12-28	WOS:000181790800003
J	Jackler, RK				Jackler, RK			A 73-year-old man with hearing loss	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OLDER ADULTS; COCHLEAR IMPLANTS; NOISE; AIDS; EPIDEMIOLOGY; PRESBYCUSIS; PREVALENCE; IMPAIRMENT; MUTATION; TOXICITY		Univ Calif San Francisco, Dept Otolaryngol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Jackler, RK (corresponding author), Univ Calif San Francisco, Dept Otolaryngol, 400 Parnassus Ave,A-730, San Francisco, CA 94143 USA.	rkj@itsa.ucsf.edu		jackler, robert/0000-0003-2525-8377				Alexiades G, 2001, LARYNGOSCOPE, V111, P1608, DOI 10.1097/00005537-200109000-00022; American Speech-Language-Hearing Association, 1997, GUID AUD SCREEN; Blanchfield B B, 2001, J Am Acad Audiol, V12, P183; Canalis RF, 2000, EAR COMPREHENSIVE OT; Christensen K, 2001, J AM GERIATR SOC, V49, P1512, DOI 10.1046/j.1532-5415.2001.4911245.x; Clark GM, 1999, AM J OTOL, V20, P4; CLARK JG, 2002, INTRO AUDIOLOGY; Cohn ES, 1999, CLIN GERIATR MED, V15, P145; Daniels RL, 2000, AM J OTOL, V21, P173, DOI 10.1016/S0196-0709(00)80005-8; Davidson HC, 2001, SEMIN ULTRASOUND CT, V22, P229, DOI 10.1016/S0887-2171(01)90009-5; DAVIDSON J, 1989, INT J PEDIATR OTORHI, V17, P239, DOI 10.1016/0165-5876(89)90051-7; Davis RR, 2001, HEARING RES, V155, P82, DOI 10.1016/S0378-5955(01)00250-7; Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885; DOBIE RA, 1995, ARCH OTOLARYNGOL, V121, P385; FARRINGTON RF, 1947, JAMA-J AM MED ASSOC, V134, P679, DOI 10.1001/jama.1947.02880250027007; Fischel-Ghodsian N, 1999, ANN NY ACAD SCI, V884, P99, DOI 10.1111/j.1749-6632.1999.tb08639.x; Forge A, 2000, AUDIOL NEURO-OTOL, V5, P3, DOI 10.1159/000013861; Fowler PD, 1999, CLIN OTOLARYNGOL, V24, P3, DOI 10.1046/j.1365-2273.1999.00212.x; Francis HW, 2002, LARYNGOSCOPE, V112, P1482, DOI 10.1097/00005537-200208000-00028; Fraysse B, 2001, OTOL NEUROTOL, V22, P952, DOI 10.1097/00129492-200111000-00041; Garcia VP, 2001, ACTA OTO-LARYNGOL, V121, P569, DOI 10.1080/000164801316878836; GATES GA, 1990, EAR HEARING, V11, P247, DOI 10.1097/00003446-199008000-00001; GATES GA, 1991, ACTA OTO-LARYNGOL, V111, P240, DOI 10.3109/00016489109137382; Ishikawa K, 2002, LARYNGOSCOPE, V112, P1494, DOI 10.1097/00005537-200208000-00030; ISING H, 1994, HNO, V42, P764; Klein AJ, 1999, MED CLIN N AM, V83, P139, DOI 10.1016/S0025-7125(05)70093-6; Kochkin S., 2002, HEAR REV, V9, P14; Kotimaki J, 2001, ACTA OTO-LARYNGOL, P14; Lalwani AK, 2002, AUDIOL NEURO-OTOL, V7, P146, DOI 10.1159/000058300; LEBO CP, 1994, WESTERN J MED, V161, P45; Levitt H, 2001, J REHABIL RES DEV, V38, P111; LICHTENSTEIN MJ, 1988, EAR HEARING, V9, P208, DOI 10.1097/00003446-198808000-00006; MANIGLIA AJ, 2001, OTOLARYNGOL CLIN AM, V34; May JJ, 2000, AM J IND MED, V37, P112, DOI 10.1002/(SICI)1097-0274(200001)37:1<112::AID-AJIM9>3.3.CO;2-R; MCBRIDE WS, 1994, AM J MED SCI, V307, P40, DOI 10.1097/00000441-199401000-00007; Meister H, 2002, OTOL NEUROTOL, V23, P457, DOI 10.1097/00129492-200207000-00011; MOSCICKI EK, 1985, EAR HEARING, V6, P184, DOI 10.1097/00003446-198507000-00003; MULROW CD, 1990, EAR HEARING, V11, P176, DOI 10.1097/00003446-199006000-00002; Nakashima T, 2000, ACTA OTO-LARYNGOL, V120, P904, DOI 10.1080/00016480050218627; National Center for Health Statistics Centers for Disease Control and Prevention, NAT HLTH INT SURV; O'Donoghue G, 2002, OTOL NEUROTOL, V23, P823, DOI 10.1097/00129492-200211000-00001; Osberger MJ, 1999, ANN OTO RHINOL LARYN, V108, P1; Petit C, 2001, ANNU REV GENET, V35, P589, DOI 10.1146/annurev.genet.35.102401.091224; Popelka MM, 1998, J AM GERIATR SOC, V46, P1075, DOI 10.1111/j.1532-5415.1998.tb06643.x; Rahman MU, 2001, CURR OPIN RHEUMATOL, V13, P184, DOI 10.1097/00002281-200105000-00006; Raut VV, 2001, J OTOLARYNGOL, V30, P289, DOI 10.2310/7070.2001.19580; Roland J T, 2000, Curr Rheumatol Rep, V2, P171, DOI 10.1007/s11926-000-0058-y; ROSEN S, 1962, ANN OTO RHINOL LARYN, V71, P727, DOI 10.1177/000348946207100313; Sorri M, 2001, SCAND AUDIOL, V30, P203, DOI 10.1080/010503901316914584; STANKIEWICZ JA, 1979, LARYNGOSCOPE, V89, P1956; Tekin M, 2001, LANCET, V358, P1082, DOI 10.1016/S0140-6736(01)06186-4; Tirzaman O, 2000, ANN OTO RHINOL LARYN, V109, P710, DOI 10.1177/000348940010900802; *US PREV SERV TASK, 1996, SCREEN HEAR IMP GUID; VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625; Vartiainen E, 1998, J LARYNGOL OTOL, V112, P1034, DOI 10.1017/S0022215100142409; Willems PJ, 2000, NEW ENGL J MED, V342, P1101, DOI 10.1056/NEJM200004133421506; Willott JF, 2001, AUDIOL NEURO-OTOL, V6, P231, DOI 10.1159/000046129; Yueh B, 2001, ARCH OTOLARYNGOL, V127, P1197, DOI 10.1001/archotol.127.10.1197; Zadeh Mani H., 2001, Comprehensive Therapy, V27, P302, DOI 10.1007/s12019-001-0028-y	59	4	6	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2003	289	12					1557	1565		10.1001/jama.289.12.1557	http://dx.doi.org/10.1001/jama.289.12.1557			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659XE	12672773				2022-12-28	WOS:000181803100034
J	Atun, RA				Atun, RA			Doctors and managers need to speak a common language	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Sch Business, Ctr Hlth Management, London SW7 2PG, England	Imperial College London	Atun, RA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Business, Ctr Hlth Management, London SW7 2PG, England.	r.atun@imperial.ac.uk	Atun, Rifat/AAH-5537-2021	Atun, Rifat/0000-0002-1531-5983				Atun RA, 1997, CLIN MANAGEMENT, V6, P6; ATUN RA, 1999, CLIN MANAGEMENT, V8, P47; Edwards N, 2003, BRIT MED J, V326, P116, DOI 10.1136/bmj.326.7381.116; LORSCH JW, 1987, HARVARD BUS REV, V65, P78; MINTZBERG H, 1975, HARVARD BUS REV, V53, P49	5	27	27	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 22	2003	326	7390					655	655		10.1136/bmj.326.7390.655	http://dx.doi.org/10.1136/bmj.326.7390.655			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	661BF	12649249	Green Published			2022-12-28	WOS:000181870800028
J	Davies, HTO; Hodges, CL; Rundall, TG				Davies, HTO; Hodges, CL; Rundall, TG			Views of doctors and managers on the doctor-manager relationship in the NHS	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ St Andrews, Ctr Publ Policy & Management, St Andrews KY16 9AL, Fife, Scotland; Univ Calif Berkeley, Div Hlth Policy & Management, Berkeley, CA 94720 USA	University of St Andrews; University of California System; University of California Berkeley	Davies, HTO (corresponding author), Univ St Andrews, Ctr Publ Policy & Management, St Andrews KY16 9AL, Fife, Scotland.	hd@st-and.ac.uk		Davies, Huw/0000-0002-2653-3695				Edwards N, 2003, BRIT MED J, V326, P116, DOI 10.1136/bmj.326.7381.116; MCLELLAN AA, 2002, HLTH SERV J     1114, P18; PROTOPSALTIS G, 2003, FAILURE TURNAROUND	3	43	44	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	2003	326	7390					626	628		10.1136/bmj.326.7390.626	http://dx.doi.org/10.1136/bmj.326.7390.626			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649235	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000181870800015
J	Malcolm, L; Wright, L; Barnett, P; Hendry, C				Malcolm, L; Wright, L; Barnett, P; Hendry, C			Building a successful partnership between management and clinical leadership: experience from New Zealand	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE		Aotearoa Hlth, Lyttelton, New Zealand; Christchurch Sch Med & Hlth Sci, Dept Publ Hlth & Gen Practice, Christchurch, New Zealand; Otago Polytech, Dunedin, New Zealand	University of Otago; Otago Polytechnic	Malcolm, L (corresponding author), Aotearoa Hlth, RD 1, Lyttelton, New Zealand.	lm@cyberxpress.co.nz						Blendon RJ, 2002, HEALTH AFFAIR, V21, P182, DOI 10.1377/hlthaff.21.3.182; FREIDSON E, 2001, PROFESSIONALISM 3RD; Hornblow A, 1997, BRIT MED J, V314, P1892, DOI 10.1136/bmj.314.7098.1892; MALCOLM I, CLIN LEADERSHIP QUAL; Malcolm L, 1999, BRIT MED J, V319, P1340, DOI 10.1136/bmj.319.7221.1340; Ministry of Health, 2000, NZ HLTH STRAT	6	9	9	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	2003	326	7390					653	654		10.1136/bmj.326.7390.653	http://dx.doi.org/10.1136/bmj.326.7390.653			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649247	Green Published			2022-12-28	WOS:000181870800026
J	Nagar, B; Hantschel, O; Young, MA; Scheffzek, K; Veach, D; Bornmann, V; Clarkson, B; Superti-Furga, G; Kuriyan, J				Nagar, B; Hantschel, O; Young, MA; Scheffzek, K; Veach, D; Bornmann, V; Clarkson, B; Superti-Furga, G; Kuriyan, J			Structural basis for the autoinhibition of c-Abl tyrosine kinase	CELL			English	Article							CRYSTAL-STRUCTURE; SRC FAMILY; BCR-ABL; CELLULAR FUNCTIONS; DIFFRACTION DATA; DOMAIN; INHIBITORS; MECHANISM; PHOSPHORYLATION; ACTIVATION	c-Abl is normally regulated by an autoinhibitory mechanism, the disruption of which leads to chronic myelogenous leukemia. The details of this mechanism have been elusive because c-Abl lacks a phosphotyrosine residue that triggers the assembly of the autoinhibited form of the closely related Src kinases by internally engaging the SH2 domain. Crystal structures of c-Abl show that the N-terminal myristoyl modification of c-Abl 1b binds to the kinase domain and induces conformational changes that allow the SH2 and SH3 domains to dock onto it. Autoinhibited c-Abl forms an assembly that is strikingly similar to that of inactive Src kinases but with specific differences that explain the differential ability of the drug STI-571/Gleevec/imatinib (STI-571) to inhibit the catalytic activity of Abl, but not that of c-Src.	European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany; Cellzome AG, D-69117 Heidelberg, Germany; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Dept Chem, Berkeley, CA 94720 USA; Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	European Molecular Biology Laboratory (EMBL); GlaxoSmithKline; Cellzome GmbH; Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Memorial Sloan Kettering Cancer Center	Kuriyan, J (corresponding author), European Mol Biol Lab, Dev Biol Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	superti@embl-heidelberg.de; kudyan@uclink.berkeley.edu	Hantschel, Oliver/M-7016-2019; Young, Matthew/AAE-2632-2020; Hantschel, Oliver D/H-4705-2013; Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015; Young, Matthew/D-2033-2011; Nagar, Bhushan/C-1297-2010	Hantschel, Oliver/0000-0001-8569-8169; Young, Matthew/0000-0003-2921-3432; Hantschel, Oliver D/0000-0001-8569-8169; Superti-Furga, Giulio/0000-0002-0570-1768; Young, Matthew/0000-0003-2921-3432; Veach, Darren/0000-0002-8201-622X	NATIONAL CANCER INSTITUTE [P01CA064593, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748, P01 CA064593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Brasher BB, 2001, ONCOGENE, V20, P7744, DOI 10.1038/sj.onc.1204978; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DeLano WL, 2002, PYMOL USERS MANUAL; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Fushman D, 1999, BIOCHEMISTRY-US, V38, P10225, DOI 10.1021/bi990897g; Gangal M, 1999, P NATL ACAD SCI USA, V96, P12394, DOI 10.1073/pnas.96.22.12394; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Koegl M, 1995, ONCOGENE, V11, P2317; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; MULLER AJ, 1993, P NATL ACAD SCI USA, V90, P3457, DOI 10.1073/pnas.90.8.3457; Nagar B, 2002, CANCER RES, V62, P4236; Nam HJ, 1996, STRUCTURE, V4, P1105, DOI 10.1016/S0969-2126(96)00116-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Sawyers CL, 2002, CANCER CELL, V1, P13, DOI 10.1016/S1535-6108(02)00022-3; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Wisniewski D, 2002, CANCER RES, V62, P4244; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zimmermann J, 1997, BIOORG MED CHEM LETT, V7, P187, DOI 10.1016/S0960-894X(96)00601-4	38	628	664	2	58	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2003	112	6					859	871		10.1016/S0092-8674(03)00194-6	http://dx.doi.org/10.1016/S0092-8674(03)00194-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	660DL	12654251	Bronze			2022-12-28	WOS:000181818500012
J	Sun, WD; Bennett, VC; Eggins, SM; Kamenetsky, VS; Arculus, RJ				Sun, WD; Bennett, VC; Eggins, SM; Kamenetsky, VS; Arculus, RJ			Enhanced mantle-to-crust rhenium transfer in undegassed arc magmas	NATURE			English	Article							OSMIUM ISOTOPIC COMPOSITION; PLATINUM-GROUP ELEMENTS; CONTINENTAL-CRUST; BASALT GLASSES; RE; OS; GEOCHEMISTRY; CONSTRAINTS; SYSTEMATICS; ABUNDANCES	Variations in the Os-187/Os-188 isotopic signature of mantle and mantle-derived rocks have been thought to provide a powerful chemical tracer of deep Earth structure. Many studies have inferred from such data that a long-lived, high-rhenium component exists in the deep mantle (Re-187 is the parent isotope decaying to Os-187, with a half-life of similar to42 billion years), and that this reservoir probably consists of subducted oceanic crust(1-3). The interpretation of these isotopic signatures is, however, dependent on accurate estimates of rhenium and osmium concentrations in all of the main geochemical reservoirs, and the crust has generally been considered to be a minor contributor to such global budgets. In contrast, we here present observations of high rhenium concentrations and low Yb/Re ratios in arc-type melt inclusions. These results indicate strong enrichment of rhenium in undegassed arc rocks, and consequently the continental crust, which results in a crustal estimate of similar to2p.p.b. rhenium, as compared to previous estimates of 0.4-0.2p.p.b. (refs 4, 5). Previous determinations of rhenium in arc materials, which were largely measured on subaerially erupted samples, are likely to be in error owing to rhenium loss during degassing. High mantle-to-crust rhenium fluxes, as observed here, require a revaluation of geochemical models based on the Re-187-Os-187 decay system(1-3).	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Australian Natl Univ, Dept Geol, Canberra, ACT 0200, Australia; Univ Tasmania, Sch Earth Sci, Hobart, Tas 7001, Australia; Univ Tasmania, CODES SRC, Hobart, Tas 7001, Australia	Australian National University; Australian National University; University of Tasmania; University of Tasmania	Bennett, VC (corresponding author), Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia.		Eggins, Stephen M/H-6943-2016; Kamenetsky, Vadim/K-2200-2019; Sun, Weidong/V-2014-2019; Sun, Weidong/AAJ-7430-2021; Kamenetsky, Vadim/CAF-7424-2022; Sun, Weidong/F-8482-2010; Kamenetsky, Vadim S/B-1019-2008	Eggins, Stephen M/0000-0002-0007-5753; Sun, Weidong/0000-0002-8931-8407; Kamenetsky, Vadim S/0000-0002-2734-8790; Arculus, Richard/0000-0002-3432-392X; Bennett, Vickie/0000-0003-0937-3471				Alves S, 2002, EARTH PLANET SC LETT, V198, P355, DOI 10.1016/S0012-821X(02)00524-1; Alves S, 1999, EARTH PLANET SC LETT, V168, P65, DOI 10.1016/S0012-821X(99)00050-3; Barth MG, 2000, CHEM GEOL, V165, P197, DOI 10.1016/S0009-2541(99)00173-4; Becker H, 2000, EARTH PLANET SC LETT, V177, P287, DOI 10.1016/S0012-821X(00)00052-2; Bennett VC, 2002, GEOCHIM COSMOCHIM AC, V66, P2615, DOI 10.1016/S0016-7037(02)00862-1; Bennett VC, 2000, EARTH PLANET SC LETT, V183, P513, DOI 10.1016/S0012-821X(00)00295-8; Borg LE, 2000, EARTH PLANET SC LETT, V177, P301, DOI 10.1016/S0012-821X(00)00051-0; Chesley J, 2002, EARTH PLANET SC LETT, V195, P211, DOI 10.1016/S0012-821X(01)00580-5; EGGINS SM, 1993, CONTRIB MINERAL PETR, V114, P79, DOI 10.1007/BF00307867; ESSER BK, 1993, GEOCHIM COSMOCHIM AC, V57, P3093, DOI 10.1016/0016-7037(93)90296-9; Hauri EH, 1997, CHEM GEOL, V139, P185, DOI 10.1016/S0009-2541(97)00035-1; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; ISHIHARA S, 1988, ECON GEOL, V83, P1047, DOI 10.2113/gsecongeo.83.5.1047; Jaffe LA, 2002, EARTH PLANET SC LETT, V198, P339, DOI 10.1016/S0012-821X(02)00526-5; Kamenetsky VS, 1997, EARTH PLANET SC LETT, V151, P205, DOI 10.1016/S0012-821X(97)81849-3; Kamenetsky VS, 2001, EARTH PLANET SC LETT, V184, P685, DOI 10.1016/S0012-821X(00)00352-6; KORZHINSKY MA, 1994, NATURE, V369, P51, DOI 10.1038/369051a0; LASSITER JC, 2002, EOS S, V83, P1447; LASSITER JC, 2001, GEOCHEM GEOPHYS GEOS, V2; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; Morford JL, 1999, GEOCHIM COSMOCHIM AC, V63, P1735, DOI 10.1016/S0016-7037(99)00126-X; Peucker-Ehrenbrink B, 2000, GEOLOGY, V28, P475, DOI 10.1130/0091-7613(2000)28<475:EOBSWO>2.0.CO;2; PEUCKEREHRENBRI.B, 2001, GEOCHEM GEOPHYS GEOS, V2; Righter K, 2002, GEOLOGY, V30, P619, DOI 10.1130/0091-7613(2002)030<0619:GOPATB>2.0.CO;2; RUDNICK RL, 1995, REV GEOPHYS, V33, P267, DOI 10.1029/95RG01302; Schiano P, 1997, EARTH PLANET SC LETT, V150, P363, DOI 10.1016/S0012-821X(97)00098-8; SUN WD, IN PRESS CHEM GEOL; Sylvester PJ, 1997, GEOSTANDARD NEWSLETT, V21, P215, DOI 10.1111/j.1751-908X.1997.tb00672.x; Walker RJ, 2002, GEOCHIM COSMOCHIM AC, V66, P329, DOI 10.1016/S0016-7037(01)00767-0; Woodland SJ, 2002, J PETROL, V43, P171, DOI 10.1093/petrology/43.1.171	30	117	135	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					294	297		10.1038/nature01482	http://dx.doi.org/10.1038/nature01482			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646918				2022-12-28	WOS:000181637300036
J	Piketty, C; Darragh, TM; Da Costa, M; Bruneval, P; Heard, I; Kazatchkine, MD; Palefsky, JM				Piketty, C; Darragh, TM; Da Costa, M; Bruneval, P; Heard, I; Kazatchkine, MD; Palefsky, JM			High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse	ANNALS OF INTERNAL MEDICINE			English	Article							SQUAMOUS INTRAEPITHELIAL LESIONS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NEGATIVE HOMOSEXUAL-MEN; BISEXUAL MEN; COST-EFFECTIVENESS; RISK-FACTORS; NEOPLASIA; IMMUNOSUPPRESSION; ABNORMALITIES; ASSOCIATION	Background: Anal cancer and its precursor lesion, anal squamous intraepithelial lesions (SILs), are associated with human papillomavirus (HPV) infection. Anal HPV infection and anal SIL are common in HIV-positive men who, have sex with men; receptive anal intercourse is presumed to be the mode of acquisition of HPV. Objective: To assess the prevalence and risk factors-for. anal HPV infection and anal SIL in HIV-positive men with no history of anal intercourse. Design: Cross-sectional study. Setting: Hopital Europeen Georges Pompidou outpatient clinic, Paris, France. Patients: 118 HIV-infected men. Measurements: 50 HIV-positive heterosexual male injection drug users with no history of anal intercourse and 67. HIV-infected men who had sex with men were evaluated by using anal cytologic, anal histologic, and anal. HPV DNA testing. Results: 23 of the 50 heterosexual Injection drug users (46%) had anal HPV infection. Low-grade SIL (LSIL) was found in 8 patients (16%) and high-grade SIL (HSIL) in 9 patients (18%). Among the 67 men who had sex with men, anal HPV infection was found in 57 patients (85%), LSIL in 33 patients (49%), and HSIL in 12 patients (18%). In univariate analysis, risk factors for abnormal anal cytologic or histologic findings in injection drug users included CD4(+) cell counts less than 250 x 10(6) cells/L (odds ratio, 5.7 [95% Cl, 1.6 to 20.4]), plasma HIV RNA viral load greater than 1.7 log copies/mL (odds ratio, 8.9 [Cl, 1.1 to 76.0]), previous AIDS-defining event (odds ratio, 4.3 [Cl, 1.2 to 15.6]), and anal HPV detection (odds ratio, 5.7 [Cl, 1.6 to 20.4]). Risk factors among men who had sex with men included having more than 10 lifetime receptive anal intercourse episodes (odds ratio, 5.6 [Cl, 1.6 to 19.8]) and anal HPV detection (odds ratio, 8.7 [Cl, 1.9 to 39.0]). Conclusions: Anal HPV infection and anal SIL may be acquired in the absence of anal intercourse in HIV-positive men. The prevalence of HSIL is high among HIV-positive injection drug users. All HIV-positive men with CD4(+) cell counts less than 500 x 10(6) cells/L, regardless of history of anal intercourse, should be considered for anal cytologic screening; however, additional studies are needed to determine the efficacy of this procedure to prevent anal cancer in these populations.	Hop Europeen Georges Pompidou, F-75015 Paris, France; INSERM, U 430, Paris, France; Univ Calif San Francisco, San Francisco, CA 94143 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Francisco	Piketty, C (corresponding author), Hop Europeen Georges Pompidou, 20 Rue Leblanc, F-75015 Paris, France.	Christophe.piketty@egp.ap-hop-paris.fr			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000079] Funding Source: NIH RePORTER; NCRR NIH HHS [5 M01-RR-00079] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BLOHME I, 1985, TRANSPLANTATION, V39, P23; Critchlow CW, 1998, AIDS, V12, P1177, DOI 10.1097/00002030-199810000-00010; CRITCHLOW CW, 1995, AIDS, V9, P1255, DOI 10.1097/00002030-199511000-00007; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; Goedert JJ, 2000, SEMIN ONCOL, V27, P390; Goldie SJ, 2000, AM J MED, V108, P634, DOI 10.1016/S0002-9343(00)00349-1; Goldie SJ, 1999, JAMA-J AM MED ASSOC, V281, P1822, DOI 10.1001/jama.281.19.1822; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; Jay N, 1997, DIS COLON RECTUM, V40, P919, DOI 10.1007/BF02051199; KIVIAT NB, 1993, AIDS, V7, P43, DOI 10.1097/00002030-199301000-00007; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210; MORRISON EAB, 1992, J CLIN MICROBIOL, V30, P2539, DOI 10.1128/JCM.30.10.2539-2543.1992; OGUNBIYI OA, 1994, BRIT J SURG, V81, P365, DOI 10.1002/bjs.1800810313; Palefsky JM, 1997, J ACQ IMMUN DEF SYND, V14, P415, DOI 10.1097/00042560-199704150-00004; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P314, DOI 10.1097/00042560-199804010-00004; Palefsky JM, 1998, AIDS, V12, P495, DOI 10.1097/00002030-199805000-00011; PALEFSKY JM, 1991, CANCER RES, V51, P1014; Palefsky JM, 1997, GENITOURIN MED, V73, P174; Palefsky JM, 1998, J INFECT DIS, V177, P361, DOI 10.1086/514194; Palefsky JM, 1999, J ACQ IMMUN DEF SYND, V21, pS42; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P320, DOI 10.1097/00042560-199804010-00005; PENN I, 1986, CANCER-AM CANCER SOC, V58, P611, DOI 10.1002/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M; Qualters J R, 1992, MMWR CDC Surveill Summ, V41, P1	26	214	229	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					453	459		10.7326/0003-4819-138-6-200303180-00008	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639077				2022-12-28	WOS:000181562400002
J	Wang, XJ; Key, JR				Wang, XJ; Key, JR			Recent trends in arctic surface, cloud, and radiation properties from space	SCIENCE			English	Article							SEA-ICE; HIGH-LATITUDES; TEMPERATURE; ALBEDO	Trends in satellite-derived cloud and surface properties for 1982 to 1999 show that the Arctic has warmed and become cloudier in spring and summer but has cooled and become less cloudy in winter. The increase in spring cloud amount radiatively balances changes in surface temperature and albedo, but during summer, fall, and winter, cloud forcing has tended toward increased cooling. This implies that, if seasonal cloud amounts were not changing, surface warming would be even greater than that observed. Strong correlations with the Arctic Oscillation indicate that the rise in surface temperature and changes in cloud amount are related to large-scale circulation rather than to local processes.	Univ Wisconsin, Cooperat Inst Meteorol Satellite Studies, Madison, WI 53706 USA; NOAA, Off Res & Applicat, Natl Environm Satellite Data & Informat Serv, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; National Oceanic Atmospheric Admin (NOAA) - USA	Wang, XJ (corresponding author), Univ Wisconsin, Cooperat Inst Meteorol Satellite Studies, 1225 W Dayton St, Madison, WI 53706 USA.		Key, Jeffrey R./AAB-7248-2020					CHAPMAN WL, 1993, B AM METEOROL SOC, V74, P33, DOI 10.1175/1520-0477(1993)074<0033:RVOSIA>2.0.CO;2; GROVES DG, 2002, J GEOPHYS RES, V107; KEY J, 2002, DOUD SURFACE PARAMET; Key JR, 2001, J GEOPHYS RES-ATMOS, V106, P12489, DOI 10.1029/2001JD900069; Kistler R, 2001, B AM METEOROL SOC, V82, P247, DOI 10.1175/1520-0477(2001)082<0247:TNNYRM>2.3.CO;2; Maslanik JA, 2001, J GEOPHYS RES-ATMOS, V106, P15233, DOI 10.1029/2000JD900284; MEIER WN, 1997, EARTH INTERACTIONS, V1; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; Overland JE, 2002, J CLIMATE, V15, P1702, DOI 10.1175/1520-0442(2002)015<1702:RTCITW>2.0.CO;2; Parkinson CL, 1999, J GEOPHYS RES-OCEANS, V104, P20837, DOI 10.1029/1999JC900082; POLYAKOV IV, 2002, IN PRESS J CLIM; Rossow WB, 1996, INT SATELLITE CLOUD; Serreze MC, 2000, CLIMATIC CHANGE, V46, P159, DOI 10.1023/A:1005504031923; Stroeve JC, 2001, REMOTE SENS ENVIRON, V75, P360, DOI 10.1016/S0034-4257(00)00179-6; Thompson DWJ, 1998, GEOPHYS RES LETT, V25, P1297, DOI 10.1029/98GL00950; Vinnikov KY, 1999, SCIENCE, V286, P1934, DOI 10.1126/science.286.5446.1934	16	177	190	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1725	1728		10.1126/science.1078065	http://dx.doi.org/10.1126/science.1078065			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637742				2022-12-28	WOS:000181519500043
J	Hays, J; Ockene, JK; Brunner, RL; Kotchen, JM; Manson, JE; Patterson, RE; Aragaki, AK; Shumaker, SA; Brzyski, RG; LaCroix, AZ; Granek, IA; Valanis, BG				Hays, J; Ockene, JK; Brunner, RL; Kotchen, JM; Manson, JE; Patterson, RE; Aragaki, AK; Shumaker, SA; Brzyski, RG; LaCroix, AZ; Granek, IA; Valanis, BG		Women's Hlth Initiative Investigat	Effects of estrogen plus progestin on health-related quality of life	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; SURVEY SF-36; SYMPTOMS; DIFFERENCE	BACKGROUND: The Women's Health Initiative (WHI) and other clinical trials indicate that significant health risks are associated with combination hormone use. Less is known about the effect of hormone therapy on health-related quality of life. METHODS: The WHI randomly assigned 16,608 postmenopausal women 50 to 79 years of age (mean, 63) with an intact uterus at base line to estrogen plus progestin (0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate, in 8506 women) or placebo (in 8102 women). Quality-of-life measures were collected at base line and at one year in all women and at three years in a subgroup of 1511 women. RESULTS: Randomization to estrogen plus progestin resulted in no significant effects on general health, vitality, mental health, depressive symptoms, or sexual satisfaction. The use of estrogen plus progestin was associated with a statistically significant but small and not clinically meaningful benefit in terms of sleep disturbance, physical functioning, and bodily pain after one year (the mean benefit in terms of sleep disturbance was 0.4 point on a 20-point scale, in terms of physical functioning 0.8 point on a 100-point scale, and in terms of pain 1.9 points on a 100-point scale). At three years, there were no significant benefits in terms of any quality-of-life outcomes. Among women 50 to 54 years of age with moderate-to-severe vasomotor symptoms at base line, estrogen and progestin improved vasomotor symptoms and resulted in a small benefit in terms of sleep disturbance but no benefit in terms of the other quality-of-life outcomes. CONCLUSIONS: In this trial in postmenopausal women, estrogen plus progestin did not have a clinically meaningful effect on health-related quality of life.	Baylor Coll Med, Dept Med, Ctr Womens Hlth, Houston, TX 77025 USA; Univ Massachusetts, Sch Med, Div Prevent & Behav Med, Worcester, MA USA; Univ Nevada, Sch Med, Womens Hlth Ctr, Reno, NV 89557 USA; Med Coll Wisconsin, Div Epidemiol, Milwaukee, WI 53226 USA; Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Univ Texas, Hlth Sci Ctr, Dept Obstet & Gynecol, San Antonio, TX 78284 USA; SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA; Kaiser Permanente Ctr Hlth Res, Epidemiol & Dis Prevent Program, Portland, OR USA	Baylor College of Medicine; University of Massachusetts System; University of Massachusetts Worcester; Nevada System of Higher Education (NSHE); University of Nevada Reno; Medical College of Wisconsin; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Fred Hutchinson Cancer Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Health San Antonio; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Kaiser Permanente	Hays, J (corresponding author), Baylor Coll Med, Dept Med, Ctr Womens Hlth, 6535 Fannin St,MS A701, Houston, TX 77025 USA.	jhays@bcm.tmc.edu		Hays-Grudo, Jennifer/0000-0002-8107-1243				*ACOG, 2002, QUEST ANS HORM THER; Alder EM, 2002, HORMONE REPLACEMENT THERAPY AND QUALITY OF LIFE, P11; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Barnabei VM, 2002, OBSTET GYNECOL, V100, P1209, DOI 10.1016/S0029-7844(02)02369-4; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; Berg AO, 2002, ANN INTERN MED, V137, P834, DOI 10.7326/0003-4819-137-10-200211190-00013; BURNAM MA, 1988, MED CARE, V26, P775, DOI 10.1097/00005650-198808000-00004; CAMPBELL S, 1977, CLIN OBSTET GYNAECOL, V4, P31; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; *FDA, 2003, FDA APPR NEW LAB EST; Girdler SS, 1999, J WOMEN HEALTH GEN-B, V8, P637, DOI 10.1089/jwh.1.1999.8.637; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 2002, JAMA-J AM MED ASSOC, V288, P1064; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; Hays RD, 2000, PHARMACOECONOMICS, V18, P419, DOI 10.2165/00019053-200018050-00001; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Judd HL, 1996, JAMA-J AM MED ASSOC, V275, P370, DOI 10.1001/jama.1996.03530290040035; LEVINE DW, IN PRESS PSYCHOL ASS; Matthews KA, 1997, AM PSYCHOL, V52, P101, DOI 10.1037/0003-066X.52.2.101; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rodstrom K, 2002, MENOPAUSE, V9, P156; Rosenthal Robert, 1994, HDB RES SYNTHESIS, V621, P231; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; ROTHERT M, 1994, EXP GERONTOL, V29, P463, DOI 10.1016/0531-5565(94)90026-4; Sarrel PM, 2000, J WOMEN HEALTH GEN-B, V9, pS25, DOI 10.1089/152460900318830; Sarrel PM, 2001, J WOMEN HEALTH GEN-B, V10, P91; *SAS I, STAT AN SYST VERS 8; Shah M G, 2001, Am J Clin Dermatol, V2, P143; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; van Walraven C, 1999, J CLIN EPIDEMIOL, V52, P717, DOI 10.1016/S0895-4356(99)00050-5; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Zethraeus N, 1997, BRIT J OBSTET GYNAEC, V104, P1191, DOI 10.1111/j.1471-0528.1997.tb10945.x; Zweifel JE, 1997, PSYCHONEUROENDOCRINO, V22, P655	38	488	511	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1839	1854		10.1056/NEJMoa030311	http://dx.doi.org/10.1056/NEJMoa030311			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	675FY	12642637	Green Published			2022-12-28	WOS:000182684100003
J	Yin, YX; Liu, YX; Jin, YJ; Hall, EJ; Barrett, JC				Yin, YX; Liu, YX; Jin, YJ; Hall, EJ; Barrett, JC			PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression	NATURE			English	Article							OXIDATIVE STRESS; DNA-BINDING; ACTIVATION; DEFICIENCY; DOMAIN; P21	p53 has a role in many cellular processes through the transcriptional regulation of target genes(1,2). PAC1 ( phosphatase of activated cells 1; also known as dual specificity phosphatase 2, DUSP2) is a dual threonine/tyrosine phosphatase that specifically dephosphorylates and inactivates mitogen-activated protein (MAP) kinases(3,4). Here we show that during apoptosis, p53 activates transcription of PAC1 by binding to a palindromic site in the PAC1 promoter. PAC1 transcription is induced in response to serum deprivation and oxidative stress, which results in p53-dependent apoptosis, but not in response to gamma-irradiation, which causes cell cycle arrest(5,6). Reduction of PAC1 transcription using small interfering RNA inhibits p53-mediated apoptosis, whereas overexpression of PAC1 increases susceptibility to apoptosis and suppresses tumour formation. Moreover, activation of p53 significantly inhibits MAP kinase activity. We conclude that, under specific stress conditions, p53 regulates transcription of PAC1 through a new p53-binding site, and that PAC1 is necessary and sufficient for p53-mediated apoptosis. Identification of a palindromic motif as a p53-binding site may reveal a novel mechanism whereby p53 regulates its target genes.	Columbia Univ, Coll Phys & Surg, Dept Radiat Oncol, New York, NY 10032 USA; NCI, Lab Biosyst & Canc, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yin, YX (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Radiat Oncol, 630 W 168th St, New York, NY 10032 USA.	yy151@columbia.edu			DIVISION OF BASIC SCIENCES - NCI [Z01BC010417] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SUIT G, 2002, P NATL ACAD SCI USA, V99, P5515; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zhao RB, 2000, GENE DEV, V14, P981	21	117	122	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2003	422	6931					527	531		10.1038/nature01519	http://dx.doi.org/10.1038/nature01519			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673251				2022-12-28	WOS:000181965400039
J	Salisbury, A; Law, K; LaGasse, L; Lester, B				Salisbury, A; Law, K; LaGasse, L; Lester, B			Maternal-fetal attachment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREGNANCY		Brown Univ, Women & Infants Hosp, Sch Med, Providence, RI 02903 USA	Brown University; Women & Infants Hospital Rhode Island	Salisbury, A (corresponding author), Brown Univ, Women & Infants Hosp, Sch Med, Providence, RI 02903 USA.		Salisbury, Amy/ABE-6228-2020	Salisbury, Amy/0000-0002-6232-1737				CONDON JT, 1993, BRIT J MED PSYCHOL, V66, P167, DOI 10.1111/j.2044-8341.1993.tb01739.x; Cranley M S, 1984, Birth Defects Orig Artic Ser, V20, P99; CRANLEY MS, 1981, NURS RES, V30, P281, DOI 10.1097/00006199-198109000-00008; ERIKSON M, 1996, ONLINE J KNOWLEDGE S, P3; GRACE JT, 1989, NURS RES, V38, P228; LERUM CW, 1989, BIRTH-ISS PERINAT C, V16, P13, DOI 10.1111/j.1523-536X.1989.tb00848.x; Lindgren K, 2001, RES NURS HEALTH, V24, P203, DOI 10.1002/nur.1023; Muller M E, 1993, West J Nurs Res, V15, P199, DOI 10.1177/019394599301500205; Narita S, 1993, Nihon Kango Kagakkaishi, V13, P1; RIHNDTUFF S, N AM WOMENS LETT DIA; Rubin R, 1975, Matern Child Nurs J, V4, P143; Shieh C, 2001, Kaohsiung J Med Sci, V17, P448; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203	13	60	63	2	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1701	1701		10.1001/jama.289.13.1701	http://dx.doi.org/10.1001/jama.289.13.1701			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	662JX	12672743	Bronze			2022-12-28	WOS:000181944500038
J	Berl, T; Hunsicker, LG; Lewis, JB; Pfeffer, MA; Porush, JG; Rouleau, JL; Drury, PL; Esmatjes, E; Hricik, D; Parikh, CR; Raz, I; Vanhille, P; Wiegmann, TB; Wolfe, BM; Locatelli, F; Goldhaber, SZ; Lewis, EJ				Berl, T; Hunsicker, LG; Lewis, JB; Pfeffer, MA; Porush, JG; Rouleau, JL; Drury, PL; Esmatjes, E; Hricik, D; Parikh, CR; Raz, I; Vanhille, P; Wiegmann, TB; Wolfe, BM; Locatelli, F; Goldhaber, SZ; Lewis, EJ		Collaborative Study Grp	Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy	ANNALS OF INTERNAL MEDICINE			English	Article							CONVERTING-ENZYME-INHIBITION; END-POINT REDUCTION; RANDOMIZED-TRIAL; ANTIHYPERTENSIVE DRUGS; ACE-INHIBITORS; LOSARTAN INTERVENTION; THERAPEUTIC BENEFITS; SWEDISH TRIAL; OLD PATIENTS; HYPERTENSION	Background: Patients with diabetes have increased risk for adverse cardiovascular events. Angiotensin-converting enzyme inhibitors are protective in type 1 diabetes. However, no definitive studies have examined the use of angiotensin-receptor blockers; in patients with type 2 diabetes and overt nephropathy. The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause. Objective: To compare rates of cardiovascular events among patients with type 2 diabetic nephropathy who received conventional anti hypertensive therapy with an angiotensin-receptor blocker (irbesartan) or a calcium-channel blocker (amlodipine), or placebo. Design: Randomized double-blind, placebo-controlled trial with a median follow-up of 2.6 years. A time event analysis was used. Setting: 209 centers in the Americas, Europe, Israel, and Australasia. Participants: 1715 adults with type 2 diabetic nephropathy and hypertension; serum creatinine levels of 89 mumol/L (1.0 mg/dL) to 266 mumol/L (3.0 mg/dL) in women and 106 mumol/L (1.2 mg/dL) to 266 mumol/L (3.0 mg/dL) in men; and urinary protein excretion rates of at least 900 mg/d. Intervention: Treatment with irbesartan, amlodipine, or placebo. Measurements: Time to cardiovascular death, myocardial infarction, congestive heart failure, strokes, and coronary revascularization. Results: The three groups were not statistically different in the composite of cardiovascular events. Among the components of the composite, there was a trend toward a decrease in strokes in patients receiving amlodipine versus those receiving placebo (hazard ratio, 0.65 [95% Cl, 0.35 to 1.22]; P = 0.18). Likewise, patients receiving amlodipine had a significantly lower rate of myocardial infarction when compared with placebo recipients (hazard ratio, 0.58 [Cl, 0.37 to 0.92]; P = 0.02). In contrast, patients receiving irbesartan had a significantly lower incidence of congestive heart failure when compared with placebo recipients (hazard ratio, 0.72 [Cl, 0.52 to 1.00]; P = 0.048) or amlodipine recipients (hazard ratio, 0.65 [Cl, 0.48 to 0.87]; P = 0.004). Conclusion: The composite cardiovascular event rate did not differ in patients with type 2 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conventional anti hypertensive therapy.	Rush Presbyterian St Lukes Med Ctr, Collaborat Study Grp, Chicago, IL 60612 USA; Univ Iowa, Coll Med, Iowa City, IA USA; Univ Colorado, Sch Med, Denver, CO USA; Vanderbilt Univ, Coll Med, Nashville, TN USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Brookdale Univ Hosp, Brooklyn, NY USA; Ctr Med, Brooklyn, NY USA; Univ Toronto, Toronto, ON, Canada; Auckland Diabet Ctr, Auckland, New Zealand; Univ Barcelona, Hosp Clin, Barcelona, Spain; Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; Hadassah Univ, Jerusalem, Israel; Ctr Hosp Valenciennes, Valenciennes, France; Univ Kansas, Ctr Med, Lawrence, KS 66045 USA; Vet Affairs Med Ctr, Coll Hlth Sci, Kansas City, KS USA; Univ Western Ontario, London, ON, Canada; Monzoni Hosp, Lecce, Italy	Rush University; University of Iowa; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Vanderbilt University; Harvard University; Brigham & Women's Hospital; University of Toronto; University of Barcelona; Hospital Clinic de Barcelona; Case Western Reserve University; Hebrew University of Jerusalem; Hadassah University Medical Center; CH de Valenciennes; University of Kansas; University of Kansas Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Western University (University of Western Ontario)	Lewis, EJ (corresponding author), Rush Presbyterian St Lukes Med Ctr, Collaborat Study Grp, 1750 W Harrison,Rawson Bldg,Rm 522, Chicago, IL 60612 USA.	csg@rush.edu	ALMEIDA, FERNANDO/S-1880-2019	ALMEIDA, FERNANDO/0000-0002-9404-9707; Parikh, Chirag/0000-0001-9051-7385; Esmatjes Mompo, Enric/0000-0002-6329-5059				ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Gerstein HC, 2000, LANCET, V355, P253; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Kaplan NM, 2001, ANN INTERN MED, V135, P1079, DOI 10.7326/0003-4819-135-12-200112180-00012; Keane WF, 1999, AM J KIDNEY DIS, V33, P1004, DOI 10.1016/S0272-6386(99)70442-7; Kshirsagar AV, 2000, AM J KIDNEY DIS, V35, P695, DOI 10.1016/S0272-6386(00)70018-7; Lee E. W., 1992, SURVIVAL ANAL STATE, P237, DOI [DOI 10.1007/978-94-015-7983-4_14, 10.1007/978-94-015-7983-4_14]; LEE ET, 1992, STAT METHODS SURVIVA, P67; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Lindholm LH, 2000, J HYPERTENS, V18, P1671, DOI 10.1097/00004872-200018110-00020; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Neal B, 2000, LANCET, V356, P1955; Pahor M, 2000, DIABETES CARE, V23, P888, DOI 10.2337/diacare.23.7.888; Pahor M, 2000, LANCET, V356, P1949, DOI 10.1016/S0140-6736(00)03306-7; Palmer CR, 2001, LANCET, V357, P715, DOI 10.1016/S0140-6736(00)04146-5; Parving HH, 2001, DIABETES CARE, V24, P177, DOI 10.2337/diacare.24.1.177-a; Rodby RA, 2000, NEPHROL DIAL TRANSPL, V15, P487, DOI 10.1093/ndt/15.4.487; Schrier RW, 2002, KIDNEY INT, V61, P1086, DOI 10.1046/j.1523-1755.2002.00213.x; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Tuttle KR, 1999, AM J KIDNEY DIS, V34, P918, DOI 10.1016/S0272-6386(99)70051-X	31	321	337	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					542	549		10.7326/0003-4819-138-7-200304010-00010	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667024				2022-12-28	WOS:000181872100003
J	Davies, HTO; Harrison, S				Davies, HTO; Harrison, S			Trends in doctor-manager relationships	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE; AUTONOMY; CULTURE; UNHAPPY; TRUST; NHS		Univ St Andrews, Ctr Publ Policy & Management, St Andrews KY16 9AL, Fife, Scotland; Univ Manchester, Dept Appl Social Sci, Manchester M13 9PL, Lancs, England	University of St Andrews; University of Manchester	Davies, HTO (corresponding author), Univ St Andrews, Ctr Publ Policy & Management, St Andrews KY16 9AL, Fife, Scotland.	hd@st-and.ac.uk		Davies, Huw/0000-0002-2653-3695				Bate P, 2000, PUBLIC ADMIN, V78, P485, DOI 10.1111/1467-9299.00215; Davies HTO, 2000, QUAL HEALTH CARE, V9, P111, DOI 10.1136/qhc.9.2.111; Davies HTO, 1998, QUAL HEALTH CARE, V7, P159, DOI 10.1136/qshc.7.3.159; Davies HTO, 2003, BMJ-BRIT MED J, V326, P626, DOI 10.1136/bmj.326.7390.626; Degeling P, 2001, Health Serv Manage Res, V14, P36, DOI 10.1258/0951484011912519; Edwards N, 2003, BRIT MED J, V326, P116, DOI 10.1136/bmj.326.7381.116; Edwards N, 2002, BMJ-BRIT MED J, V324, P835, DOI 10.1136/bmj.324.7341.835; Fairfield G, 1997, BRIT MED J, V314, P1895, DOI 10.1136/bmj.314.7098.1895; GREEN S, 1975, SOCIOL REV, V3; Harrison S, 2000, SOCIOLOGY, V34, P129, DOI 10.1017/S0038038500000092; Harrison S, 2002, SOCIOL HEALTH ILL, V24, P208, DOI 10.1111/1467-9566.00291; HARRISON S, 1994, PUBLIC MONEY MANAGE, V14, P39, DOI 10.1080/09540969409387800; HARRISON S, IN PRESS ROUTLEDGE E; Harrison S., 2003, CLIN GOVERNANCE, V8, P13; Harrison S, 1992, JUST MANAGING POWER; Harrison S., 2002, BRIT J POLIT INT REL, V4, P1, DOI DOI 10.1111/1467-856X.41068; Hearing S, 1999, Health Serv Manage Res, V12, P227; HOOD C, 1995, PUBLIC FINANCE FDN R, V7, P3; MCLELLAN AA, 2002, HLTH SERV J     1114, P18; Newman K, 1996, Health Manpow Manage, V22, P32, DOI 10.1108/09552069610113363; Putnam, 1998, DECENTRALISING PUBLI; SCHULZ R, 1983, TEAMS TOP MANAGERS N; Smith R, 2001, BMJ-BRIT MED J, V322, P1073, DOI 10.1136/bmj.322.7294.1073; Thorne M L, 1997, Health Serv Manage Res, V10, P205; Walshe K, 2002, BRIT MED J, V324, P967, DOI 10.1136/bmj.324.7343.967; Willcocks S, 1999, Health Serv Manage Res, V12, P212	26	91	91	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	2003	326	7390					646	649		10.1136/bmj.326.7390.646	http://dx.doi.org/10.1136/bmj.326.7390.646			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	661BF	12649243	Green Published, Green Submitted			2022-12-28	WOS:000181870800023
J	Grantham-McGregor, S				Grantham-McGregor, S			Learning the hard way	LANCET			English	Editorial Material									Inst Child Hlth, Ctr Int Child Hlth, London WC1N 1EH, England	University of London; University College London	Grantham-McGregor, S (corresponding author), Inst Child Hlth, Ctr Int Child Hlth, 30 Guilford St, London WC1N 1EH, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					1044	1044		10.1016/S0140-6736(03)12832-2	http://dx.doi.org/10.1016/S0140-6736(03)12832-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660073				2022-12-28	WOS:000181699700025
J	Peggs, K; Mackinnon, S				Peggs, K; Mackinnon, S			Imatinib mesylate - The new gold standard for treatment of chronic myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ABL TYROSINE KINASE; INTERFERON-ALPHA; CHRONIC-PHASE; INHIBITOR; RESPONSES; EFFICACY; CELLS		UCL Royal Free & UCL Med Sch, London, England	University of London; University College London	Peggs, K (corresponding author), UCL Royal Free & UCL Med Sch, London, England.		Mackinnon, Stephen/C-5559-2008; PEGGS, Karl/B-3869-2009					Branford S, 2002, BLOOD, V100, p96A; Delannoy A, 1997, J NATL CANCER I, V89, P1616; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2001, NEW ENGL J MED, V345, P232; Goldman J, 2001, SEMIN HEMATOL, V38, P28, DOI 10.1053/shem.2001.27081; Gratwohl A, 1998, LANCET, V352, P1087, DOI 10.1016/S0140-6736(98)03030-X; Hasford J, 1998, JNCI-J NATL CANCER I, V90, P850, DOI 10.1093/jnci/90.11.850; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Tipping AJ, 2002, LEUKEMIA, V16, P2349, DOI 10.1038/sj.leu.2402775	10	126	137	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					1048	1050		10.1056/NEJMe030009	http://dx.doi.org/10.1056/NEJMe030009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653YT	12637616				2022-12-28	WOS:000181465200011
J	Melosh, NA; Boukai, A; Diana, F; Gerardot, B; Badolato, A; Petroff, PM; Heath, JR				Melosh, NA; Boukai, A; Diana, F; Gerardot, B; Badolato, A; Petroff, PM; Heath, JR			Ultrahigh-density nanowire lattices and circuits	SCIENCE			English	Article							LITHOGRAPHY	We describe a general method for producing ultrahigh-density arrays of aligned metal and semiconductor nanowires and nanowire circuits. The technique is based on translating thin film growth thickness control into planar wire arrays. Nanowires were fabricated with diameters and pitches (center-to-center distances) as small as 8 nanometers and 16 nanometers, respectively. The nanowires have high aspect ratios (up to 10(6)), and the process can be carried out multiple times to produce simple circuits of crossed nanowires with a nanowire junction density in excess of 10(11) per square centimeter. The nanowires can also be used in nanomechanical devices; a high-frequency nanomechanical resonator is demonstrated.	Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA 90095 USA; CALTECH, Pasadena, CA 91125 USA; Univ Calif Santa Barbara, Calif Nanosyst Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Los Angeles; California Institute of Technology; University of California System; University of California Santa Barbara	Heath, JR (corresponding author), Univ Calif Los Angeles, Calif Nanosyst Inst, Box 956905, Los Angeles, CA 90095 USA.	heath@caltech.edu	Badolato, Antonio/E-9778-2015; Petroff, Pierre/M-9840-2019; Gerardot, Brian D./AHB-1102-2022; Gerardot, Brian D/D-2418-2009	Gerardot, Brian D/0000-0002-0279-898X; Badolato, Antonio/0000-0001-8266-2902				Bachtold A, 2001, SCIENCE, V294, P1317, DOI 10.1126/science.1065824; Chou SY, 1996, SCIENCE, V272, P85, DOI 10.1126/science.272.5258.85; Cleland AN, 2002, J APPL PHYS, V92, P2758, DOI 10.1063/1.1499745; Diehl MR, 2002, ANGEW CHEM INT EDIT, V41, P353, DOI 10.1002/1521-3773(20020118)41:2<353::AID-ANIE353>3.0.CO;2-Y; Heath JR, 1998, SCIENCE, V280, P1716, DOI 10.1126/science.280.5370.1716; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; Huang Y, 2001, SCIENCE, V294, P1313, DOI 10.1126/science.1066192; KUEKEN PJ, 2001, Patent No. 6256767; Luo Y, 2002, CHEMPHYSCHEM, V3, P519, DOI 10.1002/1439-7641(20020617)3:6<519::AID-CPHC519>3.0.CO;2-2; Mohanty P, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.085416; Vieu C, 2000, APPL SURF SCI, V164, P111, DOI 10.1016/S0169-4332(00)00352-4; Xia YN, 1996, SCIENCE, V273, P347, DOI 10.1126/science.273.5273.347	12	750	825	3	222	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					112	115		10.1126/science.1081940	http://dx.doi.org/10.1126/science.1081940			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12637672				2022-12-28	WOS:000181988900043
J	Kato, GJ; Loeb, DM				Kato, GJ; Loeb, DM			Tumor pseudosyncytiae	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University	Kato, GJ (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.		Kato, Gregory J/I-7615-2014	Kato, Gregory J/0000-0003-4465-3217					0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1348	1348		10.1056/NEJMicm980667	http://dx.doi.org/10.1056/NEJMicm980667			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672862				2022-12-28	WOS:000181949100006
J	Juurlink, DN; Mamdani, M; Kopp, A; Laupacis, A; Redelmeier, DA				Juurlink, DN; Mamdani, M; Kopp, A; Laupacis, A; Redelmeier, DA			Drug-drug interactions among elderly patients hospitalized for drug toxicity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual North American Congress of Clinical Toxicology	SEP 24-29, 2002	PALM SPRINGS, CA				CONVERTING ENZYME-INHIBITORS; DIGOXIN TOXICITY; P-GLYCOPROTEIN; CISAPRIDE; CLARITHROMYCIN; HYPERKALEMIA; ASSOCIATION; EVENTS; CYP2C9; SULFAMETHOXAZOLE	Context Drug-drug interactions are a preventable cause of morbidity and mortality, yet their consequences in the community are not well characterized. Objective To determine whether elderly patients admitted to hospital with specific drug toxicities were likely to have been,prescribed an interacting drug in the week prior to admission. Design Three population-based, nested case-control studies. Setting Ontario, Canada, from January 1, 1994, to December 31, 2000. Patients All Ontario residents aged 66 years or older treated with glyburide, digoxin, or an angiotensin-converting enzyme (ACE) inhibitor. Case patients were those admitted to hospital for drug-related toxicity. Prescription records of cases were compared with those of controls (matched on age, sex, use of the same medication, and presence or absence of renal disease) for receipt of interacting medications (co-trimoxazole with glyburide, clarithromycin with digoxin, and potassium-sparing diuretics with ACE inhibitors). Main Outcome Measure Odds ratio for association between hospital admission for drug toxicity (hypoglycemia, digoxin toxicity, or hyperkalemia, respectively) and use of an interacting medication in the preceding-week, adjusted for diagnoses, receipt of other medications, the number of prescription drugs, and the number of hospital admissions in the year preceding the index date. Results During the 7-year study period, 909 elderly patients receiving glyburide were admitted with a diagnosis of hypoglycemia. In the primary analysis, those patients admitted for hypoglycemia were more than 6 times as likely to have been treated with co-trimoxazole in the previous week (adjusted odds ratio, 6.6; 95% confidence interval, 4.5-9.7). Patients admitted with digoxin toxicity (n=1051) were about 12 times more likely to have been treated with clarithromycin (adjusted odds ratio, 11.7; 95% confidence interval, 7.5-18.2) in the previous week, and patients treated with ACE inhibitors admitted with a diagnosis of hyperkalemia (n=523) were about 20 times more likely to have been treated with a potassium-sparing diuretic (adjusted odds ratio, 20.3; 95% confidence interval, 13.4-30.7) in the previous week. No increased risk of drug toxicity was found for drugs with similar indications but no known interactions (amoxicillin, cefuroxime, and indapamide, respectively). Conclusions Many hospital admissions of elderly patients for drug toxicity occur after administration of a drug known to cause drug-drug interactions. Many of these interactions could have been avoided.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Clin Epidemiol & Healthcare Res Program, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Pharm, Toronto, ON M4N 3M5, Canada; Inst Clin Evaluat Sci, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Juurlink, DN (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, G Wing 106,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	david.juurlink@ices.on.ca						Ahuja TS, 2000, AM J NEPHROL, V20, P268, DOI 10.1159/000013599; Alvarez-Requejo A, 1998, EUR J CLIN PHARMACOL, V54, P483, DOI 10.1007/s002280050498; Atkin PA, 1999, DRUG AGING, V14, P141, DOI 10.2165/00002512-199914020-00005; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; BRIAN WR, 2000, METABOLIC DRUG INTER, P529; Brown BA, 1997, CLIN INFECT DIS, V24, P92, DOI 10.1093/clinids/24.1.92; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; CHRISTENSEN LK, 1969, ACTA DIABETOLOGICA S, V1, P116; Crighton EJ, 2001, BMC HEALTH SERV RES, V1, DOI 10.1186/1472-6963-1-7; Del Fiol G, 2000, J AM MED INFORM ASSN, P171; DUSSUSKE LM, 1999, CLIN THER, V21, P281; Efron B., 1994, MONOGRAPHS STAT APPL; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Glassman PA, 2002, MED CARE, V40, P1161, DOI 10.1097/00005650-200212000-00004; Gooderham MJ, 1999, ANN PHARMACOTHER, V33, P796, DOI 10.1345/aph.18330; Guerriero SE, 1997, PHARMACOTHERAPY, V17, P1035; Guzey C, 2002, DRUG SAFETY, V25, P553; Halkin H, 2001, CLIN PHARMACOL THER, V69, P260, DOI 10.1067/mcp.2001.114228; Hansten P D, 2001, J Am Pharm Assoc (Wash), V41, P161; Hazlet T K, 2001, J Am Pharm Assoc (Wash), V41, P200; Heeley E, 2001, LANCET, V358, P1872, DOI 10.1016/S0140-6736(01)06898-2; Jha AK, 2001, PHARMACOEPIDEM DR S, V10, P113, DOI 10.1002/pds.568; JOHNSON JF, 1990, DICP ANN PHARMAC, V24, P250, DOI 10.1177/106002809002400307; Jones JK, 2001, JAMA-J AM MED ASSOC, V286, P1607, DOI 10.1001/jama.286.13.1607; KIFOR I, 1991, ENDOCRINOLOGY, V129, P823, DOI 10.1210/endo-129-2-823; Kirchheiner J, 2002, CLIN PHARMACOL THER, V71, P286, DOI 10.1067/mcp.2002.122476; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; Koren G, 1998, VET HUM TOXICOL, V40, P45; Langdorf MI, 2000, ACAD EMERG MED, V7, P1321, DOI 10.1111/j.1553-2712.2000.tb00483.x; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lehmann DF, 2000, J CLIN PHARMACOL, V40, P939, DOI 10.1177/00912700022009675; Mamdani MM, 2000, CAN MED ASSOC J, V162, P1421; Mamdani MM, 2000, AM J MED, V108, P418, DOI 10.1016/S0002-9343(99)00452-0; Michalets EL, 2000, CLIN PHARMACOKINET, V39, P49, DOI 10.2165/00003088-200039010-00004; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; Moride Y, 1997, BRIT J CLIN PHARMACO, V43, P177, DOI 10.1046/j.1365-2125.1997.05417.x; Niemi M, 2002, CLIN PHARMACOL THER, V72, P326, DOI 10.1067/mcp.2002.127495; Peterson J F, 2001, J Am Pharm Assoc (Wash), V41, P159; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Potasman I, 1980, Harefuah, V98, P78; *PRACT MAN INF COR, 2003, INT CLASS DIS; Ray JG, 2001, ARCH INTERN MED, V161, P1405, DOI 10.1001/archinte.161.11.1405; Reardon LC, 1998, ARCH INTERN MED, V158, P26, DOI 10.1001/archinte.158.1.26; Roberts RL, 2002, NEW ZEAL MED J, V115, P137; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Roden DM, 2002, NAT REV DRUG DISCOV, V1, P37, DOI 10.1038/nrd705; Rosholm JU, 1998, DAN MED BULL, V45, P210; Schepkens H, 2001, AM J MED, V110, P438, DOI 10.1016/S0002-9343(01)00642-8; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Seymour RM, 1998, DRUG AGING, V12, P485, DOI 10.2165/00002512-199812060-00006; Shaoul R, 2002, PEDIATRICS, V109, P1118, DOI 10.1542/peds.109.6.1118; Shapiro LE, 1999, CAN MED ASSOC J, V161, P1266; Statistics Canada, 2010, POP AG GROUP; Tamblyn RM, 1996, CAN MED ASSOC J, V154, P1177; Wakasugi H, 1998, CLIN PHARMACOL THER, V64, P123, DOI 10.1016/S0009-9236(98)90030-3; Weideman RA, 1999, AM J HEALTH-SYST PH, V56, P1524, DOI 10.1093/ajhp/56.15.1524; Wen X, 2002, DRUG METAB DISPOS, V30, P631, DOI 10.1124/dmd.30.6.631; Wynn Richard L., 1993, General Dentistry, V41, P27; Wysowski DK, 1996, NEW ENGL J MED, V335, P290, DOI 10.1056/NEJM199607253350416; Wysowski DK, 2001, AM J GASTROENTEROL, V96, P1698, DOI 10.1016/S0002-9270(01)02490-X; ZECHNICH AD, 1994, WESTERN J MED, V160, P321	65	493	512	1	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1652	1658		10.1001/jama.289.13.1652	http://dx.doi.org/10.1001/jama.289.13.1652			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	662JX	12672733	Green Published			2022-12-28	WOS:000181944500028
J	Chapman, S; Reeve, E; Rajaratnam, G; Neary, R				Chapman, S; Reeve, E; Rajaratnam, G; Neary, R			Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care	BRITISH MEDICAL JOURNAL			English	Article							MS		Univ Keele, Dept Med Management, Keele ST5 5BG, Staffs, England; N Stoke Primary Care Trust, Stoke On Trent ST4 4LX, Staffs, England; S Stoke Primary Care Trust, Stoke On Trent ST4 4LX, Staffs, England; N Staffordshire Hosp NHS Trust, Cent Pathol Lab, Stoke On Trent ST4 7PA, Staffs, England	Keele University; University Hospital of North Staffordshire NHS Trust	Chapman, S (corresponding author), Univ Keele, Dept Med Management, Keele ST5 5BG, Staffs, England.	s.r.chapman@keele.ac.uk						BELLINGHAM C, 2001, PHARM J, V267, P672; *DEP HLTH, 2001, NAT SERV FRAM COR HE; *DEP HLTH, 1999, SAV LIV OUR HLTH NAT; Little R, 2002, BRIT MED J, V324, P316; Mayor S, 2001, BRIT MED J, V323, P1087, DOI 10.1136/bmj.323.7321.1087; *N STAFF HLTH AUTH, 2001, HLTH WELL BEING IMPR; *N STAFF HLTH AUTH, 2000, CLOS GAP HLTH IN N S; RICHARDS RG, GUARANTEED OUTCOMES; *STAND MED ADV COM, 1997, USE STAT; Taylor D, 2001, BRIT MED J, V323, P1379, DOI 10.1136/bmj.323.7326.1379; Wood D, 1998, HEART, V80, pS1	11	29	31	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 29	2003	326	7391					707	709		10.1136/bmj.326.7391.707	http://dx.doi.org/10.1136/bmj.326.7391.707			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663WL	12663411	Green Published			2022-12-28	WOS:000182029500029
J	Leizerson, I; Lipson, SG; Lyushnin, AV				Leizerson, I; Lipson, SG; Lyushnin, AV			When larger drops evaporate faster	NATURE			English	Article							FILMS; SYSTEMS; APOLAR		Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel; Perm State Pedag Univ, Dept Theoret Phys, Perm 614600, Russia	Technion Israel Institute of Technology; Perm State Humanitarian Pedagogical University	Leizerson, I (corresponding author), Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel.							BROCHARDWYATT E, 1995, SOFT MATTER PHYSICS, P7; CAZABAT AM, 1987, CONTEMP PHYS, V28, P347, DOI 10.1080/00107518708224600; DEGENNES PG, 1985, REV MOD PHYS, V57, P325; ELBAUM M, 1994, PHYS REV LETT, V72, P3562, DOI 10.1103/PhysRevLett.72.3562; IHLE T, 1993, PHYS REV LETT, V70, P3083, DOI 10.1103/PhysRevLett.70.3083; ISRAELACHVILL J, 1992, INTERMOLECULAR SURFA; McHale G, 1998, J PHYS CHEM B, V102, P1964, DOI 10.1021/jp972552i; Samid-Merzel N, 1998, PHYS REV E, V57, P2906, DOI 10.1103/PhysRevE.57.2906; Schafle C, 1999, PHYS REV LETT, V83, P5302, DOI 10.1103/PhysRevLett.83.5302; SHARMA A, 1993, LANGMUIR, V9, P3580, DOI 10.1021/la00036a038; SHARMA A, 1993, J COLLOID INTERF SCI, V161, P190, DOI 10.1006/jcis.1993.1458	11	24	26	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					395	396		10.1038/422395b	http://dx.doi.org/10.1038/422395b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660771				2022-12-28	WOS:000181801200032
J	Mendell, JR; Sahenk, Z				Mendell, JR; Sahenk, Z			Painful sensory neuropathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIABETIC PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; SMALL-FIBER NEUROPATHY; DOUBLE-BLIND; POSTHERPETIC NEURALGIA; SYMPTOMATIC TREATMENT; TOPICAL CAPSAICIN; DOSE-RESPONSE; MEXILETINE; POLYNEUROPATHY		Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Mendell, JR (corresponding author), Ohio State Univ, Dept Neurol, Rm 445,Means Hall,1654 Upham Dr, Columbus, OH 43210 USA.							Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001/jama.280.21.1831; Beydoun Ahmad, 2002, Expert Opin Pharmacother, V3, P59, DOI 10.1517/14656566.3.1.59; Chadda V S, 1978, J Assoc Physicians India, V26, P403; COOK RJ, 1995, BRIT MED J, V310, P1056; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; DEJGARD A, 1988, LANCET, V1, P9; DONOFRIO P, 1991, ARCH INTERN MED, V151, P2225; Dyck PJ, 1999, MUSCLE NERVE, V22, P659, DOI 10.1002/(SICI)1097-4598(199906)22:6<659::AID-MUS1>3.0.CO;2-X; Ertas M, 1998, PAIN, V75, P257, DOI 10.1016/S0304-3959(98)00003-7; Gorson KC, 1999, J NEUROL NEUROSUR PS, V66, P251, DOI 10.1136/jnnp.66.2.251; Hamza MA, 2000, DIABETES CARE, V23, P365, DOI 10.2337/diacare.23.3.365; Harati Y, 1998, NEUROLOGY, V50, P1842, DOI 10.1212/WNL.50.6.1842; Holland NR, 1997, NEUROLOGY, V48, P708, DOI 10.1212/WNL.48.3.708; KASTRUP J, 1987, PAIN, V28, P69, DOI 10.1016/0304-3959(87)91061-X; Kemper CA, 1998, J ACQ IMMUN DEF SYND, V19, P367, DOI 10.1097/00042560-199812010-00007; Kieburtz K, 1998, NEUROLOGY, V51, P1682, DOI 10.1212/WNL.51.6.1682; Kumar D, 1997, DIABETES CARE, V20, P1702, DOI 10.2337/diacare.20.11.1702; Lacomis D, 2002, MUSCLE NERVE, V26, P173, DOI 10.1002/mus.10181; LOW PA, 1995, PAIN, V62, P163, DOI 10.1016/0304-3959(94)00261-C; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; McCleane GJ, 1999, ANESTH ANALG, V89, P985, DOI 10.1097/00000539-199910000-00030; McQuay HJ, 1996, PAIN, V68, P217, DOI 10.1016/S0304-3959(96)03140-5; MCQUAY HJ, 1993, ANAESTHESIA, V48, P281, DOI 10.1111/j.1365-2044.1993.tb06943.x; Mendell JR, 2001, NEUROLOGY, V56, P445, DOI 10.1212/WNL.56.4.445; Morello CM, 1999, ARCH INTERN MED, V159, P1931, DOI 10.1001/archinte.159.16.1931; Nelson KA, 1997, NEUROLOGY, V48, P1212, DOI 10.1212/WNL.48.5.1212; Novak V, 2001, CLIN AUTON RES, V11, P357, DOI 10.1007/BF02292767; Oh SJ, 1999, NEUROL CLIN, V17, P593, DOI 10.1016/S0733-8619(05)70154-7; Oskarsson P, 1997, DIABETES CARE, V20, P1594, DOI 10.2337/diacare.20.10.1594; Paice JA, 2000, J PAIN SYMPTOM MANAG, V19, P45, DOI 10.1016/S0885-3924(99)00139-6; Periquet MI, 1999, NEUROLOGY, V53, P1641, DOI 10.1212/WNL.53.8.1641; Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420; RULL JA, 1969, DIABETOLOGIA, V5, P215, DOI 10.1007/BF01212087; Salvarani C, 2002, NEW ENGL J MED, V347, P261, DOI 10.1056/NEJMra011913; Sang CN, 2002, ANESTHESIOLOGY, V96, P1053, DOI 10.1097/00000542-200205000-00005; SAUDEK CD, 1977, CLIN PHARMACOL THER, V22, P196; SCHEFFLER NM, 1991, J AM PODIAT MED ASSN, V81, P288, DOI 10.7547/87507315-81-6-288; Semenchuk MR, 2001, NEUROLOGY, V57, P1583, DOI 10.1212/WNL.57.9.1583; Shlay JC, 1998, JAMA-J AM MED ASSOC, V280, P1590, DOI 10.1001/jama.280.18.1590; Simpson DM, 2000, NEUROLOGY, V54, P2115, DOI 10.1212/WNL.54.11.2115; Sindrup SH, 1999, PAIN, V83, P389, DOI 10.1016/S0304-3959(99)00154-2; SINDRUP SH, 1990, PAIN, V42, P135, DOI 10.1016/0304-3959(90)91157-E; SINDRUP SH, 1992, CLIN PHARMACOL THER, V52, P547, DOI 10.1038/clpt.1992.183; Sindrup SH, 1999, PAIN, V83, P85, DOI 10.1016/S0304-3959(99)00079-2; Sindrup SH, 2000, NEUROLOGY, V55, P915, DOI 10.1212/WNL.55.7.915; STEWART JD, 1992, MUSCLE NERVE, V15, P661, DOI 10.1002/mus.880150605; STRACKE H, 1992, DIABETES CARE, V15, P1550, DOI 10.2337/diacare.15.11.1550; TANDAN R, 1992, DIABETES CARE, V15, P8, DOI 10.2337/diacare.15.1.8; Tasmuth T, 2002, EUR J PAIN-LONDON, V6, P17, DOI 10.1053/eujp.2001.0266; Watson CPN, 1998, NEUROLOGY, V50, P1837; Wright JM, 1997, ANN PHARMACOTHER, V31, P29, DOI 10.1177/106002809703100103	51	168	181	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2003	348	13					1243	1255		10.1056/NEJMcp022282	http://dx.doi.org/10.1056/NEJMcp022282			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659RG	12660389				2022-12-28	WOS:000181790800007
J	Nash, D; Magder, L; Lustberg, M; Sherwin, RW; Rubin, RJ; Kaufmann, RB; Silbergeld, EK				Nash, D; Magder, L; Lustberg, M; Sherwin, RW; Rubin, RJ; Kaufmann, RB; Silbergeld, EK			Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NUTRITION EXAMINATION SURVEY; BONE-MINERAL CONTENT; 3RD NATIONAL-HEALTH; MIDDLE-AGED WOMEN; CARDIOVASCULAR-DISEASE; UNITED-STATES; POPULATION; EXPOSURE; RISK; OSTEOPOROSIS	Context Lead exposures have been shown to be associated with increased blood pressure and risk of hypertension in older men. In perimenopausal women, skeletal lead stores are an important source of endogenous lead exposure due to increased bone demineralization. Objective To examine the relationship of blood lead level with blood pressure and hypertension prevalence in a population-based sample of perimenopausal and postmenopausal women in the United States. Design, Setting, and Participants Cross-sectional sample of 2165 women aged 40 to 59 years, who participated in a household interview and physical examination, from the Third National Health and Nutrition Examination Survey conducted from 1988 to 1994. Main Outcome Measures Associations of blood lead with blood pressure and hypertension, with age, race and ethnicity, cigarette smoking status, body mass index, alcohol use, and kidney function as covariates. Results A change in blood lead levels from the lowest (quartile 1: range, 0.5-1.6 mug/dL) to the highest (quartile 4: range, 4.0-31.1 mug/dL) was associated with small statistically significant adjusted changes in systolic and diastolic blood pressures. Women in quartile 4 had increased risks of diastolic (>90 mm Hg) hypertension (adjusted odds ratio [OR], 3.4; 95% confidence interval [CI], 1.3-8.7), as well as moderately increased risks for general hypertension (adjusted OR, 1.4; 95% CI, 0.92-2.0) and systolic (>140 mm Hg) hypertension (adjusted OR, 1.5; 95% CI, 0.72-3.2). This association was strongest in postmenopausal women in whom adjusted ORs for diastolic hypertension increased with increasing quartile of blood lead level compared with quartile 1 (adjusted OR, 4.6; 95% CI, 1.1-19.2 for quartile 2; adjusted OR, 5.9; 95% CI, 1.5-23.1 for quartile 3; adjusted OR, 8.1; 95% CI, 2.6-24.7 for quartile 4). Conclusions At levels well below the current US occupational exposure limit guidelines (40 mug/dL); blood lead level is positively associated with both systolic and diastolic blood pressure and risks of both systolic and diastolic hypertension among women aged 40 to 59 years. The relationship between blood lead level and systolic and diastolic hypertension is most pronounced in postmenopausal women. These results provide support for continued efforts to reduce lead levels in the general population, especially women.	New York City Dept Hlth & Mental Hyg, HIV AIDS Surveillance & Epidemiol Program, New York, NY 10013 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA	New York City Department of Health & Mental Hygiene; University System of Maryland; University of Maryland Baltimore; Tulane University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Centers for Disease Control & Prevention - USA	Nash, D (corresponding author), New York City Dept Hlth & Mental Hyg, HIV AIDS Surveillance & Epidemiol Program, 346 Broadway,Room 706, New York, NY 10013 USA.		Nash, Denis/AFI-7485-2022; Lustberg, Mark/AAO-9924-2020	Nash, Denis/0000-0002-3280-5386	ATSDR CDC HHS [TS-288-14/14] Funding Source: Medline	ATSDR CDC HHS		BATUMAN V, 1983, NEW ENGL J MED, V309, P17, DOI 10.1056/NEJM198307073090104; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Cake KM, 1996, AM J IND MED, V29, P440, DOI 10.1002/(SICI)1097-0274(199605)29:5<440::AID-AJIM2>3.0.CO;2-Q; Cowley AW, 1996, JAMA-J AM MED ASSOC, V275, P1581, DOI 10.1001/jama.275.20.1581; ELWOOD PC, 1988, ENVIRON HEALTH PERSP, V78, P119, DOI 10.2307/3430511; ELWOOD PC, 1988, AM J EPIDEMIOL, V127, P942, DOI 10.1093/oxfordjournals.aje.a114897; EZZATI T, 1992, PUBLICATION PHS; GRANDJEAN P, 1992, SCAND J CLIN LAB INV, V52, P321, DOI 10.3109/00365519209088366; GRANDJEAN P, 1989, AM J EPIDEMIOL, V129, P732, DOI 10.1093/oxfordjournals.aje.a115188; GULSON BL, 1995, J LAB CLIN MED, V125, P703; Gulson BL, 1997, J LAB CLIN MED, V130, P51, DOI 10.1016/S0022-2143(97)90058-5; HARLAN WR, 1985, JAMA-J AM MED ASSOC, V253, P530, DOI 10.1001/jama.253.4.530; HARLAN WR, 1988, ENVIRON HEALTH PERSP, V78, P9; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; HENSE HW, 1993, EPIDEMIOLOGY, V4, P173, DOI 10.1097/00001648-199303000-00014; HENSE HW, 1994, EPIDEMIOLOGY, V5, P120, DOI 10.1097/00001648-199401000-00018; HERTZPICCIOTTO I, 1993, EPIDEMIOL REV, V15, P352, DOI 10.1093/oxfordjournals.epirev.a036125; Hu FB, 2002, AM J CARDIOL, V90, p26F, DOI 10.1016/S0002-9149(01)02219-6; Hu H, 1998, ENVIRON HEALTH PERSP, V106, P1, DOI 10.2307/3433626; Hu H, 1996, JAMA-J AM MED ASSOC, V275, P1171, DOI 10.1001/jama.275.15.1171; Kim R, 1996, JAMA-J AM MED ASSOC, V275, P1177, DOI 10.1001/jama.275.15.1177; KNIGHT EM, 1994, J NUTR, V124, pS943, DOI 10.1093/jn/124.suppl_6.943S; KOPP SJ, 1988, ENVIRON HEALTH PERSP, V78, P91, DOI 10.2307/3430507; Korrick SA, 1999, AM J PUBLIC HEALTH, V89, P330, DOI 10.2105/AJPH.89.3.330; KROLNER B, 1982, CLIN SCI, V62, P329, DOI 10.1042/cs0620329; LAGERKVIST BJ, 1993, SCAND J WORK ENV HEA, V19, P50; LINDQUIST O, 1981, SCAND J CLIN LAB INV, V41, P215, DOI 10.3109/00365518109092037; LINDSAY R, 1976, LANCET, V1, P1038; Lustberg M, 2002, ARCH INTERN MED, V162, P2443, DOI 10.1001/archinte.162.21.2443; MOLLER L, 1992, AM J EPIDEMIOL, V136, P1091, DOI 10.1093/oxfordjournals.aje.a116574; MULDOON SB, 1994, AM J EPIDEMIOL, V139, P599, DOI 10.1093/oxfordjournals.aje.a117049; MULDOON SB, 1997, SOC EP RES JUN CALG; Nash D, 1998, AM J EPIDEMIOL, V147, pS93; NERI LC, 1988, ENVIRON HEALTH PERSP, V78, P123, DOI 10.2307/3430512; NORDIN BEC, 1983, OSTEOPOROTIC SYNDROM; NOWACK R, 1993, EUR J CLIN INVEST, V23, P433, DOI 10.1111/j.1365-2362.1993.tb00787.x; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; POCOCK SJ, 1988, ENVIRON HEALTH PERSP, V78, P23, DOI 10.2307/3430494; Proctor SP, 1996, INT J EPIDEMIOL, V25, P528, DOI 10.1093/ije/25.3.528; Reckelhoff JF, 2001, HYPERTENSION, V37, P1199, DOI 10.1161/01.HYP.37.5.1199; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; SCHWARTZ J, 1995, ARCH ENVIRON HEALTH, V50, P31, DOI 10.1080/00039896.1995.9955010; SCHWARTZ J, 1991, ENVIRON HEALTH PERSP, V91, P71, DOI 10.2307/3430985; SCHWARTZ J, 1988, ENVIRON HEALTH PERSP, V78, P15, DOI 10.2307/3430493; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; SHARP DS, 1990, AM J EPIDEMIOL, V131, P845, DOI 10.1093/oxfordjournals.aje.a115575; SHARP DS, 1989, ARCH ENVIRON HEALTH, V44, P18, DOI 10.1080/00039896.1989.9935867; SHARP DS, 1988, ENVIRON HEALTH PERSP, V78, P131, DOI 10.2307/3430514; Silbergeld E., 1995, FUNDAM APPL TOXICOL, V25, P167; SILBERGELD E, 2001, PROGR ENV SCI, V1, P53; SILBERGELD EK, 1988, ENVIRON RES, V47, P79, DOI 10.1016/S0013-9351(88)80023-9; Smith DR, 1996, ENVIRON HEALTH PERSP, V104, P60, DOI 10.2307/3432761; STAESSEN J, 1991, J HUM HYPERTENS, V5, P485; Staessen J, 1995, Verh K Acad Geneeskd Belg, V57, P527; Staessen JA, 1998, J HUM HYPERTENS, V12, P587, DOI 10.1038/sj.jhh.1000670; Staessen JA, 1996, JAMA-J AM MED ASSOC, V275, P1563, DOI 10.1001/jama.275.20.1563; SYMANSKI E, 1995, AM J EPIDEMIOL, V141, P1047, DOI 10.1093/oxfordjournals.aje.a117369; VANDER AJ, 1988, ENVIRON HEALTH PERSP, V78, P77, DOI 10.2307/3430505; Webber CE, 1995, ENVIRON HEALTH PERSP, V103, P1150, DOI 10.2307/3432612; West WL, 1994, J NUTR, V124, P981	62	180	182	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2003	289	12					1523	1532		10.1001/jama.289.12.1523	http://dx.doi.org/10.1001/jama.289.12.1523			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659XE	12672769	Bronze			2022-12-28	WOS:000181803100030
J	Crosson, FJ				Crosson, FJ			Kaiser Permanente: a propensity for partnership	BRITISH MEDICAL JOURNAL			English	Article									Permanente Federat, Oakland, CA 94612 USA		Crosson, FJ (corresponding author), Permanente Federat, 1 Kaiser Plaza,27L, Oakland, CA 94612 USA.	jay.Crosson@KP.org							0	22	22	1	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 22	2003	326	7390					654	654		10.1136/bmj.326.7390.654	http://dx.doi.org/10.1136/bmj.326.7390.654			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649248	Green Published			2022-12-28	WOS:000181870800027
J	Spies, M; Herndon, DN; Rosenblatt, J; Sanford, AP; Wolf, SE				Spies, M; Herndon, DN; Rosenblatt, J; Sanford, AP; Wolf, SE			Prediction of mortality from catastrophic burns in children	LANCET			English	Article; Proceedings Paper	33rd Annual Meeting of the American-Burn-Association	APR 18-21, 2001	BOSTON, MASSACHUSETTS	Amer Burn Assoc			80-PERCENT; OUTCOMES; TBSA	Background We previously developed a model to predict survival in massive paediatric burns (>80% total body surface area [TBSA]). This model included not only demographic variables, but also variables obtained throughout the hospital course. We aimed to prospectively validate our model for accuracy of outcome prediction. Methods We admitted 33 paediatric burn patients with burns greater than 80% TBSA. We recorded age, burn size, inhalation injury, resuscitation, packed-cell volume at admission, base deficit, serum osmolarity, sepsis, inotropic support, platelet count, creatinine, and ventilator dependency. We entered these data into our previous models. Results 20 male and 13 female children with mean age 7.6 (SD 1) years with TBSA burns of 88% (SD 1; full thickness 86% [SD 1]) were admitted. Mortality was 39.4% (13 of 30). When all variables were integrated into our final model, we predicted outcome with 97% accuracy. When we used a model based only on demographic characteristics of age, burn size, and presence of inhalation injury, outcome was correctly predicted in only 51% of patients. Conclusions We show prospectively that mortality in severely burned children can be reliably estimated at a burn centre, and that outcome cannot be reliably predicted on the basis of demographic and injury characteristics alone. These data suggest that all severely burned children should be given a course of treatment before consideration of treatment futility.	Shriners Hosp Children, Galveston, TX 77550 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Wolf, SE (corresponding author), Shriners Hosp Children, 815 Market St, Galveston, TX 77550 USA.		Herndon, David/AAC-3354-2020	Wolf, Steven/0000-0003-2972-3440				BAUX S, 1989, BURNS, V15, P239, DOI 10.1016/0305-4179(89)90039-9; Blakeney P, 1998, J TRAUMA, V44, P625, DOI 10.1097/00005373-199804000-00011; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Meyers-Paal R, 2000, J BURN CARE REHABIL, V21, P43, DOI 10.1097/00004630-200021010-00009; O'Keefe GE, 2001, J AM COLL SURGEONS, V192, P153, DOI 10.1016/S1072-7515(00)00785-7; Ryan CM, 1998, NEW ENGL J MED, V338, P362, DOI 10.1056/NEJM199802053380604; Saffle Jeffrey R., 1995, Journal of Burn Care and Rehabilitation, V16, P219, DOI 10.1097/00004630-199505000-00002; SMITH DL, 1994, J TRAUMA, V37, P655, DOI 10.1097/00005373-199410000-00021; TOBIASEN J, 1982, SURG GYNECOL OBSTET, V154, P711; Wolf SE, 1997, ANN SURG, V225, P554, DOI 10.1097/00000658-199705000-00012	10	44	46	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					989	994		10.1016/S0140-6736(03)12824-3	http://dx.doi.org/10.1016/S0140-6736(03)12824-3			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660055				2022-12-28	WOS:000181699700008
J	Nong, Y; Huang, YQ; Ju, W; Kalia, LV; Ahmadian, G; Wang, YT; Salter, MW				Nong, Y; Huang, YQ; Ju, W; Kalia, LV; Ahmadian, G; Wang, YT; Salter, MW			Glycine binding primes NMDA receptor internalization	NATURE			English	Article							IONOTROPIC GLUTAMATE RECEPTORS; SYNAPTIC VESICLE ENDOCYTOSIS; D-ASPARTATE RECEPTOR; ACID; SITE; AMPA; TRANSMISSION; HIPPOCAMPUS; ANTAGONISTS; ACTIVATION	NMDA (N-methyl-D-aspartate) receptors (NMDARs) are a principal subtype of excitatory ligand-gated ion channel with prominent roles in physiological and disease processes in the central nervous system(1). Recognition that glycine potentiates NMDAR-mediated currents(2) as well as being a requisite co-agonist of the NMDAR subtype of 'glutamate' receptor(3) profoundly changed our understanding of chemical synaptic communication in the central nervous system. The binding of both glycine and glutamate is necessary to cause opening of the NMDAR conductance pore(1). Although binding of either agonist alone is insufficient to cause current flow through the channel, we report here that stimulation of the glycine site initiates signalling through the NMDAR complex, priming the receptors for clathrin-dependent endocytosis. Glycine binding alone does not cause the receptor to be endocytosed; this requires both glycine and glutamate site activation of NMDARs. The priming effect of glycine is mimicked by the NMDAR glycine site agonist D-serine, and is blocked by competitive glycine site antagonists. Synaptic as well as extrasynaptic NMDARs are primed for internalization by glycine site stimulation. Our results demonstrate transmembrane signal transduction through activating the glycine site of NMDARs, and elucidate a model for modulating cell-cell communication in the central nervous system.	Univ Toronto, Hosp Sick Children, Program Brain & Behav, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Pathobiol & Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5G 1X8, Canada; Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, Dept Med, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Vancouver Hosp & Hlth Sci Ctr, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of British Columbia; University of British Columbia	Salter, MW (corresponding author), Univ Toronto, Hosp Sick Children, Program Brain & Behav, Toronto, ON M5G 1X8, Canada.		Wang, Yu Tian/A-4729-2008; Wang, Yu Tian/J-8255-2015	Kalia, Lorraine/0000-0002-9384-1305				BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Danysz W, 1998, PHARMACOL REV, V50, P597; Dingledine R, 1999, PHARMACOL REV, V51, P7; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; FOSTER AC, 1992, MOL PHARMACOL, V41, P914; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HANSFORD C. G., 1961, SYDOWIA ANN MYCOLOGICI SER II SUPPL, V2, P1; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kittler JT, 2000, J NEUROSCI, V20, P7972; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Mugnaini M, 1998, J RECEPT SIGNAL TR R, V18, P91, DOI 10.3109/10799899809047739; Mugnaini M, 2000, EUR J PHARMACOL, V391, P233, DOI 10.1016/S0014-2999(00)00101-1; Popik P, 1995, EUR J PHARM-MOLEC PH, V291, P221, DOI 10.1016/0922-4106(95)90061-6; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; SALITURO FG, 1992, J MED CHEM, V35, P1791, DOI 10.1021/jm00088a014; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Snyder EM, 2001, NAT NEUROSCI, V4, P1079, DOI 10.1038/nn746; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8	29	327	339	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					302	307		10.1038/nature01497	http://dx.doi.org/10.1038/nature01497			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646920				2022-12-28	WOS:000181637300038
J	Collard, HR; Saint, S; Matthay, MA				Collard, HR; Saint, S; Matthay, MA			Prevention of ventilator-associated pneumonia: An evidence-based systematic review	ANNALS OF INTERNAL MEDICINE			English	Review							CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; STRESS-ULCER PROPHYLAXIS; SELECTIVE DIGESTIVE DECONTAMINATION; RESPIRATORY-TRACT INFECTIONS; RANDOMIZED CONTROLLED-TRIALS; NOSOCOMIAL PNEUMONIA; MECHANICAL VENTILATION; CIRCUIT CHANGES; SUBGLOTTIC SECRETIONS	Background: Ventilator-associated pneumonia is a common cause of morbidity in critically ill patients. Interventions beneficial to the prevention of ventilator-associated pneumonia would therefore have a significant impact on the care of these patients. Purpose: To perform a literature review and synthesis of methods for prevention of ventilator-associated pneumonia. Data Sources: MEDLINE (1966-2001), the Cochrane Library, and bibliographies of retrieved articles. Study Selection: Studies were required to be prospective and controlled in design and to evaluate clinically important or surrogate outcomes. Surrogate outcomes were required to have a direct link to clinically important outcomes supported by the literature. Data Extraction: Data on patients, definitions, study design, and outcomes were abstracted and graded by using preestablished criteria. Data Synthesis: The preventive practices with the strongest supportive evidence were semi-recumbent positioning, sucralfate instead of H-2-antagonists for stress ulcer prophylaxis, and selective digestive tract decontamination. Aspiration of subglottic secretions and oscillating beds may be useful in select populations. There is no evidence to support specific methods of enteral feeding or increased frequency of ventilator circuitry changes. Conclusions: After evaluation of potential benefits and risks, the authors recommend considering several specific interventions to reduce the incidence of ventilator-associated pneumonia: semi-recumbent positioning in all eligible patients, sucralfate rather than H-2-antagonists in patients at low to moderate risk for gastrointestinal tract bleeding, and aspiration of subglottic secretions and oscillating beds in select patient populations. Selective digestive tract decontamination is not recommended because. routine use may increase antimicrobial resistance.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Ann Arbor Vet Affairs Med Ctr, Ann Arbor, MI USA; Univ Michigan, Ann Arbor, MI 48109 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of California System; University of California San Francisco	Collard, HR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,Campus Box C272, Denver, CO 80262 USA.	hal.collard@uchsc.edu	Saint, Sanjay/AAF-5126-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051856] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL51856] Funding Source: Medline; PHS HHS [290-97-0013] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AERDTS SJA, 1993, BRIT MED J, V307, P525; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; BARTLETT JG, 1995, CRIT CARE MED, V23, P613, DOI 10.1097/00003246-199504000-00002; BASSIN AS, 1995, CLIN CHEST MED, V16, P195; BenMenachem T, 1996, CRIT CARE MED, V24, P338, DOI 10.1097/00003246-199602000-00026; Bonten MJM, 1996, AM J RESP CRIT CARE, V154, P394, DOI 10.1164/ajrccm.154.2.8756812; CHOI SC, 1992, J CRIT CARE, V7, P57, DOI 10.1016/0883-9441(92)90008-U; COLLARD HR, 2001, AHRQ PUBLICATION; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; Cook D, 1998, JAMA-J AM MED ASSOC, V279, P781, DOI 10.1001/jama.279.10.781; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; COOK DJ, 1995, SCAND J GASTROENTERO, V30, P48, DOI 10.3109/00365529509090271; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; Craven D E, 1996, Semin Respir Infect, V11, P32; D'Amico R, 1998, BMJ-BRIT MED J, V316, P1275, DOI 10.1136/bmj.316.7140.1275; Davis K, 2000, CRIT CARE MED, V28, P1412, DOI 10.1097/00003246-200005000-00026; DONOWITZ LG, 1986, INFECT CONT HOSP EP, V7, P23, DOI 10.1017/S0195941700063748; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; DREYFUSS D, 1991, AM REV RESPIR DIS, V143, P738, DOI 10.1164/ajrccm/143.4_Pt_1.738; Ebner W, 2000, EUR J CLIN MICROBIOL, V19, P243, DOI 10.1007/s100960050470; Erstad BL, 1997, CRIT CARE MED, V25, P1678, DOI 10.1097/00003246-199710000-00017; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; Garcia MS, 1998, AM J RESP CRIT CARE, V158, P908, DOI 10.1164/ajrccm.158.3.9712079; George DL, 1998, AM J RESP CRIT CARE, V158, P1839, DOI 10.1164/ajrccm.158.6.9610069; Heyland DK, 1999, CRIT CARE MED, V27, P2399, DOI 10.1097/00003246-199911000-00013; HEYLAND DK, 1994, CHEST, V105, P1221, DOI 10.1378/chest.105.4.1221; Heyland DK, 1999, AM J RESP CRIT CARE, V159, P1249, DOI 10.1164/ajrccm.159.4.9807050; HURLEY JC, 1995, ANTIMICROB AGENTS CH, V39, P941, DOI 10.1128/AAC.39.4.941; Ibrahim EH, 2001, CHEST, V120, P555, DOI 10.1378/chest.120.2.555; Joiner G A, 1996, Am J Med Qual, V11, P100, DOI 10.1177/0885713X9601100208; Kearns PJ, 2000, CRIT CARE MED, V28, P1742, DOI 10.1097/00003246-200006000-00007; KELLEGHAN SI, 1993, AM J INFECT CONTROL, V21, P322, DOI 10.1016/0196-6553(93)90390-P; Kimura A, 1998, J TRAUMA, V45, P383, DOI 10.1097/00005373-199808000-00032; Kirton OC, 1997, CHEST, V112, P1055, DOI 10.1378/chest.112.4.1055; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; Kollef MH, 1999, CHEST, V116, P1339, DOI 10.1378/chest.116.5.1339; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kollef MH, 1999, NEW ENGL J MED, V340, P627, DOI 10.1056/NEJM199902253400807; KOLLEF MH, 1995, ANN INTERN MED, V123, P168, DOI 10.7326/0003-4819-123-3-199508010-00002; Livingston D H, 2000, Am J Surg, V179, p12S; LODE H, 1992, Intensive Care Medicine, V18, pS24, DOI 10.1007/BF01752973; Long MN, 1996, INFECT CONT HOSP EP, V17, P14; MAHUL P, 1992, INTENS CARE MED, V18, P20, DOI 10.1007/BF01706421; Manangan LP, 2000, AM J INFECT CONTROL, V28, P222, DOI 10.1067/mic.2000.106278; MERMEL L, 1994, 4 ANN M SOC HOSP EP; Messori A, 2000, BMJ-BRIT MED J, V321, P1103, DOI 10.1136/bmj.321.7269.1103; Nathens AB, 1999, ARCH SURG-CHICAGO, V134, P170, DOI 10.1001/archsurg.134.2.170; OROZCOLEVI M, 1995, AM J RESP CRIT CARE, V152, P1387, DOI 10.1164/ajrccm.152.4.7551400; Pittet D, 2001, AM J RESP CRIT CARE, V164, P338, DOI 10.1164/ajrccm.164.3.2105072b; Quinio B, 1996, CHEST, V109, P765, DOI 10.1378/chest.109.3.765; Saint S, 1998, AM J MED, V105, P515, DOI 10.1016/S0002-9343(98)00322-2; Silvestri L, 2000, J HOSP INFECT, V45, P185, DOI 10.1053/jhin.2000.0737; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Stamm AM, 1998, AM J INFECT CONTROL, V26, P71, DOI 10.1016/S0196-6553(98)70064-1; Stoutenbeek C P, 1997, Semin Respir Infect, V12, P294; SUMMER WR, 1989, J CRIT CARE, V4, P45, DOI 10.1016/0883-9441(89)90091-9; THOMPSON R, 1994, MED CLIN N AM, V78, P1185, DOI 10.1016/S0025-7125(16)30126-2; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; TRAVER GA, 1995, J CRIT CARE, V10, P97, DOI 10.1016/0883-9441(95)90000-4; TRYBA M, 1991, CRIT CARE MED, V19, P942, DOI 10.1097/00003246-199107000-00020; TRYBA M, 1991, J CLIN GASTROENTEROL, V13, pS44; TRYBA M, 1995, SCAND J GASTROENTERO, V30, P53, DOI 10.3109/00365529509090272; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; van Nieuwenhoven CA, 2001, JAMA-J AM MED ASSOC, V286, P335, DOI 10.1001/jama.286.3.335; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; VANSAENE HKF, 1991, J HOSP INFECT, V18, P261, DOI 10.1016/0195-6701(91)90184-A; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014; Yavagal DR, 2000, CRIT CARE MED, V28, P1408, DOI 10.1097/00003246-200005000-00025	68	176	214	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					494	501		10.7326/0003-4819-138-6-200303180-00015	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00015			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639084				2022-12-28	WOS:000181562400008
J	Tang, S; Ng, PW; Ho, YW; Leung, MF				Tang, S; Ng, PW; Ho, YW; Leung, MF			Septic metastatic endophthalmitis	LANCET			English	Article									United Christian Hosp, Dept Med & Geriatr, Kowloon, Hong Kong, Peoples R China	United Christian Hospital	Tang, S (corresponding author), United Christian Hosp, Dept Med & Geriatr, Kowloon, Hong Kong, Peoples R China.		Tang, Sydney Chi Wai/C-4411-2009	Tang, Sydney Chi Wai/0000-0002-6862-1941					0	2	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 15	2003	361	9361					922	922		10.1016/S0140-6736(03)12774-2	http://dx.doi.org/10.1016/S0140-6736(03)12774-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648971				2022-12-28	WOS:000181741600010
J	Ransohoff, DF				Ransohoff, DF			Developing molecular biomarkers for cancer	SCIENCE			English	Editorial Material							DNA		Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; NCI, Div Canc Prevent, NIH, Bethesda, MD 20892 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ransohoff, DF (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.	ransohof@med.unc.edu						Ahlquist DA, 2000, GASTROENTEROLOGY, V119, P1219, DOI 10.1053/gast.2000.19580; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Langebaek Carl, 1996, PREVENTION EARLY DET, P155; MARKOWITZ S, 2002, INT J BIOL MARKER, V17, pS43; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Ransohoff DF, 2002, J CLIN EPIDEMIOL, V55, P1178, DOI 10.1016/S0895-4356(02)00524-3; Stears RL, 2003, NAT MED, V9, P140, DOI 10.1038/nm0103-140; Traverso G, 2002, NEW ENGL J MED, V346, P311, DOI 10.1056/NEJMoa012294; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Verma M, 2002, LANCET ONCOL, V3, P755, DOI 10.1016/S1470-2045(02)00932-4; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	12	63	75	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	2003	299	5613					1679	1680		10.1126/science.1083158	http://dx.doi.org/10.1126/science.1083158			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637728				2022-12-28	WOS:000181519500027
J	Reyes-Garcia, V; Godoy, R; Vadez, V; Apaza, L; Byron, E; Huanca, T; Leonard, WR; Perez, E; Wilkie, D				Reyes-Garcia, V; Godoy, R; Vadez, V; Apaza, L; Byron, E; Huanca, T; Leonard, WR; Perez, E; Wilkie, D			Ethnobotanical knowledge shared widely among Tsimane' Amerindians, Bolivia	SCIENCE			English	Article									Univ Florida, Trop Conservat & Dev Ctr, Gainesville, FL 32611 USA; Brandeis Univ, Heller Sch, Waltham, MA 02154 USA; Univ Mayor San Andres, La Paz, Bolivia; Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA; Wildlife Conservat Soc, Waltham, MA 02451 USA	State University System of Florida; University of Florida; Brandeis University; Universidad Mayor de San Andres; State University System of Florida; University of Florida; Wildlife Conservation Society	Reyes-Garcia, V (corresponding author), Univ Florida, Trop Conservat & Dev Ctr, Gainesville, FL 32611 USA.		Leonard, William R./I-5981-2019; Vadez, Vincent/GLU-8981-2022; Reyes-Garcia, Victoria/C-4552-2008; Vadez, Vincent/C-5310-2014	Reyes-Garcia, Victoria/0000-0002-2914-8055; Leonard, William/0000-0002-6233-604X				*COORD ORG IND CUE, 1998, IN PROT RIGHTS HOLD; Laird S.A, 2002, BIODIVERSITY TRADITI; POSEY D, 1990, ANTHR TODAY, V6, P4; Reyes-Garcia V., 2001, THESIS U FLORIDA; ROMNEY AK, 1999, CURR ANTHROPOL, V40, P6; Ten Kate K, 1999, COMMERCIAL USE BIODI	6	67	71	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1707	1707		10.1126/science.1080274	http://dx.doi.org/10.1126/science.1080274			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637738				2022-12-28	WOS:000181519500037
J	Gronberg, H				Gronberg, H			Prostate cancer epidemiology	LANCET			English	Article							ANDROGEN RECEPTOR GENE; GROWTH-FACTOR-I; SUSCEPTIBILITY LOCUS; UNITED-STATES; PREVENTION TRIAL; SELENIUM SUPPLEMENTATION; DOMINANT INHERITANCE; LINKAGE ANALYSIS; DAIRY-PRODUCTS; FAMILY HISTORY	Because more and more men are being diagnosed with prostate cancer worldwide, knowledge about and prevention of this disease is important. Epidemiological studies have provided some insight about the cause of prostate cancer in terms of diet and genetic factors. However, compared with other common cancers such as breast and lung cancer, the causes remain poorly understood. Several important issues could help in our understanding of this disease-the variation in incidence of prostate cancer between ethnic populations and the factors leading to familial clustering of the diseases.	Umea Univ, Dept Radiat Sci Oncol, S-90185 Umea, Sweden	Umea University	Gronberg, H (corresponding author), Umea Univ, Dept Radiat Sci Oncol, S-90185 Umea, Sweden.							ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Augustsson K, 1999, LANCET, V353, P703, DOI 10.1016/S0140-6736(98)06099-1; Berry R, 2000, AM J HUM GENET, V67, P82, DOI 10.1086/302994; Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; Bylund A, 2000, PROSTATE, V42, P304, DOI 10.1002/(SICI)1097-0045(20000301)42:4<304::AID-PROS8>3.0.CO;2-Z; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; Chan JM, 2001, AM J CLIN NUTR, V74, P549; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chan JM, 1998, CANCER CAUSE CONTROL, V9, P559, DOI 10.1023/A:1008823601897; Chang BL, 2002, HUM GENET, V110, P122, DOI 10.1007/s00439-001-0662-6; Chang BL, 2001, INT J CANCER, V95, P354, DOI 10.1002/1097-0215(20011120)95:6<354::AID-IJC1062>3.0.CO;2-3; Chen LW, 2001, JNCI-J NATL CANCER I, V93, P1872, DOI 10.1093/jnci/93.24.1872; Clark LC, 1998, BRIT J UROL, V81, P730; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Coltman CA, 1999, EUR UROL, V35, P544; Cooney KA, 1997, J NATL CANCER I, V89, P955, DOI 10.1093/jnci/89.13.955; Coughlin SS, 2002, ANN EPIDEMIOL, V12, P182, DOI 10.1016/S1047-2797(01)00310-6; Cui JS, 2001, AM J HUM GENET, V68, P1207, DOI 10.1086/320114; De Stefani E, 2000, CANCER EPIDEM BIOMAR, V9, P335; Dennis LK, 2001, EPIDEMIOL REV, V23, P110, DOI 10.1093/oxfordjournals.epirev.a000775; Eeles RA, 1998, AM J HUM GENET, V62, P653, DOI 10.1086/301745; Fleshner NE, 2001, UROLOGY, V57, P90, DOI 10.1016/S0090-4295(00)00949-3; GANN PH, 1994, J NATL CANCER I, V86, P281, DOI 10.1093/jnci/86.4.281; Gibbs M, 1999, AM J HUM GENET, V64, P776, DOI 10.1086/302287; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571; Giovannucci E, 2002, JNCI-J NATL CANCER I, V94, P391, DOI 10.1093/jnci/94.5.391; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Godley PA, 1996, CANCER EPIDEM BIOMAR, V5, P115; Goode EL, 2000, GENET EPIDEMIOL, V18, P251, DOI 10.1002/(SICI)1098-2272(200003)18:3<251::AID-GEPI5>3.0.CO;2-X; GRONBERG H, 1994, ACTA ONCOL, V33, P359; Gronberg H, 1997, CANCER RES, V57, P4707; GRONBERG H, 1994, J UROLOGY, V152, P1484, DOI 10.1016/S0022-5347(17)32452-7; Gronberg H, 1997, AM J EPIDEMIOL, V146, P552, DOI 10.1093/oxfordjournals.aje.a009313; Haiman CA, 2001, CANCER EPIDEM BIOMAR, V10, P743; Harman SM, 2000, J CLIN ENDOCR METAB, V85, P4258, DOI 10.1210/jc.85.11.4258; Harvei S, 1997, INT J CANCER, V71, P545, DOI 10.1002/(SICI)1097-0215(19970516)71:4<545::AID-IJC7>3.0.CO;2-U; HAYES RB, 1995, INT J CANCER, V60, P361, DOI 10.1002/ijc.2910600315; Hayes RB, 1999, CANCER EPIDEM BIOMAR, V8, P25; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Hickey K, 2001, EPIDEMIOL REV, V23, P115, DOI 10.1093/oxfordjournals.epirev.a000776; HOWELL MA, 1974, BRIT J CANCER, V29, P328, DOI 10.1038/bjc.1974.75; Hsing AW, 2001, JNCI-J NATL CANCER I, V93, P783, DOI 10.1093/jnci/93.10.783; Hsing AW, 2001, EPIDEMIOL REV, V23, P42, DOI 10.1093/oxfordjournals.epirev.a000795; Huggins C, 2002, J UROLOGY, V167, P948, DOI 10.1016/S0022-5347(02)80307-X; IRVINE RA, 1995, CANCER RES, V55, P1937; Klein EA, 2001, J UROLOGY, V166, P1311, DOI 10.1016/S0022-5347(05)65759-X; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Landstrom M, 1998, PROSTATE, V36, P151, DOI 10.1002/(SICI)1097-0045(19980801)36:3&lt;151::AID-PROS2&gt;3.0.CO;2-K; Lange EM, 2000, CANCER EPIDEM BIOMAR, V9, P439; Lee DY, 2000, J DERMATOL SCI, V23, P132, DOI 10.1016/S0923-1811(00)00068-2; Lee MM, 1998, CANCER CAUSE CONTROL, V9, P545, DOI 10.1023/A:1008840105531; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lieberman R, 2001, UROLOGY, V57, P224, DOI 10.1016/S0090-4295(00)00981-X; Luo J, 2002, CANCER RES, V62, P2220; Mononen N, 2001, BRIT J CANCER, V84, P1344, DOI 10.1054/bjoc.2001.1789; MONROE KR, 1995, NAT MED, V1, P827, DOI 10.1038/nm0895-827; Nam RK, 2001, UROLOGY, V57, P199, DOI 10.1016/S0090-4295(00)00928-6; Neuhausen SL, 1999, HUM MOL GENET, V8, P2437, DOI 10.1093/hmg/8.13.2437; Ogunbiyi JO, 1999, J NATL MED ASSOC, V91, P159; Osegbe DN, 1997, J UROLOGY, V157, P1340, DOI 10.1016/S0022-5347(01)64966-8; Ostrander EA, 2000, AM J HUM GENET, V67, P1367, DOI 10.1086/316916; Page WF, 1997, PROSTATE, V33, P240; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Parkin DM, 1997, CANC INCIDENCE 5 CON, VVII; Peterson HB, 1998, FERTIL STERIL, V70, P201; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; Rebbeck TR, 2000, AM J HUM GENET, V67, P1014, DOI 10.1086/303096; Redman C, 1997, CARCINOGENESIS, V18, P1195, DOI 10.1093/carcin/18.6.1195; Redman C, 1998, CANCER LETT, V125, P103, DOI 10.1016/S0304-3835(97)00497-7; Ries LA, 2002, SEER CANC STAT REV 1; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; Schaid DJ, 1998, AM J HUM GENET, V62, P1425, DOI 10.1086/301862; SEVERSON RK, 1989, CANCER RES, V49, P1857; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Stanford JL, 1997, CANCER RES, V57, P1194; *STAT SWED, 2001, CANC INC SWED 1999; Stattin P, 2000, J NATL CANCER I, V92, P1910, DOI 10.1093/jnci/92.23.1910; Stattin P, 2002, INT J CANCER, V99, P124, DOI 10.1002/ijc.10313; Stattin P, 2001, J CLIN ENDOCR METAB, V86, P1341, DOI 10.1210/jc.86.3.1341; Strom SS, 1999, NUTR CANCER, V33, P20, DOI 10.1080/01635589909514743; Suarez BK, 2000, AM J HUM GENET, V66, P933, DOI 10.1086/302818; Tut TG, 1997, J CLIN ENDOCR METAB, V82, P3777, DOI 10.1210/jc.82.11.3777; Veierod MB, 1997, INT J CANCER, V73, P634, DOI 10.1002/(SICI)1097-0215(19971127)73:5&lt;634::AID-IJC4&gt;3.0.CO;2-Y; Wabinga HR, 2000, BRIT J CANCER, V82, P1585, DOI 10.1054/bjoc.1999.1071; WHITTEMORE AS, 1995, AM J EPIDEMIOL, V141, P732, DOI 10.1093/oxfordjournals.aje.a117495; WHITTEMORE AS, 1995, JNCI-J NATL CANCER I, V87, P652, DOI 10.1093/jnci/87.9.652; Xu JF, 2001, AM J HUM GENET, V69, P341, DOI 10.1086/321967; Xu JF, 2001, AM J HUM GENET, V68, P901, DOI 10.1086/319513	91	848	904	1	61	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					859	864		10.1016/S0140-6736(03)12713-4	http://dx.doi.org/10.1016/S0140-6736(03)12713-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642065				2022-12-28	WOS:000181466600026
J	Swedlow, JR; Goldberg, I; Brauner, E; Sorger, PK				Swedlow, JR; Goldberg, I; Brauner, E; Sorger, PK			Informatics and quantitative analysis in biological Imaging	SCIENCE			English	Article								Biological imaging is now a quantitative technique for probing cellular structure and dynamics and is increasingly used for cell-based screens. However, the bioinformatics tools required for hypothesis-driven analysis of digital images are still immature. We are developing the Open Microscopy Environment (OME) as an informatics solution for the storage and analysis of optical microscope image data. OME aims to automate image analysis, modeling, and mining of large sets of images and specifies a flexible data model, a relational database, and an XML-encoded. le standard that is usable by potentially any software tool. With this design, OME provides a first step toward biological image informatics.	Univ Dundee, Wellcome Trust Bioctr, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland; NIA, Genet Lab, NIH, Baltimore, MD 21224 USA; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	University of Dundee; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Swedlow, JR (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland.	j.swedlow@dundee.ac.uk	Goldberg, Ilya/H-5307-2011	Goldberg, Ilya/0000-0001-8514-6110; Sorger, Peter/0000-0002-3364-1838; Swedlow, Jason/0000-0002-2198-1958	NATIONAL INSTITUTE ON AGING [Z01AG000671, ZICAG000671] Funding Source: NIH RePORTER; Wellcome Trust [067433] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission)		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andrews PD, 2002, TRAFFIC, V3, P29, DOI 10.1034/j.1600-0854.2002.30105.x; Bracewell RN., 1986, FOURIER TRANSFORM IT; Brazma Alvis, 2002, Adv Biochem Eng Biotechnol, V77, P113; CHEN H, 1989, HANDBOOK OF BIOLOGICAL CONFOCAL MICROSCOPY, REVISED EDITION, P141; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Huang K, 2002, 2002 IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING, PROCEEDINGS, P325, DOI 10.1109/ISBI.2002.1029259; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Platani M, 2002, NAT CELL BIOL, V4, P502, DOI 10.1038/ncb809; Waterman-Storer CM, 2002, CURR BIOL, V12, pR633, DOI 10.1016/S0960-9822(02)01139-9	10	174	180	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					100	102		10.1126/science.1082602	http://dx.doi.org/10.1126/science.1082602			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677061	Green Accepted			2022-12-28	WOS:000181988900039
J	Steinbrook, R				Steinbrook, R			How best to ventilate? Trial design and patient safety in studies of the acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE LUNG INJURY; CONTROLLED CLINICAL-TRIAL; MECHANICAL VENTILATION; METAANALYSIS; STRATEGY											Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; Bernard GR, 2000, JAMA-J AM MED ASSOC, V283, P2568, DOI 10.1001/jama.283.19.2568; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brower RG, 2002, AM J RESP CRIT CARE, V166, P1515, DOI 10.1164/ajrccm.166.11.340; CAROME MA, 2002, COMMUNICATION   1007; CAROME MA, 2002, COMMUNICATION   0828; Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1510, DOI 10.1164/rccm.200208-956OC; Eichacker PQ, 2003, AM J RESP CRIT CARE, V167, P798; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; MARTIN TR, 2002, COMMUNICATION   1212; MARTIN TR, 2003, COMMUNICATION   0106; MEYER RJ, 2002, COMMUNICATION   0208; Oba Y, 2000, NEW ENGL J MED, V343, P813; Rubenfeld G, 2001, AM J RESP CRIT CARE, V163, pA295; Rubenfeld GD, 2003, CRIT CARE MED, V31, pS276, DOI 10.1097/01.CCM.0000057904.62683.2B; SEEMAN BT, 2002, FEDS DEMAND DATA LUN; SEEMAN BT, 2002, SAFETY WARNINGS HALT; SHARAV VN, 2002, COMMUNICATION   0729; Stewart TE, 2002, AM J RESP CRIT CARE, V166, P1421, DOI 10.1164/rccm.2210002; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; TANSEY B, 2002, SAN FRANCISCO C 0728, pA1; Thompson BT, 2001, CHEST, V120, P1622, DOI 10.1378/chest.120.5.1622; Tobin MJ, 2000, NEW ENGL J MED, V342, P1360, DOI 10.1056/NEJM200005043421808; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; WEIL CJ, 2002, COMMUNICATION   1007; WEINERT CR, IN PRESS AM J RESP C	30	59	59	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1393	1401		10.1056/NEJMhpr030349	http://dx.doi.org/10.1056/NEJMhpr030349			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672870				2022-12-28	WOS:000181949100015
J	Willems, J				Willems, J			Bringing down the barriers - Public communication should be part of common scientific practice.	NATURE			English	Editorial Material									Vrije Univ Amsterdam, Dept Commun Sci, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Willems, J (corresponding author), Vrije Univ Amsterdam, Dept Commun Sci, NL-1081 HV Amsterdam, Netherlands.		Glasby, Jon/AAC-1422-2021	Glasby, Jon/0000-0003-3960-7988					0	17	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2003	422	6931					470	470		10.1038/422470a	http://dx.doi.org/10.1038/422470a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673226				2022-12-28	WOS:000181965400016
J	Green, MJ; Botkin, JR				Green, MJ; Botkin, JR			"Genetic exceptionalism" in medicine: Clarifying the differences between genetic and nongenetic tests	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CANCER SUSCEPTIBILITY GENE; BREAST-CANCER; HEALTH-INSURANCE; FAMILY-HISTORY; PRIVACY ACT; DISEASE; DISCRIMINATION; INFORMATION; DIAGNOSIS; POLICY	Predictive genetic tests are now available for assessing susceptibility to a variety of conditions, including breast and colon cancer, hemochromatosis, and Alzheimer and Huntington disease. Much controversy surrounds the application of these tests, stemming from their similarities to and differences from other tests commonly used in asymptomatic persons. Some have argued that genetic tests are unique and therefore justify special consideration with regard to informed consent and privacy. This paper examines the arguments for such "genetic exceptionalism" and concludes that no clear, significant distinctions between genetic and non-genetic tests justify a different approach to testing by clinicians. Nevertheless, with many genetic tests, the results may cause stigmatization, family discord, and psychological distress. Regardless of whether a test is genetic, when this combination of characteristics is present and when health care providers are not specifically trained to interpret results, testing should be performed with particular caution and the highest standards of informed consent and privacy protection should be applied.	Penn State Coll Med, Dept Humanities, Hershey, PA 17033 USA; Univ Utah, Sch Med, Salt Lake City, UT USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Utah System of Higher Education; University of Utah	Green, MJ (corresponding author), Penn State Coll Med, Dept Humanities, H134,Rm 1743,500 Univ Dr, Hershey, PA 17033 USA.		Green, Martin A/H-7567-2012	Green, Martin A/0000-0002-8860-396X; Green, Michael/0000-0002-4828-4749	NATIONAL CANCER INSTITUTE [R03CA070838, R01CA084770] Funding Source: NIH RePORTER; NCI NIH HHS [5R03 CA70838, R01CA84770] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen GE, 1997, GENETICA, V99, P77, DOI 10.1023/A:1018396529332; ALONZO AA, 1995, SOC SCI MED, V41, P303, DOI 10.1016/0277-9536(94)00384-6; Annas GJ, 1995, J LAW MED ETHICS, V23, P360, DOI 10.1111/j.1748-720X.1995.tb01378.x; Beckwith J, 1998, J LAW MED ETHICS, V26, P205, DOI 10.1111/j.1748-720X.1998.tb01421.x; Bernhardt Barbara A, 1997, J Genet Couns, V6, P207, DOI 10.1023/A:1025668320403; Bernstein T, 1994, RADON RENTAL HOUSING; Biesecker B B, 1997, Semin Oncol Nurs, V13, P129, DOI 10.1016/S0749-2081(97)80010-1; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BLOOM JR, 1981, AM J PUBLIC HEALTH, V71, P1228, DOI 10.2105/AJPH.71.11.1228; BOLGER A, 2000, FINANCIAL TIMES 1013; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; Capron Alexander Morgan, 1990, Emory Law J, V39, P665; CHESNEY MA, 1994, PSYCHIAT CLIN N AM, V17, P163; CODORI AM, 1994, AM J MED GENET, V54, P167, DOI 10.1002/ajmg.1320540303; COHEN MM, 1994, AM J HUM GENET, V55, pR1; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; de Vries BBA, 1998, J MED GENET, V35, P579, DOI 10.1136/jmg.35.7.579; de Vries BBA, 1999, J MED GENET, V36, P467; Dodek DY, 1997, CAN MED ASSOC J, V156, P847; Elsas LJ, 2000, POSTGRAD MED, V107, P191, DOI 10.3810/pgm.2000.04.1000; Flinter FA, 2001, BRIT MED J, V322, P1008, DOI 10.1136/bmj.322.7293.1008; FOST N, 1993, AM J DIS CHILD, V147, P1190, DOI 10.1001/archpedi.1993.02160350064009; FOST N, 1992, FASEB J, V6, P2813, DOI 10.1096/fasebj.6.10.1634044; Geller G, 1997, JAMA-J AM MED ASSOC, V277, P1467, DOI 10.1001/jama.277.18.1467; GELLER G, 1995, NAT GENET, V11, P364, DOI 10.1038/ng1295-364; Geller G, 1993, Arch Fam Med, V2, P1119, DOI 10.1001/archfami.2.11.1119; Geller Lisa N, 1996, Sci Eng Ethics, V2, P71, DOI 10.1007/BF02639319; GOSTIN L, 1991, AM J LAW MED, V17, P109; GOULD SJ, 1981, MISMEASURE MAN; Guazzo E, 1997, GERIATRICS, V52, P25; Hall MA, 2000, AM J HUM GENET, V66, P293, DOI 10.1086/302714; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; HOFMAN KJ, 1993, ACAD MED, V68, P625, DOI 10.1097/00001888-199308000-00013; HOLM S, 1999, GENETIC INFORMATION; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; HUDSON KL, 1995, SCIENCE, V270, P391, DOI 10.1126/science.270.5235.391; JOHNSTON ME, 1984, J CHRON DIS, V37, P417, DOI 10.1016/0021-9681(84)90025-0; Juengst Eric T, 1995, Genome Sci Technol, V1, P21, DOI 10.1089/gst.1995.1.21; KASH KM, 1992, J NATL CANCER I, V84, P24, DOI 10.1093/jnci/84.1.24; Keller EF., 1992, SCI SOCIAL ISSUES HU, P281; Kevles D., 1985, NAME EUGENICS; LERMAN C, 1994, ARCH INTERN MED, V154, P609, DOI 10.1001/archinte.154.6.609; Lerman C, 1994, J Natl Cancer Inst Monogr, P171; Lifton R. J., 1986, NAZI DOCTORS MED KIL; LO B, 1989, ANN INTERN MED, V110, P727; MACDONALD LA, 1984, J CHRON DIS, V37, P933, DOI 10.1016/0021-9681(84)90070-5; Markel H, 1997, Health Matrix Clevel, V7, P49; MARKEL H, 1992, AM J MED, V93, P209, DOI 10.1016/0002-9343(92)90052-D; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MCEWEN JE, 1992, AM J HUM GENET, V51, P785; MCGINISS MJ, 1997, EMORY RIMOINS PRINCI, P537; MEISSEN GJ, 1988, NEW ENGL J MED, V318, P535, DOI 10.1056/NEJM198803033180903; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOSSEY JM, 1981, CLIN INVEST MED, V4, P201; MURRAY TH, 1997, GENETIC SECRETS PROT, P60; NATOWICZ MR, 1992, AM J HUM GENET, V50, P465; Nelkin D, 1995, DNS MYSTIQUE GENE CU; *NIH, 2000, ENH OV GEN TESTS REC, P20; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; OSTRER H, 1993, AM J HUM GENET, V52, P565; POKORSKI RJ, 1989, PRINCIPLES INSURANCE, P45; Post SG, 1997, JAMA-J AM MED ASSOC, V277, P832, DOI 10.1001/jama.277.10.832; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; Rothstein Mark A, 1992, Houst Law Rev, V29, P23; Schulman J D, 1996, Cancer J Sci Am, V2, P244; SCRIVER CR, 1995, METABOLIC MOL BASES, P1052; Secretary's Advisory Committee on Genetic Testing, 2000, ENH OV GEN TESTS REC, P15; SIEGLER M, 1982, NEW ENGL J MED, V307, P1518, DOI 10.1056/NEJM198212093072411; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Troy ESF, 1997, J LAW MED ETHICS, V25, P256, DOI 10.1111/j.1748-720X.1997.tb01408.x; UBEL PA, 1995, AM J MED, V99, P190, DOI 10.1016/S0002-9343(99)80139-9; WALDHOLZ M, 1997, CURING CANC STORY ME; Wertz D C, 1997, J Contemp Health Law Policy, V13, P299; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; Wilfond BS, 1997, J LAW MED ETHICS, V25, P243, DOI 10.1111/j.1748-720X.1997.tb01406.x; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	82	147	148	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					571	575		10.7326/0003-4819-138-7-200304010-00013	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667027				2022-12-28	WOS:000181872100006
J	Snow, V; Weiss, KB; Mottur-Pilson, C				Snow, V; Weiss, KB; Mottur-Pilson, C		Clinical Efficacy Assessment Subc	The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOVASCULAR MORBIDITY; RANDOMIZED-TRIAL; PRACTICE GUIDELINES; HYPERTENSION; MORTALITY; EVENTS; INTERVENTION; NEPHROPATHY; ASSOCIATION; IRBESARTAN		Amer Coll Physicians, Philadelphia, PA 19106 USA; Hines Vet Affairs Hosp, Chicago, IL USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL USA	American College of Physicians; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Northwestern University; Feinberg School of Medicine	Snow, V (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	vincenza@acponline.org						*AM ASS CLIN END M, 2000, ENDOCR PRACT, V6, P42; Amer Diabet Assoc, 2000, DIABETES CARE, V23, pS32; Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; DAVIS BR, 1987, CIRCULATION, V75, P340, DOI 10.1161/01.CIR.75.2.340; Estacio RO, 2000, DIABETES CARE, V23, pB54; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; FULLER J, 2000, COCHRANE DB SYST REV; Gerstein HC, 2000, LANCET, V355, P253; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lindholm LH, 2000, J HYPERTENS, V18, P1671, DOI 10.1097/00004872-200018110-00020; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Meltzer S, 1998, CAN MED ASSOC J, V159, pS1; Pahor M, 2000, DIABETES CARE, V23, P888, DOI 10.2337/diacare.23.7.888; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vijan S, 2003, ANN INTERN MED, V138, P593, DOI 10.7326/0003-4819-138-7-200304010-00018; Yusuf S, 2000, NEW ENGL J MED, V342, P145	30	85	95	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					587	592		10.7326/0003-4819-138-7-200304010-00017	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00017			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667031				2022-12-28	WOS:000181872100010
J	Floto, RA; Smith, KGC				Floto, RA; Smith, KGC			The vagus nerve, macrophages, and nicotine	LANCET			English	Editorial Material							STIMULATION; SMOKING; LUNG		Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Med, Cambridge CB2 2XY, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Floto, RA (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Cambridge Inst Med Res, Cambridge CB2 2XY, England.	arf27@cam.ac.uk		Smith, Kenneth/0000-0003-3829-4326				Baughman RP, 2001, SARCOIDOSIS VASC DIF, V18, P70; BAUR X, 1992, RESPIRATION, V59, P211; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Camarena A, 2001, AM J RESP CRIT CARE, V163, P1528, DOI 10.1164/ajrccm.163.7.2004023; CORMIER Y, 1988, AM REV RESPIR DIS, V137, P1104, DOI 10.1164/ajrccm/137.5.1104; Gardam MA, 2003, LANCET INFECT DIS, V3, P148, DOI 10.1016/S1473-3099(03)00545-0; Grutters JC, 2002, AM J RESP CRIT CARE, V165, P1119, DOI 10.1164/ajrccm.165.8.200110-0320; HANCE AJ, 1986, ANN NY ACAD SCI, V465, P643, DOI 10.1111/j.1749-6632.1986.tb18541.x; Kolappan C, 2002, THORAX, V57, P964, DOI 10.1136/thorax.57.11.964; Mori H, 2002, NEUROSCI LETT, V320, P21, DOI 10.1016/S0304-3940(02)00012-5; Son YS, 2002, NEUROSCI LETT, V319, P45, DOI 10.1016/S0304-3940(01)02538-1; Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803; Vassallo R, 2000, NEW ENGL J MED, V342, P1969, DOI 10.1056/NEJM200006293422607; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wilson CJ, 2002, J AM GERIATR SOC, V50, P2041, DOI 10.1046/j.1532-5415.2002.50619.x	15	31	33	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 29	2003	361	9363					1069	1070		10.1016/S0140-6736(03)12902-9	http://dx.doi.org/10.1016/S0140-6736(03)12902-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672307				2022-12-28	WOS:000181865200005
J	Lum, L; Yao, SQ; Mozer, B; Rovescalli, A; Von Kessler, D; Nirenberg, M; Beachy, PA				Lum, L; Yao, SQ; Mozer, B; Rovescalli, A; Von Kessler, D; Nirenberg, M; Beachy, PA			Identification of Hedgehog pathway components by RNAi in Drosophila cultured cells	SCIENCE			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; DOUBLE-STRANDED-RNA; CUBITUS INTERRUPTUS; TRANSCRIPTIONAL REGULATION; TOUT-VELU; WINGLESS; GENE; PROTEIN; INTERFERENCE; SUPPRESSOR	Classical genetic screens can be limited by the selectivity of mutational targeting, the complexities of anatomically based phenotypic analysis, or difficulties in subsequent gene identification. Focusing on signaling response to the secreted morphogen Hedgehog (Hh), we used RNA interference (RNAi) and a quantitative cultured cell assay to systematically screen functional roles of all kinases and phosphatases, and subsequently 43% of predicted Drosophila genes. Two gene products reported to function in Wingless (Wg) signaling were identified as Hh pathway components: a cell surface protein (Daily-like protein) required for Hh signal reception, and casein kinase 1alpha, a candidate tumor suppressor that regulates basal activities of both Hh and Wg pathways. This type of cultured cell-based functional genomics approach may be useful in the systematic analysis of other biological processes.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA	Howard Hughes Medical Institute; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000009, Z01HL000009] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baeg GH, 2001, DEVELOPMENT, V128, P87; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; BROWN S, 1995, AM J HUM GENET, V57, P859; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Campbell GL, 2000, DEVELOPMENT, V127, P4095; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Cole F, 2003, CURR BIOL, V13, P411, DOI 10.1016/S0960-9822(03)00088-5; De Cat B, 2001, SEMIN CELL DEV BIOL, V12, P117, DOI 10.1006/scdb.2000.0240; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FORBES AJ, 1993, DEVELOPMENT, P115; GomezSkarmeta JL, 1996, GENE DEV, V10, P2935, DOI 10.1101/gad.10.22.2935; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; Kang JS, 2002, EMBO J, V21, P114, DOI 10.1093/emboj/21.1.114; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; Paine-Saunders S, 1999, GENOMICS, V57, P455, DOI 10.1006/geno.1999.5793; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; PREAT T, 1992, GENETICS, V132, P725; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; Song HH, 2002, BBA-GEN SUBJECTS, V1573, P241, DOI 10.1016/S0304-4165(02)00390-2; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VEEMON MT, IN PRESS CURR BIOL; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733	37	424	444	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2003	299	5615					2039	2045		10.1126/science.1081403	http://dx.doi.org/10.1126/science.1081403			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663920				2022-12-28	WOS:000181834200046
J	Nash, DB; Malcolm, L; Wright, L; Barnett, P; Hendry, C; Crosson, FJ; Atun, RA; Thomas, H				Nash, DB; Malcolm, L; Wright, L; Barnett, P; Hendry, C; Crosson, FJ; Atun, RA; Thomas, H			Improving the doctor-manager relationship	BRITISH MEDICAL JOURNAL			English	Article									Thomas Jefferson Univ, Jefferson Med Coll, Off Hlth Policy & Clin Outcomes, Philadelphia, PA 19107 USA	Jefferson University	Nash, DB (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Off Hlth Policy & Clin Outcomes, 1015 Walnut St,Suite 115 Curtis, Philadelphia, PA 19107 USA.	David.nash@mail.tju.edu	Atun, Rifat/AAH-5537-2021					Carpenter C E, 1998, J Health Adm Educ, V16, P357; Institute of Medicine, 2001, CROSSING QUALITY CHA; PAGE L, 2002, MOD PHYSICIAN, V12, P13	3	16	16	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 22	2003	326	7390					652	653						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649246				2022-12-28	WOS:000181870800025
J	Hoefel, F; Elgar, S				Hoefel, F; Elgar, S			Wave-induced sediment transport and sandbar migration	SCIENCE			English	Article							NEARSHORE; MODEL; BEACH; ZONE	Onshore sediment transport and sandbar migration are important to the morphological evolution of beaches but are not well understood. Here, a model that accounts for fluid accelerations in waves predicts the onshore sandbar migration observed on an ocean beach. In both the observations and the model, the location of the maximum acceleration-induced transport moves shoreward with the sandbar, resulting in feedback between waves and morphology that drives the bar shoreward until conditions change. A model that combines the effects of transport by waves and mean currents simulated both onshore and offshore bar migration observed over a 45-day period.	Woods Hole Oceanog Inst, MIT WHOI Joint Program Oceanog, Woods Hole, MA 02543 USA	Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution	Hoefel, F (corresponding author), Woods Hole Oceanog Inst, MIT WHOI Joint Program Oceanog, Mail Stop 09, Woods Hole, MA 02543 USA.	fhoefel@whoi.edu; elgar@whoi.edu						AUBREY DG, 1979, J GEOPHYS RES-OCEANS, V84, P6347, DOI 10.1029/JC084iC10p06347; Bagnold R. A., 1966, 422I US GEOL SURV; BAILARD JA, 1981, J GEOPHYS RES-OCEANS, V86, P938, DOI 10.1029/JC086iC11p10938; BOWEN A, 1980, 1080 GEOL SURV CAN, P1; Drake TG, 2001, J GEOPHYS RES-OCEANS, V106, P19859, DOI 10.1029/2000JC000611; Elgar S, 2001, J GEOPHYS RES-OCEANS, V106, P11623, DOI 10.1029/2000JC000389; ELGAR S, 1988, J GEOPHYS RES-OCEANS, V93, P9261, DOI 10.1029/JC093iC08p09261; Gallagher EL, 1998, J GEOPHYS RES-OCEANS, V103, P3203, DOI 10.1029/97JC02765; Gallagher EL, 1998, NATURE, V394, P165, DOI 10.1038/28139; HALLERMEIER RJ, 1982, CONT SHELF RES, V1, P159, DOI 10.1016/0278-4343(82)90003-6; HANES DM, 1986, CONT SHELF RES, V6, P585, DOI 10.1016/0278-4343(86)90024-5; Madsen O. S., 1974, P 14 INT C COAST ENG, V1, P776, DOI DOI 10.1061/9780872621138.048; Nielsen P, 2002, COAST ENG, V45, P53, DOI 10.1016/S0378-3839(01)00036-9; ROELVINK J, 1989, J GEOPHYS RES, V94, P4185; Thornton EB, 1996, J GEOPHYS RES-OCEANS, V101, P12097, DOI 10.1029/96JC00209; TROWBRIDGE J, 1989, J GEOPHYS RES-OCEANS, V94, P10971, DOI 10.1029/JC094iC08p10971; WRIGHT LD, 1984, MAR GEOL, V56, P93, DOI 10.1016/0025-3227(84)90008-2; WRIGHT LD, 1991, MAR GEOL, V96, P19, DOI 10.1016/0025-3227(91)90200-N	18	290	296	3	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	2003	299	5614					1885	1887		10.1126/science.1081448	http://dx.doi.org/10.1126/science.1081448			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649479				2022-12-28	WOS:000181669700043
J	Tamas, G; Lorincz, A; Simon, A; Szabadics, J				Tamas, G; Lorincz, A; Simon, A; Szabadics, J			Identified sources and targets of slow inhibition in the neocortex	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; POSTSYNAPTIC POTENTIALS; INTERNATIONAL-UNION; PHYSIOLOGICAL-ROLE; GABA(B) RECEPTORS; PYRAMIDAL CELLS; CEREBRAL-CORTEX; RAT NEOCORTEX; INTERNEURONS; HIPPOCAMPUS	There are two types of inhibitory postsynaptic potentials in the cerebral cortex. Fast inhibition is mediated by ionotropic gamma-aminobutyric acid type A (GABA(A)) receptors, and slow inhibition is due to metabotropic GABA(B) receptors. Several neuron classes elicit inhibitory postsynaptic potentials through GABA(A) receptors, but possible distinct sources of slow inhibition remain unknown. We identified a class of GABAergic interneurons, the neurogliaform cells, that, in contrast to other GABA-releasing cells, elicited combined GABA(A) and GABA(B) receptor-mediated responses with single action potentials and that predominantly targeted the dendritic spines of pyramidal neurons. Slow inhibition evoked by a distinct interneuron in spatially restricted postsynaptic compartments could locally and selectively modulate cortical excitability.	Univ Szeged, Dept Comparat Physiol, H-6726 Szeged, Hungary	Szeged University	Tamas, G (corresponding author), Univ Szeged, Dept Comparat Physiol, Kozep Fasor 52, H-6726 Szeged, Hungary.		Tamas, Gabor/AAG-9305-2020	Tamas, Gabor/0000-0002-7905-6001; Szabadics, Janos/0000-0002-4968-2562				Banks MI, 1998, J NEUROSCI, V18, P1305; Barnard EA, 1998, PHARMACOL REV, V50, P291; BENARDO LS, 1994, J PHYSIOL-LONDON, V476, P203, DOI 10.1113/jphysiol.1994.sp020124; Bowery NG, 2002, PHARMACOL REV, V54, P247, DOI 10.1124/pr.54.2.247; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Cajal S. R., 1904, TEXTURA SYSTEMA NERV, V2; DESTEXHE A, 1995, P NATL ACAD SCI USA, V92, P9515, DOI 10.1073/pnas.92.21.9515; DUTAR P, 1988, NATURE, V332, P156, DOI 10.1038/332156a0; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Fritschy JM, 1999, EUR J NEUROSCI, V11, P761, DOI 10.1046/j.1460-9568.1999.00481.x; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Hestrin S, 1996, J NEUROSCI, V16, P5290; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; JONES EG, 1975, J COMP NEUROL, V160, P205, DOI 10.1002/cne.901600204; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Kim U, 1997, SCIENCE, V278, P130, DOI 10.1126/science.278.5335.130; KISVARDAY ZF, 1990, BRAIN, V113, P793, DOI 10.1093/brain/113.3.793; KRNJEVIC K, 1967, EXP BRAIN RES, V3, P320, DOI 10.1007/BF00237558; Kulik A, 2002, EUR J NEUROSCI, V15, P291, DOI 10.1046/j.0953-816x.2001.01855.x; LACAILLE JC, 1988, J NEUROSCI, V8, P1411; Larkum ME, 1999, NATURE, V398, P338, DOI 10.1038/18686; Li JL, 2001, NEUROSCI LETT, V315, P93, DOI 10.1016/S0304-3940(01)02321-7; Lopez-Bendito G, 2002, EUR J NEUROSCI, V15, P1766, DOI 10.1046/j.1460-9568.2002.02032.x; MILES R, 1996, NEURON, V16, P816; MISGELD U, 1995, PROG NEUROBIOL, V46, P423, DOI 10.1016/0301-0082(95)00012-K; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; Overstreet LS, 2000, J NEUROSCI, V20, P7914; PEARCE RA, 1993, NEURON, V10, P189, DOI 10.1016/0896-6273(93)90310-N; QIAN N, 1990, P NATL ACAD SCI USA, V87, P8145, DOI 10.1073/pnas.87.20.8145; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Tamas G, 2000, NAT NEUROSCI, V3, P366, DOI 10.1038/73936; Thomson AM, 1996, J PHYSIOL-LONDON, V496, P81, DOI 10.1113/jphysiol.1996.sp021667; Thomson AM, 1999, NEUROSCIENCE, V92, P1193, DOI 10.1016/S0306-4522(99)00021-4; VALVERDE F, 1971, International Journal of Neuroscience, V1, P181, DOI 10.3109/00207457109146970	35	252	257	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 21	2003	299	5614					1902	1905		10.1126/science.1082053	http://dx.doi.org/10.1126/science.1082053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649485				2022-12-28	WOS:000181669700049
J	Borozdin, KN; Hogan, GE; Morris, C; Priedhorsky, WC; Saunders, A; Schultz, LJ; Teasdale, ME				Borozdin, KN; Hogan, GE; Morris, C; Priedhorsky, WC; Saunders, A; Schultz, LJ; Teasdale, ME			Surveillance: Radiographic imaging with cosmic-ray muons	NATURE			English	Article									Los Alamos Natl Lab, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Borozdin, KN (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	kbor@lanl.gov		Priedhorsky, William/0000-0003-0295-9138				ATENCIO LG, 1981, NUCL INSTRUM METHODS, V187, P381, DOI 10.1016/0029-554X(81)90364-5; Grieder PK., 2001, COSMIC RAYS EARTH; Hagiwara K, 2002, PHYS REV D, V66, DOI 10.1103/PhysRevD.66.010001; Roentgen WC, 1896, NATURE, V53, P274	4	242	262	3	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	2003	422	6929					277	277		10.1038/422277a	http://dx.doi.org/10.1038/422277a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646911	Bronze			2022-12-28	WOS:000181637300029
J	Grigera, TS; Martin-Mayor, V; Parisi, G; Verrocchio, P				Grigera, TS; Martin-Mayor, V; Parisi, G; Verrocchio, P			Phonon interpretation of the 'boson peak' in supercooled liquids	NATURE			English	Article							FREQUENCY PROPAGATING MODES; RELAXATION PROCESSES; ENERGY LANDSCAPE; VITREOUS SILICA; DYNAMICS; GLASSES; NETWORK; SADDLES	Glasses(1,2) are amorphous solids, in the sense that they display elastic behaviour. In crystalline solids, elasticity is associated with phonons, which are quantized vibrational excitations. Phonon-like excitations also exist in glasses at very high (terahertz; 10(12) Hz) frequencies; surprisingly, these persist in the supercooled liquids'. A universal feature of such amorphous systems is the boson peak: the vibrational density of states has an excess compared to the Debye squared-frequency law. Here we investigate the origin of this feature by studying the spectra of inherent structures' (local minima of the potential energy) in a realistic glass model. We claim that the peak is the signature of a phase transition in the space of the stationary points of the energy, from a minima-dominated phase (with phonons) at low energy to a saddle-point-dominated phase(5-7) (without phonons). The boson peak moves to lower frequencies on approaching the phonon-saddle transition, and its height diverges at the critical point. Our numerical results agree with the predictions of euclidean random matrix theory(8) on the existence of a sharp phase transition(9) between an amorphous elastic phase and a phonon-free one.	Univ Roma La Sapienza, SMC, Sez INFM, Dipartimento Fis, I-00185 Rome, Italy; Univ Roma La Sapienza, INFM, Unita Roma 1, I-00185 Rome, Italy; Univ Trent, Dipartimento Fis, I-38050 Trento, Italy; Univ Trent, INFM Unita Trento, I-38050 Trento, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Sapienza University Rome; University of Trento; University of Trento	Martin-Mayor, V (corresponding author), Univ Roma La Sapienza, SMC, Sez INFM, Dipartimento Fis, Piazzale Aldo Moro 2, I-00185 Rome, Italy.	victor.martin@roma1.infn.it	Martin-Mayor, Victor/B-1790-2010; Verrocchio, Paolo/F-7632-2010	Martin-Mayor, Victor/0000-0002-3376-0327; Grigera, Tomas/0000-0002-3165-4838				Angelani L, 2000, PHYS REV LETT, V85, P5356, DOI 10.1103/PhysRevLett.85.5356; ANGELL CA, 1995, SCIENCE, V267, P1924, DOI 10.1126/science.267.5206.1924; Benassi P, 1996, PHYS REV LETT, V77, P3835, DOI 10.1103/PhysRevLett.77.3835; BERNU B, 1987, PHYS REV A, V36, P4891, DOI 10.1103/PhysRevA.36.4891; Broderix K, 2000, PHYS REV LETT, V85, P5360, DOI 10.1103/PhysRevLett.85.5360; Cavagna A, 2001, J PHYS A-MATH GEN, V34, P5317, DOI 10.1088/0305-4470/34/26/302; Debenedetti PG, 2001, NATURE, V410, P259, DOI 10.1038/35065704; Engberg D, 1999, PHYS REV B, V59, P4053, DOI 10.1103/PhysRevB.59.4053; Fioretto D, 1999, PHYS REV E, V59, P4470, DOI 10.1103/PhysRevE.59.4470; Gotze W, 2000, PHYS REV E, V61, P587, DOI 10.1103/PhysRevE.61.587; GOTZE W, 1992, REP PROG PHYS, V55, P241, DOI 10.1088/0034-4885/55/3/001; Grigera TS, 2002, J PHYS-CONDENS MAT, V14, P2167, DOI 10.1088/0953-8984/14/9/306; Grigera TS, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.055502; Grigera TS, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.085502; Grigera TS, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.045102; Horbach J, 1999, J PHYS CHEM B, V103, P4104, DOI 10.1021/jp983898b; Kob W, 2000, EUROPHYS LETT, V49, P590, DOI 10.1209/epl/i2000-00191-8; KOB W, 1995, PHYS REV E, V51, P4626, DOI 10.1103/PhysRevE.51.4626; La Nave E, 2002, PHYS REV LETT, V88, DOI [10.1103/PhysRevLett.88.035501, 10.1103/PhysRevB.88.035501]; Mamedov S, 1998, J MATER SCI, V33, P41, DOI 10.1023/A:1004377125553; Martin-Mayor V, 2001, J CHEM PHYS, V114, P8068, DOI 10.1063/1.1349709; Masciovecchio C, 1996, PHYS REV LETT, V76, P3356, DOI 10.1103/PhysRevLett.76.3356; Masciovecchio C, 1997, PHYS REV B, V55, P8049, DOI 10.1103/PhysRevB.55.8049; Matic A, 2001, EUROPHYS LETT, V54, P77, DOI 10.1209/epl/i2001-00231-y; Mezard M, 1999, NUCL PHYS B, V559, P689, DOI 10.1016/S0550-3213(99)00428-9; PHILLIPS WA, 1989, PHYS REV LETT, V63, P2381, DOI 10.1103/PhysRevLett.63.2381; Pilla O, 2000, PHYS REV LETT, V85, P2136, DOI 10.1103/PhysRevLett.85.2136; PILLA O, 2002, CONDMAT0209519; Ruocco G, 2000, PHYS REV LETT, V84, P5788, DOI 10.1103/PhysRevLett.84.5788; Sette F, 1998, SCIENCE, V280, P1550, DOI 10.1126/science.280.5369.1550; STILLINGER FH, 1995, SCIENCE, V267, P1935, DOI 10.1126/science.267.5206.1935	31	264	268	4	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	2003	422	6929					289	292		10.1038/nature01475	http://dx.doi.org/10.1038/nature01475			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646916				2022-12-28	WOS:000181637300034
J	Walden, H; Podgorski, MS; Schulman, BA				Walden, H; Podgorski, MS; Schulman, BA			Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8	NATURE			English	Article							PROTEIN MODIFICATION PATHWAY; MECHANISM; COMPLEX; SYSTEM; CONJUGATION; SITE; FAMILY; LIGASE; SMT3P	Post-translational modification by ubiquitin-like proteins (Ublps) is an essential cellular regulatory mechanism(1-3). The Ublp NEDD8 regulates cell division, signalling and embryogenesis(4-6). Ublps are conjugated to their targets by the sequential action of E1, E2 and often E3 enzymes(3). Each Ublp has a dedicated E1, or activating enzyme, that initiates its conjugation cascade(1,3,7-10). First, E1 associates with the Ublp and catalyses adenylation of the carboxy terminus of the Ublp. Second, E1 forms a thioester between its catalytic cysteine and the Ublp. Next, E1 is loaded with a second Ublp molecule, adenylating the C terminus of this second Ublp while still carrying the first thioester-bound LTblp. Last, E1 binds E2 and promotes Ublp transfer to the catalytic cysteine of E2. We report here the structure and mutational analysis of human APPBP1-UBA3, the heterodimeric E1 enzyme for NEDD8 (ref. 11). Each E1 activity is specified by a domain: an adenylation domain resembling bacterial adenylating enzymes 12, an E1-specific domain organized around the catalytic cysteine, and a domain involved in E2 recognition resembling ubiquitin. The domains are arranged around two clefts that coordinate protein and nucleotide binding so that each of E1's reactions drives the next, in an assembly-line fashion.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet Tumor Cell Biol, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Schulman, BA (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	Brenda.schulman@stjude.org						Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WHITEHEAD GW, 1983, B AM MATH SOC, V8, P1, DOI 10.1090/S0273-0979-1983-15072-3	30	170	176	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	2003	422	6929					330	334		10.1038/nature01456	http://dx.doi.org/10.1038/nature01456			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646924				2022-12-28	WOS:000181637300044
J	Heath, DD; Heath, JW; Bryden, CA; Johnson, RM; Fox, CW				Heath, DD; Heath, JW; Bryden, CA; Johnson, RM; Fox, CW			Rapid evolution of egg size in captive salmon	SCIENCE			English	Article							OFFSPRING SIZE; PACIFIC SALMON; CHINOOK SALMON; NUMBER; SELECTION; POPULATIONS; RECOVERY; FITNESS; LIFE	Captive breeding and release programs, widely used to supplement populations of declining species, minimize juvenile mortality to achieve rapid population growth. However, raising animals in benign environments may promote traits that are adaptive in captivity but maladaptive in nature. In chinook salmon, hatchery rearing relaxes natural selection favoring large eggs, allowing fecundity selection to drive exceptionally rapid evolution of small eggs. Trends toward small eggs are also evident in natural populations heavily supplemented by hatcheries, but not in minimally supplemented populations. Unintentional selection in captivity can lead to rapid changes in critical life-history traits that may reduce the success of supplementation or reintroduction programs.	Univ Windsor, Great Lakes Inst Environm Res, Windsor, ON N9B 3P4, Canada; Univ Windsor, Dept Biol Sci, Windsor, ON N9B 3P4, Canada; Yellow Isl Aquaculture Ltd, Campbell River, BC V9W 6K9, Canada; AXYS Environm Consulting Ltd, Sidney, BC V8L 3S8, Canada; Univ No British Columbia, Coll Sci & Management, Prince George, BC V2N 4Z9, Canada; Univ Kentucky, Dept Entomol, Lexington, KY 40546 USA	University of Windsor; University of Windsor; University of Northern British Columbia; University of Kentucky	Heath, DD (corresponding author), Univ Windsor, Great Lakes Inst Environm Res, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	dheath@uwindsor.ca	Fox, Charles W/I-5274-2012	Fox, Charles W/0000-0002-7545-7967				ALLENDORF FW, 1993, CONSERV BIOL, V7, P416, DOI 10.1046/j.1523-1739.1993.07020416.x; Duchesne P, 2002, CONSERV GENET, V3, P47; EBENHARD T, 1995, TRENDS ECOL EVOL, V10, P438, DOI 10.1016/S0169-5347(00)89176-4; Einum S, 2002, P ROY SOC B-BIOL SCI, V269, P2325, DOI 10.1098/rspb.2002.2150; Einum S, 2000, NATURE, V405, P565, DOI 10.1038/35014600; Einum S, 2000, EVOLUTION, V54, P628, DOI 10.1111/j.0014-3820.2000.tb00064.x; Gippoliti S, 1997, CONSERV BIOL, V11, P806, DOI 10.1046/j.1523-1739.1997.96342.x; Heath DD, 1999, EVOLUTION, V53, P1605, DOI [10.2307/2640906, 10.1111/j.1558-5646.1999.tb05424.x]; Heath DD, 2002, CAN J FISH AQUAT SCI, V59, P77, DOI 10.1139/F01-192; Heath DD, 1998, MATERNAL EFFECTS AS ADAPTATIONS, P178; Hendry AP, 1999, EVOLUTION, V53, P1637, DOI 10.1111/j.1558-5646.1999.tb04550.x; Hendry AP, 2001, AM NAT, V157, P387, DOI 10.1086/319316; Kingsolver JG, 2001, AM NAT, V157, P245, DOI 10.1086/319193; LLOYD DG, 1987, AM NAT, V129, P800, DOI 10.1086/284676; Lynch M, 2001, CONSERV GENET, V2, P363, DOI 10.1023/A:1012550620717; Mousseau T.A., 1998, MATERNAL EFFECTS ADA; Noakes DJ, 2000, AQUACULTURE, V183, P363, DOI 10.1016/S0044-8486(99)00294-X; PARKER GA, 1986, AM NAT, V128, P573, DOI 10.1086/284589; PHILIPPART JC, 1995, BIOL CONSERV, V72, P281, DOI 10.1016/0006-3207(94)00090-D; Price EO, 1999, APPL ANIM BEHAV SCI, V65, P245, DOI 10.1016/S0168-1591(99)00087-8; Reisenbichler RR, 1999, ICES J MAR SCI, V56, P459, DOI 10.1006/jmsc.1999.0455; Roff D.A., 1997, EVOLUTIONARY QUANTIT; Roff Derek A., 1992; SMITH CC, 1974, AM NAT, V108, P499, DOI 10.1086/282929; Snyder NFR, 1996, CONSERV BIOL, V10, P338, DOI 10.1046/j.1523-1739.1996.10020338.x; Wang JL, 2001, CONSERV BIOL, V15, P1619, DOI 10.1046/j.1523-1739.2001.00173.x; WAPLES RS, 1994, CONSERV BIOL, V8, P884, DOI 10.1046/j.1523-1739.1994.08030863-12.x; WINKLER DW, 1987, AM NAT, V129, P708, DOI 10.1086/284667	28	245	256	1	151	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	2003	299	5613					1738	1740		10.1126/science.1079707	http://dx.doi.org/10.1126/science.1079707			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637746				2022-12-28	WOS:000181519500047
J	Sayegh, MH; Colvin, RB				Sayegh, MH; Colvin, RB			A 35-year-old man with early dysfunction of a second renal transplant - Acute humoral rejection, persistent.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							KIDNEY-TRANSPLANTATION; PATHOLOGICAL FEATURES; ALLOGRAFT RECIPIENTS; CROSS-MATCH; ANTIBODY; PLASMAPHERESIS; CLASSIFICATION; SENSITIZATION; TOLERANCE; GLOBULIN		Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Sayegh, MH (corresponding author), Brigham & Womens Hosp, Dept Med, Div Renal, 75 Francis St, Boston, MA 02115 USA.							Baid S, 2001, CURR OPIN IMMUNOL, V13, P577, DOI 10.1016/S0952-7915(00)00262-4; Bohmig Georg A, 2002, Curr Opin Urol, V12, P95, DOI 10.1097/00042307-200203000-00003; Cecka J M, 2000, Clin Transpl, P1; Collins AB, 1999, J AM SOC NEPHROL, V10, P2208; Crespo M, 2001, TRANSPLANTATION, V71, P652, DOI 10.1097/00007890-200103150-00013; DELANEY VB, 1988, TRANSPLANTATION, V45, P743, DOI 10.1097/00007890-198804000-00016; Denton MD, 1999, LANCET, V353, P1083, DOI 10.1016/S0140-6736(98)07493-5; Gebel HM, 2000, TRANSPLANTATION, V69, P1370, DOI 10.1097/00007890-200004150-00027; GRANDTNEROVA B, 1995, TRANSPLANT P, V27, P934; HALLORAN PF, 1990, TRANSPLANTATION, V49, P85, DOI 10.1097/00007890-199001000-00019; HALLORAN PF, 1992, TRANSPLANTATION, V53, P550, DOI 10.1097/00007890-199203000-00011; Jordan SC, 1998, TRANSPLANTATION, V66, P800, DOI 10.1097/00007890-199809270-00017; Kotb M, 1999, CLIN TRANSPLANT, V13, P83, DOI 10.1034/j.1399-0012.1999.130104.x; LOBO PI, 1995, TRANSPLANTATION, V59, P357, DOI 10.1097/00007890-199502150-00009; MASTRANGELO F, 1995, TRANSPLANT P, V27, P892; Mauiyyedi S, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133779; McKay DB, 2000, BRENNER RECTORS KIDN, V2, P2542; McKenna RM, 2000, TRANSPLANTATION, V69, P319, DOI 10.1097/00007890-200002150-00001; Montgomery RA, 2000, TRANSPLANTATION, V70, P887, DOI 10.1097/00007890-200009270-00006; Pascual M, 1998, TRANSPLANTATION, V66, P1460, DOI 10.1097/00007890-199812150-00008; Pascual M, 1999, TRANSPLANTATION, V67, P495; Pollak R, 1999, TRANSPLANTATION, V68, P592, DOI 10.1097/00007890-199908270-00028; Racusen LC, 1999, KIDNEY INT, V55, P713, DOI 10.1046/j.1523-1755.1999.00299.x; RACUSEN LC, IN PRESS AM J TRANSP; Salama AD, 2001, J CLIN INVEST, V108, P943, DOI 10.1172/JCI200114142; SANFILIPPO F, 1982, TRANSPLANTATION, V34, P360, DOI 10.1097/00007890-198212000-00010; Trpkov K, 1996, TRANSPLANTATION, V61, P1586, DOI 10.1097/00007890-199606150-00007; VELLA JP, 1998, GHERAPY NEPHROLOGY H, P612	28	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					1033	1044		10.1056/NEJMcpc020033	http://dx.doi.org/10.1056/NEJMcpc020033			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653YT	12637614				2022-12-28	WOS:000181465200009
J	Knapp, S				Knapp, S			Dynamic diversity	NATURE			English	Article									Nat Hist Museum, Dept Bot, London SW7 5BD, England	Natural History Museum London	Knapp, S (corresponding author), Nat Hist Museum, Dept Bot, Cromwell Rd, London SW7 5BD, England.		Knapp, Sandra/A-4856-2011	Knapp, Sandra/0000-0001-7698-3945				DALY HE, 2002, WORLD BANK ANN REV 2, P15; ORiordan T., 2002, BIODIVERSITY SUSTAIN; Orr DW, 2002, CONSERV BIOL, V16, P1457; Raven PH, 2002, SCIENCE, V297, P954, DOI 10.1126/science.297.5583.954; Rees WE, 2003, NATURE, V421, P898, DOI 10.1038/421898a; *ROYAL SOC WORK GR, 2003, MEAS BIOD	6	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2003	422	6931					475	475		10.1038/422475a	http://dx.doi.org/10.1038/422475a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673231				2022-12-28	WOS:000181965400020
J	Kedar, I; Ternullo, JL; Weinrib, CE; Kelleher, KM; Brandling-Bennett, H; Kvedar, JC				Kedar, I; Ternullo, JL; Weinrib, CE; Kelleher, KM; Brandling-Bennett, H; Kvedar, JC			Internet based consultations to transfer knowledge for patients requiring specialised care: retrospective case review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GEOGRAPHIC-VARIATION; TELEMEDICINE	Objective To assess whether transferring knowledge from specialists at centres of excellence to referring doctors through online consultations can improve the management of patients requiring specialised care. Design Retrospective case review of the first year of internet based patient initiated consultations between referring doctors and consulting specialists. Setting US teaching hospitals affiliated with an organisation providing internet based consultations. Participants Doctors in various settings around the world engaging in internet based consultations with specialists. Main outcome measures New recommendations for treatment, change in diagnosis, and turnaround time for consultation compared with time to see a specialist. Results 79 consultations took place. 90% (n=71) of consultations were for services related to oncology. 90% of consultations involved new recommendations for treatment. The most common recommendation was a new chemotherapeutic regimen (68%, n=54). Diagnosis changed in 5% (n=4) of cases. The average turnaround time was 6.8 working days compared with an average of 19 working days to see a comparable specialist Conclusions Internet based consultations between specialists at centres of excellence and referring doctors contribute to patient care through recommendations for new treatment and timely access to specialist knowledge. Although change in diagnosis occurred in only a few cases, the prognostic and therapeutic implications for these patients may be profound.	Partners Telemed, Boston, MA 02114 USA		Kvedar, JC (corresponding author), Partners Telemed, 2 Longfellow Pl,Suite 216, Boston, MA 02114 USA.	jkvedar@partners.org						Birkmeyer JD, 1998, SURGERY, V124, P917, DOI 10.1067/msy.1998.90268; *CAL HEALTHC FDN, 2000, VAR MED PRACT QUAL I; Fox S., 2002, VITAL DECISIONS INTE; Hunt D L, 2001, Evid Based Cardiovasc Med, V5, P34, DOI 10.1054/ebcm.2001.0364; Kronz JD, 1999, CANCER, V86, P2426, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2426::AID-CNCR34>3.0.CO;2-3; Krupinski EA, 1999, J DIGIT IMAGING, V12, P166, DOI 10.1007/BF03168790; McNeill KM, 1998, J AM MED INFORM ASSN, V5, P441, DOI 10.1136/jamia.1998.0050441; O'Connor GT, 1999, JAMA-J AM MED ASSOC, V281, P627, DOI 10.1001/jama.281.7.627; Person D A, 2000, Pac Health Dialog, V7, P29; Shannon G, 2002, TELEMED J E-HEALTH, V8, P61, DOI 10.1089/15305620252933400; SIMON V, 2002, PHYSICIAN COMPENSATI, V3, P1; *US DEP HHS HLTH R, 2001, 2001 TEL REP C JAN 2; Vassallo DJ, 2001, J TELEMED TELECARE, V7, P125, DOI 10.1258/1357633011936273; Wennberg JE, 1998, DARTMOUTH ATLAS HLTH; Wrobel JS, 2001, DIABETES CARE, V24, P860, DOI 10.2337/diacare.24.5.860	15	22	22	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	2003	326	7391					696	699		10.1136/bmj.326.7391.696	http://dx.doi.org/10.1136/bmj.326.7391.696			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663WL	12663408	Bronze, Green Published			2022-12-28	WOS:000182029500019
J	Niewohner, WA; Bergstrom, A; Eichele, D; Zuroff, M; Clark, JT				Niewohner, WA; Bergstrom, A; Eichele, D; Zuroff, M; Clark, JT			Manual dexterity in Neanderthals - These primitive people may have been as handy with their tools as modern humans are.	NATURE			English	Article									Calif State Univ San Bernardino, Dept Anthropol, San Bernardino, CA 92407 USA; N Dakota State Univ, Archaeol Technol Lab, Fargo, ND 58105 USA	California State University System; California State University San Bernardino; North Dakota State University Fargo	Niewohner, WA (corresponding author), Calif State Univ San Bernardino, Dept Anthropol, San Bernardino, CA 92407 USA.							Boule M, 1911, ANN PALEONTOL, V6, P1; BOULE M, 1913, ANN PALEONTOL, V8, P1; BOULE M, 1912, ANN PALEONTOL, V7, P21; Boule M., 1911, ANN PALEONTOLGIE, V6, P111; Churchill SE, 2000, YEARB PHYS ANTHROPOL, V43, P61; COONEY WP, 1981, J BONE JOINT SURG AM, V63, P1371, DOI 10.2106/00004623-198163090-00002; CRAIG SM, 1992, HAND CLIN, V8, P693; KRAEMER BA, 1992, TRAUMATIZED HAND WRI, P65; MUSGRAVE JH, 1971, NATURE, V233, P538, DOI 10.1038/233538a0; Niewoehner WA, 1997, AM J PHYS ANTHROPOL, V103, P219, DOI 10.1002/(SICI)1096-8644(199706)103:2<219::AID-AJPA7>3.0.CO;2-O; NIEWOEHNER WA, 2003, FUNCTIONAL ANATOMY L; Trinkaus, 2014, SHANIDAR NEANDERTALS; VLCEK E, 1975, B MEM SOC ANTHRO PAR, V13, P257	13	30	32	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					395	395		10.1038/422395a	http://dx.doi.org/10.1038/422395a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660770				2022-12-28	WOS:000181801200031
J	Lofthouse, CM; Akobeng, AK; Adamski, J; Brennan, B				Lofthouse, CM; Akobeng, AK; Adamski, J; Brennan, B			A 2-year-old boy with diarrhoea and failure to thrive	LANCET			English	Article							NEUROBLASTOMA		Central Manchester Hosp, Dept Paediat Gastroenterol, Manchester, Lancs, England; Central Manchester Hosp, Dept Paediat Oncol, Manchester, Lancs, England; Royal Manchester Childrens Hosp, Dept Paediat Oncol, Manchester M27 1HA, Lancs, England; Royal Manchester Childrens Hosp, Dept Paediat Gastroenterol, Manchester M27 1HA, Lancs, England	Royal Manchester Children's Hospital; Royal Manchester Children's Hospital	Akobeng, AK (corresponding author), Booth Hall Childrens Hosp, Dept Paediat Gastroenterol, Charlestown Rd, Manchester M9 7AA, Lancs, England.							Cotterill SJ, 2001, MED PEDIATR ONCOL, V36, P231, DOI 10.1002/1096-911X(20010101)36:1<231::AID-MPO1056>3.0.CO;2-U; DUPONT C, 1984, ANN MED INTERNE, V135, P400; Gao RN, 1997, CANCER CAUSE CONTROL, V8, P745, DOI 10.1023/A:1018483405637; McNally RJQ, 2001, CANCER-AM CANCER SOC, V92, P1967, DOI 10.1002/1097-0142(20011001)92:7<1967::AID-CNCR1716>3.0.CO;2-#; Simpson, 1998, Oncologist, V3, P253	5	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					1012	1012		10.1016/S0140-6736(03)12829-2	http://dx.doi.org/10.1016/S0140-6736(03)12829-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660060				2022-12-28	WOS:000181699700013
J	Shizgal, P; Arvanitogiannis, A				Shizgal, P; Arvanitogiannis, A			Neuroscience: Gambling on dopamine	SCIENCE			English	Editorial Material							REWARD		Concordia Univ, Ctr Studies Behav Neurobiol, Montreal, PQ H3G 1M8, Canada	Concordia University - Canada	Shizgal, P (corresponding author), Concordia Univ, Ctr Studies Behav Neurobiol, Montreal, PQ H3G 1M8, Canada.	shizgal@csbn.concordia.ca; andreas@csbn.concordia.ca	Shizgal, Peter/V-5602-2019; Shizgal, Peter/H-9823-2013	Shizgal, Peter/0000-0003-4265-0792; 				Bateson Melissa, 1998, P297; Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8; Dayan P, 2000, NAT NEUROSCI, V3, P1218, DOI 10.1038/81504; Fiorillo CD, 2003, SCIENCE, V299, P1898, DOI 10.1126/science.1077349; Gallistel CR, 2000, PSYCHOL REV, V107, P289, DOI 10.1037/0033-295X.107.2.289; GALLISTEL CR, FREQUENCY PROCESSING; Knutson B, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0002.2001; Koepp MJ, 1998, NATURE, V393, P266, DOI 10.1038/30498; LADOUCEUR R, 1995, J SOC BEHAV PERS, V10, P473; Ladouceur R, 2001, J NERV MENT DIS, V189, P774, DOI 10.1097/00005053-200111000-00007; Loewenstein GF, 2001, PSYCHOL BULL, V127, P267, DOI 10.1037//0033-2909.127.2.267; MONTAGUE PR, 1995, NATURE, V377, P725, DOI 10.1038/377725a0; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; PEARCE JM, 1980, PSYCHOL REV, V87, P532, DOI 10.1037/0033-295X.87.6.532; Redgrave P, 1999, NEUROSCIENCE, V89, P1009, DOI 10.1016/S0306-4522(98)00319-4; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; SLOVIC P, IN PRESS INTUITIVE J; Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4; Vezina P, 2002, J NEUROSCI, V22, P4654, DOI 10.1523/JNEUROSCI.22-11-04654.2002	23	39	41	3	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	2003	299	5614					1856	1858		10.1126/science.1083627	http://dx.doi.org/10.1126/science.1083627			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649473				2022-12-28	WOS:000181669700034
J	Xiao, Y; Patolsky, F; Katz, E; Hainfeld, JF; Willner, I				Xiao, Y; Patolsky, F; Katz, E; Hainfeld, JF; Willner, I			"Plugging into enzymes": Nanowiring of redox enzymes by a gold nanoparticle	SCIENCE			English	Article							GLUCOSE-OXIDASE; ELECTRON-TRANSFER; RECONSTITUTION; INTEGRATION; BIOSENSORS; MONOLAYER; SUPPORTS; POLYMER; SYSTEMS; SURFACE	The reconstitution of an apo-flavoenzyme, apo-glucose oxidase, on a 1.4-nanometer gold nanocrystal functionalized with the cofactor flavin adenine dinucleotide and integrated into a conductive film yields a bioelectrocatalytic system with exceptional electrical contact with the electrode support. The electron transfer turnover rate of the reconstituted bioelectrocatalyst is similar to5000 per second, compared with the rate at which molecular oxygen, the natural cosubstrate of the enzyme, accepts electrons (similar to700 per second). The gold nanoparticle acts as an electron relay or "electrical nanoplug" for the alignment of the enzyme on the conductive support and for the electrical wiring of its redox-active center.	Hebrew Univ Jerusalem, Inst Chem, IL-91904 Jerusalem, Israel; Brookhaven Natl Lab, Dept Biol, Upton, NY 11873 USA	Hebrew University of Jerusalem; United States Department of Energy (DOE); Brookhaven National Laboratory	Willner, I (corresponding author), Hebrew Univ Jerusalem, Inst Chem, IL-91904 Jerusalem, Israel.		patolsky, Fernando/AAD-1188-2021; Xiao, Yi/L-6606-2016	patolsky, Fernando/0000-0002-1382-5357; Xiao, Yi/0000-0001-7278-9811				Armstrong FA, 2000, ELECTROCHIM ACTA, V45, P2623, DOI 10.1016/S0013-4686(00)00342-X; BADIA A, 1993, J AM CHEM SOC, V115, P7053, DOI 10.1021/ja00069a001; Bard A. J., 1980, ELECTROCHEMICAL METH; BOURDILLON C, 1993, J AM CHEM SOC, V115, P12264, DOI 10.1021/ja00079a005; DEGANI Y, 1987, J PHYS CHEM-US, V91, P1285, DOI 10.1021/j100290a001; Gerard M, 2002, BIOSENS BIOELECTRON, V17, P345, DOI 10.1016/S0956-5663(01)00312-8; Hainfeld JF, 2000, J HISTOCHEM CYTOCHEM, V48, P471, DOI 10.1177/002215540004800404; HELLER A, 1990, ACCOUNTS CHEM RES, V23, P128, DOI 10.1021/ar00173a002; HELLER A, 1992, J PHYS CHEM-US, V96, P3579, DOI 10.1021/j100188a007; Kranz C, 1998, ELECTROANAL, V10, P546, DOI 10.1002/(SICI)1521-4109(199807)10:8<546::AID-ELAN546>3.3.CO;2-R; LAVIRON E, 1979, J ELECTROANAL CHEM, V101, P19, DOI 10.1016/S0022-0728(79)80075-3; Raitman OA, 2002, J AM CHEM SOC, V124, P6487, DOI 10.1021/ja012680r; Rajagopalan R, 1996, J PHYS CHEM-US, V100, P3719, DOI 10.1021/jp952160g; SCHUHMANN W, 1991, J AM CHEM SOC, V113, P1394, DOI 10.1021/ja00004a048; WILLNER I, 1992, BIOELECTROCH BIOENER, V29, P29, DOI 10.1016/0302-4598(92)80051-H; Willner I, 1996, J AM CHEM SOC, V118, P10321, DOI 10.1021/ja9608611; WILLNER I, 1993, ADV MATER, V5, P912, DOI 10.1002/adma.19930051206; Willner I, 2000, ANGEW CHEM INT EDIT, V39, P1180, DOI 10.1002/(SICI)1521-3773(20000403)39:7<1180::AID-ANIE1180>3.0.CO;2-E; Zayats M, 2002, J AM CHEM SOC, V124, P2120, DOI 10.1021/ja025503e	19	1101	1127	9	441	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 21	2003	299	5614					1877	1881		10.1126/science.1080664	http://dx.doi.org/10.1126/science.1080664			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649477				2022-12-28	WOS:000181669700041
J	Benjamin, ER; Clements, C; McCally, M; Pellett, PL; Van Rooyen, MJ; Waldman, RJ				Benjamin, ER; Clements, C; McCally, M; Pellett, PL; Van Rooyen, MJ; Waldman, RJ			The humanitarian cost of a war in Iraq	LANCET			English	Editorial Material									Ctr Econ & Social Rights, Brooklyn, NY USA; WaterWorks, Santa Fe, NM USA; Univ Oregon, Dept Publ Hlth & Prevent Med, Portland, OR USA; Univ Massachusetts, Amherst, MA 01003 USA; Johns Hopkins Univ, Ctr Int Emergency Disaster & Refugee Studies, Baltimore, MD USA; Mailman Sch Publ Hlth, Program Forced Migrat & Hlth, New York, NY USA	University of Oregon; University of Massachusetts System; University of Massachusetts Amherst; Johns Hopkins University	Benjamin, ER (corresponding author), Ctr Econ & Social Rights, Brooklyn, NY USA.							*CTR EC SOC RIGHTS, 2003, HUM COST WAR IR; *UN, 2003, PORTR CURR SOC DEV S	2	0	0	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					874	874		10.1016/S0140-6736(03)12716-X	http://dx.doi.org/10.1016/S0140-6736(03)12716-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	653ZH	12642068				2022-12-28	WOS:000181466600029
J	Vassilopoulos, G; Wang, PR; Russell, DW				Vassilopoulos, G; Wang, PR; Russell, DW			Transplanted bone marrow regenerates liver by cell fusion	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; FOAMY VIRUS VECTORS; FUMARYLACETOACETATE HYDROLASE; HEPATIC-DYSFUNCTION; KUPFFER CELLS; MOUSE-LIVER; ORIGIN; HEPATOCYTES; PHENOTYPE; KINETICS	Results from several experimental systems suggest that cells from one tissue type can form other tissue types after transplantation. This could be due to the presence of multipotential or several types of adult stem cells in donor tissues, or alternatively, to fusion of donor and recipient cells. In a model of tyrosinaemia type I, mice with mutations in the fumarylacetoacetate hydrolase gene (Fah(-/-)) regain normal liver function after transplantation of Fah(+/+) bone marrow cells, and form regenerating liver nodules with normal histology that express Fah(1). Here we show that these hepatic nodules contain more mutant than wild-type Fah alleles, and that their hepatocytes express both donor and host genes, consistent with polyploid genome formation by fusion of host and donor cells. Using bone marrow cells marked with integrated foamy virus vectors that express green fluorescent protein, we identify common proviral junctions in hepatic nodules and haematopoietic cells. We also show that the haematopoietic donor genome adopts a more hepatocyte-specific expression profile after cell fusion, as the wild-type Fah gene was activated and the pan-haematopoietic CD45 marker was no longer expressed.	Univ Washington, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Russell, DW (corresponding author), Univ Washington, Div Hematol, Seattle, WA 98195 USA.		Vassilopoulos, George/AAK-8069-2020					ARIAS IM, 1994, LIVER; BISHOP CE, 1985, NATURE, V315, P70, DOI 10.1038/315070a0; BOHM N, 1981, HISTOCHEMISTRY, V72, P55, DOI 10.1007/BF00496779; CROFTON RW, 1978, J EXP MED, V148, P1, DOI 10.1084/jem.148.1.1; EPSTEIN CJ, 1967, NATURE, V214, P1050, DOI 10.1038/2141050a0; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; GALE RP, 1978, SCIENCE, V201, P937, DOI 10.1126/science.356266; GOLDENBERG DM, 1971, CANCER RES, V31, P1148; GROMPE M, 1992, BIOCHEM MED METAB B, V48, P26, DOI 10.1016/0885-4505(92)90044-Y; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; GROMPE M, 1995, NAT GENET, V10, P453, DOI 10.1038/ng0895-453; Josephson NC, 2002, P NATL ACAD SCI USA, V99, P8295, DOI 10.1073/pnas.122131099; KERBEL RS, 1983, MOL CELL BIOL, V3, P523, DOI 10.1128/MCB.3.4.523; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; MINTZ B, 1967, P NATL ACAD SCI USA, V58, P592, DOI 10.1073/pnas.58.2.592; PARADIS K, 1990, J PEDIATR GASTR NUTR, V11, P525, DOI 10.1097/00005176-199011000-00014; PARWARESCH MR, 1986, VIRCHOWS ARCH B, V51, P89, DOI 10.1007/BF02899019; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Vassilopoulos G, 2001, BLOOD, V98, P604, DOI 10.1182/blood.V98.3.604; Vignery A, 2000, INT J EXP PATHOL, V81, P291, DOI 10.1046/j.1365-2613.2000.00164.x; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weglarz TC, 2000, AM J PATHOL, V157, P1963, DOI 10.1016/S0002-9440(10)64835-3; WIENER F, 1974, P NATL ACAD SCI USA, V71, P148, DOI 10.1073/pnas.71.1.148; WIENER F, 1972, NATURE-NEW BIOL, V238, P155, DOI 10.1038/newbio238155a0; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; ZAKIM D, 1990, HEPATOLOGY	26	1002	1093	2	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 24	2003	422	6934					901	904		10.1038/nature01539	http://dx.doi.org/10.1038/nature01539			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12665833				2022-12-28	WOS:000182432600057
J	Brei, B; Fish, D				Brei, B; Fish, D			Comment on "Parasites as a viability cost of sexual selection in natural populations of mammals"	SCIENCE			English	Editorial Material							HOME RANGE; BODY-SIZE		Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	Yale University		Durland.Fish@yale.edu						BROWN JH, 1993, AM NAT, V142, P573, DOI 10.1086/285558; HARESTAD AS, 1979, ECOLOGY, V60, P389, DOI 10.2307/1937667; LINDSTEDT SL, 1986, ECOLOGY, V67, P413, DOI 10.2307/1938584; Moore SL, 2002, SCIENCE, V297, P2015, DOI 10.1126/science.1074196; ORIANS GH, 1969, AM NAT, V103, P589, DOI 10.1086/282628; Owens IPF, 2002, SCIENCE, V297, P2008, DOI 10.1126/science.1076813; *WHO, 2001, WORLD HLTH STAT ANN; 2002, SCIENCE, V298, P1336	8	12	13	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					55A	55A		10.1126/science.1079746	http://dx.doi.org/10.1126/science.1079746			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677043				2022-12-28	WOS:000181988900019
J	Dutzler, R; Campbell, EB; MacKinnon, R				Dutzler, R; Campbell, EB; MacKinnon, R			Gating the selectivity filter in ClC chloride channels	SCIENCE			English	Article							TORPEDO ELECTROPLAX; MOLECULAR-BASIS; K+ CHANNEL; CONDUCTION; MECHANISM; RECEPTOR; CLONING; ANION	ClC channels conduct chloride (Cl-) ions across cell membranes and thereby govern the electrical activity of muscle cells and certain neurons, the transport of fluid and electrolytes across epithelia, and the acidification of intracellular vesicles. The structural basis of ClC channel gating was studied. Crystal structures of wild-type and mutant Escherichia coli ClC channels bound to a monoclonal Fab fragment reveal three Cl- binding sites within the 15-angstrom neck of an hourglass-shaped pore. The Cl- binding site nearest the extracellular solution can be occupied either by a Cl- ion or by a glutamate carboxyl group. Mutations of this glutamate residue in Torpedo ray ClC channels alter gating in electrophysiological assays. These findings reveal a form of gating in which the glutamate carboxyl group closes the pore by mimicking a Cl- ion.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockvax.rockefeller.edu						Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen MF, 2001, J GEN PHYSIOL, V118, P23, DOI 10.1085/jgp.118.1.23; Chen TY, 1996, J GEN PHYSIOL, V108, P237, DOI 10.1085/jgp.108.4.237; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Harlow E., 1989, ANTIBODIES LAB MANUA; Iyer R, 2002, NATURE, V419, P715, DOI 10.1038/nature01000; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Maduke M, 2000, ANNU REV BIOPH BIOM, V29, P411, DOI 10.1146/annurev.biophys.29.1.411; Miller C., 1980, Annals of the New York Academy of Sciences, V341, P534, DOI 10.1111/j.1749-6632.1980.tb47197.x; MILLER C, 1982, PHILOS T ROY SOC B, V299, P401, DOI 10.1098/rstb.1982.0140; Morais-Cabral JH, 2001, NATURE, V414, P37, DOI 10.1038/35102000; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; RICHARD EA, 1990, SCIENCE, V247, P1208, DOI 10.1126/science.2156338; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	26	620	641	0	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					108	112		10.1126/science.1082708	http://dx.doi.org/10.1126/science.1082708			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12649487				2022-12-28	WOS:000181988900042
J	Faivre, B; Gregoire, A; Preault, M; Cezilly, F; Sorci, G				Faivre, B; Gregoire, A; Preault, M; Cezilly, F; Sorci, G			Immune activation rapidly mirrored in a secondary sexual trait	SCIENCE			English	Article							CAROTENOIDS		Univ Bourgogne, CNRS, UMR Biogeosci 5561, Equipe Ecol Evolut, F-21000 Dijon, France; Univ Paris 06, CNRS, UMR 7103, Lab Parasitol Evolut, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Faivre, B (corresponding author), Univ Bourgogne, CNRS, UMR Biogeosci 5561, Equipe Ecol Evolut, 6 Blvd Gabriel, F-21000 Dijon, France.	bfaivre@u-bourgogne.fr	Gregoire, Arnaud/B-6321-2008	Gregoire, Arnaud/0000-0001-6103-355X; Sorci, Gabriele/0000-0002-0799-3995				Andersson Malte, 1994; BENDICH A, 1989, J NUTR, V119, P112, DOI 10.1093/jn/119.1.112; Bright A, 2002, ANIM BEHAV, V64, P207, DOI 10.1006/anbe.2002.3042; Faivre B, 2001, ANIM BEHAV, V61, P969, DOI 10.1006/anbe.2000.1669; JYONOUCHI H, 1994, NUTR CANCER, V21, P47, DOI 10.1080/01635589409514303; Mortensen A, 1997, FEBS LETT, V418, P91, DOI 10.1016/S0014-5793(97)01355-0; Olson VA, 1998, TRENDS ECOL EVOL, V13, P510, DOI 10.1016/S0169-5347(98)01484-0	7	334	340	3	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					103	103		10.1126/science.1081802	http://dx.doi.org/10.1126/science.1081802			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677062				2022-12-28	WOS:000181988900040
J	Moore, SD; McGinness, KE; Sauer, RT				Moore, SD; McGinness, KE; Sauer, RT			A glimpse into tmRNA-mediated ribosome rescue	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; TRANSFER-RNA; 10SA RNA; SSRA; PROTEINS; CODONS		MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Moore, SD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	bobsauer@.mit.edu		Sauer, Robert/0000-0002-1719-5399				Abo T, 2000, EMBO J, V19, P3762, DOI 10.1093/emboj/19.14.3762; Alberts B., 2002, MOL BIOL CELL; Hayes CS, 2002, P NATL ACAD SCI USA, V99, P3440, DOI 10.1073/pnas.052707199; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Stark H, 2002, NAT STRUCT BIOL, V9, P849, DOI 10.1038/nsb859; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; Valle M, 2003, SCIENCE, V300, P127, DOI 10.1126/science.1081798; Williams KP, 2002, NUCLEIC ACIDS RES, V30, P179, DOI 10.1093/nar/30.1.179	11	1	3	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					72	73		10.1126/science.1084034	http://dx.doi.org/10.1126/science.1084034			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677051				2022-12-28	WOS:000181988900029
J	Strauss, SH				Strauss, SH			Genetic technologies - Genomics, genetic engineering, and domestication of crops	SCIENCE			English	Editorial Material							TOLERANCE; BIOLOGY		Oregon State Univ, Dept Forest Sci, Corvallis, OR 97331 USA	Oregon State University	Strauss, SH (corresponding author), Oregon State Univ, Dept Forest Sci, Peavy Hall 154, Corvallis, OR 97331 USA.	Steve.Strauss@orst.edu						[Anonymous], 1982, AM HERITAGE DICT, VThird; Bennetzen J, 2002, SCIENCE, V296, P60, DOI 10.1126/science.1071402; Chen THH, 2002, CURR OPIN PLANT BIOL, V5, P250, DOI 10.1016/S1369-5266(02)00255-8; DUVICK D, 2001, COMMUNICATION; HANCOCK J, COMMUNICATION; KAUFMAN M, 2001, WASHINGTON POST 0301, pA17; Matsuoka M, 2001, ANNU REV PLANT PHYS, V52, P297, DOI 10.1146/annurev.arplant.52.1.297; *NAT RES COUNC, 2002, ENV EFF TRANSG PLANT; Siegal ML, 2002, P NATL ACAD SCI USA, V99, P10528, DOI 10.1073/pnas.102303999; Wolfenbarger LL, 2000, SCIENCE, V290, P2088, DOI 10.1126/science.290.5499.2088; Yeo A, 1998, J EXP BOT, V49, P915, DOI 10.1093/jexbot/49.323.915; 2002, FED REG, V68, P50578	12	51	53	3	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2003	300	5616					61	62		10.1126/science.1079514	http://dx.doi.org/10.1126/science.1079514			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677045				2022-12-28	WOS:000181988900023
J	Schober, SE; Sinks, TH; Jones, RL; Bolger, PM; McDowell, M; Osterloh, J; Garrett, ES; Canady, RA; Dillon, CF; Sun, Y; Joseph, CB; Mahaffey, KR				Schober, SE; Sinks, TH; Jones, RL; Bolger, PM; McDowell, M; Osterloh, J; Garrett, ES; Canady, RA; Dillon, CF; Sun, Y; Joseph, CB; Mahaffey, KR			Blood mercury levels in US children and women of childbearing age, 1999-2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METHYLMERCURY EXPOSURE; FISH CONSUMPTION; POPULATION; DISEASE; HAIR	Context Humans are exposed to methylmercury, a well-established neurotoxin, through fish consumption. The fetus is most sensitive to the adverse effects of, exposure. The extent of exposure to methylmercury in US women of reproductive age is not known. Objective To describe the distribution of blood mercury levels in US children and women of childbearing age and the association with sociodemographic characteristics and fish consumption. Design and Setting The 1999-2000 data from, the National Health and Nutrition Examination Survey, a cross-sectional survey of the noninstitutionalized US population. Participants In 1999-2000,1250 children aged 1 to 5 years and 2314 women aged 16 to 49 years were selected to participate in the survey. Household interviews, physical examinations, and blood mercury levels assessments were performed on 705 children (56% response rate) and 1709 women (74% response rate). Main Outcome Measure Blood concentration of total mercury. Results Blood mercury levels were approximately 3-fold higher in women compared with children. The geometric mean concentration of total blood mercury was 0.34 mug/L (95% confidence interval [CI], 0.30-0.39 mug/L) in children and 1.02 mug/L (95% Cl, 0.85-1.20 mug/L) in women. Geometric mean mercury levels were almost 4-fold higher among women who ate 3 or more servings of fish in the past 30 days compared with women who ate no fish in that period (1.94 mug/L vs 0.51 mug/L; P<.001). Conclusions Measures of mercury exposure in women of childbearing age and young children generally fall below levels of concern. However, approximately 8% of women had concentrations higher than the US Environmental Protection Agency's recommended reference dose (5.8 &mu;g/L), below which exposures are considered to be without adverse effects. Women who are pregnant or who intend to become pregnant should follow federal and state advisories on consumption of fish.	Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA; US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA; Natl Marine Fisheries Serv, Natl Ocean & Atmospher Adm, Pascagoula, MS USA; Orkand Corp, Falls Church, VA USA; US EPA, Off Sci Coordinat & Policy, Off Prevent Pesticides & Tox Subst, Washington, DC 20460 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA); National Aeronautics & Space Administration (NASA); National Oceanic Atmospheric Admin (NOAA) - USA; United States Environmental Protection Agency	Schober, SE (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4210, Hyattsville, MD 20782 USA.	sschober@cdc.gov						ABERG B, 1969, ARCH ENVIRON HEALTH, V19, P478, DOI 10.1080/00039896.1969.10666872; Agency for Toxic Substances and Disease Registry, 1999, TOX PROF MERC UPD; BAKIR F, 1973, SCIENCE, V181, P230, DOI 10.1126/science.181.4096.230; Bellanger T M, 2000, J La State Med Soc, V152, P64; BRUNE D, 1991, SCI TOTAL ENVIRON, V100, P235, DOI 10.1016/0048-9697(91)90380-W; Burge P, 1994, J Ark Med Soc, V90, P542; *CDCP, 2 NAT REP HUM EXP EN; Chen HP, 1998, ATOM SPECTROSC, V19, P176; *CTR FOOD SAF APPL, IMP MESS PREGN WOM W; Davidson PW, 1998, JAMA-J AM MED ASSOC, V280, P701, DOI 10.1001/jama.280.8.701; Elinder C.G., 1994, BIOL MONITORING META; *FOOD STAND AG, 2003, AG UPD ADV PREGN BRE; Gerstenberger SL, 1997, J TOXICOL-CLIN TOXIC, V35, P377, DOI 10.3109/15563659709043370; Grandjean P, 1999, AM J EPIDEMIOL, V150, P301, DOI 10.1093/oxfordjournals.aje.a010002; Hall RA, 1978, SSRF721 NOAA NMFS; HARADA M, 1995, CRIT REV TOXICOL, V25, P1, DOI 10.3109/10408449509089885; Kales SN, 2002, J OCCUP ENVIRON MED, V44, P143, DOI 10.1097/00043764-200202000-00009; Kjellstrom T, 1989, 3642 NAT SWED ENV PR; KNOBELOCH LM, 1995, ENVIRON HEALTH PERSP, V103, P604, DOI 10.2307/3432438; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; Mahaffey KR, 1999, PUBLIC HEALTH REP, V114, P397, DOI 10.1093/phr/114.5.397; Miettinen J. -K., 1973, MERCURY MERCURIALS M, P233; National Academy of Sciences, 2000, TOX EFF METH; National Center for Health Statistics, NAT HLTH NUTR EX SUR; Pichichero ME, 2002, LANCET, V360, P1737, DOI 10.1016/S0140-6736(02)11682-5; Rice DC, 2003, RISK ANAL, V23, P107, DOI 10.1111/1539-6924.00294; Seifert B, 2000, J EXPO ANAL ENV EPID, V10, P552, DOI 10.1038/sj.jea.7500111; SHERLOCK J, 1984, HUM TOXICOL, V3, P117, DOI 10.1177/096032718400300205; Stern AH, 2001, ARCH ENVIRON HEALTH, V56, P4, DOI 10.1080/00039890109604048; Toffleson L, 1986, ENV HLTH PERSPECT, V68, P203; Tsubaki T, 1977, MINAMATA DIS; *US EPA, 1997, MERC STUD REP C, V1; *US EPA, 2002, FISH ADV; *WHO, 1990, WHO ENV HLTH CRIT, V101; CANADA FOOD INSPECTI	35	221	228	1	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1667	1674		10.1001/jama.289.13.1667	http://dx.doi.org/10.1001/jama.289.13.1667			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662JX	12672735	Bronze			2022-12-28	WOS:000181944500030
J	Tran, SD; Pillemer, SR; Dutra, A; Barrett, AJ; Brownstein, MJ; Key, S; Pak, E; Leakan, RA; Kingman, A; Yamada, KM; Baum, BJ; Mezey, E				Tran, SD; Pillemer, SR; Dutra, A; Barrett, AJ; Brownstein, MJ; Key, S; Pak, E; Leakan, RA; Kingman, A; Yamada, KM; Baum, BJ; Mezey, E			Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study	LANCET			English	Article							HEMATOPOIETIC STEM-CELLS; OSTEOGENESIS IMPERFECTA; MESENCHYMAL CELLS; TRANSPLANTS; CHILDREN; FUSION	Background Adult bone marrow-derived (BMD) cells could be used to repair damaged organs and tissues, but the intrinsic plasticity of these cells has been questioned by results of in-vitro studies suggesting that such cells might fuse with other cells giving the appearance of differentiation. We aimed to determine whether fusion events are important in vivo. Methods To test whether BMD cells can colonise an epithelial tissue and differentiate there without fusion, we did in-situ hybridisation with Y and X chromosome probes labelled with 35-sulphur or digoxigenin, or labelled fluorescently. We did immunohistochemistry with anticytokeratin 13 along with fluorescence in-situ hybridisation to identify Y-chromosome positive buccal epithelial cells in cheek scrapings obtained from five females who had received either a bone-marrow transplant or an allogeneic mobilised peripheral-blood progenitor-cell transplant (enriched in CD34+ cells) from male donors. Findings When examined 4-6 years after male-to-female marrow-cell transplantation, all female recipients had Y-chromosome-positive buccal cells (0.8-12.7%). In more than 9700 cells studied, we detected only one XXXY-positive cell (0.01%) and one XXY cell (0.01%), both of which could have arisen when an XY cell fused with an XX cell. Interpretation Male BMD cells migrate into the cheek and differentiate into epithelial cells, an occurrence that does not depend on fusion of BMD cells to recipient cells. This finding might be an example of transdifferentiation of haemopoietic or stromal progenitor cells. Plasticity of BMD cells could be useful in regenerative medicine.	NIDCR, NIH, Gene Therapy & Therapeut Branch, Bethesda, MD 20892 USA; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD USA; NIDCR, Biostat Core, NIH, Bethesda, MD USA; NHGRI, Cytogenet Core, NIH, Bethesda, MD 20892 USA; NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA; NIMH, Genet Lab, NIH, Bethesda, MD 20892 USA; NINDS, Basic Neurosci Programme, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Tran, SD (corresponding author), NIDCR, NIH, Gene Therapy & Therapeut Branch, 10 Ctr Dr,Room 1N113,MSC 1190, Bethesda, MD 20892 USA.	stran@dir.nidcr.nih.gov	Mezey, Eva/A-8105-2008	Mezey, Eva/0000-0002-5907-4691; Yamada, Kenneth/0000-0003-1512-6805	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002342, Z01HL002342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525, Z01DE000336, ZIADE000336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002996] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abkowitz JL, 2002, NEW ENGL J MED, V346, P770, DOI 10.1056/NEJM200203073461012; Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; Brouard M, 2002, NEW ENGL J MED, V347, P218; Clarke D, 2001, CURR OPIN GENET DEV, V11, P575, DOI 10.1016/S0959-437X(00)00235-5; Fogt F, 2002, HEPATOLOGY, V36, P173, DOI 10.1053/jhep.2002.33994; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; *LAB CELL MOL REC, 2003, SECT NEUR GEN EXPR; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; NAKAHORI Y, 1986, NUCLEIC ACIDS RES, V14, P7569, DOI 10.1093/nar/14.19.7569; Nelson JL, 2002, TRENDS MOL MED, V8, P109, DOI 10.1016/S1471-4914(01)02269-9; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wells WA, 2002, J CELL BIOL, V157, P15, DOI 10.1083/jcb.200203037; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	18	133	144	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 29	2003	361	9363					1084	1088		10.1016/S0140-6736(03)12894-2	http://dx.doi.org/10.1016/S0140-6736(03)12894-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672312				2022-12-28	WOS:000181865200010
J	Caldeira, K; Jain, AK; Hoffert, MI				Caldeira, K; Jain, AK; Hoffert, MI			Climate sensitivity uncertainty and the need for energy without CO2 emission	SCIENCE			English	Article							CARBON; STABILIZATION; COSTS	The UN Framework Convention on Climate Change calls for "stabilization of greenhouse gas concentrations at a level that would prevent dangerous anthropogenic interference with the climate system." Even if we could determine a "safe" level of interference in the climate system, the sensitivity of global mean temperature to increasing atmospheric CO2 is known perhaps only to a factor of three or less. Here we show how a factor of three uncertainty in climate sensitivity introduces even greater uncertainty in allowable increases in atmospheric CO2 concentration and allowable CO2 emissions. Nevertheless, unless climate sensitivity is low and acceptable amounts of climate change are high, climate stabilization will require a massive transition to CO2 emission-free energy technologies.	Lawrence Livermore Natl Lab, Energy & Environm Directorate, Livermore, CA 94550 USA; Univ Illinois, Dept Atmospher Sci, Urbana, IL 61801 USA; NYU, Dept Phys, New York, NY 10003 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Illinois System; University of Illinois Urbana-Champaign; New York University	Caldeira, K (corresponding author), Lawrence Livermore Natl Lab, Energy & Environm Directorate, 7000 East Ave,L-103, Livermore, CA 94550 USA.	kenc@llnl.gov	Caldeira, Ken/E-7914-2011; Jain, Atul/D-2851-2016	Caldeira, Ken/0000-0002-4591-643X; Jain, Atul/0000-0002-4051-3228				ANDERSON D, 1992, OXFORD B ECON STAT, V54, P1; Andronova NG, 2001, J GEOPHYS RES-ATMOS, V106, P22605, DOI 10.1029/2000JD000259; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; Azar C, 2002, ECOL ECON, V42, P73, DOI 10.1016/S0921-8009(02)00042-3; Cess RD, 1996, J GEOPHYS RES-ATMOS, V101, P12791, DOI 10.1029/96JD00822; Cubasch U., 2001, PROJECTIONS FUTURE C, P525; Forest CE, 2002, SCIENCE, V295, P113, DOI 10.1126/science.1064419; GRUBB M, 1993, ANNU REV ENERG ENV, V18, P397, DOI 10.1146/annurev.energy.18.1.397; Hoffert MI, 2002, SCIENCE, V298, P981, DOI 10.1126/science.1072357; Hoffert MI, 1998, NATURE, V395, P881, DOI 10.1038/27638; HOUGHTON JT, 1995, IPCC 1994 REPORT RAD; JAIN AK, 1995, GLOBAL BIOGEOCHEM CY, V9, P153, DOI 10.1029/94GB02394; Jain AK, 1996, TELLUS B, V48, P583, DOI 10.1034/j.1600-0889.1996.t01-1-00012.x; JAIN AK, IN PRESS HDB ATMOSPH, V2; JAIN AK, 1994, 87 ANN M AIR WAST MA; Leggett J., 1992, CLIMATE CHANGE 1992, P75; Nakicenovic N., 2000, IPCC SPECIAL REPORT; PRATHER M, 1999, AVIATION GLOBAL ATMO, P185; Prentice IC, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P183; Schneider SH, 2002, CLIMATIC CHANGE, V52, P441, DOI 10.1023/A:1014221225434; *UN ENV PROGR WORL, 1992, UN FRAM CONV CLIM CH; Wigley TML, 1996, NATURE, V379, P240, DOI 10.1038/379240a0; *WORLD MET ORG, 1995, SCI ASS OZ DEPL 1994	23	194	201	5	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					2052	2054		10.1126/science.1078938	http://dx.doi.org/10.1126/science.1078938			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663924				2022-12-28	WOS:000181834200050
J	Brown, SGA; Wiese, MD; Blackman, KE; Heddle, RJ				Brown, SGA; Wiese, MD; Blackman, KE; Heddle, RJ			Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial	LANCET			English	Article							INSECT-STING CHALLENGE; YELLOW JACKET VENOM; ANAPHYLACTIC REACTIONS; DIAGNOSTIC METHODS; HYMENOPTERA; HYPERSENSITIVITY; ALLERGY; BEE; PREVALENCE; SEVERITY	Background The jack jumper ant Myrmecia pilosula is responsible for about 90% of ant venom anaphylaxis in southeastern Australia. We aimed to establish whether M pilosula venom immunotherapy (VIT) prevents life-threatening sting anaphylaxis in otherwise healthy adults. Methods We did a double-blind, placebo-controlled crossover trial of M pilosula VIT. Participants were randomly allocated either immunotherapy, in accordance with the semirush hyposensitisation regimen, or placebo. The primary endpoint was systemic reaction after a deliberate sting challenge. Analysis was per protocol. Findings We randomly allocated 68 healthy volunteers (aged 20-63 years) who were allergic to M pilosula venom to placebo (33) and VIT (35). Four on placebo were stopped early and 12 on VIT had their treatment allocations revealed before the sting challenge, thus 29 on placebo and 23 on VIT were included in the primary analysis. Objectively defined systemic reactions to sting challenges arose in 21 of 29 participants (72%) on placebo (8 reactions were associated with hypotension) and none of 23 on VIT (p<0.0001). Of the remaining 12 on VIT who underwent sting challenges after treatment allocations were revealed, only one reacted to sting challenge with transient urticaria that did not require treatment. After crossover of the placebo group to VIT, one of 26 had a reaction to sting challenge (transient urticaria). In all patients who had VIT, we recorded objective systemic reactions in 22 of 64 (34%) during VIT; two of which were hypotensive. Interpretation In well motivated, highly allergic, but otherwise healthy adults, VIT is highly effective in prevention of M pilosula sting anaphylaxis. The risk of systemic reactions during VIT means that treatment should be given where there is immediate access to resuscitation facilities.	Royal Hobart Hosp, Dept Emergency Med, Hobart, Tas 7001, Australia; Royal Hobart Hosp, Dept Pharm, Hobart, Tas, Australia; Flinders Univ S Australia, Bedford Pk, SA 5042, Australia; Flinders Med Ctr, Dept Immunol Allergy & Arthrit, Bedford Pk, SA, Australia	Royal Hobart Hospital; Royal Hobart Hospital; Flinders University South Australia; Flinders Medical Centre	Brown, SGA (corresponding author), Royal Hobart Hosp, Dept Emergency Med, GPO Box 1061L, Hobart, Tas 7001, Australia.	simon.brown@utas.edu.au	Wiese, Michael D/A-4743-2011	Wiese, Michael D/0000-0002-3255-9242; Brown, Simon/0000-0002-9961-0890				Blaauw PJ, 1996, J ALLERGY CLIN IMMUN, V98, P39, DOI 10.1016/S0091-6749(96)70224-5; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; Brown SGA, 2003, J ALLERGY CLIN IMMUN, V111, P187, DOI 10.1067/mai.2003.48; Brown SGA, 2001, MED J AUSTRALIA, V175, P644, DOI 10.5694/j.1326-5377.2001.tb143761.x; Chamberlain D, 2001, EMERG MED J, V18, P393; Douglas RG, 1998, J ALLERGY CLIN IMMUN, V101, P129, DOI 10.1016/S0091-6749(98)70206-4; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V110, P174, DOI 10.1067/mai.2002.125827; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Goldberg A, 1997, J ALLERGY CLIN IMMUN, V100, P139, DOI 10.1016/S0091-6749(97)70207-0; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; Ludolph-Hauser D, 2001, LANCET, V357, P361, DOI 10.1016/S0140-6736(00)03647-3; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; Muller UR., 1990, INSECT STING ALLERGY; OGATA K, 1991, J NAT HIST, V25, P1623, DOI 10.1080/00222939100771021; PARKER JL, 1982, J ALLERGY CLIN IMMUN, V69, P200, DOI 10.1016/0091-6749(82)90100-2; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; STREET MD, 1994, CLIN EXP ALLERGY, V24, P590, DOI 10.1111/j.1365-2222.1994.tb00957.x; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; VANDERLINDEN PWG, 1993, ANN INTERN MED, V118, P161, DOI 10.7326/0003-4819-118-3-199302010-00001; Weiner JM, 1995, ANN ALLERG ASTHMA IM, V74, P60	26	91	94	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	2003	361	9362					1001	1006		10.1016/S0140-6736(03)12827-9	http://dx.doi.org/10.1016/S0140-6736(03)12827-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660058				2022-12-28	WOS:000181699700011
J	Fox, DW; Yost, S; Kulkarni, SR; Torii, K; Kato, T; Yamaoka, H; Sako, M; Harrison, FA; Sari, R; Price, PA; Berger, E; Soderberg, AM; Djorgovski, SG; Barth, AJ; Pravdo, SH; Frail, DA; Gal-Yam, A; Lipkin, Y; Mauch, T; Harrison, C; Buttery, H				Fox, DW; Yost, S; Kulkarni, SR; Torii, K; Kato, T; Yamaoka, H; Sako, M; Harrison, FA; Sari, R; Price, PA; Berger, E; Soderberg, AM; Djorgovski, SG; Barth, AJ; Pravdo, SH; Frail, DA; Gal-Yam, A; Lipkin, Y; Mauch, T; Harrison, C; Buttery, H			Early optical emission from the gamma-ray burst of 4 October 2002	NATURE			English	Article							AFTERGLOWS; SEARCH	Observations of the long-lived emission-or 'afterglow'-of long-duration gamma-ray bursts place them at cosmological distances, but the origin of these energetic explosions remains a mystery. Observations of optical emission contemporaneous with the burst of gamma-rays should provide insight into the details of the explosion, as well as into the structure of the surrounding environment. One bright optical flash was detected during a burst(1) but other efforts(2,3) have produced negative results. Here we report the discovery of the optical counterpart of GRB021004 only 193 seconds after the event. The initial decline is unexpectedly slow and requires varying energy content in the gamma-ray burst blastwave over the course of the first hour. Further analysis of the X-ray and optical afterglow suggests additional energy variations over the first few days.	CALTECH, CALTECH Opt Observ 105 24, Pasadena, CA 91125 USA; CALTECH, Space Radiat Lab 220 47, Pasadena, CA 91125 USA; CALTECH, Theoret Astrophys 130 33, Pasadena, CA 91125 USA; RIKEN, Cosmic Radiat Lab, Wako, Saitama 3510198, Japan; Kyoto Univ, Dept Astron, Sakyo Ku, Kyoto 6068502, Japan; Kyushu Univ, Dept Phys, Chuo Ku, Fukuoka 8108560, Japan; Mt Stromlo & Siding Spring Observ, RSAA, Weston, ACT 2611, Australia; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Natl Radio Astron Observ, Socorro, NM 87801 USA; Tel Aviv Univ, Sch Phys & Astron, IL-69978 Tel Aviv, Israel; Univ Sydney, Sch Phys, Sydney, NSW 2006, Australia; Univ Cambridge, Cavendish Lab, Astrophys Grp, Cambridge CB3 0HE, England	California Institute of Technology; California Institute of Technology; California Institute of Technology; RIKEN; Kyoto University; Kyushu University; Australian National University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Radio Astronomy Observatory (NRAO); Tel Aviv University; University of Sydney; University of Cambridge	Fox, DW (corresponding author), CALTECH, CALTECH Opt Observ 105 24, Pasadena, CA 91125 USA.			Fox, Derek/0000-0002-3714-672X				Akerlof C, 1999, NATURE, V398, P400, DOI 10.1038/18837; BERGER E, 2002, GRB CIRC NETW, V1612, P1; Bersier D, 2003, ASTROPHYS J, V584, pL43, DOI 10.1086/373888; Briggs MS, 1999, ASTROPHYS J, V524, P82, DOI 10.1086/307808; Chevalier RA, 2000, ASTROPHYS J, V536, P195, DOI 10.1086/308914; CHORNOCK R, 2002, GRB CIRC NETW, V1605, P1; Fox D.W., 2002, GCN, V1564, P1; FOX DW, 2002, GRB CIRC NETW, V1569, P1; FOX DW, 2003, DISCOVERY EARLY OPTI; Granot J, 2002, ASTROPHYS J, V568, P820, DOI 10.1086/338966; HENDEN A, 2002, GRB CIRC NETW, V1583, P1; HEYL J, IN PRESS ASTROPHYS J; HOLLAND ST, 2002, IN PRESS ASTROPHYS J; Kehoe R, 2001, ASTROPHYS J, V554, pL159, DOI 10.1086/321719; Kobayashi S, 2003, ASTROPHYS J, V582, pL75, DOI 10.1086/367691; Kulkarni SR, 1999, NATURE, V398, P389, DOI 10.1038/18821; LAMB D, 2002, GRB COORDINATES NETW, V1600, P1; Lazzati D, 2002, ASTRON ASTROPHYS, V396, pL5, DOI 10.1051/0004-6361:20021618; LI W, 2003, EARLY LIGHT CURVE OP; MATSUMOTO K, 2002, GRB CIRC NETW, V1567, P1; NAKAR E, UNPUB NEW ASTRON; PANDEY SB, UNPUB B ASTRON SOC I; PARK HS, 2002, GRB CIRC NETW, V1736, P1; Sari R, 1999, ASTROPHYS J, V520, P641, DOI 10.1086/307508; Shirasaki Y, 2002, GRB CIRC NETW, V1565, P1; UEMURA M, 2002, GRB CIRC NETW, V1566, P1; Williams GG, 1999, ASTROPHYS J, V519, pL25, DOI 10.1086/312092; WOZNIAK P, 2002, GRB COORDINATES NETW, V1757, P1	28	109	110	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					284	286		10.1038/nature01504	http://dx.doi.org/10.1038/nature01504			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646914				2022-12-28	WOS:000181637300032
J	Lawrence, PA				Lawrence, PA			The politics of publication - Authors, reviewers and editors must act to protect the quality of research.	NATURE			English	Editorial Material							INOSITOL TRISPHOSPHATE		MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Lawrence, PA (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Lawrence, Peter/0000-0002-9554-8268				Belenkaya TY, 2002, DEVELOPMENT, V129, P4089; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Gura T, 2002, NATURE, V416, P258, DOI 10.1038/416258a; Lawrence PA, 2002, NATURE, V415, P835, DOI 10.1038/415835a; Lawrence PA, 2001, NAT REV GENET, V2, P139, DOI 10.1038/35052571; Oneill O., 2002, QUESTION TRUST BBC R; PENDLEBURY D, 1990, SCIENTIST, V4, P18; Power M., 1997, AUDIT SOC RITUALS VE	9	257	268	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					259	261		10.1038/422259a	http://dx.doi.org/10.1038/422259a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646895				2022-12-28	WOS:000181637300017
J	ten Tusscher, MPM; Jacobs, PC; Busch, MJWM; de Graaf, L; Diemont, WL				ten Tusscher, MPM; Jacobs, PC; Busch, MJWM; de Graaf, L; Diemont, WL			Drug points - Bilateral anterior toxic optic neuropathy and the use of infliximab	BRITISH MEDICAL JOURNAL			English	Article							NEURITIS		Laurentius Hosp, Dept Ophthalmol, NL-6043 CV Roermond, Netherlands; Maxima Med Ctr, NL-5631 BM Eindhoven, Netherlands; Netherlands Pharmacovigilance Ctr Lareb, NL-5237 MH sHertogenbosch, Netherlands	Maxima Medical Center	ten Tusscher, MPM (corresponding author), Laurentius Hosp, Dept Ophthalmol, NL-6043 CV Roermond, Netherlands.							Agildere AM, 1999, BRIT J RADIOL, V72, P404; *EUR MED EV AG, 2003, SUMM PROD CHAR REM; Foroozan R, 2002, ARCH OPHTHALMOL-CHIC, V120, P985; Sachs G, 1998, BRIT MED J, V316, P67	4	61	61	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 15	2003	326	7389					579	579		10.1136/bmj.326.7389.579	http://dx.doi.org/10.1136/bmj.326.7389.579			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657ZF	12637403	Green Published, Bronze			2022-12-28	WOS:000181696600019
J	Ranganathan, R				Ranganathan, R			A matter of life or death	SCIENCE			English	Editorial Material							DROSOPHILA; APOPTOSIS; DEGENERATION; TRP		Univ Texas, SW Med Ctr, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ranganathan, R (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Howard Hughes Med Inst, Dallas, TX 75390 USA.							Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549; Adler R, 1996, ARCH OPHTHALMOL-CHIC, V114, P79, DOI 10.1001/archopht.1996.01100130075012; Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Hinkovska-Galcheva V, 2003, J BIOL CHEM, V278, P974, DOI 10.1074/jbc.M206199200; Hong YS, 2002, J BIOL CHEM, V277, P33884, DOI 10.1074/jbc.M204075200; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; PAK WL, 1994, MOL GENETICS INHERIT, P29; Raghu P, 2000, NEURON, V26, P169, DOI 10.1016/S0896-6273(00)81147-2; Van Soest S, 1999, SURV OPHTHALMOL, V43, P321, DOI 10.1016/S0039-6257(98)00046-0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0	14	10	10	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1677	1679		10.1126/science.1082509	http://dx.doi.org/10.1126/science.1082509			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637727				2022-12-28	WOS:000181519500026
J	Vincent, C				Vincent, C			Understanding and responding to adverse events	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RISK MANAGEMENT; MEDICINE; SAFETY; ERROR		St Marys Hosp, Univ London Imperial Coll Sci Technol & Med, Dept Surg Oncol & Technol, London, England	Imperial College London	Vincent, C (corresponding author), St Marys Hosp, Univ London Imperial Coll Sci Technol & Med, Dept Surg Oncol & Technol, London, England.		Vincent, Charles A/D-1134-2010	Vincent, Charles A/0000-0003-0270-0222				Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Clarke DM, 1997, AUST NZ J SURG, V67, P115, DOI 10.1111/j.1445-2197.1997.tb01914.x; Czarnocka J, 2000, BRIT J CLIN PSYCHOL, V39, P35, DOI 10.1348/014466500163095; Department of Health, 2000, ORG MEM REP EXP GROU; Fonseka C, 1996, BRIT MED J, V313, P1640, DOI 10.1136/bmj.313.7072.1640; HEWETT D, 2001, BRIT MED J, P481; Kessler RC, 1997, ANNU REV PSYCHOL, V48, P191, DOI 10.1146/annurev.psych.48.1.191; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, DOI 10.17226/9728; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEHMAN DR, 1987, J PERS SOC PSYCHOL, V52, P218, DOI 10.1037/0022-3514.52.1.218; LUNDIN T, 1984, BRIT J PSYCHIAT, V144, P84, DOI 10.1192/bjp.144.1.84; PICHERT JW, 2001, CLIN RISK MANAGEMENT, P263; Reason JT, 2001, BRIT MED J, P9; Spath P, 2000, ERROR REDUCTION HLTH; Vincent C, 2000, BRIT MED J, V320, P777, DOI 10.1136/bmj.320.7237.777; Vincent C, 1998, BRIT MED J, V316, P1154, DOI 10.1136/bmj.316.7138.1154; VINCENT C, 1994, LANCET, V343, P1609, DOI 10.1016/S0140-6736(94)93062-7; Vincent C A, 1993, Qual Health Care, V2, P77, DOI 10.1136/qshc.2.2.77; Vincent CA, 2002, QUAL SAF HEALTH CARE, V11, P76, DOI 10.1136/qhc.11.1.76; Vincent CA, 1999, STRESS HLTH PROFESSI, P63; VINCENT CA, 2001, BMJ-BRIT MED J, P461; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; Wu AW, 2000, BRIT MED J, V320, P726, DOI 10.1136/bmj.320.7237.726; 2002, CLIN RISK UNIT HOME	25	281	291	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					1051	1056		10.1056/NEJMhpr020760	http://dx.doi.org/10.1056/NEJMhpr020760			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653YT	12637617				2022-12-28	WOS:000181465200012
J	Lalezari, JP; Henry, K; O'Hearn, M; Montaner, JSG; Piliero, PJ; Trottier, B; Walmsley, S; Cohen, C; Kuritzkes, DR; Eron, JJ; Chung, J; DeMasi, R; Donatacci, L; Drobnes, C; Delehanty, J; Salgo, M; Farthing, C; Graham, E; Packard, M; Ngo, L; Lederman, M; Buam, J; Pollard, R; Rauf, S; Silkowski, W; Thompson, M; Rucker, A; Harris, M; Larsen, G; Preseon, S; Cunningham, D; Guimaraes, D; Bertasso, A; Kinchelow, T; Myers, R; Phoenix, BCBP; Skolnik, PR; Adams, B; Leite, OHM; Oliveira, M; Lefebvre, E; Gomez, B; Foy, KB; Lampiris, H; Charles, S; Dobkin, J; Crawford, M; Slom, T; Murphy, R; Mikaitis, T; Witek, J; Anthony, R; Richmond, G; Appleby, VF; Smaill, F; Kelleher, L; Nieto, L; Trevino, S; Schechter, M; Fonseca, B; DeJesus, E; Ortiz, R; Wheat, J; Goldman, M; O'Connor, DK; Sierra-Madero, JG; Nino-Oberto, S; Gallant, JE; Apuzzo, L; Basgoz, N; Habeeb, K; Alpert, P; Thomas, S; Miller, T; Kempner, T; Wolfe, PR; Bautista, J; Martin, HL; Morton, ME; Henry, D; Kilcoyne, S; Glutzer, E; Rivera-Vazquez, C; Pomales, Z; Bellos, N; Hoffman, LA; Olmscheid, B; Klein, O; Miller, M; Steinhart, CR; Liebmann, A; Williams, S; Springate, L; Logue, K; Smiley, L; Miralles, GD; Haubrich, R; Nuffer, K; Beatty, G; O'Leary, S; Rouleau, D; Dufresne, S; Kilby, JM; Saag, M; Upton, K; Feinberg, J; Kohler, P; Campbell, TB; Putnam, BA; Riddler, SA; Rosener, RR; Barnett, BJ; Hansen, I; Collier, AC; Royer, BA; Haas, DW; Morgan, M; Sathasivam, K; Hersch, J				Lalezari, JP; Henry, K; O'Hearn, M; Montaner, JSG; Piliero, PJ; Trottier, B; Walmsley, S; Cohen, C; Kuritzkes, DR; Eron, JJ; Chung, J; DeMasi, R; Donatacci, L; Drobnes, C; Delehanty, J; Salgo, M; Farthing, C; Graham, E; Packard, M; Ngo, L; Lederman, M; Buam, J; Pollard, R; Rauf, S; Silkowski, W; Thompson, M; Rucker, A; Harris, M; Larsen, G; Preseon, S; Cunningham, D; Guimaraes, D; Bertasso, A; Kinchelow, T; Myers, R; Phoenix, BCBP; Skolnik, PR; Adams, B; Leite, OHM; Oliveira, M; Lefebvre, E; Gomez, B; Foy, KB; Lampiris, H; Charles, S; Dobkin, J; Crawford, M; Slom, T; Murphy, R; Mikaitis, T; Witek, J; Anthony, R; Richmond, G; Appleby, VF; Smaill, F; Kelleher, L; Nieto, L; Trevino, S; Schechter, M; Fonseca, B; DeJesus, E; Ortiz, R; Wheat, J; Goldman, M; O'Connor, DK; Sierra-Madero, JG; Nino-Oberto, S; Gallant, JE; Apuzzo, L; Basgoz, N; Habeeb, K; Alpert, P; Thomas, S; Miller, T; Kempner, T; Wolfe, PR; Bautista, J; Martin, HL; Morton, ME; Henry, D; Kilcoyne, S; Glutzer, E; Rivera-Vazquez, C; Pomales, Z; Bellos, N; Hoffman, LA; Olmscheid, B; Klein, O; Miller, M; Steinhart, CR; Liebmann, A; Williams, S; Springate, L; Logue, K; Smiley, L; Miralles, GD; Haubrich, R; Nuffer, K; Beatty, G; O'Leary, S; Rouleau, D; Dufresne, S; Kilby, JM; Saag, M; Upton, K; Feinberg, J; Kohler, P; Campbell, TB; Putnam, BA; Riddler, SA; Rosener, RR; Barnett, BJ; Hansen, I; Collier, AC; Royer, BA; Haas, DW; Morgan, M; Sathasivam, K; Hersch, J		TORO 1 Study Grp	Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIRETROVIRAL THERAPY; PEPTIDE INHIBITOR; VIRUS; T-20	BACKGROUND: The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor. METHODS: Patients from 48 sites in the United States, Canada, Mexico, and Brazil with at least six months of previous treatment with agents in three classes of antiretroviral drugs, resistance to drugs in these classes, or both, and with at least 5000 copies of HIV-1 RNA per milliliter of plasma were randomly assigned in a 2:1 ratio to receive enfuvirtide plus an optimized background regimen of three to five antiretroviral drugs or such a regimen alone (control group). The primary efficacy end point was the change in the plasma HIV-1 RNA level from base line to week 24. RESULTS: A total of 501 patients underwent randomization, and 491 received at least one dose of study drug and had at least one measurement of plasma HIV-1 RNA after treatment began. The two groups were balanced in terms of the median base-line HIV-1 RNA level (5.2 log(sub 10) copies per milliliter in both groups), median CD4+ cell count (75.5 cells per cubic millimeter in the enfuvirtide group, and 87.0 cells per cubic millimeter in the control group), demographic characteristics, and previous antiretroviral therapy. At 24 weeks, the least-squares mean change from base line in the viral load (intention-to-treat, last observation carried forward) was a decrease of 1.696 log(sub 10) copies per milliliter in the enfuvirtide group, and a decrease of 0.764 log(sub 10) copies per milliliter in the control group (P<0.001). The mean increases in CD4+ cell count were 76 cells per cubic millimeter and 32 cells per cubic millimeter, respectively (P<0.001). Reactions at the site of the injections were reported by 98 percent of patients receiving enfuvirtide. There were more cases of pneumonia in the enfuvirtide group than in the control group. CONCLUSIONS: The addition of enfuvirtide to an optimized antiretroviral regimen provided significant antiretroviral and immunologic benefit through 24 weeks in patients who had previously received multiple antiretroviral drugs and had multidrug-resistant HIV-1 infection.	Mt Zion Hosp & Med Ctr, Quest Clin Res, San Francisco, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Hennepin Cty Med Ctr, HIV Program, Minneapolis, MN 55415 USA; Oregon Hlth & Sci Univ, Portland, OR USA; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; Albany Med Coll, Clin Res Initiat, Albany, NY 12208 USA; Clin Med ACtuel, Montreal, PQ, Canada; Univ Toronto, Toronto, ON, Canada; Community Res Initiat New England, Boston, MA USA; Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Denver, CO USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; Roche, Nutley, NJ USA; Trimeris, Durham, NC USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco; Hennepin County Medical Center; Oregon Health & Science University; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; Albany Medical College; University of Toronto; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Roche Holding	Lalezari, JP (corresponding author), Quest Clin Res, 2300 Sutter St,Suite 202, San Francisco, CA 94115 USA.		Schechter, Mauro/AAG-7445-2020; Sierra Madero, Juan/AAW-8825-2021; Montaner, Julio/K-7621-2012	Walmsley, Sharon/0000-0002-3959-5692				*AIDS CLIN TRIALS, 1996, TABL GRAD SEV AD ADV; Casado JL, 1999, ANTIVIR THER, V4, P157; DeGruttola V, 2000, ANTIVIR THER, V5, P41; Dieleman JP, 2002, AIDS, V16, P737, DOI 10.1097/00002030-200203290-00009; Dresser GK, 2000, CLIN PHARMACOKINET, V38, P41, DOI 10.2165/00003088-200038010-00003; Hoetelmans RMW, 1998, ANTIVIR THER, V3, P13; Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kilby JM, 2003, AIDS RES HUM RETROV, V19, P83, DOI 10.1089/08892220360474014; Lafeuillade Alain, 2002, HIV Clin Trials, V3, P27; Lalezari JP, 2003, AIDS, V17, P691, DOI 10.1097/00002030-200303280-00007; LALEZARI JP, IN PRESS ANTIVIRAL T; Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211; Le Corfec E, 1999, STAT MED, V18, P1803, DOI 10.1002/(SICI)1097-0258(19990730)18:14<1803::AID-SIM217>3.0.CO;2-Q; Little R, 1996, BIOMETRICS, V52, P1324, DOI 10.2307/2532847; Moyle Graeme, 2002, HIV Clin Trials, V3, P89; Raboud J M, 2002, HIV Med, V3, P118, DOI 10.1046/j.1468-1293.2002.00109.x; Race E, 1999, AIDS, V13, P2061, DOI 10.1097/00002030-199910220-00008; Van Vaerenbergh K, 2000, ANTIMICROB AGENTS CH, V44, P2109, DOI 10.1128/AAC.44.8.2109-2117.2000; WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051	20	713	746	0	57	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2003	348	22					2175	2185		10.1056/NEJMoa035026	http://dx.doi.org/10.1056/NEJMoa035026			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683EK	12637625	Green Published, Bronze			2022-12-28	WOS:000183134700003
J	Schneble, D; Torii, Y; Boyd, M; Streed, EW; Pritchard, DE; Ketterle, W				Schneble, D; Torii, Y; Boyd, M; Streed, EW; Pritchard, DE; Ketterle, W			The onset of matter-wave amplification in a superradiant Bose-Einstein condensate	SCIENCE			English	Article							PHASE-COHERENT AMPLIFICATION; RAYLEIGH-SCATTERING; LIGHT; ATOMS; DIFFRACTION	The interaction of short and strong laser pulses with an atomic Bose-Einstein condensate is found to generate patterns of recoiling atoms that are different from those seen in previous light-scattering experiments. This phenomenon can only be explained by optical stimulation, showing that the previous description of superradiance as atomic stimulation is incomplete and that matter-wave amplification in Bose-Einstein condensates is suppressed at short times. Our experiments clarify the nature of bosonic stimulation in the four-wave mixing of light and atoms.	MIT, Elect Res Lab, MIT Harvard Ctr Ultracold Atoms, Cambridge, MA 02139 USA; MIT, Dept Phys, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Schneble, D (corresponding author), MIT, Elect Res Lab, MIT Harvard Ctr Ultracold Atoms, Cambridge, MA 02139 USA.	schneble@mit.edu	Streed, Erik/B-4682-2015; Schneble, Dominik/HHS-7793-2022	Streed, Erik/0000-0001-6234-4560; 				DICKE RH, 1954, PHYS REV, V93, P99, DOI 10.1103/PhysRev.93.99; GOULD PL, 1986, PHYS REV LETT, V56, P827, DOI 10.1103/PhysRevLett.56.827; GROSS M, 1982, PHYS REP, V93, P301, DOI 10.1016/0370-1573(82)90102-8; Inouye S, 1999, NATURE, V402, P641, DOI 10.1038/45194; Inouye S, 1999, SCIENCE, V285, P571, DOI 10.1126/science.285.5427.571; Ketterle W, 2001, CR ACAD SCI IV-PHYS, V2, P339, DOI 10.1016/S1296-2147(01)01180-5; Ketterle W, 2001, PHYS REV LETT, V86, P4203, DOI 10.1103/PhysRevLett.86.4203; Kozuma M, 1999, SCIENCE, V286, P2309, DOI 10.1126/science.286.5448.2309; Kozuma M, 1999, PHYS REV LETT, V82, P871, DOI 10.1103/PhysRevLett.82.871; MARTIN PJ, 1988, PHYS REV LETT, V60, P515, DOI 10.1103/PhysRevLett.60.515; Moore MG, 1999, PHYS REV LETT, V83, P5202, DOI 10.1103/PhysRevLett.83.5202; Moore MG, 2001, PHYS REV LETT, V86, P4199, DOI 10.1103/PhysRevLett.86.4199; Mustecaplioglu OE, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.063615; Ovchinnikov YB, 1999, PHYS REV LETT, V83, P284, DOI 10.1103/PhysRevLett.83.284; Piovella N, 2001, OPT COMMUN, V187, P165, DOI 10.1016/S0030-4018(00)01106-8; Stenger J, 1999, PHYS REV LETT, V82, P4569, DOI 10.1103/PhysRevLett.82.4569; Trifonov ED, 2001, J EXP THEOR PHYS+, V93, P969, DOI 10.1134/1.1427108	17	169	180	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2003	300	5618					475	478		10.1126/science.1083171	http://dx.doi.org/10.1126/science.1083171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12663817				2022-12-28	WOS:000182295900036
J	Kieffer, J				Kieffer, J			Materials science: Not too hot to handle	SCIENCE			English	Editorial Material							BRILLOUIN-SCATTERING		Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kieffer, J (corresponding author), Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA.	kieffer@umich.edu						AASLAND S, 1994, NATURE, V369, P633, DOI 10.1038/369633a0; Kieffer J, 1998, PHYS REV B, V58, P694, DOI 10.1103/PhysRevB.58.694; MOUNTAIN RD, 1966, J RES NBS A PHYS CH, VA 70, P207, DOI 10.6028/jres.070A.017; Pilla O, 2002, PHILOS MAG B, V82, P223, DOI 10.1080/13642810110094721; Sinn H, 2003, SCIENCE, V299, P2047, DOI 10.1126/science.1080950; Sokolov AP, 1999, PHYS REV E, V60, pR2464, DOI 10.1103/PhysRevE.60.R2464; TAO NJ, 1991, PHYS REV B, V43, P5815, DOI 10.1103/PhysRevB.43.5815; Youngman RE, 1997, J NON-CRYST SOLIDS, V222, P190, DOI 10.1016/S0022-3093(97)90113-7; 2002, J NONCRYST SOLIDS, V207	9	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					1998	1999		10.1126/science.1083284	http://dx.doi.org/10.1126/science.1083284			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663905				2022-12-28	WOS:000181834200030
J	Bond, HE; Henden, A; Levay, ZG; Panagia, N; Sparks, WB; Starrfield, S; Wagner, RM; Corradi, RLM; Munari, U				Bond, HE; Henden, A; Levay, ZG; Panagia, N; Sparks, WB; Starrfield, S; Wagner, RM; Corradi, RLM; Munari, U			An energetic stellar outburst accompanied by circumstellar light echoes	NATURE			English	Article							V838 MON; EVOLUTION; DISCOVERY; ERUPTION; M31	Some classes of stars, including novae and supernovae, undergo explosive outbursts that eject stellar material into space. In 2002, the previously unknown variable star V838 Monocerotis brightened suddenly by a factor of similar to10(4). Unlike a supernova or nova, it did not explosively eject its outer layers; rather, it simply expanded to become a cool supergiant with a moderate-velocity stellar wind. Superluminal light echoes were discovered(1,2) as light from the outburst propagated into the surrounding, pre-existing circumstellar dust. Here we report high-resolution imaging and polarimetry of those light echoes, which allow us to set direct geometric distance limits to the object. At a distance of >6 kpc, V838 Mon at its maximum brightness was temporarily the brightest star in the Milky Way. The presence of the circumstellar dust implies that previous eruptions have occurred, and spectra show it to be a binary system. When combined with the high luminosity and unusual outburst behaviour, these characteristics indicate that V838 Mon represents a hitherto unknown type of stellar outburst, for which we have no completely satisfactory physical explanation.	Space Telescope Sci Inst, Baltimore, MD 21218 USA; Univ Space Res Assoc, Flagstaff, AZ 86002 USA; USN Observ, Flagstaff Stn, Flagstaff, AZ 86002 USA; Arizona State Univ, Dept Phys & Astron, Tempe, AZ 85287 USA; Univ Arizona, Large Binocular Telescope Observ, Tucson, AZ 85721 USA; Isaac Newton Grp Telescopes, Santa Cruz De La Palma 38700, Canarias, Spain; Osserv Astron Padova, INAF, I-36012 Asiago, VI, Italy	Space Telescope Science Institute; Universities Space Research Association (USRA); United States Department of Defense; United States Navy; Arizona State University; Arizona State University-Tempe; University of Arizona; Isaac Newton Group of Telescopes; Istituto Nazionale Astrofisica (INAF); University of Padua	Bond, HE (corresponding author), Space Telescope Sci Inst, 3700 San Martin Dr, Baltimore, MD 21218 USA.	bond@stsci.edu	Starrfield, Sumner/AAJ-2900-2020					BOND HE, 1990, ASTROPHYS J, V354, pL49, DOI 10.1086/185720; BROWN NJ, 2002, 7785 IAU; BRYAN J, 1992, PUBL ASTRON SOC PAC, V104, P179, DOI 10.1086/132975; Casalegno R, 2000, ASTRON ASTROPHYS, V361, P725; CHEVALIER RA, 1986, ASTROPHYS J, V308, P225, DOI 10.1086/164492; Couderc P., 1939, ANAP, V2, P271; CRAUSE LA, IN PRESS MON NOT R A; GEBALLE TR, 2002, 8016 IAU; Goranskii VP, 2002, ASTRON LETT+, V28, P691, DOI 10.1134/1.1512226; HENDEN A, 2002, 7859 IAU; IBEN I, 1992, ASTROPHYS J, V389, P369, DOI 10.1086/171211; Kapteyn J.C., 1901, AN, V157, P201, DOI [10.1002/asna.19011571203, DOI 10.1002/ASNA.19011571203]; Kimeswenger S, 2002, MON NOT R ASTRON SOC, V336, pL43, DOI 10.1046/j.1365-8711.2002.06017.x; Martini P, 1999, ASTRON J, V118, P1034, DOI 10.1086/300951; Mould J., 1990, Astrophysical Journal, Letters, V353, pL35, DOI 10.1086/185702; Munari U, 2002, AIP CONF PROC, V637, P52, DOI 10.1063/1.1518177; Munari U, 2002, ASTRON ASTROPHYS, V389, pL51, DOI 10.1051/0004-6361:20020715; MUNARI U, 2002, 8005 IAU; OSIWALA JP, IN PRESS ASP C SERIE; PRIALNIK D, 1995, ASTROPHYS J, V445, P789, DOI 10.1086/175741; PRICE A, 2002, IAU INFORM B VAR STA, V5315, P1; Ritchey GW, 1902, ASTROPHYS J, V15, P129, DOI 10.1086/140896; RUSSELL HN, 1945, ASTRONOMY REVISION Y, P786; SCHAEFER BE, 1988, ASTROPHYS J, V327, P347, DOI 10.1086/166196; Soker N, 2003, ASTROPHYS J, V582, pL105, DOI 10.1086/367759; SPARKS WB, 1994, ASTROPHYS J, V433, P19, DOI 10.1086/174621; Sparks WB, 1999, ASTROPHYS J, V523, P585, DOI 10.1086/307766; WAGNER RM, 2002, 7992 IAU; ZWITTER T, 2002, 7812 IAU	29	164	167	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					405	408		10.1038/nature01508	http://dx.doi.org/10.1038/nature01508			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660776	Green Submitted			2022-12-28	WOS:000181801200037
J	Cools, J; DeAngelo, DJ; Gotlib, J; Stover, EH; Legare, RD; Cortes, J; Kutok, J; Clark, J; Galinsky, I; Griffin, JD; Cross, NCP; Tefferi, A; Malone, J; Alam, R; Schrier, SL; Schmid, J; Rose, M; Vandenberghe, P; Verhoef, G; Boogaerts, M; Wlodarska, I; Kantarjian, H; Marynen, P; Coutre, SE; Stone, R; Gilliland, DG				Cools, J; DeAngelo, DJ; Gotlib, J; Stover, EH; Legare, RD; Cortes, J; Kutok, J; Clark, J; Galinsky, I; Griffin, JD; Cross, NCP; Tefferi, A; Malone, J; Alam, R; Schrier, SL; Schmid, J; Rose, M; Vandenberghe, P; Verhoef, G; Boogaerts, M; Wlodarska, I; Kantarjian, H; Marynen, P; Coutre, SE; Stone, R; Gilliland, DG			A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; BCR-ABL; CLINICAL RESISTANCE; RECEPTOR-BETA; BLAST CRISIS; IN-VITRO; C-KIT; GROWTH; INHIBITOR	BACKGROUND: Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia associated with organ dysfunction. It is of unknown cause. Recent reports of responses to imatinib in patients with the syndrome suggested that an activated kinase such as ABL, platelet-derived growth factor receptor (PDGFR), or KIT, all of which are inhibited by imatinib, might be the cause. METHODS: We treated 11 patients with the hypereosinophilic syndrome with imatinib and identified the molecular basis for the response. RESULTS: Nine of the 11 patients treated with imatinib had responses lasting more than three months in which the eosinophil count returned to normal. One such patient had a complex chromosomal abnormality, leading to the identification of a fusion of the Fip1-like 1 (FIP1L1) gene to the PDGFR(alpha) (PDGFRA) gene generated by an interstitial deletion on chromosome 4q12. FIP1L1-PDGFR(alpha) is a constitutively activated tyrosine kinase that transforms hematopoietic cells and is inhibited by imatinib (50 percent inhibitory concentration, 3.2 nM). The FIP1L1-PDGFRA fusion gene was subsequently detected in 9 of 16 patients with the syndrome and in 5 of the 9 patients with responses to imatinib that lasted more than three months. Relapse in one patient correlated with the appearance of a T674I mutation in PDGFRA that confers resistance to imatinib. CONCLUSIONS: The hypereosinophilic syndrome may result from a novel fusion tyrosine kinase - FIP1L1-PDGFR(alpha) - that is a consequence of an interstitial chromosomal deletion. The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFR(alpha) is the target of imatinib. Our data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Stanford Univ, Med Ctr, Sch Med, Stanford, CA 94305 USA; Brown Univ, Women & Infants Hosp, Sch Med, Providence, RI USA; Westerly Hosp, Westerly, RI USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Wessex Reg Genet Lab, Salisbury, Wilts, England; Mayo Clin, Rochester, MN USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Tulane Univ, Sch Med, New Orleans, LA 70112 USA; Yale Univ, Sch Med, New Haven, CT USA; Univ Hosp Leuven, Louvain, Belgium; Flanders Interuniv Inst Biotechnol, Louvain, Belgium; Catholic Univ Louvain, Ctr Human Genet, B-3000 Louvain, Belgium; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Stanford University; Brown University; Women & Infants Hospital Rhode Island; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; National Jewish Health; Tulane University; Yale University; KU Leuven; University Hospital Leuven; Universite Catholique Louvain; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute	Gilliland, DG (corresponding author), Harvard Univ, Inst Med, 4 Blackfan Cir,Rm 418, Boston, MA 02115 USA.	rstone@partners.org; gilliland@hihg.med.harvard.edu	Stover, Elizabeth/GYD-3476-2022; Cross, Nicholas/B-4817-2009	Cross, Nicholas/0000-0001-5481-2555; Cools, Jan/0000-0001-6626-5843; Cortes, Jorge/0000-0002-8636-1071; Coutre, Steven/0000-0001-8420-5748; Vandenberghe, Peter/0000-0003-4719-1935	NCI NIH HHS [CA66996] Funding Source: Medline; NHLBI NIH HHS [K23HL04409] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NIGMS NIH HHS [T32GMO7753-24, T32 GM007753] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chang HW, 1999, BLOOD, V93, P1651, DOI 10.1182/blood.V93.5.1651.405k20_1651_1657; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Cools J, 2002, BLOOD, V99, P1776, DOI 10.1182/blood.V99.5.1776; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Dierlamm J, 1996, GENE CHROMOSOME CANC, V16, P261, DOI 10.1002/(SICI)1098-2264(199608)16:4<261::AID-GCC6>3.0.CO;2-W; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2001, NEW ENGL J MED, V345, P232; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016/S0140-6736(02)08505-7; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; KAWAGISHI J, 1995, GENOMICS, V30, P224, DOI 10.1006/geno.1995.9883; LUPPI M, 1994, BLOOD, V84, P349; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Schwaller J, 2001, BLOOD, V97, P3910, DOI 10.1182/blood.V97.12.3910; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759; Willis TG, 1997, BLOOD, V90, P2456	29	1299	1377	1	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2003	348	13					1201	1214		10.1056/NEJMoa025217	http://dx.doi.org/10.1056/NEJMoa025217			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659RG	12660384				2022-12-28	WOS:000181790800002
J	Forkey, JN; Quinlan, ME; Shaw, MA; Corrie, JET; Goldman, YE				Forkey, JN; Quinlan, ME; Shaw, MA; Corrie, JET; Goldman, YE			Three-dimensional structural dynamics of myosin V by single-molecule fluorescence polarization	NATURE			English	Article							MUSCLE-CONTRACTION; KINETIC MECHANISM; ACTIN; MOTOR; FLUOROPHORE; KINESIN; MICROSCOPY; ROTATION; PURIFICATION; PROTEINS	The structural change that generates force and motion in actomyosin motility has been proposed to be tilting of the myosin light chain domain, which serves as a lever arm. Several experimental approaches have provided support for the lever arm hypothesis; however, the extent and timing of tilting motions are not well defined in the motor protein complex of functioning actomyosin. Here we report three-dimensional measurements of the structural dynamics of the light chain domain of brain myosin V using a single-molecule fluorescence polarization technique that determines the orientation of individual protein domains with 20-40-ms time resolution. Single fluorescent calmodulin light chains tilted back and forth between two well-defined angles as the myosin molecule processively translocated along actin. The results provide evidence for lever arm rotation of the calmodulin-binding domain in myosin V, and support a 'hand-over-hand' mechanism for the translocation of double-headed myosin V molecules along actin filaments. The technique is applicable to the study of real-time structural changes in other biological systems.	Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA; Natl Inst Med Res, London NW7 1AA, England	University of Pennsylvania; MRC National Institute for Medical Research	Goldman, YE (corresponding author), Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA.							Adachi K, 2000, P NATL ACAD SCI USA, V97, P7243, DOI 10.1073/pnas.120174297; AXELROD D, 1984, ANNU REV BIOPHYS BIO, V13, P247, DOI 10.1146/annurev.bb.13.060184.001335; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; Block SM, 1998, CELL, V93, P5, DOI 10.1016/S0092-8674(00)81138-1; Bopp MA, 1997, P NATL ACAD SCI USA, V94, P10630, DOI 10.1073/pnas.94.20.10630; Burgess S, 2002, J CELL BIOL, V159, P983, DOI 10.1083/jcb.200208172; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Corrie JET, 1998, BIOCONJUGATE CHEM, V9, P160, DOI 10.1021/bc970174e; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Dickson RM, 1998, PHYS REV LETT, V81, P5322, DOI 10.1103/PhysRevLett.81.5322; Empedocles SA, 1999, NATURE, V399, P126, DOI 10.1038/20138; Forkey JN, 2000, PROG BIOPHYS MOL BIO, V74, P1, DOI 10.1016/S0079-6107(00)00015-8; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Ha T, 1998, PHYS REV LETT, V80, P2093, DOI 10.1103/PhysRevLett.80.2093; Hua W, 2002, SCIENCE, V295, P844, DOI 10.1126/science.1063089; Irving M, 1997, NEWS PHYSIOL SCI, V12, P249; Mehta A, 2001, J CELL SCI, V114, P1981; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; MOISESCU DG, 1979, BIOCHIM BIOPHYS ACTA, V546, P64, DOI 10.1016/0005-2728(79)90170-1; Moore JR, 2001, J CELL BIOL, V155, P625, DOI 10.1083/jcb.200103128; Nishikawa S, 2002, BIOCHEM BIOPH RES CO, V290, P311, DOI 10.1006/bbrc.2001.6142; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; PRESS WH, 1992, NUMERICAL RECIPES; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; PUTKEY JA, 1983, J BIOL CHEM, V258, P1864; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Sase I, 1997, P NATL ACAD SCI USA, V94, P5646, DOI 10.1073/pnas.94.11.5646; Sosa H, 2001, NAT STRUCT BIOL, V8, P540, DOI 10.1038/88611; Spudich JA, 2001, NAT REV MOL CELL BIO, V2, P387, DOI 10.1038/35073086; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Warshaw DM, 1998, P NATL ACAD SCI USA, V95, P8034, DOI 10.1073/pnas.95.14.8034	44	359	364	1	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					399	404		10.1038/nature01529	http://dx.doi.org/10.1038/nature01529			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660775				2022-12-28	WOS:000181801200036
J	Ugwumadu, A; Manyonda, I; Reid, F; Hay, P				Ugwumadu, A; Manyonda, I; Reid, F; Hay, P			Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial	LANCET			English	Article							PREMATURE BIRTH; EARLY-PREGNANCY; GENITAL-TRACT; GRAM STAIN; METRONIDAZOLE; ASSOCIATION; INFECTIONS; INFANTS; THERAPY; AGENTS	Background Abnormal vaginal flora and bacterial vaginosis are associated with amplified risks of late miscarriage and spontaneous preterm delivery. We aimed to establish whether antibiotic treatment early in the second trimester might reduce these risks in a general obstetric population. Methods We screened 6120 pregnant women attending hospital for their first antenatal visit-who were at 12-22 weeks' gestation (mean 15.6 weeks)-for bacterial vaginosis or abnormal vaginal flora. We used gram-stained slides of vaginal smears to diagnose abnormal vaginal flora or bacterial vaginosis, in accordance with Nugent's criteria. We randomly allocated 494 women with one of these signs to receive either clindamycin 300 mg or placebo orally twice daily for 5 days. Primary endpoints were spontaneous preterm delivery (birth greater than or equal to24 but <37 weeks) and late miscarriage (pregnancy loss &GE;13 but <24 weeks). Analysis was intention to treat. Findings Nine women were lost to follow-up or had elective termination. Thus, we analysed 485 women with complete outcome data. Women receiving clindamycin had significantly fewer miscarriages or preterm deliveries (13/244) than did those in the placebo group (38/241; percentage difference 10.4%, 95% CI 5.0-15.8, p=0.0003). Clindamycin also reduced adverse outcomes across the range of abnormal Nugent scores, with maximum effect in women with the highest Nugent score of 10. Interpretation Treatment of asymptomatic abnormal vaginal flora and bacterial vaginosis with oral clindamycin early in the second trimester significantly reduces the rate of late miscarriage and spontaneous preterm birth in a general obstetric population.	Univ London St Georges Hosp, Dept Obstet & Gynaecol, London SW17 0QT, England; St George Hosp, Sch Med, London SW17 0RE, England; Univ London St Georges Hosp, Dept Genitourinary Med, London SW17 0QT, England	St Georges University London; St Georges University London; St Georges University London	Ugwumadu, A (corresponding author), Univ London St Georges Hosp, Dept Obstet & Gynaecol, Blackshaw Rd, London SW17 0QT, England.							Carey JC, 2000, NEW ENGL J MED, V342, P534, DOI 10.1056/NEJM200002243420802; ESTERLY NB, 1978, J INVEST DERMATOL, V70, P51, DOI 10.1111/1523-1747.ep12543487; GARRAFFO R, 1989, PATHOL BIOL, V37, P643; GIBBS RS, 1992, AM J OBSTET GYNECOL, V166, P1515, DOI 10.1016/0002-9378(92)91628-N; Gratacos E, 1998, ACTA OBSTET GYN SCAN, V77, P37, DOI 10.1080/00016349808565808; Gray PH, 1997, AUST NZ J OBSTET GYN, V37, P161, DOI 10.1111/j.1479-828X.1997.tb02245.x; HACK M, 1993, NEW ENGL J MED, V329, P1649, DOI 10.1056/NEJM199311253292210; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; Hillier SL, 1990, SEXUALLY TRANSMITTED, P547; Kekki M, 2001, OBSTET GYNECOL, V97, P643, DOI 10.1016/S0029-7844(01)01321-7; KORN AP, 1995, OBSTET GYNECOL, V85, P387, DOI 10.1016/0029-7844(94)00400-8; KURKI T, 1992, OBSTET GYNECOL, V80, P173; Kurkinen-Raty M, 2000, BRIT J OBSTET GYNAEC, V107, P1427, DOI 10.1111/j.1471-0528.2000.tb11660.x; LlahiCamp JM, 1996, HUM REPROD, V11, P1575; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; McDonald HM, 1997, BRIT J OBSTET GYNAEC, V104, P1391, DOI 10.1111/j.1471-0528.1997.tb11009.x; MCGREGOR JA, 1995, AM J OBSTET GYNECOL, V173, P157, DOI 10.1016/0002-9378(95)90184-1; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8; Morgan DJ, 1996, BRIT J OBSTET GYNAEC, V103, P1105, DOI 10.1111/j.1471-0528.1996.tb09591.x; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; Ralph SG, 1999, BRIT MED J, V319, P220, DOI 10.1136/bmj.319.7204.220; RIDUAN JM, 1993, AM J OBSTET GYNECOL, V169, P175, DOI 10.1016/0002-9378(93)90157-E; Rosenstein I J, 2000, Infect Dis Obstet Gynecol, V8, P158, DOI 10.1155/S1064744900000211; RUSH RW, 1979, S AFR MED J, V56, P1085; SPIEGEL CA, 1987, ANTIMICROB AGENTS CH, V31, P249, DOI 10.1128/AAC.31.2.249; SPIEGEL CA, 1983, J INFECT DIS, V148, P817, DOI 10.1093/infdis/148.5.817	28	215	223	1	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					983	988		10.1016/S0140-6736(03)12823-1	http://dx.doi.org/10.1016/S0140-6736(03)12823-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660054				2022-12-28	WOS:000181699700007
J	Gerlich, D; Beaudouin, J; Kalbfuss, B; Daigle, N; Eils, R; Ellenberg, J				Gerlich, D; Beaudouin, J; Kalbfuss, B; Daigle, N; Eils, R; Ellenberg, J			Global chromosome positions are transmitted through mitosis in mammalian cells	CELL			English	Article							LIVING HUMAN-CELLS; NUCLEAR-ORGANIZATION; PERICENTRIC HETEROCHROMATIN; CENTROMERE SEPARATION; SPATIAL-ORGANIZATION; GENE ACTIVITY; INTERPHASE; CHROMATIN; DYNAMICS; TERRITORIES	We investigated positioning of chromosomes during the cell cycle in live mammalian cells with a combined experimental and computational approach. By non-invasive labeling of chromosome subsets and tracking by 4D imaging, we could show that no global rearrangements occurred in interphase. Using the same assay, we also observed a striking order of chromosomes throughout mitosis. By contrast, our computer simulation based on stochastic movements of individual chromosomes predicted randomization of chromosome order in mitosis. In vivo, a quantitative assay for single chromosome positioning during mitosis revealed strong similarities between daughter and mother cells. These results demonstrate that global chromosome positions are heritable through the cell cycle in mammalian cells. Based on tracking of labeled chromosomes and centromeres during chromosome segregation and experimental perturbations of chromosomal order, we propose that chromosome specific timing of sister chromatid separation transmits chromosomal positions from one cell generation to the next.	German Canc Res Ctr, D-69120 Heidelberg, Germany; European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany; European Mol Biol Lab, Cell Biol Biophys Programme, D-69117 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Eils, R (corresponding author), German Canc Res Ctr, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	r.eils@dkfz.de	Ellenberg, Jan/I-4688-2014; Eils, Roland/B-6121-2009; Gerlich, Daniel Wolfram W/A-6991-2016	Ellenberg, Jan/0000-0001-5909-701X; Eils, Roland/0000-0002-0034-4036; Gerlich, Daniel Wolfram W/0000-0003-1637-3365				Abney JR, 1997, J CELL BIOL, V137, P1459, DOI 10.1083/jcb.137.7.1459; AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; ALEXANDER SP, 1991, J CELL BIOL, V113, P805, DOI 10.1083/jcb.113.4.805; Allison DC, 1999, J CELL BIOL, V145, P1, DOI 10.1083/jcb.145.1.1; Baxter J, 2002, CURR OPIN CELL BIOL, V14, P372, DOI 10.1016/S0955-0674(02)00339-3; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bin Sun H, 2000, BIOPHYS J, V79, P184, DOI 10.1016/S0006-3495(00)76282-5; BORDEN J, 1988, SCIENCE, V242, P1687, DOI 10.1126/science.3201257; Boyle S, 2001, HUM MOL GENET, V10, P211, DOI 10.1093/hmg/10.3.211; Bridger JM, 2000, CURR BIOL, V10, P149, DOI 10.1016/S0960-9822(00)00312-2; Chubb JR, 2002, CURR BIOL, V12, P439, DOI 10.1016/S0960-9822(02)00695-4; CHUNG HMM, 1990, EMBO J, V9, P2611, DOI 10.1002/j.1460-2075.1990.tb07443.x; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Croft JA, 1999, J CELL BIOL, V145, P1119, DOI 10.1083/jcb.145.6.1119; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; Ferreira J, 1997, J CELL BIOL, V139, P1597, DOI 10.1083/jcb.139.7.1597; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Franklin AE, 1999, PLANT CELL, V11, P523, DOI 10.1105/tpc.11.4.523; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Galy V, 2000, NATURE, V403, P108, DOI 10.1038/47528; Gasser SM, 2001, CELL, V104, P639, DOI 10.1016/S0092-8674(01)00259-8; Gerlich D, 2001, NAT CELL BIOL, V3, P852, DOI 10.1038/ncb0901-852; Haaf T, 2000, CYTOGENET CELL GENET, V91, P113, DOI 10.1159/000056830; Heun P, 2001, SCIENCE, V294, P2181, DOI 10.1126/science.1065366; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Manders EMM, 1999, J CELL BIOL, V144, P813, DOI 10.1083/jcb.144.5.813; Marshall WF, 1996, MOL BIOL CELL, V7, P825, DOI 10.1091/mbc.7.5.825; Marshall WF, 1997, CURR BIOL, V7, P930, DOI 10.1016/S0960-9822(06)00412-X; Martou G, 2000, EXP CELL RES, V256, P131, DOI 10.1006/excr.1999.4793; Muller WG, 2001, J CELL BIOL, V154, P33, DOI 10.1083/jcb.200011069; NAGELE R, 1995, SCIENCE, V270, P1831, DOI 10.1126/science.270.5243.1831; Parada LA, 2002, TRENDS CELL BIOL, V12, P425, DOI 10.1016/S0962-8924(02)02351-6; Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Rabl C, 1885, MORPHOL JB, V10, P214; Sachs RK, 1997, INT J RADIAT BIOL, V71, P1, DOI 10.1080/095530097144364; Sadoni N, 1999, J CELL BIOL, V146, P1211, DOI 10.1083/jcb.146.6.1211; Shelby RD, 1996, J CELL BIOL, V135, P545, DOI 10.1083/jcb.135.3.545; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Tanabe H, 2002, P NATL ACAD SCI USA, V99, P4424, DOI 10.1073/pnas.072618599; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Tumbar T, 2001, NAT CELL BIOL, V3, P134, DOI 10.1038/35055033; Tvarusko W, 1999, P NATL ACAD SCI USA, V96, P7950, DOI 10.1073/pnas.96.14.7950; Vazquez J, 2001, CURR BIOL, V11, P1227, DOI 10.1016/S0960-9822(01)00390-6; Vig BK, 1998, CHROMOSOMA, V107, P417, DOI 10.1007/s004120050325; VIG BK, 1983, CANCER GENET CYTOGEN, V8, P249, DOI 10.1016/0165-4608(83)90142-5; Zink D, 1998, HUM GENET, V102, P241, DOI 10.1007/s004390050686	53	217	225	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2003	112	6					751	764		10.1016/S0092-8674(03)00189-2	http://dx.doi.org/10.1016/S0092-8674(03)00189-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	660DL	12654243	Bronze			2022-12-28	WOS:000181818500004
J	Heeschen, C; Dimmeler, S; Hamm, CW; van den Brand, MJ; Boersma, E; Zeiher, AM; Simoons, ML; CAPTURE Study Investigators				Heeschen, C; Dimmeler, S; Hamm, CW; van den Brand, MJ; Boersma, E; Zeiher, AM; Simoons, ML; CAPTURE Study Investigators			Soluble CD40 ligand in acute coronary syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; REFRACTORY UNSTABLE ANGINA; TROPONIN-I PREDICTS; ENDOTHELIAL-CELLS; PROGNOSTIC VALUE; TISSUE FACTOR; P-SELECTIN; T LEVELS; ACTIVATION; RISK	Background: CD40 ligand is expressed on platelets and released from them on activation. We investigated the predictive value of soluble CD40 ligand as a marker for clinical outcome and the therapeutic effect of glycoprotein IIb/IIIa receptor inhibition in patients with acute coronary syndromes. Methods: Serum levels of soluble CD40 ligand were measured in 1088 patients with acute coronary syndromes who had previously been enrolled in a randomized trial comparing abciximab with placebo before coronary angioplasty and in 626 patients with acute chest pain. Results: The levels of soluble CD40 ligand were elevated (above 5.0 mug per liter) in 221 patients with acute coronary syndromes (40.6 percent). Among patients receiving placebo, elevated soluble CD40 ligand levels indicated a significantly increased risk of death or nonfatal myocardial infarction during six months of follow-up (adjusted hazard ratio as compared with patients with low levels of the ligand [less than or equal to5.0 mug per liter], 2.71; 95 percent confidence interval, 1.51 to 5.35; P=0.001). The prognostic value of this marker was validated in the patients with chest pain, among whom elevated soluble CD40 ligand levels identified those with acute coronary syndromes who were at high risk for death or nonfatal myocardial infarction (adjusted hazard ratio as compared with those with low levels of the ligand, 6.65; 95 percent confidence interval, 3.18 to 13.89; P<0.001). The increased risk in patients with elevated soluble CD40 ligand levels was significantly reduced by treatment with abciximab (adjusted hazard ratio as compared with those receiving placebo, 0.37; 95 percent confidence interval, 0.20 to 0.68; P=0.001), whereas there was no significant treatment effect of abciximab in patients with low levels of soluble CD40 ligand. Conclusions: In patients with unstable coronary artery disease, elevation of soluble CD40 ligand levels indicated an increased risk of cardiovascular events. Elevation of soluble CD40 ligand identifies a subgroup of patients at high risk who are likely to benefit from antiplatelet treatment with abciximab.	c7E3 Fab Antiplatelet Therapy Unstable Refractory, Frankfurt, Germany; Univ Frankfurt, Dept Internal Med 4, D-6000 Frankfurt, Germany; Kerckhoff Heart Ctr, Bad Nauheim, Germany; Erasmus Univ, Thoraxctr, NL-3000 DR Rotterdam, Netherlands	Goethe University Frankfurt; Kerckhoff Clinic; Erasmus University Rotterdam; Erasmus MC	Heeschen, C (corresponding author), Univ Frankfurt, Dept Mol Cardiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Guba, Markus/M-4309-2019; Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161; Heeschen, Christopher/0000-0002-1158-8554; Dimmeler, Stefanie/0000-0002-1045-2436				Andre P, 2002, CIRCULATION, V106, P896, DOI 10.1161/01.CIR.0000028962.04520.01; Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Aukrust P, 1999, CIRCULATION, V100, P614, DOI 10.1161/01.CIR.100.6.614; Benamer H, 1999, AM HEART J, V137, P815, DOI 10.1016/S0002-8703(99)70404-7; Braunwald E, 1998, EUR HEART J, V19, pD22; Cipollone F, 2002, CIRCULATION, V106, P399, DOI 10.1161/01.CIR.0000025419.95769.F0; COX DR, 1972, J R STAT SOC B, V34, P187; Davies MJ, 1997, NEW ENGL J MED, V336, P1312, DOI 10.1056/NEJM199705013361809; DAVIES MJ, 1985, BRIT HEART J, V53, P363; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; Hamm CW, 1999, NEW ENGL J MED, V340, P1623, DOI 10.1056/NEJM199905273402103; Hamm CW, 2001, LANCET, V358, P1533, DOI 10.1016/S0140-6736(01)06585-0; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; Hamm CW, 2000, CIRCULATION, V102, P118, DOI 10.1161/01.CIR.102.1.118; Heeschen C, 1999, CIRCULATION, V100, P1509, DOI 10.1161/01.CIR.100.14.1509; Heeschen C, 1999, LANCET, V354, P1757, DOI 10.1016/S0140-6736(99)10285-X; Henn V, 2001, BLOOD, V98, P1047, DOI 10.1182/blood.V98.4.1047; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; Januzzi JL, 2001, J THROMB THROMBOLYS, V11, P211, DOI 10.1023/A:1011956703031; Kotowicz K, 2000, IMMUNOLOGY, V100, P441, DOI 10.1046/j.1365-2567.2000.00061.x; Lee Y, 1999, CARDIOLOGY, V92, P11, DOI 10.1159/000006940; Lindahl B, 2001, J AM COLL CARDIOL, V38, P979, DOI 10.1016/S0735-1097(01)01501-7; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Mach F, 1997, CIRCULATION, V96, P396; Michelson AD, 2001, CIRCULATION, V104, P1533, DOI 10.1161/hc3801.095588; Miller DL, 1998, J LEUKOCYTE BIOL, V63, P373, DOI 10.1002/jlb.63.3.373; Nannizzi-Alaimo L, 2002, CIRCULATION, V105, P2849, DOI 10.1161/01.CIR.0000019068.32280.B3; Newby LK, 2001, CIRCULATION, V103, P2891, DOI 10.1161/01.CIR.103.24.2891; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; Schonbeck U, 2001, CIRCULATION, V104, P2266, DOI 10.1161/hc4401.099447; Simoons ML, 1997, LANCET, V349, P1429; Urbich C, 2001, J CLIN INVEST, V108, P1451, DOI 10.1172/JCI200113620; 1997, LANCET, V350, P744	39	702	753	0	11	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1104	1111		10.1056/NEJMoa022600	http://dx.doi.org/10.1056/NEJMoa022600			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646667	Green Published			2022-12-28	WOS:000181628400006
J	McGee, DC; Gould, MK				McGee, DC; Gould, MK			Current concepts - Preventing complications of central venous catheterization	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BLOOD-STREAM INFECTION; PROSPECTIVE RANDOMIZED TRIAL; SUBCLAVIAN-VEIN CATHETERIZATION; ANTISEPTIC-IMPREGNATED CATHETER; PULMONARY-ARTERY CATHETERS; TOTAL PARENTERAL-NUTRITION; INTENSIVE-CARE PATIENTS; CRITICALLY ILL PATIENTS; DOUBLE-BLIND TRIAL; INTRAVASCULAR-CATHETER		Vet Affairs Palo Alto Hlth Care Syst, Pulm & Crit Care Sect 111P, Hlth Serv Res & Dev Serv, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Div Pulm & Crit Care Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Palo Alto, CA 94304 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Gould, MK (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Pulm & Crit Care Sect 111P, Hlth Serv Res & Dev Serv, 3801 Miranda Ave, Palo Alto, CA 94304 USA.							Abraham E, 2000, CRIT CARE MED, V28, P232, DOI 10.1097/00003246-200001000-00039; ARNOW PM, 1993, CLIN INFECT DIS, V16, P778, DOI 10.1093/clind/16.6.778; BOCK SN, 1990, J CLIN ONCOL, V8, P161, DOI 10.1200/JCO.1990.8.1.161; Bold RJ, 1998, ARCH SURG-CHICAGO, V133, P1089, DOI 10.1001/archsurg.133.10.1089; BONAWITZ SC, 1991, AM SURGEON, V57, P618; BRYANT JK, 1987, AM J CLIN PATHOL, V88, P113, DOI 10.1093/ajcp/88.1.113; CLARKCHRISTOFF N, 1992, JPEN-PARENTER ENTER, V16, P403, DOI 10.1177/0148607192016005403; COBB DK, 1992, NEW ENGL J MED, V327, P1062, DOI 10.1056/NEJM199210083271505; Collin GR, 1999, CHEST, V115, P1632, DOI 10.1378/chest.115.6.1632; CONLY JM, 1989, J INFECT DIS, V159, P310, DOI 10.1093/infdis/159.2.310; Cook D, 1997, CRIT CARE MED, V25, P1417, DOI 10.1097/00003246-199708000-00033; Cookson ST, 1998, INFECT CONT HOSP EP, V19, P23; Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101; DesJardin JA, 1999, ANN INTERN MED, V131, P641, DOI 10.7326/0003-4819-131-9-199911020-00002; Durbec O, 1997, CRIT CARE MED, V25, P1986, DOI 10.1097/00003246-199712000-00014; ENGERVALL P, 1995, J HOSP INFECT, V29, P275, DOI 10.1016/0195-6701(95)90274-0; EYER S, 1990, CRIT CARE MED, V18, P1073, DOI 10.1097/00003246-199010000-00005; FARES LG, 1986, AM SURGEON, V52, P108; FARKAS JC, 1992, AM J MED, V93, P277, DOI 10.1016/0002-9343(92)90233-2; FLOWERS RH, 1989, JAMA-J AM MED ASSOC, V261, P878, DOI 10.1001/jama.261.6.878; HALPIN DP, 1991, NUTRITION, V7, P33; Heard SO, 1998, ARCH INTERN MED, V158, P81, DOI 10.1001/archinte.158.1.81; Henrickson KJ, 2000, J CLIN ONCOL, V18, P1269, DOI 10.1200/JCO.2000.18.6.1269; HIRSCH DR, 1995, JAMA-J AM MED ASSOC, V274, P335, DOI 10.1001/jama.274.4.335; JERNIGAN JA, 1993, ANN INTERN MED, V119, P304, DOI 10.7326/0003-4819-119-4-199308150-00010; Laura R, 2000, Haematologica, V85, P275; Lefrant JY, 1998, ANESTHESIOLOGY, V88, P1195, DOI 10.1097/00000542-199805000-00009; Ma TY, 1998, CLIN INFECT DIS, V27, P500, DOI 10.1086/514687; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1994, CRIT CARE MED, V22, P1729; MAKI DG, 1981, AM J MED, V70, P739, DOI 10.1016/0002-9343(81)90605-7; MAKI DG, 1988, AM J MED, V85, P307, DOI 10.1016/0002-9343(88)90579-7; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MANSFIELD PF, 1994, NEW ENGL J MED, V331, P1735, DOI 10.1056/NEJM199412293312602; MARTIN C, 1990, CRIT CARE MED, V18, P400, DOI 10.1097/00003246-199004000-00010; Martinez E, 1999, BONE MARROW TRANSPL, V23, P41, DOI 10.1038/sj.bmt.1701538; McDonald LC, 1998, INFECT CONT HOSP EP, V19, P772; McKinley S, 1999, ANAESTH INTENS CARE, V27, P164, DOI 10.1177/0310057X9902700206; Merrer J, 2001, JAMA-J AM MED ASSOC, V286, P700, DOI 10.1001/jama.286.6.700; MICHEL LA, 1988, INT SURG, V73, P180; Mimoz O, 1996, CRIT CARE MED, V24, P1818, DOI 10.1097/00003246-199611000-00010; Pearson ML, 1996, INFECT CONT HOSP EP, V17, P438; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; Raad I, 1998, LANCET, V351, P893, DOI 10.1016/S0140-6736(97)10006-X; Raad II, 1998, CANCER, V82, P403, DOI 10.1002/(SICI)1097-0142(19980115)82:2<412::AID-CNCR22>3.0.CO;2-0; RAAD II, 1992, DIAGN MICR INFEC DIS, V15, P13, DOI 10.1016/0732-8893(92)90052-U; RAAD II, 1994, INFECT CONT HOSP EP, V15, P231; RAAD II, 1992, DIAGN MICR INFEC DIS, V15, P384; RADD I, 1993, J INFECT DIS, V168, P400, DOI 10.1093/infdis/168.2.400; Randolph AG, 1996, CRIT CARE MED, V24, P2053, DOI 10.1097/00003246-199612000-00020; Richards MJ, 1999, CRIT CARE MED, V27, P887, DOI 10.1097/00003246-199905000-00020; SALZMAN MB, 1993, J INFECT DIS, V167, P487, DOI 10.1093/infdis/167.2.487; Segura M, 1996, ANN SURG, V223, P363, DOI 10.1097/00000658-199604000-00004; SHERERTZ RJ, 1990, J CLIN MICROBIOL, V28, P76, DOI 10.1128/JCM.28.1.76-82.1990; Sherertz RJ, 1997, J CLIN MICROBIOL, V35, P641, DOI 10.1128/JCM.35.3.641-646.1997; SMITH HO, 1995, GYNECOL ONCOL, V58, P92, DOI 10.1006/gyno.1995.1189; SZNAJDER JI, 1986, ARCH INTERN MED, V146, P259, DOI 10.1001/archinte.146.2.259; Teichgraber UKM, 1997, AM J ROENTGENOL, V169, P731, DOI 10.2214/ajr.169.3.9275887; Timsit JF, 1998, CHEST, V114, P207, DOI 10.1378/chest.114.1.207; Timsit JF, 1999, ANN INTERN MED, V130, P729, DOI 10.7326/0003-4819-130-9-199905040-00004; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V281, P261, DOI 10.1001/jama.281.3.261; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V282, P554, DOI 10.1001/jama.282.6.554; Venus Bahman, 1997, P521; WASHINGTON JA, 1986, REV INFECT DIS, V8, P792; ZAKRZEWSKABODE A, 1995, J HOSP INFECT, V31, P189, DOI 10.1016/0195-6701(95)90065-9	68	1307	1417	2	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1123	1133		10.1056/NEJMra011883	http://dx.doi.org/10.1056/NEJMra011883			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646670	Bronze			2022-12-28	WOS:000181628400009
J	Christian, P; Khatry, SK; Katz, J; Pradhan, EK; LeClerq, SC; Shrestha, SR; Adhikari, RK; Sommer, A; West, KP				Christian, P; Khatry, SK; Katz, J; Pradhan, EK; LeClerq, SC; Shrestha, SR; Adhikari, RK; Sommer, A; West, KP			Effects of alternative maternal micronutrient supplements on low birth weight in rural Nepal: double blind randomised community trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IRON SUPPLEMENTATION; ZINC SUPPLEMENTATION; BETA-CAROTENE; VITAMIN-A; PREGNANCY; MORTALITY; CONSEQUENCES; GROWTH; WOMEN	Objective To assess the impact on birth size and risk of low birth weight of alternative combinations of micronutrients given to pregnant women. Design Double blind cluster randomised controlled trial. Setting Rural community in south eastern Nepal. Participants 4926 pregnant women and 4130 live born infants. Interventions 426 communities were randomised to five regimens in which pregnant women received daily supplements of folic acid, folic acid-iron, folic acid-iron-zinc, or multiple micronutrients all given with vitamin A, or vitamin A alone (control). Main outcome measures Birth weight, length, and head and chest circumference assessed within 72 hours of birth. Low birth weight was defined < 2500 g. Results Supplementation with maternal folic acid alone had no effect on birth size. Folic acid-iron increased mean birth weight by 37 g (95% confidence interval - 16 g to 90 g) and reduced the percentage of low birthweight babies (< 2500 g) from 43% to 34% (16%; relative risk=0.84, 0.72 to 0.99). Folic acid-iron-zinc had no effect on birth size compared with controls. Multiple micronutrient supplementation increased birth weight by 64 g (12 g to 115 g) and reduced the percentage of low birthweight babies by 14% (0.86, 0.74 to 0.99). None of the supplement combinations reduced the incidence of preterm births. Folic acid-iron and multiple micronutrients increased head and chest circumference of babies, but not length. Conclusions Antenatal folic acid-iron supplements modestly reduce the risk of low birth weight. Multiple micronutrients confer no additional benefit over folic acid-iron in reducing this risk.	Johns Hopkins Bloomberg Sch Publ Hlth, Div Human Nutr, Baltimore, MD 21205 USA; Nepal Netra Jyoti Sangh, Nepal Nutr Intervent Project Sarlahi, Kathmandu, Nepal; Johns Hopkins Bloomberg Sch Publ Hlth, Div Dis Prevent & Control, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Christian, P (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Div Human Nutr, 615 N Wolfe St, Baltimore, MD 21205 USA.	pchristi@jhsph.edu		Katz, Joanne/0000-0002-5997-7823				Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X; Allen LH, 2001, J NUTR, V131, p581S, DOI 10.1093/jn/131.2.581S; Ashworth A, 1998, EUR J CLIN NUTR, V52, pS34; Caulfield LE, 1999, J NUTR, V129, P1563, DOI 10.1093/jn/129.8.1563; Ceesay SM, 1997, BMJ-BRIT MED J, V315, P786, DOI 10.1136/bmj.315.7111.786; Child Health Research Project, 1999, SPEC REP RED PER NEO; de Onis M, 1998, EUR J CLIN NUTR, V52, pS83; DREYFUSS ML, 1997, 18 INT VIT A CONS GR; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GARNER P, 1992, LANCET, V340, P1021, DOI 10.1016/0140-6736(92)93022-F; Katz J, 2000, AM J CLIN NUTR, V71, P1570; LAWLESS JW, 1994, J NUTR, V124, P645, DOI 10.1093/jn/124.5.645; LECHTIG A, 1975, AM J CLIN NUTR, V28, P1223, DOI 10.1093/ajcn/28.11.1223; LECHTIG A, 1975, PEDIATRICS, V56, P508; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Osendarp SJM, 2000, AM J CLIN NUTR, V71, P114; Preziosi P, 1997, AM J CLIN NUTR, V66, P1178, DOI 10.1093/ajcn/66.5.1178; Ramakrishnan U, 1999, NUTR RES, V19, P103, DOI 10.1016/S0271-5317(98)00178-X; Rasmussen KM, 2001, J NUTR, V131, p590S, DOI 10.1093/jn/131.2.590S; Solomons NW, 1997, NUTR RES, V17, P177, DOI 10.1016/S0271-5317(96)00243-6; SOLOMONS NW, 1986, J NUTR, V116, P927, DOI 10.1093/jn/116.6.927; Stoltzfus RJ, 1998, GUIDELINES USE IRON; West KP, 1999, BMJ-BRIT MED J, V318, P570, DOI 10.1136/bmj.318.7183.570	23	266	267	1	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2003	326	7389					571	574		10.1136/bmj.326.7389.571	http://dx.doi.org/10.1136/bmj.326.7389.571			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657ZF	12637400	Bronze, Green Published			2022-12-28	WOS:000181696600016
J	Rieder, CL; Khodjakov, A				Rieder, CL; Khodjakov, A			Mitosis through the microscope: Advances in seeing inside live dividing cells	SCIENCE			English	Review							MITOTIC SPINDLE; MAMMALIAN-CELLS; LIVING CELLS; DYNAMIC INSTABILITY; GAMMA-TUBULIN; ANAPHASE-A; KINETOCHORES; MICROTUBULES; POLEWARD; PROTEIN	The most visually spectacular events in the life of a cell occur when it divides. This is especially true in higher eukaryotes, where the size and geometry of cells allow the division process to be followed through a microscope with considerable clarity. In these organisms, the membrane surrounding the nucleus breaks down after the replicated DNA has condensed to form discrete chromosomes. Several new structures are then assembled to separate the chromosomes and partition the cytoplasm into two separate cells.	Wadsworth Ctr, Div Mol Med, Lab Cell Regulat, Albany, NY 12201 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA; Marine Biol Lab, Woods Hole, MA 02543 USA	Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Marine Biological Laboratory - Woods Hole	Rieder, CL (corresponding author), Wadsworth Ctr, Div Mol Med, Lab Cell Regulat, POB 509, Albany, NY 12201 USA.	rieder@wadsworth.org; khodj@wadsworth.org			NIGMS NIH HHS [GMS 59363, R37 GM040198, R01 GM059363-05, R01 GM059363, R37 GM040198-20, GMS 40198] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040198, R01GM040198, R01GM059363] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B., 1994, MOL BIOL CELL; BRINKLEY BR, 1971, J CELL BIOL, V50, P416, DOI 10.1083/jcb.50.2.416; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; DUPRAW EJ, 1969, CELL MOL BIOL; FLEMMING W, 1882, ZELLSUBSTANZ ZELLTHE; Gerlich D, 2001, NAT CELL BIOL, V3, P852, DOI 10.1038/ncb0901-852; Gonczy P, 1999, J CELL BIOL, V144, P927, DOI 10.1083/jcb.144.5.927; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAYDEN JH, 1990, J CELL BIOL, V111, P1039, DOI 10.1083/jcb.111.3.1039; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; INOUE S, 1967, J GEN PHYSIOL, V50, P259, DOI 10.1085/jgp.50.6.259; Inoue S., 1981, Journal of Cell Biology, V91, P131; INOUE S, 1997, VIDEOMICROSCOPY; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; Kapoor TM, 2002, J CELL BIOL, V157, P551, DOI 10.1083/jcb.200202073; Kapoor TM, 2001, J CELL BIOL, V154, P1125, DOI 10.1083/jcb.200106011; Khodjakov A, 1997, CELL MOTIL CYTOSKEL, V38, P311, DOI 10.1002/(SICI)1097-0169(1997)38:4<311::AID-CM1>3.3.CO;2-M; Khodjakov A, 1999, J CELL BIOL, V146, P585, DOI 10.1083/jcb.146.3.585; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lee L, 2000, SCIENCE, V287, P2260, DOI 10.1126/science.287.5461.2260; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Maddox P, 2002, CURR BIOL, V12, P1670, DOI 10.1016/S0960-9822(02)01183-1; Maney T, 2000, INT REV CYTOL, V194, P67; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; Mitchison TJ, 2001, NAT CELL BIOL, V3, pE17, DOI 10.1038/35050656; OSTERGREN G, 1960, ANN NY ACAD SCI, V90, P381, DOI 10.1111/j.1749-6632.1960.tb23258.x; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Savoian MS, 2000, NAT CELL BIOL, V2, P948, DOI 10.1038/35046605; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SCHRADER F, 1953, MITOSIS MOVEMENT CHR, P1; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Tavormina PA, 2002, J CELL BIOL, V158, P23, DOI 10.1083/jcb.200202053; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Wallace W, 2001, BIOTECHNIQUES, V31, P1076, DOI 10.2144/01315bi01; Waterman-Storer CM, 2002, CURR BIOL, V12, pR633, DOI 10.1016/S0960-9822(02)01139-9; White RA, 2000, MICROSC RES TECHNIQ, V49, P451, DOI 10.1002/(SICI)1097-0029(20000601)49:5<451::AID-JEMT7>3.0.CO;2-9; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; ZHAI Y, 1995, J CELL BIOL, V131, P721, DOI 10.1083/jcb.131.3.721; Zhou J, 2002, J CELL SCI, V115, P3547, DOI 10.1242/jcs.00029	47	82	88	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2003	300	5616					91	96		10.1126/science.1082177	http://dx.doi.org/10.1126/science.1082177			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677059	Green Submitted			2022-12-28	WOS:000181988900037
J	Stephens, DJ; Allan, VJ				Stephens, DJ; Allan, VJ			Light microscopy techniques for live cell Imaging	SCIENCE			English	Review							GREEN FLUORESCENT PROTEINS; DYNAMICS; ACTIVATION; ACTIN	Since the earliest examination of cellular structures, biologists have been fascinated by observing cells using light microscopy. The advent of fluorescent labeling technologies plus the plethora of sophisticated light microscope techniques now available make studying dynamic processes in living cells almost commonplace. For anyone new to this area, however, it can be daunting to decide which techniques or equipment to try. Here, we aim to give a brief overview of the main approaches to live cell imaging, with some mention of their pros and cons.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Manchester; University of Bristol	Allan, VJ (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.	viki.allan@man.ac.uk		Stephens, David/0000-0001-5297-3240; Allan, Victoria/0000-0003-4583-0836				Ando R, 2002, P NATL ACAD SCI USA, V99, P12651, DOI 10.1073/pnas.202320599; ARNOS WB, 2000, PROTEIN LOCALIZATION, P67; Balla T., 2002, SCI STKE, V2002, p3pl; Blake Robert A., 2001, Current Opinion in Pharmacology, V1, P533, DOI 10.1016/S1471-4892(01)00092-3; Booth MJ, 2002, P NATL ACAD SCI USA, V99, P5788, DOI 10.1073/pnas.082544799; Christie RH, 2001, J NEUROSCI, V21, P858, DOI 10.1523/JNEUROSCI.21-03-00858.2001; de Lange F, 2001, J CELL SCI, V114, P4153; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Dyba M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.163901; Fradkov AF, 2000, FEBS LETT, V479, P127, DOI 10.1016/S0014-5793(00)01895-0; Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; Haugland R.P., 2002, HDB FLUORESCENT PROB; Helmchen F, 2001, NEURON, V31, P903, DOI 10.1016/S0896-6273(01)00421-4; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Ishijima A, 2001, TRENDS BIOCHEM SCI, V26, P438, DOI 10.1016/S0968-0004(01)01860-6; Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Kano H, 2002, ULTRAMICROSCOPY, V90, P207, DOI 10.1016/S0304-3991(01)00132-2; Klar TA, 2000, P NATL ACAD SCI USA, V97, P8206, DOI 10.1073/pnas.97.15.8206; LAKOWICZ JR, 1992, ANAL BIOCHEM, V202, P316, DOI 10.1016/0003-2697(92)90112-K; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Pawley J, 1995, HDB BIOL CONFOCAL MI; Pawley JB, 2002, SCANNING, V24, P241, DOI 10.1002/sca.4950240504; Pepperkok R, 1999, CURR BIOL, V9, P269, DOI 10.1016/S0960-9822(99)80117-1; Phair RD, 2001, NAT REV MOL CELL BIO, V2, P898, DOI 10.1038/35103000; Piston DW, 1999, TRENDS ENDOCRIN MET, V10, P413, DOI 10.1016/S1043-2760(99)00204-0; Ploem J.S., 1999, LIGHT MICROSCOPY BIO, P275; Ray P, 2002, P NATL ACAD SCI USA, V99, P3105, DOI 10.1073/pnas.052710999; Rieder CL, 2003, SCIENCE, V300, P91, DOI 10.1126/science.1082177; *ROP SCI, 2002, 14 ROP SCI; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103; Simpson JC, 2001, HISTOCHEM CELL BIOL, V115, P23, DOI 10.1007/s004180000236; Stelzer EHK, 2002, NATURE, V417, P806, DOI 10.1038/417806a; Steyer JA, 1999, BIOPHYS J, V76, P2262, DOI 10.1016/S0006-3495(99)77382-0; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Straub M, 2000, EUR J CELL BIOL, V79, P726, DOI 10.1078/0171-9335-00105; Stroffekova K, 2001, PFLUG ARCH EUR J PHY, V442, P859, DOI 10.1007/s004240100619; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Sund SE, 2000, BIOPHYS J, V79, P1655, DOI 10.1016/S0006-3495(00)76415-0; Swedlow JR, 2002, P NATL ACAD SCI USA, V99, P2014, DOI 10.1073/pnas.022554999; Swedlow JR, 2003, SCIENCE, V300, P100, DOI 10.1126/science.1082602; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; Wallace W, 2001, BIOTECHNIQUES, V31, P1076, DOI 10.2144/01315bi01; Waterman-Storer CM, 1998, CURR BIOL, V8, P1227, DOI 10.1016/S0960-9822(07)00515-5; Watson TF, 2002, J MICROSC-OXFORD, V207, P37, DOI 10.1046/j.1365-2818.2002.01043.x; Weiss D. G., 1999, LIGHT MICROSCOPY BIO, P73; Wu JC, 2002, CIRCULATION, V105, P1631, DOI 10.1161/01.CIR.0000014984.95520.AD; Xu X, 1998, NUCLEIC ACIDS RES, V26, P2034, DOI 10.1093/nar/26.8.2034; Zicha D, 1999, J CELL SCI, V112, P447; Zimmermann T, 2002, FEBS LETT, V531, P245, DOI 10.1016/S0014-5793(02)03508-1	60	868	918	13	337	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					82	86		10.1126/science.1082160	http://dx.doi.org/10.1126/science.1082160			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677057				2022-12-28	WOS:000181988900035
J	Grunberg, SM; Cefalu, WT				Grunberg, SM; Cefalu, WT			The integral role of clinical research in clinical care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRIALS; ETHICS; WOMEN		Univ Vermont, Sch Med, Div Hematol Oncol, Burlington, VT 05405 USA; Univ Vermont, Sch Med, Div Endocrinol Diabet & Metab, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Grunberg, SM (corresponding author), Univ Vermont, Sch Med, Div Hematol Oncol, Burlington, VT 05405 USA.							ANTMAN KH, 2001, J NCI MONOGR, V30, P114; BENSON AB, 1991, J CLIN ONCOL, V9, P2067, DOI 10.1200/JCO.1991.9.11.2067; Drazen JM, 2000, NEW ENGL J MED, V343, P1643, DOI 10.1056/NEJM200011303432212; Du XLL, 2003, ANN INTERN MED, V138, P90, DOI 10.7326/0003-4819-138-2-200301210-00009; Emanuel EJ, 2001, NEW ENGL J MED, V345, P915, DOI 10.1056/NEJM200109203451211; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; INGELFINGER FJ, 1972, NEW ENGL J MED, V287, P100, DOI 10.1056/NEJM197207132870211; KODISH E, 1995, J CLIN ONCOL, V13, P1817, DOI 10.1200/JCO.1995.13.7.1817; LEMONICK MD, 2002, TIME            0422, P46; Marquis D, 1999, NEW ENGL J MED, V341, P691, DOI 10.1056/NEJM199908263410912; Miller FG, 2003, NEW ENGL J MED, V348, P1383, DOI 10.1056/NEJMsb030228; *NCI, 2002, STAT REQ HLTH PLANS; PASSAMANI E, 1991, NEW ENGL J MED, V324, P1589, DOI 10.1056/NEJM199105303242209; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Saaddine JB, 2002, ANN INTERN MED, V136, P565, DOI 10.7326/0003-4819-136-8-200204160-00005; SCHAFER A, 1982, NEW ENGL J MED, V307, P721, DOI 10.1056/NEJM198209163071204; Steinbrook R, 2002, NEW ENGL J MED, V346, P716, DOI 10.1056/NEJM200202283460924; Tishler CL, 2002, J CLIN PHARMACOL, V42, P365, DOI 10.1177/0091270002424001	18	30	30	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1386	1388		10.1056/NEJMsb025342	http://dx.doi.org/10.1056/NEJMsb025342			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672868				2022-12-28	WOS:000181949100013
J	Juo, ZS; Kassavetis, GA; Wang, JM; Geiduschek, EP; Sigler, PB				Juo, ZS; Kassavetis, GA; Wang, JM; Geiduschek, EP; Sigler, PB			Crystal structure of a transcription factor IIIB core interface ternary complex	NATURE			English	Article							RNA-POLYMERASE-III; TATA-BINDING PROTEIN; FACTOR TFIIIB; YEAST TFIIIB; FACTOR BRF; DNA; BOX; REFINEMENT; MODEL; NOMENCLATURE	Transcription factor IIIB ( TFIIIB), consisting of the TATA-binding protein (TBP), TFIIB-related factor (Brf1) and Bdp1, is a central component in basal and regulated transcription by RNA polymerase III1-4. TFIIIB recruits its polymerase to the promoter and subsequently has an essential role in the formation of the open initiation complex. The amino-terminal half of Brf1 shares a high degree of sequence similarity with the polymerase II general transcription factor TFIIB, but it is the carboxy-terminal half of Brf1 that contributes most of its binding affinity with TBP5-8. The principal anchoring region is located between residues 435 and 545 of yeast Brf1, comprising its homology domain II. The same region also provides the primary interface for assembling Bdp1 into the TFIIIB complex(9). We report here a 2.95 Angstrom resolution crystal structure of the ternary complex containing Brf1 homology domain II, the conserved region of TBP and 19 base pairs of U6 promoter DNA. The structure reveals the core interface for assembly of TFIIIB and demonstrates how the loosely packed Brf1 domain achieves remarkable binding specificity with the convex and lateral surfaces of TBP.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Yale University; University of California System; University of California San Diego	Juo, ZS (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.	juo@csb.yale.edu						Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; Colbert T, 1998, MOL CELL BIOL, V18, P1682, DOI 10.1128/MCB.18.3.1682; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Huet J, 1997, J BIOL CHEM, V272, P18341, DOI 10.1074/jbc.272.29.18341; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; Kassavetis GA, 1998, MOL CELL BIOL, V18, P5587, DOI 10.1128/MCB.18.9.5587; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Martel LS, 2002, MOL CELL BIOL, V22, P2788, DOI 10.1128/MCB.22.8.2788-2798.2002; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Rost B, 1996, METHOD ENZYMOL, V266, P525; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Shen YH, 1998, MOL CELL BIOL, V18, P1692, DOI 10.1128/MCB.18.3.1692; Stebbins CE, 2001, NATURE, V414, P77, DOI 10.1038/35102073; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WHITE RJ, 1998, RNA POLYM 3 TRANSCRI; Willis IM, 2002, GENE DEV, V16, P1337, DOI 10.1101/gad.998102; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	29	71	72	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2003	422	6931					534	539		10.1038/nature01534	http://dx.doi.org/10.1038/nature01534			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12660736				2022-12-28	WOS:000181965400041
J	Foss, FM; Aquino, SL; Ferry, JA; Harris, NL; Park, D; Spitzer, TR; Colvin, RB				Foss, FM; Aquino, SL; Ferry, JA; Harris, NL; Park, D; Spitzer, TR; Colvin, RB			Case 10-2003: A 72-year-old man with rapidly progressive leukemia, rash, and multiorgan failure - Adult T-cell leukemia-lymphoma, HTLV-I-associated, acute form	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ENDEMIC AREA; VIRUS-I; MONOCLONAL-ANTIBODY; LEUKEMIA/LYMPHOMA; PATIENT; STRONGYLOIDIASIS; TRANSPLANTATION; OVEREXPRESSION; INTERLEUKIN-2; COMBINATION		Tufts Univ New England Med Ctr, Dept Hematol Oncol, Boston, MA 02111 USA; Tufts Univ, Med Ctr, Dept Med, Boston, MA 02111 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Tufts Medical Center; Tufts University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Foss, FM (corresponding author), Tufts Univ New England Med Ctr, Dept Hematol Oncol, 750 Washington St, Boston, MA 02111 USA.		Spitzer, Thomas/AAR-7652-2020					Abe Y, 2002, INT J HEMATOL, V76, P91, DOI 10.1007/BF02982725; Agape P, 1999, J ACQ IMMUN DEF SYND, V20, P394, DOI 10.1097/00042560-199904010-00011; Arima N, 2001, LEUKEMIA LYMPHOMA, V40, P267, DOI 10.3109/10428190109057925; BRODER S, 1984, ANN INTERN MED, V100, P543, DOI 10.7326/0003-4819-100-4-543; Gabet AS, 2000, ONCOGENE, V19, P4954, DOI 10.1038/sj.onc.1203870; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603; Gotuzzo E, 2000, INFECT DIS CLIN N AM, V14, P211, DOI 10.1016/S0891-5520(05)70225-7; GROSSMAN B, 1981, AM J CLIN PATHOL, V75, P149; HARRINGTON DS, 1988, CLIN LAB MED, V8, P97, DOI 10.1016/S0272-2712(18)30700-5; Hatta Y, 2002, LEUKEMIA, V16, P1069, DOI 10.1038/sj.leu.2402458; HAYASHI T, 1995, INT J HEMATOL, V61, P215; IKEDA K, 1995, MINER ELECTROL METAB, V21, P166; KIKUCHI M, 2001, PATHOLOGY GENETICS T, P200; Kumagawa M, 2001, LEUKEMIA LYMPHOMA, V41, P593, DOI 10.3109/10428190109060350; MANNS A, 1993, LANCET, V342, P1447, DOI 10.1016/0140-6736(93)92931-I; Ohtake Naoki, 1997, Journal of Dermatology (Tokyo), V24, P165; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; SHIMOYAMA M, 1991, LEUKEMIA RES, V15, P81; TAJIMA K, 1992, ADV ADULT T CELL LEU, P129; TOBINAI K, 1991, LEUKEMIA RES, V15, P837, DOI 10.1016/0145-2126(91)90468-9; Tsukasaki K, 2000, BEST PRACT RES CL HA, V13, P231, DOI 10.1053/beha.1999.0070; Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038/sj.bmt.1702731; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1995, BLOOD, V86, P4063, DOI 10.1182/blood.V86.11.4063.bloodjournal86114063; Waldmann TA, 2000, ANN ONCOL, V11, P101, DOI 10.1023/A:1008324701986; WALDMANN TA, 1988, BLOOD, V72, P1805; White JD, 2001, LEUKEMIA LYMPHOMA, V40, P287, DOI 10.3109/10428190109057927	29	10	11	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2003	348	13					1267	1275		10.1056/NEJMcpc030003	http://dx.doi.org/10.1056/NEJMcpc030003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659RG	12660391				2022-12-28	WOS:000181790800009
J	Levin, LI; Munger, KL; Rubertone, MV; Peck, CA; Lennette, ET; Spiegelman, D; Ascherio, A				Levin, LI; Munger, KL; Rubertone, MV; Peck, CA; Lennette, ET; Spiegelman, D; Ascherio, A			RETRACTED: Multiple sclerosis and Epstein-Barr virus (Retracted Article. See vol 293, pg 2466, 2005)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Retracted Publication							NUCLEAR ANTIGEN; ANTIBODY-TITERS; MONONUCLEOSIS; INFECTION; DISEASE; EBNA-2	Context Infection with Epstein-Barr virus (EBV) has been associated with an increased risk of multiple sclerosis (MS), but the temporal relationship remains unclear. Objective To determine whether antibodies to EBV are elevated before the onset of MS. Design, Setting, and Population Nested case-control study conducted among more than 3 million US military personnel with blood samples collected between 1988 and 2000 and stored in the Department of Defense Serum Repository. Cases were identified as individuals granted temporary or permanent disability because of MS. For each case (n=83), 2 controls matched by age, sex, race/ethnicity, and dates of blood sample collection were selected. Main Outcome Measures Antibodies including IgA against EBV viral capsid antigen (VCA) and IgG against VCA, nuclear antigens (EBNA complex, EBNA-1, and EBNA-2), diffuse and restricted early antigens, and cytomegalovirus. Results The average time between blood collection and MS onset was 4 years. The strongest predictors of MS were serum levels of IgG antibodies to VCA or EBNA complex. The risk of MS increased monotonically with these antibody titers; relative risk (RR) in persons in the highest category of VCA (greater than or equal to2560) compared with those in the lowest (less than or equal to160) was 19.7 (95% confidence interval [CI], 2.2-174; P for trend =.004). For EBNA complex titers, the RR for those in the highest category (greater than or equal to1280) was 33.9 (95% CI, 4.1-283; P for trend <.001) vs those in the lowest category (<= 40). Similarly strong positive associations between EBV antibodies and risk of MS were already present in samples collected 5 or more years before MS onset. No association was found between cytomegalovirus antibodies and MS. Conclusion These results suggest a relationship between EBV infection and development of MS.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Div Prevent Med, Washington, DC 20307 USA; USA, Med Surveillance Act, Ctr Hlth Promot & Prevent Med, Washington, DC 20310 USA; USA, Phys Disabil Agcy, Washington, DC 20310 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Virolab Inc, Berkeley, CA USA	Harvard University; Harvard T.H. Chan School of Public Health; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	Ascherio, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	Alberto.Ascherio@channing.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042194] Funding Source: NIH RePORTER; NINDS NIH HHS [NS42194] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ascherio A, 2001, JAMA-J AM MED ASSOC, V286, P3083, DOI 10.1001/jama.286.24.3083; Brex PA, 1999, NEUROLOGY, V53, P1184, DOI 10.1212/WNL.53.6.1184; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0; DETHE G, 1982, HERPESVIRUSES, V1, P25; Diggle P, 1994, ANAL LONGITUDINAL DA, VXI, P253; HENLE W, 1987, P NATL ACAD SCI USA, V84, P570, DOI 10.1073/pnas.84.2.570; HENLE W, 1971, J INFECT DIS, V124, P58, DOI 10.1093/infdis/124.1.58; HORWITZ CA, 1985, J INFECT DIS, V151, P1150, DOI 10.1093/infdis/151.6.1150; KUSUNOKI Y, 1993, MICROBIOL IMMUNOL, V37, P461, DOI 10.1111/j.1348-0421.1993.tb03237.x; LARSEN PD, 1985, NEUROLOGY, V35, P435, DOI 10.1212/WNL.35.3.435; LENNETTE ET, 1993, EUR J CANCER, V29A, P1584, DOI 10.1016/0959-8049(93)90299-U; LENNETTE ET, 2000, CLIN VIROLOGY MANUAL, P140; LENNETTE ET, 1999, MANUAL CLIN MICROBIO, P912; MUELLER N, 1989, NEW ENGL J MED, V320, P689, DOI 10.1056/NEJM198903163201103; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900; SHIRODARIA PV, 1987, ARCH NEUROL-CHICAGO, V44, P1237, DOI 10.1001/archneur.1987.00520240019006	19	107	111	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2003	289	12					1533	1536		10.1001/jama.289.12.1533	http://dx.doi.org/10.1001/jama.289.12.1533			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659XE	12672770	Bronze			2022-12-28	WOS:000181803100031
J	Bindman, AB; Majeed, A				Bindman, AB; Majeed, A			Primary care in the United States - Organisation of primary care in the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT PROGRAMS; HOSPITALIST MODEL; HEALTH PLANS; PHYSICIANS; ATTITUDES; VOLUME		Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA; UCL, Sch Publ Policy, Primary Care Res Unit, London WC1H 9QU, England	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of London; University College London	Bindman, AB (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA.	Bindman@itsa.ucsf.edu		Majeed, Azeem/0000-0002-2357-9858				*AM MED ASS, 2000, PHYS MAST MARCH 2000; *AM MED ASS, 2000, PHYS SOC STAT 1999 2; Auerbach AD, 2000, AM J MED, V109, P648, DOI 10.1016/S0002-9343(00)00597-0; *DEP HLTH, 2002, STAT GEN MED PRACT E; Department of Health, 1997, NEW NHS MOD DEP; Diamond HS, 1998, ANN INTERN MED, V129, P197, DOI 10.7326/0003-4819-129-3-199808010-00006; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; Felt-Lisk S, 2002, HEALTH AFFAIR, V21, P210, DOI 10.1377/hlthaff.21.5.210; Ferguson JA, 1998, J GEN INTERN MED, V13, P123, DOI 10.1046/j.1525-1497.1998.00029.x; Fernandez A, 2000, ARCH INTERN MED, V160, P2902, DOI 10.1001/archinte.160.19.2902; Fernandez A, 2001, J GEN INTERN MED, V16, P163, DOI 10.1046/j.1525-1497.2001.91226.x; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; Forrest CB, 2000, JAMA-J AM MED ASSOC, V284, P2077, DOI 10.1001/jama.284.16.2077; Forrest CB, 2001, JAMA-J AM MED ASSOC, V285, P2223, DOI 10.1001/jama.285.17.2223; Grumbach K, 1999, JAMA-J AM MED ASSOC, V282, P261, DOI 10.1001/jama.282.3.261; GRUMBACH K, 2002, PRACTICE MED CALIFOR; Halm EA, 1997, JAMA-J AM MED ASSOC, V278, P1677, DOI 10.1001/jama.278.20.1677; Office for National Statistics, 2000, LIV BRIT RES 1998 GE; Piette JD, 2000, AM J MED, V108, P20, DOI 10.1016/S0002-9343(99)00298-3; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Seifer SD, 1996, JAMA-J AM MED ASSOC, V276, P695, DOI 10.1001/jama.276.9.695; St Peter RF, 1999, NEW ENGL J MED, V341, P1980, DOI 10.1056/NEJM199912233412606; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487; Wachter RM, 1999, ANN INTERN MED, V130, P338, DOI 10.7326/0003-4819-130-4-199902161-00002; Wagner E H, 1998, Eff Clin Pract, V1, P2; Wanger EH, 1998, ANN INTERN MED, V129, P654, DOI 10.7326/0003-4819-129-8-199810150-00015; 2000, REV BODY DOCTORS DEN; 2001, 30 STAT OFF S	28	26	27	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	2003	326	7390					631	634		10.1136/bmj.326.7390.631	http://dx.doi.org/10.1136/bmj.326.7390.631			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649238	Bronze, Green Published			2022-12-28	WOS:000181870800018
J	Bligh, J; Farrow, R				Bligh, J; Farrow, R			Interactive case report - A 66 year old woman with a rash: case progression	BRITISH MEDICAL JOURNAL			English	Review									Peninsula Med Sch, Plymouth PL6 8BX, Devon, England	University of Plymouth	Bligh, J (corresponding author), Peninsula Med Sch, Tamar Sci Pk, Plymouth PL6 8BX, Devon, England.	j.bligh@pms.ac.uk						ZANTOS D, 1994, J RHEUMATOL, V21, P1855	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 22	2003	326	7390					640	640		10.1136/bmj.326.7390.640	http://dx.doi.org/10.1136/bmj.326.7390.640			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649240	Green Published, Green Accepted			2022-12-28	WOS:000181870800020
J	Farnert, A; Lindberg, J; Gil, P; Swedberg, G; Berqvist, Y; Thapar, MM; Lindegardh, N; Berezcky, S; Bjorkman, A				Farnert, A; Lindberg, J; Gil, P; Swedberg, G; Berqvist, Y; Thapar, MM; Lindegardh, N; Berezcky, S; Bjorkman, A			Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Karolinska Hosp, Karolinska Inst, Dept Med, Div Infect Dis, S-17176 Stockholm, Sweden; Sahlgrens Univ Hosp, Dept Infect Dis, Gothenburg, Sweden; Uppsala Univ, Dept Pharmaceut Biosci, Div Microbiol, Uppsala, Sweden; Univ Nova Lisboa, Inst Higiene & Med Trop, Ctr Malaria & Outras Doencas Trop, P-1200 Lisbon, Portugal; Falun & Dalarna Univ Coll, Falun Cent Hosp, Dept Clin Chem, Borlange, Sweden	Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital; Uppsala University; Universidade Nova de Lisboa; Institute of Hygiene & Tropical Medicine - UNL; Falun Hospital	Farnert, A (corresponding author), Karolinska Hosp, Karolinska Inst, Dept Med, Div Infect Dis, S-17176 Stockholm, Sweden.	anna.farnert@medks.ki.se		Farnert, Anna/0000-0001-7583-282X; Gil, Jose Pedro/0000-0002-6107-9379				Fivelman Quinton L, 2002, Malar J, V1, P1; Korsinczky M, 2000, ANTIMICROB AGENTS CH, V44, P2100, DOI 10.1128/AAC.44.8.2100-2108.2000; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P533, DOI 10.4269/ajtmh.1999.60.533; Sabchareon A, 1998, T ROY SOC TROP MED H, V92, P201, DOI 10.1016/S0035-9203(98)90749-0; Sirawaraporn W, 1997, P NATL ACAD SCI USA, V94, P1124, DOI 10.1073/pnas.94.4.1124	5	63	66	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	2003	326	7390					628	629		10.1136/bmj.326.7390.628	http://dx.doi.org/10.1136/bmj.326.7390.628			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649236	Bronze, Green Published			2022-12-28	WOS:000181870800016
J	Goldacre, MJ; Evans, J; Lambert, TW				Goldacre, MJ; Evans, J; Lambert, TW			Media criticism of doctors: review of UK junior doctors' concerns raised in surveys	BRITISH MEDICAL JOURNAL			English	Article							UNITED-KINGDOM; CAREER		Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Unit Hlth Care Epidemiol,UK Med Careers Res Grp, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Inst Hlth Sci, Dept Publ Hlth, Unit Hlth Care Epidemiol,UK Med Careers Res Grp, Oxford OX3 7LF, England.	michael.goldacre@dphpc.ox.ac.uk		Lambert, Trevor/0000-0001-9688-3036				Goldacre MJ, 1999, MED EDUC, V33, P882, DOI 10.1046/j.1365-2923.1999.00560.x; Lambert TW, 1996, BRIT MED J, V313, P19, DOI 10.1136/bmj.313.7048.19; *QSR INT, 2000, N5 NONN UNSTR DAT IN	3	6	7	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 22	2003	326	7390					629	630		10.1136/bmj.326.7390.629	http://dx.doi.org/10.1136/bmj.326.7390.629			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649237	Bronze, Green Published			2022-12-28	WOS:000181870800017
J	Sharp, D				Sharp, D			Hogwash from hogwarts	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.							GRESH L, 2002, SCI SUPERHEROES, P200; HIGHFIELD R, 2002, SCI H POTTER, P322	2	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					982	982		10.1016/S0140-6736(03)12842-5	http://dx.doi.org/10.1016/S0140-6736(03)12842-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660053				2022-12-28	WOS:000181699700006
J	Blom, T; Franzen, A; Heinegard, D; Holmdahl, R				Blom, T; Franzen, A; Heinegard, D; Holmdahl, R			Comment on "The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease"	SCIENCE			English	Editorial Material							MACROPHAGE INFLAMMATORY PROTEIN-2; COLLAGEN-INDUCED ARTHRITIS; MOLECULAR-CLONING; CHROMOSOMAL LOCALIZATION; DEFICIENT MICE; GROWTH-FACTOR; EXPRESSION; BONE; CELLS; GENE		Lund Univ, Dept Med Inflammat Res, S-22184 Lund, Sweden; Lund Univ, Dept Connect Tissue Biol, S-22184 Lund, Sweden	Lund University; Lund University	Blom, T (corresponding author), Lund Univ, Dept Med Inflammat Res, Solvegatan 19, S-22184 Lund, Sweden.		Holmdahl, Rikard/AAI-7682-2020	Baranzini, Sergio/0000-0003-0067-194X				Abdul-Majid KB, 2000, J NEUROIMMUNOL, V111, P23, DOI 10.1016/S0165-5728(00)00360-X; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; DICKIE MN, 1963, MOUSE NEWS LETT, V29, P39; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Faucheux C, 1997, BIOCHEM BIOPH RES CO, V241, P787, DOI 10.1006/bbrc.1997.7792; Glabinski AR, 1998, NEUROIMMUNOMODULAT, V5, P166, DOI 10.1159/000026333; GUSTAFSSON K, 1990, EUR J IMMUNOL, V20, P2127, DOI 10.1002/eji.1830200935; Horton MR, 1998, J BIOL CHEM, V273, P35088, DOI 10.1074/jbc.273.52.35088; Jansson M, 2002, J IMMUNOL, V168, P2096, DOI 10.4049/jimmunol.168.5.2096; JERRELLS TR, 1981, INFECT IMMUN, V31, P1014, DOI 10.1128/IAI.31.3.1014-1022.1981; Johansson ACM, 2001, J IMMUNOL, V167, P3505, DOI 10.4049/jimmunol.167.6.3505; Karlsson J, 2003, J IMMUNOL, V170, P1019, DOI 10.4049/jimmunol.170.2.1019; LYONS CR, 1992, J BIOL CHEM, V267, P6370; O'Regan AW, 2001, AM J RESP CRIT CARE, V164, P2243, DOI 10.1164/ajrccm.164.12.2104139; Ohshima S, 2002, ARTHRITIS RHEUM, V46, P1094, DOI 10.1002/art.10143; Olofsson P, 2003, NAT GENET, V33, P25, DOI 10.1038/ng1058; Oritani K, 1997, BLOOD, V90, P3404, DOI 10.1182/blood.V90.9.3404; Oritani K, 1996, J CELL BIOL, V134, P771, DOI 10.1083/jcb.134.3.771; Ozawa K, 1996, MOL BRAIN RES, V41, P279, DOI 10.1016/0169-328X(96)00108-8; PELEG L, 1984, J HERED, V75, P126, DOI 10.1093/oxfordjournals.jhered.a109886; Potter MR, 2002, INFECT IMMUN, V70, P1372, DOI 10.1128/IAI.70.3.1372-1381.2002; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; Rossi DL, 1999, J IMMUNOL, V162, P5490; Sakata M, 2001, J RHEUMATOL, V28, P1492; SMITH JB, 1995, J BIOL CHEM, V270, P16756, DOI 10.1074/jbc.270.28.16756; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; TANNENBAUM CS, 1988, J IMMUNOL, V140, P3640; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; Velazquez L, 2002, J EXP MED, V195, P1599, DOI 10.1084/jem.20011883; Wuyts A, 1996, J IMMUNOL, V157, P1736; Xia LJ, 2002, J CLIN INVEST, V109, P939; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; Yumoto K, 2002, P NATL ACAD SCI USA, V99, P4556, DOI 10.1073/pnas.052523599	39	56	64	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	2003	299	5614												2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649465				2022-12-28	WOS:000181669700023
J	Ghosh, K; Shankarkumar, U; Shetty, S; Mohanty, D				Ghosh, K; Shankarkumar, U; Shetty, S; Mohanty, D			Chronic synovitis and HLA B27 in patients with severe haemophilia	LANCET			English	Article								Chronic synovitis affects about 10% of patients with severe haemophilia in India. This disease has some features in common with ankylosing spondylitis, which has been linked to HLA B27. We therefore aimed to test whether there is an association between HLA B27 and chronic synovitis. We studied 473 patients with severe haemophilia (33 of whom had chronic synovitis), and 1175 healthy controls using a standard serological technique and the reverse line strip assay. 64% (21 of 33) of patients with haemophilia and chronic synovitis were positive for HLA B27, compared with 5% (23 of 440) of those with severe haemophilia, but not chronic synovitis (odds ratio 31.6 [95% CI 9.28-39.38], p<0.0001), and 9% (100 of 1175) of healthy controls (18.81 [9.6-27.7], p<0.0001). We conclude that there is a strong association between HLA B27 and chronic synovitis in Indian patients with severe haemophilia and screening in this population could allow treatment and prevention of the complication.	Inst Immunohaematol, Bombay 400012, Maharashtra, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Immunohaemotology (NIIH)	Mohanty, D (corresponding author), Inst Immunohaematol, Floor 13,New Bldg,KEM Hosp Campus, Bombay 400012, Maharashtra, India.		Ghosh, Kanjaksha/D-7621-2015	Ghosh, Kanjaksha/0000-0002-0645-6565				Ghosh K, 2001, HAEMOPHILIA, V7, P273, DOI 10.1046/j.1365-2516.2001.00505.x; MACK SJ, 2000, HLA 2000 IHWG TECHNI; Rodriguez-Merchan EC, 1998, HAEMOPHILIA, V4, P506, DOI 10.1046/j.1365-2516.1998.440506.x; SENGUPTA S, 1977, LANCET, V1, P1209; SHANKARKUMAR U, 2002, BRIT J BIOMED SCI, V59, P11	5	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 15	2003	361	9361					933	934		10.1016/S0140-6736(03)12763-8	http://dx.doi.org/10.1016/S0140-6736(03)12763-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648975				2022-12-28	WOS:000181741600014
J	Bell, AT				Bell, AT			The impact of nanoscience on heterogeneous catalysis	SCIENCE			English	Article							OXIDATIVE DEHYDROGENATION; ALKANES	Most catalysts consist of nanometer-sized particles dispersed on a high-surface-area support. Advances in characterization methods have led to a molecular-level understanding of the relationships between nanoparticle properties and catalytic performance. Together with novel approaches to nanoparticle synthesis, this knowledge is contributing to the design and development of new catalysts.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Chem Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Bell, AT (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Chem Sci, Berkeley, CA 94720 USA.	bell@cchem.berkeley.edu		Bell, Alexis/0000-0002-5738-4645				Besenbacher F, 1998, SCIENCE, V279, P1913, DOI 10.1126/science.279.5358.1913; Blasco T, 1997, APPL CATAL A-GEN, V157, P117, DOI 10.1016/S0926-860X(97)00029-X; Bond GC, 1999, CATAL REV, V41, P319, DOI 10.1081/CR-100101171; Chen KD, 2002, J CATAL, V209, P35, DOI 10.1006/jcat.2002.3620; Clausen B.S., 1996, CATAL SCI TECHNOL, V11; Corker J, 1996, SCIENCE, V271, P966, DOI 10.1126/science.271.5251.966; De Jong KP, 2000, CATAL REV, V42, P481, DOI 10.1081/CR-100101954; Duke C.B., 2002, FRONTIERS SURFACE IN; DURSCHER G, 1998, PHYS STATUS SOLIDI A, V166, P327; Gai PL, 2002, TOP CATAL, V21, P161, DOI 10.1023/A:1021333310817; IWASAWA Y, IN PRESS J CATAL; Kolb DM, 2002, SURF SCI, V500, P722, DOI 10.1016/S0039-6028(01)01583-7; KOMAYA T, 1994, J CATAL, V150, P400, DOI 10.1006/jcat.1994.1358; MAISEL R, 1996, PRINCIPLES ADSORPTIO; Nozaki C, 2002, J AM CHEM SOC, V124, P13194, DOI 10.1021/ja020388t; SCHOGL R, COMMUNICATIOHN; Thune PC, 2001, MACROMOL SYMP, V173, P37, DOI 10.1002/1521-3900(200108)173:1<37::AID-MASY37>3.0.CO;2-9; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Vidal V, 1997, SCIENCE, V276, P99, DOI 10.1126/science.276.5309.99; Weyland M, 2002, TOP CATAL, V21, P175, DOI 10.1023/A:1021385427655; 2002, CHEM IND        0121, P22	21	2099	2153	21	1202	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	2003	299	5613					1688	1691		10.1126/science.1083671	http://dx.doi.org/10.1126/science.1083671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637733	Green Submitted			2022-12-28	WOS:000181519500032
J	Schwartz, RS				Schwartz, RS			Shattuck Lecture - diversity of the immune repertoire and immunoregulation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Massachusetts-Medical-Society	JUN 01, 2002	BOSTON, MA	Massachusetts Med Soc			PROMISCUOUS GENE-EXPRESSION; T-CELL; SELF-PEPTIDES; IMMUNOLOGICAL SYNAPSE; AUTOIMMUNE OOPHORITIS; NEGATIVE SELECTION; MOLECULAR MEDICINE; DENDRITIC CELLS; ACTIVATION; ANTIGEN											ABBAS AK, 1991, IMMUNOL REV, V123, P5, DOI 10.1111/j.1600-065X.1991.tb00603.x; Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Anderton SM, 2002, NAT REV IMMUNOL, V2, P487, DOI 10.1038/nri842; Anderton SM, 2001, J EXP MED, V193, P1, DOI 10.1084/jem.193.1.1; ANDRE JA, 1962, BLOOD, V19, P313, DOI 10.1182/blood.V19.3.313.313; Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Bjorses P, 1998, HUM MOL GENET, V7, P1547, DOI 10.1093/hmg/7.10.1547; Blanden RV, 1998, IMMUNOL CELL BIOL, V76, P288, DOI 10.1046/j.1440-1711.1998.00738.x; Bleesing JJH, 2000, PEDIATR CLIN N AM, V47, P1291, DOI 10.1016/S0031-3955(05)70272-8; BRETSCHER PA, 1968, NATURE, V220, P444, DOI 10.1038/220444a0; Bretscher PA, 1999, P NATL ACAD SCI USA, V96, P185, DOI 10.1073/pnas.96.1.185; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; CALNE RY, 1960, LANCET, V1, P417; CAMBROSIO A, 1993, ISIS, V84, P662, DOI 10.1086/356636; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; Coyle AJ, 2001, NAT IMMUNOL, V2, P203, DOI 10.1038/85251; Croonian lecture, 1900, P R SOC LOND, V66, P424, DOI [DOI 10.1098/RSPL.1899.0121, 10.1098/rspl.1899.0121]; DAMESHEK W, 1959, BLOOD, V14, P1151, DOI 10.1182/blood.V14.10.1151.1151; DAMESHEK W, 1960, T ASSOC AM PHYSICIAN, V73, P113; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; Dieckmann, 2002, J EXP MED, V196, P867; Dieckmann D, 2002, J EXP MED, V196, P559; Dieckmann D, 2002, J EXP MED, V196, P247, DOI 10.1084/jem.20020642; Dutoit V, 2002, J EXP MED, V196, P207, DOI 10.1084/jem.20020242; Dyer MJS, 1999, SEMIN ONCOL, V26, P52; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; Ellis CN, 2001, NEW ENGL J MED, V345, P248, DOI 10.1056/NEJM200107263450403; Fugmann SD, 2002, SCIENCE, V295, P1244, DOI 10.1126/science.1070023; Germain RN, 2002, ADV EXP MED BIOL, V512, P97; Germain RN, 2001, SCIENCE, V293, P240, DOI 10.1126/science.1062946; GERSHON RK, 1971, IMMUNOLOGY, V21, P903; Gibson TJ, 1998, TRENDS BIOCHEM SCI, V23, P242, DOI 10.1016/S0968-0004(98)01231-6; Gorman JD, 2002, NEW ENGL J MED, V346, P1349, DOI 10.1056/NEJMoa012664; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Granstein RD, 2001, NEW ENGL J MED, V345, P284, DOI 10.1056/NEJM200107263450410; *HLTH US, 2002, 2002 CHARTB TRENDS H; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JERNE NK, 1955, P NATL ACAD SCI USA, V41, P849, DOI 10.1073/pnas.41.11.849; Johnson PWM, 2001, BRIT J CANCER, V85, P1619, DOI 10.1054/bjoc.2001.2127; KABAT EA, 1980, J IMMUNOL, V125, P961; Kamradt T, 2001, NEW ENGL J MED, V344, P655, DOI 10.1056/NEJM200103013440907; Kelsoe G, 1996, Semin Immunol, V8, P179, DOI 10.1006/smim.1996.0022; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Klein J, 2000, NEW ENGL J MED, V343, P1504; Klein J, 2000, NEW ENGL J MED, V343, P702, DOI 10.1056/NEJM200009073431006; KROPSHOFER H, 1993, J IMMUNOL, V151, P4732; Kyewski B, 2002, TRENDS IMMUNOL, V23, P364, DOI 10.1016/S1471-4906(02)02248-2; Le Campion A, 2002, P NATL ACAD SCI USA, V99, P4538, DOI 10.1073/pnas.062621699; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; LOHOFF M, 1992, EUR J IMMUNOL, V22, P599, DOI 10.1002/eji.1830220246; Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Margulies DH, 2001, NAT IMMUNOL, V2, P669, DOI 10.1038/90601; Matsuda F, 1996, ADV IMMUNOL, V62, P1, DOI 10.1016/S0065-2776(08)60426-5; McHugh RS, 2001, MICROBES INFECT, V3, P919, DOI 10.1016/S1286-4579(01)01453-8; MEEKER W, 1959, P SOC EXP BIOL MED, V102, P459; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Moudgil K D, 2000, Rev Immunogenet, V2, P26; Munder M, 2002, J EXP MED, V196, P1151, DOI 10.1084/jem.20020390; MURRAY JE, 1963, NEW ENGL J MED, V268, P1315, DOI 10.1056/NEJM196306132682401; Najafian N, 2000, EXPERT OPIN INV DRUG, V9, P2147, DOI 10.1517/13543784.9.9.2147; NAPARSTEK Y, 1986, J EXP MED, V164, P614, DOI 10.1084/jem.164.2.614; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ohashi PS, 2002, SCIENCE, V298, P1348, DOI 10.1126/science.1079323; PATTERSON JF, 1971, AM J DIG DIS, V16, P327, DOI 10.1007/BF02235208; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; Quaratino S, 2000, P NATL ACAD SCI USA, V97, P10911, DOI 10.1073/pnas.190204697; Rottman JB, 2001, NAT IMMUNOL, V2, P605, DOI 10.1038/89750; RUDD CE, 2002, SCI STKE, pPE18; SANDRIN MS, 1993, J IMMUNOL, V151, P4606; Sasaki T, 2001, INT J BIOCHEM CELL B, V33, P1041, DOI 10.1016/S1357-2725(01)00075-9; SCHWARTZ R, 1958, P SOC EXP BIOL MED, V99, P164; SCHWARTZ R, 1962, BLOOD, V19, P483, DOI 10.1182/blood.V19.4.483.483; SCHWARTZ RH, 1993, SCI AM, P62; SCHWARTZ RS, 1995, NEW ENGL J MED, V332, P941, DOI 10.1056/NEJM199504063321408; SCHWARTZ RS, 1995, NEW ENGL J MED, V333, P42, DOI 10.1056/NEJM199507063330108; SCHWARTZ RS, 1994, IMMUNOL TODAY, V15, P27, DOI 10.1016/0167-5699(94)90022-1; Shaw AS, 2001, NAT IMMUNOL, V2, P575, DOI 10.1038/89712; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x; Silverstein AM, 2001, NAT IMMUNOL, V2, P569, DOI 10.1038/89706; Silverstein AM, 2002, P EHRLICHS RECEPTOR; SMITH H, 1991, J IMMUNOL, V147, P2928; SOUROUJON M, 1988, J IMMUNOL, V140, P4173; Sperling AI, 2001, NAT IMMUNOL, V2, P573, DOI 10.1038/89709; Stefanova I, 2002, NATURE, V420, P429, DOI 10.1038/nature01146; STEWART AK, 1994, BLOOD, V83, P1717; Taams LS, 2002, EUR J IMMUNOL, V32, P1621, DOI 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q; TALMAGE DW, 1959, SCIENCE, V129, P1643, DOI 10.1126/science.129.3364.1643; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; TUNG KSK, 1987, AM J PATHOL, V126, P293; Tuosto L, 2001, EUR J IMMUNOL, V31, P345, DOI 10.1002/1521-4141(200102)31:2<345::AID-IMMU345>3.3.CO;2-C; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Wong DC, 2001, KIDNEY INT, V60, P1777, DOI 10.1046/j.1523-1755.2001.00014.x; Zuklys S, 2000, J IMMUNOL, V165, P1976, DOI 10.4049/jimmunol.165.4.1976; ZUKOSKI C F, 1960, Surg Forum, V11, P470	105	32	34	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					1017	1026		10.1056/NEJMsa022766	http://dx.doi.org/10.1056/NEJMsa022766			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	653YT	12637612				2022-12-28	WOS:000181465200007
J	Coste, J; Cochand-Priollet, A; de Cremoux, P; Le Gales, C; Cartier, I; Molinie, V; Labbe, S; Vacher-Lavenu, MC; Vielh, P				Coste, J; Cochand-Priollet, A; de Cremoux, P; Le Gales, C; Cartier, I; Molinie, V; Labbe, S; Vacher-Lavenu, MC; Vielh, P		French Soc Clin Cytol Study Grp	Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PAPANICOLAOU SMEARS; ACCURACY; WOMEN; NEOPLASIA; DIAGNOSIS; COST; RISK	Objectives To compare the sensitivity, specificity, and interobserver reliability of conventional cervical smear tests, monolayer cytology, and human papillomavirus testing for screening for cervical cancer. Design Cross sectional study in which the three techniques were performed simultaneously with a reference standard (colposcopy and histology). Setting Public university and private practices in France, with complete independence from the suppliers. Participants 828 women refer-red for colposcopy because of previously detected cytological abnormalities and 1757 women attending for routine smears. Main outcome measures Clinical readings and optimised interpretation (two blind readings followed if necessary, by consensus). Sensitivity, specificity, and weighted kappa computed for various thresholds of abnormalities. Results Conventional cervical smear tests were more often satisfactory (91% v 87%) according to the Bethesda system, more reliable (weighted kappa 0.70 v 0.57), and had consistently better sensitivity and specificity than monolayer cytology. These findings applied to clinical readings and optimised interpretations, low and high grade lesions, and populations with low and high incidence of abnormalities. Human papillomavirus testing associated with monolayer cytology, whether systematic or for atypical cells of undetermined significance, performed no better than conventional smear tests. Conclusions Monolayer cytology is less reliable and more likely to give false positive and false negative results than conventional cervical smear tests for screening for cervical cancer.	Univ Paris 05, Dept Biostat, Hop Cochin,Fac Med Cochin Port Royal, Assistance Publ Hop Paris, Paris, France; Hop Lariboisiere, Serv Anat & Cytol Patol, Assistance Publ Hop Paris, F-75475 Paris, France; Ctr Hlth Econ & Adm Res, INSERM, U537,CNRS, UPRESA 8052, Le Kremlin Bicetre, France; Lab Cartier, Paris, France; Hop Foch, Serv Anat & Cytol Pathol, Suresnes, France; Ctr Anat Pathol, Besancon, France; Hop Cochin, Serv Anat & Cytol Pathol, Paris, France; Inst Curie, Serv Cytopathol & Cytometrie Clin, Paris, France; Inst Curie, Lab Physiopathol, Dept Biol Tumeurs, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Hospital Foch; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Coste, J (corresponding author), Univ Paris 05, Dept Biostat, Hop Cochin,Fac Med Cochin Port Royal, Assistance Publ Hop Paris, Paris, France.	coste@cochin.univ-paris5.fr						[Anonymous], 1993, ACTA CYTOL, V37, P115; Bergeron C, 2000, OBSTET GYNECOL, V95, P821, DOI 10.1016/S0029-7844(00)00795-X; Bergeron C, 2001, ACTA CYTOL, V45, P519, DOI 10.1159/000327858; Bernstein SJ, 2001, AM J OBSTET GYNECOL, V185, P308, DOI 10.1067/mob.2001.116736; Bishop DVM, 2001, J CHILD PSYCHOL PSYC, V42, P189, DOI 10.1111/1469-7610.00710; Bishop JW, 1998, ACTA CYTOL, V42, P189, DOI 10.1159/000331545; Bolick DR, 1998, ACTA CYTOL, V42, P209, DOI 10.1159/000331548; Cochand-Priollet B, 2001, DIAGN CYTOPATHOL, V24, P412, DOI 10.1002/dc.1091; Ferenczy A, 1996, ACTA CYTOL, V40, P1136; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Hartmann KE, 2001, OBSTET GYNECOL SURV, V56, P765, DOI 10.1097/00006254-200112000-00003; Hutchinson ML, 1999, CANCER CYTOPATHOL, V87, P48, DOI 10.1002/(SICI)1097-0142(19990425)87:2&lt;48::AID-CNCR2&gt;3.0.CO;2-D; Kaufman RH, 2001, OBSTET GYNECOL, V98, P724, DOI 10.1016/S0029-7844(01)01617-9; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; Merea E, 2002, DIAGN CYTOPATHOL, V27, P251, DOI 10.1002/dc.10177; Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009; Park IA, 2001, ACTA CYTOL, V45, P525, DOI 10.1159/000327859; Poljak M, 1999, J CLIN MICROBIOL, V37, P796, DOI 10.1128/JCM.37.3.796-797.1999; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; Roberts JM, 1997, MED J AUSTRALIA, V167, P466, DOI 10.5694/j.1326-5377.1997.tb126672.x; Ronnett BM, 1999, HUM PATHOL, V30, P816, DOI 10.1016/S0046-8177(99)90143-0; Schneider A, 2000, INT J CANCER, V89, P529, DOI 10.1002/1097-0215(20001120)89:6&lt;529::AID-IJC11&gt;3.0.CO;2-G; SHEETS EE, 1995, J GYNECOL TECH, V1, P27; STAFL A, 1991, OBSTET GYNECOL, V77, P313, DOI 10.1097/00006250-199102000-00032	24	110	115	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2003	326	7392					733	736A		10.1136/bmj.326.7392.733	http://dx.doi.org/10.1136/bmj.326.7392.733			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665LF	12676841	Green Published, Bronze			2022-12-28	WOS:000182121600013
J	Arz, HW; Lamy, F; Patzold, J; Muller, PJ; Prins, M				Arz, HW; Lamy, F; Patzold, J; Muller, PJ; Prins, M			Mediterranean moisture source for an early-Holocene humid period in the northern Red Sea	SCIENCE			English	Article							AEGEAN SEA; INSOLATION; RECORDS; VARIABILITY; CLIMATE; MONSOON; OMAN	Paleosalinity and terrigenous sediment input changes reconstructed on two sediment cores from the northernmost Red Sea were used to infer hydrological changes at the southern margin of the Mediterranean climate zone during the Holocene. Between approximately 9.25 and 7.25 thousand years ago, about 3parts per thousand reduced surface water salinities and enhanced fluvial sediment input suggest substantially higher rainfall and freshwater runoff, which thereafter decreased to modern values. The northern Red Sea humid interval is best explained by enhancement and southward extension of rainfall from Mediterranean sources, possibly involving strengthened early-Holocene Arctic Oscillation patterns and a regional monsoon-type circulation induced by increased land-sea temperature contrasts. We conclude that Afro-Asian monsoonal rains did not cross the subtropical desert zone during the early to mid-Holocene.	Univ Bremen, Res Ctr Ocean Margins, DFG, D-28359 Bremen, Germany; Vrije Univ Amsterdam, Fac Earth Sci, NL-1081 HV Amsterdam, Netherlands	German Research Foundation (DFG); University of Bremen; Vrije Universiteit Amsterdam	Arz, HW (corresponding author), Univ Bremen, Res Ctr Ocean Margins, DFG, Klagenfurter Str, D-28359 Bremen, Germany.	helge.arz@uni-bremen.de	Arz, Helge/A-6659-2013; Lamy, Frank/H-3611-2014; Patzold, Jurgen/D-5111-2017	Prins, Maarten A./0000-0001-7679-1134; Lamy, Frank/0000-0001-5952-1765; Patzold, Jurgen/0000-0001-8074-4103; Arz, Helge Wolfgang/0000-0002-1997-1718				Aksu AE, 1999, MAR GEOL, V153, P275, DOI 10.1016/S0025-3227(98)00078-4; ARZ HW, UNPUB; Bar-Matthews M, 2000, CHEM GEOL, V169, P145, DOI 10.1016/S0009-2541(99)00232-6; Budziak D, 2000, PALEOCEANOGRAPHY, V15, P307, DOI 10.1029/1999PA000433; Burns SJ, 1998, GEOLOGY, V26, P499, DOI 10.1130/0091-7613(1998)026<0499:SBPRFN>2.3.CO;2; Claussen M, 1999, GEOPHYS RES LETT, V26, P2037, DOI 10.1029/1999GL900494; deMenocal P, 2000, QUATERNARY SCI REV, V19, P347, DOI 10.1016/S0277-3791(99)00081-5; Eshel G, 1997, J PHYS OCEANOGR, V27, P1233, DOI 10.1175/1520-0485(1997)027<1233:CCJCIW>2.0.CO;2; Ganssen G, 1991, PALEOCEANOGRAPHY, V6, P73, DOI 10.1029/90PA01976; Gasse F, 2000, QUATERNARY SCI REV, V19, P189, DOI 10.1016/S0277-3791(99)00061-X; Gasse F, 2002, QUATERNARY SCI REV, V21, P737, DOI 10.1016/S0277-3791(01)00125-1; GIORGI F, 2001, CLIMATE CDHANGE 2001, pCH10; Harrison SP, 1996, QUATERNARY RES, V45, P138, DOI 10.1006/qres.1996.0016; Haug GH, 2001, SCIENCE, V293, P1304, DOI 10.1126/science.1059725; Hemleben C, 1996, PALEOCEANOGRAPHY, V11, P147, DOI 10.1029/95PA03838; Hewitt CD, 1996, J CLIMATE, V9, P3505, DOI 10.1175/1520-0442(1996)009<3505:GSOTCO>2.0.CO;2; Hoelzmann P, 2000, GLOBAL PLANET CHANGE, V26, P105, DOI 10.1016/S0921-8181(00)00038-2; HSU CPF, 1976, MONTH WEATH REV, V104, P607; Kallel N, 1997, OCEANOL ACTA, V20, P697; Marchal O, 2002, QUATERNARY SCI REV, V21, P455, DOI 10.1016/S0277-3791(01)00105-6; Neff U, 2001, NATURE, V411, P290, DOI 10.1038/35077048; RIMBU N, IN PRESS GEOPHYS RES; Roberts Neil, 1993, P194; Rohling EJ, 2002, CLIM DYNAM, V18, P587, DOI 10.1007/s00382-001-0194-8; Rohling EJ, 1998, PALEOCEANOGRAPHY, V13, P316, DOI 10.1029/98PA00671; Rossignol-Strick M, 1999, QUATERNARY SCI REV, V18, P515, DOI 10.1016/S0277-3791(98)00093-6; ROSSIGNOLSTRICK M, 1985, PALAEOGEOGR PALAEOCL, V49, P237, DOI 10.1016/0031-0182(85)90056-2; SCHMELZER I, 1999, THESIS U TUBINGEN	28	218	221	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2003	300	5616					118	121		10.1126/science.1080325	http://dx.doi.org/10.1126/science.1080325			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677064	Green Submitted			2022-12-28	WOS:000181988900045
J	Charron, F; Stein, E; Jeong, J; McMahon, AP; Tessier-Lavigne, M				Charron, F; Stein, E; Jeong, J; McMahon, AP; Tessier-Lavigne, M			The morphogen Sonic hedgehog is an axonal chemoattractant that collaborates with Netrin-1 in midline axon guidance	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; FLOOR PLATE; SPINAL-CORD; COMMISSURAL AXONS; GROWTH CONES; C-ELEGANS; CELL FATES; SPECIFICATION; RECEPTOR; GENE	Developing axons are guided to their targets by attractive and repulsive guidance cues. In the embryonic spinal cord, the floor plate chemoattractant Netrin-1 is required to guide commissural neuron axons to the midline. However, genetic evidence suggests that other chemoattractant(s) are also involved. We show that the morphogen Sonic hedgehog (Shh) can mimic the additional chemoattractant activity of the floor plate in vitro and can act directly as a chemoattractant on isolated axons. Cyclopamine-mediated inhibition of the Shh signaling mediator Smoothened (Smo) or conditional inactivation of Smo in commissural neurons indicate that Smo activity is important for the additional chemoattractant activity of the floor plate in vitro and for the normal projection of commissural axons to the floor plate in vivo. These results provide evidence that Shh, acting via Smo, is a midline-derived chemoattractant for commissural axons and show that a morphogen can also act as an axonal chemoattractant.	Stanford Univ, Howard Hughes Med Inst, Dept Biol Sci, Stanford, CA 94305 USA; Harvard Univ, Dept Mol & Cellular Biol, Biolabs, Cambridge, MA 02138 USA	Howard Hughes Medical Institute; Stanford University; Harvard University	Tessier-Lavigne, M (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Biol Sci, Stanford, CA 94305 USA.		Charron, Frederic/D-2140-2009; McMahon, Andrew P/ABE-7520-2020; Charron, Frederic/O-8017-2019; Stein, Elke/E-8107-2013	Charron, Frederic/0000-0003-3483-8672; Charron, Frederic/0000-0003-3483-8672; Stein, Elke/0000-0001-8965-5692	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS033642, R01NS033642] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 33642] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Augsburger A, 1999, NEURON, V24, P127, DOI 10.1016/S0896-6273(00)80827-2; Briscoe J, 2001, MOL CELL, V7, P1279, DOI 10.1016/S1097-2765(01)00271-4; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; de la Torre JR, 1997, NEURON, V19, P1211, DOI 10.1016/S0896-6273(00)80413-4; Deshpande G, 2001, CELL, V106, P759, DOI 10.1016/S0092-8674(01)00488-3; Ding Q, 1998, DEVELOPMENT, V125, P2533; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hao JC, 2001, NEURON, V32, P25, DOI 10.1016/S0896-6273(01)00448-2; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Lee KJ, 1999, ANNU REV NEUROSCI, V22, P261, DOI 10.1146/annurev.neuro.22.1.261; Long FX, 2001, DEVELOPMENT, V128, P5099; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; Matise MP, 1999, DEVELOPMENT, V126, P3649; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Mo R, 1997, DEVELOPMENT, V124, P113; O'Connor R, 1999, NEURON, V24, P165, DOI 10.1016/S0896-6273(00)80830-2; PLACZEK M, 1990, DEVELOPMENT, V110, P19; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Testaz S, 2001, P NATL ACAD SCI USA, V98, P12521, DOI 10.1073/pnas.221108698; Trousse F, 2001, DEVELOPMENT, V128, P3927; Wang YS, 2002, J NEUROSCI, V22, P8563; Wijgerde M, 2002, GENE DEV, V16, P2849, DOI 10.1101/gad.1025702; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	44	503	529	0	35	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 4	2003	113	1					11	23		10.1016/S0092-8674(03)00199-5	http://dx.doi.org/10.1016/S0092-8674(03)00199-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679031	Bronze			2022-12-28	WOS:000182282900003
J	Baughman, RP; Lower, EE; du Bois, RM				Baughman, RP; Lower, EE; du Bois, RM			Sarcoidosis	LANCET			English	Review							TUMOR-NECROSIS-FACTOR; MAJOR HISTOCOMPATIBILITY COMPLEX; ENZYME ACE GENE; ACTIVE PULMONARY SARCOIDOSIS; HUMAN ALVEOLAR MACROPHAGES; FACTOR-ALPHA PRODUCTION; LUNG LYMPHOCYTES-T; ISLE-OF-MAN; JAPANESE PATIENTS; TNF-ALPHA	There have been several new insights into the cause and treatment of sarcoidosis. Studies of genetic variation have shown that specific genetic polymorphisms are associated with Increased risk of disease or affect disease presentation. These polymorphisms include variation of MHC and cytokines such as tumour necrosis factor (TNF). Not all investigators have come to the same conclusion, suggesting an interaction of various factors, including the patient's ethnic origin. Treatment of sarcoidosis varies considerably. Patients with symptomatic disease for more than 2-5 years have been of particular interest. Corticosteroids remain the standard of care in such cases, but immunosuppressive drugs have proved steroid-sparing in many patients. New agents, including pentoxifylline, thalidomide, and infliximab have proved useful in selected cases. The effectiveness of these agents seems to lie in their ability to block TNF, especially in the treatment of chronic disease.	Univ Cincinnati, Cincinnati Med Ctr, Dept Internal Med, Cincinnati, OH 45267 USA; Royal Brompton Hosp, Resp Directorate, London SW3 6LY, England	University System of Ohio; University of Cincinnati; Royal Brompton Hospital	Baughman, RP (corresponding author), Univ Cincinnati, Cincinnati Med Ctr, Dept Internal Med, 1001 HH Eden Ave,ML 565, Cincinnati, OH 45267 USA.	bob.baughman@uc.edu						ADAMS JS, 1989, ANN INTERN MED, V111, P437, DOI 10.7326/0003-4819-111-5-437; Aoki J, 2001, RADIOLOGY, V219, P774, DOI 10.1148/radiology.219.3.r01ma08774; BADRINAS F, 1989, LANCET, V2, P455; Baltzan M, 1999, AM J RESP CRIT CARE, V160, P192, DOI 10.1164/ajrccm.160.1.9809024; Baughman RP, 2001, AM J RESP CRIT CARE, V164, P1885, DOI 10.1164/ajrccm.164.10.2104046; BAUGHMAN RP, 1990, AM REV RESPIR DIS, V142, P1268, DOI 10.1164/ajrccm/142.6_Pt_1.1268; Baughman RP, 2000, SARCOIDOSIS VASC DIF, V17, P60; Baughman RP, 2002, CHEST, V122, P227, DOI 10.1378/chest.122.1.227; BAUGHMAN RP, 1994, SARCOIDOSIS, V11, P217; Baughman RP, 2001, SARCOIDOSIS VASC DIF, V18, P133; Baughman RP, 2001, SARCOIDOSIS VASC DIF, V18, P70; Baughman RP, 1999, THORAX, V54, P742, DOI 10.1136/thx.54.8.742; Baughman RP, 1997, SARCOIDOSIS VASC DIF, V14, P121; BAUGHMAN RP, 1990, J LAB CLIN MED, V115, P36; BAUGHMAN RP, IN PRESS SARCOIDOSIS; Baughman RP, 2002, AM J RESP CRIT CARE, V165, pA495; Baumer I, 1997, AM J RESP CELL MOL, V16, P171; Berlin M, 1997, AM J RESP CRIT CARE, V156, P1601, DOI 10.1164/ajrccm.156.5.9704069; BOST TW, 1994, AM J RESP CELL MOL, V10, P506, DOI 10.1165/ajrcmb.10.5.8179912; CARLESIMO M, 1995, J AM ACAD DERMATOL, V32, P866, DOI 10.1016/0190-9622(95)91549-4; CEUPPENS JL, 1984, AM REV RESPIR DIS, V129, P563; DALY PA, 1988, THORAX, V43, P407, DOI 10.1136/thx.43.5.407; du Bois RM, 1999, EUR RESPIR J, V13, P1345, DOI 10.1034/j.1399-3003.1999.13f19.x; EDMONDSTONE WM, 1988, THORAX, V43, P342, DOI 10.1136/thx.43.4.342; Foley PJ, 1999, AM J RESP CRIT CARE, V160, P1009, DOI 10.1164/ajrccm.160.3.9810032; Foley PJ, 2001, AM J RESP CELL MOL, V25, P272, DOI 10.1165/ajrcmb.25.3.4261; Furuya K, 1996, THORAX, V51, P777, DOI 10.1136/thx.51.8.777; Gedalia A, 1997, J PEDIATR-US, V130, P25, DOI 10.1016/S0022-3476(97)70306-8; Gibson GJ, 1996, THORAX, V51, P238, DOI 10.1136/thx.51.3.238; Gottlieb JE, 1997, CHEST, V111, P623, DOI 10.1378/chest.111.3.623; GRUNEWALD J, 1994, P NATL ACAD SCI USA, V91, P4965, DOI 10.1073/pnas.91.11.4965; Grutters JC, 2002, AM J RESP CRIT CARE, V165, P1119, DOI 10.1164/ajrccm.165.8.200110-0320; Hance A J, 1998, Semin Respir Infect, V13, P197; HENNESSY TW, 1988, J CLIN EPIDEMIOL, V41, P565, DOI 10.1016/0895-4356(88)90060-1; HILLS SE, 1987, THORAX, V42, P427, DOI 10.1136/thx.42.6.427; Hiraga Y, 1994, Nihon Rinsho, V52, P1438; HONEYBOURNE D, 1980, BRIT J DIS CHEST, V74, P63, DOI 10.1016/S0007-0971(80)80172-0; HOSODA Y, 1976, ANN NY ACAD SCI, V278, P355, DOI 10.1111/j.1749-6632.1976.tb47046.x; HUNNINGHAKE CW, 1994, AM J RESP CRIT CARE, V149, P893, DOI 10.1164/ajrccm.149.4.8143052; Hunninghake GW, 1999, SARCOIDOSIS VASC DIF, V16, P149; HUNNINGHAKE GW, 1981, NEW ENGL J MED, V305, P429, DOI 10.1056/NEJM198108203050804; INA Y, 1989, CHEST, V95, P1257, DOI 10.1378/chest.95.6.1257; Ishige I, 1999, LANCET, V354, P120, DOI 10.1016/S0140-6736(98)12310-3; Ishihara M, 1996, HUM IMMUNOL, V49, P144, DOI 10.1016/0198-8859(96)82496-7; Ishihara M, 1996, HUM IMMUNOL, V45, P105, DOI 10.1016/0198-8859(95)00167-0; ISHIHARA M, 1995, TISSUE ANTIGENS, V46, P59, DOI 10.1111/j.1399-0039.1995.tb02477.x; ISRAEL HL, 1973, AM REV RESPIR DIS, V107, P609, DOI 10.1164/arrd.1973.107.4.609; Johns CJ, 1999, MEDICINE, V78, P65, DOI 10.1097/00005792-199903000-00001; Jones SK, 1999, BRIT J DERMATOL, V140, P3, DOI 10.1046/j.1365-2133.1999.02600.x; Judson MA, 1999, SARCOIDOSIS VASC DIF, V16, P75; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; KERN DG, 1993, AM REV RESPIR DIS, V148, P974, DOI 10.1164/ajrccm/148.4_Pt_1.974; KUNIKANE H, 1987, AM REV RESPIR DIS, V135, P688; KUNIKANE H, 1994, THORAX, V49, P573, DOI 10.1136/thx.49.6.573; Lebtahi R, 2001, J NUCL MED, V42, P21; LENHART K, 1990, DIS MARKERS, V8, P23; Lewis SJ, 1999, SARCOIDOSIS VASC DIF, V16, P87; LOWER EE, 1995, ARCH INTERN MED, V155, P846, DOI 10.1001/archinte.155.8.846; Lower EE, 2001, SARCOIDOSIS VASC DIF, V18, P301; LYNCH JP, 1992, AM REV RESPIR DIS, V145, P1433, DOI 10.1164/ajrccm/145.6.1433; Maliarik MJ, 1998, AM J RESP CRIT CARE, V158, P111, DOI 10.1164/ajrccm.158.1.9708111; Maliarik MJ, 1998, AM J RESP CRIT CARE, V158, P1566, DOI 10.1164/ajrccm.158.5.9804123; Mana J, 1999, AM J MED, V107, P240, DOI 10.1016/S0002-9343(99)00223-5; MANA J, 1995, THORAX, V50, P1264, DOI 10.1136/thx.50.12.1264; Marques LJ, 1999, AM J RESP CRIT CARE, V159, P508, DOI 10.1164/ajrccm.159.2.9804085; MARTINET Y, 1988, AM REV RESPIR DIS, V138, P1242, DOI 10.1164/ajrccm/138.5.1242; MARTINETTI M, 1995, AM J RESP CRIT CARE, V152, P557, DOI 10.1164/ajrccm.152.2.7633707; McGrath DS, 2000, THORAX, V55, P751, DOI 10.1136/thorax.55.9.751; McGrath DS, 2001, SARCOIDOSIS VASC DIF, V18, P149; McGrath DS, 2001, AM J RESP CRIT CARE, V164, P197, DOI 10.1164/ajrccm.164.2.2011009; MITCHELL DN, 1969, LANCET, V2, P81; Moller DR, 1996, J IMMUNOL, V156, P4952; Muller-Quernheim J, 1999, EUR RESPIR J, V14, P1117, DOI 10.1183/09031936.99.14511179; NEVILLE E, 1983, Q J MED, V52, P525; NOWACK D, 1987, ARCH INTERN MED, V147, P481, DOI 10.1001/archinte.147.3.481; PANAYEAS S, 1991, LANCET, V338, P510, DOI 10.1016/0140-6736(91)90581-9; Paramothayan S, 2002, JAMA-J AM MED ASSOC, V287, P1301, DOI 10.1001/jama.287.10.1301; PARKES SA, 1987, THORAX, V42, P420, DOI 10.1136/thx.42.6.420; Pietinalho A, 1999, EUR RESPIR J, V13, P723, DOI 10.1034/j.1399-3003.1999.13d04.x; Pietinalho A, 2002, CHEST, V121, P24, DOI 10.1378/chest.121.1.24; Pietinalho A, 1996, SARCOIDOSIS VASC DIF, V13, P159; Pietinalho A, 1999, CHEST, V116, P424, DOI 10.1378/chest.116.2.424; PINKSTON P, 1983, NEW ENGL J MED, V308, P793, DOI 10.1056/NEJM198304073081401; Popper HH, 1999, SARCOIDOSIS VASC DIF, V16, P32; Prezant DJ, 1999, CHEST, V116, P1183, DOI 10.1378/chest.116.5.1183; PUERINGER RJ, 1993, CHEST, V103, P832, DOI 10.1378/chest.103.3.832; REMYJARDIN M, 1990, RADIOLOGY, V177, P133, DOI 10.1148/radiology.177.1.2399312; Rizzato G, 1998, SARCOIDOSIS VASC DIF, V15, P52; Rizzato G, 1996, SARCOIDOSIS VASC DIF, V13, P167; ROBINSON BWS, 1985, J CLIN INVEST, V75, P1488, DOI 10.1172/JCI111852; Rybicki BA, 1999, HUM IMMUNOL, V60, P867, DOI 10.1016/S0198-8859(99)00050-6; Rybicki BA, 2001, AM J EPIDEMIOL, V153, P188, DOI 10.1093/aje/153.2.188; Rybicki BA, 2001, AM J RESP CRIT CARE, V164, P2085, DOI 10.1164/ajrccm.164.11.2106001; SARTWELL PE, 1974, AM J EPIDEMIOL, V99, P250, DOI 10.1093/oxfordjournals.aje.a121609; Schurmann M, 2000, AM J RESP CRIT CARE, V162, P861, DOI 10.1164/ajrccm.162.3.9901099; Schurmann M, 2001, J INTERN MED, V249, P77, DOI 10.1046/j.1365-2796.2001.00776.x; Sharma OP, 1998, ARCH NEUROL-CHICAGO, V55, P1248, DOI 10.1001/archneur.55.9.1248; Shigehara K, 2001, J IMMUNOL, V166, P642, DOI 10.4049/jimmunol.166.1.642; Silverman EK, 2000, AM J RESP CELL MOL, V22, P645, DOI 10.1165/ajrcmb.22.6.f191; Somoskovi A, 1999, CYTOKINE, V11, P882, DOI 10.1006/cyto.1999.0498; SULAVIK SB, 1993, CHEST, V103, P403, DOI 10.1378/chest.103.2.403; Swider C, 1999, EUR CYTOKINE NETW, V10, P143; Takashige N, 1999, TISSUE ANTIGENS, V54, P191, DOI 10.1034/j.1399-0039.1999.540211.x; Tavares JL, 1997, RESP MED, V91, P31, DOI 10.1016/S0954-6111(97)90134-7; Tomita H, 1997, AM J RESP CRIT CARE, V156, P255, DOI 10.1164/ajrccm.156.1.9612011; TRAMONTANA JM, 1995, MOL MED, V1, P384, DOI 10.1007/BF03401576; Vokurka M, 1997, AM J RESP CRIT CARE, V156, P1000, DOI 10.1164/ajrccm.156.3.9612035; WARD K, 1989, THORAX, V44, P6, DOI 10.1136/thx.44.1.6; WARSHAUER DM, 1995, RADIOLOGY, V195, P757, DOI 10.1148/radiology.195.3.7754007; Wyser CP, 1997, AM J RESP CRIT CARE, V156, P1371, DOI 10.1164/ajrccm.156.5.9506031; Yamaguchi E, 2001, CHEST, V119, P753, DOI 10.1378/chest.119.3.753; Yee AMF, 2001, ANN INTERN MED, V135, P27, DOI 10.7326/0003-4819-135-1-200107030-00010; YOUNG RL, 1970, ANN INTERN MED, V73, P207, DOI 10.7326/0003-4819-73-2-207; Zabel P, 1997, AM J RESP CRIT CARE, V155, P1665, DOI 10.1164/ajrccm.155.5.9154873; Zajicek JP, 1999, QJM-INT J MED, V92, P103, DOI 10.1093/qjmed/92.2.103; Ziegenhagen MW, 1997, AM J RESP CRIT CARE, V156, P1586, DOI 10.1164/ajrccm.156.5.97-02050; 1997, MMWR MORB MORTAL WKL, V46, P539	117	512	538	1	31	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 29	2003	361	9363					1111	1118		10.1016/S0140-6736(03)12888-7	http://dx.doi.org/10.1016/S0140-6736(03)12888-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672326				2022-12-28	WOS:000181865200024
J	Schiermeier, Q				Schiermeier, Q			Europe told to unite on spy satellites	NATURE			English	News Item																		2003, NATURE, V421, P465	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					361	361		10.1038/422361b	http://dx.doi.org/10.1038/422361b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660740	Bronze			2022-12-28	WOS:000181801200004
J	Nardi, F; Spinsanti, G; Boore, JL; Carapelli, A; Dallai, R; Frati, F				Nardi, F; Spinsanti, G; Boore, JL; Carapelli, A; Dallai, R; Frati, F			Hexapod origins: Monophyletic or paraphyletic?	SCIENCE			English	Article							MITOCHONDRIAL GENES; PHYLOGENY; ARTHROPODS; INSECTS; CRUSTACEANS; MYRIAPODS; NUCLEAR	Recent morphological and molecular evidence has changed interpretations of arthropod phylogeny and evolution. Here we compare complete mitochondrial genomes to show that Collembola, a wingless group traditionally considered as basal to all insects, appears instead to constitute a separate evolutionary lineage that branched much earlier than the separation of many crustaceans and insects and independently adapted to life on land. Therefore, the taxon Hexapoda, as commonly defined to include all six-legged arthropods, is not monophyletic.	Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; US DOE, Joint Genome Inst, Walnut Creek, CA 94598 USA; Lawrence Berkeley Lab, Walnut Creek, CA 94598 USA	University of Siena; United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Nardi, F (corresponding author), Univ Siena, Dept Evolutionary Biol, Via Aldo Moro 2, I-53100 Siena, Italy.		Nardi, Francesco/E-5516-2011; Carapelli, Antonio/H-9216-2019	Nardi, Francesco/0000-0003-0271-9855; Carapelli, Antonio/0000-0002-3165-9620; Dallai, Romano/0000-0002-2258-8891				Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; Bitsch C, 2000, ZOOL SCR, V29, P131, DOI 10.1046/j.1463-6409.2000.00036.x; Boore JL, 1998, NATURE, V392, P667, DOI 10.1038/33577; BRIGGS DEG, 1989, SCIENCE, V246, P241, DOI 10.1126/science.246.4927.241; Carapelli A, 2000, PEDOBIOLOGIA, V44, P361, DOI 10.1078/S0031-4056(04)70055-4; Cook CE, 2001, CURR BIOL, V11, P759, DOI 10.1016/S0960-9822(01)00222-6; Dallai R, 1999, MALE GAMETE: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS, P333; Dohle W, 2001, ANN SOC ENTOMOL FR, V37, P85; Duman-Scheel M, 1999, DEVELOPMENT, V126, P2327; EMERSON MJ, 1997, ARTHROPOD RELATIONSH, P67; FRIEDRICH M, 1995, NATURE, V376, P165, DOI 10.1038/376165a0; Garcia-Machado E, 1999, J MOL EVOL, V49, P142, DOI 10.1007/PL00006527; Giribet G, 2000, CLADISTICS, V16, P204, DOI 10.1111/j.1096-0031.2000.tb00353.x; Helfenbein KG, 2001, MOL BIOL EVOL, V18, P1734, DOI 10.1093/oxfordjournals.molbev.a003961; Hennig W., 1981, INSECT PHYLOGENY; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Hwang UW, 2001, NATURE, V413, P154, DOI 10.1038/35093090; Klass KD, 2001, ANN SOC ENTOMOL FR, V37, P265; KRAUS O., 1997, ARTHROPOD RELATIONSH, P295; Nardi F, 2001, MOL BIOL EVOL, V18, P1293, DOI 10.1093/oxfordjournals.molbev.a003914; Shimodaira H, 2002, SYST BIOL, V51, P492, DOI 10.1080/10635150290069913; Shultz JW, 2000, P ROY SOC B-BIOL SCI, V267, P1011, DOI 10.1098/rspb.2000.1104; SPEARS T, 1997, ARTHROPOD RELATIONSH, P169; Swofford David L., 1996, P407	24	279	306	2	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 21	2003	299	5614					1887	1889		10.1126/science.1078607	http://dx.doi.org/10.1126/science.1078607			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649480				2022-12-28	WOS:000181669700044
J	Onoa, B; Dumont, S; Liphardt, J; Smith, SB; Tinoco, I; Bustamante, C				Onoa, B; Dumont, S; Liphardt, J; Smith, SB; Tinoco, I; Bustamante, C			Identifying kinetic barriers to mechanical unfolding of the T-thermophila ribozyme	SCIENCE			English	Article							CRYSTAL-STRUCTURE; RNA; STABILITY; DOMAIN	Mechanical unfolding trajectories for single molecules of the Tetrahymena thermophila ribozyme display eight intermediates corresponding to discrete kinetic barriers that oppose mechanical unfolding with lifetimes of seconds and rupture forces between 10 and 30 piconewtons. Barriers are magnesium dependent and correspond to known intra- and interdomain interactions. Several barrier structures are "brittle," breakage requiring high forces but small (1 to 3 nanometers) deformations. Barrier crossing is stochastic, leading to variable unfolding paths. The response of complex RNA structures to locally applied mechanical forces may be analogous to the responses of RNA during translation, messenger RNA export from the nucleus, and viral replication.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Biophys Grad Grp, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Bustamante, C (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	carlos@alice.berkeley.edu	Liphardt, Jan/A-5906-2012	Liphardt, Jan/0000-0003-2835-5025; Bustamante, Carlos/0000-0002-2970-0073	NIGMS NIH HHS [GM-10840, R01 GM010840, GM-32543] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010840, R37GM032543, R01GM032543, R37GM010840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Batey RT, 1999, ANGEW CHEM INT EDIT, V38, P2327; Bockelmann U, 2002, BIOPHYS J, V82, P1537, DOI 10.1016/S0006-3495(02)75506-9; Bockelmann U, 1998, PHYS REV E, V58, P2386, DOI 10.1103/PhysRevE.58.2386; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Gerland U, 2001, BIOPHYS J, V81, P1324, DOI 10.1016/S0006-3495(01)75789-X; GERLAND U, IN PRESS BIOPHYS; Golden BL, 1998, SCIENCE, V282, P259, DOI 10.1126/science.282.5387.259; Juneau K, 2001, STRUCTURE, V9, P221, DOI 10.1016/S0969-2126(01)00579-2; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; Liphardt J, 2001, SCIENCE, V292, P733, DOI 10.1126/science.1058498; LIPHARDT J, UNPUB; Ralston CY, 2000, NAT STRUCT BIOL, V7, P371; Russell R, 2002, P NATL ACAD SCI USA, V99, P155, DOI 10.1073/pnas.221593598; Sclavi B, 1998, SCIENCE, V279, P1940, DOI 10.1126/science.279.5358.1940; Silverman SK, 2000, BIOCHEMISTRY-US, V39, P12465, DOI 10.1021/bi000828y; Smith SB, 2003, METHOD ENZYMOL, V361, P134; Thirumalai D, 2001, ANNU REV PHYS CHEM, V52, P751, DOI 10.1146/annurev.physchem.52.1.751; Tinoco I, 1999, J MOL BIOL, V293, P271, DOI 10.1006/jmbi.1999.3001; Treiber DK, 2001, CURR OPIN STRUC BIOL, V11, P309, DOI 10.1016/S0959-440X(00)00206-2; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	23	205	211	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	2003	299	5614					1892	1895		10.1126/science.1081338	http://dx.doi.org/10.1126/science.1081338			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649482	Green Accepted			2022-12-28	WOS:000181669700046
J	Cooper, RS; Kaufman, JS; Ward, R				Cooper, RS; Kaufman, JS; Ward, R			Race and genomics	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SOCIOECONOMIC-STATUS; GENETIC-STRUCTURE; HEART-FAILURE; BLACK; WHITE; POLYMORPHISMS; HYPERTENSION; POPULATIONS; PREVALENCE; PATTERNS		Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL 60153 USA; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; Univ Oxford, Dept Biol Anthropol, Oxford, England	Loyola University Chicago; University of North Carolina; University of North Carolina Chapel Hill; University of Oxford	Cooper, RS (corresponding author), Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, 2160 S 1st Ave, Maywood, IL 60153 USA.	rcooper@lumc.edu	Templeton, Alan R./F-5963-2011; Williams, Scott/Q-4812-2019	Williams, Scott/0000-0002-4835-9544; Kaufman, Jay/0000-0003-1606-401X				*ALLHAT OFF COORD, 2000, JAMA-J AM MED ASSOC, V288, P2981; Brancati FL, 1996, ANN EPIDEMIOL, V6, P67, DOI 10.1016/1047-2797(95)00095-X; Brewster LM, 2000, J HYPERTENS, V18, P1537, DOI 10.1097/00004872-200018110-00002; Carson P, 1999, J Card Fail, V5, P178, DOI 10.1016/S1071-9164(99)90001-5; Chase Allan, 1977, LEGACY MALTHUS SOCIA; Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160; Cooper RS, 1997, DIABETES CARE, V20, P343, DOI 10.2337/diacare.20.3.343; Dries DL, 2002, J AM COLL CARDIOL, V40, P311, DOI 10.1016/S0735-1097(02)01943-5; Dries DL, 2002, J AM COLL CARDIOL, V40, P1019; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Franciosa JA, 2002, J CARD FAIL, V8, P128, DOI 10.1054/jcaf.2002.124730; Freedman BI, 2002, NEPHROL DIAL TRANSPL, V17, P198, DOI 10.1093/ndt/17.2.198; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gould S. J., 1996, MISMEASURE MAN; Grim CE, 1996, SEMIN NEPHROL, V16, P83; Hajjar RJ, 2002, NEW ENGL J MED, V347, P1196, DOI 10.1056/NEJMe020105; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Henderson SO, 2000, AM J MED SCI, V320, P18, DOI 10.1097/00000441-200007000-00004; Kimm SYS, 2002, AM J CLIN NUTR, V75, P714, DOI 10.1093/ajcn/75.4.714; Montagu A., 1964, CONCEPT RACE; Muntaner C, 1996, AM J EPIDEMIOL, V144, P531; Risch N., 2002, GENOME BIOL, V3, pcomm, DOI [10.1186/gb-2002-3-7-comment2007, 10.1186/GB-2002-3-7-COMMENT2007]; Robbins AS, 2000, AM J EPIDEMIOL, V151, P409; Romualdi C, 2002, GENOME RES, V12, P602, DOI 10.1101/gr.214902; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Stephens JC, 2001, SCIENCE, V293, P1048; Templeton AR, 1998, AM ANTHROPOL, V100, P632, DOI 10.1525/aa.1998.100.3.632; Wade N, 2002, N Y Times Web, pF2; Wilson JF, 2001, NAT GENET, V29, P265, DOI 10.1038/ng761; Yancy Clyde W, 2002, Curr Cardiol Rep, V4, P218, DOI 10.1007/s11886-002-0054-0; 2002, NAT GENET, V30, P125	34	454	459	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1166	1170		10.1056/NEJMsb022863	http://dx.doi.org/10.1056/NEJMsb022863			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646675				2022-12-28	WOS:000181628400014
J	Wei, XP; Decker, JM; Wang, SY; Hui, HX; Kappes, JC; Wu, XY; Salazar-Gonzalez, JF; Salazar, MG; Kilby, JM; Saag, MS; Komarova, NL; Nowak, MA; Hahn, BH; Kwong, PD; Shaw, GM				Wei, XP; Decker, JM; Wang, SY; Hui, HX; Kappes, JC; Wu, XY; Salazar-Gonzalez, JF; Salazar, MG; Kilby, JM; Saag, MS; Komarova, NL; Nowak, MA; Hahn, BH; Kwong, PD; Shaw, GM			Antibody neutralization and escape by HIV-1	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GP120 ENVELOPE GLYCOPROTEIN; PRIMARY INFECTION; TYPE-1; VARIANTS; GLYCOSYLATION; INDIVIDUALS; EMERGENCE; RESPONSES; RESIDUES	Neutralizing antibodies (Nab) are a principal component of an effective human immune response to many pathogens, yet their role in HIV-1 infection is unclear(1-6). To gain a better understanding of this role, we examined plasma from patients with acute HIV infection. Here we report the detection of autologous Nab as early as 52 days after detection of HIV-specific antibodies. The viral inhibitory activity of Nab resulted in complete replacement of neutralization-sensitive virus by successive populations of resistant virus. Escape virus contained mutations in the env gene that were unexpectedly sparse, did not map generally to known neutralization epitopes, and involved primarily changes in N-linked glycosylation. This pattern of escape, and the exceptional density of HIV-1 envelope glycosylation generally(7,8) led us to postulate an evolving 'glycan shield' mechanism of neutralization escape whereby selected changes in glycan packing prevent Nab binding but not receptor binding. Direct support for this model was obtained by mutational substitution showing that Nab-selected alterations in glycosylation conferred escape from both autologous antibody and epitope-specific monoclonal antibodies. The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire.	Univ Alabama, Howard Hughes Med Inst, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Inst Adv Study, Princeton, NJ 08540 USA; NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA	Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Institute for Advanced Study - USA; National Institutes of Health (NIH) - USA	Shaw, GM (corresponding author), Univ Alabama, Howard Hughes Med Inst, 720 S 20th St,KAUL 816, Birmingham, AL 35294 USA.		Nowak, Martin A/A-6977-2008	Hahn, Beatrice/0000-0002-9400-9887; Salazar-Gonzalez, Jesus F./0000-0003-4626-6448; Kilby, J. Michael/0000-0003-3222-1003	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005023, ZIAAI005023] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT J, 1990, AIDS, V4, P107, DOI 10.1097/00002030-199002000-00002; BACK NKT, 1994, VIROLOGY, V199, P431, DOI 10.1006/viro.1994.1141; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Chackerian B, 1997, J VIROL, V71, P7719, DOI 10.1128/JVI.71.10.7719-7727.1997; Gorny MK, 2002, J VIROL, V76, P9035, DOI 10.1128/JVI.76.18.9035-9045.2002; Kolchinsky P, 2001, J VIROL, V75, P2041, DOI 10.1128/JVI.75.5.2041-2050.2001; KUIKEN CL, 2000, HUMAN RETROVIRUSES A; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; MARKOWITZ M, IN PRESS J VIROL; MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519; Montefiori DC, 2001, J VIROL, V75, P10200, DOI 10.1128/JVI.75.21.10200-10207.2001; Moog C, 1997, J VIROL, V71, P3734, DOI 10.1128/JVI.71.5.3734-3741.1997; MYERS G, 1992, AIDS RES HUM RETROV, V8, P1459, DOI 10.1089/aid.1992.8.1459; Nowak M.A., 2000, VIRAL DYNAMICS; Parren PWHI, 1999, AIDS, V13, pS137; Pilgrim AK, 1997, J INFECT DIS, V176, P924, DOI 10.1086/516508; Poignard P, 1999, IMMUNITY, V10, P431, DOI 10.1016/S1074-7613(00)80043-6; Poignard P, 2001, ANNU REV IMMUNOL, V19, P253, DOI 10.1146/annurev.immunol.19.1.253; Ramratnam B, 1999, LANCET, V354, P1782, DOI 10.1016/S0140-6736(99)02035-8; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; RICHMAN DD, IN PRESS P NATL ACAD; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Stewart J. J., 1999, PROFILE QUASISPECIES; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884	30	1882	1968	1	183	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					307	312		10.1038/nature01470	http://dx.doi.org/10.1038/nature01470			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646921				2022-12-28	WOS:000181637300039
J	Li, CI; Anderson, BO; Daling, JR; Moe, RE				Li, CI; Anderson, BO; Daling, JR; Moe, RE			Trends in incidence rates of invasive lobular and ductal breast carcinoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; ESTROGEN; CANCER; WOMEN; MANAGEMENT; DIAGNOSIS; PROGESTIN; PATTERNS; RISK	Context Research has suggested that use of combined estrogen and progestin hormone replacement therapy (CHRT) increases breast cancer risk and that CHRT use more strongly associated with the risk of invasive lobular breast carcinoma than that invasive ductal carcinoma. Lobular carcinoma is less common than ductal carcinoma can be more difficult to diagnose because of its subtle elusive. infiltrative pattern. Objective To evaluate trends in invasive lobular and ductal carcinoma incidence from 1987 through 1999, during which time use of CHRT increased in the United Design Descriptive epidemiologic study. Setting Nine cancer registries that participate in the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute and that cover Atlanta, Ga; Detroit, Mich; San Francisco-Oakland, Calif; Seattle, Wash; and Connecticut, Hawaii, Iowa, New Mexico, and Utah., Population Women 30 years of age and older residing in the areas covered by the 9 SEER registries. Main Outcome Measures Proportional changes in incidence rates of invasive lobular and ductal carcinoma among women with no prior history of breast cancer. Results A total of 190458 women were included in this analysis who were identified through the registries as having invasive breast cancer; 7682 of the 198140 potentially eligible women (ie, those identified as not having in situ breast cancer) were I excluded from this analysis because stage of cancer was unknown. Invasive breast cancer incidence rates adjusted for age and for SEER historic stage increased 1.04-fold (95% confidence interval [CI], 1.004-1.07) from 1987-1999 (206.7/100000 to 214.1/100000, age-adjusted). However, incidence rates of tumors classified as lobular increased 1.52-fold (95% CI, 1.42-1.63), and those classified as mixed ductal-lobular increased 1.96-fold (95% CI, 1.80-2.14); rates of these types combined increased 1.65-fold (95% CI, 1.55-1.78) (19.8/100000 to 33.4/100000, age-adjusted). In contrast, ductal carcinoma rates remained largely constant (153.8/100000 to 155.3/100000, age-adjusted; proportional change, 1.03 [95% CI, 0.99-1.061). The proportion of breast cancers with a lobular component increased from 9.5% in 1987 to 15.6% in 1999. Conclusions Ductal carcinoma incidence rates remained essentially constant from 1987-1999 while lobular carcinoma rates increased steadily. This increase presents a clinical challenge given that lobular carcinoma is more difficult to detect than ductal carcinoma by both physical examination and mammography.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Li, CI (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,MP 381,POB 19024, Seattle, WA 98109 USA.				NATIONAL CANCER INSTITUTE [T32CA009168, R01CA085913] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 85913, T32 CA 09168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Brett KM, 1997, AM J EPIDEMIOL, V145, P536; Carr BR, 1996, EUR J OBSTET GYN R B, V64, pS17, DOI 10.1016/0301-2115(95)02351-8; Chen CL, 2002, JAMA-J AM MED ASSOC, V287, P734, DOI 10.1001/jama.287.6.734; Daling JR, 2002, CANCER-AM CANCER SOC, V95, P2455, DOI 10.1002/cncr.10984; DAVIS RP, 1979, ARCH SURG-CHICAGO, V114, P485; DIXON JM, 1982, HISTOPATHOLOGY, V6, P149, DOI 10.1111/j.1365-2559.1982.tb02712.x; DUTOIT RS, 1991, EUR J SURG ONCOL, V17, P251; Evans N, 2000, CLIN RADIOL, V55, P261, DOI 10.1053/crad.1999.0291; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; HEMMINKI E, 1988, American Journal of Public Health, V78, P1479, DOI 10.2105/AJPH.78.11.1479; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; Li CI, 2000, CANCER, V88, P2561, DOI 10.1002/1097-0142(20000601)88:11<2561::AID-CNCR19>3.3.CO;2-O; Li CI, 2000, CANCER, V88, P2570, DOI 10.1002/1097-0142(20000601)88:11<2570::AID-CNCR20>3.0.CO;2-O; Munot K, 2002, BRIT J SURG, V89, P1296, DOI 10.1046/j.1365-2168.2002.02208.x; *NAT CANC I, SEER DAT QUAL; *NAT CANC I, ABOUT SEER; *NAT CANC I, CHAR SEER POP COMP T; Newcomb PA, 2002, CANCER EPIDEM BIOMAR, V11, P593; Newcomer LM, 1999, AM J EPIDEMIOL, V149, pS79; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SILVERSTEIN MJ, 1994, CANCER-AM CANCER SOC, V73, P1673, DOI 10.1002/1097-0142(19940315)73:6<1673::AID-CNCR2820730620>3.0.CO;2-B; Skaane P, 1999, ACTA RADIOL, V40, P369, DOI 10.3109/02841859909177749; STIERER M, 1993, ANN SURG, V218, P13, DOI 10.1097/00000658-199307000-00004; Weinstein SP, 2001, AM J ROENTGENOL, V176, P399, DOI 10.2214/ajr.176.2.1760399; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; YEATMAN TJ, 1995, ANN SURG, V222, P549	28	350	361	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	2003	289	11					1421	1424		10.1001/jama.289.11.1421	http://dx.doi.org/10.1001/jama.289.11.1421			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656PM	12636465	Bronze			2022-12-28	WOS:000181616200034
J	Kamien, RD				Kamien, RD			Topology from the bottom up	SCIENCE			English	Editorial Material							COMPLEX		Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA	University of Pennsylvania	Kamien, RD (corresponding author), Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA.			Kamien, Randall/0000-0003-1598-5626				Bausch AR, 2003, SCIENCE, V299, P1716, DOI 10.1126/science.1081160; Cao WY, 2002, NAT MATER, V1, P111, DOI 10.1038/nmat727; DEOLIVEIRACOSTA A, 1995, ASTROPHYS J, V448, P477, DOI 10.1086/175977; Finkelmann H, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.015501; Percec V, 2002, NATURE, V419, P384, DOI 10.1038/nature01072; Tschierske C, 2002, CURR OPIN COLLOID IN, V7, P69, DOI 10.1016/S1359-0294(02)00014-6; WITTEN E, 1989, COMMUN MATH PHYS, V121, P351, DOI 10.1007/BF01217730	7	31	32	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1671	1673		10.1126/science.1082510	http://dx.doi.org/10.1126/science.1082510			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637724				2022-12-28	WOS:000181519500023
J	Schoemaker, HE; Mink, D; Wubbolts, MG				Schoemaker, HE; Mink, D; Wubbolts, MG			Dispelling the myths - Biocatalysis in industrial synthesis	SCIENCE			English	Article							DIRECTED EVOLUTION; ENZYME; ACID; COMBINATORIAL; BIOSYNTHESIS; ALDOLASE	Biocatalysis has emerged as an important tool in the industrial synthesis of bulk chemicals, pharmaceutical and agrochemical intermediates, active pharmaceuticals, and food ingredients. However, the number and diversity of the applications are modest, perhaps in part because of perceived or real limitations of biocatalysts, such as limited enzyme availability, substrate scope, and operational stability. Recent scientific breakthroughs in genomics, directed enzyme evolution, and the exploitation of biodiversity should help to overcome these limitations. As a result, we expect many new industrial applications of biocatalysis to be realized, from single-step enzymatic conversions to customized multistep microbial synthesis by means of metabolic pathway engineering.	DSM Res & Patents, Life Sci Prod, NL-6160 MD Geleen, Netherlands; Univ Amsterdam, Inst Mol Chem, NL-1018 WS Amsterdam, Netherlands; DSM Biotech, D-52428 Julich, Germany	DSM NV; University of Amsterdam	Schoemaker, HE (corresponding author), DSM Res & Patents, Life Sci Prod, POB 18, NL-6160 MD Geleen, Netherlands.	hans.schoemaker@dsm.com						Berry A, 2002, J IND MICROBIOL BIOT, V28, P127, DOI 10.1038/sj/jim/7000228; Bruggink A, 1998, ORG PROCESS RES DEV, V2, P128, DOI 10.1021/op9700643; DeSantis G, 2002, J AM CHEM SOC, V124, P9024, DOI 10.1021/ja0259842; Doekel S, 2001, METAB ENG, V3, P64, DOI 10.1006/mben.2000.0170; DRATHS KM, 1994, J AM CHEM SOC, V116, P399, DOI 10.1021/ja00080a057; Drauz K., 2002, ENZYME CATALYSIS ORG; Effenberger F, 2000, CURR OPIN BIOTECH, V11, P532, DOI 10.1016/S0958-1669(00)00141-5; Fahrenkamp-Uppenbrink J, 2002, SCIENCE, V297, P798; Fong S, 2000, CHEM BIOL, V7, P873, DOI 10.1016/S1074-5521(00)00035-1; Gibson JM, 2001, ANGEW CHEM INT EDIT, V40, P1945, DOI 10.1002/1521-3773(20010518)40:10<1945::AID-ANIE1945>3.3.CO;2-X; Griengl H, 2000, TRENDS BIOTECHNOL, V18, P252, DOI 10.1016/S0167-7799(00)01452-9; Halling PJ, 2000, CURR OPIN CHEM BIOL, V4, P74, DOI 10.1016/S1367-5931(99)00055-1; Jokela J, 2002, ENZYME MICROB TECH, V31, P67, DOI 10.1016/S0141-0229(02)00074-1; Kimura T, 1997, J AM CHEM SOC, V119, P11734, DOI 10.1021/ja9720422; Lee MY, 2002, CURR OPIN BIOTECH, V13, P376, DOI 10.1016/S0958-1669(02)00337-3; Liese A., 2000, IND BIOTRANSFORMATIO; Liu JJ, 2002, ANGEW CHEM INT EDIT, V41, P1404, DOI 10.1002/1521-3773(20020415)41:8<1404::AID-ANIE1404>3.0.CO;2-G; May O, 2000, NAT BIOTECHNOL, V18, P317, DOI 10.1038/73773; Michels PC, 1998, TRENDS BIOTECHNOL, V16, P210, DOI 10.1016/S0167-7799(98)01190-1; OYAMA K, 1992, CHIRALITY IND; Panke S, 2002, CURR OPIN BIOTECH, V13, P111, DOI 10.1016/S0958-1669(02)00302-6; Patel R.N., 2000, STEREOSELECTIVE BIOC, Vfirst; Persson BA, 1999, J AM CHEM SOC, V121, P1645, DOI 10.1021/ja983819+; Petersen M, 1999, GREEN CHEM, V1, P99, DOI 10.1039/a809538h; Pfeifer BA, 2001, MICROBIOL MOL BIOL R, V65, P106, DOI 10.1128/MMBR.65.1.106-118.2001; Reetz MT, 2001, ANGEW CHEM INT EDIT, V40, P284, DOI 10.1002/1521-3773(20010119)40:2<284::AID-ANIE284>3.0.CO;2-N; Reetz MT, 2002, TETRAHEDRON, V58, P6595, DOI 10.1016/S0040-4020(02)00668-3; Robin J, 2001, APPL MICROBIOL BIOT, V57, P357; Rondon MR, 2000, APPL ENVIRON MICROB, V66, P2541, DOI 10.1128/AEM.66.6.2541-2547.2000; Rutjes FPJT, 2000, J CHEM SOC PERK T 1, P4197, DOI 10.1039/b001538p; Schmid A, 2001, NATURE, V409, P258, DOI 10.1038/35051736; Short JM, 1997, NAT BIOTECHNOL, V15, P1322, DOI 10.1038/nbt1297-1322; Stemmer Willem P. C., 2002, Biotechnology and Bioprocess Engineering, V7, P121; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Stewart JD, 2001, CURR OPIN CHEM BIOL, V5, P120, DOI 10.1016/S1367-5931(00)00180-0; Straathof AJJ, 2002, CURR OPIN BIOTECH, V13, P548, DOI 10.1016/S0958-1669(02)00360-9; Takayama S, 1997, ANNU REV MICROBIOL, V51, P285, DOI 10.1146/annurev.micro.51.1.285; Thomas SM, 2002, TRENDS BIOTECHNOL, V20, P238, DOI 10.1016/S0167-7799(02)01935-2; Ulijn RV, 2002, BIOTECHNOL BIOENG, V80, P509, DOI 10.1002/bit.10396; Wolf LB, 2001, ADV SYNTH CATAL, V343, P662, DOI 10.1002/1615-4169(200108)343:6/7<662::AID-ADSC662>3.0.CO;2-I; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391; ZAKS A, 1985, P NATL ACAD SCI USA, V82, P3192, DOI 10.1073/pnas.82.10.3192; Zhu MM, 2002, BIOTECHNOL PROGR, V18, P694, DOI 10.1021/bp020281+	43	615	656	4	235	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	2003	299	5613					1694	1697		10.1126/science.1079237	http://dx.doi.org/10.1126/science.1079237			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637735				2022-12-28	WOS:000181519500034
J	Weaver, AJ; Saenko, OA; Clark, PU; Mitrovica, JX				Weaver, AJ; Saenko, OA; Clark, PU; Mitrovica, JX			Meltwater pulse 1A from Antarctica as a trigger of the bolling-allerod warm interval	SCIENCE			English	Article							LAST GLACIAL MAXIMUM; SEA-LEVEL RECORD; YOUNGER DRYAS; THERMOHALINE CIRCULATION; ICE-SHEET; CLIMATE-CHANGE; MODEL; AGES; INSTABILITY; TIMESCALE	Meltwater pulse 1A (mwp-1A) was a prominent feature of the last deglaciation, which led to a sea-level rise of similar to20 meters in less than 500 years. Concurrent with mwp-1A was the onset of the Bolling-Allerod interstadial event (14,600 years before the present), which marked the termination of the last glacial period. Previous studies have been unable to reconcile a warm Northern Hemisphere with mwp-1A originating from the Laurentide or Fennoscandian ice sheets. With the use of a climate model of intermediate complexity, we demonstrate that with mwp-1A originating from the Antarctic Ice Sheet, consistent with recent sea-level fingerprinting inferences, the strength of North Atlantic Deep Water (NADW) formation increases, thereby warming the North Atlantic region and providing an explanation for the onset of the Boiling-Allerod warm interval. The established mode of active NADW formation is then able to respond to subsequent freshwater forcing from the Laurentide and Fennoscandian ice sheets, setting the stage for the Younger Dryas cold period.	Univ Victoria, Sch Earth & Ocean Sci, Victoria, BC V8W 3P6, Canada; Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA; Univ Toronto, Dept Phys, Toronto, ON M5S 1A7, Canada	University of Victoria; Oregon State University; University of Toronto	Weaver, AJ (corresponding author), Univ Victoria, Sch Earth & Ocean Sci, POB 3055, Victoria, BC V8W 3P6, Canada.	weaver@uvic.ca	Weaver, Andrew J/E-7590-2011	Weaver, Andrew J/0000-0001-8919-3598				Alley RB, 1999, ANNU REV EARTH PL SC, V27, P149, DOI 10.1146/annurev.earth.27.1.149; BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; Bard E, 1996, NATURE, V382, P241, DOI 10.1038/382241a0; Bard E, 2000, SCIENCE, V289, P1321, DOI 10.1126/science.289.5483.1321; BARD E, 1993, RADIOCARBON, V35, P191, DOI 10.1017/S0033822200013886; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; BROECKER WS, 1989, NATURE, V341, P318, DOI 10.1038/341318a0; Clark PU, 2001, SCIENCE, V293, P283, DOI 10.1126/science.1062517; Clark PU, 2002, SCIENCE, V295, P2438; Clark PU, 2002, NATURE, V415, P863, DOI 10.1038/415863a; Clark PU, 1996, PALEOCEANOGRAPHY, V11, P563, DOI 10.1029/96PA01419; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; ENGLAND MH, 1993, J PHYS OCEANOGR, V23, P1553, DOI 10.1175/1520-0485(1993)023<1553:TMFAIW>2.0.CO;2; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; Fanning AF, 1997, PALEOCEANOGRAPHY, V12, P307, DOI 10.1029/96PA03726; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Hanebuth T, 2000, SCIENCE, V288, P1033, DOI 10.1126/science.288.5468.1033; Hughen KA, 2000, SCIENCE, V290, P1951, DOI 10.1126/science.290.5498.1951; Kanfoush SL, 2000, SCIENCE, V288, P1815, DOI 10.1126/science.288.5472.1815; Kienast M, 2003, GEOLOGY, V31, P67, DOI 10.1130/0091-7613(2003)031<0067:SOMPAT>2.0.CO;2; Kitagawa H, 2000, RADIOCARBON, V42, P369; Manabe S, 1997, PALEOCEANOGRAPHY, V12, P321, DOI 10.1029/96PA03932; Manabe S, 1999, TELLUS A, V51, P400, DOI 10.1034/j.1600-0870.1999.t01-3-00005.x; McCartney M. S., 1979, VOYAGE DISCOVERY G D, P103; Mikolajewicz U, 1998, ANN GLACIOL, V27, P311; Monnin E, 2001, SCIENCE, V291, P112, DOI 10.1126/science.291.5501.112; Montaggioni LF, 1997, GEOLOGY, V25, P555, DOI 10.1130/0091-7613(1997)025<0555:CRORGO>2.3.CO;2; Rahmstorf S, 1996, CLIM DYNAM, V12, P799, DOI 10.1007/s003820050144; Saenko OA, 2002, J PHYS OCEANOGR, V32, P3376, DOI 10.1175/1520-0485(2002)032<3376:OTROWD>2.0.CO;2; SAENKO OA, IN PRESS J PHYS OCEA; Schiller A, 1997, CLIM DYNAM, V13, P325, DOI 10.1007/s003820050169; Schmittner A, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2001PA000633; Schmittner A, 2002, SCIENCE, V295, P1489, DOI 10.1126/science.1066174; Seidov D, 2001, GEOPH MONOG SERIES, V126, P147; STOCKER TF, 1991, NATURE, V351, P729, DOI 10.1038/351729a0; STOMMEL H, 1961, TELLUS, V13, P224, DOI 10.1111/j.2153-3490.1961.tb00079.x; Stuiver M, 2000, QUATERNARY RES, V53, P277, DOI 10.1006/qres.2000.2127; Weaver AJ, 2001, ATMOS OCEAN, V39, P361, DOI 10.1080/07055900.2001.9649686; Weaver AJ, 1999, GEOPH MONOG SERIES, V112, P285; Yokoyama Y, 2000, NATURE, V406, P713, DOI 10.1038/35021035; [No title captured]	41	358	364	2	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	2003	299	5613					1709	1713		10.1126/science.1081002	http://dx.doi.org/10.1126/science.1081002			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637739				2022-12-28	WOS:000181519500038
J	Boersma, E; Mercado, N; Poldermans, D; Gardien, M; Vos, J; Simoons, ML				Boersma, E; Mercado, N; Poldermans, D; Gardien, M; Vos, J; Simoons, ML			Acute myocardial infarction	LANCET			English	Review							CORONARY-HEART-DISEASE; TISSUE-PLASMINOGEN ACTIVATOR; GLYCOPROTEIN IIB/IIIA INHIBITION; INTRAVENOUS THROMBOLYTIC THERAPY; LEFT-VENTRICULAR FUNCTION; C-REACTIVE PROTEIN; PRIMARY ANGIOPLASTY; CARDIOVASCULAR-DISEASE; EVENT RATES; RECEPTOR BLOCKADE	Acute myocardial infarction is a common disease with serious consequences in mortality, morbidity, and cost to the society. Coronary atherosclerosis plays a pivotal part as the underlying substrate in many patients. In addition, a new definition of myocardial infarction has recently been introduced that has major implications from the epidemiological, societal, and patient points of view. The advent of coronary-care units and the results of randomised clinical trials on reperfusion therapy, lytic or percutaneous coronary intervention, and chronic medical treatment with various pharmacological agents have substantially changed the therapeutic approach, decreased in-hospital mortality, and improved the long-term outlook in survivors of the acute phase. New treatments will continue to emerge, but the greatest challenge will be to effectively implement preventive actions in all high-risk individuals and to expand delivery of acute treatment in a timely fashion for all eligible patients.	Erasmus MC, NL-3015 GD Rotterdam, Netherlands; Thorax Ctr Rotterdam, Dept Cardiol, NL-3015 GD Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Boersma, E (corresponding author), Erasmus MC, Room H543, NL-3015 GD Rotterdam, Netherlands.	h.boersma@erasmusmc.nl						Alpert JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/euhj.2000.2305; Anand SS, 1999, JAMA-J AM MED ASSOC, V282, P2058, DOI 10.1001/jama.282.21.2058; ANDERSEN HR, 2002, AM COLL CARD ANN SCI; Andreotti F, 2002, HEART, V87, P107, DOI 10.1136/heart.87.2.107; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1988, BRIT MED J, V296, P320; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Armstrong PW, 2000, LANCET, V356, P1849, DOI 10.1016/S0140-6736(05)73310-9; Aronow HD, 2001, LANCET, V357, P1063, DOI 10.1016/S0140-6736(00)04257-4; Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P1943, DOI 10.1001/jama.287.15.1943; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Blake GJ, 2001, CIRC RES, V89, P763, DOI 10.1161/hh2101.099270; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; Boersma E, 2000, NEW ENGL J MED, V342, P890; Boersma E, 1997, EUR HEART J, V18, P1703; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; Brodie BR, 2001, AM J CARDIOL, V88, P1085, DOI 10.1016/S0002-9149(01)02039-2; Brouwer MA, 1996, AM J CARDIOL, V78, P497, DOI 10.1016/S0002-9149(96)00352-9; Cannon CP, 1998, CIRCULATION, V98, P2805, DOI 10.1161/01.CIR.98.25.2805; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Danesh J, 2002, EUR HEART J, V23, P371, DOI 10.1053/euhj.2001.2801; Danesh J, 1998, BRIT MED J, V316, P1130, DOI 10.1136/bmj.316.7138.1130; Danesh J, 2000, CIRCULATION, V102, P1082, DOI 10.1161/01.CIR.102.10.1082; de Korte CL, 2002, CIRCULATION, V105, P1627, DOI 10.1161/01.CIR.0000014988.66572.2E; de Lemos JA, 2000, CIRCULATION, V101, P239, DOI 10.1161/01.CIR.101.3.239; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; Dixon SR, 2002, J AM COLL CARDIOL, V39, P387, DOI 10.1016/S0735-1097(01)01771-5; Eagle KA, 2002, LANCET, V359, P373, DOI 10.1016/S0140-6736(02)07595-5; FATHORDOUBAD F, 1994, CIRCULATION, V90, P325; Fayad ZA, 2001, CIRC RES, V89, P305, DOI 10.1161/hh1601.095596; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; Freemantle N, 2002, PROG CARDIOVASC DIS, V44, P243, DOI 10.1053/pcad.2002.31586; Fuster V, 1997, LANCET, V350, P389; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; Grijseels EWM, 1995, EUR HEART J, V16, P1833, DOI 10.1093/oxfordjournals.eurheartj.a060836; Grines CL, 2002, J AM COLL CARDIOL, V39, P1713, DOI 10.1016/S0735-1097(02)01870-3; Gupta S, 1997, CLIN CARDIOL, V20, P829, DOI 10.1002/clc.4960201008; Hamm CW, 2001, LANCET, V358, P1533, DOI 10.1016/S0140-6736(01)06585-0; Harrington RA, 1998, J AM COLL CARDIOL, V32, P2003; Hasdai D, 2002, EUR HEART J, V23, P1190, DOI 10.1053/euhj.2002.3193; Heeschen C, 2002, CIRCULATION, V105, P1446, DOI 10.1161/01.CIR.0000012530.68333.C8; Hennekens CH, 1998, CIRCULATION, V97, P1095, DOI 10.1161/01.CIR.97.11.1095; HERMENS WT, 1992, LANCET, V340, P1297, DOI 10.1016/0140-6736(92)93003-6; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; HUNT D, 1992, LANCET, V339, P753; Hurlen M, 2002, NEW ENGL J MED, V347, P969, DOI 10.1056/NEJMoa020496; *INTR NPA TREATM I, 2000, EUR HEART J, V21, P2005; Ito H, 1996, CIRCULATION, V93, P1993, DOI 10.1161/01.CIR.93.11.1993; Jaffe A S, 2001, Cardiol Rev, V9, P318, DOI 10.1097/00045415-200111000-00006; Julian DG, 2001, CARDIOVASC RES, V51, P621, DOI 10.1016/S0008-6363(01)00365-0; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Kent D M, 2001, Eff Clin Pract, V4, P214; Kesteloot H, 2002, EUR HEART J, V23, P384, DOI 10.1053/euhj.2001.2839; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Kong DF, 1998, CIRCULATION, V98, P2829, DOI 10.1161/01.CIR.98.25.2829; Kotseva K, 2001, LANCET, V357, P995, DOI 10.1016/S0140-6736(00)04235-5; Lamfers EJP, 1999, AM J CARDIOL, V84, P928, DOI 10.1016/S0002-9149(99)00468-3; Latini R, 2000, J AM COLL CARDIOL, V35, P1801, DOI 10.1016/S0735-1097(00)00638-0; Lincoff AM, 2002, JAMA-J AM MED ASSOC, V288, P2130, DOI 10.1001/jama.288.17.2130; Madsen JK, 1997, CIRCULATION, V96, P748; Mehta SR, 2000, LANCET, V356, P449, DOI 10.1016/S0140-6736(00)02552-6; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Neumann FJ, 2000, J AM COLL CARDIOL, V35, P915, DOI 10.1016/S0735-1097(99)00635-X; Neumann FJ, 1998, CIRCULATION, V98, P2695, DOI 10.1161/01.CIR.98.24.2695; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Ohman EM, 1997, CIRCULATION, V95, P846; OUNPUU S, 2002, 14 WORLD C CARD SYDN; Porter TR, 1998, AM J CARDIOL, V82, P1173, DOI 10.1016/S0002-9149(98)00597-9; Rauch U, 2001, ANN INTERN MED, V134, P224, DOI 10.7326/0003-4819-134-3-200102060-00014; Reitsma JB, 1999, HEART, V82, P52, DOI 10.1136/hrt.82.1.52; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Ronner E, 1998, EUR HEART J, V19, P1608, DOI 10.1053/euhj.1998.1222; Ronner E, 2000, EUR HEART J, V21, P1530, DOI 10.1053/euhj.1999.2035; ROSS A, 2002, AM COLL CARD ANN SCI; Ross AM, 2001, CIRCULATION, V104, P648, DOI 10.1161/hc3101.093866; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; Sans S, 1997, EUR HEART J, V18, P1231; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Shah A, 2000, J AM COLL CARDIOL, V35, P666, DOI 10.1016/S0735-1097(99)00601-4; Simoons ML, 2002, EUR HEART J, V23, P1282, DOI 10.1053/euhj.2001.3083; SMALLING RW, 1995, CIRCULATION, V91, P2725, DOI 10.1161/01.CIR.91.11.2725; Srikanthan VS, 1997, HEART, V78, P198, DOI 10.1136/hrt.78.2.198; Stefanadis C, 1999, CIRCULATION, V99, P1965, DOI 10.1161/01.CIR.99.15.1965; Stenestrand U, 2001, JAMA-J AM MED ASSOC, V285, P430, DOI 10.1001/jama.285.4.430; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2000, CIRCULATION, V101, P2788; Topol EJ, 2001, LANCET, V357, P1905; Tunstall-Pedoe H, 2000, LANCET, V355, P688, DOI 10.1016/S0140-6736(99)11181-4; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; Tunstall-Pedoe H, 2001, EUR HEART J, V22, P613, DOI 10.1053/euhj.2000.2579; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; Van de Werf F, 2001, LANCET, V358, P605; van Es RF, 2002, LANCET, V360, P109, DOI 10.1016/S0140-6736(02)09409-6; VANDEWERF F, 1990, LANCET, V336, P71; VandeWerf F, 1997, NEW ENGL J MED, V337, P1124; Vermeer F, 1999, HEART, V82, P426, DOI 10.1136/hrt.82.4.426; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; White HD, 2001, LANCET, V358, P1855; Widimsky P, 2000, EUR HEART J, V21, P823, DOI 10.1053/euhj.1999.1993; Widimsky P, 2003, EUR HEART J, V24, P94, DOI 10.1016/S0195-668X(02)00468-2; Wood D, 1998, ATHEROSCLEROSIS, V140, P199, DOI 10.1016/S0021-9150(98)90209-X; Wu AHB, 1999, CLIN CHEM, V45, P1104; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Yusuf S, 2002, LANCET, V359, P294; Zhu MM, 2001, AM J CARDIOL, V88, P297, DOI 10.1016/S0002-9149(01)01645-9; Zijistra F, 2002, EUR HEART J, V23, P550, DOI 10.1053/euhj.2001.2901; Zijlstra F, 1999, NEW ENGL J MED, V341, P1413, DOI 10.1056/NEJM199911043411901	123	235	260	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 8	2003	361	9360					847	858		10.1016/S0140-6736(03)12712-2	http://dx.doi.org/10.1016/S0140-6736(03)12712-2			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642064				2022-12-28	WOS:000181466600025
J	Sharp, D				Sharp, D			Prostate cancer: hopes and controversies	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Sharp, D (corresponding author), The Lancet, London NW1 7BY, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					798	798		10.1016/S0140-6736(03)12722-5	http://dx.doi.org/10.1016/S0140-6736(03)12722-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642044				2022-12-28	WOS:000181466600006
J	Yoshikawa, S; McKinnon, RD; Kokel, M; Thomas, JB				Yoshikawa, S; McKinnon, RD; Kokel, M; Thomas, JB			Wnt-mediated axon guidance via the Drosophila derailed receptor	NATURE			English	Article							TYROSINE KINASE FAMILY; ROBO RECEPTORS; CNS MIDLINE; COMMISSURAL AXONS; VENTRAL ECTODERM; WINGLESS GENE; EXPRESSION; PROTEIN; RYK; DIFFERENTIATION	In nervous systems with bilateral symmetry, many neurons project axons across the midline to the opposite side. In each segment of the Drosophila embryonic nervous system, axons that display this projection pattern choose one of two distinct tracts: the anterior or posterior commissure. Commissure choice is controlled by Derailed, an atypical receptor tyrosine kinase expressed on axons projecting in the anterior commissure. Here we show that Derailed keeps these axons out of the posterior commissure by acting as a receptor for Wnt5, a member of the Wnt family of secreted signalling molecules. Our results reveal an unexpected role in axon guidance for a Wnt family member, and show that the Derailed receptor is an essential component of Wnt signalling in these guidance events.	Salk Inst Biol Studies, Mol Neurobiol Lab, San Diego, CA 92186 USA; Robert Wood Johnson Med Sch, Dept Surg, Piscataway, NJ 08854 USA; Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol, Piscataway, NJ 08854 USA	Salk Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Thomas, JB (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, POB 85800, San Diego, CA 92186 USA.		McKinnon, Randall D/B-4699-2010	McKinnon, Randall/0000-0002-7539-9613				Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Bonkowsky JL, 1999, NATURE, V402, P540, DOI 10.1038/990122; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Callahan CA, 1998, CURR OPIN NEUROBIOL, V8, P582, DOI 10.1016/S0959-4388(98)80084-6; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; Chen CM, 1999, DEVELOPMENT, V126, P5441; Cohen ED, 2002, DEV CELL, V2, P437, DOI 10.1016/S1534-5807(02)00142-9; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Dittrich R, 1997, DEVELOPMENT, V124, P2515; EISENBERG LM, 1992, DEV BIOL, V154, P73, DOI 10.1016/0012-1606(92)90049-M; FRADKIN LG, 1995, DEV BIOL, V168, P202, DOI 10.1006/dbio.1995.1072; Gieseler K, 1999, MECH DEVELOP, V85, P123, DOI 10.1016/S0925-4773(99)00097-0; Golembo M, 1996, DEVELOPMENT, V122, P3363; Halford MM, 1999, J BIOL CHEM, V274, P7379, DOI 10.1074/jbc.274.11.7379; Halford MM, 2000, NAT GENET, V25, P414, DOI 10.1038/78099; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Katso RM, 1999, MOL CELL BIOL, V19, P6427; Keleman K, 2002, CELL, V110, P415, DOI 10.1016/S0092-8674(02)00901-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Krylova O, 2002, NEURON, V35, P1043, DOI 10.1016/S0896-6273(02)00860-7; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Moreau-Fauvarque C, 2002, NEUROREPORT, V13, P2309, DOI 10.1097/00001756-200212030-00028; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; Oates AC, 1998, MECH DEVELOP, V78, P165, DOI 10.1016/S0925-4773(98)00167-1; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; Patthy L, 2000, TRENDS BIOCHEM SCI, V25, P12, DOI 10.1016/S0968-0004(99)01504-2; Rajagopalan S, 2000, CELL, V103, P1033, DOI 10.1016/S0092-8674(00)00207-5; Rajagopalan S, 2000, NEURON, V28, P767, DOI 10.1016/S0896-6273(00)00152-5; RUSSELL J, 1992, DEVELOPMENT, V115, P475; Savant-Bhonsale S, 1999, GENE, V231, P155, DOI 10.1016/S0378-1119(99)00061-X; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Simpson JH, 2000, NEURON, V28, P753, DOI 10.1016/S0896-6273(00)00151-3; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; Yoshikawa S, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-01-j0002.2001	50	328	333	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 10	2003	422	6932					583	588		10.1038/nature01522	http://dx.doi.org/10.1038/nature01522			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665GN	12660735				2022-12-28	WOS:000182111400033
J	Barbosa-Cesnik, C; Schwartz, K; Foxman, B				Barbosa-Cesnik, C; Schwartz, K; Foxman, B			Lactation mastitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BREAST-FEEDING WOMEN; PUERPERAL MASTITIS; STAPHYLOCOCCUS-AUREUS; PROSPECTIVE COHORT; RISK-FACTORS; INFLAMMATION; MANAGEMENT; POSTPARTUM		Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Mol & Clin Epidemiol Infect Dis, Ann Arbor, MI 48109 USA; Wayne State Univ, Dept Family Med, Detroit, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Wayne State University	Barbosa-Cesnik, C (corresponding author), Univ Michigan, Dept Epidemiol, 109 Observ St, Ann Arbor, MI 48109 USA.	cibele@umich.edu	Dahlen, Hannah/V-1034-2019	Dahlen, Hannah/0000-0002-4450-3078; Foxman, Betsy/0000-0001-6682-238X				Amir L H, 1999, J Hum Lact, V15, P221, DOI 10.1177/089033449901500312; Bedinghaus JM, 1997, PRIMARY CARE, V24, P147; BRODRIBB W, 1991, BREASTFEEDING MANAGE; Buescher ES, 2001, CELL IMMUNOL, V210, P87, DOI 10.1006/cimm.2001.1813; Castro M, 1999, J NURSE-MIDWIFERY, V44, P280, DOI 10.1016/S0091-2182(99)00040-3; DEVEREUX WP, 1970, AM J OBSTET GYNECOL, V108, P78, DOI 10.1016/0002-9378(70)90208-5; DIXON JM, 1988, BRIT MED J, V297, P1517, DOI 10.1136/bmj.297.6662.1517; EIDELMAN AI, 1979, OBSTET GYNECOL, V53, P550; EVANS M, 1995, BREASTFEED REV, V3, P65; Fetherston C, 2001, Breastfeed Rev, V9, P5; Fetherston C, 1997, Breastfeed Rev, V5, P13; Fetherston C, 1998, J Hum Lact, V14, P101, DOI 10.1177/089033449801400209; Fetherston C, 1997, Breastfeed Rev, V5, P5; Foxman B, 2002, AM J EPIDEMIOL, V155, P103, DOI 10.1093/aje/155.2.103; Fujiwara Y, 2001, Kansenshogaku Zasshi, V75, P898; Hager WD, 1992, INFECT PROTOCOLS OBS, P27; Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593; Hunt C, 1999, JAMA-J AM MED ASSOC, V282, P1123; JONSSON S, 1994, ANN CHIR GYNAECOL FE, V83, P84; KAUFMANN R, 1991, SOC SCI MED, V33, P701, DOI 10.1016/0277-9536(91)90024-7; Kinlay JR, 1998, MED J AUSTRALIA, V169, P310, DOI 10.5694/j.1326-5377.1998.tb140282.x; Kinlay JR, 2001, AUST NZ J PUBL HEAL, V25, P115, DOI 10.1111/j.1753-6405.2001.tb01831.x; Marchant DJ, 2002, OBSTET GYN CLIN N AM, V29, P89, DOI 10.1016/S0889-8545(03)00054-8; MARSHALL BR, 1975, JAMA-J AM MED ASSOC, V233, P1377, DOI 10.1001/jama.233.13.1377; MCLACHLAN Z, 1993, BREASTFEEDING REV, V2, P316; NIEBYL JR, 1978, J REPROD MED, V20, P97; OGLE KS, 1978, J FAM PRACTICE, V26, P139; OLSEN CG, 1990, AM FAM PHYSICIAN, V41, P1509; Osterman K L, 2000, J Hum Lact, V16, P297, DOI 10.1177/089033440001600405; Peacock SJ, 2001, TRENDS MICROBIOL, V9, P605, DOI 10.1016/S0966-842X(01)02254-5; Riordan J M, 1990, J Hum Lact, V6, P53, DOI 10.1177/089033449000600213; Ryan AS, 2002, PEDIATRICS, V110, P1103, DOI 10.1542/peds.110.6.1103; Schwartz K, 2002, J FAM PRACTICE, V51, P439; Shellshear M, 1981, Aust J Physiother, V27, P15, DOI 10.1016/S0004-9514(14)60742-X; THOMSEN AC, 1984, AM J OBSTET GYNECOL, V149, P492, DOI 10.1016/0002-9378(84)90022-X; THOMSEN AC, 1983, AM J OBSTET GYNECOL, V146, P938, DOI 10.1016/0002-9378(83)90969-9; Vogel A, 1999, BIRTH-ISS PERINAT C, V26, P218, DOI 10.1046/j.1523-536x.1999.00218.x; World Health Organization, 2000, MAST CAUS MAN	38	72	77	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1609	1612		10.1001/jama.289.13.1609	http://dx.doi.org/10.1001/jama.289.13.1609			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662JX	12672715				2022-12-28	WOS:000181944500001
J	Stormer, N				Stormer, N			Seeing the fetus: The role of technology and image in the maternal-fetal relationship	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ Maine, Orono, ME 04473 USA	University of Maine System; University of Maine Orono	Stormer, N (corresponding author), Univ Maine, Orono, ME 04473 USA.							Casper Monica, 1998, MAKING UNBORN PATIEN; Chervenak F A, 1996, J Matern Fetal Med, V5, P115; Duden B., 1993, DISEMBODYING WOMEN; Fasouliotis SJ, 2000, EUR J OBSTET GYN R B, V89, P101, DOI 10.1016/S0301-2115(99)00166-9; Lloyd G. E. R., 1983, STUDIES LIFE SCI ANC; Martin Emily, 1987, WOMAN BODY CULTURAL; NASH JM, TIME; Paternan C., 1988, SEXUAL CONTRACT; PETCHESKY RP, 1987, FEMINIST STUD, V13, P263, DOI 10.2307/3177802; Stormer N, 1997, Q J SPEECH, V83, P172, DOI 10.1080/00335639709384179	10	13	13	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1700	1700		10.1001/jama.289.13.1700	http://dx.doi.org/10.1001/jama.289.13.1700			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	662JX	12672742	Bronze			2022-12-28	WOS:000181944500037
J	Hoagland, MB				Hoagland, MB			Celebrating complementarity	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								The 1950s witnessed prodigious growth in our knowledge of the chemical nature of the gene, the mechanisms by which the information inherent in its sequence of nucleotide units was conveyed to the cell's machinery for synthesizing proteins, and the mode of operation of that machinery. Watson and Crick raised the curtain by revealing the structure of DNA, notably the complementary pairing of the nucleotides in its twin chains. Identified with the new field of molecular biology, Crick defined and expanded the field of genetic information coding and led attempts to elucidate principles governing information translation into protein. On a parallel and complementary track, biochemists-notably the group led by Paul Zamecnik-were working out the details of the mechanism of protein synthesis: how and where in the cell amino acids were energized, sequenced, and polymerized. These two approaches to closely related problems, separated by a considerable cultural gap, merged dramatically in 1956. Crick's thinking led him to postulate the existence of adaptors-short chains of RNA nucleotide bases that, when linked to amino acids, might make the latter chemically "recognizable" to an RNA template by complementary pairing of their bases with those of the template. Simultaneously, the Zamecnik group discovered enzymes (amino acyl-tRNA synthetases) capable of energizing amino acids and, thence, attaching them to a hitherto unsuspected cellular RNA (transfer RNA). These RNA molecules, in turn, donated their bound amino acids to elongating protein chains on ribosomes, thus appearing to serve the function of adaptors.			Hoagland, MB (corresponding author), POB 183, Thetford, VT 05074 USA.								0	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					583	586		10.7326/0003-4819-138-7-200304010-00016	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00016			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667030				2022-12-28	WOS:000181872100009
J	Watson, JD; Crick, FH				Watson, JD; Crick, FH			A structure for deoxyribose nucleic acid	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Cavevdish Lab, Med Res Council Unit Study Mol Struct Biol Syst, Cambridge, England	University of Cambridge	Watson, JD (corresponding author), Cavevdish Lab, Med Res Council Unit Study Mol Struct Biol Syst, Cambridge, England.							ASTBURY WT, 1947, SYM SOC EXP BIOL, V1, P66; FURBERG S, 1952, ACTA CHEM SCAND, V6, P634, DOI 10.3891/acta.chem.scand.06-0634; PAULING L, 1953, P NATL ACAD SCI USA, V39, P84, DOI 10.1073/pnas.39.2.84; WILKINS MHF, 1953, BIOCHIM BIOPHYS ACTA, V10, P192, DOI 10.1016/0006-3002(53)90232-7; WYATT GR, 1952, J GEN PHYSIOL, V36, P201, DOI 10.1085/jgp.36.2.201; ZAMENHOF S, 1952, BIOCHIM BIOPHYS ACTA, V9, P402, DOI 10.1016/0006-3002(52)90184-4	6	7	7	12	196	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					581	582		10.7326/0003-4819-138-7-200304010-00015	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667029				2022-12-28	WOS:000181872100008
J	Picard, C; Puel, A; Bonnet, M; Ku, CL; Bustamante, J; Yang, K; Soudais, C; Dupuis, S; Feinberg, J; Fieschi, C; Elbim, C; Hitchcock, R; Lammas, D; Davies, G; Al-Ghonaium, A; Al-Rayes, H; Al-Jumaah, S; Al-Hajjar, S; Al-Mohsen, IZ; Frayha, HH; Rucker, R; Hawn, TR; Aderem, A; Tufenkeji, H; Haraguchi, S; Day, NK; Good, RA; Gougerot-Pocidalo, MA; Ozinsky, A; Casanova, JL				Picard, C; Puel, A; Bonnet, M; Ku, CL; Bustamante, J; Yang, K; Soudais, C; Dupuis, S; Feinberg, J; Fieschi, C; Elbim, C; Hitchcock, R; Lammas, D; Davies, G; Al-Ghonaium, A; Al-Rayes, H; Al-Jumaah, S; Al-Hajjar, S; Al-Mohsen, IZ; Frayha, HH; Rucker, R; Hawn, TR; Aderem, A; Tufenkeji, H; Haraguchi, S; Day, NK; Good, RA; Gougerot-Pocidalo, MA; Ozinsky, A; Casanova, JL			Pyogenic bacterial infections in humans with IRAK-4 deficiency	SCIENCE			English	Article							ECTODERMAL DYSPLASIA; RECEPTOR; INTERLEUKIN-1; MUTATIONS; IMMUNITY; FAMILY; MEMBER; TIRAP; NEMO; MICE	Members of the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) superfamily share an intracytoplasmic Toll-IL-1 receptor (TIR) domain, which mediates recruitment of the interleukin-1 receptor-associated kinase (IRAK) complex via TIR-containing adapter molecules. We describe three unrelated children with inherited IRAK-4 deficiency. Their blood and fibroblast cells did not activate nuclear factor kappaB and mitogein-activated protein kinase (MAPK)and failed to induce downstream cytokines in response to any of the known ligands of TIR-bearing receptors. The otherwise healthy children developed infections caused by pyogenic bacteria. These findings suggest that, in humans, the TIR-IRAK signaling pathway is crucial for protective immunity against specific bacteria but is redundant against most other microorganisms.	Univ Paris 05, Fac Necker, INSERM,U550, Lab Genet Humaine Malad Infect, F-75015 Paris, France; Fac Xavier Bichat, INSERM, U294, Serv Immunol Cellulaire,Lab Hematol & Immunol, F-75018 Paris, France; Univ S Florida, Dept Pediat, Div Allergy & Immunol, St Petersburg, FL 33701 USA; All Childrens Hosp, St Petersburg, FL 33701 USA; Univ Birmingham, Sch Med, MRC, Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England; Great Ormond St Hosp Sick Children, Infect Dis Unit, London WC1N 3JH, England; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; Inst Syst Biol, Seattle, WA 98103 USA; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, F-75015 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; State University System of Florida; University of South Florida; University of Birmingham; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; King Faisal Specialist Hospital & Research Center; Institute for Systems Biology (ISB); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Casanova, JL (corresponding author), Univ Paris 05, Fac Necker, INSERM,U550, Lab Genet Humaine Malad Infect, 156 Rue Vaugirard, F-75015 Paris, France.	casanova@necker.fr	KU, Cheng-Lung/L-6073-2015; Picard, Capucine/H-3914-2017; Boisson-Dupuis, Stephanie/AAF-5066-2021; Bustamante, Jacinta/H-7877-2017; Bonnet, Marion C/C-5612-2014; Puel, Anne/H-7305-2017; Casanova, Jean-Laurent/I-3418-2017; KU, Cheng-Lung/AAT-1033-2020; soudais, claire/F-9756-2016; Boisson-Dupuis, Stéphanie/I-2040-2017	KU, Cheng-Lung/0000-0002-0643-2256; Picard, Capucine/0000-0001-8788-5056; Bustamante, Jacinta/0000-0002-3439-2482; Bonnet, Marion C/0000-0002-7559-2413; Puel, Anne/0000-0003-2603-0323; KU, Cheng-Lung/0000-0002-0643-2256; soudais, claire/0000-0002-4387-6649; Boisson-Dupuis, Stéphanie/0000-0002-7115-116X; Casanova, Jean-Laurent/0000-0002-7782-4169				Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Casanova Jean-Laurent, 2002, Trends in Immunology, V23, P469, DOI 10.1016/S1471-4906(02)02289-5; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; DUPUIS S, 2003, NAT GENET, V18, P18; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Haraguchi S, 1998, P NATL ACAD SCI USA, V95, P13125, DOI 10.1073/pnas.95.22.13125; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kuhns DB, 1997, J IMMUNOL, V158, P3959; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; PICARD C, UNPUB; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Suzuki N, 2002, TRENDS IMMUNOL, V23, P503, DOI 10.1016/S1471-4906(02)02298-6; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; TAKEDA K, 2003, ANNU REV IMMUNOL, V9, P9; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	28	689	747	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					2076	2079		10.1126/science.1081902	http://dx.doi.org/10.1126/science.1081902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12637671				2022-12-28	WOS:000181834200058
J	Beroud, C; Karliova, M; Bonnefont, JP; Benachi, A; Munnich, A; Dumez, Y; Lacour, B; Paterlini-Brechot, P				Beroud, C; Karliova, M; Bonnefont, JP; Benachi, A; Munnich, A; Dumez, Y; Lacour, B; Paterlini-Brechot, P			Prenatal diagnosis of spinal muscular atrophy by genetic analysis of circulating fetal cells	LANCET			English	Article							MATERNAL BLOOD	Spinal muscular atrophy (SMA) has a prevalence of one in 6000 births and a one in 40 heterozygote frequency. We aimed to develop a routine test for non-invasive prenatal diagnosis. We tested blood with ISET (isolation by size of epithelial tumour or trophoblastic cells) in 12 pregnant women whose babies were at risk of SMA. Using genetic analysis of fetal cells, we identified SMA In all nine Isolated from the three mothers carrying an affected child. There was no mutation in any of the 26 fetal cells isolated from the nine women with an unaffected child. Our results show that non-invasive detection of genetic diseases by the analysis of maternal blood is feasible.	Hop Necker Enfants Malad, Lab Biochim A, Paris, France; Hop Necker Enfants Malad, Serv Matern, Paris, France; Hop Necker Enfants Malad, Med Genet Lab, Paris, France; Hop Necker Enfants Malad, Lab Biochim B, Paris, France; Fac Med Necker Enfants Malad, INSERM, U370, F-75730 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Paterlini-Brechot, P (corresponding author), Hop Necker Enfants Malad, Lab Biochim A, Paris, France.		BEROUD, Christophe/A-8381-2008	BEROUD, Christophe/0000-0003-2986-8738; BONNEFONT, Jean-Paul/0000-0002-4235-1197; Paterlini- Brechot, Patrizia/0000-0001-7981-6325				Bianchi DW, 1999, BRIT J HAEMATOL, V105, P574, DOI 10.1046/j.1365-2141.1999.01383.x; Chan V, 1998, LANCET, V352, P1196, DOI 10.1016/S0140-6736(05)60535-1; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Saugier-Veber P, 2001, J MED GENET, V38, P240, DOI 10.1136/jmg.38.4.240; Vona G, 2002, AM J PATHOL, V160, P51, DOI 10.1016/S0002-9440(10)64348-9	5	31	56	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					1013	1014		10.1016/S0140-6736(03)12798-5	http://dx.doi.org/10.1016/S0140-6736(03)12798-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660061				2022-12-28	WOS:000181699700014
J	Wilczak, N; de Vos, RAI; De Keyser, J				Wilczak, N; de Vos, RAI; De Keyser, J			Free insulin-like growth factor (IGF)-I and IGF binding proteins 2, 5, and 6 in spinal motor neurons in amyotrophic lateral sclerosis	LANCET			English	Article							PROGRAMMED CELL-DEATH; FACTOR-I; ALS; SYSTEM; MUSCLE; CORDS; NERVE	Background Insulin-like growth factor-I (IGF-I) is a potent survival factor for motor neurons and is being investigated as possible therapeutic agent for amyotrophic lateral sclerosis. However, very little information is available on the components of the IGF-I system in this disease. Insulinlike growth factor binding proteins (IGFBPs) play an important part in regulating the bioavailability of IGF-I. Methods We investigated the components of the IGF-I system in spinal cord sections of ten patients with amyotrophic lateral sclerosis and in ten controls without neurological disease. IGF-I was studied by western immunoblotting. IGFBPs and IGF-I receptors were investigated by immunohistochemistry and Western immunoblotting. Findings Total IGF-I in ventral horn homogenates did not differ between patients and controls. However, free IGF-I was 53% lower in patients than in controls. Compared with controls, immunoreactivity in the spinal motor neurons of patients with amyotrophic lateral sclerosis was 64% higher for IGFBP2, 46% higher for IGFBP5, and 33% higher for IGFBP6, with upregulation of IGF-I receptors. Immunoreactivity for IGFBPs1, 3, and 4 did not differ between patients and controls. Interpretation In the ventral horns of patients, free IGF-I is reduced, which could be because of specific increases in IGFBPs 2, 5, and 6 in spinal motor neurons. This abnormality might have an important role in the processes leading to motor neuron death, and should be taken into account when developing treatments aimed to stimulate IGF-I receptors in motor neurons.	Acad Ziekenhuis Groningen, Dept Neurol, Groningen, Netherlands; Oost Nederland, Dept Pathol, Enschede, Netherlands	University of Groningen	De Keyser, J (corresponding author), Univ Groningen Hosp, Dept Neurol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.		Wilczak, Nadine/G-4422-2011; De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757				ADEM A, 1994, MOL NEUROBIOL, V9, P225, DOI 10.1007/BF02816121; Babajko S, 1997, J ENDOCRINOL, V152, P221, DOI 10.1677/joe.0.1520221; Borasio GD, 1998, NEUROLOGY, V51, P583, DOI 10.1212/WNL.51.2.583; BRAUNSTEIN GD, 1987, J NEUROL NEUROSUR PS, V50, P792, DOI 10.1136/jnnp.50.6.792; Brooke MH, 1996, NEUROLOGY, V47, pS108, DOI 10.1212/WNL.47.4_Suppl_2.108S; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; Chou SM, 1998, J NEUROL SCI, V160, pS73, DOI 10.1016/S0022-510X(98)00202-0; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; D'Costa AP, 1998, J NEUROBIOL, V36, P379; DENYS EH, 1988, MUSCLE NERVE, V11, P1000; Dore S, 1996, MOL BRAIN RES, V41, P128, DOI 10.1016/0169-328X(96)00081-2; FESTOFF BW, 1995, J NEUROL SCI, V129, P114, DOI 10.1016/0022-510X(95)00080-L; Gustafsson T, 1999, J ENDOCRINOL, V161, P245, DOI 10.1677/joe.0.1610245; Hammarberg H, 1998, J COMP NEUROL, V400, P57; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KERKHOFF H, 1994, ACTA NEUROPATHOL, V87, P411, DOI 10.1007/BF00313611; Lai EC, 1997, NEUROLOGY, V49, P1621, DOI 10.1212/WNL.49.6.1621; LEWIS ME, 1993, EXP NEUROL, V124, P73, DOI 10.1006/exnr.1993.1177; Loddick SA, 1998, P NATL ACAD SCI USA, V95, P1894, DOI 10.1073/pnas.95.4.1894; Meins M, 2001, J NEUROSCI, V21, P8830, DOI 10.1523/JNEUROSCI.21-22-08830.2001; NEUHOFF V, 1979, H-S Z PHYSIOL CHEM, V360, P1657, DOI 10.1515/bchm2.1979.360.2.1657; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sueoka N, 2000, AM J RESP CELL MOL, V23, P297, DOI 10.1165/ajrcmb.23.3.4013; Sueoka N, 2000, ONCOGENE, V19, P4432, DOI 10.1038/sj.onc.1203813; Torres-Aleman I, 1998, NEUROLOGY, V50, P772, DOI 10.1212/WNL.50.3.772; Yuan QJ, 2000, NEUROREPORT, V11, P2237, DOI 10.1097/00001756-200007140-00035	27	71	76	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					1007	1011		10.1016/S0140-6736(03)12828-0	http://dx.doi.org/10.1016/S0140-6736(03)12828-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660059				2022-12-28	WOS:000181699700012
J	Grueber, WB; Jan, LY; Jan, YN				Grueber, WB; Jan, LY; Jan, YN			Different levels of the homeodomain protein cut regulate distinct dendrite branching patterns of Drosophila multidendritic neurons	CELL			English	Article							SENSORY ORGAN IDENTITY; PERIPHERAL NERVOUS-SYSTEM; ACHAETE-SCUTE-COMPLEX; DNA-BINDING; BICOID PROTEIN; MOTOR-NEURON; EXPRESSION; LOCUS; SPECIFICATION; TRANSFORMATION	Functionally similar neurons can share common dendrite morphology, but how different neurons are directed into similar forms is not understood. Here, we show in embryonic and larval development that the level of Cut immunoreactivity in individual dendritic arborization (da) sensory neurons correlates with distinct patterns of terminal dendrites: high Cut in neurons with extensive unbranched terminal protrusions (dendritic spikes), medium levels in neurons with expansive and complex arbors, and low or nondetectable Cut in neurons with simple dendrites. Loss of Cut reduced dendrite growth and class-specific terminal branching, whereas overexpression of Cut or a mammalian homolog in lower-level neurons resulted in transformations toward the branch morphology of high-Cut neurons. Thus, different levels of a homeoprotein can regulate distinct patterns of dendrite branching.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, Dept Biochem, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Jan, YN (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, Dept Biochem, 533 Parnassus Ave,Room U226, San Francisco, CA 94143 USA.	ynjan@itsa.ucsf.edu		Grueber, Wesley/0000-0001-6751-256X; Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299	NINDS NIH HHS [1R01 NS 40929-0, 1 F32 NS43027-01A1, T32 NS007067-23] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007067, F32NS043027, R01NS040929] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Beck JC, 2000, J NEUROSCI METH, V98, P155, DOI 10.1016/S0165-0270(00)00200-4; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; BREWSTER R, 1995, DEVELOPMENT, V121, P2923; Brewster R, 2001, MECH DEVELOP, V105, P57, DOI 10.1016/S0925-4773(01)00375-6; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; Burz DS, 1998, EMBO J, V17, P5998, DOI 10.1093/emboj/17.20.5998; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Gao FB, 1999, GENE DEV, V13, P2549, DOI 10.1101/gad.13.19.2549; Grueber WB, 2002, DEVELOPMENT, V129, P2867; Hausser M, 2000, SCIENCE, V290, P739, DOI 10.1126/science.290.5492.739; Huang ML, 2000, NEURON, V25, P57, DOI 10.1016/S0896-6273(00)80871-5; JACK JW, 1985, CELL, V42, P869, DOI 10.1016/0092-8674(85)90283-1; Jan YN, 2001, GENE DEV, V15, P2627, DOI 10.1101/gad.916501; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Kaminker JS, 2002, NAT NEUROSCI, V5, P746, DOI 10.1038/nn889; KOESTER SE, 1992, J NEUROSCI, V12, P1382; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lee TM, 2000, NEURON, V25, P307, DOI 10.1016/S0896-6273(00)80896-X; LIU S, 1991, GENETICS, V127, P151; Livet J, 2002, NEURON, V35, P877, DOI 10.1016/S0896-6273(02)00863-2; Ludlow C, 1996, DEV BIOL, V178, P149, DOI 10.1006/dbio.1996.0205; MacNeil MA, 1998, NEURON, V20, P971, DOI 10.1016/S0896-6273(00)80478-X; Merritt DJ, 1997, MICROSC RES TECHNIQ, V39, P492, DOI 10.1002/(SICI)1097-0029(19971215)39:6<492::AID-JEMT4>3.0.CO;2-G; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Quaggin SE, 1996, J BIOL CHEM, V271, P22624, DOI 10.1074/jbc.271.37.22624; Scott EK, 2001, NAT NEUROSCI, V4, P359, DOI 10.1038/86006; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; VALARCHE I, 1993, DEVELOPMENT, V119, P881; Vallstedt A, 2001, NEURON, V31, P743, DOI 10.1016/S0896-6273(01)00412-3; Vetter P, 2001, J NEUROPHYSIOL, V85, P926, DOI 10.1152/jn.2001.85.2.926; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; YOON SO, 1994, J BIOL CHEM, V269, P18453; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	47	226	231	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 21	2003	112	6					805	818		10.1016/S0092-8674(03)00160-0	http://dx.doi.org/10.1016/S0092-8674(03)00160-0			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	660DL	12654247	Bronze			2022-12-28	WOS:000181818500008
J	Stive, MJF; Reniers, AJHM				Stive, MJF; Reniers, AJHM			Geophysics: Sandbars in motion	SCIENCE			English	Editorial Material							COASTAL PROFILE EVOLUTION; SEDIMENT TRANSPORT; NORTH-CAROLINA; BEACH CUSPS; MODEL; NEARSHORE; WAVES; DUCK		Delft Univ Technol, Fac Civil Engn & Geosci, NL-2600 GA Delft, Netherlands; USN, Postgrad Sch, Monterey, CA 93943 USA	Delft University of Technology; United States Department of Defense; United States Navy; Naval Postgraduate School	Stive, MJF (corresponding author), Delft Univ Technol, Fac Civil Engn & Geosci, NL-2600 GA Delft, Netherlands.	m.j.f.stive@ct.tudelft.nl; areniers@nps.navy.mil						Ashton A, 2001, NATURE, V414, P296, DOI 10.1038/35104541; BAILARD JA, 1981, J GEOPHYS RES-OCEANS, V86, P938, DOI 10.1029/JC086iC11p10938; Bowen A., 1980, COASTLINE CANADA, P1; Coco G, 2000, J GEOPHYS RES-OCEANS, V105, P21991, DOI 10.1029/2000JC900095; Deigaard R, 1999, COAST ENG, V36, P171, DOI 10.1016/S0378-3839(99)00005-8; Drake TG, 2001, J GEOPHYS RES-OCEANS, V106, P19859, DOI 10.1029/2000JC000611; Elgar S, 2001, J GEOPHYS RES-OCEANS, V106, P4625, DOI 10.1029/2000JC000493; Elgar S, 2001, J GEOPHYS RES-OCEANS, V106, P11623, DOI 10.1029/2000JC000389; ELGAR S, 1988, J GEOPHYS RES-OCEANS, V93, P9261, DOI 10.1029/JC093iC08p09261; FALQUES A, 2000, J GEOPHYS RES, V105, P24701; Gallagher EL, 1998, J GEOPHYS RES-OCEANS, V103, P3203, DOI 10.1029/97JC02765; GUZA RT, 1975, J GEOPHYS RES-OC ATM, V80, P2997, DOI 10.1029/JC080i021p02997; Hoefel F, 2003, SCIENCE, V299, P1885, DOI 10.1126/science.1081448; Kessler MA, 2003, SCIENCE, V299, P380, DOI 10.1126/science.1077309; LIPPMANN TC, 1990, J GEOPHYS RES-OCEANS, V95, P11575, DOI 10.1029/JC095iC07p11575; ROELVINK JA, 1989, J GEOPHYS RES-OCEANS, V94, P4785, DOI 10.1029/JC094iC04p04785; Southgate HN, 2000, J GEOPHYS RES-OCEANS, V105, P11489, DOI 10.1029/2000JC900021; Thornton EB, 1996, J GEOPHYS RES-OCEANS, V101, P12097, DOI 10.1029/96JC00209; WERNER BT, 1993, SCIENCE, V260, P968, DOI 10.1126/science.260.5110.968; WRIGHT LD, 1984, MAR GEOL, V56, P93, DOI 10.1016/0025-3227(84)90008-2	20	13	14	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	2003	299	5614					1855	1856		10.1126/science.1082512	http://dx.doi.org/10.1126/science.1082512			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649472				2022-12-28	WOS:000181669700033
J	Laloe, F				Laloe, F			Obituary - Jean Brossel (1918-2003)	NATURE			English	Biographical-Item									ENS, Dept Phys, Lab Kastler Brossel, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; College de France; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS)	Laloe, F (corresponding author), ENS, Dept Phys, Lab Kastler Brossel, 24 Rue Lhomond, F-75005 Paris, France.			Laloe, Franck/0000-0003-0595-3647					0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					274	274		10.1038/422274a	http://dx.doi.org/10.1038/422274a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646909	Bronze			2022-12-28	WOS:000181637300028
J	Whitfield, J				Whitfield, J			Alien-hunters get scope to search	NATURE			English	News Item																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					249	249		10.1038/422249b	http://dx.doi.org/10.1038/422249b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646886	Bronze			2022-12-28	WOS:000181637300010
J	Kaniecki, R				Kaniecki, R			Headache assessment and management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TENSION-TYPE HEADACHE; AMERICAN MIGRAINE; UNITED-STATES; SUMATRIPTAN; POPULATION; EPIDEMIOLOGY; PREVALENCE; MEDICATION		Univ Pittsburgh, Dept Neurol, Headache Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kaniecki, R (corresponding author), Univ Pittsburgh, Dept Neurol, Headache Ctr, 120 Lytton Ave,Suite 300, Pittsburgh, PA 15213 USA.	kanieckirg@msx.upmc.edu						*AM AC NEUR, 2003, AAN ENC KIT HEAD; Bahra A, 2002, NEUROLOGY, V58, P354, DOI 10.1212/WNL.58.3.354; Barbanti P, 2002, CEPHALALGIA, V22, P256, DOI 10.1046/j.1468-2982.2002.00358.x; Bigal ME, 2000, HEADACHE, V40, P241, DOI 10.1046/j.1526-4610.2000.00035.x; Cady RK, 2000, CLIN THER, V22, P1035, DOI 10.1016/S0149-2918(00)80083-1; CARP H, 1994, ANESTH ANALG, V79, P180; DOWSON A, 2002, CEPHALALGIA, V22, P590; FRISHBERG BM, 2003, EVIDENCE BASED GUIDE; Halpern MT, 2002, HEADACHE, V42, P984, DOI 10.1046/j.1526-4610.2002.02228.x; Holroyd KA, 2001, JAMA-J AM MED ASSOC, V285, P2208, DOI 10.1001/jama.285.17.2208; Jensen Rigmor, 2001, Curr Treat Options Neurol, V3, P169, DOI 10.1007/s11940-001-0052-3; Kaniecki RG, 2002, NEUROLOGY, V58, pS15, DOI 10.1212/WNL.58.9_suppl_6.S15; Kaniecki RG, 2001, HEADACHE, V41, P862, DOI 10.1046/j.1526-4610.2001.01157.x; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Lipton RB, 2000, JAMA-J AM MED ASSOC, V284, P2599, DOI 10.1001/jama.284.20.2599; Lipton RB, 2001, HEADACHE, V41, P638, DOI 10.1046/j.1526-4610.2001.041007638.x; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; MAIZELS M, 2002, HEADACHE, V42, P416; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; ROSENBERG J, 1995, NEUROLOGY, V45, P1411; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; SCHREIBER C, 2002, ANN SCI M AM HEAD SO; Schwartz BS, 1998, JAMA-J AM MED ASSOC, V279, P381, DOI 10.1007/s11916-010-0146-2; Sheftell FD, 2002, HEADACHE, V42, P58, DOI 10.1046/j.1526-4610.2002.02015.x; Silberstein SD, 2000, NEUROLOGY, V55, P754, DOI 10.1212/WNL.55.6.754; Snow V, 2002, ANN INTERN MED, V137, P840, DOI 10.7326/0003-4819-137-10-200211190-00014; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Wiest FC, 2002, JAMA-J AM MED ASSOC, V288, P2609, DOI 10.1001/jama.288.20.2609	28	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	2003	289	11					1430	1433		10.1001/jama.289.11.1430	http://dx.doi.org/10.1001/jama.289.11.1430			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656PM	12636467				2022-12-28	WOS:000181616200036
J	Bosch, J; Garcia-Pagan, JC				Bosch, J; Garcia-Pagan, JC			Prevention of variceal rebleeding	LANCET			English	Review							PORTAL-HYPERTENSION; ISOSORBIDE MONONITRATE; PHARMACOLOGICAL THERAPY; ENDOSCOPIC LIGATION; PRESSURE RESPONSE; RANDOMIZED TRIAL; MEDICAL THERAPY; LA-CARTE; CIRRHOSIS; PROPRANOLOL	Context Variceal bleeding is the most frequent severe complication of portal hypertension and a leading cause of death and liver transplantation in patients with cirrhosis. Patients surviving a variceal bleed are at high risk of rebleeding (over 60% at 1 year). Portacaval shunts and transjugular intrahepatic portasystemic shunts (TIPS) are effective for prevention of rebleeding but carry a high risk of hepatic encephalopathy. Endoscopic techniques include band ligation (EBL) and injection. sclerotherapy (EIS). Drug approaches are based on non-selective beta blocker with or without isosorbide-5-mononitrate (ISMN). Starting point David Patch and colleagues (Gastroenterology 2002; 123: 1013-19) randomised 102 patients surviving a variceal bleeding to EBL or drug therapy with propranolol with the addition of ISMN if target reductions in portal pressure (evaluated by the hepatic venous pressure-gradient [HVPG]) were not achieved at 3 months. Overall, results of drug therapy were similar to those of EBL (44% vs 54% rebleeding at 1 year). There were no differences in survival or nonbleeding complications. Christophe Bureau and colleagues (Hepatoloy 2002; 36: 1361-66) treated 34 patients with cirrhosis and portal hypertension with propranolol and measured HVPG after a median of 4 days. Target HVPG reductions were achieved in 13 "responders". ISMN was added in the 21 "non-responders" and HVPG, measured again: seven more patients achieved target HPVG reduction. Re-bleeding rates were lower in responders than in nonresponders (10% vs 64%). Both studies suggest that drug therapy-can be improved by adding ISMN to b blockers in those patients with an insufficient decrease in HVPG. Where next? Long-term drug therapy is emerging as effective treatment for the prevention of variceal rebleeding. The role of HVPG monitoring as a guide to identifying patients requiring further treatment needs to be further evaluated. Trials to determine the best treatment for, patients who do not respond to drug therapies are also required.	Univ Barcelona, IDIBAPS, Hosp Clin,Inst Malalties Digest, Liver Unit,Hepat Haemodynam Lab, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bosch, J (corresponding author), Univ Barcelona, IDIBAPS, Hosp Clin,Inst Malalties Digest, Liver Unit,Hepat Haemodynam Lab, E-08036 Barcelona, Spain.		Bosch, Jaime/AAF-1006-2022; Bosch, Jaime/AFF-8344-2022; Garcia-Pagan, Juan-Carlos/P-6291-2015; Burroughs, Andrew K/C-5645-2009	Garcia-Pagan, Juan-Carlos/0000-0001-9032-4954; Burroughs, Andrew K/0000-0001-6527-457X				Bosch J, 2000, J HEPATOL, V32, P141, DOI 10.1016/S0168-8278(00)80422-5; Bosch J, 2002, HEPATOLOGY, V36, P1330, DOI 10.1053/jhep.2002.37354; Bureau C, 2002, HEPATOLOGY, V36, P1361, DOI 10.1053/jhep.2002.36945; Burroughs AK, 2002, SCAND J GASTROENTERO, V37, P249, DOI 10.1080/003655202317284138; D'Amico G, 1999, SEMIN LIVER DIS, V19, P475, DOI 10.1055/s-2007-1007133; DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145; de Franchis R, 2000, J HEPATOL, V33, P846; de Franchis R, 1999, SEMIN LIVER DIS, V19, P439, DOI 10.1055/s-2007-1007131; Escorsell A, 2000, HEPATOLOGY, V31, P1061, DOI 10.1053/he.2000.6779; Escorsell A, 2002, HEPATOLOGY, V35, P385, DOI 10.1053/jhep.2002.30418; FEU F, 1995, LANCET, V346, P1056, DOI 10.1016/S0140-6736(95)91740-3; Garcia-Pagan JC, 1999, SEMIN LIVER DIS, V19, P427, DOI 10.1055/s-2007-1007130; Garcia-Pagan JC, 2001, GASTROENTEROLOGY, V121, P908, DOI 10.1053/gast.2001.27993; GARCIAPAGAN JC, 1990, J HEPATOL, V11, P189, DOI 10.1016/0168-8278(90)90112-5; GARCIAPAGAN JC, 1991, ANN INTERN MED, V114, P869, DOI 10.7326/0003-4819-114-10-869; Gournay J, 2000, HEPATOLOGY, V31, P1239, DOI 10.1053/jhep.2000.8106; Groszmann RJ, 2002, GASTROENTEROLOGY, V123, P1388, DOI 10.1053/gast.2002.36364; GROSZMANN RJ, 1990, GASTROENTEROLOGY, V99, P1401, DOI 10.1016/0016-5085(90)91168-6; Gupta TK, 1998, HEPATOLOGY, V28, P926, DOI 10.1002/hep.510280405; Lo GH, 2000, HEPATOLOGY, V32, P461, DOI 10.1053/jhep.2000.16236; Patch D, 2002, GASTROENTEROLOGY, V123, P1013, DOI 10.1053/gast.2002.35955; Villanueva C, 1996, NEW ENGL J MED, V334, P1624, DOI 10.1056/NEJM199606203342502; Villanueva C, 2001, NEW ENGL J MED, V345, P647, DOI 10.1056/NEJMoa003223	23	257	280	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 15	2003	361	9361					952	954		10.1016/S0140-6736(03)12778-X	http://dx.doi.org/10.1016/S0140-6736(03)12778-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648985				2022-12-28	WOS:000181741600023
J	Burns, P; Gough, S; Bradbury, AW				Burns, P; Gough, S; Bradbury, AW			Management of peripheral arterial disease in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTERMITTENT CLAUDICATION; MYOCARDIAL-INFARCTION; EXERCISE; ANGIOPLASTY; THERAPY; SMOKING; DEATH; RISK; LONG	Best medical treatment for peripheral arterial disease, including managing hypertension and diabetes, reduces morbidity and mortality and can obviate the need for invasive intervention.	Univ Birmingham, Dept Vasc Surg, Birmingham B9 5SS, W Midlands, England; Univ Birmingham, Dept Med, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Bradbury, AW (corresponding author), Birmingham Heartlands Hosp, Univ Dept Vasc Surg, Lincoln House Res Inst, Bordesley Green E, Birmingham B9 5SS, W Midlands, England.							Abbot NC, 2000, COCHRANE DB SYST REV; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], J GEOPHYSICAL RES SO, V123, P2028, DOI [10.1002/2016jb013844, DOI 10.1002/2016JB013844, DOI 10.1002/14651858.CD002000]; BALSANO F, 1989, J LAB CLIN MED, V114, P84; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Dawson DL, 1999, AM J SURG, V178, P141, DOI 10.1016/S0002-9610(99)00147-6; *DIAB UK, 2002, DIAB UK POS STAT EAR; Dormandy J, 1999, Semin Vasc Surg, V12, P118; Dormandy J, 1999, Semin Vasc Surg, V12, P123; Elam MB, 1998, ARTERIOSCL THROM VAS, V18, P1942, DOI 10.1161/01.ATV.18.12.1942; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; GARDNER AW, 1995, JAMA-J AM MED ASSOC, V274, P975, DOI 10.1001/jama.274.12.975; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gerstein HC, 2000, LANCET, V355, P253; Gutteridge W, 1997, EUR J VASC ENDOVASC, V14, P134, DOI 10.1016/S1078-5884(97)80210-9; HAJEK P, 2000, COCHRANE DB SYST REV; HEINTZEN MP, 1994, EUR HEART J, V15, P2, DOI 10.1093/eurheartj/15.suppl_C.2; Hirsch A T, 1997, Vasc Med, V2, P243; Holm KJ, 2000, DRUGS, V59, P1007, DOI 10.2165/00003495-200059040-00019; JONASON T, 1987, ACTA MED SCAND, V221, P253; KLEIJNEN J, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000987; LENG GC, 1992, J CLIN EPIDEMIOL, V45, P1101, DOI 10.1016/0895-4356(92)90150-L; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; Leng GC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000990; LONDON NJM, 1994, EUR J VASCULAR SURG, V8, P148, DOI 10.1016/S0950-821X(05)80450-5; McCarthy RJ, 2000, BRIT J SURG, V87, P1361, DOI 10.1046/j.1365-2168.2000.01633.x; Money SR, 1998, J VASC SURG, V27, P267, DOI 10.1016/S0741-5214(98)70357-X; ORCHARD TJ, 1993, CIRCULATION, V88, P819, DOI 10.1161/01.CIR.88.2.819; Patterson RB, 1997, J VASC SURG, V25, P312, DOI 10.1016/S0741-5214(97)70352-5; Perkins JMT, 1996, EUR J VASC ENDOVASC, V11, P409, DOI 10.1016/S1078-5884(96)80171-7; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; Robless P, 2001, BRIT J SURG, V88, P787, DOI 10.1046/j.0007-1323.2001.01774.x; Shephard RJ, 1999, CIRCULATION, V99, P963, DOI 10.1161/01.CIR.99.7.963; SILAGY C, 2000, COCHRANE DB SYST REV; Stead LF, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001497.pub2, 10.1002/14651858.CD001007.pub2]; Stead LF, 2008, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000165.PUB3; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; TASC Working Group, 2000, EUR J VASC ENDOVASC, V19, pS1; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; UK Prospect Diabet Study Grp, 1999, BMJ-BRIT MED J, V318, P29; WHELTON PK, 1999, CLIN TRIALS CARDIOVA, P341; WHITE AR, 2000, COCHRANE DB SYST REV; Whyman MR, 1997, J VASC SURG, V26, P551, DOI 10.1016/S0741-5214(97)70052-1; Yusuf S, 2000, NEW ENGL J MED, V342, P145	46	103	109	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2003	326	7389					584	588		10.1136/bmj.326.7389.584	http://dx.doi.org/10.1136/bmj.326.7389.584			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657ZF	12637405	Green Published			2022-12-28	WOS:000181696600021
J	Prince, M; Acosta, D; Chiu, H; Scazufca, M; Varghese, M				Prince, M; Acosta, D; Chiu, H; Scazufca, M; Varghese, M		1066 Dementia Res Grp	Dementia diagnosis in developing countries: a cross-cultural validation study	LANCET			English	Article							INFORMANT QUESTIONNAIRE; ALZHEIMERS-DISEASE; COGNITIVE DECLINE; SCREENING INTERVIEW; ELDERLY IQCODE; GMS-AGECAT; PREVALENCE; VERSION; PERFORMANCE; EPIDEMIOLOGY	Background Research into dementia is needed in developing countries. Assessment of variations in disease frequency between regions might enhance our understanding of the disease, but methodological difficulties need to be addressed. We aimed to develop and test a culturally and educationally unbiased diagnostic instrument for dementia. Methods In a multicentre study, the 10/66 Dementia Research Group interviewed 2885 people aged 60 years and older in 25 centres, most in Universities, in India, China and southeast Asia, Latin America and the Caribbean, and Africa. 729 had dementia and three groups were free of dementia: 702 had depression, 694 had high education (as defined by each centre), and 760 had low education (as defined by each centre). Local clinicians diagnosed dementia and depression. An interviewer, masked to dementia diagnosis, administered the geriatric mental state, the community screening instrument for dementia, and the modified Consortium to Establish a Registry of Alzheimer's Disease (CERAD) ten-word list-learning task. Findings Each measure independently predicted a diagnosis of dementia. In an analysis of half the sample, an algorithm derived from all-three measures gave better results than any individual measure. Applied to the other half of the sample, this algorithm identified 94% of dementia cases with false-positive rates of 15%, 3%, and 6% in the depression, high education, and low education groups, respectively. I Interpretation Our algorithm is a sound basis for culturally and educationally sensitive dementia diagnosis in clinical and population-based research, supported by translations of its constituent measures into most languages used in the developing world.	Kings Coll London, Inst Psychiat, London SE5 8AF, England; Univ Nacl Pedro Henriquez Urena, Dept Psychiat, Santo Domingo, Dominican Rep; Chinese Univ Hong Kong, Dept Psychiat, Shatin, Hong Kong, Peoples R China; Univ Sao Paulo, Inst Psychiat, Sao Paulo, Brazil; Natl Inst Mental Hlth & Neurosci, Bangalore 560029, Karnataka, India	University of London; King's College London; Universidad Nacional Pedro Henriquez Urena; Chinese University of Hong Kong; Universidade de Sao Paulo; National Institute of Mental Health & Neurosciences - India	Prince, M (corresponding author), Kings Coll London, Inst Psychiat, De Crespigny Pk, London SE5 8AF, England.	m.prince@iop.kcl.ac.uk	Menezes, Paulo R/C-9985-2010; Domingos, Neide M/E-5209-2012; Scazufca, Marcia/K-7418-2012; Prince, Martin J/A-9170-2010; Varghese, Mathew/AAG-8341-2019; Dewey, Michael E/E-2049-2010; Rodriguez, Juan J Llibre/D-2380-2010; Menezes, Paulo/AAM-3529-2021	Menezes, Paulo R/0000-0001-6330-3314; Domingos, Neide M/0000-0002-9001-4283; Prince, Martin J/0000-0003-1379-7146; Varghese, Mathew/0000-0001-5670-5710; Dewey, Michael E/0000-0002-7522-3677; Rodriguez, Juan J Llibre/0000-0002-8215-3160; Menezes, Paulo/0000-0001-6330-3314; Scazufca, Marcia/0000-0002-4545-006X				AnzolaPerez E, 1996, INT J GERIATR PSYCH, V11, P429, DOI 10.1002/(SICI)1099-1166(199605)11:5<429::AID-GPS324>3.0.CO;2-2; BLAND RC, 1988, ACTA PSYCHIAT SCAND, V77, P57, DOI 10.1111/j.1600-0447.1988.tb08548.x; BROE GA, 1976, J NEUROL NEUROSUR PS, V39, P362, DOI 10.1136/jnnp.39.4.362; CHANDRA V, 1994, AGING-CLIN EXP RES, V6, P307, DOI 10.1007/BF03324258; COPELAND JRM, 1991, EUR ARCH PSY CLIN N, V240, P212, DOI 10.1007/BF02189529; COPELAND JRM, 1987, BRIT J PSYCHIAT, V150, P815, DOI 10.1192/bjp.150.6.815; COPELAND JRM, 1986, PSYCHOL MED, V16, P89, DOI 10.1017/S0033291700057779; Copeland JRM, 1999, BRIT J PSYCHIAT, V174, P312, DOI 10.1192/bjp.174.4.312; FUH JL, 1995, NEUROLOGY, V45, P92, DOI 10.1212/WNL.45.1.92; GANGULI M, 1995, INT J GERIATR PSYCH, V10, P367, DOI 10.1002/gps.930100505; Ganguli M, 1996, Int Psychogeriatr, V8, P507, DOI 10.1017/S1041610296002852; GOODGLASS H, 1983, ASSESSMENT DYSPHASIA; Hall KS, 2000, INT J GERIATR PSYCH, V15, P521, DOI 10.1002/1099-1166(200006)15:6<521::AID-GPS182>3.0.CO;2-F; HALL KS, 1993, INT J METHOD PSYCH, V3, P1; HENDERSON AS, 1993, PSYCHOL MED, V23, P719, DOI 10.1017/S0033291700025496; Hendrie H C, 1993, Int Psychogeriatr, V5, P5, DOI 10.1017/S1041610293001358; HENDRIE HC, 1995, AM J PSYCHIAT, V152, P1485; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; KRAL VA, 1989, CAN J PSYCHIAT, V34, P445, DOI 10.1177/070674378903400515; LAW S, 1995, BRIT J PSYCHIAT, V167, P541, DOI 10.1192/bjp.167.4.541; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; MORALES JM, 1995, ALZ DIS ASSOC DIS, V9, P105, DOI 10.1097/00002093-199509020-00008; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Prince M, 2000, INT J GERIATR PSYCH, V15, P14, DOI 10.1002/(SICI)1099-1166(200001)15:1<14::AID-GPS70>3.0.CO;2-8; Prince M, 2000, INT J GERIATR PSYCH, V15, P21, DOI 10.1002/(SICI)1099-1166(200001)15:1<21::AID-GPS71>3.0.CO;2-5; Rajkumar S, 1997, INT J GERIATR PSYCH, V12, P702, DOI 10.1002/(SICI)1099-1166(199707)12:7<702::AID-GPS489>3.0.CO;2-H; RITCHIE K, 1992, J CLIN EPIDEMIOL, V45, P627, DOI 10.1016/0895-4356(92)90135-A; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; WEISSMAN MM, 1988, PSYCHOL MED, V18, P141, DOI 10.1017/S0033291700001975; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609	30	391	413	4	47	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	2003	361	9361					909	917		10.1016/S0140-6736(03)12772-9	http://dx.doi.org/10.1016/S0140-6736(03)12772-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648969				2022-12-28	WOS:000181741600008
J	Fruchter, O; Dragu, R				Fruchter, O; Dragu, R			A deadly examination	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NIH, Bethesda, MD 20892 USA; Rambam Med Ctr, IL-31096 Haifa, Israel	National Institutes of Health (NIH) - USA; Rambam Health Care Campus; Technion Israel Institute of Technology	Fruchter, O (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.								0	24	25	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					1016	1016		10.1056/NEJMicm020803	http://dx.doi.org/10.1056/NEJMicm020803			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653YT	12637611				2022-12-28	WOS:000181465200006
J	Blount, JD; Metcalfe, NB; Birkhead, TR; Surai, PF				Blount, JD; Metcalfe, NB; Birkhead, TR; Surai, PF			Carotenoid modulation of immune function and sexual attractiveness in zebra finches	SCIENCE			English	Article							BEAK COLOR; SIGNALS; IMMUNOCOMPETENCE; PIGMENTATION; EXPRESSION; FITNESS	One hypothesis for why females in many animal species frequently prefer to mate with the most elaborately ornamented males predicts that availability of carotenoid pigments is a potentially limiting factor for both ornament expression and immune function. An implicit assumption of this hypothesis is that males that can afford to produce more elaborate carotenoid-dependent displays must be healthier individuals with superior immunocompetence. However, whether variation in circulating carotenoid levels causes variation in both immune function and sexual attractiveness has not been determined in any species. In this study, we show that manipulation of dietary carotenoid supply invokes parallel changes in cell-mediated immune function and sexual attractiveness in male zebra finches (Taeniopygia guttata).	Univ Glasgow, Inst Biomed & Life Sci, Div Environm & Evolutionary Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; Scottish Agr Coll, Avian Sci Res Ctr, Auchincruive KA6 5HW, Ayr, Scotland	University of Glasgow; University of Sheffield; Scottish Agricultural College	Blount, JD (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Environm & Evolutionary Biol, Glasgow G12 8QQ, Lanark, Scotland.	j.blount@bio.gla.ac.uk	Surai, Peter/T-6183-2019; Blount, Jonathan/K-7695-2012; Metcalfe, Neil B./C-5997-2009	Blount, Jonathan/0000-0002-0016-0130; Metcalfe, Neil B./0000-0002-1970-9349; Surai, Peter/0000-0002-5012-8681				Andersson Malte, 1994; Birkhead TR, 1999, P ROY SOC B-BIOL SCI, V266, P385, DOI 10.1098/rspb.1999.0649; BURLEY N, 1987, ETHOLOGY, V76, P133; Chew BP, 1996, ANIM FEED SCI TECH, V59, P103, DOI 10.1016/0377-8401(95)00891-8; Collins SA, 1996, ANIM BEHAV, V52, P105, DOI 10.1006/anbe.1996.0156; COLLINS SA, 1994, BEHAV ECOL SOCIOBIOL, V35, P21, DOI 10.1007/s002650050065; DeKogel CH, 1996, ANIM BEHAV, V51, P699, DOI 10.1006/anbe.1996.0073; Gonzalez G, 1999, J ANIM ECOL, V68, P1225, DOI 10.1046/j.1365-2656.1999.00364.x; GRAFEN A, 1990, J THEOR BIOL, V144, P517, DOI 10.1016/S0022-5193(05)80088-8; HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238; Hill GE, 2000, J AVIAN BIOL, V31, P559, DOI 10.1034/j.1600-048X.2000.310415.x; HILL GE, 1992, AUK, V109, P1; Hill GE, 1999, AM NAT, V154, P589, DOI 10.1086/303264; HOUTMAN AM, 1992, P ROY SOC B-BIOL SCI, V249, P3, DOI 10.1098/rspb.1992.0075; HUDON J, 1994, AUK, V111, P218, DOI 10.2307/4088529; KODRICBROWN A, 1989, BEHAV ECOL SOCIOBIOL, V25, P393, DOI 10.1007/BF00300185; LOZANO GA, 1994, OIKOS, V70, P309, DOI 10.2307/3545643; MCCORKLE F, 1980, POULTRY SCI, V59, P616, DOI 10.3382/ps.0590616; McGraw KJ, 2000, P ROY SOC B-BIOL SCI, V267, P1525, DOI 10.1098/rspb.2000.1174; McGraw KJ, 2002, COMP BIOCHEM PHYS B, V132, P811, DOI 10.1016/S1096-4959(02)00100-8; McGraw KJ, 2001, PHYSIOL BIOCHEM ZOOL, V74, P843, DOI 10.1086/323797; Moller AP, 2000, AVIAN POULT BIOL REV, V11, P137; Olson VA, 1998, TRENDS ECOL EVOL, V13, P510, DOI 10.1016/S0169-5347(98)01484-0; Stahl W., 1999, ANTIOXIDANT FOOD SUP, P183; von Schantz T, 1999, P ROY SOC B-BIOL SCI, V266, P1, DOI 10.1098/rspb.1999.0597; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	26	521	528	2	175	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					125	127		10.1126/science.1082142	http://dx.doi.org/10.1126/science.1082142			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677066				2022-12-28	WOS:000181988900047
J	Demaurex, N; Distelhorst, C				Demaurex, N; Distelhorst, C			Apoptosis - the calcium connection	SCIENCE			English	Editorial Material							ENDOPLASMIC-RETICULUM; CA2+ CONCENTRATION; MITOCHONDRIA; BAX; BCL-2; MICRODOMAINS; EXPRESSION; RELEASE; SIGNALS; DRIVEN		Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva, Switzerland; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA	University of Geneva; Case Western Reserve University	Demaurex, N (corresponding author), Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva, Switzerland.	nicolas.demaurex@medecine.unige.ch; cwd@cwru.edu		Demaurex, Nicolas/0000-0002-9933-6772				Arnaudeau S, 2002, J BIOL CHEM, V277, P46696, DOI 10.1074/jbc.M202395200; Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hajnoczky G, 2002, CELL CALCIUM, V32, P363, DOI 10.1016/S0143416002001872; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108	23	277	295	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					65	67		10.1126/science.1083628	http://dx.doi.org/10.1126/science.1083628			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677047				2022-12-28	WOS:000181988900025
J	Dolan, JF; Christofferson, SA; Shaw, JH				Dolan, JF; Christofferson, SA; Shaw, JH			Recognition of paleoearthquakes on the Puente Hills blind thrust fault, California	SCIENCE			English	Article							SAN-ANDREAS FAULT; LOS-ANGELES; EARTHQUAKES	Borehole data from young sediments folded above the Puente Hills blind thrust fault beneath Los Angeles reveal that the folding extends to the surface as a discrete zone (less than or equal to145 meters wide). Buried fold scarps within an upward-narrowing zone of deformation, which extends from the upward termination of the thrust ramp at 3 kilometers depth to the surface, document the occurrence of at least four large (moment-magnitude 7.2 to 7.5) earthquakes on this fault during the past 11,000 years. Future events of this type pose a seismic hazard to metropolitan Los Angeles. Moreover, the methods developed in this study can be used to re. ne seismic hazard assessments of blind thrusts in other metropolitan regions.	Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	University of Southern California; Harvard University	Dolan, JF (corresponding author), Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA.	dolan@earth.usc.edu						Blatt H., 1980, ORIGIN SEDIMENTARY R; DOLAN JF, 1995, SCIENCE, V267, P199, DOI 10.1126/science.267.5195.199; DOLAN JF, 1998, GEOL SOC AM ABSTR, V30, P12; Gumprecht B., 1999, ANGELES RIVER ITS LI, V2001st ed.; Novoa E, 2000, AAPG BULL, V84, P787; PRATT TL, 2002, GEOPHYS RES LETT, V29; Schneider CL, 1996, TECTONICS, V15, P341, DOI 10.1029/95TC02523; SCHWARTZ DP, 1984, J GEOPHYS RES, V89, P5681, DOI 10.1029/JB089iB07p05681; SHAW JH, 1994, GEOL SOC AM BULL, V106, P607, DOI 10.1130/0016-7606(1994)106<0607:AFAGFI>2.3.CO;2; Shaw JH, 1999, SCIENCE, V283, P1516, DOI 10.1126/science.283.5407.1516; Shaw JH, 2002, B SEISMOL SOC AM, V92, P2946, DOI 10.1785/0120010291; SIEH KE, 1978, J GEOPHYS RES, V83, P3907, DOI 10.1029/JB083iB08p03907; SUPPE J, 1992, THRUST TECTONICS, P105; WELLS DL, 1994, B SEISMOL SOC AM, V84, P974	14	77	82	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2003	300	5616					115	118		10.1126/science.1080593	http://dx.doi.org/10.1126/science.1080593			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677063				2022-12-28	WOS:000181988900044
J	Meier, P; Genoud, N; Prinz, M; Maissen, M; Rulicke, T; Zurbriggen, A; Raeber, AJ; Aguzzi, A				Meier, P; Genoud, N; Prinz, M; Maissen, M; Rulicke, T; Zurbriggen, A; Raeber, AJ; Aguzzi, A			Soluble dimeric prion protein binds PrPSc in vivo and antagonizes prion disease	CELL			English	Article							MICE; RESISTANT; PROPAGATION; FORM; REPLICATION; INFECTIVITY; CONVERSION; VARIANT; STRAIN; DOMAIN	Conversion of cellular prion protein (PrPc) into a pathological conformer (PrPSc) is thought to be promoted by PrPSc in a poorly understood process. Here, we report that in wild-type mice, the expression of PrPC rendered soluble and dimeric by fusion to immunoglobulin Fcgamma (PrP-Fc(2)) delays PrPSc accumulation, agent replication, and onset of disease following inoculation with infective prions. In infected PrP-expressing brains, PrP-Fc(2) relocates to lipid rafts and associates with PrPSc without acquiring protease resistance, indicating that PrP-Fc(2) resists conversion. Accordingly, mice expressing PrP-Fc(2) but lacking endogenous PrPc are resistant to scrapie, do not accumulate PrP-Fc(2)(Sc), and do not transmit disease to others. These results indicate that various PrP isoforms engage in a complex in vivo, whose distortion by PrP-Fc(2) affects prion propagation and scrapie pathogenesis. The unique properties of PrP-Fc(2) suggest that soluble PrP derivatives may represent a new class of prion replication antagonists.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich, Inst Lab Anim Sci, CH-8091 Zurich, Switzerland; Univ Bern, Inst Anim Neurol, CH-3012 Bern, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University of Bern	Aguzzi, A (corresponding author), Univ Zurich Hosp, Inst Neuropathol, Schmelzbergstr, CH-8091 Zurich, Switzerland.	adriano@pathol.unizh.ch	Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Aguzzi A, 2001, NAT REV NEUROSCI, V2, P745, DOI 10.1038/35094590; AGUZZI A, 2003, IN PRESS ADV IMMUNOL; Behrens A, 2002, TRENDS NEUROSCI, V25, P150, DOI 10.1016/S0166-2236(00)02089-0; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; CARLSON GA, 1994, P NATL ACAD SCI USA, V91, P5690, DOI 10.1073/pnas.91.12.5690; DOHERTY P, 1995, NEURON, V14, P57, DOI 10.1016/0896-6273(95)90240-6; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; Gatti JL, 2002, BIOL REPROD, V67, P393, DOI 10.1095/biolreprod67.2.393; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; Kaeser PS, 2001, J VIROL, V75, P7097, DOI 10.1128/JVI.75.15.7097-7106.2001; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LANSBURY PT, 1994, SCIENCE, V265, P1510, DOI 10.1126/science.8079159; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; LUND J, 1991, J IMMUNOL, V147, P2657; Mabbott NA, 2000, NAT MED, V6, P719, DOI 10.1038/77401; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; Maissen M, 2001, LANCET, V357, P2026, DOI 10.1016/S0140-6736(00)05110-2; Montrasio F, 2000, SCIENCE, V288, P1257, DOI 10.1126/science.288.5469.1257; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Parizek P, 2001, J BIOL CHEM, V276, P44627, DOI 10.1074/jbc.M107458200; Perini F, 1996, BIOCHEM BIOPH RES CO, V223, P572, DOI 10.1006/bbrc.1996.0936; Perrier V, 2002, P NATL ACAD SCI USA, V99, P13079, DOI 10.1073/pnas.182425299; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P2793, DOI 10.1073/pnas.90.7.2793; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SAILER A, 1994, CELL, V77, P967, DOI 10.1016/0092-8674(94)90436-7; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; TAGLIAVINI F, 1992, BIOCHEM BIOPH RES CO, V184, P1398, DOI 10.1016/S0006-291X(05)80038-5; TAO MH, 1993, J EXP MED, V178, P661, DOI 10.1084/jem.178.2.661; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0	46	105	113	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	2003	113	1					49	60		10.1016/S0092-8674(03)00201-0	http://dx.doi.org/10.1016/S0092-8674(03)00201-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679034	Bronze			2022-12-28	WOS:000182282900006
J	Vijan, S; Hayward, RA				Vijan, S; Hayward, RA			Treatment of hypertension in type 2 diabetes mellitus: Blood pressure goals, choice of agents, and setting priorities in diabetes care	ANNALS OF INTERNAL MEDICINE			English	Article							CONVERTING ENZYME-INHIBITION; IMPAIRED GLUCOSE-TOLERANCE; CORONARY-HEART-DISEASE; MIDDLE-AGED PATIENTS; STAGE RENAL-DISEASE; CARDIOVASCULAR MORBIDITY; RANDOMIZED-TRIAL; GLYCEMIC CONTROL; KIDNEY-FUNCTION; MICROVASCULAR COMPLICATIONS	Background: Hypertension in patients with type 2 diabetes mellitus is a prevalent condition that leads to substantial morbidity and mortality. Purpose: To evaluate the goals and optimal agents for treatment of hypertension in type 2 diabetes. Data Sources: Review of the medical literature Study Selection: Randomized trials that evaluated the pharmacologic treatment of hypertension in patients with diabetes and reported microvascular and macrovascular outcomes. Data Extraction: Studies were identified by using the Cochrane Library, MEDLINE, meta-analyses, review articles, and expert recommendation. The searches of the Cochrane Library and MEDLINE were performed in May 2000 and updated in April 2002. Data were abstracted to standardized forms by a single reviewer and were confirmed by a second reviewer. Data Synthesis: Treatment of hypertension in type 2 diabetes provides dramatic benefit. Target diastolic blood pressures of less than 80 mm Hg appear optimal; systolic targets have not been as rigorously evaluated, but targets of 135 mm Hg or less are reasonable. Studies that compare drug classes do not suggest obviously superior agents. However, it is reasonable to conclude that thiazide diuretics, angiotensin-II receptor blockers, and perhaps angiotensin-converting enzyme (ACE) inhibitors may be the preferred first-line agents for treatment of hypertension in diabetes. beta-Blockers and calcium-channel blockers are more effective than placebo, but they may not be as effective as diuretics, angiotensin-II receptor blockers, or ACE inhibitors; however, study results are inconsistent in this regard. Conclusions: Treatment of hypertension in type 2 diabetes, with blood pressure goals of 135/80 mm Hg, provides dramatic benefits. Thiazide diuretics, angiotensin II receptor blockers, and ACE inhibitors may be the best first-line treatments, although other agents are usually necessary and goals may not be achieved even with three or four agents. Aggressive blood pressure control may be the most important factor in preventing adverse outcomes in patients with type 2 diabetes.	Univ Michigan, Dev Ctr Practice Management & Outcomes Res, Vet Affairs Hlth Serv Res & Dev, Ann Arbor, MI 48113 USA; Michigan Diabet Res & Training Ctr, Ann Arbor, MI USA	University of Michigan System; University of Michigan	Vijan, S (corresponding author), Univ Michigan, Dev Ctr Practice Management & Outcomes Res, Vet Affairs Hlth Serv Res & Dev, POB 130170, Ann Arbor, MI 48113 USA.	svijan@umich.edu						Agardh CD, 1996, J HUM HYPERTENS, V10, P185; Ahmad J, 1997, DIABETES CARE, V20, P1576, DOI 10.2337/diacare.20.10.1576; ANDERSSON DKG, 1995, DIABETES CARE, V18, P1534, DOI 10.2337/diacare.18.12.1534; ANDERSSON OK, 1991, J INTERN MED, V229, P89; BERNE C, 1991, DIABETES CARE, V14, P39, DOI 10.2337/diacare.14.4.39; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; DEGRAUW WJC, 1995, DIABETIC MED, V12, P117; DOYLE AE, 1991, BRIT MED J, V302, P210; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Eastman RC, 1997, DIABETES CARE, V20, P725, DOI 10.2337/diacare.20.5.725; Elliott W J, 2000, Curr Hypertens Rep, V2, P402, DOI 10.1007/s11906-000-0045-8; Estacio RO, 2000, DIABETES CARE, V23, pB54; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; FULLER J, 2000, COCHRANE DB SYST REV; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; Gerstein HC, 2000, LANCET, V355, P253; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Harris EL, 1999, DIABETES CARE, V22, P779, DOI 10.2337/diacare.22.5.779; Harris M I, 1990, Clin Geriatr Med, V6, P703; HARRIS MI, 1991, DIABETES CARE, V14, P639, DOI 10.2337/diacare.14.7.639; HARRIS MI, 1990, DIABETES METAB REV, V6, P71, DOI 10.1002/dmr.5610060202; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; Kerr EA, 2001, AM J MANAG CARE, V7, P1033; Klag MJ, 1997, JAMA-J AM MED ASSOC, V277, P1293, DOI 10.1001/jama.277.16.1293; KLEINMAN JC, 1988, AM J EPIDEMIOL, V128, P389, DOI 10.1093/oxfordjournals.aje.a114979; KROLEWSKI AS, 1977, DIABETOLOGIA, V13, P345, DOI 10.1007/BF01223277; Laakso M, 1996, ANN INTERN MED, V124, P127, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00009; LACOURCIERE Y, 1993, HYPERTENSION, V21, P786, DOI 10.1161/01.HYP.21.6.786; Lacourciere Y, 2000, KIDNEY INT, V58, P762, DOI 10.1046/j.1523-1755.2000.00224.x; LANGFORD HG, 1990, J HUM HYPERTENS, V4, P491; LEBOVITZ HE, 1994, KIDNEY INT, V45, pS150; Lehto S, 1997, DIABETES, V46, P1354, DOI 10.2337/diabetes.46.8.1354; Lehto S, 1996, STROKE, V27, P63, DOI 10.1161/01.STR.27.1.63; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lindholm LH, 2000, J HYPERTENS, V18, P1671, DOI 10.1097/00004872-200018110-00020; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; LOVELL HG, 1998, ARE ANGIOTENSIN CONV, P3; Meigs JB, 1997, AM J MED, V102, P38, DOI 10.1016/S0002-9343(96)00383-X; MORRISH NJ, 1991, DIABETOLOGIA, V34, P584, DOI 10.1007/BF00400278; Nielsen FS, 1997, DIABETES, V46, P1182, DOI 10.2337/diabetes.46.7.1182; *NIH NAT I DIAB DI, 1995, DIAB AM; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Pinol C, 1996, KIDNEY INT, pS85; Ravid M, 1998, ANN INTERN MED, V128, P982, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00004; Ravid M, 1996, ARCH INTERN MED, V156, P286, DOI 10.1001/archinte.156.3.286; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; Ray NF, 1998, DIABETES CARE, V21, P296; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; Sano T, 1996, DIABETIC MED, V13, P120, DOI 10.1002/(SICI)1096-9136(199602)13:2<120::AID-DIA6>3.0.CO;2-F; Schnack C, 1996, DIABETOLOGIA, V39, P1611, DOI 10.1007/s001250050623; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Staessen JA, 2001, LANCET, V358, P1305, DOI 10.1016/S0140-6736(01)06411-X; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Velussi M, 1996, DIABETES, V45, P216, DOI 10.2337/diabetes.45.2.216; Vijan S, 1997, ANN INTERN MED, V127, P788, DOI 10.7326/0003-4819-127-9-199711010-00003; Wang JG, 2000, ARCH INTERN MED, V160, P211, DOI 10.1001/archinte.160.2.211; Welch HG, 1996, ANN INTERN MED, V124, P577, DOI 10.7326/0003-4819-124-6-199603150-00007; WINGARD DL, 1993, DIABETES CARE, V16, P1022, DOI 10.2337/diacare.16.7.1022; Yusuf S, 2000, NEW ENGL J MED, V342, P145	72	170	173	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					593	602		10.7326/0003-4819-138-7-200304010-00018	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00018			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667032				2022-12-28	WOS:000181872100011
J	Hafner, SD				Hafner, SD			Is fertilization efficiency misleading?	NATURE			English	Article									SUNY Coll Environm Sci & Forestry, Dept Environm & Forest Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) College of Environmental Science & Forestry	Hafner, SD (corresponding author), SUNY Coll Environm Sci & Forestry, Dept Environm & Forest Biol, Syracuse, NY 13210 USA.		Hafner, Sasha/N-3970-2013	Hafner, Sasha/0000-0003-0955-0327				Case Karl E., 1996, PRINCIPLES MICROECON; SRAFFA P, 1951, WORKS CORRES D RICAR, V3; Sraffa P., 1951, WORKS CORRES D RICAR, VIV; Tilman D, 2002, NATURE, V418, P671, DOI 10.1038/nature01014	4	2	2	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					397	398		10.1038/422397a	http://dx.doi.org/10.1038/422397a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660773				2022-12-28	WOS:000181801200034
J	Leibfried, D; DeMarco, B; Meyer, V; Lucas, D; Barrett, M; Britton, J; Itano, WM; Jelenkovic, B; Langer, C; Rosenband, T; Wineland, DJ				Leibfried, D; DeMarco, B; Meyer, V; Lucas, D; Barrett, M; Britton, J; Itano, WM; Jelenkovic, B; Langer, C; Rosenband, T; Wineland, DJ			Experimental demonstration of a robust, high-fidelity geometric two ion-qubit phase gate	NATURE			English	Article							QUANTUM; STATE; IONS; DECOHERENCE	Universal logic gates for two quantum bits (qubits) form an essential ingredient of quantum computation. Dynamical gates have been proposed(1,2) in the context of trapped ions; however, geometric phase gates (which change only the phase of the physical qubits) offer potential practical advantages because they have higher intrinsic resistance to certain small errors and might enable faster gate implementation. Here we demonstrate a universal geometric pi-phase gate between two beryllium ion-qubits, based on coherent displacements induced by an optical dipole force. The displacements depend on the internal atomic states; the motional state of the ions is unimportant provided that they remain in the regime in which the force can be considered constant over the extent of each ion's wave packet. By combining the gate with single-qubit rotations, we have prepared ions in an entangled Bell state with 97% fidelity-about six times better than in a previous experiment(3) demonstrating a universal gate between two ion-qubits. The particular properties of the gate make it attractive for a multiplexed trap architecture(4,5) that would enable scaling to large numbers of ionqubits.	Natl Inst Stand & Technol, Time & Frequency Div, Boulder, CO 80305 USA; Univ Colorado, Dept Phys, Boulder, CO 80309 USA; Univ Oxford, Dept Phys, Oxford OX1 3PU, England; Inst Phys, YU-11001 Belgrade, Serbia	National Institute of Standards & Technology (NIST) - USA; University of Colorado System; University of Colorado Boulder; University of Oxford; University of Belgrade	Wineland, DJ (corresponding author), Natl Inst Stand & Technol, Time & Frequency Div, 325 Broadway, Boulder, CO 80305 USA.	david.wineland@boulder.nist.gov	Barrett, Murray D/G-2732-2012; Jelenkovic, Brana/AAE-8831-2020; Itano, Wayne/AAV-8781-2020	Barrett, Murray D/0000-0002-1483-8029; Britton, Joe/0000-0001-8103-7347; DeMarco, Brian/0000-0002-2791-0413				CARRUTHERS P, 1965, AM J PHYS, V33, P537, DOI 10.1119/1.1971895; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; Cirac JI, 2000, NATURE, V404, P579, DOI 10.1038/35007021; DeVoe RG, 1998, PHYS REV A, V58, P910, DOI 10.1103/PhysRevA.58.910; Kielpinski D, 2002, NATURE, V417, P709, DOI 10.1038/nature00784; King BE, 1998, PHYS REV LETT, V81, P1525, DOI 10.1103/PhysRevLett.81.1525; Milburn GJ, 2000, FORTSCHR PHYS, V48, P801, DOI 10.1002/1521-3978(200009)48:9/11<801::AID-PROP801>3.0.CO;2-1; Monroe C, 1996, SCIENCE, V272, P1131, DOI 10.1126/science.272.5265.1131; Roos C, 1999, PHYS REV LETT, V83, P4713, DOI 10.1103/PhysRevLett.83.4713; Rowe MA, 2002, QUANTUM INF COMPUT, V2, P257; Rowe MA, 2001, NATURE, V409, P791, DOI 10.1038/35057215; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Steane A, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.042305; STEANE AM, 2002, QUANTPH0207119; Walls D. F., 1994, QUANTUM OPT; Wang XG, 2001, PHYS REV LETT, V86, P3907, DOI 10.1103/PhysRevLett.86.3907; WINELAND DJ, QUANTPH0212079	22	852	866	5	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 27	2003	422	6930					412	415		10.1038/nature01492	http://dx.doi.org/10.1038/nature01492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660778				2022-12-28	WOS:000181801200039
J	Azam, M; Latek, RR; Daley, GQ				Azam, M; Latek, RR; Daley, GQ			Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL	CELL			English	Article							CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TYROSINE KINASE; C-ABL; CLINICAL RESISTANCE; BLAST CRISIS; SH3 DOMAINS; INTRAMOLECULAR INTERACTIONS; REGULATORY DOMAINS	The Bcr-Abl fusion protein kinase causes chronic myeloid leukemia and is targeted by the signal transduction inhibitor STI-571/Gleevec/imatinib (STI-571). Sequencing of the BCR-ABL gene in patients who have relapsed after STI-571 chemotherapy has revealed a limited set of kinase domain mutations that mediate drug resistance. To obtain a more comprehensive survey of the amino acid substitutions that confer STI-571 resistance, we performed an in vitro screen of randomly mutagenized BCR-ABL and recovered all of the major mutations previously identified in patients and numerous others that illuminate novel mechanisms of acquired drug resistance. Structural modeling implies that a novel class of variants acts allosterically to destabilize the autoinhibited conformation of the ABL kinase to which STI-571 preferentially binds' This screening strategy is a paradigm applicable to a growing list of target-directed anti-cancer agents and provides a means of anticipating the drug-resistant amino acid substitutions that are likely to be clinically problematic.	Whitehead Inst, Cambridge, MA 02142 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute	Daley, GQ (corresponding author), Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	daley@wi.mit.edu			NATIONAL CANCER INSTITUTE [R01CA086991, R29CA076418] Funding Source: NIH RePORTER; NCI NIH HHS [CA76418, CA86991] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Bradshaw JM, 2000, J MOL BIOL, V299, P521; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Brasher BB, 2001, ONCOGENE, V20, P7744, DOI 10.1038/sj.onc.1204978; CICCHETTI P, 1995, EMBO J, V14, P3127, DOI 10.1002/j.1460-2075.1995.tb07315.x; Corbin AS, 2002, J BIOL CHEM, V277, P32214, DOI 10.1074/jbc.M111525200; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Emini EA, 1995, ADV EXP MED BIOL, V390, P187; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Hochhaus A, 2001, SCIENCE, V293, P2163; Hofmann WK, 2002, BLOOD, V99, P1860, DOI 10.1182/blood.V99.5.1860; Hoover RR, 2002, BLOOD, V100, P1068, DOI 10.1182/blood.V100.3.1068; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; KANTARJIAN HM, 2002, BLOOD, V29, P29; Koh EY, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf142; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Nagar B, 2002, CANCER RES, V62, P4236; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nam HJ, 1996, STRUCTURE, V4, P1105, DOI 10.1016/S0969-2126(96)00116-5; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Panni S, 2002, J BIOL CHEM, V277, P21666, DOI 10.1074/jbc.M109788200; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VANETTEN RA, 1995, ONCOGENE, V10, P1977; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wisniewski D, 2002, CANCER RES, V62, P4244; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4	47	517	541	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2003	112	6					831	843		10.1016/S0092-8674(03)00190-9	http://dx.doi.org/10.1016/S0092-8674(03)00190-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	660DL	12654249	Bronze			2022-12-28	WOS:000181818500010
J	Schiermeier, Q				Schiermeier, Q			NATO reform promises more publicity for less science	NATURE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					248	248		10.1038/422248b	http://dx.doi.org/10.1038/422248b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646885	Bronze			2022-12-28	WOS:000181637300008
J	Vermeer, PD; Einwalter, LA; Moniger, TO; Rokhlina, T; Kern, JA; Zabner, J; Welsh, MJ				Vermeer, PD; Einwalter, LA; Moniger, TO; Rokhlina, T; Kern, JA; Zabner, J; Welsh, MJ			Segregation of receptor and ligand regulates activation of epithelial growth factor receptor	NATURE			English	Article							CELL POLARITY; EXPRESSION; LUNG; PRECURSOR	Interactions between ligands and receptors are central to communication between cells and tissues. Human airway epithelia constitutively produce both a ligand, the growth factor heregulin, and its receptors-erbB2, erbB3 and erbB4 (refs 1-3). Although heregulin binding initiates cellular proliferation and differentiation(8), airway epithelia have a low rate of cell division(8). This raises the question of how ligand-receptor interactions are controlled in epithelia. Here we show that in differentiated human airway epithelia, heregulin-alpha is present exclusively in the apical membrane and the overlying airway surface liquid, physically separated from erbB2-4, which segregate to the basolateral membrane. This physical arrangement creates a ligand-receptor pair poised for activation whenever epithelial integrity is disrupted. Indeed, immediately following a mechanical injury, heregulin-alpha activates erbB2 in cells at the edge of the wound, and this process hastens restoration of epithelial integrity. Likewise, when epithelial cells are not separated into apical and basolateral membranes ('polarized'), or when tight Junctions between adjacent cells are opened, heregulin-alpha activates its receptor. This mechanism of ligand-receptor segregation on either side of epithelial tight junctions may be vital for rapid restoration of integrity following injury, and hence critical for survival. This model also suggests a mechanism for abnormal receptor activation in diseases with increased epithelial permeability.	Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Roy J & Lucille A Carver Coll Med, Cent Microscopy Res Facil, Iowa City, IA 52242 USA; Roy J & Lucille A Carver Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Howard Hughes Medical Institute; University Hospitals of Cleveland	Zabner, J (corresponding author), Roy J & Lucille A Carver Coll Med, Dept Internal Med, Iowa City, IA 52242 USA.	joseph-zabner@uiowa.edu; michael-weish@uiowa.edu	Vermeer, Paola D/O-2572-2013	Welsh, Michael/0000-0002-1646-6206; Kern, Jeffrey/0000-0001-9709-9622; Zabner, Joseph/0000-0002-9606-1339				Aguilar Z, 2001, J BIOL CHEM, V276, P44099, DOI 10.1074/jbc.M103442200; AIDA S, 1994, RESPIRATION, V61, P161; Al Moustafa AE, 1999, ANTICANCER RES, V19, P481; Campiglio M, 1999, J CELL BIOCHEM, V73, P522, DOI 10.1002/(SICI)1097-4644(19990615)73:4<522::AID-JCB10>3.0.CO;2-4; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Godfrey RWA, 1997, MICROSC RES TECHNIQ, V38, P488, DOI 10.1002/(SICI)1097-0029(19970901)38:5<488::AID-JEMT5>3.0.CO;2-E; Goto Y, 2000, AM J RESP CELL MOL, V23, P712, DOI 10.1165/ajrcmb.23.6.4031; Karp Philip H, 2002, Methods Mol Biol, V188, P115; KENNEDY SM, 1984, AM REV RESPIR DIS, V129, P143; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; SOBONYA RE, 1986, AM REV RESPIR DIS, V134, P290; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Walker RA, 1998, J PATHOL, V185, P234, DOI 10.1002/(SICI)1096-9896(199807)185:3<234::AID-PATH128>3.0.CO;2-8; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; Wang GS, 1998, J VIROL, V72, P9818, DOI 10.1128/JVI.72.12.9818-9826.1998; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	19	287	304	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	2003	422	6929					322	326		10.1038/nature01440	http://dx.doi.org/10.1038/nature01440			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646923				2022-12-28	WOS:000181637300042
J	Grayburn, PA; Hillis, LD				Grayburn, PA; Hillis, LD			Cardiac events in patients undergoing noncardiac surgery: Shifting the paradigm from noninvasive risk stratification to therapy	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CORONARY-ARTERY-DISEASE; DIPYRIDAMOLE-THALLIUM SCINTIGRAPHY; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; ABDOMINAL AORTIC-ANEURYSM; MAJOR VASCULAR-SURGERY; 8 COMMON OPERATIONS; PREOPERATIVE ASSESSMENT; MYOCARDIAL-INFARCTION; SURGICAL VOLUME; PREDICTION	Internists and cardiologists are often asked to estimate the risk for perioperative myocardial infarction or cardiac death in patients being considered for noncardiac surgery. Estimating this risk in an individual patient is difficult and complex. Although noninvasive imaging tests are often used for this purpose, a review of the literature reveals that the positive predictive value of noninvasive imaging tests is uniformly low and that they do not provide information beyond that obtained by assessing simple clinical risk variables. Moreover, no evidence exists that noninvasive imaging tests lead to a therapeutic strategy that reduces the risk for perioperative myocardial infarction or cardiac death. Since the publication of guidelines for preoperative risk stratification by the American College of Cardiology American Heart Association in 1996 and the American College of Physicians in 1997, three clinical trials have shown that 13-blocker therapy reduces the risk for perioperative cardiac events. This paper focuses on the relationship between risk stratification and subsequent therapy to minimize or eliminate risk. In short, the paradigm is shifting from predicting which patient is at high risk for having a perioperative cardiac event to minimizing the likelihood of such an event with specific perioperative pharmacologic therapy.	Univ Texas, SW Med Ctr, Dallas, TX USA; Vet Affairs Med Ctr, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Grayburn, PA (corresponding author), Baylor Heart & Vasc Inst, 3500 Gaston Ave, Dallas, TX 75246 USA.				NHLBI NIH HHS [K24-HL03980] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL003980] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Afridi I, 1998, AM J CARDIOL, V82, P564, DOI 10.1016/S0002-9149(98)00398-1; Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206; BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; Bodenheimer MM, 1996, ANN INTERN MED, V124, P763, DOI 10.7326/0003-4819-124-8-199604150-00010; Boersma E, 2001, JAMA-J AM MED ASSOC, V285, P1865, DOI 10.1001/jama.285.14.1865; Brittenden J, 1999, BRIT J SURG, V86, P206, DOI 10.1046/j.1365-2168.1999.01027.x; BROWN KA, 1993, J AM COLL CARDIOL, V21, P325, DOI 10.1016/0735-1097(93)90670-V; BRY JDL, 1994, J VASC SURG, V19, P112, DOI 10.1016/S0741-5214(94)70126-1; Cohen MC, 1999, CARDIOVASC PATHOL, V8, P133, DOI 10.1016/S1054-8807(98)00032-5; CRAWFORD ES, 1978, ANN THORAC SURG, V26, P215, DOI 10.1016/S0003-4975(10)63673-9; CUTLER BS, 1987, J VASC SURG, V5, P91, DOI 10.1067/mva.1987.avs0050091; Das MK, 2000, J AM COLL CARDIOL, V35, P1647, DOI 10.1016/S0735-1097(00)00586-6; Dawood MM, 1996, INT J CARDIOL, V57, P37, DOI 10.1016/S0167-5273(96)02769-6; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; Eagle KA, 1997, CIRCULATION, V96, P1882, DOI 10.1161/01.CIR.96.6.1882; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; Eagle KA, 1996, J AM COLL CARDIOL, V27, P910; FLEISHER LA, 1994, ANESTH ANALG, V79, P661; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HENDEL RC, 1992, AM J CARDIOL, V70, P1243, DOI 10.1016/0002-9149(92)90756-O; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; ISKANDRIAN AS, 1991, AM J CARDIOL, V68, P674, DOI 10.1016/0002-9149(91)90363-P; Kaluza GL, 2000, J AM COLL CARDIOL, V35, P1288, DOI 10.1016/S0735-1097(00)00521-0; Khuri SF, 1999, ANN SURG, V230, P429; Khuri SF, 1999, ANN SURG, V230, P414, DOI 10.1097/00000658-199909000-00014; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Lee TH, 1999, NEW ENGL J MED, V341, P1838, DOI 10.1056/NEJM199912093412410; LETTE J, 1992, AM J CARDIOL, V69, P1553, DOI 10.1016/0002-9149(92)90702-Z; Makaroun MS, 1999, J VASC SURG, V29, P306; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; Mangano DT, 1995, NEW ENGL J MED, V333, P1750, DOI 10.1056/NEJM199512283332607; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MASON JJ, 1995, JAMA-J AM MED ASSOC, V273, P1919, DOI 10.1001/jama.273.24.1919; MASSIE BM, 1993, CIRCULATION, V87, P1752, DOI 10.1161/01.CIR.87.5.1752; MASSIE BM, 1993, J AM COLL CARDIOL, V21, P1353, DOI 10.1016/0735-1097(93)90308-N; MCNEILL AJ, 1992, AM J CARDIOL, V70, P41, DOI 10.1016/0002-9149(92)91387-J; Moore WS, 1999, ANN SURG, V230, P298, DOI 10.1097/00000658-199909000-00003; NIELSEN JL, 1992, AM J SURG, V164, P423, DOI 10.1016/S0002-9610(05)81173-0; Palda VA, 1997, ANN INTERN MED, V127, P313, DOI 10.7326/0003-4819-127-4-199708150-00012; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012; Pearce WH, 1999, J VASC SURG, V29, P768, DOI 10.1016/S0741-5214(99)70202-8; POLDERMANS D, 1995, J AM COLL CARDIOL, V26, P648, DOI 10.1016/0735-1097(95)00240-5; POLDERMANS D, 1993, CIRCULATION, V87, P1506, DOI 10.1161/01.CIR.87.5.1506; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; RABY KE, 1992, JAMA-J AM MED ASSOC, V268, P222, DOI 10.1001/jama.268.2.222; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; REUL GJ, 1986, J VASC SURG, V3, P788, DOI 10.1067/mva.1986.avs0030788; Roghi A, 1999, AM J CARDIOL, V83, P169, DOI 10.1016/S0002-9149(98)00819-4; Sawyer W, 1999, J VASC SURG, V29, P777; Vanzetto G, 1996, AM J CARDIOL, V77, P143, DOI 10.1016/S0002-9149(96)90585-8; Veith FJ, 1999, ANN SURG, V230, P306; WILSON R, 1987, SCIENCE, V236, P267, DOI 10.1126/science.3563505; YOUNIS L, 1994, AM J CARDIOL, V74, P311, DOI 10.1016/0002-9149(94)90395-6; YOUNIS LT, 1990, AM HEART J, V119, P1287, DOI 10.1016/S0002-8703(05)80177-2; ZARET BL, 1993, NEW ENGL J MED, V329, P775, DOI 10.1056/NEJM199309093291107; Zarins CK, 1999, J VASC SURG, V29, P292, DOI 10.1016/S0741-5214(99)70382-4	57	95	100	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					506	511		10.7326/0003-4819-138-6-200303180-00017	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00017			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639086				2022-12-28	WOS:000181562400010
J	Sterling, TR; Lehmann, HP; Frieden, TR				Sterling, TR; Lehmann, HP; Frieden, TR			Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	97th International Conference of the American-Thoracic-Society	MAY 18-23, 2001	SAN FRANCISCO, CA	Amer Thorac Soc			SHORT-COURSE CHEMOTHERAPY; DRUG-RESISTANCE	Objective This study sought to determine the impact of the World Health Organization's tuberculosis treatment strategy (DOTS) compared with that of DOTS-plus on tuberculosis deaths, mainly in the developing world. Design Decision analysis with Monte Carlo simulation of a Markov decision tree. Data sources People with smear positive pulmonary tuberculosis. Data analysis Analyses modelled different levels of programme effectiveness of DOTS and DOTS-plus, and high (10%) and intermediate (3%) proportions of primary multidrug resistant tuberculosis, while accounting for exogenous reinfection. Main outcome measure The cumulative number of tuberculosis deaths per 100 000 population over 10 years. Results The model predicted that under DOTS, 276 people would die from tuberculosis (24 multidrug resistant and 252 not multidrug resistant) over 10 years under optimal implementation in an area with 3% primary multidrug resistant tuberculosis. Optimal implementation of DOTS-plus would result in four (1.5%) fewer deaths. If implementation of DOTS-plus were to result in a decrease of just 5% in the effectiveness of DOTS, 16% more people would die with tuberculosis than under DOTS alone. In an area with 10% primary multidrug resistant tuberculosis, 10% fewer deaths would occur under optimal DOTS-plus than under optimal DOTS, but 16% more deaths would occur if implementation of DOTS-plus were to result in a 5% decrease in the effectiveness of DOTS Conclusions Under optimal implementation, fewer tuberculosis deaths would occur under DOTS-plus than under DOTS. If, however, implementation of DOTS-plus Were associated with even minimal decreases in the effectiveness of treatment, substantially more patients would die than under DOTS.	Johns Hopkins Univ, Ctr TB Res, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Hlth Sci Informat, Baltimore, MD 21287 USA; New York City Dept Hlth, New York, NY 10013 USA	Johns Hopkins University; Johns Hopkins University; New York City Department of Health & Mental Hygiene	Sterling, TR (corresponding author), Johns Hopkins Univ, Ctr TB Res, 424 N Bond St, Baltimore, MD 21231 USA.	tsterls@jhmi.edu		Lehmann, Harold/0000-0002-7698-219X; Frieden, Thomas/0000-0002-4759-2256	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001654] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01654, K23 AI001654] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; DROLET G. J., 1938, American Review of Tuberculosis and Pulmonary Diseases, V37, P125; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Espinal MA, 1999, INT J TUBERC LUNG D, V3, P561; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861; Khatri GR, 2000, INT J TUBERC LUNG D, V4, P193; Kim HJ, 2001, INT J TUBERC LUNG D, V5, P1129; Lambregts-van Weezenbeek KSB, 2000, INT J TUBERC LUNG D, V4, P995; Ledru S, 1996, TUBERCLE LUNG DIS, V77, P429, DOI 10.1016/S0962-8479(96)90116-1; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; Narayanan PR, 2001, INT J TUBERC LUNG D, V5, P40; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Spellman CW, 1998, AIDS, V12, P191, DOI 10.1097/00002030-199802000-00009; Styblo K, 1980, Adv Tuberc Res, V20, P1; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; SULLIVAN EA, 1995, LANCET, V345, P1148, DOI 10.1016/S0140-6736(95)90980-X; Tahaoglu K, 2001, NEW ENGL J MED, V345, P170, DOI 10.1056/NEJM200107193450303; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; Thompson BC, 1943, BRIT MED J, V1943, P721, DOI 10.1136/bmj.2.4326.721; *WHO, 1999, WHOTB99259; *WHO, 2000, WHOCDSTB2000175; WHO, 2001, REP M GROUND LARV BL; *WHO, 2000, JOINT TUB PROGR REV; World Health Organization, 1997, WHOCDSTB97220; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1	30	45	47	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2003	326	7389					574	577		10.1136/bmj.326.7389.574	http://dx.doi.org/10.1136/bmj.326.7389.574			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	657ZF	12637401	Bronze, Green Published			2022-12-28	WOS:000181696600017
J	Haug, GH; Gunther, D; Peterson, LC; Sigman, DM; Hughen, KA; Aeschlimann, B				Haug, GH; Gunther, D; Peterson, LC; Sigman, DM; Hughen, KA; Aeschlimann, B			Climate and the collapse of Maya civilization	SCIENCE			English	Article							CLASSIC MAYA; HOLOCENE; HISTORY	In the anoxic Cariaco Basin of the southern Caribbean, the bulk titanium content of undisturbed sediment reflects variations in riverine input and the hydrological cycle over northern tropical South America. A seasonally resolved record of titanium shows that the collapse of Maya civilization in the Terminal Classic Period occurred during an extended regional dry period, punctuated by more intense multiyear droughts centered at approximately 810, 860, and 910 A.D. These new data suggest that a century-scale decline in rainfall put a general strain on resources in the region, which was then exacerbated by abrupt drought events, contributing to the social stresses that led to the Maya demise.	Swiss Fed Inst Technol, Dept Earth Sci, CH-8092 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Chem, CH-8092 Zurich, Switzerland; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Miami; Princeton University; Woods Hole Oceanographic Institution	Haug, GH (corresponding author), Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany.		Sigman, Daniel M/A-2649-2008	Sigman, Daniel M/0000-0002-7923-1973				ADAMS REW, 1991, SCIENCE, V251, P632, DOI 10.1126/science.251.4994.632; Anderson, 1996, GEOLOGICAL SOC SPECI, V116, P171, DOI [10.1144/GSL.SP.1996.116.01.15, DOI 10.1144/GSL.SP.1996.116.01.15]; Baker PA, 2001, SCIENCE, V291, P640, DOI 10.1126/science.291.5504.640; BRADBURY JP, 1981, SCIENCE, V214, P1299, DOI 10.1126/science.214.4527.1299; Culbert T.P., 1990, PRECOLUMBIAN POPULAT; deMenocal PB, 2001, SCIENCE, V292, P667, DOI 10.1126/science.1059827; Gill Richardson, 2000, GREAT MAYA DROUGHTS; Haug GH, 2001, SCIENCE, V293, P1304, DOI 10.1126/science.1059725; Hodell DA, 2001, SCIENCE, V292, P1367, DOI 10.1126/science.1057759; HODELL DA, 1995, NATURE, V375, P391, DOI 10.1038/375391a0; HODELL DA, 1991, NATURE, V352, P790, DOI 10.1038/352790a0; KARLEN W, 1984, CLIMATIC CHANGES YEA; Lucero LJ, 2002, AM ANTHROPOL, V104, P814, DOI 10.1525/aa.2002.104.3.814; Peterson LC, 1991, PALEOCEANOGRAPHY, V6, P99, DOI 10.1029/90PA02497; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; SCARBOROUGH VL, 1994, RES EXPLOR, V10, P184; Sharer Robert J., 1994, ANCIENT MAYA; Sigurdsson H., 1997, PROC OCEAN DRILL INI, V165, P359; Webster David, 2002, FALL ANCIENT MAYA	19	631	679	5	248	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1731	1735		10.1126/science.1080444	http://dx.doi.org/10.1126/science.1080444			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	654WM	12637744				2022-12-28	WOS:000181519500045
J	Rolison, DR				Rolison, DR			Catalytic nanoarchitectures - The importance of nothing and the unimportance of periodicity	SCIENCE			English	Review							METHANOL OXIDATION; POROUS MATERIALS; FUEL-CELLS; CARBON; ELECTROCATALYSTS; AEROGELS; CHEMISTRY; SOL	Heterogeneous catalysis has always been an inherently nanoscopic phenomenon with important technological and societal consequences for energy conversion and the production of chemicals. New opportunities for improved performance arise when the multifunctionality inherent in catalytic processes, including molecular transport of reactants and products, is rethought in light of architectures designed and fabricated from the appropriate nanoscale building blocks, including the use of "nothing" (void space) and deliberate disorder as design components. Architectures with all of the appropriate electrochemical and catalytic requirements, including large surface areas readily accessible to molecules, may now be assembled on the benchtop. Designing catalytic nanoarchitectures that depart from the hegemony of periodicity and order offers the promise of even higher activity.	USN, Res Lab, Adv Electrochem Mat Sect, Washington, DC 20375 USA	United States Department of Defense; United States Navy; Naval Research Laboratory	Rolison, DR (corresponding author), USN, Res Lab, Adv Electrochem Mat Sect, Code 6171, Washington, DC 20375 USA.	rolison@nrl.navy.mil		Rolison, Debra/0000-0003-0493-9931				Anderson ML, 2000, ADV ENG MATER, V2, P481, DOI 10.1002/1527-2648(200008)2:8<481::AID-ADEM481>3.0.CO;2-O; Anderson ML, 2002, NANO LETT, V2, P235, DOI [10.1021/nl015707d, 10.1021/n1015707d]; Bond GC, 1999, CATAL REV, V41, P319, DOI 10.1081/CR-100101171; Brinker C.J., 1990, SOL GEL SCI, DOI [10.1016/B978-0-08-057103-4.50013-1, DOI 10.1016/C2009-0-22386-5]; BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801; Chen NY., 1994, MOL TRANSPORT REACTI; Davis ME, 2002, NATURE, V417, P813, DOI 10.1038/nature00785; Dmowski W, 2002, J PHYS CHEM B, V106, P12677, DOI 10.1021/jp026228l; Forster S, 1998, ADV MATER, V10, P195, DOI 10.1002/(SICI)1521-4095(199802)10:3<195::AID-ADMA195>3.0.CO;2-V; Hulteen JC, 1997, J MATER CHEM, V7, P1075, DOI 10.1039/a700027h; Husing N, 1998, ANGEW CHEM INT EDIT, V37, P23, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<22::AID-ANIE22>3.0.CO;2-I; KORESH J, 1977, J ELECTROCHEM SOC, V124, P1379, DOI 10.1149/1.2133657; LEVER ABP, 1999, ELECT STRUCTURE SPEC, V1, P1; Long JW, 2000, J PHYS CHEM B, V104, P9772, DOI 10.1021/jp001954e; Lu ZL, 2002, CHEM REV, V102, P3543, DOI 10.1021/cr010358t; Markovic NM, 2002, SURF SCI REP, V45, P121, DOI 10.1016/S0167-5729(01)00022-X; MCBREEN J, 1981, J APPL ELECTROCHEM, V11, P787, DOI 10.1007/BF00615184; Morris CA, 1999, SCIENCE, V284, P622, DOI 10.1126/science.284.5414.622; Mukerjee S, 2002, ELECTROCHIM ACTA, V47, P3219, DOI 10.1016/S0013-4686(02)00242-6; Pierre AC, 2002, CHEM REV, V102, P4243, DOI 10.1021/cr0101306; Pietron JJ, 2002, NANO LETT, V2, P545, DOI 10.1021/nl025536s; POCARD NL, 1992, J MATER CHEM, V2, P771, DOI 10.1039/jm9920200771; Polarz S, 2002, CHEM COMMUN, P2593, DOI 10.1039/b205708p; Rolison DR, 2001, J MATER CHEM, V11, P963, DOI 10.1039/b007591o; Schmidt-Winkel P, 2000, CHEM MATER, V12, P686, DOI 10.1021/cm991097v; SCHNEIDER M, 1995, CATAL REV, V37, P515, DOI 10.1080/01614949508006450; Schuth F, 2001, CHEM MATER, V13, P3184, DOI 10.1021/cm011030j; Service RF, 1999, SCIENCE, V285, P682, DOI 10.1126/science.285.5428.682; SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603; Stroud RA, 2002, MICROSC MICROANAL, V8, P50, DOI [10.1017/S1431927602010097, 10.1017/51431927601010091]; Swider KE, 1996, J ELECTROCHEM SOC, V143, P813, DOI 10.1149/1.1836542; Swider-Lyons K., 2002, 2002 ANN PROGR REPOR, P413; Templeton AC, 2000, ACCOUNTS CHEM RES, V33, P27, DOI 10.1021/ar9602664; Toshima N, 2001, APPL ORGANOMET CHEM, V15, P178, DOI 10.1002/aoc.146.abs; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Ye SY, 1997, CAN J CHEM, V75, P1666, DOI 10.1139/v97-198; Ying JY, 1999, ANGEW CHEM INT EDIT, V38, P56, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<56::AID-ANIE56>3.0.CO;2-E	37	909	925	5	411	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	2003	299	5613					1698	1701		10.1126/science.1082332	http://dx.doi.org/10.1126/science.1082332			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637736				2022-12-28	WOS:000181519500035
J	Wang, J; Neaton, JB; Zheng, H; Nagarajan, V; Ogale, SB; Liu, B; Viehland, D; Vaithyanathan, V; Schlom, DG; Waghmare, UV; Spaldin, NA; Rabe, KM; Wuttig, M; Ramesh, R				Wang, J; Neaton, JB; Zheng, H; Nagarajan, V; Ogale, SB; Liu, B; Viehland, D; Vaithyanathan, V; Schlom, DG; Waghmare, UV; Spaldin, NA; Rabe, KM; Wuttig, M; Ramesh, R			Epitaxial BiFeO3 multiferroic thin film heterostructures	SCIENCE			English	Article							PEROVSKITE; FERROELECTRICITY; FERROMAGNETISM; POLARIZATION; CRYSTAL	Enhancement of polarization and related properties in heteroepitaxially constrained thin films of the ferroelectromagnet, BiFeO3, is reported. Structure analysis indicates that the crystal structure of film is monoclinic in contrast to bulk, which is rhombohedral. The films display a room-temperature spontaneous polarization (50 to 60 microcoulombs per square centimeter) almost an order of magnitude higher than that of the bulk (6.1 microcoulombs per square centimeter). The observed enhancement is corroborated by first-principles calculations and found to originate from a high sensitivity of the polarization to small changes in lattice parameters. The films also exhibit enhanced thickness-dependent magnetism compared with the bulk. These enhanced and combined functional responses in thin film form present an opportunity to create and implement thin film devices that actively couple the magnetic and ferroelectric order parameters.	Univ Maryland, Dept Phys, College Pk, MD 20742 USA; Univ Maryland, Dept Mat Sci & Engn, College Pk, MD 20742 USA; Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA; Virginia Polytech Inst & State Univ, Dept Mat Sci & Engn, Blacksburg, VA 24061 USA; Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India; Univ Calif Santa Barbara, Dept Mat, Santa Barbara, CA 94805 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; Rutgers State University New Brunswick; Virginia Polytechnic Institute & State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); University of California System; University of California Santa Barbara	Ramesh, R (corresponding author), Univ Maryland, Dept Phys, College Pk, MD 20742 USA.	rrl36@umail.umd.edu	Spaldin, Nicola A/A-1017-2010; Schlom, Darrell G/J-2412-2013; valanoor, nagarajan/B-4159-2012; Ramesh, Ramamoorthy/ABI-4883-2020; Neaton, Jeffrey/F-8578-2015; WANG, Junling/B-3596-2009	Spaldin, Nicola A/0000-0003-0709-9499; Schlom, Darrell G/0000-0003-2493-6113; valanoor, nagarajan/0000-0003-2534-5868; Neaton, Jeffrey/0000-0001-7585-6135; WANG, Junling/0000-0003-3663-7081; Zheng, Haimei/0000-0003-3813-4170				BUCCI JD, 1972, J APPL CRYSTALLOGR, V5, P187, DOI 10.1107/S0021889872009173; dos Santos AM, 2002, SOLID STATE COMMUN, V122, P49, DOI 10.1016/S0038-1098(02)00087-X; EOM CB, 1992, SCIENCE, V258, P1766, DOI 10.1126/science.258.5089.1766; Fiebig M, 2002, NATURE, V419, P818, DOI 10.1038/nature01077; Filippetti A, 2001, J MAGN MAGN MATER, V236, P176, DOI 10.1016/S0304-8853(01)00445-0; Gonze X, 2002, COMP MATER SCI, V25, P478, DOI 10.1016/S0927-0256(02)00325-7; HAUN MJ, 1989, FERROELECTRICS, V99, P63, DOI 10.1080/00150198908221440; Hill NA, 1999, PHYS REV B, V59, P8759, DOI 10.1103/PhysRevB.59.8759; KINGSMITH RD, 1993, PHYS REV B, V47, P1651, DOI 10.1103/PhysRevB.47.1651; Kiselev SV, 1963, SOV PHYS DOKL, V7, P742; Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169; KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558; Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758; KUBEL F, 1990, ACTA CRYSTALLOGR B, V46, P698, DOI 10.1107/S0108768190006887; Kumar MM, 1998, J MAGN MAGN MATER, V188, P203, DOI 10.1016/S0304-8853(98)00167-X; MICHEL C, 1969, SOLID STATE COMMUN, V7, P701, DOI 10.1016/0038-1098(69)90597-3; Pertsev NA, 1998, PHYS REV LETT, V80, P1988, DOI 10.1103/PhysRevLett.80.1988; RAJARAM HG, 1991, THESIS PENNSYLVANIA; Reague J. R., 1970, SOLID STATE COMMUN, V8, P1073; ROGINSKAYA YE, 1966, ZH EKSP TEOR FIZ, V23, P47; Salje E. K. H., 1990, PHASE TRANSITIONS FE; Seshadri R, 2001, CHEM MATER, V13, P2892, DOI 10.1021/cm010090m; Smolenskii G. A., 1982, Soviet Physics - Uspekhi, V25, P475, DOI 10.1070/PU1982v025n07ABEH004570; Ueda K, 1999, APPL PHYS LETT, V75, P555, DOI 10.1063/1.124420; VANDERBILT D, 1993, PHYS REV B, V48, P4442, DOI 10.1103/PhysRevB.48.4442; ZHONG W, 1994, PHYS REV LETT, V72, P3618, DOI 10.1103/PhysRevLett.72.3618	26	5113	5284	93	2712	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	2003	299	5613					1719	1722		10.1126/science.1080615	http://dx.doi.org/10.1126/science.1080615			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637741	Green Accepted			2022-12-28	WOS:000181519500041
J	Sakai, Y; Atsumi, T; Itoh, T; Koike, T				Sakai, Y; Atsumi, T; Itoh, T; Koike, T			Uveitis, pancarditis, haemophagocytosis, and abdominal masses	LANCET			English	Editorial Material							ROSAI-DORFMAN-DISEASE; SINUS HISTIOCYTOSIS; LYMPHADENOPATHY		Hokkaido Univ, Sch Med, Dept Med 2, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ Hosp, Dept Surg Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University	Atsumi, T (corresponding author), Hokkaido Univ, Sch Med, Dept Med 2, Kita Ku, N15 W7, Sapporo, Hokkaido 0608638, Japan.		Atsumi, Tatsuya/G-1739-2012					FOUCAR E, 1990, SEMIN DIAGN PATHOL, V7, P19; PAULLI M, 1992, HUM PATHOL, V23, P647, DOI 10.1016/0046-8177(92)90320-3; Pulsoni A, 2002, AM J HEMATOL, V69, P67, DOI 10.1002/ajh.10008; ROSAI J, 1969, ARCH PATHOL, V87, P63; WRIGHT DH, 1981, HISTOPATHOLOGY, V5, P697, DOI 10.1111/j.1365-2559.1981.tb01836.x	5	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					834	834		10.1016/S0140-6736(03)12711-0	http://dx.doi.org/10.1016/S0140-6736(03)12711-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642051				2022-12-28	WOS:000181466600013
J	Knapp, S; Mallet, J				Knapp, S; Mallet, J			Refuting refugia?	SCIENCE			English	Editorial Material							RAIN-FOREST; SOUTH-AMERICA; DIVERSIFICATION; CONSERVATION; SPECIATION; BIRDS		Nat Hist Museum, Dept Bot, London SW7 5BD, England; UCL, Dept Biol, London NW1 2HE, England	Natural History Museum London; University of London; University College London	Knapp, S (corresponding author), Nat Hist Museum, Dept Bot, Cromwell Rd, London SW7 5BD, England.	s.knapp@nhm.ac.uk; j.mallet@ucl.ac.uk	mallet, james L.B./B-5114-2008; Knapp, Sandra/A-4856-2011	Knapp, Sandra/0000-0001-7698-3945; Mallet, James/0000-0002-3370-0367				BEVEN S, 1984, J BIOGEOGR, V11, P383, DOI 10.2307/2844803; Brower AVZ, 1997, P ROY SOC B-BIOL SCI, V264, P969, DOI 10.1098/rspb.1997.0134; Colinvaux PA, 2001, AMAZONIANA, V16, P609; FJELDSA J, 1994, BIODIVERS CONSERV, V3, P207, DOI 10.1007/BF00055939; GENTRY AH, 1982, ANN MO BOT GARD, V69, P557, DOI 10.2307/2399084; HAFFER J, 1969, SCIENCE, V165, P131, DOI 10.1126/science.165.3889.131; Haffer J, 2001, AMAZONIANA, V16, P579; Hooghiemstra H, 2001, AMAZONIANA, V16, P653; Moritz C, 2000, ANNU REV ECOL SYST, V31, P533, DOI 10.1146/annurev.ecolsys.31.1.533; Richardson JE, 2001, SCIENCE, V293, P2242, DOI 10.1126/science.1061421; Thomas WW, 1999, BIODIVERS CONSERV, V8, P1007, DOI 10.1023/A:1008857429787	11	62	68	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2003	300	5616					71	72		10.1126/science.1083007	http://dx.doi.org/10.1126/science.1083007			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677050				2022-12-28	WOS:000181988900028
J	Thompson, PD; Clarkson, P; Karas, RH				Thompson, PD; Clarkson, P; Karas, RH			Statin-associated myopathy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY-DISEASE; COA REDUCTASE INHIBITORS; LIPID-LOWERING THERAPY; SERUM UBIQUINONE CONCENTRATIONS; COENZYME-A REDUCTASE; SMOOTH-MUSCLE-CELLS; LONG-TERM SAFETY; CHOLESTEROL LEVELS; ANGIOGRAPHIC RESTENOSIS; METABOLIC INTERACTIONS	Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with skeletal muscle complaints, including clinically important myositis and rhabdomyolysis, mild serum creatine kinase (CK) elevations, myalgia with and without elevated CK levels, muscle weakness, muscle cramps, and persistent myalgia and CK elevations after statin withdrawal. We performed a literature review to provide a clinical summary of statin-associated myopathy and discuss possible mediating mechanisms. We also update the US Food and Drug Administration (FDA) reports on statin-associated rhabdomyolysis. Articles on statin myopathy were identified via a PubMed search through November 2002 and articles on statin clinical trials, case series, and review articles were identified via a PubMed search through January 2003. Adverse event reports of statin-associated rhabdomyolysis were also collected from the FDA MEDWATCH database. The literature review found that reports of muscle problems during statin clinical trials are extremely rare. The FDA MEDWATCH Reporting System lists 3339 cases of statin-associated rhabdomyolysis reported between January 1, 1990, and March 31, 2002. Cerivastatin was the most commonly implicated statin. Few data are available regarding the frequency of less-serious events such as muscle pain and weakness, which may affect 1% to 5% of patients. The risk of rhabdomyolysis and other adverse effects with statin use can be exacerbated by several factors, including compromised hepatic and renal function, hypothyroidism, diabetes, and concomitant medications. Medications such as the fibrate gemfibrozil alter statin metabolism and increase statin plasma concentration. How statins injure skeletal muscle is not clear, although recent evidence suggests that statins reduce the production of small regulatory proteins that are important for myocyte maintenance.	Hartford Hosp, Div Cardiol, Hartford, CT 06102 USA; Univ Connecticut, Dept Med, Farmington, CT 06032 USA; Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Amherst, MA 01003 USA; Univ Massachusetts, Dept Exercise Sci, Amherst, MA 01003 USA; Tufts Univ, Sch Med, Tufts New England Med Ctr, Dept Med, Boston, MA 02111 USA	Hartford Hospital; University of Connecticut; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; Tufts Medical Center; Tufts University	Thompson, PD (corresponding author), Hartford Hosp, Div Cardiol, 80 Seymour St, Hartford, CT 06102 USA.	pthomps@harthosp.org						Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Arntz HR, 2000, AM J CARDIOL, V86, P1293, DOI 10.1016/S0002-9149(00)01230-3; Athyros VG, 2002, CURR MED RES OPIN, V18, P220, DOI 10.1185/030079902125000787; Azancot I, 2003, CIRCULATION, V107, P422, DOI 10.1161/01.CIR.0000046488.52939.BF; Baker SK, 2001, CLIN INVEST MED, V24, P258; BALLANTYNE CM, 1989, JAMA-J AM MED ASSOC, V262, P53, DOI 10.1001/jama.262.1.53; Bertrand ME, 1997, J AM COLL CARDIOL, V30, P863, DOI 10.1016/S0735-1097(97)00259-3; Bestehorn HP, 1997, EUR HEART J, V18, P226; BOCCUZZI SJ, 1991, AM J CARDIOL, V68, P1127, DOI 10.1016/0002-9149(91)90182-K; Bolego C, 2002, CURR OPIN LIPIDOL, V13, P637, DOI 10.1097/00041433-200212000-00007; Bottorff M, 2000, ARCH INTERN MED, V160, P2273, DOI 10.1001/archinte.160.15.2273; Bramow S, 2001, PHARMACOL TOXICOL, V89, P133, DOI 10.1034/j.1600-0773.2001.d01-147.x; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN MS, 1990, Patent No. 4933165; Campeau L, 1997, NEW ENGL J MED, V336, P153; CHARIOT P, 1993, AM J MED, V94, P109, DOI 10.1016/0002-9343(93)90129-D; CHRYSANTHOPOULOS C, 1992, BRIT MED J, V304, P1225, DOI 10.1136/bmj.304.6836.1225; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Coleman ML, 2002, CELL DEATH DIFFER, V9, P493, DOI 10.1038/sj.cdd.4400987; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; Davidson MH, 1997, AM J CARDIOL, V79, P38, DOI 10.1016/S0002-9149(96)00742-4; Davidson MH, 2002, J AM COLL CARDIOL, V40, P2125, DOI 10.1016/S0735-1097(02)02610-4; DePinieux G, 1996, BRIT J CLIN PHARMACO, V42, P333, DOI 10.1046/j.1365-2125.1996.04178.x; DESLYPERE JP, 1991, ANN INTERN MED, V114, P342, DOI 10.7326/0003-4819-114-4-342_1; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; EAST C, 1988, NEW ENGL J MED, V318, P47; Flens MJ, 1996, AM J PATHOL, V148, P1237; Flint OP, 1997, TOXICOL APPL PHARM, V145, P91, DOI 10.1006/taap.1997.8131; FUHRMANS V, 2002, WALL STREET J   0121, pA10; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI 10.1001/jama.288.23.2998; GHARAVI AG, 1994, AM J CARDIOL, V74, P841, DOI 10.1016/0002-9149(94)90453-7; GHIRLANDA G, 1993, J CLIN PHARMACOL, V33, P226, DOI 10.1002/j.1552-4604.1993.tb03948.x; GISSI Prevenzione Investigators, 2000, ITAL HEART J, V1, P810; GOLDMAN JA, 1989, ARTHRITIS RHEUM, V32, P358, DOI 10.1002/anr.1780320324; Green ML, 2002, J GEN INTERN MED, V17, P797, DOI 10.1046/j.1525-1497.2002.20201.x; Guijarro C, 1998, CIRC RES, V83, P490, DOI 10.1161/01.RES.83.5.490; Hamilton-Craig I, 2001, MED J AUSTRALIA, V175, P486, DOI 10.5694/j.1326-5377.2001.tb143683.x; Herd JA, 1997, AM J CARDIOL, V80, P278, DOI 10.1016/S0002-9149(97)00346-9; Herman RJ, 1999, CAN MED ASSOC J, V161, P1281; Holdaas H, 2001, KIDNEY INT, V60, P1990, DOI 10.1046/j.1523-1755.2001.00010.x; Hsiang BN, 1999, J BIOL CHEM, V274, P37161, DOI 10.1074/jbc.274.52.37161; JUKEMA JW, 1995, CIRCULATION, V91, P2528, DOI 10.1161/01.CIR.91.10.2528; Knapp AC, 2000, ATHEROSCLEROSIS, V152, P217, DOI 10.1016/S0021-9150(99)00462-1; KNOCHEL JP, 1990, KIDNEY INT, V38, P709, DOI 10.1038/ki.1990.263; LAAKSONEN R, 1995, CLIN PHARMACOL THER, V57, P62, DOI 10.1016/0009-9236(95)90266-X; Laaksonen R, 1996, AM J CARDIOL, V77, P851, DOI 10.1016/S0002-9149(97)89180-1; LAAKSONEN R, 1994, EUR J CLIN PHARMACOL, V46, P313; LANGER T, 1968, NEW ENGL J MED, V279, P856, DOI 10.1056/NEJM196810172791604; *LEJ COMM INC, 2002, CARD TRIALS REV; *LEJ COMM INC, 2001, CARD TRIALS REV; Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109; Marschner IC, 2001, J AM COLL CARDIOL, V38, P56, DOI 10.1016/S0735-1097(01)01360-2; Matzno S, 1997, J LIPID RES, V38, P1639; McCormick LS, 1997, AM J CARDIOL, V80, P1130, DOI 10.1016/S0002-9149(97)00627-9; *MED EC, 2002, PHYS DESK REF; MERCK CO INC, 1990, Patent No. 4929437; Nolting PRWD, 2002, AM J CARDIOL, V90, P181, DOI 10.1016/S0002-9149(02)02449-9; NORMAN DJ, 1988, NEW ENGL J MED, V318, P46; Olbricht C, 1997, CLIN PHARMACOL THER, V62, P311, DOI 10.1016/S0009-9236(97)90034-5; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Omar MA, 2002, ANN PHARMACOTHER, V36, P288, DOI 10.1345/aph.1A289; Omar MA, 2001, ANN PHARMACOTHER, V35, P1096, DOI 10.1345/aph.10228; Pasternak RC, 2002, J AM COLL CARDIOL, V40, P567, DOI 10.1016/S0735-1097(02)02030-2; PEDERSEN TR, 1994, LANCET, V344, P1383; Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009; PIERCE LR, 1990, JAMA-J AM MED ASSOC, V264, P71, DOI 10.1001/jama.264.1.71; Pitt B, 1999, NEW ENGL J MED, V341, P70, DOI 10.1056/NEJM199907083410202; PITT B, 1995, J AM COLL CARDIOL, V26, P1133, DOI 10.1016/0735-1097(95)00301-0; Prueksaritanont T, 2002, J PHARMACOL EXP THER, V301, P1042, DOI 10.1124/jpet.301.3.1042; Prueksaritanont T, 2002, DRUG METAB DISPOS, V30, P1280, DOI 10.1124/dmd.30.11.1280; Prueksaritanont T, 2002, CIRCULATION, V106, P185; Prueksaritanont T, 2002, DRUG METAB DISPOS, V30, P505, DOI 10.1124/dmd.30.5.505; Riegger G, 1999, ATHEROSCLEROSIS, V144, P263, DOI 10.1016/S0021-9150(99)00062-3; ROSENBERG AD, 1995, ANESTH ANALG, V81, P1089, DOI 10.1097/00000539-199511000-00034; Rotig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SACKS FM, 1991, AM J CARDIOL, V68, P1436, DOI 10.1016/0002-9149(91)90276-Q; Sawayama Y, 2002, J AM COLL CARDIOL, V39, P610, DOI 10.1016/S0735-1097(01)01783-1; Schartl M, 2001, CIRCULATION, V104, P387, DOI 10.1161/hc2901.093188; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Serruys PW, 1999, EUR HEART J, V20, P58, DOI 10.1053/euhj.1998.1150; Shek A, 2001, ANN PHARMACOTHER, V35, P908, DOI 10.1345/aph.10315; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMALS AGH, 1977, NEW ENGL J MED, V296, P942; SoRelle R, 1998, CIRCULATION, V98, P831, DOI 10.1161/01.CIR.98.9.831; Staffa JA, 2002, NEW ENGL J MED, V346, P539, DOI 10.1056/NEJM200202143460721; Thompson PD, 1997, METABOLISM, V46, P1206, DOI 10.1016/S0026-0495(97)90218-3; THOMPSON PD, 1990, JAMA-J AM MED ASSOC, V264, P2992, DOI 10.1001/jama.1990.03450230024013; Ucar M, 2000, DRUG SAFETY, V22, P441, DOI 10.2165/00002018-200022060-00003; vanBoven AJ, 1996, CIRCULATION, V94, P1503, DOI 10.1161/01.CIR.94.7.1503; WALRAVENS PA, 1989, LANCET, V2, P1097; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; Wenke K, 1997, CIRCULATION, V96, P1398, DOI 10.1161/01.CIR.96.5.1398; Widegren U, 2000, PFLUG ARCH EUR J PHY, V441, P317, DOI 10.1007/s004240000417; Wretman C, 2001, J PHYSIOL-LONDON, V535, P155, DOI 10.1111/j.1469-7793.2001.00155.x; Yamazaki M, 1997, DRUG METAB DISPOS, V25, P1123; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; 2003, PHYSICIANS DESK REFE, V57, P2126	100	985	1034	1	73	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1681	1690		10.1001/jama.289.13.1681	http://dx.doi.org/10.1001/jama.289.13.1681			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662JX	12672737				2022-12-28	WOS:000181944500032
J	Hippisley-Cox, J; Cater, R; Pringle, M; Coupland, C				Hippisley-Cox, J; Cater, R; Pringle, M; Coupland, C			Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; PRAVASTATIN	Objective To compare the effectiveness of lipid lowering drugs in lowering serum cholesterol concentrations. Design Cross sectional study. Setting 17 practices within 17 primary care groups in Trent region, United Kingdom. Participants Patients aged 35 years or over taking lipid lowering drugs and with at least two serum cholesterol concentrations recorded on computer. Main outcome measures Proportion of patients achieving serum cholesterol concentration of less than or equal to5 mmol/l and mean percentage reduction in serum cholesterol concentration. Results 1353 of 2469 (54.8%) patients receiving lipid lowering treatment had a last recorded serum cholesterol concentration of less than or equal to 5 mmol/l. Significantly more patients taking statins achieved the target value for serum cholesterol (5 mmol/l) than those taking fibrates (1307 (57%) v 46 (26%); P < 0.0001). Atorvastatin and simvastatin were the most effective drugs in achieving the target. Lipid lowering drugs differed significantly for pretreatment serum cholesterol concentration, most recent cholesterol concentration, and the associated percentage reduction. Atorvastatin and simvastatin achieved the greatest percentage reduction in serum cholesterol concentrations (30.1%,95% confidence interval 28.8% to 31.4% and 28.0%, 26.7% to 29.3%, respectively). Although the mean serum cholesterol concentrations in this unselected population tended to be higher than those in clinical trials, the percentage reduction was consistent with the trials. Conclusion The ability of individual statins to lower serum cholesterol concentration varied, with atorvastatin and simvastatin being the most effective. The percentage reductions agreed with those of randomised controlled trials indicating likely benefits in unselected patients in primary care. As the initial serum cholesterol concentrations were higher than those in randomised controlled trials, target serum cholesterol values of <= 5 mmol/l may be unrealistic even for patients on the most efficacious drugs. Also, the higher initial concentrations could mean that the absolute reduction in cardiovascular risk in primary care patients is greater than thought.	Univ Nottingham, Div Gen Practice, Nottingham NG7 2RD, England	University of Nottingham	Hippisley-Cox, J (corresponding author), Univ Nottingham, Div Gen Practice, Nottingham NG7 2RD, England.	julia.hippisley-cox@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Coupland, Carol/0000-0002-2327-3306				Chong PH, 2001, AM J MED, V111, P390, DOI 10.1016/S0002-9343(01)00870-1; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Department of Health, 2000, NAT SERV FRAM COR AR; Hammersley V, 2002, BRIT J GEN PRACT, V52, P463; Hippisley-Cox J, 2001, BRIT MED J, V323, P269, DOI 10.1136/bmj.323.7307.269; Hippisley-Cox J, 2001, BMJ-BRIT MED J, V322, P832, DOI 10.1136/bmj.322.7290.832; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; PEDERSEN TR, 1994, LANCET, V344, P1383; Primatesta P, 2000, BMJ-BRIT MED J, V321, P1322, DOI 10.1136/bmj.321.7272.1322; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Wood D, 2000, BRIT MED J, V320, P705, DOI 10.1136/bmj.320.7236.705	12	26	26	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	2003	326	7391					689	692		10.1136/bmj.326.7391.689	http://dx.doi.org/10.1136/bmj.326.7391.689			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663WL	12663406	Bronze, Green Published			2022-12-28	WOS:000182029500017
J	Tattersfield, AE; Harrison, TW				Tattersfield, AE; Harrison, TW			Low-dose budesonide for asthma	LANCET			English	Editorial Material							LONG-TERM TREATMENT; FOLLOW-UP; ADULTS		City Hosp, Div Resp Med, Nottingham NG5 1PB, England	University of Nottingham	Tattersfield, AE (corresponding author), City Hosp, Div Resp Med, Nottingham NG5 1PB, England.	anne.tattersfield@nottingham.ac.uk						AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1	9	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 29	2003	361	9363					1066	1067		10.1016/S0140-6736(03)12899-1	http://dx.doi.org/10.1016/S0140-6736(03)12899-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672304				2022-12-28	WOS:000181865200002
J	Harberd, NP				Harberd, NP			Botany: Relieving DELLA restraint	SCIENCE			English	Editorial Material							GIBBERELLIN		John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Harberd, NP (corresponding author), John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England.				Biotechnology and Biological Sciences Research Council [BBS/E/J/00000583] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Fu XD, 2003, NATURE, V421, P740, DOI 10.1038/nature01387; Fu XD, 2002, PLANT CELL, V14, P3191, DOI 10.1105/tpc.006197; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Harberd NP, 1998, BIOESSAYS, V20, P1001, DOI 10.1002/(SICI)1521-1878(199812)20:12&lt;1001::AID-BIES6&gt;3.0.CO;2-O; Itoh H, 2002, PLANT CELL, V14, P57, DOI 10.1105/tpc.010319; Lee SC, 2002, GENE DEV, V16, P646, DOI 10.1101/gad.969002; MCGINNIS KM, IN PRESS PLANT CELL, V15; Richards DE, 2001, ANNU REV PLANT PHYS, V52, P67, DOI 10.1146/annurev.arplant.52.1.67; Sasaki A, 2003, SCIENCE, V299, P1896, DOI 10.1126/science.1081077	10	79	82	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 21	2003	299	5614					1853	1854		10.1126/science.1083217	http://dx.doi.org/10.1126/science.1083217			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649470				2022-12-28	WOS:000181669700031
J	Schadt, EE; Monks, SA; Drake, TA; Lusis, AJ; Che, N; Colinayo, V; Ruff, TG; Milligan, SB; Lamb, JR; Cavet, G; Linsley, PS; Mao, M; Stoughton, RB; Friend, SH				Schadt, EE; Monks, SA; Drake, TA; Lusis, AJ; Che, N; Colinayo, V; Ruff, TG; Milligan, SB; Lamb, JR; Cavet, G; Linsley, PS; Mao, M; Stoughton, RB; Friend, SH			Genetics of gene expression surveyed in maize, mouse and man	NATURE			English	Article							QUANTITATIVE TRAIT LOCI; MODEL; SUSCEPTIBILITY; IDENTIFICATION; DISSECTION; DENSITY; LINKAGE; MICE	Treating messenger RNA transcript abundances as quantitative traits and mapping gene expression quantitative trait loci for these traits has been pursued in gene-specific ways. Transcript abundances often serve as a surrogate for classical quantitative traits in that the levels of expression are significantly correlated with the classical traits across members of a segregating population. The correlation structure between transcript abundances and classical traits has been used to identify susceptibility loci for complex diseases such as diabetes' and allergic asthma(2). One study recently completed the first comprehensive dissection of transcriptional regulation in budding yeast(3), giving a detailed glimpse of a genome-wide survey of the genetics of gene expression. Unlike classical quantitative traits, which often represent gross clinical measurements that may be far removed from the biological processes giving rise to them, the genetic linkages associated with transcript abundance affords a closer look at cellular biochemical processes. Here we describe comprehensive genetic screens of mouse, plant and human transcriptomes by considering gene expression values as quantitative traits. We identify a gene expression pattern strongly associated with obesity in a murine cross, and observe two distinct obesity subtypes. Furthermore, we find that these obesity subtypes are under the control of different loci.	Rosetta Inpharmat LLC, Kirkland, WA 98034 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA; Monsanto Co, St Louis, MO 63167 USA; Merck & Co Inc, Merck Res Labs, West Point, PA 19486 USA	Merck & Company; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Monsanto; Merck & Company	Schadt, EE (corresponding author), Rosetta Inpharmat LLC, 12040 115th Ave NE, Kirkland, WA 98034 USA.	eric_schadt@merck.com; stephen_friend@merck.com	Califano, Andrea/F-7239-2012					AMOS CI, 1994, AM J HUM GENET, V54, P535; BASTEN CA, 1999, QTL CARTOGRAPHER USE; Borecki I B, 1994, Obes Res, V2, P213; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Byrne PF, 1996, P NATL ACAD SCI USA, V93, P8820, DOI 10.1073/pnas.93.17.8820; CAUSSE M, 1995, MOL BREEDING, V1, P259, DOI 10.1007/BF02277426; Claudio L, 1997, FUND APPL TOXICOL, V35, P84, DOI 10.1006/faat.1996.2265; DAMERVAL C, 1994, GENETICS, V137, P289; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; Drake TA, 2001, PHYSIOL GENOMICS, V5, P205, DOI 10.1152/physiolgenomics.2001.5.4.205; Eaves IA, 2002, GENOME RES, V12, P232, DOI 10.1101/gr.214102. Article published online before print in January 2002; Fisch RD, 1996, GENETICS, V143, P571; Huang YH, 2002, NUCLEIC ACIDS RES, V30, P186, DOI 10.1093/nar/30.1.186; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Lembertas AV, 1997, J CLIN INVEST, V100, P1240, DOI 10.1172/JCI119637; LINCOLN SE, 1993, MAPMAKERQTL USERS MA; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Swift LL, 2001, J LIPID RES, V42, P218; Timm DE, 2001, PROTEIN SCI, V10, P997, DOI 10.1110/ps.52201; TOSATIO G, 1991, CURR PROTOC IMMUNOL, V1; Troyer AF, 1999, CROP SCI, V39, P601, DOI 10.2135/cropsci1999.0011183X003900020001x; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Yan L, 1998, DNA CELL BIOL, V17, P659, DOI 10.1089/dna.1998.17.659	25	1087	1152	0	103	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	2003	422	6929					297	302		10.1038/nature01434	http://dx.doi.org/10.1038/nature01434			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646919				2022-12-28	WOS:000181637300037
J	Derse, D; Heidecker, G				Derse, D; Heidecker, G			Forced entry - or does HTLV-I have the key?	SCIENCE			English	Editorial Material							T-CELLS; IMMUNOLOGICAL SYNAPSE; INFECTION		NCI, Basic Res Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Derse, D (corresponding author), NCI, Basic Res Lab, Frederick, MD 21702 USA.				NATIONAL CANCER INSTITUTE [Z01BC010003, ZIABC010003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Davis DM, 2002, TRENDS IMMUNOL, V23, P356, DOI 10.1016/S1471-4906(02)02243-3; Derse D, 2001, J VIROL, V75, P8461, DOI 10.1128/JVI.75.18.8461-8468.2001; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Gummuluru S, 2002, J VIROL, V76, P10692, DOI 10.1128/JVI.76.21.10692-10701.2002; Hildreth JEK, 1997, J VIROL, V71, P1173, DOI 10.1128/JVI.71.2.1173-1180.1997; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Johnson DC, 2002, J VIROL, V76, P1, DOI 10.1128/JVI.76.1.1-8.2002; Manel N, 2003, BLOOD, V101, P1913, DOI 10.1182/blood-2002-09-2681; NATH MD, IN PRESS BLOOD; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	11	15	20	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1670	1671		10.1126/science.1083218	http://dx.doi.org/10.1126/science.1083218			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637723				2022-12-28	WOS:000181519500022
J	Nelson, FE				Nelson, FE			(Un)frozen in time	SCIENCE			English	Editorial Material							PERMAFROST; CLIMATE; NORTH; VARIABILITY		Univ Delaware, Dept Geog, Newark, DE 19716 USA	University of Delaware	Nelson, FE (corresponding author), Univ Delaware, Dept Geog, Newark, DE 19716 USA.	fnelson@udel.edu						*AM GEOPH UN, 2002 FALL M AM GEOPH; Anisimov OA, 2002, ECOL MODEL, V153, P217, DOI 10.1016/S0304-3800(02)00016-9; Bockheim JG, 1999, SOIL SCI SOC AM J, V63, P934, DOI 10.2136/sssaj1999.634934x; Brown J., 2000, POLAR GEOGRAPHY, V24, P166, DOI [10.1080/10889370009377698, DOI 10.1080/10889370009377698]; Cabrol NA, 2000, ICARUS, V145, P91, DOI 10.1006/icar.1999.6326; French HM, 1998, PERMAFROST PERIGLAC, V9, P297, DOI 10.1002/(SICI)1099-1530(199810/12)9:4<297::AID-PPP296>3.0.CO;2-B; Hagen JO, 2001, CLIMATE CHANGE 2001: IMPACTS, ADAPTATION, AND VULNERABILITY, P801; HINZMAN LD, 2002, EOS, V83, pF256; HINZMAN LD, 2002, EOS, V83, pF241; Jorgenson MT, 2001, CLIMATIC CHANGE, V48, P551, DOI 10.1023/A:1005667424292; LACHENBRUCH AH, 1986, SCIENCE, V234, P689, DOI 10.1126/science.234.4777.689; Nelson FE, 2002, NAT HAZARDS, V26, P203, DOI 10.1023/A:1015612918401; Pavlov AV, 2002, PERMAFROST PERIGLAC, V13, P43, DOI 10.1002/ppp.409; ROMANOVSKY V, 2002, EOS T AM GEOPHYS UN, V83, P593; Seligman BJ, 2000, PERMAFROST PERIGLAC, V11, P5, DOI 10.1002/(SICI)1099-1530(200001/03)11:1&lt;5::AID-PPP335&gt;3.0.CO;2-C; Smith S., 2002, EOS T AM GEOPHYS UN, V83, P589, DOI [DOI 10.1029/2002EO000402, 10.1029/2002EO000402]; Stendel M, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014345; Turetsky MR, 2002, SOIL BIOL BIOCHEM, V34, P907, DOI 10.1016/S0038-0717(02)00022-6; Williams PJ, 1989, FROZEN EARTH FUNDAME	19	113	128	2	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	2003	299	5613					1673	1675		10.1126/science.1081111	http://dx.doi.org/10.1126/science.1081111			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637725				2022-12-28	WOS:000181519500024
J	Moller, JE; Connolly, HM; Rubin, J; Seward, JB; Modesto, K; Pellikka, PA				Moller, JE; Connolly, HM; Rubin, J; Seward, JB; Modesto, K; Pellikka, PA			Factors associated with progression of carcinoid heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRICUSPID REGURGITATION; NEUROENDOCRINE TUMORS; SOMATOSTATIN ANALOG; ENDOCRINE TUMORS; PHASE-II; SEROTONIN; OCTREOTIDE; EFFICACY; ECHOCARDIOGRAPHY; ABNORMALITIES	Background: By releasing vasoactive substances into the circulation, carcinoid tumors can cause right-sided valvular heart disease. Factors associated with the progression of carcinoid heart disease are poorly understood. We conducted a retrospective study to identify such factors. Methods: Our sample included 71 patients with the carcinoid syndrome who underwent serial echocardiographic studies performed more than one year apart and 32 patients referred directly for surgical intervention after an initial echocardiographic evaluation. A score for carcinoid heart disease was determined on the basis of an assessment of valvular anatomy and function and the function of the right ventricle. An increase of more than 25 percent in the score between studies was considered suggestive of disease progression. Tumor progression was assessed on the basis of abdominal computed tomographic scans and changes in the level of urinary 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin. Results: Of the patients with serial echocardiographic studies, 25 (35 percent) had an increase of more than 25 percent in the cardiac score. As compared with patients whose score changed by 25 percent or less, these patients had higher urinary peak 5-HIAA levels (median, 265 mg per 24 hours [interquartile range, 209 to 593] vs. 189 mg per 24 hours [interquartile range, 75 to 286]; P=0.004) and were more likely to have biochemical progression (10 of 25 patients vs. 9 of 46, P=0.05) and to have received chemotherapy (13 of 25 vs. 10 of 46, P=0.009). Logistic-regression analysis showed that a higher peak urinary 5-HIAA level and previous chemotherapy were predictors of an increase in the cardiac score that exceeded 25 percent (odds ratio for each increase in 5-HIAA of 25 mg per 24 hours, 1.08 [95 percent confidence interval, 1.03 to 1.13]; P=0.009); odds ratio associated with chemotherapy, 3.65 [95 percent confidence interval, 1.74 to 7.48]; P=0.001). Conclusions: Serotonin is related to the progression of carcinoid heart disease, and the risk of progressive heart disease is higher in patients who receive chemotherapy than in those who do not.	Mayo Clin & Mayo Fdn, Echocardiog Lab, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Med Oncol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Pellikka, PA (corresponding author), Mayo Clin & Mayo Fdn, Echocardiog Lab, Div Cardiovasc Dis, Gonda 6-138 NW,200 1st St SW, Rochester, MN 55905 USA.		Pellikka, Patricia A/N-5387-2014	Pellikka, Patricia A/0000-0001-6800-3521; Moller, Jacob Eifer/0000-0003-2873-5845				Ansell SM, 2001, CANCER-AM CANCER SOC, V91, P1543, DOI 10.1002/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N; Caplin ME, 1998, LANCET, V352, P799, DOI 10.1016/S0140-6736(98)02286-7; CUBEDDU LX, 1992, BRIT J CANCER, V66, P198, DOI 10.1038/bjc.1992.242; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; Denney WD, 1998, J AM COLL CARDIOL, V32, P1017, DOI 10.1016/S0735-1097(98)00354-4; DiBartolomeo M, 1996, CANCER-AM CANCER SOC, V77, P402, DOI 10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4; Eriksson BK, 1998, CANCER, V83, P2293, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.3.CO;2-5; KUBOTA A, 1994, J CLIN INVEST, V93, P1321, DOI 10.1172/JCI117090; Kulke MH, 1999, NEW ENGL J MED, V340, P858, DOI 10.1056/NEJM199903183401107; KVOLS LK, 1986, NEW ENGL J MED, V315, P663, DOI 10.1056/NEJM198609113151102; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; LUNDIN L, 1988, CIRCULATION, V77, P264, DOI 10.1161/01.CIR.77.2.264; Modlin IM, 1997, CANCER-AM CANCER SOC, V79, P813, DOI 10.1002/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2; OBERG K, 1987, ACTA ONCOL, V26, P429; Oberg K, 2001, ANN ONCOL, V12, pS111, DOI 10.1093/annonc/12.suppl_2.S111; PELLIKKA PA, 1993, CIRCULATION, V87, P1188, DOI 10.1161/01.CIR.87.4.1188; PENNESTRI F, 1984, AM J CARDIOL, V54, P363, DOI 10.1016/0002-9149(84)90198-X; Rajamannan NM, 2001, J HEART VALVE DIS, V10, P827; Rivera J M, 1994, J Am Soc Echocardiogr, V7, P480; ROBIOLIO PA, 1995, CIRCULATION, V92, P790, DOI 10.1161/01.CIR.92.4.790; Roy A, 2000, J HEART VALVE DIS, V9, P256; Rubin J, 1999, J CLIN ONCOL, V17, P600, DOI 10.1200/JCO.1999.17.2.600; RUSZNIEWSKI P, 1993, CANCER, V71, P2624, DOI 10.1002/1097-0142(19930415)71:8<2624::AID-CNCR2820710830>3.0.CO;2-B; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SUZUKI Y, 1986, AM J CARDIOL, V57, P811, DOI 10.1016/0002-9149(86)90619-3	25	194	198	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					1005	1015		10.1056/NEJMoa021451	http://dx.doi.org/10.1056/NEJMoa021451			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653YT	12637610				2022-12-28	WOS:000181465200005
J	Lyon, BE				Lyon, BE			Egg recognition and counting reduce costs of avian conspecific brood parasitism	NATURE			English	Article							NEST PARASITISM; CUCULUS-CANORUS; CLUTCH SIZE; DISCRIMINATION; COEVOLUTION; CUCKOO; COOTS; MODEL	Birds parasitized by interspecific brood parasites often adopt defences based on egg recognition but such behaviours are puzzlingly rare in species parasitized by members of the same species. Here I show that conspecific egg recognition is frequent, accurate and used in three defences that reduce the high costs of conspecific brood parasitism in American coots. Hosts recognized and rejected many parasitic eggs, reducing the fitness costs of parasitism by half. Recognition without rejection also occurred and some hosts banished parasitic eggs to inferior outer incubation positions. Clutch size comparisons revealed that females combine egg recognition and counting to make clutch size decisions - by counting their own eggs, while ignoring distinctive parasitic eggs, females avoid a maladaptive clutch size reduction. This is clear evidence that female birds use visual rather than tactile cues to regulate their clutch sizes, and provides a rare example of the ecological and evolutionary context of counting in animals.	Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Lyon, BE (corresponding author), Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA.	lyon@biology.ucsc.edu	Lyon, Bruce E/E-8491-2011					ANDERSSON M, 1982, AM NAT, V120, P1, DOI 10.1086/283965; Andersson M., 1984, ANIM BEHAV, V33, P1394; ARNOLD TW, 1987, CONDOR, V89, P675, DOI 10.2307/1368662; BERTRAM BCR, 1992, OSTRICH COMMUNAL NES, P109; BROOKE MD, 1988, NATURE, V335, P630; Davies N.B., 2000, CUCKOOS COWBIRDS OTH; Davies NB, 1996, P ROY SOC B-BIOL SCI, V263, P925, DOI 10.1098/rspb.1996.0137; DAVIES NB, 1989, J ANIM ECOL, V58, P225, DOI 10.2307/4996; Eadie J, 1998, BEHAVIORAL ECOLOGY AND CONSERVATION BIOLOGY, P306; GALLISTEL CR, 1988, BEHAV BRAIN SCI, V11, P585, DOI 10.1017/S0140525X00053504; Hauser MD, 2000, AM SCI, V88, P144, DOI 10.1511/2000.19.863; HAYWOOD S, 1993, Q REV BIOL, V68, P33, DOI 10.1086/417910; Jackson WM, 1998, OX ORN SER, V9, P407; Jamieson IG, 2000, AUK, V117, P250, DOI 10.1642/0004-8038(2000)117[0250:HROCBP]2.0.CO;2; KEMAL RE, 1988, ANIM BEHAV, V36, P175, DOI 10.1016/S0003-3472(88)80261-6; LYON BE, 1993, ANIM BEHAV, V46, P911, DOI 10.1006/anbe.1993.1273; Lyon BE, 2002, EVOLUTION, V56, P1253, DOI 10.1111/j.0014-3820.2002.tb01436.x; LYON BE, 1993, BEHAV ECOL SOCIOBIOL, V33, P87; Lyon BE, 1998, NATURE, V392, P380, DOI 10.1038/32878; LYON BE, 1992, ECOLOGY EVOLUTION CO; ROHWER FC, 1989, CAN J ZOOL, V67, P239, DOI 10.1139/z89-035; ROTHSTEIN SI, 1982, AM ZOOL, V22, P547; ROTHSTEIN SI, 1990, ANNU REV ECOL SYST, V21, P481, DOI 10.1146/annurev.es.21.110190.002405; SEIBT U, 1988, BEHAV BRAIN SCI, V11, P597, DOI 10.1017/S0140525X00053644; Sherman Paul W., 1997, P69; Shettleworth, 2010, COGNITION EVOLUTION	26	197	203	1	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2003	422	6931					495	499		10.1038/nature01505	http://dx.doi.org/10.1038/nature01505			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673243				2022-12-28	WOS:000181965400030
J	Galmiche, JP; des Varannes, SB				Galmiche, JP; des Varannes, SB			Endoluminal therapies for gastro-oesophageal reflux disease	LANCET			English	Review							RADIOFREQUENCY ENERGY DELIVERY; LOWER ESOPHAGEAL SPHINCTER; GASTROESOPHAGEAL REFLUX; PORCINE MODEL; ENDOSCOPIC IMPLANTATION; GERD; JUNCTION; AUGMENTATION; CARDIA; TRIAL	Context Gastro-oesophageal reflux disease (GORD) is a common chronic disorder that has severe impact on quality of life and often requires continuous acid suppression therapy. Proton-pump inhibitors (PPIs) are extremely effective but expensive, and do not restore the normal antireflux barrier at the gastro-oesophageal junction. Antireflux surgery, even with the laparoscopic approach, has not proven more cost effective than maintenance therapy with PPIs. Postoperative morbidity is substantial, especially when procedures are done outside expert centres. In the past few years several endoscopic techniques have bene developed to treat chronic GORD on an outpatient basis. These techniques include radiofrequency-energy delivery and endoscopic suturing although other approaches are now under development. Starting point Two prospective open-label studies have recently reported 1-year follow-up GORD patients treated either by radiofrequency-energy delivery (G Triadafilopoulos and colleagues Gastrointest Endosc 2002, 55: 149-56) or endoscopic suturing (Z-Mahmood and colleagues Gut 2003; 52: 34-39). In a US multicentre trial, Triadafilopoulos and colleagues delivered radiofrequency energy to the cardia and distal oesophagus in patients with chronic heartburn, regurgitation or both (the Stretta procedure). All patients were on continuous acid-suppression therapy but none had severe oesophagitis or hiatus hernia of ore than 2 (cm. At 12 months, 94 patients available for follow-up showed significant improvement in GORD symptoms, quality of life, and oesophageal acid-exposure. The need for PPI therapy fell from 98% to 30% of patients. In the Mahmood study, 26 similar patients had endoscopic suturing in a single centre. After 1 year symptoms and quality of life improved and the need for PPIs was reduced to 36% from 100%. In both studies, only minor complications occurred, none of which required specific therapeutic intervention. Where next? An effective outpatient procedure to treat chronic GORD would represent a major step forward. However, further studies are needed before an endoscopic approach can be adopted as none of the published trials are well-controlled studies. Longer follow-up is needed to ensure that relapses do not occur rapidly, complications do not occur more frequently with less skilled operators, or that endoscopic induced changes do not complicate or comprise subsequent antireflux surgery. Comparative studies of the cost-effectiveness of endoscopic therapy should also include medical strategies such as intermittent for on-demand PPI therapy.	CHU Nantes, INSERM, CIC, Dept Gastroenterol & Hepatol, F-44093 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes	Galmiche, JP (corresponding author), CHU Nantes, INSERM, CIC, Dept Gastroenterol & Hepatol, F-44093 Nantes, France.	galmiche@easynet.fr	Bourreille, Arnaud/K-2398-2015; Bruley des Varannes, Stanislas/K-2434-2015					Corley DA, 2002, GASTROINTEST ENDOSC, V55, pAB100; Deviere J, 2002, GASTROINTEST ENDOSC, V55, P335, DOI 10.1067/mge.2002.121596; DiBaise JK, 2002, AM J GASTROENTEROL, V97, P833; Feretis C, 2001, GASTROINTEST ENDOSC, V53, P423, DOI 10.1067/mge.2001.113912; Filipi CJ, 2001, GASTROINTEST ENDOSC, V53, P416, DOI 10.1067/mge.2001.113502; Fockens P, 2002, GASTROINTEST ENDOSC, V55, pAB90; Galmiche JP, 2002, GUT, V51, P472, DOI 10.1136/gut.51.4.472; Kadirkamanathan SS, 1999, GUT, V44, P782, DOI 10.1136/gut.44.6.782; Kim MS, 2003, GASTROINTEST ENDOSC, V57, P17, DOI 10.1067/mge.2003.23; Mahmood Z, 2003, GUT, V52, P34, DOI 10.1136/gut.52.1.34; Martinez-Serna T, 2000, GASTROINTEST ENDOSC, V52, P663, DOI 10.1067/mge.2000.109871; Mason RJ, 2002, SURG ENDOSC, V16, P386, DOI 10.1007/s004640080189; Spechler SJ, 2001, JAMA-J AM MED ASSOC, V285, P2331, DOI 10.1001/jama.285.18.2331; TAM W, 2002, CLIN GASTROENTEROL, V16, P811; Triadafilopoulos G, 2002, GASTROINTEST ENDOSC, V55, P149, DOI 10.1067/mge.2002.121227; Triadafilopoulos G, 2001, J LAPAROENDOSC ADV A, V11, P333, DOI 10.1089/10926420152761842; Triadafilopoulos G, 2001, GASTROINTEST ENDOSC, V53, P407, DOI 10.1067/mge.2001.112843; Utley DS, 2000, GASTROINTEST ENDOSC, V52, P81, DOI 10.1067/mge.2000.105981; Vakil N, 2003, AM J MED, V114, P1, DOI 10.1016/S0002-9343(02)01390-6; Ye WM, 2001, GASTROENTEROLOGY, V121, P1286, DOI 10.1053/gast.2001.29569	20	28	28	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 29	2003	361	9363					1119	1121		10.1016/S0140-6736(03)12889-9	http://dx.doi.org/10.1016/S0140-6736(03)12889-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672327				2022-12-28	WOS:000181865200025
J	White, T				White, T			Paleoanthropology: Early hominids - Diversity or distortion?	SCIENCE			English	Editorial Material							AFRICA; CHAD		Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	White, T (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.							Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; GOULD SJ, 1976, NAT HIST, V85, P24; Leakey MG, 2001, NATURE, V410, P433, DOI 10.1038/35068500; LI TY, 1992, NATURE, V357, P404; Lieberman DE, 1998, NATURE, V393, P158, DOI 10.1038/30227; MAYR E, 1950, COLD SPRING HARB SYM, V15, P109, DOI 10.1101/SQB.1950.015.01.013; SCHULTZ CB, 1956, B AM MUS NAT HIST, V109, P1; SIMPSON GG, 1963, CLASSIFICATION HUMAN, P4; Spoor F, 1999, NATURE, V397, P572, DOI 10.1038/17505; STEVENS MS, 1996, TERRESTRIAL EOCENE O, pCH25; TATTERSALL I, 2000, EXTINCT HUMANS; WILFORD JN, 2001, NY TIMES        0325; Wood B, 2002, NATURE, V418, P133, DOI 10.1038/418133a	13	81	84	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2003	299	5615					1994	+		10.1126/science.1078294	http://dx.doi.org/10.1126/science.1078294			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663903				2022-12-28	WOS:000181834200028
J	Schuwirth, LWT; van der Vleuten, CPM				Schuwirth, LWT; van der Vleuten, CPM			ABC of learning and teaching in medicine - Written assessment	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ Maastricht, Dept Educ Dev & Res, Maastricht, Netherlands	Maastricht University	Schuwirth, LWT (corresponding author), Univ Maastricht, Dept Educ Dev & Res, Maastricht, Netherlands.							Bordage G., 1987, FURTHER DEV ASSESSIN, P59; Case SM, 1993, TEACH LEARN MED, V5, P107; FREDERIKSEN N, 1984, AM PSYCHOL, V39, P193, DOI 10.1037/0003-066X.39.3.193; SCHUWIRTH LWT, 1998, THESIS MAASTRICHT U; SWANSON D, 1987, ASSESS EVAL HIGH EDU, V12, P220, DOI DOI 10.1080/0260293870120307; WARD WC, 1982, APPL PSYCH MEAS, V6, P1, DOI 10.1177/014662168200600101	6	77	84	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	2003	326	7390					643	645		10.1136/bmj.326.7390.643	http://dx.doi.org/10.1136/bmj.326.7390.643			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	661BF	12649242	Green Published			2022-12-28	WOS:000181870800022
J	Kullander, K; Butt, SJB; Lebret, JM; Lundfald, L; Restrepo, CE; Rydstrom, A; Klein, R; Kiehn, O				Kullander, K; Butt, SJB; Lebret, JM; Lundfald, L; Restrepo, CE; Rydstrom, A; Klein, R; Kiehn, O			Role of EphA4 and EphrinB3 in local neuronal circuits that control walking	SCIENCE			English	Article							CENTRAL PATTERN GENERATOR; VITRO NEONATAL RAT; SPINAL-CORD; IN-VITRO; CORTICOSPINAL TRACT; AXONS; LOCOMOTION; MECHANISMS; RECEPTORS; NETWORKS	Local circuits in the spinal cord that generate locomotion are termed central pattern generators (CPGs). These provide coordinated bilateral control over the normal limb alternation that underlies walking. The molecules that organize the mammalian CPG are unknown. Isolated spinal cords from mice lacking either the EphA4 receptor or its ligand ephrinB3 have lost left-right limb alternation and instead exhibit synchrony. We identified EphA4-positive neurons as an excitatory component of the locomotor CPG. Our study shows that dramatic locomotor changes can occur as a consequence of local genetic rewiring and identifies genes required for the development of normal locomotor behavior.	Univ Gothenburg, Dept Biochem Med, S-40530 Gothenburg, Sweden; AstraZeneca Transgen & Comparat Genom, S-43183 Molndal, Sweden; Karolinska Inst, Dept Neurosci, Mammalian Locomotor Lab, S-17177 Stockholm, Sweden; Max Planck Inst Neurobiol, D-82152 Martinsried, Germany	University of Gothenburg; AstraZeneca; Karolinska Institutet; Max Planck Society	Kullander, K (corresponding author), Univ Gothenburg, Dept Biochem Med, Medicinaregatan 9A, S-40530 Gothenburg, Sweden.	klas.kullander@medkem.gu.se; ole.kiehn@neuro.ki.se	kiehn, ole/AAT-7881-2021; Butt, Simon/I-2689-2019; Klein, Ruediger/C-6147-2008; kiehn, ole/AAB-1262-2019; Kiehn, Ole/C-4679-2008	Butt, Simon/0000-0002-2399-0102; Klein, Ruediger/0000-0002-3109-0163; Kiehn, Ole/0000-0002-5954-469X; Kullander, Klas/0000-0001-6418-5460				ARSHAVSKY YI, 1993, TRENDS NEUROSCI, V16, P227, DOI 10.1016/0166-2236(93)90161-E; Butt SJB, 2002, BRAIN RES REV, V40, P107, DOI 10.1016/S0165-0173(02)00194-7; COWLEY KC, 1995, J NEUROPHYSIOL, V74, P1109, DOI 10.1152/jn.1995.74.3.1109; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; Dottori M, 1998, P NATL ACAD SCI USA, V95, P13248, DOI 10.1073/pnas.95.22.13248; Fremeau RT, 2001, NEURON, V31, P247, DOI 10.1016/S0896-6273(01)00344-0; Gianino S, 1999, DEV BRAIN RES, V112, P189, DOI 10.1016/S0165-3806(98)00168-0; GRILLNER S, 1995, TRENDS NEUROSCI, V18, P270, DOI 10.1016/0166-2236(95)93914-J; Grillner S., 1981, HDB PHYSL NERVOUS SY, P1179, DOI DOI 10.1002/CPHY.CP010226; Kiehn O, 1996, J NEUROPHYSIOL, V75, P1472, DOI 10.1152/jn.1996.75.4.1472; Kiehn O, 1998, ANN NY ACAD SCI, V860, P110, DOI 10.1111/j.1749-6632.1998.tb09043.x; KIEHN O, 1997, NEURONS NETWORKS MOT, P47; Kjaerulff O, 1996, J NEUROSCI, V16, P5777; Kullander K, 2001, GENE DEV, V15, P877, DOI 10.1101/gad.868901; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Leighton PA, 2001, NATURE, V410, P174, DOI 10.1038/35065539; Stokke MF, 2002, J COMP NEUROL, V446, P349, DOI 10.1002/cne.10211; Suster ML, 2002, NATURE, V416, P174, DOI 10.1038/416174a; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Whelan P, 2000, J NEUROPHYSIOL, V84, P2821, DOI 10.1152/jn.2000.84.6.2821; Whelan PJ, 1997, J NEUROPHYSIOL, V78, P1643, DOI 10.1152/jn.1997.78.3.1643; Wickelgren I, 1998, SCIENCE, V279, P319, DOI 10.1126/science.279.5349.319; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; Yokoyama N, 2001, NEURON, V29, P85, DOI 10.1016/S0896-6273(01)00182-9	25	257	264	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	2003	299	5614					1889	1892		10.1126/science.1079641	http://dx.doi.org/10.1126/science.1079641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649481				2022-12-28	WOS:000181669700045
J	Murray, M				Murray, M			Anthropology: Overkill and sustainable use	SCIENCE			English	Editorial Material									Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Murray, M (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.			Murray, Martyn/0000-0003-4371-388X				Bleek W.H.I., 1911, SPECIMENS BUSHMEN FO; Bowen-Jones E, 1999, ORYX, V33, P233, DOI 10.1046/j.1365-3008.1999.00066.x; Diamond Jared, 1992, RISE FALL 3 CHIMPANZ; Etnier M. A., 2002, THESIS U WASHINGTON; *IUCN, 2001, STRAT APPR INT BIOD; Jones Brian, 2001, P38; Kay Charles E., 2002, WILDERNESS POLITICAL; Krech S., 1999, ECOLOGICAL INDIAN MY; Krech Shepard III, 1981, INDIANS ANIMALS FUR; LISTERKAYE J, 1994, 3 SCOTT NAT HER; Marshall Lorna., 1976, KUNG NYAE NYAE; Martin Calvin, 1978, KEEPERS GAME INDIAN; MARTIN PS, 1973, SCIENCE, V179, P969, DOI 10.1126/science.179.4077.969; MARTIN PS, 1966, NATURE, V212, P339, DOI 10.1038/212339a0; Milner-Gulland E., 1998, CONSERVATION BIOL RE; MUIR J, 1913, STORY MY BOYHOOD YOU, P161; Robinson J., 2000, HUNTING SUSTAINABILI; Silberbauer GeorgeB., 1981, HUNTER HABITAT CENTR; Sinclair ARE, 1998, CONSERV BIOL, V12, P564, DOI 10.1046/j.1523-1739.1998.97030.x; Stevens S., 1997, CONSERVATION CULTURA; TRENCH CC, 1967, POACHER SQUIRE; *WORLD CONS UN UN, 1991, CAR EARTH STRAT SUST; Worthy T. H., 2002, LOST WORLD MOA PREHI	23	13	13	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 21	2003	299	5614					1851	1853		10.1126/science.1079823	http://dx.doi.org/10.1126/science.1079823			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649469				2022-12-28	WOS:000181669700030
J	Sasaki, A; Itoh, H; Gomi, K; Ueguchi-Tanaka, M; Ishiyama, K; Kobayashi, M; Jeong, DH; An, G; Kitano, H; Ashikari, M; Matsuoka, M				Sasaki, A; Itoh, H; Gomi, K; Ueguchi-Tanaka, M; Ishiyama, K; Kobayashi, M; Jeong, DH; An, G; Kitano, H; Ashikari, M; Matsuoka, M			Accumulation of phosphorylated repressor for gibberellin signaling in an F-box mutant	SCIENCE			English	Article							RESPONSE MUTANT; GENE; DEGRADATION; RICE; ENCODES; PATHWAY; PROTEIN; ALPHA; SLN1	Gibberellin (GA) regulates growth and development in plants. We isolated and characterized a rice GA-insensitive dwarf mutant, gid2. The GID2 gene encodes a putative F-box protein, which interacted with the rice Skp1 homolog in a yeast two-hybrid assay. In gid2, a repressor for GA signaling, SLR1, was highly accumulated in a phosphorylated form and GA increased its concentration, whereas SLR1 was rapidly degraded by GA through ubiquitination in the wild type. We conclude that GID2 is a positive regulator of GA signaling and that regulated degradation of SLR1 is initiated through GA-dependent phosphorylation and finalized by an SCFGID2-proteasome pathway.	Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan; RIKEN, Bioresources Ctr, Tsukuba, Ibaraki 3050074, Japan; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan	Nagoya University; RIKEN; Pohang University of Science & Technology (POSTECH); Nagoya University	Matsuoka, M (corresponding author), Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan.	makoto@agr.nagoya-u.ac.jp	Kobayashi, Masatomo/A-5945-2016	Gomi, Kenji/0000-0002-6736-1113				Ashikari M, 1999, P NATL ACAD SCI USA, V96, P10284, DOI 10.1073/pnas.96.18.10284; Ashikari M, 2002, BREEDING SCI, V52, P143, DOI 10.1270/jsbbs.52.143; Chandler PM, 2002, PLANT PHYSIOL, V129, P181, DOI 10.1104/pp.010917; Davies P. J, 1995, PLANT HORMONES; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dill A, 2001, P NATL ACAD SCI USA, V98, P14162, DOI 10.1073/pnas.251534098; Fu XD, 2002, PLANT CELL, V14, P3191, DOI 10.1105/tpc.006197; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Gubler F, 2002, PLANT PHYSIOL, V129, P191, DOI 10.1104/pp.010918; Ikeda A, 2001, PLANT CELL, V13, P999, DOI 10.1105/tpc.13.5.999; Itoh H, 2002, PLANT CELL, V14, P57, DOI 10.1105/tpc.010319; Itoh H, 2001, P NATL ACAD SCI USA, V98, P8909, DOI 10.1073/pnas.141239398; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Peng JR, 1999, NATURE, V400, P256, DOI 10.1038/22307; SASAKI A, UNPUB; Silverstone AL, 1998, PLANT CELL, V10, P155, DOI 10.1105/tpc.10.2.155; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Steber CM, 1998, GENETICS, V149, P509; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Xu LH, 2002, PLANT CELL, V14, P1919, DOI 10.1105/tpc.003368; Yang M, 1999, P NATL ACAD SCI USA, V96, P11416, DOI 10.1073/pnas.96.20.11416	24	463	533	4	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	2003	299	5614					1896	1898		10.1126/science.1081077	http://dx.doi.org/10.1126/science.1081077			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649483				2022-12-28	WOS:000181669700047
J	Jamora, C; DasGupta, R; Kocieniewski, P; Fuchs, E				Jamora, C; DasGupta, R; Kocieniewski, P; Fuchs, E			Links between signal transduction, transcription and adhesion in epithelial bud development	NATURE			English	Article							HAIR FOLLICLE MORPHOGENESIS; E-CADHERIN; BETA-CATENIN; GENE-EXPRESSION; SONIC HEDGEHOG; FACTOR SNAIL; DIFFERENTIATION	The morphogenesis of organs as diverse as lungs, teeth and hair follicles is initiated by a downgrowth from a layer of epithelial stem cells(1,2). During follicular morphogenesis, stem cells form this bud structure by changing their polarity and cell-cell contacts. Here we show that this process is achieved through simultaneous receipt of two external signals: a Writ protein to stabilize beta-catenin, and a bone morphogenetic protein (BMP) inhibitor to produce Lef1. beta-Catenin then binds to, and activates, Lef1 transcription complexes that appear to act uncharacteristically by downregulating the gene encoding E-cadherin, an important component of polarity and intercellular adhesion. When either signal is missing, functional Lef1 complexes are not made, and E-cadherin downregulation and follicle morphogenesis are impaired. In Drosophila, E-cadherin can influence the plane of cell division and cytoskeletal dynamics(3). Consistent with this notion, we show that forced elevation of E-cadherin levels block invagination and follicle production. Our findings reveal an intricate molecular programme that links two extracellular signalling pathways to the formation of a nuclear transcription factor that acts on target genes to remodel cellular junctions and permit follicle formation.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Fuchs, E (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mammalian Cell Biol & Dev, 1230 York Ave, New York, NY 10021 USA.	fuchs@rockefeller.edu	Fuchs, Elaine/G-1565-2016	Dasgupta, Ramanuj/0000-0001-9015-3729	NIAMS NIH HHS [R01 AR031737-24, R01 AR031737] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031737] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Botchkarev VA, 1999, NAT CELL BIOL, V1, P158, DOI 10.1038/11078; Boussadia O, 2002, MECH DEVELOP, V115, P53, DOI 10.1016/S0925-4773(02)00090-4; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chan SK, 2002, CELL, V111, P265, DOI 10.1016/S0092-8674(02)01037-1; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HIRAI Y, 1989, DEVELOPMENT, V105, P271; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jan YN, 2001, NAT REV NEUROSCI, V2, P772, DOI 10.1038/35097516; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; Kulessa H, 2000, EMBO J, V19, P6664, DOI 10.1093/emboj/19.24.6664; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Reddy S, 2001, MECH DEVELOP, V107, P69, DOI 10.1016/S0925-4773(01)00452-X; SHIMAMURA K, 1994, DEVELOPMENT, V120, P2225; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	29	455	482	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	2003	422	6929					317	322		10.1038/nature01458	http://dx.doi.org/10.1038/nature01458			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646922	Green Accepted			2022-12-28	WOS:000181637300041
J	Herman-Giddens, ME; Smith, JB; Mittal, M; Carlson, M; Butts, JD				Herman-Giddens, ME; Smith, JB; Mittal, M; Carlson, M; Butts, JD			Newborns killed, or left to die by a parent - A population-based study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEONATICIDE; PREGNANCY; MURDER	Context Interest in the discarding or killing of newborns by parents has increased due to wide news coverage and efforts by states to provide Safe Haven legislation to combat the problem. Objective To describe the characteristics of these cases in North Carolina. Design, Setting, and Population Case series derived from data on all deaths among liveborn infants 0 to 4 days of age reported to the North Carolina medical examiner from 1985 through 2000. Main Outcome Measures incidence of newborns known to have been killed or discarded by a parent; epidemiological characteristics of newborns and parents. Results There were 34 newborns known to have been killed or discarded by a parent, comprising 0.002% of all liveborn infants during the 16-year study period, giving a rate of 2.1 per 100000 per year. A total of 58.8% were male, 41.1% were white, and 52.9% were black. For 29 cases, the perpetrator was determined to be the mother. Among mothers, 50% were single and 20.6% were married (marital status of the remainder was unknown). Thirty-five percent had had other children. Eight mothers (23.5%) were known to have received some prenatal care. The mean age of the mothers, was 19.1 years (range, 14-35 years) and more than half were aged 18 years or older. The most common causes of death were asphyxiation/strangulation (41.1%) and drowning (26.5%). Conclusions In North Carolina, at least 2.1 per 100000 newborns are known to be killed or left to die per year, usually by their mothers. It is unknown how many of these deaths might be prevented by Safe Haven laws. Efforts to educate the public about these laws need to target the general public. Where resources are limited, the focus should be on on adolescent pregnancy prevention programs, young adults, prenatal care clinics, and married women.	N Carolina Child Advocacy Inst, Raleigh, NC 27601 USA; Univ N Carolina, Sch Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; State Ctr Hlth Stat, Raleigh, NC USA; Off Chief Med Examiner, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Herman-Giddens, ME (corresponding author), N Carolina Child Advocacy Inst, 311 E Edenton St, Raleigh, NC 27601 USA.	mherman-giddens@unc.edu						BONNET C, 1993, CHILD ABUSE NEGLECT, V17, P501, DOI 10.1016/0145-2134(93)90025-Z; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P187; Cesario SK, 2002, APSAC ADVISOR, V14, P24; DAILARD C, 2000, GUTTMACHER REPORT PU, V3, P1; DALLARD C, 2000, GUTTMACHER REPORT, V3, P11; FINNEGAN P, 1982, CAN J PSYCHIAT, V27, P672, DOI 10.1177/070674378202700813; GREEN CM, 1990, BRIT J PSYCHIAT, V156, P121, DOI 10.1192/bjp.156.1.121; Guileyardo JM, 1999, AM J FOREN MED PATH, V20, P286, DOI 10.1097/00000433-199909000-00014; KAYE NS, 1990, J FORENSIC SCI, V35, P133; LESTER D, 1991, SOC PSYCH PSYCH EPID, V26, P83, DOI 10.1007/BF00791532; Mendlowicz MV, 1999, J FORENSIC SCI, V44, P741; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; RESNICK PJ, 1970, AM J PSYCHIAT, V126, P1414, DOI 10.1176/ajp.126.10.1414; SADOFF RL, 1995, PSYCHIAT ANN, V25, P601, DOI 10.3928/0048-5713-19951001-04; Spielvogel AM, 1995, BIRTH-ISS PERINAT C, V22, P220, DOI 10.1111/j.1523-536X.1995.tb00262.x; *U N CAR CHAP HILL, 1997, N CAR MED EX DAT; Warren J I, 1991, Bull Am Acad Psychiatry Law, V19, P63	17	79	83	1	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	2003	289	11					1425	1429		10.1001/jama.289.11.1425	http://dx.doi.org/10.1001/jama.289.11.1425			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	656PM	12636466	Bronze			2022-12-28	WOS:000181616200035
J	Sirovich, BE; Schwartz, LM; Woloshin, S				Sirovich, BE; Schwartz, LM; Woloshin, S			Screening men for prostate and colorectal cancer in the United States - Does practice reflect the evidence?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FECAL-OCCULT-BLOOD; RANDOMIZED CONTROLLED TRIAL; PRIMARY-CARE PHYSICIANS; PATIENTS SELF-REPORTS; PAP SMEAR; PART I; MORTALITY; ANTIGEN; QUEBEC; VALIDITY	Context The debate about the efficacy of prostate-specific antigen (PSA) screening for prostate cancer has received substantial attention in the medical literature and the media, but the extent to which men are actually screened is unknown. If practice were evidence-based, PSA screening would be less common among men than colorectal cancer screening, a preventive service of broad acceptance and proven efficacy. Objective To compare the prevalences of PSA and colorectal cancer screening among US men. Design, Setting, and Population The 2001 Behavioral Risk Factor Surveillance System, an annual population-based telephone survey of US adults conducted by the Centers for Disease Control and Prevention, was used to gather data on a representative sample of men aged 40 years or older from all 50 states and the District of Columbia (n=49315). Main Outcome Measures Proportions of men ever screened and up to date on screening for prostate cancer (with PSA testing) and colorectal cancer (with fecal occult blood testing, flexible sigmoidoscopy, or colonoscopy). Results Overall, men are more likely to report having ever been screened for prostate cancer than for colorectal cancer; 75% of those aged 50 years or older have had a PSA test vs 63% for any colorectal cancer test (risk ratio [RR], 1.20; 95% confidence interval [CI], 1.18-1.21). Up-to-date PSA screening is also more common than colorectal cancer screening for men of all ages. Among men aged 50 to 69 years (those for whom there is the greatest consensus in favor of screening), 54% reported an up-to-date PSA screen, while 45% reported up-to-date testing for colorectal cancer (RR, 1.19; 95% CI, 1.16-1.21). In state-level analyses of this age group, men were significantly more likely to be up to date on prostate cancer screening compared with colorectal cancer screening in 27 states, while up-to-date colorectal cancer screening was more common in only 1 state. Conclusion Among men in the United States, prostate cancer screening is more common than colorectal cancer screening. Physicians should ensure that men who choose to be screened for cancer are aware of the known mortality benefit of colorectal cancer screening and the uncertain benefits of screening for prostate cancer.	Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Norris Cotton Canc Ctr, Hanover, NH 03756 USA	VA Outcomes Group; Dartmouth College; Norris Cotton Cancer Center	Sirovich, BE (corresponding author), Dept Vet Affairs Med Ctr, VA Outcomes Grp, 111B,, White River Jct, VT 05009 USA.				NCI NIH HHS [CA91052-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R18CA091052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander FE, 1999, PROSTATE, V40, P135; [Anonymous], 2001, MMWR MORB MORTAL WKL, V50, P162; Baier M, 2000, CANCER EPIDEM BIOMAR, V9, P229; Barry MJ, 2000, J GEN INTERN MED, V15, P749, DOI 10.1046/j.1525-1497.2000.00816.x; Boer R, 1999, PROSTATE, V40, P130; BOWMAN JA, 1991, HEALTH SERV RES, V26, P97; Brawer MK, 1999, CA-CANCER J CLIN, V49, P264, DOI 10.3322/canjclin.49.5.264; Carroll P, 2001, UROLOGY, V57, P217, DOI 10.1016/S0090-4295(00)00993-6; Catalona WJ, 2000, UROLOGY, V55, P791, DOI 10.1016/S0090-4295(99)00602-0; *CDCP, 2002, 2001 BEH RISK FACT S; Centers for Disease Control and Prevention, 2002, BEH RISK FACT SURV S; Coley CM, 1997, ANN INTERN MED, V126, P480; Donovan JL, 2001, BMJ-BRIT MED J, V323, P763, DOI 10.1136/bmj.323.7316.763; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; FARRELL MH, 2002, EFF CLIN PRACT, V5, P91; Fowler FJ, 1998, AM J MED, V104, P526, DOI 10.1016/S0002-9343(98)00124-7; Hahn DL, 1999, J FAM PRACTICE, V48, P679; Hankey BF, 1999, JNCI-J NATL CANCER I, V91, P1017, DOI 10.1093/jnci/91.12.1017; Hawley ST, 2001, CANCER DETECT PREV, V25, P309; Hoffman RM, 1996, AM J PREV MED, V12, P277, DOI 10.1016/S0749-3797(18)30325-8; Jordan TR, 1999, PREV MED, V28, P297, DOI 10.1006/pmed.1998.0430; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; Labrie F, 2000, PROSTATE, V43, P215, DOI 10.1002/(SICI)1097-0045(20000515)43:3<215::AID-PROS7>3.0.CO;2-G; Labrie F, 1999, PROSTATE, V38, P83, DOI 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B; Labrie F, 1999, PROSTATE, V40, P132; Labrie F, 1999, PROSTATE, V40, P137; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; Mandelson MT, 1999, AM J EPIDEMIOL, V150, P617; McGovern PG, 1998, AM J PREV MED, V14, P201, DOI 10.1016/S0749-3797(97)00076-7; Mettlin C, 1997, PROSTATE, V31, P71; MULLER AD, 1995, ANN INTERN MED, V123, P904, DOI 10.7326/0003-4819-123-12-199512150-00002; *NAT CTR HLTH STAT, 2000, NAT HLTH INT SURV DA; *NAT CTR HLTH STAT, 2002, NCHS DEF ALPH LIST M; *NCI, 2002, SEER INC US MORT STA; Pignone M, 2000, ANN INTERN MED, V133, P761, DOI 10.7326/0003-4819-133-10-200011210-00008; *POP EST PROGR POP, 2002, ANN POP EST AG GROUP; Prorok PC, 2000, CONTROL CLIN TRIALS, V21, p273S, DOI 10.1016/S0197-2456(00)00098-2; Ransohoff DF, 2002, NEW ENGL J MED, V346, P40, DOI 10.1056/NEJMcp010886; Rex DK, 2000, AM J GASTROENTEROL, V95, P868, DOI 10.1111/j.1572-0241.2000.02059.x; Ries LA, 2002, SEER CANC STAT REV 1; Schroy PC, 2001, PREV MED, V33, P381, DOI 10.1006/pmed.2001.0903; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Smith RA, 2002, CA-CANCER J CLIN, V52, P8, DOI 10.3322/canjclin.52.1.8; Standaert B, 1997, CANCER, V80, P1830; SUAREZ L, 1995, AM J PREV MED, V11, P94, DOI 10.1016/S0749-3797(18)30483-5; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P119; US Preventive Services Task Force United States. Office of Disease Prevention Health Promotion, 1996, GUID CLIN PREV SERV, P89; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; Volk RJ, 2002, AM J PREV MED, V22, P56, DOI 10.1016/S0749-3797(01)00397-X; Voss JD, 2001, J GEN INTERN MED, V16, P831, DOI 10.1046/j.1525-1497.2001.10133.x; WHITMAN S, 1993, INT J EPIDEMIOL, V22, P393, DOI 10.1093/ije/22.3.393; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Woloshin S, 1999, NEW ENGL J MED, V340, P884, DOI 10.1056/NEJM199903183401112	54	266	271	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	2003	289	11					1414	1420		10.1001/jama.289.11.1414	http://dx.doi.org/10.1001/jama.289.11.1414			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656PM	12636464				2022-12-28	WOS:000181616200033
J	Spencer, J				Spencer, J			ABC of learning and. teaching in medicine - Learning and teaching in the clinical environment	BMJ-BRITISH MEDICAL JOURNAL			English	Review							EXPERIENCE; PATIENT		Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK	Spencer, J (corresponding author), Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.							COX K, 1993, MED J AUSTRALIA, V159, P64, DOI 10.5694/j.1326-5377.1993.tb137710.x; COX K, 1993, MED J AUSTRALIA, V158, P789, DOI 10.5694/j.1326-5377.1993.tb121968.x; COX K, 1993, MED J AUSTRALIA, V158, P607, DOI 10.5694/j.1326-5377.1993.tb137629.x; COX K, 1993, MED J AUSTRALIA, V158, P493, DOI 10.5694/j.1326-5377.1993.tb137586.x; COX K, 1993, MED J AUSTRALIA, V158, P417, DOI 10.5694/j.1326-5377.1993.tb121840.x; COX K, 1993, MED J AUSTRALIA, V158, P355, DOI 10.5694/j.1326-5377.1993.tb121800.x; COX K, 1993, MED J AUSTRALIA, V158, P280, DOI 10.5694/j.1326-5377.1993.tb121757.x; COX K, 1993, MED J AUSTRALIA, V158, P571, DOI 10.5694/j.1326-5377.1993.tb121881.x; HARGREAVES DH, 1997, JOB LEARNING PHYSICI; Parsell G, 2001, MED EDUC, V35, P409, DOI 10.1046/j.1365-2923.2001.00900.x	10	269	285	1	40	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2003	326	7389					591	594		10.1136/bmj.326.7389.591	http://dx.doi.org/10.1136/bmj.326.7389.591			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657ZF	12637408	Green Published			2022-12-28	WOS:000181696600024
J	Toma, TP; Hopkinson, NS; Hillier, J; Hansell, DM; Morgan, C; Goldstraw, PG; Polkey, MI; Geddes, DM				Toma, TP; Hopkinson, NS; Hillier, J; Hansell, DM; Morgan, C; Goldstraw, PG; Polkey, MI; Geddes, DM			Bronchoscopic volume reduction with valve implants in patients with severe emphysema.	LANCET			English	Article								Eight patients with severe emphysema entered a pilot study of unilateral volume reduction by endobronchial valve insertion. Five patients had emphysema judged too severe for volume reduction surgery and three refused the operation. After valve insertions, the median forced expiratory volume in 1 s (FEV1) increased from 0.79 L (range 0.61-1.07) to 1.06 L (0.75-1.22) (difference 34%, p=0.028) and the median diffusing capacity (TLco) increased from 3.05 mL/min/mm Hg (2.35-4.71) to 3.92 mL/min/mm Hg (2.89-5.40) (difference 29%, p=0.017). CT scans showed a substantial reduction in regional volume in four of the eight patients. Two patients developed a transient pneumothorax (one requiring drainage) but we recorded no other important adverse effects during follow-up. Lung-volume reduction can be achieved with unilateral bronchoscopically placed valve implants in patients with severe emphysema with acceptable short-term safety and worthwhile functional benefits.	Royal Brompton Hosp, Dept Resp Med, London SW3 6NP, England; Royal Brompton Hosp, Dept Radiol, London SW3 6NP, England; Royal Brompton Hosp, Dept Anaesthesia, London SW3 6NP, England; Royal Brompton Hosp, Dept Thorac Surg, London SW3 6NP, England; Natl Heart & Lung Inst, Dept Thorac Med, London, England	Royal Brompton Hospital; Royal Brompton Hospital; Royal Brompton Hospital; Royal Brompton Hospital; Imperial College London	Geddes, DM (corresponding author), Royal Brompton Hosp, Dept Resp Med, London SW3 6NP, England.			Hillier, James/0000-0001-9591-6510				Fishman A, 2001, NEW ENGL J MED, V345, P1075; Geddes D, 2000, NEW ENGL J MED, V343, P239, DOI 10.1056/NEJM200007273430402; Ingenito EP, 2003, AM J RESP CRIT CARE, V167, P771, DOI 10.1164/rccm.200208-842OC; SNELL GI, 2001, ACCP M; Toma TP, 2001, LANCET, V357, P1621, DOI 10.1016/S0140-6736(00)04761-9	5	208	239	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 15	2003	361	9361					931	933		10.1016/S0140-6736(03)12762-6	http://dx.doi.org/10.1016/S0140-6736(03)12762-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648974				2022-12-28	WOS:000181741600013
J	Weinshenker, BG				Weinshenker, BG			Neuromyelitis optica: what it is and what it might be	LANCET			English	Editorial Material							MULTIPLE-SCLEROSIS		Mayo Clin Mayo Fdn, Rochester, MN 55902 USA	Mayo Clinic	Weinshenker, BG (corresponding author), Mayo Clin Mayo Fdn, Rochester, MN 55902 USA.	weinb@mayo.edu	Weinshenker, Brian G/ABH-6146-2020	Weinshenker, Brian G/0000-0001-5806-6203				Bonnet F, 1999, LUPUS, V8, P244, DOI 10.1191/096120399678847696; de Seze J, 2002, J NEUROL SCI, V197, P57, DOI 10.1016/S0022-510X(02)00043-6; Devic C., 1894, B MED, V35; Karussis D, 1998, ANN NEUROL, V44, P629, DOI 10.1002/ana.410440408; Katz JD, 2000, ARCH NEUROL-CHICAGO, V57, P355, DOI 10.1001/archneur.57.3.355; Keegan M, 2002, NEUROLOGY, V58, P143, DOI 10.1212/WNL.58.1.143; KUROIWA Y, 1982, JPN J MED, V21, P135; Lucchinetti CF, 2002, BRAIN, V125, P1450, DOI 10.1093/brain/awf151; Mandler RN, 1998, NEUROLOGY, V51, P1219, DOI 10.1212/WNL.51.4.1219; Masuhr F, 2002, EUR J NEUROL, V9, P430, DOI 10.1046/j.1468-1331.2002.t01-1-00417.x; Misu T, 2002, BRAIN, V125, P2460, DOI 10.1093/brain/awf260; Mochizuki A, 2000, NEUROLOGY, V54, P1391, DOI 10.1212/WNL.54.6.1391; Ono T, 1998, TISSUE ANTIGENS, V52, P539, DOI 10.1111/j.1399-0039.1998.tb03084.x; Weinshenker BG, 1999, FRONTIERS IN MULTIPLE SCLEROSIS, VOL 2, P37; Wingerchuk DM, 1999, NEUROLOGY, V53, P1107, DOI 10.1212/WNL.53.5.1107; Yamasaki K, 1999, BRAIN, V122, P1689, DOI 10.1093/brain/122.9.1689	16	68	70	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	2003	361	9361					889	890		10.1016/S0140-6736(03)12784-5	http://dx.doi.org/10.1016/S0140-6736(03)12784-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648964				2022-12-28	WOS:000181741600003
J	Cole-Hamilton, DJ				Cole-Hamilton, DJ			Homogeneous catalysis - new approaches to catalyst separation, recovery, and recycling	SCIENCE			English	Review							SUPERCRITICAL CARBON-DIOXIDE; HIGHLY SELECTIVE HYDROFORMYLATION; IONIC LIQUIDS; PHOSPHINE-LIGANDS; PHASE CATALYSIS; HYDROGENATION; SILICA; CO2; ULTRAFILTRATION; IMMOBILIZATION	Homogeneous catalysts have many attractive properties, such as high selectivities. However, many homogeneous catalytic systems cannot be commercialized because of difficulties associated with separating the products from the catalyst. Recent approaches to tackling this problem are reviewed and compared.	Univ St Andrews, Sch Chem, St Andrews, Fife, Scotland	University of St Andrews	Cole-Hamilton, DJ (corresponding author), Univ St Andrews, Sch Chem, St Andrews, Fife, Scotland.							Arya P, 2001, J AM CHEM SOC, V123, P2889, DOI 10.1021/ja003854s; Arya P, 2000, J ORG CHEM, V65, P1881, DOI 10.1021/jo991621h; Blanchard LA, 2001, IND ENG CHEM RES, V40, P287, DOI 10.1021/ie000710d; Blanchard LA, 1999, NATURE, V399, P28, DOI 10.1038/19887; Bosmann A, 2001, ANGEW CHEM INT EDIT, V40, P2697, DOI 10.1002/1521-3773(20010716)40:14<2697::AID-ANIE2697>3.0.CO;2-W; Bourque SC, 2000, J AM CHEM SOC, V122, P956, DOI 10.1021/ja993196f; Brasse CC, 2000, ORGANOMETALLICS, V19, P3818, DOI 10.1021/om000183y; Bronger RPJ, 2002, CHEM COMMUN, P3044, DOI 10.1039/b209486j; BROWNSTEIN AM, 1991, CHEMTECH, V21, P506; CHAUVIN Y, 1996, ANGEW CHEM INT EDIT, V34, P2698; CORNILS B, 1996, APPL HOMOGENEOUS CAT, V1, P577; de Groot D, 1999, CHEM COMMUN, P1623, DOI 10.1039/a904455h; Foster DF, 2002, TETRAHEDRON, V58, P3901, DOI 10.1016/S0040-4020(02)00215-6; FROHNING CD, 1996, APPL HOMOGENEOUS CAT, V1, P27, DOI DOI 10.1002/9783527619351.CH2A; HIDECKI S, 1997, Patent No. 235250; Horvath IT, 1998, J AM CHEM SOC, V120, P3133, DOI 10.1021/ja9738337; Hou ZS, 2002, NEW J CHEM, V26, P1246, DOI 10.1039/b201997c; HOWARD MJ, 1993, CATAL TODAY, V18, P325, DOI 10.1016/0920-5861(93)80060-E; Kainz S, 1999, J AM CHEM SOC, V121, P6421, DOI 10.1021/ja984309i; Koch D, 1998, J AM CHEM SOC, V120, P13398, DOI 10.1021/ja980729w; Lozano P, 2002, CHEM COMMUN, P692, DOI 10.1039/b200055e; Meehan NJ, 2000, CHEM COMMUN, P1497, DOI 10.1039/b002526g; Mehnert CP, 2002, J AM CHEM SOC, V124, P12932, DOI 10.1021/ja0279242; Mullineaux R. D., 1966, US, Patent No. [3239569 A, 3239569]; MULLINEUX RD, 1966, Patent No. 3269570; Nair D, 2002, GREEN CHEM, V4, P319, DOI 10.1039/b203232p; Reetz MT, 2002, CHEM COMMUN, P992, DOI 10.1039/b202322a; ROPARTZ L, 1908, J CHEM SOC DA, P4323; Sandee AJ, 1999, ANGEW CHEM INT EDIT, V38, P3231, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3231::AID-ANIE3231>3.0.CO;2-B; Sandee AJ, 2001, ADV SYNTH CATAL, V343, P201; Sandee AJ, 2001, J AM CHEM SOC, V123, P8468, DOI 10.1021/ja010150p; Schwab E, 2001, ORGANOMETALLICS, V20, P5504, DOI 10.1021/om0107542; Sellin MF, 2002, J CHEM SOC DALTON, P4569, DOI 10.1039/b207747g; Sellin MF, 2001, CHEM COMMUN, P781, DOI 10.1039/b101046h; Tupitsyn SB, 1996, PETROL CHEM+, V36, P249; Tzschucke CC, 2002, ANGEW CHEM INT EDIT, V41, P3964, DOI 10.1002/1521-3773(20021104)41:21<3964::AID-ANIE3964>3.0.CO;2-3; van den Broeke LJP, 2001, ANGEW CHEM INT EDIT, V40, P4473, DOI 10.1002/1521-3773(20011203)40:23<4473::AID-ANIE4473>3.0.CO;2-0; Vogt D., 2002, APPL HOMOGENEOUS CAT, V1, P245; WEBB PB, 2002, 13 INT S HOM CAT TAR; Zheng XL, 1998, CATAL TODAY, V44, P175, DOI 10.1016/S0920-5861(98)00188-6	40	931	952	14	452	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1702	1706		10.1126/science.1081881	http://dx.doi.org/10.1126/science.1081881			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637737				2022-12-28	WOS:000181519500036
J	Baloh, RW				Baloh, RW			Vestibular neuritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIAL; DOUBLE-BLIND; VERTIGO; COMPENSATION; DIMENHYDRINATE; ACYCLOVIR; EXERCISES; EMERGENCY		Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Baloh, RW (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, Box 951769, Los Angeles, CA 90095 USA.	rwbaloh@ucla.edu			NIA NIH HHS [AG09693] Funding Source: Medline; NIDCD NIH HHS [DC05224] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P50DC005224] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adour KK, 1996, ANN OTO RHINOL LARYN, V105, P371, DOI 10.1177/000348949610500508; ARIYASU L, 1990, ARCH OTOLARYNGOL, V116, P700; Baloh RW, 1996, OTOLARYNG HEAD NECK, V114, P586, DOI 10.1016/S0194-5998(96)70251-6; COOKSEY FS, 1946, P ROY SOC MED, V39, P273, DOI 10.1177/003591574603900523; DAVIS LE, 1990, AM J OTOLARYNG, V11, P382, DOI 10.1016/0196-0709(90)90116-D; Fetter M, 1996, BRAIN, V119, P755, DOI 10.1093/brain/119.3.755; Furstenberg AC, 1934, ANN OTO RHINOL LARYN, V43, P1035, DOI 10.1177/000348943404300407; Goebel JA, 2001, OTOL NEUROTOL, V22, P512, DOI 10.1097/00129492-200107000-00018; HALMAGYI GM, 1988, ARCH NEUROL-CHICAGO, V45, P737, DOI 10.1001/archneur.1988.00520310043015; Herdman S., 1996, DISORDERS VESTIBULAR, P583; HERDMAN SJ, 1995, OTOLARYNG HEAD NECK, V113, P77, DOI 10.1016/S0194-5998(95)70148-6; HIRATA Y, 1993, ACTA OTO-LARYNGOL, P79; Honrubia V., 2001, CLIN NEUROPHYSIOLOGY; Hotson JR, 1998, NEW ENGL J MED, V339, P680, DOI 10.1056/NEJM199809033391007; IGARASHI M, 1988, PROG BRAIN RES, V76, P395; Irving C, 2002, ACAD EMERG MED, V9, P650, DOI 10.1111/j.1553-2712.2002.tb02309.x; Marill KA, 2000, ANN EMERG MED, V36, P310, DOI 10.1067/mem.2000.110580; PEPPARD SB, 1986, LARYNGOSCOPE, V96, P878; RASCOL O, 1995, DRUGS, V50, P777, DOI 10.2165/00003495-199550050-00002; Schmid-Priscoveanu A, 2001, JARO-J ASSOC RES OTO, V2, P72, DOI 10.1007/s101620010060; SCHUKNECHT HF, 1981, ANN OTO RHINOL LARYN, V90, P1; SHUKNECHT HF, 1999, ANN NEUROL, V46, P416; Stokroos RJ, 1998, ACTA OTO-LARYNGOL, V118, P488, DOI 10.1080/00016489850154603; Strupp M, 1998, NEUROLOGY, V51, P838, DOI 10.1212/WNL.51.3.838; WOOD MJ, 1994, NEW ENGL J MED, V330, P896, DOI 10.1056/NEJM199403313301304	25	193	214	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					1027	1032		10.1056/NEJMcp021154	http://dx.doi.org/10.1056/NEJMcp021154			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653YT	12637613				2022-12-28	WOS:000181465200008
J	Buesseler, KO; Boyd, PW				Buesseler, KO; Boyd, PW			Will ocean fertilization work?	SCIENCE			English	Editorial Material							IRON FERTILIZATION; SOUTHERN-OCEAN; PHYTOPLANKTON; BLOOM		Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Univ Otago, Dept Chem, Natl Inst Water & Atmospher Res, Ctr Phys & Chem Oceanog, Dunedin 9001, New Zealand	Woods Hole Oceanographic Institution; National Institute of Water & Atmospheric Research (NIWA) - New Zealand; University of Otago	Buesseler, KO (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.	kbuesseler@whoi.edu; p.boyd@niwa.co.nz	Boyd, Philip W/J-7624-2014	Boyd, Philip W/0000-0001-7850-1911				Abbott MR, 2001, DEEP-SEA RES PT II, V48, P3891, DOI 10.1016/S0967-0645(01)00073-X; Boyd PW, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014130; Boyd PW, 2000, NATURE, V407, P695, DOI 10.1038/35037500; BUESSELER KO, 2002, EOS S, V83; Charette MA, 2000, GEOCHEM GEOPHY GEOSY, V1, DOI 10.1029/2000GC000069; Chisholm SW, 2001, SCIENCE, V294, P309, DOI 10.1126/science.1065349; COALE K, 2002, EOS S, V83; Feely R.A., 2001, OCEANOGRAPHY, V14, P18, DOI DOI 10.5670/0CEAN0G.2001.03; Johnson KS, 2002, SCIENCE, V296, P467; Lawrence MG, 2002, SCIENCE, V297, P1993; Ledwell JR, 1998, J GEOPHYS RES-OCEANS, V103, P21499, DOI 10.1029/98JC01738; MARKELS M, 2000, 220 ACS ANN M S CO2; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; Nodder SD, 2001, GEOPHYS RES LETT, V28, P2409, DOI 10.1029/2001GL013008; SCHLERMEIER Q, 2003, NATURE, V421, P109; Smetacek V., 2001, US JGOFS NEWS, V11, P11; SUNDA WG, 1995, MAR CHEM, V50, P189, DOI 10.1016/0304-4203(95)00035-P	17	79	81	2	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					67	68		10.1126/science.1082959	http://dx.doi.org/10.1126/science.1082959			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677048				2022-12-28	WOS:000181988900026
J	Martin, P; Parkhurst, SM				Martin, P; Parkhurst, SM			May the force be with you	SCIENCE			English	Editorial Material							DROSOPHILA DORSAL CLOSURE; DYNAMIC ANALYSIS; MORPHOGENESIS; AMNIOSEROSA; EPIDERMIS; MOVEMENT; ADHESION; KINASE		UCL, Dept Anat, London WC1E 6BT, England; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	University of London; University College London; Fred Hutchinson Cancer Center	Martin, P (corresponding author), UCL, Dept Anat, Gower St, London WC1E 6BT, England.	paul.martin@ucl.ac.uk; susanp@fhcrc.org		Martin, Paul/0000-0002-2665-5086; Parkhurst, Susan/0000-0001-5806-9930				Bloor JW, 2002, DEVELOPMENT, V129, P3173; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Harden N, 2002, DIFFERENTIATION, V70, P181, DOI 10.1046/j.1432-0436.2002.700408.x; Harden N, 2002, J CELL SCI, V115, P2119; Hutson MS, 2003, SCIENCE, V300, P145, DOI 10.1126/science.1079552; Jacinto A, 2002, CURR BIOL, V12, P1245, DOI 10.1016/S0960-9822(02)00955-7; Jacinto A, 2002, DEV CELL, V3, P9, DOI 10.1016/S1534-5807(02)00208-3; Jacinto A, 2000, CURR BIOL, V10, P1420, DOI 10.1016/S0960-9822(00)00796-X; Kaltschmidt JA, 2002, NAT CELL BIOL, V4, P937, DOI 10.1038/ncb882; Kiehart DP, 2000, J CELL BIOL, V149, P471, DOI 10.1083/jcb.149.2.471; Magie CR, 1999, DEVELOPMENT, V126, P5353; Ramet M, 2002, DEV BIOL, V241, P145, DOI 10.1006/dbio.2001.0502; Reed BH, 2001, CURR BIOL, V11, P1098, DOI 10.1016/S0960-9822(01)00318-9; Schock F, 2002, DEV BIOL, V248, P29, DOI 10.1006/dbio.2002.0698; Wang N, 2002, CELL MOTIL CYTOSKEL, V52, P97, DOI 10.1002/cm.10037; Wood W, 2002, NAT CELL BIOL, V4, P907, DOI 10.1038/ncb875; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	17	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					63	+		10.1126/science.1084148	http://dx.doi.org/10.1126/science.1084148			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677046				2022-12-28	WOS:000181988900024
J	Valle, M; Gillet, R; Kaur, S; Henne, A; Ramakrishnan, V; Frank, J				Valle, M; Gillet, R; Kaur, S; Henne, A; Ramakrishnan, V; Frank, J			Visualizing tmRNA entry into a stalled ribosome	SCIENCE			English	Article							ELONGATION-FACTOR TU; AMINOACYL-TRANSFER-RNA; PROTEIN S1; CONFORMATIONAL-CHANGE; CRYSTAL-STRUCTURE; MESSENGER-RNA; SMPB SYSTEM; EF-TU; BINDING; GTP	Bacterial ribosomes stalled on defective messenger RNAs (mRNAs) are rescued by tmRNA, an similar to300-nucleotide-long molecule that functions as both transfer RNA (tRNA) and mRNA. Translation then switches from the defective message to a short open reading frame on tmRNA that tags the defective nascent peptide chain for degradation. However, the mechanism by which tmRNA can enter and move through the ribosome is unknown. We present a cryo-electron microscopy study at similar to13 to 15 angstroms of the entry of tmRNA into the ribosome. The structure reveals how tmRNA could move through the ribosome despite its complicated topology and also suggests roles for proteins S1 and SmpB in the function of tmRNA.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Hlth Res Inc, Wadsworth Ctr, Howard Hughes Med Inst, Albany, NY 12201 USA; Inst Microbiol & Genet, Gottingen Genom Lab, D-37077 Gottingen, Germany; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA	MRC Laboratory Molecular Biology; Health Research Inc; Howard Hughes Medical Institute; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Ramakrishnan, V (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	ramak@mrc-lmb.cam.ac.uk; joachim@wadsworth.org	Valle, Mikel/F-7598-2011	Valle, Mikel/0000-0001-8268-6912; Ramakrishnan, V/0000-0002-4699-2194	NIGMS NIH HHS [GM55440, GM 44973, GM29169] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029169, R01GM029169, R01GM055440] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barends S, 2000, BIOCHEMISTRY-US, V39, P2652, DOI 10.1021/bi992439d; Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; BEAR DG, 1976, P NATL ACAD SCI USA, V73, P1824, DOI 10.1073/pnas.73.6.1824; Bordeau V, 2002, BIOCHIMIE, V84, P723, DOI 10.1016/S0300-9084(02)01442-6; Dong G, 2002, EMBO J, V21, P1845, DOI 10.1093/emboj/21.7.1845; Felden B, 1997, RNA, V3, P89; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; Gillet R, 2001, MOL MICROBIOL, V42, P879, DOI 10.1046/j.1365-2958.2001.02701.x; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 2000, P NATL ACAD SCI USA, V97, P7778, DOI 10.1073/pnas.97.14.7778; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Knudsen B, 2001, NUCLEIC ACIDS RES, V29, P171, DOI 10.1093/nar/29.1.171; LAUGHREA M, 1977, J MOL BIOL, V112, P399, DOI 10.1016/S0022-2836(77)80189-7; Lee S, 2001, RNA, V7, P999, DOI 10.1017/S1355838201010342; Nameki N, 2000, FEBS LETT, V470, P345, DOI 10.1016/S0014-5793(00)01349-1; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; Rudinger-Thirion J, 1999, RNA, V5, P989, DOI 10.1017/S135583829999101X; Sengupta J, 2001, P NATL ACAD SCI USA, V98, P11991, DOI 10.1073/pnas.211266898; Stagg SM, 2001, J MOL BIOL, V309, P727, DOI 10.1006/jmbi.2001.4632; Stark H, 2002, NAT STRUCT BIOL, V9, P849, DOI 10.1038/nsb859; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; Williams KP, 1996, RNA, V2, P1306; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Withey JH, 2002, CURR OPIN MICROBIOL, V5, P154, DOI 10.1016/S1369-5274(02)00299-0; Wower IK, 2000, EMBO J, V19, P6612, DOI 10.1093/emboj/19.23.6612; Wower J, 2002, BIOCHEMISTRY-US, V41, P8826, DOI 10.1021/bi0201365; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4; Zvereva MI, 2001, J BIOL CHEM, V276, P47702, DOI 10.1074/jbc.M106786200; Zwieb C, 1999, NUCLEIC ACIDS RES, V27, P2063, DOI 10.1093/nar/27.10.2063	38	121	128	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					127	130		10.1126/science.1081798	http://dx.doi.org/10.1126/science.1081798			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677067				2022-12-28	WOS:000181988900048
J	Walsh, NP; Alba, BM; Bose, B; Gross, CA; Sauer, RT				Walsh, NP; Alba, BM; Bose, B; Gross, CA; Sauer, RT			OMP peptide signals initiate the envelope-stress response by activating DegS protease via relief of inhibition mediated by its PDZ domain	CELL			English	Article							OUTER-MEMBRANE PROTEINS; TAIL-SPECIFIC PROTEASE; ESCHERICHIA-COLI K-12; EXTRACYTOPLASMIC STRESS; SUBSTRATE RECOGNITION; HIGH-TEMPERATURE; SIGMA-FACTOR; CHAPERONE; GENE; RSEA	Transmembrane signaling between intracellular compartments is often controlled by regulated proteolysis. Escherichia coli respond to misfolded or unfolded outer-membrane porins (OMPs) in the periplasm by inducing sigma(E)-dependent transcription of stress genes in the cytoplasm. This process requires a proteolytic cascade initiated by the DegS protease, which destroys a transmembrane protein (RseA) that normally binds to and inhibits sigma(E). Here, we show that peptides ending with OMP-like C-terminal sequences bind the DegS PDZ domain, activate DegS cleavage of RseA, and induce sigma(E)-dependent transcription. These results suggest that DegS acts as a sensor of envelope stress by binding unassembled OMPs. DegS activation involves relief of inhibitory interactions between its PDZ and protease domains. Peptide binding to inhibitory PDZ domains. in proteases related to DegS, including DegP/HtrA, may also regulate the degradation of specific substrates by these enzymes.	MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco Med Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, San Francisco Med Ctr, Dept Microbiol & Immunol, Dept Stomatol, San Francisco, CA 94143 USA	Massachusetts Institute of Technology (MIT); University of California System; University of California San Francisco; University of California System; University of California San Francisco	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-15706] Funding Source: Medline; NIGMS NIH HHS [GM36278-19] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015706, R01AI015706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036278, R01GM036278] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ades SE, 1999, GENE DEV, V13, P2449, DOI 10.1101/gad.13.18.2449; ADES SE, 2003, IN PRESS J BACTERIOL; Alba BM, 2002, GENE DEV, V16, P2156, DOI 10.1101/gad.1008902; Alba BM, 2001, MOL MICROBIOL, V40, P1323, DOI 10.1046/j.1365-2958.2001.02475.x; Beebe KD, 2000, BIOCHEMISTRY-US, V39, P3149, DOI 10.1021/bi992709s; Behrens S, 2001, EMBO J, V20, P285, DOI 10.1093/emboj/20.1.285; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMPBELL EA, 2003, IN PRESS MOL CELL; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Collinet B, 2000, J BIOL CHEM, V275, P33898, DOI 10.1074/jbc.M006214200; COWAN SW, 1995, STRUCTURE, V3, P1041, DOI 10.1016/S0969-2126(01)00240-4; DeLasPenas A, 1997, MOL MICROBIOL, V24, P373, DOI 10.1046/j.1365-2958.1997.3611718.x; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FLYNN JM, 2003, IN PRESS MOL CELL; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HARA H, 1991, J BACTERIOL, V173, P4799, DOI 10.1128/jb.173.15.4799-4813.1991; Harms N, 2001, J BIOL CHEM, V276, P18804, DOI 10.1074/jbc.M011194200; Harris BZ, 2001, J CELL SCI, V114, P3219; Kanehara K, 2001, GENE, V281, P71, DOI 10.1016/S0378-1119(01)00823-X; Kanehara K, 2002, GENE DEV, V16, P2147, DOI 10.1101/gad.1002302; Keiler KC, 1996, J BIOL CHEM, V271, P2589, DOI 10.1074/jbc.271.5.2589; Kloser A, 1998, MOL MICROBIOL, V27, P1003, DOI 10.1046/j.1365-2958.1998.00746.x; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; LAIRD MW, 1994, J BACTERIOL, V176, P2259, DOI 10.1128/JB.176.8.2259-2264.1994; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; LIPINSKA B, 1989, J BACTERIOL, V171, P1574, DOI 10.1128/jb.171.3.1574-1584.1989; MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618; MILLER JH, 1972, EXPT MOL GENETICS, P274; Missiakas D, 1997, MOL MICROBIOL, V24, P355, DOI 10.1046/j.1365-2958.1997.3601713.x; Missiakas D, 1996, MOL MICROBIOL, V21, P871, DOI 10.1046/j.1365-2958.1996.561412.x; Raivio TL, 2001, ANNU REV MICROBIOL, V55, P591, DOI 10.1146/annurev.micro.55.1.591; RIED G, 1990, J BACTERIOL, V172, P6048, DOI 10.1128/jb.172.10.6048-6053.1990; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; Sambrook J., 2002, MOL CLONING LAB MANU; Schafer U, 1999, J BIOL CHEM, V274, P24567, DOI 10.1074/jbc.274.35.24567; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Spiers A, 2002, J BIOL CHEM, V277, P39443, DOI 10.1074/jbc.M202790200; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; WALSH NP, 2002, THESIS MIT CAMBRIDGE	45	407	414	0	16	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 4	2003	113	1					61	71		10.1016/S0092-8674(03)00203-4	http://dx.doi.org/10.1016/S0092-8674(03)00203-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679035	Bronze			2022-12-28	WOS:000182282900007
J	Karlawish, JHT				Karlawish, JHT			Research involving cognitively impaired adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CLINICAL RESEARCH; INFORMED CONSENT; TRIAL		Univ Penn, Dept Med, Div Geriatr Med, Philadelphia, PA 19104 USA; Univ Penn, Inst Aging, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Alzheimers Dis Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Karlawish, JHT (corresponding author), Univ Penn, Dept Med, Div Geriatr Med, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE ON AGING [K01AG000931] Funding Source: NIH RePORTER; NIA NIH HHS [P30 AG-01024, K01 AG-00931] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM BAR ASS, 2001, SURR CONS ABS ADV DI; Appelbaum P.S., 2001, MACARTHUR COMPETENCE; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CAROME MA, 2003, M1025 MPA OFF HUM RE; CAROME MA, 2002, M1115 MPA OFF HUM RE; Casarett David J, 2002, IRB, V24, P1, DOI 10.2307/3564132; Charney DS, 1999, BIOL PSYCHIAT, V46, P1007; Coppolino M, 2001, CHEST, V119, P603, DOI 10.1378/chest.119.2.603; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P2476; *DEP HLTH ED WELF, 1978, FED REGISTER, V43, P53950; Department of Health and Human Services. Federal policy for the protection of human subjects, 1991, FED REGISTER, V56, P28003; Department of Health Education and Welfare, 1979, FED REGISTER, V44, P192; Drazen JM, 2003, NEW ENGL J MED, V348, P1377, DOI 10.1056/NEJMe030031; Dresser R, 2001, IRB, V23, P1, DOI 10.2307/3563979; Erb TO, 2002, ANESTH ANALG, V94, P1155, DOI 10.1097/00000539-200205000-00018; Fletcher John C, 1985, IRB, V7, P1, DOI 10.2307/3563702; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freedman Benjamin, 1987, IRB, V9, P7, DOI 10.2307/3563623; GRISSO T, 1998, ASSESSING COMPETENCE, P127; Karlawish JHT, 2002, J AM GERIATR SOC, V50, P2019, DOI 10.1046/j.1532-5415.2002.50615.x; Karlawish JHT, 2001, NEUROLOGY, V56, P789, DOI 10.1212/WNL.56.6.789; Karlawish JHT, 1996, AM J RESP CRIT CARE, V153, P499, DOI 10.1164/ajrccm.153.2.8564087; Kim SYH, 2001, AM J PSYCHIAT, V158, P712, DOI 10.1176/appi.ajp.158.5.712; MELNICK VL, 1985, ALZHEIMERS DEMENT, P295; *NAT BIOETH ADV CO, 1998, RES INV PERS MENT DI, V1, P88; National Bioethics Advisory Commission, 2001, ETH POL ISS RES INV, V1, P69; *OHRP, 2002, OHRP INV MULT CTR PH; *OHRP, 2003, OHRP INV MULT DOUBL; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; SEEMAN BT, 2002, SEATTLE TIMES   1212, pA25; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; Steinbrook R, 2003, NEW ENGL J MED, V348, P1393, DOI 10.1056/NEJMhpr030349; WARREN JW, 1986, NEW ENGL J MED, V315, P1124, DOI 10.1056/NEJM198610303151804; Weijer C, 2000, J LAW MED ETHICS, V28, P344, DOI 10.1111/j.1748-720X.2000.tb00686.x; Wendler D, 2002, AM J PSYCHIAT, V159, P585, DOI 10.1176/appi.ajp.159.4.585; WHITE LJ, 1989, ANN INTERN MED, V111, P843, DOI 10.7326/0003-4819-111-10-843	38	65	67	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1389	1392		10.1056/NEJMsb030172	http://dx.doi.org/10.1056/NEJMsb030172			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672869				2022-12-28	WOS:000181949100014
J	Flum, DR; Dellinger, EP; Cheadle, A; Chan, L; Koepsell, T				Flum, DR; Dellinger, EP; Cheadle, A; Chan, L; Koepsell, T			Intraoperative cholangiography and risk of common bile duct injury during cholecystectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLICATIONS FOLLOWING CHOLECYSTECTOMY; BILIARY-TRACT COMPLICATIONS; LAPAROSCOPIC CHOLECYSTECTOMY; OPERATIVE CHOLANGIOGRAPHY; UNITED-STATES; ULTRASONOGRAPHY	Context Intraciperative cholangiography (IOC) may decrease the risk of common bile duct (CBD) injury during cholecystectomy by helping to avoid misidentification of the CBD. Objective To characterize the relationship of IOC use and CBD injury while controlling for patient and surgeon characteristics. Design, Setting, and Patients Retrospective nationwide cohort analysis of Medicare patients undergoing cholecystectomy from January 1, 1992, to December 31, 1999. Patients were identified using Current Procedural Terminology codes from the Medicare Part B depository. Common bile duct injury was defined by a second surgical procedure to repair the CBD injury within 1 year of cholecystectomy. Surgeon demographic features were obtained from matching the Medicare Part B data to the American Medical Association Physician Masterfile database. Main Outcome Measure Frequency of CBD injury in patients who did and did not have IOC performed during cholecystectomy, controlling for patient-level (age, sex, race, and case complexity) and surgeon-level (surgeon's age, sex, race, year of surgical procedure, case order, percentage of IOC use in prior surgical procedures, years in medical practice, board certification, and specialization) factors. Results The database search identified 1570361 cholecystectomies and 7911 CBD injuries (0.5%). Common bile duct injury was found in 2380 (0.39%) of 613 706 patients undergoing cholecystectomy with IOC and in 5531 (0.58%) of 956 655 patients undergoing cholecystectomy without IOC (unadjusted relative risk, 1.49; 95% confidence interval, 1.42-1.57). After controlling for patient-level factors and surgeon-level factors, the risk of injury was increased when IOC was not used (adjusted relative risk, 1.71; 95% confidence interval, 1.38-2.28). While surgeons performing IOCs routinely had a lower rate of CBD injuries than those who did not, this difference disappeared when IOC was not used. Conclusions In this study of Medicare patients undergoing cholecystectomy in the 1990s, the risk of CBD injury was significantly higher when IOC was not used. Although IOCs may not prevent all CBD injuries, this study suggests, that the routine use of IOC may decrease the rate of CBD injury.	Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Robert Wood Johnson Clin Scholars Program, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Ctr Medicare & Medicaid Serv, Div Clin Stand & Qual, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centers for Medicare & Medicaid Services	Flum, DR (corresponding author), Univ Washington, Dept Surg, BB 431,1959 NE Pacific St,Box 356410, Seattle, WA 98195 USA.	daveflum@u.washington.edu	Flum, David/GPX-7976-2022					Archer SB, 2001, ANN SURG, V234, P549, DOI 10.1097/00000658-200110000-00014; ASBUN HJ, 1994, SURG CLIN N AM, V74, P755, DOI 10.1016/S0039-6109(16)46405-4; Baldwin LM, 2002, MED CARE, V40, P82; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Birth M, 1996, SURG ENDOSC-ULTRAS, V10, P794, DOI 10.1007/BF00189535; *CDCP NAT CTR HLTH, HOSP CAR STAT BRANCH; Contini S, 1999, J LAPAROENDOSC ADV A, V9, P197, DOI 10.1089/lap.1999.9.197; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Fiore NF, 1997, SURGERY, V122, P817, DOI 10.1016/S0039-6060(97)90092-1; Fletcher DR, 1999, ANN SURG, V229, P449, DOI 10.1097/00000658-199904000-00001; Flum DR, 2003, J AM COLL SURGEONS, V196, P385, DOI 10.1016/S1072-7515(02)01806-9; Flum DR, 2001, ARCH SURG-CHICAGO, V136, P1287, DOI 10.1001/archsurg.136.11.1287; Fowles J B, 1995, Health Care Financ Rev, V16, P189; Gigot JF, 1997, SURG ENDOSC-ULTRAS, V11, P1171, DOI 10.1007/s004649900563; *ING INC, 2000, ICD 9 CM EXP; Johnson SR, 2000, SURGERY, V128, P668, DOI 10.1067/msy.2000.108422; Katkhouda N, 2000, SURG ENDOSC-ULTRAS, V14, P88, DOI 10.1007/s004649900020; Ladocsi LT, 1997, AM SURGEON, V63, P150; Machi J, 1999, J AM COLL SURGEONS, V188, P360, DOI 10.1016/S1072-7515(98)00313-5; Mahmud S, 2002, SURG ENDOSC, V16, P581, DOI 10.1007/s00464-001-9094-6; Mirizzi PL, 1937, SURG GYNECOL OBSTET, V65, P702; Moskovitz A H, 2001, Surg Endosc, V15, P1227; *PHYS INS ASS AM, 2000, LAP INJ STUD 2000, P11; *PHYS INS ASS AM, 2000, RISK MAN REV GEN SUR, P15; Podnos YD, 2001, AM J SURG, V182, P663, DOI 10.1016/S0002-9610(01)00808-X; POSTA CG, 1995, SURG LAPAROSC ENDOSC, V5, P412; Roviaro GC, 1997, J ROY COLL SURG EDIN, V42, P324; SOPER NJ, 1994, SURG CLIN N AM, V74, P953, DOI 10.1016/S0039-6109(16)46397-8; TANIGUCHI Y, 1993, AM J GASTROENTEROL, V88, P1258; Taylor B, 1998, CAN MED ASSOC J, V158, P481; Valinsky LJ, 1999, J CLIN EPIDEMIOL, V52, P893, DOI 10.1016/S0895-4356(99)00043-8; Vecchio R, 1998, INT SURG, V83, P215; Vezakis A, 2000, SURG ENDOSC-ULTRAS, V14, P1118, DOI 10.1007/s004640000076; Wherry DC, 1996, ANN SURG, V224, P145, DOI 10.1097/00000658-199608000-00006; WOODS MS, 1994, AM J SURG, V167, P27, DOI 10.1016/0002-9610(94)90050-7; WOODS MS, 1995, SURG ENDOSC-ULTRAS, V9, P1076; Z'graggen K, 1998, SURG ENDOSC-ULTRAS, V12, P1303, DOI 10.1007/s004649900846; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	38	306	318	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1639	1644		10.1001/jama.289.13.1639	http://dx.doi.org/10.1001/jama.289.13.1639			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662JX	12672731				2022-12-28	WOS:000181944500026
J	Read, RC; Cannings, C; Naylor, SC; Timms, JM; Maheswaran, R; Borrow, R; Kaczmarski, EB; Duff, GW				Read, RC; Cannings, C; Naylor, SC; Timms, JM; Maheswaran, R; Borrow, R; Kaczmarski, EB; Duff, GW			Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY-DISEASE; PLASMINOGEN-ACTIVATOR-INHIBITOR-1 GENE; CYTOKINE PRODUCTION; ULCERATIVE-COLITIS; INCREASED RISK; ALLELE 2; POLYMORPHISM; ASSOCIATION; SUSCEPTIBILITY; IL-1-BETA	Background: Genetically determined variation in proinflammatory cytokine release influences severity of meningococcal disease and other serious infections. Objective: To ascertain the relative frequencies of single nucleotide polymorphisms within the interleukin-1 gene locus among patients who survived and those who died of meningococcal disease and a control population of blood donors. Design: Association study. Setting: England and Wales. Patients: 1106 consecutively received blood samples from persons with microbiologically confirmed meningococcal disease and 839 samples from blood donors. Measurements: Patient demographic and outcome data, infecting meningococcal serogroups, and genotype at the IL1B(-511) and IL1RN(+2018) loci of patients and blood donor controls. Results: Genotype frequency did not differ between patients with meningococcal disease and blood donor controls. Logistic regression analysis revealed that the likelihood of death was significantly influenced by age but not socioeconomic status and was higher in patients who were infected with serogroup C (odds ratio for survival, 0.50 [95% Cl, 0.33 to 0.78]). Patients carrying the common allele at IL1B(-511) were more likely to survive (odds ratio, 2.01 [Cl, 1.11 to 3.79]). Patients with this allele were less likely to survive if they also carried the rare allele at IL1RN(+2018) (odds ratio, 0.61 [Cl, 0.38 to 0.993]). Conclusion: Genotype at the interleukin-1 gene locus influences likelihood of survival of meningococcal disease but has no effect on susceptibility to the infection. Increasing age and infection with serogroup C also influence the likelihood of death.	Univ Sheffield, Sch Med, Div Genom Med, Sheffield S10 2RX, S Yorkshire, England; Manchester Publ Hlth Lab, Meningococcal Ref Unit England & Wales, Manchester, Lancs, England	University of Sheffield	Read, RC (corresponding author), Univ Sheffield, Sch Med, Div Genom Med, F Floor,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	r.c.read@sheffield.ac.uk		Read, Robert/0000-0002-4297-6728; Maheswaran, Ravi/0000-0002-3899-4421				Andus T, 1997, GUT, V41, P651, DOI 10.1136/gut.41.5.651; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Booy R, 2001, ARCH DIS CHILD, V85, P386, DOI 10.1136/adc.85.5.386; Carter MJ, 2001, GUT, V48, P461, DOI 10.1136/gut.48.4.461; Cox A, 1999, HUM MOL GENET, V8, P1707, DOI 10.1093/hmg/8.9.1707; Cox A, 1998, AM J HUM GENET, V62, P1180, DOI 10.1086/301817; DANIS VA, 1995, CLIN EXP IMMUNOL, V99, P303; Di Giovine F. S., 1992, Human Molecular Genetics, V1, P450; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Donaldson P, 2001, GUT, V48, P397, DOI 10.1136/gut.48.3.397; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Fijen CAP, 2000, CLIN EXP IMMUNOL, V120, P338, DOI 10.1046/j.1365-2249.2000.01208.x; Francis SE, 1999, CIRCULATION, V99, P861, DOI 10.1161/01.CIR.99.7.861; GIRAUD T, 1991, ARCH INTERN MED, V151, P310, DOI 10.1001/archinte.151.2.310; Hefler LA, 2001, FERTIL STERIL, V76, P377, DOI 10.1016/S0015-0282(01)01914-8; Hermans PWM, 1999, LANCET, V354, P556, DOI 10.1016/S0140-6736(99)02220-5; Hibberd ML, 1999, LANCET, V353, P1049, DOI 10.1016/S0140-6736(98)08350-0; Kondaveeti S, 1999, PEDIATR INFECT DIS J, V18, P893, DOI 10.1097/00006454-199910000-00011; Kornman KS, 1997, J CLIN PERIODONTOL, V24, P72, DOI 10.1111/j.1600-051X.1997.tb01187.x; Makela S, 2001, NEPHROL DIAL TRANSPL, V16, P1368, DOI 10.1093/ndt/16.7.1368; Momiyama Y, 2001, J AM COLL CARDIOL, V38, P712, DOI 10.1016/S0735-1097(01)01438-3; Murphy GM, 2001, NEUROLOGY, V56, P1595, DOI 10.1212/WNL.56.11.1595; Nadel S, 1996, J INFECT DIS, V174, P878, DOI 10.1093/infdis/174.4.878; NICKLIN MJH, 1994, GENOMICS, V19, P382, DOI 10.1006/geno.1994.1076; Niino M, 2001, J NEUROIMMUNOL, V118, P295, DOI 10.1016/S0165-5728(01)00339-3; Read RC, 2000, J INFECT DIS, V182, P1557, DOI 10.1086/315889; RIORDAN FAI, 1995, EUR J PEDIATR, V154, P472; Santtila S, 1998, SCAND J IMMUNOL, V47, P195; TARLOW JK, 1993, HUM GENET, V91, P403; Tountas NA, 1999, GASTROENTEROLOGY, V117, P806, DOI 10.1016/S0016-5085(99)70338-0; Townsend PP., 1988, HLTH DEPRIVATION INE; Trotter CL, 2002, J MED MICROBIOL, V51, P855, DOI 10.1099/0022-1317-51-10-855; vanDeuren M, 1997, BLOOD, V90, P1101, DOI 10.1182/blood.V90.3.1101.1101_1101_1108; Westendorp RGJ, 1999, LANCET, V354, P561, DOI 10.1016/S0140-6736(98)09376-3; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6; Whyte M, 2000, AM J RESP CRIT CARE, V162, P755, DOI 10.1164/ajrccm.162.2.9909053	37	55	55	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					534	541		10.7326/0003-4819-138-7-200304010-00009	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667023				2022-12-28	WOS:000181872100002
J	Frankel, S; Smith, GD; Donovan, J; Neal, D				Frankel, S; Smith, GD; Donovan, J; Neal, D			Screening for prostate cancer	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; RADICAL PROSTATECTOMY; SURVEILLANCE SERIES; INTERPRETING TRENDS; INTERNATIONAL TRENDS; PREVENTION TRIAL; MORTALITY; MEN; ANTIGEN; DEATH	Epidemiologically, screening is,justified by the importance of the disease and the lack of prospects for primary prevention, but evidence from natural history is unhelpful since men are more likely to die with, rather than from, prostate cancer. The available screening tests do not always detect men whose lesions could result in future morbidity or mortality. Evidence is limited for the benefits of treatment for localised cancers detected through screening, whereas the evidence for harm is clear. Observational evidence for the effect of population screening programmes is mixed, with no clear association between intensity of screening and reduced prostate cancer mortality. Screening for prostate cancer cannot be justified in low-risk populations, but the balance of benefit and harm will be more favourable after risk stratification. Prostate cancer screening can be justified only in research programmes designed to assess its effectiveness and help identify the groups who may benefit.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Addenbrookes Hosp, Ctr Oncol, Cambridge, England	University of Bristol; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Neal, David/0000-0002-6033-5086				Albertsen PC, 1998, JAMA-J AM MED ASSOC, V280, P975, DOI 10.1001/jama.280.11.975; Albertsen PC, 2000, J UROLOGY, V163, P519, DOI 10.1016/S0022-5347(05)67915-3; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; Alexander FE, 1999, PROSTATE, V40, P135; *AM UR SOC, 1992, EX COMM REP; Bangma CH, 1997, J UROLOGY, V157, P2191, DOI 10.1016/S0022-5347(01)64712-8; Bartsch G, 2001, UROLOGY, V58, P417, DOI 10.1016/S0090-4295(01)01264-X; Boer R, 1999, PROSTATE, V40, P130; Bonneux L, 2003, BRIT MED J, V326, P53, DOI 10.1136/bmj.326.7379.53; Caldas C, 2002, NATURE, V415, P484, DOI 10.1038/415484a; Carter HB, 1997, J UROLOGY, V157, P2206, DOI 10.1016/S0022-5347(01)64719-0; Catalona WJ, 1997, JAMA-J AM MED ASSOC, V277, P1452, DOI 10.1001/jama.277.18.1452; Coley CM, 1997, ANN INTERN MED, V126, P480; Collins MM, 1997, JAMA-J AM MED ASSOC, V278, P1516, DOI 10.1001/jama.278.18.1516; Coltman CA, 1999, EUR UROL, V35, P544; Cookson M M, 2001, Cancer Control, V8, P133; Coughlin SS, 2002, ANN EPIDEMIOL, V12, P182, DOI 10.1016/S1047-2797(01)00310-6; DAVEYSMITH G, 1994, BRIT MED J, V308, P72; DIGUISEPPI C, 1996, GUIDE CLIN PREVENTIV; Donovan J, 2002, BMJ-BRIT MED J, V325, P766, DOI 10.1136/bmj.325.7367.766; Donovan Jenny L., 1999, BMJ, V318, P299; Donovan JL, 2001, BMJ-BRIT MED J, V323, P763, DOI 10.1136/bmj.323.7316.763; Egger M, 1998, BRIT MED J, V316, P140; Etzioni R, 1999, J NATL CANCER I, V91, P1033, DOI 10.1093/jnci/91.12.1033; Farkas A, 1998, UROLOGY, V52, P444, DOI 10.1016/S0090-4295(98)00242-8; Ferriman A, 2002, BRIT MED J, V324, P255; Ferrini R, 1998, AM J PREV MED, V15, P81, DOI 10.1016/S0749-3797(98)00050-6; FERRINI R, 2000, AM CANC SOC PROST CA; Feuer EJ, 1999, JNCI-J NATL CANCER I, V91, P1025, DOI 10.1093/jnci/91.12.1025; Fossa SD, 2001, LANCET ONCOL, V2, P741, DOI 10.1016/S1470-2045(01)00588-5; Fowler FJ, 2000, JAMA-J AM MED ASSOC, V283, P3217, DOI 10.1001/jama.283.24.3217; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; Gunnell D, 2001, EPIDEMIOL REV, V23, P313, DOI 10.1093/oxfordjournals.epirev.a000809; Hakama M, 2001, J UROLOGY, V166, P2189, DOI 10.1016/S0022-5347(05)65532-2; Hankey BF, 1999, JNCI-J NATL CANCER I, V91, P1017, DOI 10.1093/jnci/91.12.1017; Hanna CL, 2002, BJU INT, V90, P558, DOI 10.1046/j.1464-410X.2002.02970.x; Hoeksema MJ, 1996, J NATL CANCER I, V88, P1706, DOI 10.1093/jnci/88.23.1706; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; Horninger W, 2000, EUR J CANCER, V36, P1322, DOI 10.1016/S0959-8049(00)00113-1; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; Jani AB, 2003, LANCET, V361, P1045, DOI 10.1016/S0140-6736(03)12833-4; JOHANSSON JE, 1989, LANCET, V1, P799; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Klein EA, 2001, J UROLOGY, V166, P1311, DOI 10.1016/S0022-5347(05)65759-X; Kranse R, 1999, PROSTATE, V39, P316, DOI 10.1002/(SICI)1097-0045(19990601)39:4<316::AID-PROS14>3.0.CO;2-O; Labrie F, 1999, PROSTATE, V38, P83, DOI 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B; Littrup PJ, 1997, CANCER-AM CANCER SOC, V80, P1864; Lu-Yao G, 2002, BMJ-BRIT MED J, V325, P740, DOI 10.1136/bmj.325.7367.740; Maattanen L, 1999, BRIT J CANCER, V79, P1210, DOI 10.1038/sj.bjc.6690194; McGregor M, 1998, CAN MED ASSOC J, V159, P1368; MEIKLE AW, 1990, UROL CLIN N AM, V17, P709; Mettlin CJ, 1998, CANCER, V82, P249, DOI 10.1002/(SICI)1097-0142(19980115)82:2<249::AID-CNCR1>3.0.CO;2-M; Neal D E, 2000, Lancet Oncol, V1, P17, DOI 10.1016/S1470-2045(00)00005-X; Newschaffer CJ, 2000, JNCI-J NATL CANCER I, V92, P613, DOI 10.1093/jnci/92.8.613; *OFF NAT STAT, 1999, 1993 CANC STAT REG; Oliver S, 2000, LANCET, V355, P1788, DOI 10.1016/S0140-6736(00)02269-8; Oliver SE, 2001, INT J CANCER, V92, P893, DOI 10.1002/ijc.1260; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Parkinson MC, 2002, J PATHOL, V197, P139, DOI 10.1002/path.1088; Perron L, 2002, CAN MED ASSOC J, V166, P586; Pollak M, 2001, EPIDEMIOL REV, V23, P59, DOI 10.1093/oxfordjournals.epirev.a000796; POPE A, ESSAY MAN; Reissigl A, 1997, PROSTATE, V30, P20; Schroder FH, 2001, BJU INT, V88, P811, DOI 10.1046/j.1464-4096.2001.02449.x; Schroder FH, 2000, J UROLOGY, V163, P806, DOI 10.1016/S0022-5347(05)67809-3; Selley S, 1997, HLTH TECHNOLOGY ASSE, V1, P1; Siegel T, 2001, J UROLOGY, V165, P430, DOI 10.1097/00005392-200102000-00019; Slevin TJ, 1999, MED J AUSTRALIA, V171, P185, DOI 10.5694/j.1326-5377.1999.tb123594.x; Smith DP, 1998, MED J AUSTRALIA, V169, P17, DOI 10.5694/j.1326-5377.1998.tb141471.x; Smith GD, 2001, BRIT MED J, V322, P184, DOI 10.1136/bmj.322.7280.184; SMITH GD, 1993, J EPIDEMIOL COMMUNIT, V47, P403; Stanford JL, 2000, JAMA-J AM MED ASSOC, V283, P354, DOI 10.1001/jama.283.3.354; Stanford JL, 2001, EPIDEMIOL REV, V23, P19, DOI 10.1093/oxfordjournals.epirev.a000789; Steineck G, 2002, NEW ENGL J MED, V347, P790, DOI 10.1056/NEJMoa021483; UK National Screening Committee, CRIT APPR VIAB EFF A; vonEschenbach A, 1997, CANCER, V80, P1805, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1805::AID-CNCR17>3.3.CO;2-8; Walsh PC, 2002, NEW ENGL J MED, V347, P839, DOI 10.1056/NEJMe020089; Weldon VE, 1997, J UROLOGY, V158, P1470, DOI 10.1016/S0022-5347(01)64245-9; WHITMORE WF, 1994, LANCET, V343, P1263, DOI 10.1016/S0140-6736(94)92156-3; Wilson JMB, 1968, 34 WHO; YARNEY G, 2002, SAN FRANCISCO C 0118	81	140	143	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 29	2003	361	9363					1122	1128		10.1016/S0140-6736(03)12890-5	http://dx.doi.org/10.1016/S0140-6736(03)12890-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672328				2022-12-28	WOS:000181865200026
J	Gu, LH; Baldocchi, DD; Wofsy, SC; Munger, JW; Michalsky, JJ; Urbanski, SP; Boden, TA				Gu, LH; Baldocchi, DD; Wofsy, SC; Munger, JW; Michalsky, JJ; Urbanski, SP; Boden, TA			Response of a deciduous forest to the Mount Pinatubo eruption: Enhanced photosynthesis	SCIENCE			English	Article							CARBON-DIOXIDE; VOLCANIC SIGNAL; ATMOSPHERIC O-2; CO2; AEROSOLS; EXCHANGE; CLIMATE; CLOUDS; FLUXES; WATER	Volcanic aerosols from the 1991 Mount Pinatubo eruption greatly increased diffuse radiation worldwide for the following 2 years. We estimated that this increase in diffuse radiation alone enhanced noontime photosynthesis of a deciduous forest by 23% in 1992 and 8% in 1993 under cloudless conditions. This finding indicates that the aerosol-induced increase in diffuse radiation by the volcano enhanced the terrestrial carbon sink and contributed to the temporary decline in the growth rate of atmospheric carbon dioxide after the eruption.	Oak Ridge Natl Lab, Div Environm Sci, Oak Ridge, TN 37831 USA; Univ Calif Berkeley, Dept Environm Sci Policy & Management, Ecosyst Sci Div, Berkeley, CA 94720 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; SUNY Albany, Atmospher Sci Res Ctr, Albany, NY 12203 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of California System; University of California Berkeley; Harvard University; Harvard University; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Gu, LH (corresponding author), Oak Ridge Natl Lab, Div Environm Sci, Bldg 1509, Oak Ridge, TN 37831 USA.	lianhong-gu@ornl.gov	Gu, Lianhong/H-8241-2014; Munger, J William/H-4502-2013; Manchun, Kang/D-3194-2011; Baldocchi, Dennis/A-1625-2009	Gu, Lianhong/0000-0001-5756-8738; Munger, J William/0000-0002-1042-8452; Baldocchi, Dennis/0000-0003-3496-4919				Baldocchi D, 1997, PLANT CELL ENVIRON, V20, P1108, DOI 10.1046/j.1365-3040.1997.d01-147.x; Baldocchi DD, 2002, TREE PHYSIOL, V22, P1065, DOI 10.1093/treephys/22.15-16.1065; BARAN AJ, 1994, J GEOPHYS RES-ATMOS, V99, P25673, DOI 10.1029/94JD02044; Battle M, 2000, SCIENCE, V287, P2467, DOI 10.1126/science.287.5462.2467; BLUMTHALER M, 1994, TELLUS B, V46, P76, DOI 10.1034/j.1600-0889.1994.00007.x; BLUTH GJS, 1992, GEOPHYS RES LETT, V19, P151, DOI 10.1029/91GL02792; Bousquet P, 2000, SCIENCE, V290, P1342, DOI 10.1126/science.290.5495.1342; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; CONWAY TJ, 1994, J GEOPHYS RES-ATMOS, V99, P22831, DOI 10.1029/94JD01951; DUTTON EG, 1992, GEOPHYS RES LETT, V19, P2313, DOI 10.1029/92GL02495; Freedman JM, 2001, J CLIMATE, V14, P180, DOI 10.1175/1520-0442(2001)013<0180:BLCAVA>2.0.CO;2; GOUDRIAAN J, 1977, P249; Gu LH, 1999, J GEOPHYS RES-ATMOS, V104, P31421, DOI 10.1029/1999JD901068; Gu LH, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001242; Hansen J, 1996, GEOPHYS RES LETT, V23, P1665, DOI 10.1029/96GL01040; Herber A, 1996, J GEOPHYS RES-ATMOS, V101, P3921, DOI 10.1029/95JD02462; HOLLINGER DY, 1994, ECOLOGY, V75, P134, DOI 10.2307/1939390; Houghton JT, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P1; Jones CD, 2001, GLOBAL BIOGEOCHEM CY, V15, P453, DOI 10.1029/2000GB001281; KEELING CD, 1995, NATURE, V375, P666, DOI 10.1038/375666a0; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; Lucht W, 2002, SCIENCE, V296, P1687, DOI 10.1126/science.1071828; MCCORMICK MP, 1995, NATURE, V373, P399, DOI 10.1038/373399a0; MICHALSKY JJ, 1994, SOL ENERGY, V52, P205, DOI 10.1016/0038-092X(94)90070-1; MINNIS P, 1993, SCIENCE, V259, P1411, DOI 10.1126/science.259.5100.1411; Molineaux B, 1996, SOL ENERGY, V58, P91, DOI 10.1016/0038-092X(96)00051-5; Olmo FJ, 1996, SOL ENERGY, V57, P433; Parker DE, 1996, INT J CLIMATOL, V16, P487, DOI 10.1002/(SICI)1097-0088(199605)16:5<487::AID-JOC39>3.0.CO;2-J; PRICE DT, 1990, AGR FOREST METEOROL, V50, P139, DOI 10.1016/0168-1923(90)90050-G; Ramanathan V, 2001, SCIENCE, V294, P2119, DOI 10.1126/science.1064034; Randel DL, 1996, B AM METEOROL SOC, V77, P1233, DOI 10.1175/1520-0477(1996)077<1233:ANGWVD>2.0.CO;2; ROBOCK A, 1995, J CLIMATE, V8, P1086, DOI 10.1175/1520-0442(1995)008<1086:TVSIST>2.0.CO;2; Robock A, 2002, SCIENCE, V295, P1242, DOI 10.1126/science.1069903; Robock A, 2000, REV GEOPHYS, V38, P191, DOI 10.1029/1998RG000054; Roderick ML, 2001, OECOLOGIA, V129, P21, DOI 10.1007/s004420100760; Schimel DS, 1996, GLOBAL BIOGEOCHEM CY, V10, P677, DOI 10.1029/96GB01524; Song NH, 1996, GEOPHYS RES LETT, V23, P2657, DOI 10.1029/96GL02372; Stenchikov GL, 1998, J GEOPHYS RES-ATMOS, V103, P13837, DOI 10.1029/98JD00693; STOWE LL, 1992, GEOPHYS RES LETT, V19, P159, DOI 10.1029/91GL02958; TREPTE CR, 1993, J GEOPHYS RES-ATMOS, V98, P18563, DOI 10.1029/93JD01362; Tucker CJ, 2001, INT J BIOMETEOROL, V45, P184, DOI 10.1007/s00484-001-0109-8; WOFSY SC, 1993, SCIENCE, V260, P1314, DOI 10.1126/science.260.5112.1314	42	437	486	6	186	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					2035	2038		10.1126/science.1078366	http://dx.doi.org/10.1126/science.1078366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663919				2022-12-28	WOS:000181834200045
J	Xu, J; Bjursell, MK; Himrod, J; Deng, S; Carmichael, LK; Chiang, HC; Hooper, LV; Gordon, JI				Xu, J; Bjursell, MK; Himrod, J; Deng, S; Carmichael, LK; Chiang, HC; Hooper, LV; Gordon, JI			A genomic view of the human-Bacteroides thetaiotaomicron symbiosis	SCIENCE			English	Article							OUTER-MEMBRANE PROTEINS; COMMENSAL; STARCH	The human gut is colonized with a vast community of indigenous microorganisms that help shape our biology. Here, we present the complete genome sequence of the Gram-negative anaerobe Bacteroides thetaiotaomicron, a dominant member of our normal distal intestinal microbiota. Its 4779-member proteome includes an elaborate apparatus for acquiring and hydrolyzing otherwise indigestible dietary polysaccharides and an associated environment-sensing system consisting of a large repertoire of extracytoplasmic function sigma factors and one- and two-component signal transduction systems. These and other expanded paralogous groups shed light on the molecular mechanisms underlying symbiotic host-bacterial relationships in our intestine.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA.	jgordon@molecool.wustl.edu	Xu, Jian/A-6831-2008; Xu, Jian/G-8430-2012	Xu, Jian/0000-0002-0548-8477	NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BERGMAN EN, 1990, PHYSIOL REV, V70, P567, DOI 10.1152/physrev.1990.70.2.567; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cho KH, 2001, J BACTERIOL, V183, P7224, DOI 10.1128/JB.183.24.7224-7230.2001; Della JN, 1996, J BACTERIOL, V178, P7180; Helmann JD, 2002, ADV MICROB PHYSIOL, V46, P47; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Hooper LV, 1999, P NATL ACAD SCI USA, V96, P9833, DOI 10.1073/pnas.96.17.9833; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Hooper LV, 2002, ANNU REV NUTR, V22, P283, DOI 10.1146/annurev.nutr.22.011602.092259; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Krinos CM, 2001, NATURE, V414, P555, DOI 10.1038/35107092; MOORE WEC, 1974, APPL MICROBIOL, V27, P961, DOI 10.1128/AEM.27.5.961-979.1974; Reeves AR, 1997, J BACTERIOL, V179, P643, DOI 10.1128/jb.179.3.643-649.1997; SALYERS AA, 1993, GENETICS MOL BIOL AN, P505; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; Shoemaker NB, 2001, APPL ENVIRON MICROB, V67, P561, DOI 10.1128/AEM.67.2.561-568.2001; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Whittle G, 2002, J BACTERIOL, V184, P3839, DOI 10.1128/JB.184.14.3839-3847.2002; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4	20	966	1454	6	235	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					2074	2076		10.1126/science.1080029	http://dx.doi.org/10.1126/science.1080029			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663928				2022-12-28	WOS:000181834200057
J	Bowers, JE; Chapman, BA; Rong, JK; Paterson, AH				Bowers, JE; Chapman, BA; Rong, JK; Paterson, AH			Unravelling angiosperm genome evolution by phylogenetic analysis of chromosomal duplication events	NATURE			English	Article							NUCLEOTIDE SUBSTITUTION; ARABIDOPSIS; RICE; ORGANIZATION; SEGMENTS; SEQUENCE; SYNTENY; DICOTS; TOMATO; PLANTS	Conservation of gene order in vertebrates is evident after hundreds of millions of years of divergence(1,2), but comparisons of the Arabidopsis thaliana sequence(3) to partial gene orders of other angiosperms (flowering plants) sharing common ancestry, similar to170-235 million years ago(4) yield conflicting results(5-11). This difference may be largely due to the propensity of angiosperms to undergo chromosomal duplication ('polyploidization') and subsequent gene loss(12) ('diploidization'); these evolutionary mechanisms have profound consequences for comparative biology. Here we integrate a phylogenetic approach (relating chromosomal duplications to the tree of life) with a genomic approach (mitigating information lost to diploidization) to show that a genome-wide duplication(3,13-17) post-dates the divergence of Arabidopsis from most dicots. We also show that an inferred ancestral gene order for Arabidopsis reveals more synteny with other dicots (exemplified by cotton), and that additional, more ancient duplication events affect more distant taxonomic comparisons. By using partial sequence data for many diverse taxa to better relate the evolutionary history of completely sequenced genomes to the tree of life, we foster comparative approaches to the study of genome organization, consequences of polyploidy, and the molecular basis of quantitative traits.	Univ Georgia, Plant Genome Mapping Lab, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Paterson, AH (corresponding author), Univ Georgia, Plant Genome Mapping Lab, Athens, GA 30602 USA.	paterson@uga.edu	Bowers, John/AAD-7601-2019; Bowers, John/B-9245-2009	Bowers, John/0000-0001-8984-9796; Chapman, Brad/0000-0002-3026-1856; Bowers, John/0000-0001-5693-2796				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BENNETT MD, 1976, PHILOS T R SOC B, V274, P227, DOI 10.1098/rstb.1976.0044; BENTON MJ, 1993, FOSSIL RECORD, V2; Blanc G, 2000, PLANT CELL, V12, P1093, DOI 10.1105/tpc.12.7.1093; Bowe LM, 2000, P NATL ACAD SCI USA, V97, P4092, DOI 10.1073/pnas.97.8.4092; Brubaker CL, 1999, GENOME, V42, P184, DOI 10.1139/gen-42-2-184; Eckardt NA, 2001, PLANT CELL, V13, P1699, DOI 10.1105/tpc.13.8.1699; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Grant D, 2000, P NATL ACAD SCI USA, V97, P4168, DOI 10.1073/pnas.070430597; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Koch M, 1999, PLANT BIOLOGY, V1, P529, DOI 10.1055/s-2007-978548; Ku HM, 2000, P NATL ACAD SCI USA, V97, P9121, DOI 10.1073/pnas.160271297; Lee JM, 2001, THEOR APPL GENET, V103, P765, DOI 10.1007/s001220100658; Liu H, 2001, GENOME RES, V11, P2020, DOI 10.1101/gr.194501; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Mayer K, 2001, GENOME RES, V11, P1167, DOI 10.1101/gr.GR-1617R; Paterson AH, 2000, PLANT CELL, V12, P1523, DOI 10.1105/tpc.12.9.1523; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; Paterson AH, 1996, NAT GENET, V14, P380, DOI 10.1038/ng1296-380; Rossberg M, 2001, PLANT CELL, V13, P979, DOI 10.1105/tpc.13.4.979; Salse J, 2002, NUCLEIC ACIDS RES, V30, P2316, DOI 10.1093/nar/30.11.2316; Simillion C, 2002, P NATL ACAD SCI USA, V99, P13627, DOI 10.1073/pnas.212522399; Smith SF, 2002, GENOME RES, V12, P776, DOI 10.1101/gr.221802; Strauss E, 1999, SCIENCE, V283, P1435, DOI 10.1126/science.283.5407.1435; Tilman D, 2002, NATURE, V418, P671, DOI 10.1038/nature01014; Vision TJ, 2000, SCIENCE, V290, P2114, DOI 10.1126/science.290.5499.2114; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Yang CQ, 2000, TEXT CHEM COLOR AM D, V32, P43; Yang YW, 1999, J MOL EVOL, V48, P597, DOI 10.1007/PL00006502; Zhang LQ, 2002, MOL BIOL EVOL, V19, P1464, DOI 10.1093/oxfordjournals.molbev.a004209	30	1145	1203	7	198	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 27	2003	422	6930					433	438		10.1038/nature01521	http://dx.doi.org/10.1038/nature01521			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660784				2022-12-28	WOS:000181801200045
J	Bruch-Gerharz, D; Gerharz, CD; Stege, H; Krutmann, J; Pohl, M; Koester, R; Ruzicka, T				Bruch-Gerharz, D; Gerharz, CD; Stege, H; Krutmann, J; Pohl, M; Koester, R; Ruzicka, T			Cutaneous vascular malformations in disappearing bone (Gorham-Stout) disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Univ Dusseldorf, Dept Dermatol, D-40001 Dusseldorf, Germany; Univ Dusseldorf, Dept Pathol, D-4000 Dusseldorf, Germany; Univ Dusseldorf, Dept Radiol, D-4000 Dusseldorf, Germany; Lukas Krankenhaus, Inst Radiol, Neuss, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Bruch-Gerharz, D (corresponding author), Univ Dusseldorf, Dept Dermatol, Bldg 11-80,POB 101007, D-40001 Dusseldorf, Germany.							GORHAM LW, 1955, J BONE JOINT SURG AM, V37, P985, DOI 10.2106/00004623-195537050-00008; Jackson JB., 1838, BOSTON MED SURG J, V18, P368; MULLIKEN JB, 1982, PLAST RECONSTR SURG, V69, P412, DOI 10.1097/00006534-198203000-00002	3	10	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2003	289	12					1479	1480		10.1001/jama.289.12.1479	http://dx.doi.org/10.1001/jama.289.12.1479			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659XE	12672746				2022-12-28	WOS:000181803100002
J	Rosenbaum, S				Rosenbaum, S			The impact of United States law on medicine as a profession	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									George Washington Univ, Med Ctr, Sch Publ Hlth & Hlth Serv, Dept Hlth Policy Hlth Law & Policy, Washington, DC 20037 USA	George Washington University	Rosenbaum, S (corresponding author), George Washington Univ, Sch Publ Hlth, Hirsh Hlth & Policy Program, 2021 K St NW,Suite 800, Washington, DC 20006 USA.							Barate R., 2001, EUR PHYS J C, V19, P213; Bonanno M. A., 1995, ANN HLTH LAW, V4, P151; CANTWELL RD, 1994, ST LOUIS U PUBL L RE, V14, P323; CUMMINGS J, 2003, WALL ST J       0826, pA4; *DEP HLTH HUM RES, 2000, FED REGISTER, V65, P4968; *DEP HLTH HUM RES, 2000, FED REGISTER, V65, P52762; Druss BG, 2003, NEW ENGL J MED, V348, P130, DOI 10.1056/NEJMsa020993; Friedman Lawrence M., 2002, LAW AM SHORT HIST; GEBBIEK K, 2002, WHO WILL KEEP PUBLIC; Greaney TL, 2002, HEALTH AFFAIR, V21, P185, DOI 10.1377/hlthaff.21.2.185; HAVIGHURST CC, 2002, HEALTHCARE LAW POLIC; JONES JH, 1994, BAD BLOOD TUSKEEGEE; Muris Timothy J., 2002, 7 ANN COMP HLTH CAR; Nelson AR, 2002, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; PEREZ TE, 2002, UNEQUAL TREATMENT CO, P626; REID KE, 2001, SCI WITNESS STAND EV, P81; ROSENBLATT R, 2001, LAW AM HLTH CARE S S; ROSENBLATT R, 1997, LAW AM HLTH CARE SYS; SCOFIELD GR, 1995, SECTON HALL L REV, V25, P927; STARR P, 1982, SOCIAL TRANSFORMATIO, P144; 1902, JAMA, V38, P1688	21	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2003	289	12					1546	1556		10.1001/jama.289.12.1546	http://dx.doi.org/10.1001/jama.289.12.1546			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659XE	12672772				2022-12-28	WOS:000181803100033
J	Burchard, EG; Ziv, E; Coyle, N; Gomez, SL; Tang, H; Karter, AJ; Mountain, JL; Perez-Stable, EJ; Sheppard, D; Risch, N				Burchard, EG; Ziv, E; Coyle, N; Gomez, SL; Tang, H; Karter, AJ; Mountain, JL; Perez-Stable, EJ; Sheppard, D; Risch, N			The importance of race and ethnic background in biomedical research and clinical practice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FACTOR-V-LEIDEN; GENETIC-STRUCTURE; AFRICAN-AMERICAN; CROHNS-DISEASE; ADMIXTURE; POPULATIONS; DISPARITIES; ASSOCIATION; PREVALENCE; EVOLUTION		Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Effectiveness Res Ctr Diverse Populat, San Francisco, CA 94143 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA; Stanford Univ, Sch Med, Dept Hlth Res & Policy, Div Epidemiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA; Stanford Univ, Dept Anthropol Sci, Stanford, CA 94305 USA; No Calif Canc Ctr, Union City, CA USA; Kaiser Permanente, Div Res, Dept Epidemiol & Hlth Serv Res, Oakland, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; Stanford University; Stanford University; Stanford University; Stanford University; Kaiser Permanente	Burchard, EG (corresponding author), Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA.		Ziv, Elad/L-5396-2014		NCI NIH HHS [K22 CA109351] Funding Source: Medline; NHLBI NIH HHS [K23 HL004464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA109351] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM CIV RIGHTS COA, 2002, RAC PRIV IN; Angier Natalie, 2000, NY TIMES        1107, pF1; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; Calafell F, 1998, EUR J HUM GENET, V6, P38, DOI 10.1038/sj.ejhg.5200151; DEAN M, 1994, AM J HUM GENET, V55, P788; Epstein AM, 2000, NEW ENGL J MED, V343, P1537, DOI 10.1056/NEJM200011233432106; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Foster MW, 2002, GENOME RES, V12, P844, DOI 10.1101/gr.99202; Gifford AL, 2002, NEW ENGL J MED, V346, P1373, DOI 10.1056/NEJMsa011565; HANIS CL, 1991, DIABETES CARE, V14, P618, DOI 10.2337/diacare.14.7.618; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Judson R, 2002, PHARMACOGENOMICS, V3, P379, DOI 10.1517/14622416.3.3.379; Karter AJ, 2002, JAMA-J AM MED ASSOC, V287, P2519, DOI 10.1001/jama.287.19.2519; Kaufman JS, 2001, AM J EPIDEMIOL, V154, P291, DOI 10.1093/aje/154.4.291; LANDER E, 2001, CRACKING CODE LIFE; Merryweather-Clarke AT, 2000, GENET TEST, V4, P183, DOI 10.1089/10906570050114902; Mountain JL, 1997, AM J HUM GENET, V61, P705, DOI 10.1086/515510; Nelson AR, 2002, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; RISCH N, 2002, GENOME BIOL, V3; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Sankar P, 2002, SCIENCE, V298, P1337, DOI 10.1126/science.1074447; Schulman KA, 1999, NEW ENGL J MED, V340, P1130; Schwartz RS, 2001, NEW ENGL J MED, V344, P1392, DOI 10.1056/NEJM200105033441810; Shen MC, 1997, THROMB RES, V87, P377, DOI 10.1016/S0049-3848(97)00141-2; Smith MW, 2001, AM J HUM GENET, V69, P1080, DOI 10.1086/323922; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867; Stephens JC, 2001, SCIENCE, V293, P1048; Williams RC, 2000, AM J HUM GENET, V66, P527, DOI 10.1086/302773; Wilson JF, 2001, NAT GENET, V29, P265, DOI 10.1038/ng761; Yamazaki K, 2002, J HUM GENET, V47, P469, DOI 10.1007/s100380200067; YU MC, 1994, J NATL CANCER I, V86, P712, DOI 10.1093/jnci/86.9.712	35	756	784	1	37	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1170	1175		10.1056/NEJMsb025007	http://dx.doi.org/10.1056/NEJMsb025007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646676				2022-12-28	WOS:000181628400015
J	Lane, JM; Goldstein, J				Lane, JM; Goldstein, J			Evaluation of 21st-century risks of smallpox vaccination and policy options	ANNALS OF INTERNAL MEDICINE			English	Review							VACCINIA VIRUS; INTRAFAMILIAL TRANSMISSION; COMPLICATIONS; RESPONSES; BIOTERRORISM; SURVEILLANCE; OUTBREAK; PAKISTAN; THERAPY; EUROPE	The United States stopped vaccinating against smallpox in 1972 because the risks were judged to outweigh the benefits. The possibility of a terrorist attack using smallpox has led to renewed interest in a vaccination program. Smallpox vaccination carries considerable risks, which may be of greater concern today than in the late 1960s. because of. the increased prevalence of immunosuppression and atopy in the population. This paper reviews the clinical presentations of major adverse events after vaccination and the rates of occurrence of these events observed in the 1960s. The normal dynamics of the spread of smallpox is slow, and usually only persons who have had close personal contact with an overtly ill patient are affected. There are several preattack vaccination policy options, but immunization of medical workers, especially those who might have close contact with infected patients, is sufficient in the absence of a known threat of a bioterrorist attack or the identification of a smallpox-infected person.			Lane, JM (corresponding author), 869 Clifton Rd NE, Atlanta, GA 30307 USA.							Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357; BLATTNER RJ, 1964, J PEDIATR-US, V64, P839, DOI 10.1016/S0022-3476(64)80642-9; Bradbury J, 2002, LANCET, V359, P1041, DOI 10.1016/S0140-6736(02)08115-1; *CDCP, 1972, EPISEP72912 CDC; Cohen J, 2001, SCIENCE, V294, P985, DOI 10.1126/science.294.5544.985; COPEMAN PWM, 1964, BRIT MED J, V2, P906, DOI 10.1136/bmj.2.5414.906; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; DEVRIES E, 1959, POSTVACCINIAL PERIVE; ELAD B, 1990, J INFECT DIS, V161, P446, DOI 10.1093/infdis/161.3.446; Enserink M, 2002, SCIENCE, V296, P1592, DOI 10.1126/science.296.5573.1592; Fauci AS, 2002, NEW ENGL J MED, V346, P1319, DOI 10.1056/NEJM200204253461711; Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534; FULGINIT.VA, 1965, ARCH OPHTHALMOL-CHIC, V74, P539, DOI 10.1001/archopht.1965.00970040541019; FULGINITI VA, 1968, NEW YORK NATL FDN MA, V4, P129; Gani R, 2001, NATURE, V414, P748, DOI 10.1038/414748a; GOLDSTEIN JA, 1975, PEDIATRICS, V55, P342; Harber P, 1996, AM J RESP CRIT CARE, V154, P1153, DOI 10.1164/ajrccm.154.4.8887621; Henderson D A, 1999, VACCINES; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; Jezek Z, 1988, HUMAN MONKEYPOX; KEMPE CH, 1960, PEDIATRICS, V26, P176; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201; LANE JM, 1970, J AMER MED ASSOC, V212, P441, DOI 10.1001/jama.212.3.441; LANE JM, 1969, NEW ENGL J MED, V281, P1220, DOI 10.1056/NEJM196911272812205; LeDuc JW, 2002, EMERG INFECT DIS, V8, P743, DOI 10.3201/eid0807.020032; MACK TM, 1972, J INFECT DIS, V125, P161, DOI 10.1093/infdis/125.2.161; MACK TM, 1972, AM J EPIDEMIOL, V95, P169, DOI 10.1093/oxfordjournals.aje.a121382; Meltzer MI, 2001, EMERG INFECT DIS, V7, P959, DOI 10.3201/eid0706.010607; MUKHERJEE MK, 1974, B WORLD HEALTH ORGAN, V51, P219; Neff JM, 2002, JAMA-J AM MED ASSOC, V288, P1901, DOI 10.1001/jama.288.15.1901; NEFF JM, 1972, PEDIATRICS, V50, P481; Raimer SS, 2000, CLIN PEDIATR, V39, P1, DOI 10.1177/000992280003900101; RAO AR, 1968, INDIAN J MED RES, V56, P1826; Rosenthal SR, 2001, EMERG INFECT DIS, V7, P920, DOI 10.3201/eid0706.010602; RUBEN FL, 1970, ARCH OPHTHALMOL-CHIC, V84, P45, DOI 10.1001/archopht.1970.00990040047012; SOMMER A, 1974, AM J EPIDEMIOL, V99, P291, DOI 10.1093/oxfordjournals.aje.a121614; STEVENSON RW, 2002, NY TIMES        1126, pA1; Stittelaar KJ, 2001, VACCINE, V19, P3700, DOI 10.1016/S0264-410X(01)00075-5; TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B; THOMAS DB, 1971, AM J EPIDEMIOL, V93, P373, DOI 10.1093/oxfordjournals.aje.a121270; WEHRLE PF, 1970, B WORLD HEALTH ORGAN, V43, P669; 2001, MMWR MORB MORTAL WEE, V50, P1	43	55	55	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					488	493		10.7326/0003-4819-138-6-200303180-00014	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00014			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639083				2022-12-28	WOS:000181562400007
J	Rey, E; Kahn, SR; David, M; Shrier, I				Rey, E; Kahn, SR; David, M; Shrier, I			Thrombophilic disorders and fetal loss: a meta-analysis	LANCET			English	Article							FACTOR-V-LEIDEN; ACTIVATED PROTEIN-C; RECURRENT PREGNANCY LOSS; FIRST-TRIMESTER; NIMES OBSTETRICIANS; VENOUS THROMBOSIS; GENE MUTATION; RISK FACTOR; WOMEN; RESISTANCE	Background Our aim was to assess the strength of the controversial association between thrombophilia and fetal loss, and to examine whether it varies according to the timing or definition of fetal loss. Methods We searched Medline and Current Contents for articles published between 1975 and 2002 and their references with terms denoting recurrent fetal and nonrecurrent fetal loss combined with various thrombophilic disorders. We included in our meta-analysis case-control, cohort, and cross-sectional studies published in English, the methodological quality of which was rated as moderate or strong. Pooled odds ratios (OR) with 95% CI were generated by random effects,models with Cochrane Review Manager software. Findings We included 31 studies. Factor V Leiden was associated with early (OR 2.01, 95% CI 1.13-3.58) and late (7.83, 2.83-21.67) recurrent fetal loss, and late nonrecurrent fetal loss (3.26, 1.82-5.83). Exclusion of women with other pathologies that could explain fetal loss strengthened the association between Factor V Leiden and recurrent fetal loss. Activated protein C resistance was associated with early recurrent fetal loss (3.48, 1.58-7.69), and prothrombin G20210A mutation with early recurrent (2.56, 1.04-6.29) and late non-recurrent (2.30, 1.09-4.87) fetal loss. Protein S deficiency was associated with recurrent fetal loss (14.72, 0.99-218.01) and late non-recurrent fetal loss (7.39, 1.28-42.63). Methylenetetrahydrofolate mutation, protein C, and antithrombin deficiencies were not significantly associated with fetal loss. Interpretation The magnitude of the association between thrombophilia and fetal loss varies, according to type of fetal loss and type of thrombophilia.	Hop St Justine, Dept Obstet & Gynecol, Montreal, PQ H3T 1C5, Canada; SMBD Jewish Gen Hosp, Ctr Clin Epidemiol & Community Studies, Montreal, PQ, Canada; Hop St Justine, Dept Pediat, Hematol Serv, Montreal, PQ H3T 1C5, Canada	Universite de Montreal; Universite de Montreal	Rey, E (corresponding author), Hop St Justine, Dept Obstet & Gynecol, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.		Shrier, Ian/AAI-6502-2020	Shrier, Ian/0000-0001-9914-3498				Alfirevic Z, 2001, OBSTET GYNECOL, V97, P753, DOI 10.1016/S0029-7844(01)01190-5; Alfirevic Z, 2002, EUR J OBSTET GYN R B, V101, P6, DOI 10.1016/S0301-2115(01)00496-1; Alhenc-Gelas M, 1999, THROMB HAEMOSTASIS, V81, P506; Arias F, 1998, J Matern Fetal Med, V7, P277; Balasch J, 1997, HUM REPROD, V12, P1094; Bare SN, 2000, AUST NZ J OBSTET GYN, V40, P186, DOI 10.1111/j.1479-828X.2000.tb01144.x; BRANCH DW, 1992, OBSTET GYNECOL, V80, P614; Clark P, 2001, THROMB HAEMOSTASIS, V85, P30; de Visser MCH, 1999, BLOOD, V93, P1271, DOI 10.1182/blood.V93.4.1271.404k22_1271_1276; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DizonTomson DS, 1997, AM J OBSTET GYNECOL, V177, P402, DOI 10.1016/S0002-9378(97)70205-9; Fatini C, 2000, BLOOD COAGUL FIBRIN, V11, P657, DOI 10.1097/00001721-200010000-00010; Foka ZJ, 2000, HUM REPROD, V15, P458, DOI 10.1093/humrep/15.2.458; Grandone E, 1997, THROMB HAEMOSTASIS, V77, P822; Gris JC, 1999, THROMB HAEMOSTASIS, V81, P891; Gris JC, 1997, THROMB HAEMOSTASIS, V77, P1096; Hatzis T, 1999, EUR J CONTRACEP REPR, V4, P135, DOI 10.3109/13625189909040808; Holmes ZR, 1999, BRIT J HAEMATOL, V105, P98; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; Kurz X, 1999, INT ANGIOL, V18, P83; Kutteh WH, 1999, FERTIL STERIL, V71, P1048, DOI 10.1016/S0015-0282(99)00133-8; Lindqvist PG, 1999, THROMB HAEMOSTASIS, V81, P532; Lissak A, 1999, AM J OBSTET GYNECOL, V181, P126, DOI 10.1016/S0002-9378(99)70447-3; Many A, 2002, OBSTET GYNECOL, V99, P684, DOI 10.1016/S0029-7844(02)01938-5; Martinelli I, 2000, NEW ENGL J MED, V343, P1015, DOI 10.1056/NEJM200010053431405; Mousa HA, 2000, HUM REPROD, V15, P1830, DOI 10.1093/humrep/15.8.1830; Murphy RP, 2000, ARTERIOSCL THROM VAS, V20, P266, DOI 10.1161/01.ATV.20.1.266; Nelen W L, 1997, Br J Hosp Med, V58, P511; Nelen WLDM, 2000, FERTIL STERIL, V74, P1196, DOI 10.1016/S0015-0282(00)01595-8; Pickering W, 2001, CLIN APPL THROMB-HEM, V7, P25, DOI 10.1177/107602960100700106; Pihusch R, 2001, AM J REPROD IMMUNOL, V46, P124, DOI 10.1111/j.8755-8920.2001.460202.x; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; Rai R, 2001, HUM REPROD, V16, P961, DOI 10.1093/humrep/16.5.961; Rand JH, 1997, AM J OBSTET GYNECOL, V177, P918, DOI 10.1016/S0002-9378(97)70294-1; Raziel A, 2001, AM J REPROD IMMUNOL, V45, P65, DOI 10.1111/j.8755-8920.2001.450201.x; Reznikoff-Etievant MF, 2001, BRIT J OBSTET GYNAEC, V108, P1251, DOI 10.1016/S0306-5456(01)00298-4; Ridker PM, 1998, ANN INTERN MED, V128, P1000, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00007; Seligsohn U, 2001, NEW ENGL J MED, V344, P1222, DOI 10.1056/NEJM200104193441607; Tal J, 1999, HUM REPROD, V14, P1624, DOI 10.1093/humrep/14.6.1624; TRAUSCHTVANHORN JJ, 1992, AM J OBSTET GYNECOL, V167, P968, DOI 10.1016/S0002-9378(12)80021-4; Wramsby ML, 2000, FERTIL STERIL, V74, P987, DOI 10.1016/S0015-0282(00)01545-4; Younis JS, 2000, AM J REPROD IMMUNOL, V43, P31, DOI 10.1111/j.8755-8920.2000.430106.x	42	593	641	0	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 15	2003	361	9361					901	908		10.1016/S0140-6736(03)12771-7	http://dx.doi.org/10.1016/S0140-6736(03)12771-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648968				2022-12-28	WOS:000181741600007
J	Schulze, ED; Mollicone, D; Achard, F; Matteucci, G; Federici, S; Eva, HD; Valentini, R				Schulze, ED; Mollicone, D; Achard, F; Matteucci, G; Federici, S; Eva, HD; Valentini, R			Climate change - Making deforestation pay under the Kyoto Protocol?	SCIENCE			English	Editorial Material							FORESTS		Commiss European Communities, Joint Res Ctr, Inst Environm & Sustainabil, TP 440, I-21020 Ispra, Italy; Max Planck Inst Biogeochem, D-07701 Jena, Germany; Univ Tuscia, Dept Forest Environm & Resources, I-01100 Viterbo, Italy	European Commission Joint Research Centre; EC JRC ISPRA Site; Max Planck Society; Tuscia University	Achard, F (corresponding author), Commiss European Communities, Joint Res Ctr, Inst Environm & Sustainabil, TP 440, I-21020 Ispra, Italy.		Valentini, Riccardo/D-1226-2010; Schulze, Ernst-Detlef/K-9627-2014; Matteucci, Giorgio/N-3526-2015; EVA, Hugh D/F-8412-2011; Matteucci, Giorgio/AAB-7022-2021	Valentini, Riccardo/0000-0002-6756-5634; Matteucci, Giorgio/0000-0002-4790-9540; 				Achard F, 2002, SCIENCE, V297, P999, DOI 10.1126/science.1070656; BROWN S, 2000, LAND USE LAND USE CH, pCH5; Schimel DS, 2001, NATURE, V414, P169, DOI 10.1038/35102500; Schulze ED, 2002, GLOBAL CHANGE BIOL, V8, P505, DOI 10.1046/j.1365-2486.2002.00523.x; Steffen W, 1998, SCIENCE, V280, P1393; *UNFCCC, 2002, ACT IMPL JOINTL LIST; *UNFCCC, 2001, BONN AGR IMPL BUEN A; *UNFCCC, 2002, METH ISS SUBM PART; UNFCCC, 2002, MARR ACC; UNFCCC, 1997, KYOT PROT; Valentini R, 2000, NATURE, V404, P861, DOI 10.1038/35009084; *WINR INT, 2000, PRACT EXP PIL PROJ N	12	16	16	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1669	1669		10.1126/science.1079024	http://dx.doi.org/10.1126/science.1079024			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637722				2022-12-28	WOS:000181519500021
J	Petticrew, M				Petticrew, M			Why certain systematic reviews reach uncertain conclusions	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NO		Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow	Petticrew, M (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.	mark@msoc.mrc.gla.ac.uk	Petticrew, Mark/AAY-6274-2021					Alderson P, 2000, BRIT MED J, V320, P376, DOI 10.1136/bmj.320.7231.376; [Anonymous], 2000, EXPT KNOWING GENDER; Black N, 2001, BRIT MED J, V323, P275, DOI 10.1136/bmj.323.7307.275; Campbell S, 2000, ULTRASOUND OBST GYN, V15, P1, DOI 10.1046/j.1469-0705.2000.00060.x; Connor J, 1999, J EPIDEMIOL COMMUN H, V53, P725, DOI 10.1136/jech.53.11.725; Egger M, 2001, SYSTEMATIC REV HLTH; Elvik R, 1997, ACCIDENT ANAL PREV, V29, P191, DOI 10.1016/S0001-4575(96)00070-X; Farrington DP, 2002, JUSTICE Q, V19, P313, DOI 10.1080/07418820200095261; LEGGE JT, ANALECTS CONFICIUS; MACINTYRE S, 2002, EVALUATING EVIDENCE; Millward L, 2001, PUBLIC HLTH INTERVEN; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; Mulrow CD, 1998, SYSTEMATIC REV SYNTH; Mulrow CD, 1994, COCHRANE LIB; *NHS CTR REV DISS, 2001, 4 CRD U YORK; NUTBEAM D, 2001, IUHPE PROMOT ED S, V2, P15; Petticrew M, 1999, INT J TECHNOL ASSESS, V15, P671, DOI 10.1017/S0266462399015469; Rossi Peter H., 1987, RES SOCIAL PROBLEMS, V4, P3; Waters E, 2002, J PUBLIC HEALTH MED, V24, P227, DOI 10.1093/pubmed/24.3.227; Welsh BC., 2012, OXFORD HDB CRIME PRE	20	107	108	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2003	326	7392					756	758		10.1136/bmj.326.7392.756	http://dx.doi.org/10.1136/bmj.326.7392.756			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665LF	12676848	Green Published, Green Accepted			2022-12-28	WOS:000182121600020
J	Young, JC; Hartl, FU				Young, JC; Hartl, FU			A stress sensor for the bacterial periplasm	CELL			English	Editorial Material							HEAT-SHOCK RESPONSE; BINDING; DOMAIN		Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Young, JC (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Hartl, F. Ulrich/Y-8206-2019					Alba BM, 2001, MOL MICROBIOL, V40, P1323, DOI 10.1046/j.1365-2958.2001.02475.x; BUKAU B, 1993, MOL MICROBIOL, V9, P671, DOI 10.1111/j.1365-2958.1993.tb01727.x; Collinet B, 2000, J BIOL CHEM, V275, P33898, DOI 10.1074/jbc.M006214200; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Walsh NP, 2003, CELL, V113, P61, DOI 10.1016/S0092-8674(03)00203-4; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445	10	27	30	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 4	2003	113	1					1	2		10.1016/S0092-8674(03)00192-2	http://dx.doi.org/10.1016/S0092-8674(03)00192-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679025	Bronze			2022-12-28	WOS:000182282900001
J	Frank, SA; Nowak, MA				Frank, SA; Nowak, MA			Developmental predisposition to cancer	NATURE			English	Article									Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; Inst Adv Study, Princeton, NJ 08540 USA	University of California System; University of California Irvine; Institute for Advanced Study - USA	Frank, SA (corresponding author), Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA.	safrank@uci.edu	Nowak, Martin A/A-6977-2008	Frank, Steven/0000-0001-7348-7794				CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Cairns J, 2002, P NATL ACAD SCI USA, V99, P10567, DOI 10.1073/pnas.162369899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; PREHN RT, 1975, SCIENCE, V190, P1095, DOI 10.1126/science.1188386; Zheng Q, 2002, MATH BIOSCI, V176, P237, DOI 10.1016/S0025-5564(02)00087-1; Zheng Q, 1999, MATH BIOSCI, V162, P1, DOI 10.1016/S0025-5564(99)00045-0	7	70	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2003	422	6931					494	494		10.1038/422494a	http://dx.doi.org/10.1038/422494a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673242				2022-12-28	WOS:000181965400029
J	Hutchinson, JR; Famini, D; Lair, R; Kram, R				Hutchinson, JR; Famini, D; Lair, R; Kram, R			Are fast-moving elephants really running?	NATURE			English	Article							LOCOMOTION; MAMMALS; SPEED		Stanford Univ, Biomech Engn Div, Stanford, CA 94305 USA; Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA; Thai Elephant Conservat Ctr, Lampang 52000, Thailand; Univ Colorado, Dept Kinesiol & Appl Physiol, Boulder, CO 80309 USA	Stanford University; University of California System; University of California Davis; University of Colorado System; University of Colorado Boulder	Hutchinson, JR (corresponding author), Stanford Univ, Biomech Engn Div, Stanford, CA 94305 USA.	jrhutch@stanford.edu	Hutchinson, John/AAH-1593-2020	Hutchinson, John/0000-0002-6767-7038				ALEXANDER RM, 1983, J ZOOL, V201, P135, DOI 10.1111/j.1469-7998.1983.tb04266.x; ALEXANDER RM, 1979, J ZOOL, V189, P135, DOI 10.1111/j.1469-7998.1979.tb03956.x; Cavagna G. A., 1977, SCALE EFFECTS ANIMAL, P111; Dickinson MH, 2000, SCIENCE, V288, P100, DOI 10.1126/science.288.5463.100; FARLEY CT, 1991, SCIENCE, V253, P306, DOI 10.1126/science.1857965; Gambaryan P. P., 1974, MAMMALS RUN; Gatesy SM, 1999, J MORPHOL, V240, P115, DOI 10.1002/(SICI)1097-4687(199905)240:2<115::AID-JMOR3>3.0.CO;2-Y; HEGLUND NC, 1982, J EXP BIOL, V97, P41; HILDEBRAND M, 1980, AM ZOOL, V20, P255; Howell A. B, 1944, SPEED IN ANIMALS; MCMAHON TA, 1987, J APPL PHYSIOL, V62, P2326, DOI 10.1152/jappl.1987.62.6.2326; Muybridge Eadweard, 1902, ANIMALS MOTION, P20	12	94	94	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2003	422	6931					493	494		10.1038/422493a	http://dx.doi.org/10.1038/422493a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673241	Green Submitted			2022-12-28	WOS:000181965400028
J	Junquera, J; Ghosez, P				Junquera, J; Ghosez, P			Critical thickness for ferroelectricity in perovskite ultrathin films	NATURE			English	Article							THIN-FILMS; AB-INITIO; POLARIZATION; ELECTRODES; HETEROSTRUCTURES; OXIDES; MODEL	The integration of ferroelectric oxide films into microelectronic devices(1,2), combined with the size reduction constraints imposed by the semiconductor industry, have revived interest in the old question concerning the possible existence of a critical thickness for ferroelectricity. Current experimental techniques have allowed the detection of ferroelectricity in perovskite films down to a thickness of 40 Angstrom (ten unit cells), ref. 3. Recent atomistic simulations(4,5) have confirmed the possibility of retaining the ferroelectric ground state at ultralow thicknesses, and suggest the absence of a critical size. Here we report first-principles calculations on a realistic ferroelectric-electrode interface. We show that, contrary to current thought, BaTiO(3) thin films between two metallic SrRuO(3) electrodes in short circuit lose their ferroelectric properties below a critical thickness of about six unit cells (similar to24 Angstrom). A depolarizing electrostatic field, caused by dipoles at the ferroelectric-metal interfaces, is the reason for the disappearance of the ferroelectric instability. Our results suggest the existence of a lower limit for the thickness of useful ferroelectric layers in electronic devices.	Univ Liege, Dept Phys, B-4000 Sart Tilman Par Liege, Belgium	University of Liege	Ghosez, P (corresponding author), Univ Liege, Dept Phys, Batiment B-5, B-4000 Sart Tilman Par Liege, Belgium.	Philippe.Ghosez@ulg.ac.be	Junquera, Javier/G-7224-2015; Ghosez, Philippe/F-1954-2014	Junquera, Javier/0000-0002-9957-8982; 				Ahn CH, 1997, APPL PHYS LETT, V70, P206, DOI 10.1063/1.118203; Ahn CH, 1997, SCIENCE, V276, P1100, DOI 10.1126/science.276.5315.1100; BALDERESCHI A, 1988, PHYS REV LETT, V61, P734, DOI 10.1103/PhysRevLett.61.734; Bernardini F, 1998, PHYS REV B, V58, P15292, DOI 10.1103/PhysRevB.58.15292; Bune AV, 1998, NATURE, V391, P874, DOI 10.1038/36069; CHANDRA P, 2002, THICKNESS DEPENDENCE; COHEN RE, 1992, NATURE, V358, P136, DOI 10.1038/358136a0; Eisenbeiser K, 2000, APPL PHYS LETT, V76, P1324, DOI 10.1063/1.126023; EOM CB, 1992, SCIENCE, V258, P1766, DOI 10.1126/science.258.5089.1766; EOM CB, 1993, APPL PHYS LETT, V63, P2570, DOI 10.1063/1.110436; Fu HX, 2000, NATURE, V403, P281, DOI 10.1038/35002022; Ghosez P, 2000, APPL PHYS LETT, V76, P2767, DOI 10.1063/1.126469; Hartmann AJ, 2000, APPL PHYS A-MATER, V70, P239, DOI 10.1007/s003390050041; Hwang CS, 1998, J APPL PHYS, V83, P3703, DOI 10.1063/1.366595; KINGSMITH RD, 1993, PHYS REV B, V47, P1651, DOI 10.1103/PhysRevB.47.1651; KOHLSTEDT H, 2002, MAT RES SOC S P, V688; Lines M.E., 2001, PRINCIPLES APPL FERR; McKee RA, 1998, PHYS REV LETT, V81, P3014, DOI 10.1103/PhysRevLett.81.3014; McKee RA, 2001, SCIENCE, V293, P468, DOI 10.1126/science.293.5529.468; Meyer B, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.205426; Nagaraj B, 2001, J APPL PHYS, V90, P375, DOI 10.1063/1.1371947; Neaton JB, 2002, MATER RES SOC SYMP P, V718, P311; Rao FY, 1997, PHYS REV B, V55, P13953, DOI 10.1103/PhysRevB.55.13953; SCOTT JF, 1989, SCIENCE, V246, P1400, DOI 10.1126/science.246.4936.1400; Soler JM, 2002, J PHYS-CONDENS MAT, V14, P2745, DOI 10.1088/0953-8984/14/11/302; Tybell T, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.097601; Tybell T, 1999, APPL PHYS LETT, V75, P856, DOI 10.1063/1.124536; Tybell T, 1998, APPL PHYS LETT, V72, P1454, DOI 10.1063/1.120591; Zimmer M, 2002, AIP CONF PROC, V626, P232, DOI 10.1063/1.1499572	30	1248	1266	43	788	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2003	422	6931					506	509		10.1038/nature01501	http://dx.doi.org/10.1038/nature01501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673246				2022-12-28	WOS:000181965400033
J	Shishehbor, MH; Aviles, RJ; Brennan, ML; Fu, XM; Goormastic, M; Pearce, GL; Gokce, N; Keaney, JF; Penn, MS; Sprecher, DL; Vita, JA; Hazen, SL				Shishehbor, MH; Aviles, RJ; Brennan, ML; Fu, XM; Goormastic, M; Pearce, GL; Gokce, N; Keaney, JF; Penn, MS; Sprecher, DL; Vita, JA; Hazen, SL			Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; ACUTE CORONARY SYNDROMES; NITRIC-OXIDE SYNTHASE; IN-VIVO; ENDOTHELIAL DYSFUNCTION; LIPOPROTEIN OXIDATION; SUPEROXIDE PRODUCTION; HUMAN ATHEROSCLEROSIS; ARTERY DISEASE; MYELOPEROXIDASE	Context Formation of nitric oxide-derived oxidants may serve as a mechanism linking inflammation to development of atherosclerosis. Nitrotyrosine, a specific marker for protein modification by nitric oxide-derived oxidants, is enriched in human atherosclerotic lesions and low-density lipoprotein (LDL) recovered from human atheroma. Objectives To determine whether systemic levels of nitrotyrosine. are associated with the prevalence of coronary artery disease (CAD) and are modulated by hydroxymethylglutaryl coenzyme-A reductase inhibitor (statin) therapy. Design, Setting, and Patients A case-control and interventional study at 2 urban tertiary-care referral centers; recruitment for each was from June 1, 2001, until January 1, 2002. For the case-control study, 100 case-patients with established CAD and 108 patients with no clinically evident CAD were recruited consecutively. In the interventional study, participants aged 21 years or older with hypercholesterolemia (LDL cholesterol greater than or equal to130 mg/dL [greater than or equal to3.5 mmol/L]) underwent nutrition and exercise counseling. Those whose levels did not decrease with 6 to 8 weeks were enrolled in the study (n=35). For 12 weeks, they received 10 mg/d of oral atorvastatin therapy. Main Outcome Measures In the case-control study, the association between systemic levels of protein-bound nitrotyrosine, CAD risk, and presence of CAD. In the interventional study, the change in nitrotyrosine, lipoprotein, and C-reactive protein (CRP) levels. Results Nitrotyrosine levels were significantly higher among patients with CAD (median 9.1 mumol/mol [interquartile range, 4.8-13.8 mumol/mol] tyrosine vs 5.2 mumol/mol [interquartile range, 2.2-8.4 mumol/mol]; P<.001). Patients in the upper quartile of nitrotyrosine (29%; P<.001) had a higher odds of CAD compared with those in the lowest quartile (unadjusted odds ratio, 6.1; 95% confidence interval, 2.6-14.0; P<.001). In multivariate models adjusting for Framingham Global Risk Score and CRP, upper quartiles of nitrotyrosine remained associated with CAD (odds ratio, 4.4; 95% confidence interval, 1.8-10.6; P<.001). Statin therapy reduced nitrotyrosine levels significantly (25%; P<.02) with a magnitude similar to reductions in total cholesterol levels (25%; P<.001) and LDL particle number (29%; P<.001) yet were independent of alterations in lipoproteins and inflammatory markers like CRP. Conclusions The findings from this preliminary study indicate that nitrotyrosine levels are associated with the presence of CAD and appear to be modulated by statin therapy. These results suggest a potential role for nitric oxide-derived oxidants as inflammatory mediators in CAD and may have implications for atherosclerosis risk assessment and monitoring of anti-inflammatory actions of statins.	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Boston University	Hazen, SL (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	hazens@ccf.org	Hazen, Stanley L/ABD-5845-2021	Keaney, John/0000-0002-0866-1837; Gokce, Noyan/0000-0003-2920-3445; Vita, Joseph/0000-0001-5607-1797	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062526, R01HL061878, R01HL070621, P01HL060886] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60886, HL62526, HL70621, HL61878] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Abu-Soud Husam M., 2000, Nitric Oxide, V4, P179; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Ceriello A, 2001, DIABETOLOGIA, V44, P834; Ceriello A, 2002, CIRCULATION, V106, P1211, DOI 10.1161/01.CIR.0000027569.76671.A8; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Freedman JE, 1998, CIRCULATION, V98, P1481, DOI 10.1161/01.CIR.98.15.1481; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Hazen SL, 1999, CIRC RES, V85, P950; Heinecke JW, 2001, ARTERIOSCL THROM VAS, V21, P1261, DOI 10.1161/hq0801.095084; Ignarro LJ, 2002, CIRC RES, V90, P21, DOI 10.1161/hh0102.102330; Kinlay S, 2001, CURR OPIN LIPIDOL, V12, P383, DOI 10.1097/00041433-200108000-00003; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Loscalzo J, 2001, CIRC RES, V88, P756, DOI 10.1161/hh0801.089861; Moncada S, 1999, J ROY SOC MED, V92, P164, DOI 10.1177/014107689909200402; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; Pannala AS, 1999, METHOD ENZYMOL, V301, P319; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Ridker P M, 2000, Curr Cardiol Rep, V2, P269, DOI 10.1007/s11886-000-0080-8; Ridker PM, 2001, CIRCULATION, V103, P1191; Ridker PM, 2001, NEW ENGL J MED, V344, P1959, DOI 10.1056/NEJM200106283442601; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Rifai N, 1999, CLIN CHEM, V45, P2136; Sorescu D, 2002, CIRCULATION, V105, P1429, DOI 10.1161/01.CIR.0000012917.74432.66; Stroes E, 1998, FEBS LETT, V438, P161, DOI 10.1016/S0014-5793(98)01292-7; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Wassmann S, 2002, ARTERIOSCL THROM VAS, V22, P300, DOI 10.1161/hq0202.104081; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	40	365	396	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1675	1680		10.1001/jama.289.13.1675	http://dx.doi.org/10.1001/jama.289.13.1675			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662JX	12672736	Bronze			2022-12-28	WOS:000181944500031
J	Cooper, RS; Psaty, BM				Cooper, RS; Psaty, BM			Genomics and medicine: Distraction, incremental progress, or the dawn of a new age?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							DISEASE; GENETICS; LEUKEMIA; THERAPY; HYPERTENSION; RESISTANCE; VARIANT; STROKE	The technology of molecular genetics has profoundly altered the conduct of biomedical research. An entire universe of problems that in the past had been addressed only through conjecture, including whole genome analysis, can now be studied directly. The rapidity and scope of these changes in research capacity have in turn led to speculation that medicine will be radically altered by the application of genomics; to everyday practice. To date, gene therapy and several new tests for genetic susceptibility have been successfully implemented, although their impact on medicine as a whole remains very limited and their future contribution is hotly contested. The potential of molecular genetics, like all technology, must be evaluated on the basis of established principles of clinical and epidemiologic research. The rhetoric of some enthusiasts focuses instead on an optimistic best-case scenario of the future of DNA science, and many of their most far-reaching claims cannot be substantiated on the basis of what is currently known. The tension between the long-term goal of public health and medicine to identify and remove the causes of ill health, in contrast to the development of technological innovations that can cure disease or identify individual susceptibility, emerges as a major theme in this debate.	Loyola Univ, Stritch Sch Med, Dept Prevent Med & Epidemiol, Maywood, IL 60153 USA; Univ Washington, Seattle, WA 98195 USA	Loyola University Chicago; University of Washington; University of Washington Seattle	Cooper, RS (corresponding author), Loyola Univ, Stritch Sch Med, Dept Prevent Med & Epidemiol, 2160 S 1st Ave, Maywood, IL 60153 USA.	rcooper@lumc.edu						Altmuller J, 2001, AM J HUM GENET, V69, P936, DOI 10.1086/324069; Badano JL, 2002, NAT REV GENET, V3, P779, DOI 10.1038/nrg910; Burke W, 2002, NAT REV GENET, V3, P561, DOI 10.1038/nrg845; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Cooper R, 2000, CIRCULATION, V102, P3137; Coulthard S. A., 2001, Pharmacogenomics Journal, V1, P254; Cox R, 2002, HUM MOL GENET, V11, P2969, DOI 10.1093/hmg/11.23.2969; Doris PA, 2002, HYPERTENSION, V39, P323, DOI 10.1161/hy0202.104087; Guttmacher AE, 2002, NEW ENGL J MED, V347, P1512, DOI 10.1056/NEJMra012240; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hofmann WK, 2002, LANCET, V359, P481, DOI 10.1016/S0140-6736(02)07678-X; Holtzman NA, 2000, NEW ENGL J MED, V343, P141, DOI 10.1056/NEJM200007133430213; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Khoury MJ, 2003, NEW ENGL J MED, V348, P50, DOI 10.1056/NEJMra013182; McKusick VA, 2001, JAMA-J AM MED ASSOC, V286, P2289, DOI 10.1001/jama.286.18.2289; Motulsky AG, 1999, LANCET, V354, pSI35; National Institute for Health Care Management Research and Education Foundation, 2002, PRESCR DRUG EXP 2001; Psaty BM, 2002, JAMA-J AM MED ASSOC, V287, P1680, DOI 10.1001/jama.287.13.1680; Roth DA, 2001, NEW ENGL J MED, V344, P1735, DOI 10.1056/NEJM200106073442301; Tsai YJ, 2002, CLIN GENET, V62, P257, DOI 10.1034/j.1399-0004.2002.620401.x; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WHO, 2002, REP ADV COMM HLTH RE; 2002, NAT GENET, V32, P553	25	43	43	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					576	580		10.7326/0003-4819-138-7-200304010-00014	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00014			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667028				2022-12-28	WOS:000181872100007
J	Forrest, CB				Forrest, CB			Primary care in the United States - Primary care gatekeeping and referrals: effective filter or failed experiment?	BRITISH MEDICAL JOURNAL			English	Article							HEALTH; PHYSICIANS; DECISIONS; CHILDREN; PATTERNS; TRENDS; EUROPE; COSTS		Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Hlth Serv Res & Dev Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Forrest, CB (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Hlth Serv Res & Dev Ctr, Baltimore, MD 21205 USA.	cforrest@jhsph.edu	Forrest, Christopher/CAF-1379-2022	Forrest, Christopher/0000-0003-1252-068X				Anderson GF, 2000, HEALTH AFFAIR, V19, P150, DOI 10.1377/hlthaff.19.3.150; Boerma WGW, 1997, BRIT J GEN PRACT, V47, P481; Ferris TG, 2001, NEW ENGL J MED, V345, P1312, DOI 10.1056/NEJMsa010097; Ferris TGG, 2001, PEDIATRICS, V108, P283, DOI 10.1542/peds.108.2.283; FLEMING DM, 1992, 56 ROYAL COLL GEN PR; Forrest CB, 2003, MED CARE, V41, P242, DOI 10.1097/00005650-200302000-00006; Forrest CB, 2002, BRIT MED J, V325, P370, DOI 10.1136/bmj.325.7360.370; Forrest CB, 2002, J FAM PRACTICE, V51, P215; Forrest CB, 2001, J FAM PRACTICE, V50, P427; Forrest CB, 2001, JAMA-J AM MED ASSOC, V285, P2223, DOI 10.1001/jama.285.17.2223; Forrest CB, 1999, PEDIATRICS, V104, P28, DOI 10.1542/peds.104.1.28; GERVAS J, 1994, FAM PRACT, V11, P307, DOI 10.1093/fampra/11.3.307; HURLEY RE, 1991, J FAM PRACTICE, V32, P167; *KAIS FAM FDN HLTH, 2000, EMPL HLTH BEN 2000; Kralewski JE, 2000, HEALTH SERV RES, V35, P591; Majeed A, 1999, BRIT MED J, V318, P772, DOI 10.1136/bmj.318.7186.772; MARTIN DP, 1989, AM J PUBLIC HEALTH, V79, P1628, DOI 10.2105/AJPH.79.12.1628; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MOORE SH, 1983, NEW ENGL J MED, V309, P1400, DOI 10.1056/NEJM198312013092239; National Institute for Clinical Excellence, 2000, REF PRACT GUID APPR; Stoddard J, 1998, HEALTH AFFAIR, V17, P252, DOI 10.1377/hlthaff.17.1.252; SURENDER R, 1995, BRIT MED J, V311, P1205, DOI 10.1136/bmj.311.7014.1205; 2001, NY TIMES        1115, P30; 2003, RES INTERFACE PRIMAR	24	118	121	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 29	2003	326	7391					692	695		10.1136/bmj.326.7391.692	http://dx.doi.org/10.1136/bmj.326.7391.692			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663WL	12663407	Bronze, Green Published			2022-12-28	WOS:000182029500018
J	Taxis, K; Barber, N				Taxis, K; Barber, N			Ethnographic study of incidence and severity of intravenous drug errors	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADVERSE EVENTS; HOSPITALIZED-PATIENTS; OBSERVATIONAL METHODS; HEALTH-CARE	Objectives To determine the incidence and clinical importance of errors in the preparation and administration of intravenous drugs and the stages of the process in which errors occur. Design Prospective ethriographic study using disguised observation. Participants Nurses who prepared and administered intravenous drugs. Setting 10 wards in a teaching and non-teaching hospital in the United Kingdom. Main outcome measures Number, type, and clinical importance of errors. Results 249 errors were identified. At least one error occurred in 212 out of 430 intravenous drug doses (49%,95% confidence interval 45% to 54%). Three doses (1%) had potentially severe errors, 126 (29%) potentially moderate errors, and 83 (19%) potentially minor errors. Most errors occurred when giving bolus doses or making up drugs that required multiple step preparation. Conclusions The rate of intravenous drug errors was high. Although most errors would cause only short term adverse effects, a few could have been serious. A combination of reducing the amount of preparation on the ward, training, and technology to administer slow bolus doses would probably have the greatest effect on error rates.	Univ London, Sch Pharm, Dept Practice & Policy, London WC1 1AX, England	University of London; University College London; University of London School of Pharmacy	Taxis, K (corresponding author), Univ Tubingen, Inst Pharmazeut, Morgenstelle 8, D-72076 Tubingen, Germany.	katja.taxis@uni-tuebingen.de	Taxis, Katja/ABE-2637-2021	Taxis, Katja/0000-0001-8539-2004				Armour DJ, 1996, PHARMACOECONOMICS, V10, P386, DOI 10.2165/00019053-199610040-00007; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRZOZOWSKI DF, 1987, AM J HOSP PHARM, V44, P2077, DOI 10.1093/ajhp/44.9.2077; CHAN R, 1993, EUR J HOSP PHARM, V3, P93; CLARK CM, 1986, PHARM J, V236, P453; COUSINS DH, 1989, PHARM J, V242, pHS14; Dean B, 2001, AM J HEALTH-SYST PH, V58, P54, DOI 10.1093/ajhp/58.1.54; Dean BS, 1999, AM J HEALTH-SYST PH, V56, P57, DOI 10.1093/ajhp/56.1.57; Delaney T, 1996, EUR HOSP PHARM, V2, P92; *DEP HLTH SOC SEC, 1976, REP WORK PART ADD DR; Department of Health, 2001, BUILD SAF NHS PAT; Dyer C, 1999, BRIT MED J, V318, P148; Flynn EA, 1997, AM J HEALTH-SYST PH, V54, P904, DOI 10.1093/ajhp/54.8.904; Gardner M. J., 1989, STAT CONFIDENCE; Hartley GM, 1998, INT J PHARM PRACT, V6, P38, DOI [10.1111/j.2042-7174.1998.tb00914.x, DOI 10.1111/J.2042-7174.1998.TB00914.X]; *I MED COMM QUAL H, 2000, ERR HUM; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MAYS N, 1995, BRIT MED J, V311, P182, DOI 10.1136/bmj.311.6998.182; OHARE MCB, 1995, BRIT MED J, V310, P1536, DOI 10.1136/bmj.310.6993.1536c; THUR MP, 1972, AM J HOSP PHARM, V72, P298, DOI 10.1093/ajhp/29.4.298; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; WEICK KE, 1968, HDB SOCIAL PSYCHOL, P357; WILSON M, 1990, P GUILD, V27, P3; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x	24	178	198	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	2003	326	7391					684	687		10.1136/bmj.326.7391.684	http://dx.doi.org/10.1136/bmj.326.7391.684			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663WL	12663404	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000182029500015
J	Hastings, A; Palmer, MA				Hastings, A; Palmer, MA			Mathematics and biology: A bright future for biologists and mathematicians?	SCIENCE			English	Editorial Material							MOUTH EPIDEMIC; DEPENDENCE; DISPERSAL; PATTERN; MOTOR; FOOT		Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA; Univ Maryland, Dept Entomol, College Pk, MD 20742 USA	University of California System; University of California Davis; University System of Maryland; University of Maryland College Park	Hastings, A (corresponding author), Univ Calif Davis, Dept Environm Sci & Policy, Davis, CA 95616 USA.	amhastings@ucdavis.edu; mp3@umail.umd.edu	Hastings, Alan/A-7423-2008; Hastings, Alan/O-6864-2019	Hastings, Alan/0000-0002-0717-8026				Bjornstad ON, 2001, SCIENCE, V293, P638, DOI 10.1126/science.1062226; Bolker B, 1997, THEOR POPUL BIOL, V52, P179, DOI 10.1006/tpbi.1997.1331; Botsford LW, 2001, ECOL LETT, V4, P144; Cytrynbaum EN, 2003, BIOPHYS J, V84, P757, DOI 10.1016/S0006-3495(03)74895-4; Ferguson NM, 2001, SCIENCE, V292, P1155, DOI 10.1126/science.1061020; Hastings A, 2003, QUANTITATIVE BIOL 21; Keeling MJ, 2001, SCIENCE, V294, P813, DOI 10.1126/science.1065973; Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118; Mogilner A, 2001, J THEOR BIOL, V211, P143, DOI 10.1006/jtbi.2001.2336; Palmer MA, 2003, JOINT NSF NIH WORKSH; *USDA, 1998, NCR602 USDA S; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; VanKirk RW, 1997, B MATH BIOL, V59, P107, DOI 10.1016/S0092-8240(96)00060-2; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409	14	33	34	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					2003	2004		10.1126/science.1081522	http://dx.doi.org/10.1126/science.1081522			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663907				2022-12-28	WOS:000181834200033
J	Knowles, J				Knowles, J			Chemistry: Seeing is believing	SCIENCE			English	Editorial Material									Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Knowles, J (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.							GUTFREUND H., 1967, ESSAYS BIOCHEM, VVol. 3-3, P25; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; Xie XS, 2002, J CHEM PHYS, V117, P11024, DOI 10.1063/1.1521159	6	14	15	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2003	299	5615					2002	2003		10.1126/science.1084036	http://dx.doi.org/10.1126/science.1084036			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12637674				2022-12-28	WOS:000181834200032
J	Schwartz, T; Blobel, G				Schwartz, T; Blobel, G			Structural basis for the function of the beta subunit of the eukaryotic signal recognition particle receptor	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTP-BINDING PROTEINS; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; CHAIN COMPLEXES; ALPHA-SUBUNIT; DOMAIN; RAS; RIBOSOME; MEMBRANE	Protein translocation across and insertion into membranes is a process essential to all life forms. In higher eukaryotes, this process is initiated by targeting the translating ribosome to the endoplasmic reticulum via the signal recognition particle (SRP) and its membrane-associated heterodimeric receptor (SR). This targeting step is regulated by three G proteins, SRP54, SRalpha, and SRbeta, which act in concert. Little is known about the regulatory role of SRbeta. Here, we present the 1.7 Angstrom crystal structure of the SRbeta-GTP subunit in complex with the interaction domain of SRalpha. Strikingly, the binding interface overlaps largely with the switch 1 region of SRbeta. This finding, together with additional biochemical data, shows that the eukaryotic SR is a conditional and not an obligate heterodimer. The results suggest that the GTP/GDP switch cycle of SRbeta functions as a regulatory switch for the receptor dimerization. We discuss the implications for the translocation pathway.	Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Blobel, G (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.	blobel@rockefeller.edu	Schwartz, Thomas/ABA-1770-2021; Schwartz, Thomas/K-9029-2017	Schwartz, Thomas/0000-0001-8012-1512; Schwartz, Thomas/0000-0001-8012-1512				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Bacher G, 1999, J CELL BIOL, V146, P723, DOI 10.1083/jcb.146.4.723; Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; Fulga TA, 2001, EMBO J, V20, P2338, DOI 10.1093/emboj/20.9.2338; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Hanzal-Bayer M, 2002, EMBO J, V21, P2095, DOI 10.1093/emboj/21.9.2095; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Neuhof A, 1998, MOL BIOL CELL, V9, P103, DOI 10.1091/mbc.9.1.103; Ogg SC, 1998, J CELL BIOL, V142, P341, DOI 10.1083/jcb.142.2.341; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Pasqualato S, 2002, EMBO REP, V3, P1035, DOI 10.1093/embo-reports/kvf221; Pasqualato S, 2001, EMBO REP, V2, P234, DOI 10.1093/embo-reports/kve043; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; Rapiejko PJ, 1997, CELL, V89, P703, DOI 10.1016/S0092-8674(00)80253-6; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Song WQ, 2000, CELL, V100, P333, DOI 10.1016/S0092-8674(00)80669-8; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; TAJIMA S, 1986, J CELL BIOL, V103, P1167, DOI 10.1083/jcb.103.4.1167; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wittke S, 2002, MOL BIOL CELL, V13, P2223, DOI 10.1091/mbc.01-10-0518; YOUNG JC, 1995, J BIOL CHEM, V270, P15650, DOI 10.1074/jbc.270.26.15650	43	77	84	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2003	112	6					793	803		10.1016/S0092-8674(03)00161-2	http://dx.doi.org/10.1016/S0092-8674(03)00161-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	660DL	12654246	Bronze			2022-12-28	WOS:000181818500007
J	Wang, X; Willenbring, H; Akkari, Y; Torimaru, Y; Foster, M; Al-Dhalimy, M; Lagasse, E; Finegold, M; Olson, S; Grompe, M				Wang, X; Willenbring, H; Akkari, Y; Torimaru, Y; Foster, M; Al-Dhalimy, M; Lagasse, E; Finegold, M; Olson, S; Grompe, M			Cell fusion is the principal source of bone-marrow-derived hepatocytes	NATURE			English	Article							FUMARYLACETOACETATE HYDROLASE; HEPATIC-DYSFUNCTION; GENE-THERAPY; MURINE MODEL; STEM-CELLS; LIVER; MICE; REPOPULATION; PHENOTYPE; VIVO	Evidence suggests that haematopoietic stem cells might have unexpected developmental plasticity, highlighting therapeutic potential. For example, bone-marrow-derived hepatocytes can repopulate the liver of mice with fumarylacetoacetate hydrolase deficiency and correct their liver disease(1). To determine the underlying mechanism in this murine model, we performed serial transplantation of bone-marrow-derived hepatocytes. Here we show by Southern blot analysis that the repopulating hepatocytes in the liver were heterozygous for alleles unique to the donor marrow, in contrast to the original homozygous donor cells. Furthermore, cytogenetic analysis of hepatocytes transplanted from female donor mice into male recipients demonstrated 80,XXXY (diploid to diploid fusion) and 120,XXXXYY (diploid to tetraploid fusion) karyotypes, indicative of fusion between donor and host cells. We conclude that hepatocytes derived form bone marrow arise from cell fusion and not by differentiation of haematopoietic stem cells.	Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA; Stem Cells Inc, Palo Alto, CA 94304 USA; Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA	Oregon Health & Science University; Baylor College of Medicine	Grompe, M (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.	grompem@ohsu.edu		Grompe, Markus/0000-0002-6616-4345				Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; FAKTOR VM, 1975, TSITOLOGIYA+, V17, P909; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; GROMPE M, 1995, NAT GENET, V10, P453, DOI 10.1038/ng0895-453; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LABELLE Y, 1993, BIOCHIM BIOPHYS ACTA, V1180, P250, DOI 10.1016/0925-4439(93)90046-4; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; MACGREGOR GR, 1987, SOMAT CELL MOLEC GEN, V13, P253, DOI 10.1007/BF01535207; MARTIN G M, 1970, Experimental Cell Research, V63, P466, DOI 10.1016/0014-4827(70)90241-7; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; MITCHELL GA, 2001, METABOLIC MOL BASES, P1777; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Overturf K, 1998, HUM GENE THER, V9, P295, DOI 10.1089/hum.1998.9.3-295; Overturf K, 1999, AM J PATHOL, V155, P2135, DOI 10.1016/S0002-9440(10)65531-9; Overturf K, 1997, AM J PATHOL, V151, P1273; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; PEREIRA RF, 1997, SCIENCE, V276, P71; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pira GL, 1998, HUM IMMUNOL, V59, P137, DOI 10.1016/S0198-8859(98)00004-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Wang X, 2002, AM J PATHOL, V161, P565, DOI 10.1016/S0002-9440(10)64212-5; Whitney MA, 1996, BLOOD, V88, P49; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	30	1243	1364	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 24	2003	422	6934					897	901		10.1038/nature01531	http://dx.doi.org/10.1038/nature01531			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	670WR	12665832				2022-12-28	WOS:000182432600056
J	Gewin, V				Gewin, V			Biosphere owner sues sponsor	NATURE			English	News Item																		Rosenstiel TN, 2003, NATURE, V421, P256, DOI 10.1038/nature01312; 2003, NATURE, V421, P466	2	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2003	422	6931					461	461		10.1038/422461b	http://dx.doi.org/10.1038/422461b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673218	Bronze			2022-12-28	WOS:000181965400009
J	Salzman, NH; Ghosh, D; Huttner, KM; Paterson, Y; Bevins, CL				Salzman, NH; Ghosh, D; Huttner, KM; Paterson, Y; Bevins, CL			Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin	NATURE			English	Article							INNATE HOST-DEFENSE; PANETH CELL; ANTIMICROBIAL PEPTIDE; EPITHELIAL-CELLS; ALPHA-DEFENSINS; GENE; LOCALIZATION; MACROPHAGES; SECRETION; GROWTH	Genetically encoded antibiotic peptides are evolutionarily ancient and widespread effector molecules of immune defence(1-3). Mammalian defensins, one subset of such peptides, have been implicated in the antimicrobial defence capacity of phagocytic leukocytes and various epithelial cells(4), but direct evidence of the magnitude of their in vivo effects have not been clearly demonstrated. Paneth cells, specialized epithelia of the small intestinal crypt, secrete abundant alpha-defensins and other antimicrobial polypeptides(5,6) including human defensin 5 (HD-5; also known as DEFA5)(7-9). Although antibiotic activity of HD-5 has been demonstrated in vitro(9,10), functional studies of HD-5 biology have been limited by the lack of in vivo models. To study the in vivo role of HD-5, we developed a transgenic mouse model using a 2.9-kilobase HD-5 minigene containing two HD-5 exons and 1.4 kilobases of 5'-flanking sequence. Here we show that HD-5 expression in these mice is specific to Paneth cells and reflects endogenous enteric defensin gene expression. The storage and processing of transgenic HD-5 also matches that observed in humans. HD-5 transgenic mice were markedly resistant to oral challenge with virulent Salmonella typhimurium. These findings provide support for a critical in vivo role of epithelial-derived defensins in mammalian host defence.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Med Coll Wisconsin, Dept Pediat, Div Gastroenterol, Milwaukee, WI 53226 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neonatol, Boston, MA 02114 USA; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Cleveland Clinic Foundation; Medical College of Wisconsin; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Bevins, CL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	bevinsc@ccf.org	Bevins, Charles L/P-4438-2015	Bevins, Charles L/0000-0003-2725-2622; Paterson, Yvonne/0000-0002-9406-4958; Salzman, Nita/0000-0003-0939-6139	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001525] Funding Source: NIH RePORTER; NIAID NIH HHS [K08 AI001525-03] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999; Bevins CL, 1996, GENOMICS, V31, P95, DOI 10.1006/geno.1996.0014; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Cole AM, 2000, BIOTECHNIQUES, V29, P822, DOI 10.2144/00294rv01; COUTO MA, 1994, INFECT IMMUN, V62, P2375, DOI 10.1128/IAI.62.6.2375-2378.1994; Cunliffe RN, 2001, GUT, V48, P176, DOI 10.1136/gut.48.2.176; Darmoul D, 1996, AM J PHYSIOL-GASTR L, V271, pG68, DOI 10.1152/ajpgi.1996.271.1.G68; Ghosh D, 2002, NAT IMMUNOL, V3, P583, DOI 10.1038/ni797; HARPER ME, 1982, AM J HUM GENET, V34, P227; IWABUCHI Y, 1994, ARCH INT PHARMACOD T, V328, P315; JONES DE, 1992, J BIOL CHEM, V267, P23216; Kisich KO, 2001, INFECT IMMUN, V69, P2692, DOI 10.1128/IAI.69.4.2692-2699.2001; LEHRER RI, 1998, MUCOSAL IMMUNOLOGY, P89; Mallow EB, 1996, J BIOL CHEM, V271, P4038; Meister M, 2000, CURR TOP MICROBIOL, V248, P17; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ouellette AJ, 2000, J BIOL CHEM, V275, P33969, DOI 10.1074/jbc.M004062200; OUELLETTE AJ, 1999, DEV GASTROINTESTINAL, P147; Porter EM, 1997, INFECT IMMUN, V65, P2389, DOI 10.1128/IAI.65.6.2389-2395.1997; Porter EM, 1997, INFECT IMMUN, V65, P2396, DOI 10.1128/IAI.65.6.2396-2401.1997; Porter EM, 2002, CELL MOL LIFE SCI, V59, P156, DOI 10.1007/s00018-002-8412-z; Porter EM, 1998, FEBS LETT, V434, P272, DOI 10.1016/S0014-5793(98)00994-6; Putsep K, 2000, J BIOL CHEM, V275, P40478, DOI 10.1074/jbc.M007816200; SATOH Y, 1995, GASTROENTEROLOGY, V108, P1345, DOI 10.1016/0016-5085(95)90681-9; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Wang MSC, 1997, ANAL BIOCHEM, V253, P225, DOI 10.1006/abio.1997.2347; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	30	584	618	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2003	422	6931					522	526		10.1038/nature01520	http://dx.doi.org/10.1038/nature01520			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12660734				2022-12-28	WOS:000181965400038
J	Trieloff, M; Jessberger, EK; Herrwerth, I; Hopp, J; Fieni, C; Ghelis, M; Bourot-Denise, M; Pellas, P				Trieloff, M; Jessberger, EK; Herrwerth, I; Hopp, J; Fieni, C; Ghelis, M; Bourot-Denise, M; Pellas, P			Structure and thermal history of the H-chondrite parent asteroid revealed by thermochronometry	NATURE			English	Article							ACAPULCO METEORITE; SYSTEMATIC-ERRORS; DECAY CONSTANTS; 40AR/39AR AGE; COOLING RATES; FRAGMENTATION; METAMORPHISM; PLAGIOCLASE	Our Solar System formed, similar to4.6 billion years ago from the collapse of a dense core inside an interstellar molecular cloud. The subsequent formation of solid bodies took place rapidly. The period of < 10 million years over which planetesimals were assembled can be investigated through the study of meteorites(1-3). Although some planetesimals differentiated and formed metallic cores like the larger terrestrial planets, the parent bodies of undifferentiated chondritic meteorites experienced comparatively mild thermal metamorphism that was insufficient to separate metal from silicate(4,5). There is debate about the nature of the heat source(6-9) as well as the structure and cooling history of the parent bodies(10-12). Here we report a study of Pu-244 fission-track and 40Ar-39Ar thermochronologies of unshocked H chondrites, which are presumed to have a common, single, parent body. We show that, after fast accretion, an internal heating source ( most probably Al-26 decay(8-10,13)) resulted in a layered parent body(6) that cooled relatively undisturbed: rocks in the outer shells reached lower maximum metamorphic temperatures and cooled faster than the more recrystallized and chemically equilibrated rocks from the centre, which needed similar to 160 Myr to reach 390K.	Heidelberg Univ, Inst Mineral, D-69120 Heidelberg, Germany; Univ Munster, Inst Planetol, D-48149 Munster, Germany; Max Planck Inst Kernphys, D-69117 Heidelberg, Germany; Museum Lab Mineral, F-75005 Paris, France	Ruprecht Karls University Heidelberg; University of Munster; Max Planck Society	Trieloff, M (corresponding author), Heidelberg Univ, Inst Mineral, Neuenheimer Feld 236, D-69120 Heidelberg, Germany.	trieloff@min.uni-heidelberg.de						ALLEGRE CJ, 1995, GEOCHIM COSMOCHIM AC, V59, P1445, DOI 10.1016/0016-7037(95)00054-4; Begemann F, 2001, GEOCHIM COSMOCHIM AC, V65, P111, DOI 10.1016/S0016-7037(00)00512-3; Brazzle RH, 1999, GEOCHIM COSMOCHIM AC, V63, P739, DOI 10.1016/S0016-7037(98)00314-7; CHEN JH, 1981, EARTH PLANET SC LETT, V52, P1, DOI 10.1016/0012-821X(81)90202-8; CHERNIAK DJ, 1991, GEOCHIM COSMOCHIM AC, V55, P1663, DOI 10.1016/0016-7037(91)90137-T; DODD RT, 1969, GEOCHIM COSMOCHIM AC, V33, P161, DOI 10.1016/0016-7037(69)90138-0; GOPEL C, 1994, EARTH PLANET SC LETT, V121, P153, DOI 10.1016/0012-821X(94)90038-8; GRIMM RE, 1985, J GEOPHYS RES-SOLID, V90, P2022, DOI 10.1029/JB090iB02p02022; Herndon J. M., 1977, Meteoritics, V12, P459, DOI 10.1111/j.1945-5100.1977.tb00464.x; JORDAN J, 1980, Z NATURFORSCH A, V35, P145; Knodlseder J, 2002, ASTRON ASTROPHYS, V390, P945, DOI 10.1051/0004-6361:20020799; LAVIELLE B, 1992, METEORITICS, V27, P382, DOI 10.1111/j.1945-5100.1992.tb00219.x; LEE T, 1976, GEOPHYS RES LETT, V3, P109, DOI 10.1029/GL003i002p00109; LUGMAIR GW, 1992, GEOCHIM COSMOCHIM AC, V56, P1673, DOI 10.1016/0016-7037(92)90234-A; Miyamoto M., 1981, 12 LUNAR PLANETARY S, P1145; PELLAS P, 1975, CR ACAD SCI D NAT, V280, P225; Pellas P, 1997, GEOCHIM COSMOCHIM AC, V61, P3477, DOI 10.1016/S0016-7037(97)00167-1; Pravec P, 2000, ICARUS, V148, P12, DOI 10.1006/icar.2000.6482; Renne PR, 2000, EARTH PLANET SC LETT, V175, P13, DOI 10.1016/S0012-821X(99)00287-3; SCHAEFFER GA, 1977, P LUNAR PLANET SCI C, V8, P2253; SCOTT ERD, 1981, GEOCHIM COSMOCHIM AC, V45, P53, DOI 10.1016/0016-7037(81)90263-5; STEIGER RH, 1977, EARTH PLANET SC LETT, V36, P359, DOI 10.1016/0012-821X(77)90060-7; TAYLOR GJ, 1987, ICARUS, V69, P1, DOI 10.1016/0019-1035(87)90002-9; Trieloff M, 2001, EARTH PLANET SC LETT, V190, P267, DOI 10.1016/S0012-821X(01)00384-3; Trieloff M, 1998, METEORIT PLANET SCI, V33, P361, DOI 10.1111/j.1945-5100.1998.tb01640.x; TURNER G, 1978, P LUNAR PLANET SCI C, P989; VANSCHMUS WR, 1967, GEOCHIM COSMOCHIM AC, V31, P747, DOI 10.1016/S0016-7037(67)80030-9; WOOD JA, 1964, ICARUS, V3, P429, DOI 10.1016/0019-1035(64)90004-1; WOOD JA, 1991, SUN TIME, P741; Zinner E, 2002, METEORIT PLANET SCI, V37, P1001, DOI 10.1111/j.1945-5100.2002.tb00872.x	30	234	237	2	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 3	2003	422	6931					502	506		10.1038/nature01499	http://dx.doi.org/10.1038/nature01499			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673245				2022-12-28	WOS:000181965400032
J	Tonks, A				Tonks, A			Extracts from "Best Treatments" - Treating generalised anxiety disorder	BMJ-BRITISH MEDICAL JOURNAL			English	Review									BMJ Unified, London WC1H 9JR, England		Tonks, A (corresponding author), BMJ Unified, London WC1H 9JR, England.	atonks@bmj.com	Gale, Christopher Kennington/C-6513-2009	Gale, Christopher Kennington/0000-0001-8032-765X				Barbee J G, 1998, Ann Clin Psychiatry, V10, P15, DOI 10.3109/10401239809148814; Gould RA, 1997, BEHAV THER, V28, P285, DOI 10.1016/S0005-7894(97)80048-2; Hidalgo RB, 2001, MED CLIN N AM, V85, P691, DOI 10.1016/S0025-7125(05)70336-9; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Ninan PT, 2001, J CLIN PSYCHIAT, V62, P5; Rickels K, 2000, J CLIN PSYCHOPHARM, V20, P12, DOI 10.1097/00004714-200002000-00004; Wittchen HU, 2001, J CLIN PSYCHIAT, V62, P23; Wittchen HU, 2001, J CLIN PSYCHIAT, V62, P15	8	12	13	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	2003	326	7391					700	701		10.1136/bmj.326.7391.700	http://dx.doi.org/10.1136/bmj.326.7391.700			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663WL	12663409	Green Published			2022-12-28	WOS:000182029500024
J	Alley, RB; Marotzke, J; Nordhaus, WD; Overpeck, JT; Peteet, DM; Pielke, RA; Pierrehumbert, RT; Rhines, PB; Stocker, TF; Talley, LD; Wallace, JM				Alley, RB; Marotzke, J; Nordhaus, WD; Overpeck, JT; Peteet, DM; Pielke, RA; Pierrehumbert, RT; Rhines, PB; Stocker, TF; Talley, LD; Wallace, JM			Abrupt climate change	SCIENCE			English	Review							THERMOHALINE CIRCULATION; VARIABILITY; OCEAN; STABILIZATION; VEGETATION; COLLAPSE; PACIFIC; MONSOON; EVENT; END	Large, abrupt, and widespread climate changes with major impacts have occurred repeatedly in the past, when the Earth system was forced across thresholds. Although abrupt climate changes can occur for many reasons, it is conceivable that human forcing of climate change is increasing the probability of large, abrupt events. Were such an event to recur, the economic and ecological impacts could be large and potentially serious. Unpredictability exhibited near climate thresholds in simple models shows that some uncertainty will always be associated with projections. In light of these uncertainties, policy-makers should consider expanding research into abrupt climate change, improving monitoring systems, and taking actions designed to enhance the adaptability and resilience of ecosystems and economies.	Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Penn State Univ, EMS Environm Inst, University Pk, PA 16802 USA; Univ Southampton, Southampton Oceanog Ctr, Southampton SO14 3ZH, Hants, England; Yale Univ, Dept Econ, New Haven, CT 06520 USA; Univ Arizona, Inst Study Planet Earth, Tucson, AZ 85721 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; NASA, Goddard Inst Space Studies, New York, NY 10025 USA; Univ Colorado, Ctr Sci & Technol Policy Res, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA; Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA; Univ Washington, Dept Oceanog, Seattle, WA 98195 USA; Univ Bern, Inst Phys, CH-3012 Bern, Switzerland; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; NERC National Oceanography Centre; University of Southampton; Yale University; University of Arizona; Columbia University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Colorado System; University of Colorado Boulder; University of Chicago; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Bern; University of California System; University of California San Diego; Scripps Institution of Oceanography	Alley, RB (corresponding author), Penn State Univ, Dept Geosci, University Pk, PA 16802 USA.		Stocker, Thomas/B-1273-2013					Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; Alley RB, 2001, PALEOCEANOGRAPHY, V16, P190, DOI 10.1029/2000PA000518; Barber DC, 1999, NATURE, V400, P344, DOI 10.1038/22504; Barlow LK, 1997, HOLOCENE, V7, P489, DOI 10.1177/095968369700700411; Bice KL, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2001PA000678; Biswas MR, 1980, DESERTIFICATION; Bond G, 2001, SCIENCE, V294, P2130, DOI 10.1126/science.1065680; Broecker W.S., 2002, GLACIAL WORLD ACCORD; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582; Brook EJ, 1999, GEOPH MONOG SERIES, V112, P165; CAPPELEN J, 2002, 0206 DAN MET I; Cayan D.R., 1990, P 7 ANN PAC CLIM PAC, P115; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Cuffey KM, 1997, J GEOPHYS RES-OCEANS, V102, P26383, DOI 10.1029/96JC03981; Delworth TL, 2000, SCIENCE, V287, P2246, DOI 10.1126/science.287.5461.2246; Dickson B, 2002, NATURE, V416, P832, DOI 10.1038/416832a; Gasse F, 2000, QUATERNARY SCI REV, V19, P189, DOI 10.1016/S0277-3791(99)00061-X; GRAHAM NE, 1994, CLIM DYNAM, V10, P135, DOI 10.1007/BF00210626; Hartmann DL, 2000, P NATL ACAD SCI USA, V97, P1412, DOI 10.1073/pnas.97.4.1412; HASTENRATH S, 1977, Q J ROY METEOR SOC, V103, P77, DOI 10.1002/qj.49710343505; HODELL DA, 1995, NATURE, V375, P391, DOI 10.1038/375391a0; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; HURT DR, 1981, AGR SOCIAL HIST DUST; IPCC, 2001, ADV CLIM CHANG RES; Keller K, 2000, CLIMATIC CHANGE, V47, P17, DOI 10.1023/A:1005624909182; Knutti R, 2002, J CLIMATE, V15, P179, DOI 10.1175/1520-0442(2002)015<0179:LPOTFT>2.0.CO;2; Kutzbach J, 1996, NATURE, V384, P623, DOI 10.1038/384623a0; LAIRD KR, 1998, WORLD DATA CTR A PAL; Latif M, 2000, J CLIMATE, V13, P1809, DOI 10.1175/1520-0442(2000)013<1809:L>2.0.CO;2; Liu KB, 2001, ANN ASSOC AM GEOGR, V91, P453, DOI 10.1111/0004-5608.00253; LORENZ EN, 1963, J ATMOS SCI, V20, P130, DOI 10.1175/1520-0469(1963)020<0130:DNF>2.0.CO;2; Manabe S, 1997, PALEOCEANOGRAPHY, V12, P321, DOI 10.1029/96PA03932; Mantua NJ, 1997, B AM METEOROL SOC, V78, P1069, DOI 10.1175/1520-0477(1997)078<1069:APICOW>2.0.CO;2; MAROTZKE J, 1996, DECADAL CLIMATE VARI; MORRILL CT, IN PRESS HOLOCENE; *NAT RES COUNC, 65 NRC; National Research Council, 2002, ABR CLIM CHANG IN SU; Nicholson SE, 1998, B AM METEOROL SOC, V79, P815, DOI 10.1175/1520-0477(1998)079<0815:DDASVA>2.0.CO;2; Nordhaus W. D, 2000, WARMING WORLD EC MOD; OVERPECK JT, 2003, IGBP SYNTHESIS VOLUM, P81; Peteet D, 2000, P NATL ACAD SCI USA, V97, P1359, DOI 10.1073/pnas.97.4.1359; PETEET DM, 1990, QUATERNARY RES, V33, P219, DOI 10.1016/0033-5894(90)90020-L; Peterson BJ, 2002, SCIENCE, V298, P2171, DOI 10.1126/science.1077445; Polzin KL, 1997, SCIENCE, V276, P93, DOI 10.1126/science.276.5309.93; Portner H.-O., 2022, CLIMATE CHANGE 2022, P3; Reilly J, 2000, CLIMATIC CHANGE, V45, P253, DOI 10.1023/A:1005669807945; REILLY J, 1993, 93012WP MITCEEPR; SEAGER R, 2002, Q J R METEOROL SOC; Sellers W.D., 1969, J APPL METEOROL, V8, P392, DOI [DOI 10.1175/1520-0450(1969)008<0392:AGCMBO>2.0.CO;2, 10.1175/1520-0450(1969)0082.0.CO;2]; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Stocker TF, 2000, QUATERNARY SCI REV, V19, P301, DOI 10.1016/S0277-3791(99)00067-0; Stocker TF, 2002, SCIENCE, V297, P1814, DOI 10.1126/science.1075870; Stocker TF, 1997, NATURE, V388, P862, DOI 10.1038/42224; STOMMEL H, 1961, TELLUS, V13, P224, DOI 10.1111/j.2153-3490.1961.tb00079.x; Streets DG, 2000, GLOBAL ENVIRON CHANG, V10, P97, DOI 10.1016/S0959-3780(00)00015-7; Tinner W, 2001, GEOLOGY, V29, P551, DOI 10.1130/0091-7613(2001)029<0551:CEVRTA>2.0.CO;2; WALKER JCG, 1981, J GEOPHYS RES-OCEANS, V86, P9776, DOI 10.1029/JC086iC10p09776; Wallace JM, 2002, PHYS TODAY, V55, P28, DOI 10.1063/1.1461325; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618; WEISS H, 1993, SCIENCE, V261, P995, DOI 10.1126/science.261.5124.995; Woodhouse CA, 1998, B AM METEOROL SOC, V79, P2693, DOI 10.1175/1520-0477(1998)079<2693:YODVIT>2.0.CO;2; Yohe GW, 1998, CLIMATIC CHANGE, V38, P447, DOI 10.1023/A:1005338413531; [No title captured]	63	761	811	23	439	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					2005	2010		10.1126/science.1081056	http://dx.doi.org/10.1126/science.1081056			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663908				2022-12-28	WOS:000181834200034
J	La Scola, B; Audic, S; Robert, C; Jungang, L; de Lamballerie, X; Drancourt, M; Birtles, R; Claverie, JM; Raoult, D				La Scola, B; Audic, S; Robert, C; Jungang, L; de Lamballerie, X; Drancourt, M; Birtles, R; Claverie, JM; Raoult, D			A giant virus in amoebae	SCIENCE			English	Article									CNRS, UPR 2589, Struct & Genom Informat Lab, Marseille, France; Univ Mediterranee, CNRS, UMR 6020, Unite Rickettsies, F-13385 Marseille, France; Univ Mediterranee, UVE, F-13385 Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Claverie, JM (corresponding author), CNRS, UPR 2589, Struct & Genom Informat Lab, Marseille, France.		Claverie, Jean-Michel/AAG-4889-2019; Claverie, Jean Michel/Z-2183-2019; RAOULT, Didier/A-8434-2008; LA SCOLA, Bernard/P-6477-2016	Claverie, Jean-Michel/0000-0003-1424-0315; RAOULT, Didier/0000-0002-0633-5974; LA SCOLA, Bernard/0000-0001-8006-7704; Birtles, Richard/0000-0002-4216-5044; Audic, Stephane/0000-0001-6193-4374				Birtles RJ, 1997, LANCET, V349, P925, DOI 10.1016/S0140-6736(05)62701-8; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; HUTSON MS, 1995, BIOPOLYMERS, V35, P297, DOI 10.1002/bip.360350305; Iyer LM, 2001, J VIROL, V75, P11720, DOI 10.1128/JVI.75.23.11720-11734.2001; Sandaa RA, 2001, VIROLOGY, V290, P272, DOI 10.1006/viro.2001.1161; van Regenmortel M.H.V., 2000, VIRUS TAXONOMY 7 REP	6	563	580	4	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2003	299	5615					2033	2033						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663918				2022-12-28	WOS:000181834200044
J	Paulsen, IT; Banerjei, L; Myers, GSA; Nelson, KE; Seshadri, R; Read, TD; Fouts, DE; Eisen, JA; Gill, SR; Heidelberg, JF; Tettelin, H; Dodson, RJ; Umayam, L; Brinkac, L; Beanan, M; Daugherty, S; DeBoy, RT; Durkin, S; Kolonay, J; Madupu, R; Nelson, W; Vamathevan, J; Tran, B; Upton, J; Hansen, T; Shetty, J; Khouri, H; Utterback, T; Radune, D; Ketchum, KA; Dougherty, BA; Fraser, CM				Paulsen, IT; Banerjei, L; Myers, GSA; Nelson, KE; Seshadri, R; Read, TD; Fouts, DE; Eisen, JA; Gill, SR; Heidelberg, JF; Tettelin, H; Dodson, RJ; Umayam, L; Brinkac, L; Beanan, M; Daugherty, S; DeBoy, RT; Durkin, S; Kolonay, J; Madupu, R; Nelson, W; Vamathevan, J; Tran, B; Upton, J; Hansen, T; Shetty, J; Khouri, H; Utterback, T; Radune, D; Ketchum, KA; Dougherty, BA; Fraser, CM			Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis	SCIENCE			English	Article							STREPTOCOCCUS-PNEUMONIAE; PLASMID PAD1; VIRULENCE; PRECURSORS; TOLERANCE	The complete genome sequence of Enterococcusfaecalis V583, a vancomycin-resistant clinical isolate, revealed that more than a quarter of the genome consists of probable mobile or foreign DNA. One of the predicted mobile elements is a previously unknown vanB vancomycin-resistance conjugative transposon. Three plasmids were identified, including two pheromone-sensing conjugative plasmids, one encoding a previously undescribed pheromone inhibitor. The apparent propensity for the incorporation of mobile elements probably contributed to the rapid acquisition and dissemination of drug resistance in the enterococci.	Inst Genom Res, Rockville, MD 20850 USA; Johns Hopkins Univ, Baltimore, MD 21218 USA; George Washington Univ, Sch Med, Dept Pharmacol, Washington, DC 20037 USA; George Washington Univ, Sch Med, Dept Microbiol, Washington, DC 20037 USA; George Washington Univ, Sch Med, Dept Trop Med, Washington, DC 20037 USA	J. Craig Venter Institute; Johns Hopkins University; George Washington University; George Washington University; George Washington University	Paulsen, IT (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.		Nelson, William C/E-9263-2016; Eisen, Jonathan A./H-2706-2019; Paulsen, Ian T/K-3832-2012; Read, Timothy/E-6240-2011; Myers, Garry/E-7708-2011	Nelson, William C/0000-0002-1873-3929; Eisen, Jonathan A./0000-0002-0159-2197; Paulsen, Ian T/0000-0001-9015-9418; Heidelberg, John/0000-0003-0673-3224; Myers, Garry/0000-0002-4756-4810; Fraser, Claire/0000-0003-1462-2428; Vamathevan, Jessica/0000-0003-2016-9754; Read, Timothy/0000-0001-8966-9680	NIAID NIH HHS [AI40963-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040963] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR M, 1992, ANTIMICROB AGENTS CH, V36, P867, DOI 10.1128/AAC.36.4.867; Bensing BA, 2001, INFECT IMMUN, V69, P6186, DOI 10.1128/IAI.69.10.6186-6192.2001; Clewell DB, 2000, MOL MICROBIOL, V35, P246, DOI 10.1046/j.1365-2958.2000.01687.x; Dunny GM, 1997, ANNU REV MICROBIOL, V51, P527, DOI 10.1146/annurev.micro.51.1.527; Francia MV, 2001, PLASMID, V46, P117, DOI 10.1006/plas.2001.1533; Garnier F, 2000, MICROBIOL-UK, V146, P1481, DOI 10.1099/00221287-146-6-1481; Huycke MM, 2002, CARCINOGENESIS, V23, P529, DOI 10.1093/carcin/23.3.529; Huycke MM, 1998, EMERG INFECT DIS, V4, P239, DOI 10.3201/eid0402.980211; Klare I, 2001, Contrib Microbiol, V8, P108; Novak R, 1999, NATURE, V399, P590, DOI 10.1038/21202; PONTIUS LT, 1991, PLASMID, V26, P172, DOI 10.1016/0147-619X(91)90041-T; Robertson GT, 2002, J BACTERIOL, V184, P6987, DOI 10.1128/JB.184.24.6987-7000.2002; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P1588, DOI 10.1128/AAC.33.9.1588; Shankar N, 2002, NATURE, V417, P746, DOI 10.1038/nature00802; Sussmuth SD, 2000, INFECT IMMUN, V68, P4900; TAILOR SAN, 1993, ANN PHARMACOTHER, V27, P1231, DOI 10.1177/106002809302701014; WELLS CL, 1990, J INFECT DIS, V162, P82, DOI 10.1093/infdis/162.1.82; [No title captured]	18	700	1206	2	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2003	299	5615					2071	2074		10.1126/science.1080613	http://dx.doi.org/10.1126/science.1080613			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663927				2022-12-28	WOS:000181834200056
J	Foreman, J; Demidchik, V; Bothwell, JHF; Mylona, P; Miedema, H; Torres, MA; Linstead, P; Costa, S; Brownlee, C; Jones, JDG; Davies, JM; Dolan, L				Foreman, J; Demidchik, V; Bothwell, JHF; Mylona, P; Miedema, H; Torres, MA; Linstead, P; Costa, S; Brownlee, C; Jones, JDG; Davies, JM; Dolan, L			Reactive oxygen species produced by NADPH oxidase regulate plant cell growth	NATURE			English	Article							ROOT HAIRS; CALCIUM-CHANNELS; ARABIDOPSIS; CA2+; GENERATION; HOMOLOGS; DEFENSE; PROTEIN; TIP	Cell expansion is a central process in plant morphogenesis, and the elongation of roots and root hairs is essential for uptake of minerals and water from the soil. Ca2+ influx from the extracellular store is required for ( and sets the rates of) cell elongation in roots(1). Arabidopsis thaliana rhd2 mutants are defective in Ca2+ uptake and consequently cell expansion is compromised rhd2 mutants have short root hairs(2,3) and stunted roots. To determine the regulation of Ca2+ acquisition in growing root cells we show here that RHD2 is an NADPH oxidase, a protein that transfers electrons from NADPH to an electron acceptor leading to the formation of reactive oxygen species (ROS). We show that ROS accumulate in growing wild-type (WT) root hairs but their levels are markedly decreased in rhd2 mutants. Blocking the activity of the NADPH oxidase with diphenylene iodonium (DPI) inhibits ROS formation and phenocopies Rhd2(-). Treatment of rhd2 roots with ROS partly suppresses the mutant phenotype and stimulates the activity of plasma membrane hyperpolarization-activated Ca2+ channels, the predominant root Ca2+ acquisition system. This indicates that NADPH oxidases control development by making ROS that regulate plant cell expansion through the activation of Ca2+ channels.	John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England; Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England; Marine Biol Assoc UK, Plymouth PL1 2PB, Devon, England; John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Cambridge; Marine Biological Association United Kingdom; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dolan, L (corresponding author), John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England.	liam.dolan@bbsrc.ac.uk	Lacruz, Miguel Angel Torres/H-6969-2015; Jones, Jonathan DG/J-5129-2012; Demidchik, Vadim/N-9314-2019	Lacruz, Miguel Angel Torres/0000-0002-0435-1786; Jones, Jonathan DG/0000-0002-4953-261X; Demidchik, Vadim/0000-0003-3765-8386; Dolan, Liam/0000-0003-1206-7096; Costa, Silvia/0000-0001-9931-3493; Bothwell, John/0000-0003-2964-5980	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000168] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bolwell GP, 1997, PHYSIOL MOL PLANT P, V51, P347, DOI 10.1006/pmpp.1997.0129; Carroll AD, 1998, PLANT CELL, V10, P1267, DOI 10.1105/tpc.10.8.1267; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; Cramer GR, 1996, PLANT CELL ENVIRON, V19, P1291, DOI 10.1111/j.1365-3040.1996.tb00007.x; Demidchik V, 2002, PLANT J, V32, P799, DOI 10.1046/j.1365-313X.2002.01467.x; DOLAN L, 1994, DEVELOPMENT, V120, P2465; Felle HH, 1997, PLANT PHYSIOL, V114, P39, DOI 10.1104/pp.114.1.39; Fry SC, 1998, BIOCHEM J, V332, P507, DOI 10.1042/bj3320507; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hirsch RE, 1998, SCIENCE, V280, P918, DOI 10.1126/science.280.5365.918; Jones MA, 2002, PLANT CELL, V14, P763, DOI 10.1105/tpc.010359; Keller T, 1998, PLANT CELL, V10, P255, DOI 10.1105/tpc.10.2.255; Kiegle E, 2000, PLANT J, V21, P225, DOI 10.1046/j.1365-313x.2000.00659.x; KISS T, 1994, PHARMACOL REV, V46, P245; Miedema H, 2001, TRENDS PLANT SCI, V6, P514, DOI 10.1016/S1360-1385(01)02124-0; Molendijk AJ, 2001, EMBO J, V20, P2779, DOI 10.1093/emboj/20.11.2779; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; SCHIEFELBEIN JW, 1990, PLANT CELL, V2, P235, DOI 10.1105/tpc.2.3.235; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tissier AF, 1999, PLANT CELL, V11, P1841, DOI 10.1105/tpc.11.10.1841; Torres MA, 1998, PLANT J, V14, P365, DOI 10.1046/j.1365-313X.1998.00136.x; Torres MA, 2002, P NATL ACAD SCI USA, V99, P517, DOI 10.1073/pnas.012452499; Very AA, 2000, P NATL ACAD SCI USA, V97, P9801, DOI 10.1073/pnas.160250397; WILLIAMS AJ, 1981, THORAX, V36, P866, DOI 10.1136/thx.36.11.866; Wymer CL, 1997, PLANT J, V12, P427, DOI 10.1046/j.1365-313X.1997.12020427.x; Zhang WH, 1998, PLANT J, V15, P147, DOI 10.1046/j.1365-313X.1998.00188.x	29	1610	1739	20	430	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 27	2003	422	6930					442	446		10.1038/nature01485	http://dx.doi.org/10.1038/nature01485			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660786				2022-12-28	WOS:000181801200047
J	Schwab, JM; Schluesener, HJ; Laufer, S				Schwab, JM; Schluesener, HJ; Laufer, S			COX-3: just another COX or the solitary elusive target of paracetamol?	LANCET			English	Editorial Material							EXPRESSION; TRANSCRIPT; MICE		Sch Med, Inst Brain Res, D-72076 Tubingen, Germany; Univ Tubingen, Inst Pharm, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Schwab, JM (corresponding author), Sch Med, Inst Brain Res, D-72076 Tubingen, Germany.			Schwab, Jan/0000-0001-6784-4919; Laufer, Stefan/0000-0001-6952-1486				Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Botting RM, 2000, CLIN INFECT DIS, V31, pS202, DOI 10.1086/317520; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Crofford LJ, 1997, J RHEUMATOL, V24, P15; Hla T, 1996, PROSTAG OTH LIPID M, V51, P81, DOI 10.1016/0090-6980(95)00158-1; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Laulederkind SJF, 2002, LAB INVEST, V82, P919, DOI 10.1097/01.LAB.0000020407.98665.98; Mazario J, 2001, NEUROPHARMACOLOGY, V40, P937, DOI 10.1016/S0028-3908(01)00020-X; Plant MH, 1999, BIOCHEM J, V344, P677, DOI 10.1042/0264-6021:3440677; VANE JR, 1971, NATURE, V23, P232; Warner TD, 2002, P NATL ACAD SCI USA, V99, P13371, DOI 10.1073/pnas.222543099; Willoughby DA, 2000, LANCET, V355, P646, DOI 10.1016/S0140-6736(99)12031-2	12	68	74	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					981	982		10.1016/S0140-6736(03)12841-3	http://dx.doi.org/10.1016/S0140-6736(03)12841-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660052				2022-12-28	WOS:000181699700005
J	Amundsen, SK; Smith, GR				Amundsen, SK; Smith, GR			Interchangeable parts of the Escherichia coli recombination machinery	CELL			English	Review							RECBCD ENZYME; RECA PROTEIN; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; DNA-REPAIR; SUBUNIT; SSDNA; ROLES	In Escherichia coli, at least two groups of proteins, or "recombination machines," can operate independently on broken DNA to produce a X-terminated single-stranded DNA filament coated with RecA protein and ready for synapsis with intact homologous DNA. Recent analyses of mutants lacking one or more of the activities required for presynaptic filament formation by one recombination machine demonstrate that parts of the two normally separate machines can interchange to initiate homologous recombination.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Smith, GR (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	gsmith@fhcrc.org		Smith, Gerald/0000-0002-8747-1352				Amundsen SK, 2000, P NATL ACAD SCI USA, V97, P7399, DOI 10.1073/pnas.130192397; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1999, J BIOL CHEM, V274, P27139, DOI 10.1074/jbc.274.38.27139; CLARK AJ, 1971, ANNU REV MICROBIOL, V25, P437, DOI 10.1146/annurev.mi.25.100171.002253; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Hegde SP, 1996, P NATL ACAD SCI USA, V93, P14468, DOI 10.1073/pnas.93.25.14468; Ivancic-Bace I, 2003, GENETICS, V163, P485; Jockovich ME, 2001, MOL MICROBIOL, V41, P949, DOI 10.1046/j.1365-2958.2001.02573.x; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; LOVETT ST, 1988, GENETICS, V120, P37; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; SMITH GR, 1989, GENOME, V31, P520, DOI 10.1139/g89-100; Smith GR, 2001, ANNU REV GENET, V35, P243, DOI 10.1146/annurev.genet.35.102401.090509; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; Yu M, 1998, J MOL BIOL, V283, P797, DOI 10.1006/jmbi.1998.2127	17	73	74	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2003	112	6					741	744		10.1016/S0092-8674(03)00197-1	http://dx.doi.org/10.1016/S0092-8674(03)00197-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	660DL	12654241	Bronze			2022-12-28	WOS:000181818500002
J	Gibson, M				Gibson, M			Conservation: Fate of Iraqi archaeology	SCIENCE			English	Editorial Material									Amer Assoc Res, Baghdad, Iraq; Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Gibson, M (corresponding author), Amer Assoc Res, Baghdad, Iraq.	m-gibson@uchicago.edu						Lawler A, 2003, SCIENCE, V299, P1827; Lawler A, 2001, SCIENCE, V293, P32, DOI 10.1126/science.293.5527.32; WILFORD JN, 2003, NY TIMES        0225, P81	3	5	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	2003	299	5614					1848	1849		10.1126/science.1083494	http://dx.doi.org/10.1126/science.1083494			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649467				2022-12-28	WOS:000181669700027
J	Zuger, A				Zuger, A			Behind the research - Medical detection in the 21st century	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									St Lukes Roosevelt Hosp, New York, NY 10019 USA	Mount Sinai St. Luke's; Mount Sinai West	Zuger, A (corresponding author), St Lukes Roosevelt Hosp, New York, NY 10019 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1079	1080		10.1056/NEJMp030016	http://dx.doi.org/10.1056/NEJMp030016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646662				2022-12-28	WOS:000181628400001
J	Tsang, KW; Ho, PL; Ooi, GC; Yee, WK; Wang, T; Chan-Yeung, M; Lam, WK; Seto, WH; Yam, LY; Cheung, TM; Wong, PC; Lam, B; Ip, MS; Chan, J; Yuen, KY; Lai, KN				Tsang, KW; Ho, PL; Ooi, GC; Yee, WK; Wang, T; Chan-Yeung, M; Lam, WK; Seto, WH; Yam, LY; Cheung, TM; Wong, PC; Lam, B; Ip, MS; Chan, J; Yuen, KY; Lai, KN			A cluster of cases of severe acute respiratory syndrome in Hong Kong	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORGANIZING PNEUMONIA; CT FINDINGS	BACKGROUND Information on the clinical features of the severe acute respiratory syndrome (SARS) will be of value to physicians caring for patients suspected of having this disorder. METHODS We abstracted data on the clinical presentation and course of disease in 10 epidemiologically linked Chinese patients (5 men and 5 women 38 to 72 years old) in whom SARS was diagnosed between February 22, 2003, and March 22, 2003, at our hospitals in Hong Kong, China. RESULTS Exposure between the source patient and subsequent patients ranged from minimal to that between patient and health care provider. The incubation period ranged from 2 to 11 days. All patients presented with fever (temperature, >38 degreesC for over 24 hours), and most presented with rigor, dry cough, dyspnea, malaise, headache, and hypoxemia. Physical examination of the chest revealed crackles and percussion dullness. Lymphopenia was observed in nine patients, and most patients had mildly elevated aminotransferase levels but normal serum creatinine levels. Serial chest radiographs showed progressive air-space disease. Two patients died of progressive respiratory failure; histologic analysis of their lungs showed diffuse alveolar damage. There was no evidence of infection by Mycoplasma pneumoniae, Chlamydia pneumoniae, or Legionella pneumophila. All patients received corticosteroid and ribavirin therapy a mean (+/-SD) of 9.6+/-5.42 days after the onset of symptoms, and eight were treated earlier with a combination of beta-lactams and macrolide for 4+/-1.9 days, with no clinical or radiologic efficacy. CONCLUSIONS SARS appears to be infectious in origin. Fever followed by rapidly progressive respiratory compromise is the key complex of signs and symptoms from which the syndrome derives its name. The microbiologic origins of SARS remain unclear. .	Univ Hong Kong, Dept Clin Microbiol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Diagnost Radiol, Hong Kong, Hong Kong, Peoples R China; Kwong Wah Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Pamela Youde Nethersole Eastern Hosp, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; Kwong Wah Hospital; Pamela Youde Nethersole Eastern Hospital; University of Hong Kong	Lai, KN (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam, Hong Kong, Peoples R China.		何栢良, Pak-Leung HO/C-4310-2009; Yuen, Kwok Yung/C-4465-2009; Lai, Kar Neng/C-4300-2009; Ip, Mary Sau Man/C-4284-2009	何栢良, Pak-Leung HO/0000-0002-8811-1308; Ip, Mary Sau Man/0000-0002-8692-6933; Seto, Wing Hong/0000-0002-1139-9200; Yuen, Kwok-yung/0000-0002-2083-1552				*CDCP, 2003, SEV AC RESP SYNDR SA; HAWKER J, 2001, COMMUNICABLE DIS CON, P152; JACKSON LA, 2000, MANDELL DOUGLAS BENN, V2, P2007; LEE KS, 1994, AM J ROENTGENOL, V162, P543, DOI 10.2214/ajr.162.3.8109493; MULLER NL, 1990, AM J ROENTGENOL, V154, P983; PRIMACK SL, 1993, RADIOLOGY, V188, P817, DOI 10.1148/radiology.188.3.8351354; *WHO, 2003, AC RESP SYNDR CHIN U; *WHO, 2003, CASE DEF SURV SEV AC	8	732	849	1	82	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					1977	1985		10.1056/NEJMoa030666	http://dx.doi.org/10.1056/NEJMoa030666			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12671062	Bronze, Green Published			2022-12-28	WOS:000182823400006
J	Borchardt, J; Smirnov, A; Metchnik, L; Malnick, S				Borchardt, J; Smirnov, A; Metchnik, L; Malnick, S			Lesson of the week - Treating hepatic hydrothorax	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTRAHEPATIC PORTOSYSTEMIC SHUNT; MANAGEMENT; OCTREOTIDE		Kaplan Med Ctr, Dept Internal Med C, IL-76100 Rehovot, Israel; Kaplan Med Ctr, Dept Geriatr, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Kaplan Medical Center	Malnick, S (corresponding author), Kaplan Med Ctr, Dept Internal Med C, IL-76100 Rehovot, Israel.	stevash@trendline.co.il						ALBERTS WM, 1991, ARCH INTERN MED, V151, P2383, DOI 10.1001/archinte.151.12.2383; BOITEAU R, 1990, American Review of Respiratory Disease, V141, pA770; de Campos JRM, 2000, CHEST, V118, P13, DOI 10.1378/chest.118.1.13; Dumortier J, 2000, EUR J GASTROEN HEPAT, V12, P817, DOI 10.1097/00042737-200012070-00018; FALCHUK KR, 1977, GASTROENTEROLOGY, V72, P319; Gordon FD, 1997, HEPATOLOGY, V25, P1366, DOI 10.1002/hep.510250611; HARVEY J, 1994, BRIT MED J, V309, P1338, DOI 10.1136/bmj.309.6965.1338; IKARD RW, 1980, ARCH SURG-CHICAGO, V115, P1125; Jeffries MA, 1998, LIVER TRANSPLANT SUR, V4, P416, DOI 10.1002/lt.500040506; Lazaridis KN, 1999, AM J MED, V107, P262, DOI 10.1016/S0002-9343(99)00217-X; LIEBERMAN FL, 1966, ANN INTERN MED, V64, P341, DOI 10.7326/0003-4819-64-2-341; Lin C C, 2000, Zhonghua Yi Xue Za Zhi (Taipei), V63, P704; Mouroux J, 1996, CHEST, V109, P1093, DOI 10.1378/chest.109.4.1093; Pfammatter R, 2001, EUR J GASTROEN HEPAT, V13, P977, DOI 10.1097/00042737-200108000-00019; RodriguezPanadero F, 1997, EUR RESPIR J, V10, P1648, DOI 10.1183/09031936.97.10071648; RUNYON BA, 1986, AM J GASTROENTEROL, V81, P566; Siegerstetter V, 2001, EUR J GASTROEN HEPAT, V13, P529, DOI 10.1097/00042737-200105000-00011; STRAUSS RM, 1994, AM J GASTROENTEROL, V89, P1520; Xiol X, 1996, HEPATOLOGY, V23, P719, DOI 10.1053/jhep.1996.v23.pm0008666323	19	29	31	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2003	326	7392					751	752		10.1136/bmj.326.7392.751	http://dx.doi.org/10.1136/bmj.326.7392.751			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665LF	12676846	Green Published			2022-12-28	WOS:000182121600018
J	Raghunath, A; Hungin, APS; Wooff, D; Childs, A				Raghunath, A; Hungin, APS; Wooff, D; Childs, A			Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GASTROESOPHAGEAL REFLUX; BARRETTS-ESOPHAGUS; INTESTINAL METAPLASIA; CAMPYLOBACTER-PYLORI; ATROPHIC GASTRITIS; OMEPRAZOLE THERAPY; DUODENAL-ULCER; INFECTION; ASSOCIATION; CAGA	Objectives To ascertain the prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease and its association with the disease. Design Systematic review of studies reporting the prevalence of H pylori in patients with and without gastro-oesophageal reflux disease. Data sources Four electronic databases, searched to November 2001, experts, pharmaceutical companies, and journals. Main outcome measure Odds ratio for prevalence of H pylori in patients with gastro-oesophageal reflux disease. Results 20 studies were included. The pooled estimate of the odds ratio for prevalence of H pylori was 0.60 (95% confidence interval 0.47 to 0.78), indicating a lower prevalence in patients with gastro-oesophageal reflux disease. Substantial heterogeneity was observed between studies. Location seemed to be an important factor, with a much lower prevalence of H pylori in patients with gastro-oesophageal reflux disease in studies from the Far East, despite a higher overall prevalence of infection than western Europe and North America. Year of study was not a source of heterogeneity. Conclusion The prevalence of H pylori infection was significantly lower in patients with than without gastro-oesophageal reflux, with geographical location being a strong contributor to the heterogeneity between studies. Patients from die Far East with reflux disease had a lower prevalence of H pylori infection than patients from western Europe and North America, despite a higher prevalence in the general population.	Univ Durham, Ctr Integrated Hlth Care Res, Wolfson Res Inst, Stoke On Tees TS17 6BH, Staffs, England; Univ Durham, Dept Math Sci, Stat & Math Consultancy Unit, Sci Labs, Durham DH1 3LE, England; Northumbria Univ, Informat Management Res Inst, Sch Informat Studies, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England	Durham University; Durham University; Northumbria University	Raghunath, A (corresponding author), Univ Durham, Ctr Integrated Hlth Care Res, Wolfson Res Inst, Stoke On Tees TS17 6BH, Staffs, England.	raghu@nath.freeserve.co.uk		hungin, amritpal Pali/0000-0001-7275-8927				ABBAS Z, 1995, J GASTROEN HEPATOL, V10, P331, DOI 10.1111/j.1440-1746.1995.tb01102.x; [Anonymous], 2000, EUR J GASTROEN HEPAT, V12, P129; BATE CM, 1998, J DRUG ASSESS, V1, P209; Berstad AE, 1997, GUT, V41, P740, DOI 10.1136/gut.41.6.740; Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468; Boixeda D, 1995, MED CLIN-BARCELONA, V105, P774; CHENG EH, 1989, ARCH INTERN MED, V149, P1373, DOI 10.1001/archinte.149.6.1373; COOPER BT, 1991, CULLEI, V1, P173; Csendes A, 1997, Dis Esophagus, V10, P38; DEKOSTER E, GASTROENTEROLOGY S, V108, pA81; Deng J, 2001, BRIT MED J, V322, P344, DOI 10.1136/bmj.322.7282.344; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DeVault KR, 1999, AM J GASTROENTEROL, V94, P1434; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; El-Serag HB, 1999, GUT, V45, P181, DOI 10.1136/gut.45.2.181; Fallone CA, 2000, AM J GASTROENTEROL, V95, P659, DOI 10.1111/j.1572-0241.2000.01970.x; Gisbert JP, 2001, J CLIN GASTROENTEROL, V32, P210, DOI 10.1097/00004836-200103000-00005; Goldblum JR, 1998, GASTROENTEROLOGY, V114, P633, DOI 10.1016/S0016-5085(98)70576-1; Graham DY, 1998, HELICOBACTER, V3, P145, DOI 10.1046/j.1523-5378.1998.08031.x; Hackelsberger A, 1998, EUR J GASTROEN HEPAT, V10, P465, DOI 10.1097/00042737-199806000-00005; Haruma K, 2000, HELICOBACTER, V5, P24, DOI 10.1046/j.1523-5378.2000.00003.x; Ho KY, 1999, AM J GASTROENTEROL, V94, P1186, DOI 10.1111/j.1572-0241.1999.01063.x; Holtmann G, 1999, GASTROENTEROLOGY, V117, P11, DOI 10.1016/S0016-5085(99)70544-5; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; JONES R, 1995, SCAND J GASTROENTERO, V30, P35, DOI 10.3109/00365529509090292; Koike T, 1999, AM J GASTROENTEROL, V94, P3468, DOI 10.1111/j.1572-0241.1999.01593.x; Koike T, 2001, GUT, V49, P330, DOI 10.1136/gut.49.3.330; KROES RM, 1999, EUR J GEN PRACT, P88; KUIPERS EJ, 1993, SCAND J GASTROENTERO, V28, P978, DOI 10.3109/00365529309098295; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; Liston R, 1996, POSTGRAD MED J, V72, P221, DOI 10.1136/pgmj.72.846.221; MACCHIARELLI R, 1998, GASTROENTEROL INT, V11, P194; Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x; Manes G, 1999, SCAND J GASTROENTERO, V34, P658, DOI 10.1080/003655299750025840; MCCALLUM RW, 1987, GASTROENTEROLOGY, V92, P1524; Mihara M., 1996, Gut, V39, pA94; Newton M, 1997, GUT, V40, P9, DOI 10.1136/gut.40.1.9; Oberg S, 1999, ARCH SURG-CHICAGO, V134, P722, DOI 10.1001/archsurg.134.7.722; OCONNOR HJ, 1994, IRISH J MED SCI, V163, P369, DOI 10.1007/BF02942830; *OFF HLTH EC, 1996, HLTH EXP UK; Pieramico O, 2000, DIGEST LIVER DIS, V32, P567, DOI 10.1016/S1590-8658(00)80837-3; Richter JE, 1998, AM J GASTROENTEROL, V93, P1800, DOI 10.1111/j.1572-0241.1998.00523.x; Schenk BE, 1999, AM J GASTROENTEROL, V94, P884, DOI 10.1111/j.1572-0241.1999.982_e.x; SCHUBERT TT, 1989, AM J GASTROENTEROL, V84, P637; Sekiguchi T, 1996, GASTROENTEROLOGY, V110, pA755; Shirota T, 1999, J GASTROENTEROL, V34, P553, DOI 10.1007/s005350050372; Thompson SG, 1995, SYSTEMATIC REV; Vaezi MF, 2000, AM J GASTROENTEROL, V95, P2206, DOI 10.1111/j.1572-0241.2000.02305.x; Varanasi RV, 1998, HELICOBACTER, V3, P188, DOI 10.1046/j.1523-5378.1998.08001.x; VELANOVICH V, 1995, ANN SURG, V62, P60; Vicari JJ, 1998, GASTROENTEROLOGY, V115, P50, DOI 10.1016/S0016-5085(98)70364-6; Warburton-Timms VJ, 2001, GUT, V49, P341, DOI 10.1136/gut.49.3.341; Werdmuller BFM, 1997, DIGEST DIS SCI, V42, P103, DOI 10.1023/A:1018841222856; Wu JCY, 1999, AM J GASTROENTEROL, V94, P1790, DOI 10.1111/j.1572-0241.1999.01207.x; Yerra L N, 1999, Trop Gastroenterol, V20, P175	55	222	243	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2003	326	7392					737	739		10.1136/bmj.326.7392.737	http://dx.doi.org/10.1136/bmj.326.7392.737			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665LF	12676842	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000182121600014
J	Blow, JJ				Blow, JJ			A new role for Ran in ensuring precise duplication of chromosomal DNA	CELL			English	Editorial Material							REPLICATION; PHOSPHORYLATION		Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Blow, JJ (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.		Blow, J. Julian/B-3977-2009	Blow, J. Julian/0000-0002-9524-5849	Cancer Research UK [A3135] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Nguyen VQ, 2001, NATURE, V411, P1068, DOI 10.1038/35082600; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Vas A, 2001, MOL CELL BIOL, V21, P5767, DOI 10.1128/MCB.21.17.5767-5777.2001; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Wuarin J, 2002, CELL, V111, P419, DOI 10.1016/S0092-8674(02)01042-5; Yamaguchi R, 2003, CELL, V113, P115, DOI 10.1016/S0092-8674(03)00200-9	9	3	5	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 4	2003	113	1					2	4		10.1016/S0092-8674(03)00236-8	http://dx.doi.org/10.1016/S0092-8674(03)00236-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679026	Green Accepted, Bronze			2022-12-28	WOS:000182282900002
J	Maskell, NA; Gleeson, FV				Maskell, NA; Gleeson, FV			Effect of intrapleural streptokinase on a loculated malignant pleural effusion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Churchill Hosp, Oxford OX3 7LJ, England	University of Oxford	Maskell, NA (corresponding author), Churchill Hosp, Oxford OX3 7LJ, England.			maskell, nick/0000-0002-1276-6500					0	18	18	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					E4	U9		10.1056/ENEJMicm020531	http://dx.doi.org/10.1056/ENEJMicm020531			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672879				2022-12-28	WOS:000181949100039
J	Spehr, M; Gisselmann, G; Poplawski, A; Riffell, JA; Wetzel, CH; Zimmer, RK; Hatt, H				Spehr, M; Gisselmann, G; Poplawski, A; Riffell, JA; Wetzel, CH; Zimmer, RK; Hatt, H			Identification of a testicular odorant receptor mediating human sperm chemotaxis	SCIENCE			English	Article							FUNCTIONAL EXPRESSION; OLFACTORY RECEPTORS; HUMAN SPERMATOZOA; ADENYLYL-CYCLASE; GERM-CELLS; PROGESTERONE; CHANNEL; SYSTEM	Although it has been known for some time that olfactory receptors (ORs) reside in spermatozoa, the function of these ORs is unknown. Here, we identified, cloned, and functionally expressed a previously undescribed human testicular OR, hOR17-4. With the use of raticifluorometric imaging, Ca2+ signals were induced by a small subset of applied chemical stimuli, establishing the molecular receptive fields for the recombinantly expressed receptor in human embryonic kidney (HEK) 293 cells and the native receptor in human spermatozoa. Bourgeonal was a powerful agonist for both recombinant and native receptor types, as well as a strong chemoattractant in subsequent behavioral bioassays. In contrast, undecanal was a potent OR antagonist to bourgeonal and related compounds. Taken together, these results indicate that hOR17-4 functions in human sperm chemotaxis and may be a critical component of the fertilization process.	Ruhr Univ Bochum, Dept Cell Physiol, D-44780 Bochum, Germany; Univ Calif Los Angeles, Program Neurosci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA	Ruhr University Bochum; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Hatt, H (corresponding author), Ruhr Univ Bochum, Dept Cell Physiol, 150 Univ St, D-44780 Bochum, Germany.		Spehr, Marc/B-3140-2011; Wetzel, Christian H/N-9880-2017; Wetzel, Christian/C-2501-2009; Spehr, Marc/AAK-3162-2021; Wetzel, Christian/F-1366-2018	Spehr, Marc/0000-0001-6616-4196; Wetzel, Christian H/0000-0002-5762-0003; Wetzel, Christian/0000-0002-5762-0003; Spehr, Marc/0000-0001-6616-4196; 				Baldi E, 2002, J REPROD IMMUNOL, V53, P121, DOI 10.1016/S0165-0378(01)00089-4; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; Eisenbach M, 1999, BIOESSAYS, V21, P203, DOI 10.1002/(SICI)1521-1878(199903)21:3<203::AID-BIES4>3.0.CO;2-T; Firestein S, 2001, NATURE, V413, P211, DOI 10.1038/35093026; Garcia MA, 1999, BIOL REPROD, V60, P102, DOI 10.1095/biolreprod60.1.102; Gautier-Courteille C, 1998, ENDOCRINOLOGY, V139, P2588, DOI 10.1210/en.139.5.2588; Glusman G, 2000, MAMM GENOME, V11, P1016, DOI 10.1007/s003350010196; Glusman G, 2001, GENOME RES, V11, P685, DOI 10.1101/gr.171001; Jaiswal BS, 2001, J BIOL CHEM, V276, P31698, DOI 10.1074/jbc.M011698200; Kobori H, 2000, BIOL REPROD, V63, P113, DOI 10.1095/biolreprod63.1.113; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; Wellerdieck C, 1997, CHEM SENSES, V22, P467, DOI 10.1093/chemse/22.4.467; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; Wetzel CH, 2001, P NATL ACAD SCI USA, V98, P9377, DOI 10.1073/pnas.151103998; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0	19	554	581	6	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2003	299	5615					2054	2058		10.1126/science.1080376	http://dx.doi.org/10.1126/science.1080376			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663925				2022-12-28	WOS:000181834200051
J	Story, GM; Peier, AM; Reeve, AJ; Eid, SR; Mosbacher, J; Hricik, TR; Earley, TJ; Hergarden, AC; Andersson, DA; Hwang, SW; McIntyre, P; Jegla, T; Bevan, S; Patapoutian, A				Story, GM; Peier, AM; Reeve, AJ; Eid, SR; Mosbacher, J; Hricik, TR; Earley, TJ; Hergarden, AC; Andersson, DA; Hwang, SW; McIntyre, P; Jegla, T; Bevan, S; Patapoutian, A			ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures	CELL			English	Article							NERVE GROWTH-FACTOR; RAT SENSORY NEURONS; CAPSAICIN-RECEPTOR; CATION CHANNEL; ION-CHANNEL; HEAT; TRANSDUCTION; DROSOPHILA; PROTEIN; SENSITIVITY	Mammals detect temperature with specialized neurons in the peripheral nervous system. Four TRPV-class channels have been implicated in sensing heat, and one TRPM-class channel in sensing cold. The combined range of temperatures that activate these channels covers a majority of the relevant physiological spectrum sensed by most mammals, with a significant gap in the noxious cold range. Here, we describe the characterization of ANKTM1, a cold-activated channel with a lower activation temperature compared to the cold and menthol receptor, TRPM8. ANKTM1 is a distant family member of TRP channels with very little amino acid similarity to TRPM8. It is found in a subset of nociceptive sensory neurons where it is coexpressed with TRPV1/VR1 (the capsaicin/heat receptor) but not TRPM8. Consistent with the expression of ANKTM1, we identify noxious cold-sensitive sensory neurons that also respond to capsaicin but not to menthol.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Novartis Inst Med Sci, London WC1E 6BN, England; Novartis Pharma AG, Nervous Syst Res, CH-4002 Basel, Switzerland	Scripps Research Institute; Novartis; Novartis; Novartis	Patapoutian, A (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.	ardem@scripps.edu	Bevan, Stuart/A-8821-2008; Mcintyre, Peter/N-4109-2013; Andersson, David A/C-3435-2008	Andersson, David A/0000-0001-7451-8548; Bevan, Stuart John/0000-0002-8977-1797; Jegla, Timothy/0000-0001-8616-2390; McIntyre, Peter/0000-0001-9506-5998; Hwang, Sun Wook/0000-0001-8460-7480				AGUAYO LG, 1992, BRAIN RES, V570, P61, DOI 10.1016/0006-8993(92)90564-P; Askwith CC, 2001, P NATL ACAD SCI USA, V98, P6459, DOI 10.1073/pnas.111155398; Campero M, 1996, J PHYSIOL-LONDON, V497, P565, DOI 10.1113/jphysiol.1996.sp021789; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Davis KD, 2002, PAIN, V98, P179, DOI 10.1016/S0304-3959(02)00043-X; DODT E, 1952, ACTA PHYSIOL SCAND, V26, P358, DOI 10.1111/j.1748-1716.1952.tb00917.x; Guler AD, 2002, J NEUROSCI, V22, P6408; Hensel H, 1981, Monogr Physiol Soc, V38, P1; Jaquemar D, 1999, J BIOL CHEM, V274, P7325, DOI 10.1074/jbc.274.11.7325; Jegla T, 1997, J NEUROSCI, V17, P32, DOI 10.1523/JNEUROSCI.17-01-00032.1997; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; MONTELL C, 2001, PHYSL PHYLOGENY FUNC; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Perl ER, 1998, NAT NEUROSCI, V1, P177, DOI 10.1038/624; Reid G, 2002, J PHYSIOL-LONDON, V545, P595, DOI 10.1113/jphysiol.2002.024331; Reid G, 2001, NEUROSCI LETT, V297, P171, DOI 10.1016/S0304-3940(00)01694-3; Scott SA, 1992, SENSORY NEURONS DIVE; Shu XQ, 1999, NEUROSCI LETT, V274, P159, DOI 10.1016/S0304-3940(99)00701-6; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tobin DM, 2002, NEURON, V35, P307, DOI 10.1016/S0896-6273(02)00757-2; UPDIKE J, 1980, MORE MATTER ESSAYS C, P133; Viana F, 2002, NAT NEUROSCI, V5, P254, DOI 10.1038/nn809; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; WEI ET, 1983, J PHARM PHARMACOL, V35, P110, DOI 10.1111/j.2042-7158.1983.tb04279.x; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882	35	1796	1906	4	138	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2003	112	6					819	829		10.1016/S0092-8674(03)00158-2	http://dx.doi.org/10.1016/S0092-8674(03)00158-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	660DL	12654248	Bronze			2022-12-28	WOS:000181818500009
J	Fischhoff, B; Wessely, S				Fischhoff, B; Wessely, S			Managing patients with inexplicable health problems	BRITISH MEDICAL JOURNAL			English	Article							UNEXPLAINED SYMPTOMS; PERSPECTIVES; DOCTORS; CARE	People need to rationalise their health problems, and those with medical mysteries will find some explanation. The best way to manage such patients is unclear, but the principles described in this article should help improve the satisfaction of both patients and doctors.	Guys Kings & St Thomas Sch Med, Acad Dept Psychol Med, London SE5 8AF, England; Inst Psychiat, London SE5 8AF, England; Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA	University of London; King's College London; University of London; King's College London; Carnegie Mellon University	Wessely, S (corresponding author), Guys Kings & St Thomas Sch Med, Acad Dept Psychol Med, London SE5 8AF, England.		Wessely, Simon C/A-8713-2008; Fischhoff, Baruch/I-9859-2014	Fischhoff, Baruch/0000-0002-3030-6874; Wessely, Simon Charles/0000-0002-6743-9929				[Anonymous], 1982, JUDGMENT UNCERTAINTY; BUDESCU DV, 1995, DECISION MAKING COGN, P275; Bursztajn HJ, 1981, MED CHOICES MED CHAN; Byram S, 2001, BEHAV MED, V27, P4, DOI 10.1080/08964280109595767; Deyo RA, 1997, NEW ENGL J MED, V336, P1176, DOI 10.1056/NEJM199704173361611; Engel CC, 2002, ENVIRON HEALTH PERSP, V110, P641, DOI 10.1289/ehp.02110s4641; Finestone AJ, 1997, ARCH INTERN MED, V157, P491, DOI 10.1001/archinte.157.5.491; FISCHHOFF B, 1992, AM PSYCHOL, V47, P577, DOI 10.1037/0003-066X.47.4.577; FISCHHOFF B, 1995, RISK ANAL, V15, P137, DOI 10.1111/j.1539-6924.1995.tb00308.x; Fischhoff B, 2002, OXFORD TXB PUBLIC HL, P1105; FISCHHOFF B, 1999, J NATL CANC I MONOGR, V25, P7, DOI DOI 10.1093/OXFORDJOURNALS.JNCIMONOGRAPHS.A024213; FURNHAM AF, 1987, LAY THEORIES; Gilovich T., 1993, WE KNOW WHAT ISNT SO; Hartz AJ, 2000, GEN HOSP PSYCHIAT, V22, P144, DOI 10.1016/S0163-8343(00)00060-8; Hassett AL, 2002, ARCH INTERN MED, V162, P1809, DOI 10.1001/archinte.162.16.1809; Jason LA, 2001, J HEALTH PSYCHOL, V6, P61, DOI 10.1177/135910530100600105; KOMAROFF AL, 1979, P I ELECT ELECT ENG, V67, P17; KROENKE K, 1993, ARCH INTERN MED, V153, P2474, DOI 10.1001/archinte.153.21.2474; Lupton Deborah., 1999, RISK KEY IDEAS; MCNEIL B, 1978, NEW ENGL J MED, V289, P1397; Mechanic D, 1998, J HEALTH POLIT POLIC, V23, P661; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Morgan M. G., 2001, RISK COMMUNICATION M; Pennebaker JW, 2000, LIT MED, V19, P3, DOI 10.1353/lm.2000.0011; POWELL D, 1997, MAD COWS MOTHERS MIL; Schwarz N, 1999, AM PSYCHOL, V54, P93, DOI 10.1037/0003-066X.54.2.93; Sharpe M, 2002, J PSYCHOSOM RES, V52, P437, DOI 10.1016/S0022-3999(02)00408-7; Slovic P., 2001, PERCEPTION RISK; VANDULMEN AM, 1995, PSYCHOL MED, V25, P1011, DOI 10.1017/S0033291700037508; WALLSTEN TS, 1986, J EXP PSYCHOL GEN, V115, P348, DOI 10.1037/0096-3445.115.4.348; Woloshin S, 2000, MED DECIS MAKING, V20, P298, DOI 10.1177/0272989X0002000306	31	15	16	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 15	2003	326	7389					595	597		10.1136/bmj.326.7389.595	http://dx.doi.org/10.1136/bmj.326.7389.595			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	657ZF	12637409	Green Submitted, Green Published			2022-12-28	WOS:000181696600025
J	Thorsteinsdottir, H; Daar, AS; Smith, RD; Singer, PA				Thorsteinsdottir, H; Daar, AS; Smith, RD; Singer, PA			Genomics - a global public good?	LANCET			English	Editorial Material							SEQUENCE		Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5G 1L4, Canada; Canadian Program Genom & Global Hlth, Program Appl Eth & Biotechnol, Toronto, ON M5G 1L4, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON M5G 1L4, Canada; Univ Toronto, Dept Surg, Toronto, ON M5G 1L4, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 1L4, Canada; Univ E Anglia, Sch Med Hlth Policy & Practice, Hlth Econ Law & Eth Grp, Norwich NR4 7TJ, Norfolk, England	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of East Anglia	Singer, PA (corresponding author), Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5G 1L4, Canada.	peter.singer@utoronto.ca		Smith, Richard/0000-0003-3837-6559				[Anonymous], 2001, IND CORP CHANGE, V10, P761, DOI [10.1093/icc/10.3.761, DOI 10.1093/ICC/10.3.761]; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; DOWDESWELL E, IN PRESS GLOBAL GOVE; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; KAUL I, 1999, GLOBAL PUBLIC GOOD I; Pang T, 2003, NAT GENET, V33, P18, DOI 10.1038/ng0103-18; Sandler Todd., 1997, SANDLER SHOOP; Singer PA, 2001, SCIENCE, V294, P87, DOI 10.1126/science.1062633; Stiglitz J. E., 1999, GLOBAL PUBLIC GOODS, V308, P308; THORSTEINSDOTTI.H, GLOBAL PUBLIC GOODS; WHO, 2002, GEN WORLD HLTH REP A; World Health Organization, 2001, MACR HLTH INV HLTH E	13	19	21	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	2003	361	9361					891	892		10.1016/S0140-6736(03)12786-9	http://dx.doi.org/10.1016/S0140-6736(03)12786-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648966				2022-12-28	WOS:000181741600005
J	Buffett, BA				Buffett, BA			The thermal state of Earth's core	SCIENCE			English	Editorial Material							MANTLE BOUNDARY; POTASSIUM; PRESSURE		Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago	Buffett, BA (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.							Alfe D, 2002, EARTH PLANET SC LETT, V195, P91, DOI 10.1016/S0012-821X(01)00568-4; Anderson OL, 2002, PHYS EARTH PLANET IN, V131, P1, DOI 10.1016/S0031-9201(02)00009-2; BIRCH F, 1952, J GEOPHYS RES, V57, P227, DOI 10.1029/JZ057i002p00227; Boehler R, 2000, REV GEOPHYS, V38, P221, DOI 10.1029/1998RG000053; BRAGINSKII SI, 1963, DOKL AKAD NAUK SSSR+, V149, P1311; BUFFETT BA, 2002, GEOPHYS RES LETT, V29, DOI DOI 10.1029/2001GL014649; CHRISTENSEN UR, 1994, J GEOPHYS RES-SOL EA, V99, P19867, DOI 10.1029/93JB03403; Gessmann CK, 2002, EARTH PLANET SC LETT, V200, P63, DOI 10.1016/S0012-821X(02)00593-9; Labrosse S, 2001, EARTH PLANET SC LETT, V190, P111, DOI 10.1016/S0012-821X(01)00387-9; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; MCELHINNY MW, 1980, J GEOPHYS RES, V85, P3523, DOI 10.1029/JB085iB07p03523; Parker LJ, 1996, SCIENCE, V273, P95, DOI 10.1126/science.273.5271.95; Roberts P.H., 2003, EARTHS CORE LOWER MA; VERHOOGEN J, 1961, GEOPHYS J ROY ASTR S, V4, P276, DOI 10.1111/j.1365-246X.1961.tb06819.x; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528	15	86	87	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1675	1677		10.1126/science.1081518	http://dx.doi.org/10.1126/science.1081518			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637726				2022-12-28	WOS:000181519500025
J	Schmidt, T; Brandenburg, VM; Kruger, S; Haage, P				Schmidt, T; Brandenburg, VM; Kruger, S; Haage, P			Situs inversus and severe pulmonaryhypertension	LANCET			English	Editorial Material									Univ Technol, Dept Diagnost Radiol, D-52057 Aachen, Germany; Univ Technol, Dept Nephrol, D-52057 Aachen, Germany; Univ Technol, Dept Cardiol, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University; RWTH Aachen University	Schmidt, T (corresponding author), Univ Technol, Dept Diagnost Radiol, D-52057 Aachen, Germany.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					820	820		10.1016/S0140-6736(03)12708-0	http://dx.doi.org/10.1016/S0140-6736(03)12708-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642048				2022-12-28	WOS:000181466600010
J	Susser, E; Terry, MB				Susser, E; Terry, MB			A conception-to-death cohort	LANCET			English	Editorial Material							SCHIZOPHRENIA		Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Dept Epidemiol Brain Disorders, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute	Susser, E (corresponding author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA.	ess8@columbia.edu		Terry, Mary Beth/0000-0002-4106-5033				Barker DJP, 1992, FETAL INFANT ORIGINS; Broman S., 1984, HDB LONGITUDINAL RES, V1, P185; Delongchamp RR, 1997, RADIAT RES, V147, P385, DOI 10.2307/3579348; Eaton WW, 2002, ANN EPIDEMIOL, V12, P445, DOI 10.1016/S1047-2797(01)00314-3; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; Kuh D, 1997, LIFE COURSE APPROACH; Susser E, 1999, PSYCHIAT ANN, V29, P161, DOI 10.3928/0048-5713-19990301-13; Susser E, 1998, AM J EPIDEMIOL, V147, P213; Terry MB, 2001, INT J EPIDEMIOL, V30, P95, DOI 10.1093/ije/30.1.95; VANDENBERG BJ, 1984, HDB LONGITUDINAL RES, V1, P166; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; Wyatt RJ, 2000, SCHIZOPHRENIA BULL, V26, P255, DOI 10.1093/oxfordjournals.schbul.a033450	12	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 8	2003	361	9360					797	798		10.1016/S0140-6736(03)12721-3	http://dx.doi.org/10.1016/S0140-6736(03)12721-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642043				2022-12-28	WOS:000181466600005
J	Norcini, JJ				Norcini, JJ			ABC of learning and teaching in medicine - Work based assessment	BMJ-BRITISH MEDICAL JOURNAL			English	Review							COMPETENCE		Fdn Adv Int Med Educ & Res, Philadelphia, PA USA		Norcini, JJ (corresponding author), Fdn Adv Int Med Educ & Res, Philadelphia, PA USA.			Norcini, John/0000-0002-8464-4115				Cunnington JPW, 1997, ACAD MED, V72, P9; McKinley RK, 2001, BRIT MED J, V322, P712, DOI 10.1136/bmj.322.7288.712; MILLER GE, 1990, ACAD MED, V65, pS63, DOI 10.1097/00001888-199009000-00045; Norcini JJ, 1999, BRIT MED J, V319, P1183, DOI 10.1136/bmj.319.7218.1183	4	134	138	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2003	326	7392					753	755		10.1136/bmj.326.7392.753	http://dx.doi.org/10.1136/bmj.326.7392.753			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665LF	12676847	Green Published			2022-12-28	WOS:000182121600019
J	Walters, K; Buszewicz, M; Russell, J; Humphrey, C				Walters, K; Buszewicz, M; Russell, J; Humphrey, C			Teaching as therapy: cross sectional and qualitative evaluation of patients' experiences of undergraduate psychiatry teaching in the community	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-STUDENTS; PATIENTS ATTITUDES; GENERAL-PRACTICE; PATIENTS VIEWS; INVOLVEMENT; EDUCATION; CONSENT; CARE	Objective To explore the impact of participating in undergraduate teaching in general practice for patients with common mental disorders. Design Questionnaire survey and qualitative in-depth interviews. Setting Community based undergraduate teaching programme for fourth year students at a London medical school doing a psychiatry attachment. Participants Questionnaire survey: all patients involved in the teaching programme over one academic year. In-depth interviews: 20 patients, 14 students, and 12 general practitioner tutors participating in the programme. Results The questionnaire showed high levels of satisfaction with teaching encounters for participating patients, which were corroborated in the interviews. Many patients and general practitioners reported specific therapeutic benefits for patients from contact with students, including raised self esteem and empowerment; the development of a coherent "illness narrative"; new insights into their problems; and a deeper, more balanced, and understanding doctor-patient relationship. For a few patients the teaching caused some distress, which may relate to a lack of insight into their condition or deficits in students' interviewing skills. Conclusions Participation in teaching can have additional positive therapeutic outcomes for selected patients with common mental disorders, although a small minority report negative effects. Testing in a larger sample is needed to determine the characteristics of patients in these two subgroups and establish whether these effects persist.	UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London N19 5LW, England; Kings Coll London, Florence Nightingale Sch Nursing & Midwifery, London WC2R 2LS, England	University of London; University College London; UCL Medical School; University of London; King's College London	Walters, K (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London N19 5LW, England.	k.walters@pcps.ucl.ac.uk		Walters, Kate/0000-0003-2173-2430				Black AE, 1998, MED EDUC, V32, P472, DOI 10.1046/j.1365-2923.1998.00247.x; Cooke F, 1996, BRIT J GEN PRACT, V46, P361; CREENHALGH T, 1997, BRIT MED J, V315, P740; Devera-Sales A, 1999, ACAD MED, V74, P550, DOI 10.1097/00001888-199905000-00024; EVANS T, 1994, BRIT J GEN PRACT, V44, P479; Franks A, 1997, PALLIATIVE MED, V11, P395, DOI 10.1177/026921639701100510; Greenhalgh T, 1997, BMJ-BRIT MED J, V315, P740, DOI 10.1136/bmj.315.7110.740; Guimon J, 2000, EUR J PSYCHIAT, V14, P52; Hartley S, 1999, BRIT MED J, V319, P1168, DOI 10.1136/bmj.319.7218.1168; Hartz MB, 2000, ACAD MED, V75, P1010, DOI 10.1097/00001888-200010000-00018; Lynoe N, 1998, MED EDUC, V32, P465; MALAN DH, 1975, ARCH GEN PSYCHIAT, V32, P110; OFlynn N, 1997, BRIT MED J, V315, P1142; Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI [10.4324/9780203413081, DOI 10.4324/9780203413081_CHAPTER_9]; Salter RH, 1996, POSTGRAD MED J, V72, P385, DOI 10.1136/pgmj.72.849.385; Sharpe M, 1996, J ROY COLL PHYS LOND, V30, P202; Simon SR, 2000, J GEN INTERN MED, V15, P457, DOI 10.1046/j.1525-1497.2000.06409.x; Spencer J, 2000, MED EDUC, V34, P851, DOI 10.1046/j.1365-2923.2000.00779.x; Stacy R, 1999, MED EDUC, V33, P688, DOI 10.1046/j.1365-2923.1999.00454.x; Strauss A., 1998, BASICS QUALITATIVE R; Svartberg M, 2001, PSYCHOTHER RES, V11, P201; Walters K, 2001, ACAD MED, V76, P563, DOI 10.1097/00001888-200105000-00112; Walton H, 1999, MED EDUC, V33, P204, DOI 10.1046/j.1365-2923.1999.00390.x; YORK NL, 1995, AM J SURG, V169, P421, DOI 10.1016/S0002-9610(99)80189-5	24	53	53	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2003	326	7392					740	743		10.1136/bmj.326.7392.740	http://dx.doi.org/10.1136/bmj.326.7392.740			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665LF	12676843	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000182121600015
J	Tielens, AGGM				Tielens, AGGM			Peering into stardust	SCIENCE			English	Editorial Material							RED GIANTS; COMETS; SPECTRUM; GRAINS; DUST		Kapteyn Astron Inst, SRON, NL-9700 AV Groningen, Netherlands; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Univ Calif Berkeley, Miller Inst Astron, Berkeley, CA 94720 USA	University of Groningen; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Tielens, AGGM (corresponding author), Kapteyn Astron Inst, SRON, NL-9700 AV Groningen, Netherlands.	tielens@astro.rug.nl						AMARI S, 1995, ASTROPHYS J, V447, pL147, DOI 10.1086/309573; Bockelee-Morvan D, 2002, ASTRON ASTROPHYS, V384, P1107, DOI 10.1051/0004-6361:20020086; Boothroyd AI, 1999, ASTROPHYS J, V510, P232, DOI 10.1086/306546; BRADLEY JP, 1994, SCIENCE, V265, P925, DOI 10.1126/science.265.5174.925; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; DOMINGUEZ G, UNPUB; Hanner MS, 1999, SPACE SCI REV, V90, P99, DOI 10.1023/A:1005285711945; LEWIS RS, 1987, NATURE, V326, P160, DOI 10.1038/326160a0; Malfait K, 1998, ASTRON ASTROPHYS, V332, pL25; MATHIS JS, 1990, ANNU REV ASTRON ASTR, V28, P37, DOI 10.1146/annurev.aa.28.090190.000345; Messenger S, 2003, SCIENCE, V300, P105, DOI 10.1126/science.1080576; MEYER BS, 1995, METEORITICS, V30, P325, DOI 10.1111/j.1945-5100.1995.tb01131.x; Reipurth B, 2001, ANNU REV ASTRON ASTR, V39, P403, DOI 10.1146/annurev.astro.39.1.403; SMITH VV, 1990, ASTROPHYS J SUPPL S, V72, P387, DOI 10.1086/191421	15	10	10	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2003	300	5616					68	+		10.1126/science.1082234	http://dx.doi.org/10.1126/science.1082234			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677049				2022-12-28	WOS:000181988900027
J	Berman, MA; Lazar, EJ				Berman, MA; Lazar, EJ			Hospital emergency preparedness - Lessons learned since Northridge	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									New York Presbyterian Hosp Healthcare Syst, New York, NY 10021 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Cornell Univ, Weil Med Coll, New York, NY USA	NewYork-Presbyterian Hospital; Columbia University; Cornell University	Berman, MA (corresponding author), New York Presbyterian Hosp Healthcare Syst, New York, NY 10021 USA.								0	14	14	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1307	1308		10.1056/NEJMp030022	http://dx.doi.org/10.1056/NEJMp030022			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672858				2022-12-28	WOS:000181949100001
J	Schefuss, E; Schouten, S; Jansen, JHF; Damste, JSS				Schefuss, E; Schouten, S; Jansen, JHF; Damste, JSS			African vegetation controlled by tropical sea surface temperatures in the mid-Pleistocene period	NATURE			English	Article							MIDPLEISTOCENE CLIMATE TRANSITION; ATMOSPHERIC CO2; LATE MIOCENE; C-4 GRASSES; ATLANTIC; PAST; EXPANSION; PLANTS; MODEL; CYCLE	The dominant forcing factors for past large-scale changes in vegetation are widely debated. Changes in the distribution of C-4 plants-adapted to warm, dry conditions and low atmospheric CO2 concentrations(1)-have been attributed to marked changes in environmental conditions, but the relative impacts of changes in aridity, temperature(2,3) and CO2 concentration(4,5) are not well understood. Here, we present a record of African C-4 plant abundance between 1.2 and 0.45 million years ago, derived from compound-specific carbon isotope analyses of wind-transported terrigenous plant waxes. We find that large-scale changes in African vegetation are linked closely to sea surface temperatures in the tropical Atlantic Ocean. We conclude that, in the mid-Pleistocene, changes in atmospheric moisture content-driven by tropical sea surface temperature changes and the strength of the African monsoon-controlled aridity on the African continent, and hence large-scale vegetation changes.	Royal Netherlands Inst Sea Res, NL-1790 AB Den Burg, Netherlands	Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ)	Schefuss, E (corresponding author), Royal Netherlands Inst Sea Res, POB 59, NL-1790 AB Den Burg, Netherlands.		Schefuß, Enno/A-7101-2015; Damste, Jaap S Sinninghe/F-6128-2011	Schefuß, Enno/0000-0002-5960-930X; Damste, Jaap S Sinninghe/0000-0002-8683-1854				BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; CERLING TE, 1993, NATURE, V361, P344, DOI 10.1038/361344a0; Cerling TE, 1997, NATURE, V389, P153, DOI 10.1038/38229; Collatz GJ, 1998, OECOLOGIA, V114, P441, DOI 10.1007/s004420050468; COLLISTER JW, 1994, ORG GEOCHEM, V21, P619, DOI 10.1016/0146-6380(94)90008-6; DEMENOCAL PB, 1995, SCIENCE, V270, P53, DOI 10.1126/science.270.5233.53; Dupont LM, 2001, GEOLOGY, V29, P195, DOI 10.1130/0091-7613(2001)029<0195:MPECIT>2.0.CO;2; EGLINTON G, 1967, SCIENCE, V156, P1322, DOI 10.1126/science.156.3780.1322; Ehleringer JR, 1997, OECOLOGIA, V112, P285, DOI 10.1007/s004420050311; FONTAINE B, 1993, INT J CLIMATOL, V13, P271, DOI 10.1002/joc.3370130304; Ganopolski A, 1998, NATURE, V391, P351, DOI 10.1038/34839; Huang Y, 2001, SCIENCE, V293, P1647, DOI 10.1126/science.1060143; JANSEN JHF, 2001, P OC DRILL PROGR SCI, V175; Katz EJ, 1982, J MAR RES, V40, P307; Kuypers MMM, 1999, NATURE, V399, P342, DOI 10.1038/20659; McIntyre A, 1989, PALEOCEANOGRAPHY, V4, P19, DOI 10.1029/PA004i001p00019; Mudelsee M, 1997, EARTH PLANET SC LETT, V151, P117, DOI 10.1016/S0012-821X(97)00114-3; OLEARY MH, 1981, PHYTOCHEMISTRY, V20, P553, DOI 10.1016/0031-9422(81)85134-5; Pagani M, 1999, SCIENCE, V285, P876, DOI 10.1126/science.285.5429.876; Partridge TC, 1997, QUATERNARY SCI REV, V16, P1125, DOI 10.1016/S0277-3791(97)00005-X; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; PHILANDER SGH, 1986, J GEOPHYS RES-OCEANS, V91, P14192, DOI 10.1029/JC091iC12p14192; PRELL WL, 1987, J GEOPHYS RES-ATMOS, V92, P8411, DOI 10.1029/JD092iD07p08411; Raymo ME, 1997, PALEOCEANOGRAPHY, V12, P546, DOI 10.1029/97PA01019; Sage RF, 2001, PLANT BIOLOGY, V3, P202, DOI 10.1055/s-2001-15206; SCHEFUSS E, IN PRESS GEOCHIM COS; SCHNEIDER RR, 1995, PALEOCEANOGRAPHY, V10, P197, DOI 10.1029/94PA03308; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782; Shackleton NJ., 1976, GEOLOGICAL SOC AM ME, P449, DOI DOI 10.1130/MEM145-P449; Wyputta U, 1999, PALAEOGEOGR PALAEOCL, V146, P53, DOI 10.1016/S0031-0182(98)00142-4	30	169	181	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					418	421		10.1038/nature01500	http://dx.doi.org/10.1038/nature01500			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660780				2022-12-28	WOS:000181801200041
J	MacKenzie, EJ; Hoyt, DB; Sacra, JC; Jurkovich, GJ; Carlini, AR; Teitelbaum, SD; Teter, H				MacKenzie, EJ; Hoyt, DB; Sacra, JC; Jurkovich, GJ; Carlini, AR; Teitelbaum, SD; Teter, H			National inventory of hospital trauma centers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INJURED PATIENTS; UNITED-STATES; VOLUME; MORTALITY; SYSTEM; INSTITUTION; EXPERIENCE; IMPACT	Context Trauma centers benefit thousands of injured individuals everyday and play a critical role in responding to disasters. The last full accounting of the number and distribution of trauma centers identified 471 trauma centers in the United States in 1991. Objective To determine the number and configuration of trauma centers and identify gaps in coverage. Design, Setting, and Subjects Interviews with trauma center directors (September 2001 to April 2002), data from the American Hospital Association's Annual Survey of Hospitals (2000), and the US Health Resources Administration's Area Resource File (2001) were used to determine characteristics of trauma center hospitals and the geographic areas they serve in all 50 states and in the District of Columbia. Characteristics of trauma centers were examined by level of care and compared with nontrauma centers. Hospitals are designated or certified as trauma centers by a state or regional authority or verified as trauma centers by the American College of Surgeons Committee on Trauma. Trauma centers that treat only children (n=31) were excluded. Main Outcome Measure Total number of trauma centers and number of trauma centers per million population. Results In 2002, there were 1154 trauma centers in the United States, including 190 level I centers and 263 level II centers. Several states have categorized every hospital with an emergency department at some level of trauma care while others have designated a limited number of level I and level II centers only. The number of level I and II centers per million population ranges from 0.19 to 7.8 by state. When compared with nontrauma center hospitals, trauma centers are larger, more likely to be teaching hospitals, and more likely to offer specialized services. Conclusions Although the availability of trauma centers has improved, challenges remain to ensure the optimal number, distribution, and configuration of trauma centers. These challenges must be addressed, especially in light of the recent emphasis on hospital preparedness and homeland security.	Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD 21205 USA; Univ Calif San Diego, Sch Med, Dept Surg, San Diego, CA 92103 USA; Oklahoma Emergency Med Serv Author, Tulsa, OK USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98195 USA; Amer Trauma Soc, Upper Marlboro, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California San Diego; University of Washington; University of Washington Seattle	MacKenzie, EJ (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, 624 N Broadway,Room 554, Baltimore, MD 21205 USA.	emackenz@jhsph.edu	Carlini, Anthony/AAN-1153-2020	Carlini, Anthony/0000-0003-1419-4515	ODCDC CDC HHS [H28/CCH319122] Funding Source: Medline	ODCDC CDC HHS		*AM COLL EM PHYS, 1987, ANN EMERG MED, V16, P459; *AM HOSP ASS, 2002, AHA ANN SURV HOSP 20; Baer LD, 1997, J RURAL HEALTH, V13, P329, DOI 10.1111/j.1748-0361.1997.tb00975.x; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BAZZOLI GJ, 1995, JAMA-J AM MED ASSOC, V273, P395; BAZZOLI GJ, 1995, J TRAUMA, V38, P103, DOI 10.1097/00005373-199501000-00026; Bonnie RL, 1999, REDUCING BURDEN INJU, P138; Branas CC, 2000, HEALTH SERV RES, V35, P489; *BUR HLTH PROF, 2002, 2001 AR RES FIL ARF; *BUR HLTH RES DEV, 1992, MOD TRAUM CAR SYST P; *COMM TRAUM, 2002, NAT TRAUM DAT BANK 2; Committee on Trauma, 1999, RES OPT CAR INJ PAT; Cooper A, 2000, J TRAUMA, V48, P16, DOI 10.1097/00005373-200001000-00004; Dunn LT, 1997, INJURY, V28, P427, DOI 10.1016/S0020-1383(97)00051-X; Gerberding JL, 2002, JAMA-J AM MED ASSOC, V287, P898, DOI 10.1001/jama.287.7.898; Jurkovich GJ, 1999, J TRAUMA, V47, pS46, DOI 10.1097/00005373-199909001-00011; KONVOLINKA CW, 1995, AM J SURG, V170, P333, DOI 10.1016/S0002-9610(99)80299-2; MacKenzie EJ, 1999, J TRAUMA, V47, pS34, DOI 10.1097/00005373-199909001-00008; Mann NC, 2001, MED CARE, V39, P643, DOI 10.1097/00005650-200107000-00001; Mann NC, 1999, J TRAUMA, V47, pS25, DOI 10.1097/00005373-199909001-00007; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; NATHENS AB, IN PRESS J TRAUMA; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; SMITH RF, 1990, J TRAUMA, V30, P1066, DOI 10.1097/00005373-199009000-00002; Tepas JJ, 1998, J TRAUMA, V44, P827, DOI 10.1097/00005373-199805000-00014; *US BUR CENS, POP EST STAT	28	206	208	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2003	289	12					1515	1522		10.1001/jama.289.12.1515	http://dx.doi.org/10.1001/jama.289.12.1515			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659XE	12672768	Bronze			2022-12-28	WOS:000181803100029
J	Hamers, FF; Downs, AM				Hamers, FF; Downs, AM			HIV in central and eastern Europe	LANCET			English	Review							INJECTING DRUG-USERS; SEXUALLY-TRANSMITTED-DISEASES; NEWLY INDEPENDENT STATES; RISK BEHAVIOR; AIDS EPIDEMIC; RUSSIAN MEN; INFECTION; PREVALENCE; PREDICTORS; PREVENTION	We describe recent trends in the HIV epidemic and the differences between eastern and central Europe, using surveillance data, and published and unpublished reports. During the past 5 years, most countries of the former Soviet Union have been severely affected by HIV epidemics that continue to spread as a result of injecting drug use. With an estimated 1 million individuals already infected-mostly injecting drug users-and high rates of syphilis, the region may soon also face a large-scale epidemic of sexually-transmitted HIV infection. Indeed, data indicate that an HIV epidemic, fuelled by heterosexual transmission, is emerging; its expansion will depend on the size of so-called bridge populations that link high-risk groups with the general population. The lack of evidence to indicate increased rates of HIV as a result of homosexual transmission could indicate the social vulnerability of homosexual and bisexual men in the region rather than the true epidemiological picture. In view of the current levels of HIV prevalence, eastern Europe will soon be confronted with a major AIDS epidemic. By contrast, rates of HIV in central Europe remain low at present, but behaviours that promote HIV transmission are present in all countries. Improved measures to prevent further HIV spread are urgently needed.	Inst Veille Sanit, Dept Infect Dis, EuroHIV, F-94415 St Maurice, France	Institute of Public Health Surveillance	Hamers, FF (corresponding author), Inst Veille Sanit, Dept Infect Dis, EuroHIV, F-94415 St Maurice, France.	f.hamers@invs.sante.fr						ALBOV AP, 1994, 10 INT C AIDS YOK AU; Amirkhanian YA, 2001, AIDS, V15, P407, DOI 10.1097/00002030-200102160-00014; Amirkhanian YA, 2001, INT J STD AIDS, V12, P50, DOI 10.1258/0956462011916613; Amirkhanian YA, 2001, FAM PLANN PERSPECT, V33, P106, DOI 10.2307/2673766; Atlani L, 2000, SOC SCI MED, V50, P1547, DOI 10.1016/S0277-9536(99)00464-5; BLINOVA O, 2000, ZH MIKROBIOL EPIDEMI, V4, P40; Bobkov A, 2001, AIDS RES HUM RETROV, V17, P257, DOI 10.1089/088922201750063188; Cazein F, 1998, J ACQ IMMUN DEF SYND, V19, P296, DOI 10.1097/00042560-199811010-00013; Centers for Disease Control, 2001, Morbidity and Mortality Weekly Report, V50, P59; Chaplinskas S, 2001, INT J STD AIDS, V12, P176, DOI 10.1258/0956462011916983; Csepe P, 2002, INT J STD AIDS, V13, P192, DOI 10.1258/0956462021924785; Danziger R, 1996, AIDS CARE, V8, P701, DOI 10.1080/09540129650125416; DAVIDOVA A, 1998, 2 C AIDS SOC SCI EUR; Dehne KL, 2000, AIDS, V14, pS75; Dehne KL, 1999, AIDS, V13, P741, DOI 10.1097/00002030-199905070-00002; Domok Istvan, 2001, Acta Microbiologica et Immunologica Hungarica, V48, P299, DOI 10.1556/AMicr.48.2001.3-4.4; *EUR CTR EP MON AI, 2001, HIV AIDS SURV EUR EN; *EUR CTR EP MON AI, 2001, HIV AIDS SURV EUR MI; European Centre for the Epidemiological Monitoring of AIDS, 2000, HIV AIDS SURV EUR EN HIV AIDS SURV EUR EN; Ferdats A, 1999, AIDS RES HUM RETROV, V15, P1487, DOI 10.1089/088922299310007; Girardi E, 2000, AIDS, V14, pS47; GOLUBKOVA AA, 2000, EPIDEMIOL INFECT DIS, V4, P32; Hamers FF, 2000, REV EPIDEMIOL SANTE, V48, P3; Hamers FF, 1997, AIDS, V11, P1365, DOI 10.1097/00002030-199711000-00011; HAMERS FF, IN PRESS J ACQUIR IM; HERSH BS, 1993, AIDS, V7, P1617, DOI 10.1097/00002030-199312000-00012; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; Houweling H, 1998, AIDS, V12, P85, DOI 10.1097/00002030-199801000-00010; Kabakchieva E, 2002, INT J STD AIDS, V13, P184, DOI 10.1258/0956462021924893; Kacena KA, 2001, SEX TRANSM DIS, V28, P356, DOI 10.1097/00007435-200106000-00010; Kelly JA, 2001, AIDS EDUC PREV, V13, P175, DOI 10.1521/aeap.13.2.175.19734; Kilibarda M., 1993, Bulletin on Narcotics, V45, P135; KOBYSHCHA Y, 1966, HIV INFECT DRUG USER; Kurova T, 1998, ACTA OBSTET GYN SCAN, V77, P83, DOI 10.1080/00016349808565818; Leinikki P, 1997, LANCET, V349, P1914, DOI 10.1016/S0140-6736(05)63918-9; Liitsola K, 1998, AIDS, V12, P1907, DOI 10.1097/00002030-199814000-00023; LINGLOF T, 1995, SEX TRANSM DIS, V22, P160, DOI 10.1097/00007435-199505000-00005; Macovei M, 1999, Med Law, V18, P335; Mashkilleyson N, 1999, J CLIN VIROL, V12, P37, DOI 10.1016/S0928-0197(98)00069-5; MEDVEDEV ZA, 1990, BRIT MED J, V300, P932, DOI 10.1136/bmj.300.6729.932; Mikl J, 1998, SEX TRANSM INFECT, V74, P128, DOI 10.1136/sti.74.2.128; MIKL J, 2001, CENT EUR J PUBL HEAL, V4, P228; Mills S, 2000, AIDS, V14, pS267; NOSOV NN, 1999, ZH MIKROBIOL EPIDEMI, V1, P96; ONISHCHENKO GG, 2000, ZH MIKROBIOL EPIDEMI, V4, P5; POKROVSKY VV, 1990, ZH MIKROB EPID IMMUN, P17; Polanecky V, 1996, Cent Eur J Public Health, V4, P176; Prochazka I, 1998, Cent Eur J Public Health, V6, P192; Rhodes T, 1999, ADDICTION, V94, P1323, DOI 10.1046/j.1360-0443.1999.94913235.x; RILEY B, 1999, ZH MIKROBIOL EPIDEMI, V1, P91; Robinson NJ, 2000, REV EPIDEMIOL SANTE, V48, P17; SALAMOV G, 1998, EPIDEMIOL INFECT DIS, V5, P23; SMOLSKAIA TT, 2000, ZH MIKROBIOL EPIDEMI, V4, P31; Stanekova D, 2000, Cent Eur J Public Health, V8, P172; STARK K, 1994, J ACQ IMMUN DEF SYND, V7, P877; Tchoudomirova K, 1997, INT J STD AIDS, V8, P187, DOI 10.1258/0956462971919697; Tichonova L, 1997, LANCET, V350, P210, DOI 10.1016/S0140-6736(97)01382-2; *UANIDS WHO, 2001, AIDS EP UPD; *UNAIDS WHO, 1998, REP HIV AIDS GLOB EP; United Nations Office for Drug Control and Crime Prevention, 2000, WORLD DRUG REP 2000; Uuskula A, 1997, INT J STD AIDS, V8, P446, DOI 10.1258/0956462971920505; *WORLD BANK, 2001, WORLD BANK DEV IND 2; World Health Organization, 2002, WHOCDSTB2002295	63	163	168	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	2003	361	9362					1035	1044		10.1016/S0140-6736(03)12831-0	http://dx.doi.org/10.1016/S0140-6736(03)12831-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660072				2022-12-28	WOS:000181699700024
J	Jani, AB; Hellman, S				Jani, AB; Hellman, S			Early prostate cancer: clinical decision-making	LANCET			English	Review							EXTERNAL-BEAM RADIATION; QUALITY-OF-LIFE; RADICAL RETROPUBIC PROSTATECTOMY; POSITIVE SURGICAL MARGINS; FAILURE-FREE SURVIVAL; NATURAL-HISTORY; CONSERVATIVE MANAGEMENT; CONFORMAL RADIOTHERAPY; ERECTILE DYSFUNCTION; ANDROGEN SUPPRESSION	Prostate cancer is one of the most common malignant diseases for which health-care intervention is sought worldwide, and in many developed countries it is the most common. Some patients with early-stage prostate cancer, especially those who are elderly and have comorbidities, can be observed without treatment. Surgery (radical prostatectomy) and radiotherapy (external-beam radiotherapy, brachytherapy, or both) are the most widely accepted curative options for patients with early-stage disease who need intervention. All these local treatments have been refined, resulting in comparable cure rates; however, they all have different side-effect profiles. Adjuvant systemic treatments (hormones or chemotherapy), which are effective for advanced-stage disease, might have a greater role in early-stage disease. Selecting the best option for individuals from the available options Is challenging-the decision on whether and how to treat is based on many disease and patient factors. Here, we review the major treatment options, discuss their relative advantages and disadvantages, and provide a general approach to management of patients with early-stage prostate cancer.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	University of Chicago	Hellman, S (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 5758 S Maryland Ave,MC 9001, Chicago, IL 60637 USA.	s-hellman@uchicago.edu						Abdalla I, 2002, CANCER J, V8, P40, DOI 10.1097/00130404-200201000-00008; ADOLFSSON J, 1991, J UROLOGY, V146, P96, DOI 10.1016/S0022-5347(17)37722-4; Adolfsson J, 1997, UROLOGY, V50, P722, DOI 10.1016/S0090-4295(97)00320-8; Akakura K, 1999, UROLOGY, V54, P313, DOI 10.1016/S0090-4295(99)00106-5; Albertsen P C, 2001, J Urol, V165, P731; Albertsen PC, 1998, JAMA-J AM MED ASSOC, V280, P975, DOI 10.1001/jama.280.11.975; Anderson J, 2001, EUR UROL, V40, P24, DOI 10.1159/000049881; [Anonymous], 1997, Int J Radiat Oncol Biol Phys, V37, P1035; Anscher MS, 2000, INT J RADIAT ONCOL, V48, P369, DOI 10.1016/S0360-3016(00)00645-3; Arai Y, 2001, INT J UROL, V8, pS15, DOI 10.1046/j.1442-2042.2001.00328.x; Aus G, 1997, JAMA-J AM MED ASSOC, V278, P205; BAGSHAW MA, 1994, J UROLOGY, V152, P1781, DOI 10.1016/S0022-5347(17)32385-6; Beard CJ, 1996, INT J RADIAT ONCOL, V34, P451, DOI 10.1016/0360-3016(95)02081-0; Beerlage HP, 2000, EUR UROL, V37, P2, DOI 10.1159/000020091; Begg CB, 2002, NEW ENGL J MED, V346, P1138, DOI 10.1056/NEJMsa011788; Beyer DC, 2000, RADIOTHER ONCOL, V57, P263, DOI 10.1016/S0167-8140(00)00286-3; Blasko JC, 1996, J CLIN ONCOL, V14, P1965, DOI 10.1200/JCO.1996.14.6.1965; Blasko JC, 2000, RADIOTHER ONCOL, V57, P273, DOI 10.1016/S0167-8140(00)00288-7; Blasko JC, 2000, INT J RADIAT ONCOL, V46, P839, DOI 10.1016/S0360-3016(99)00499-X; Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140-6736(02)09408-4; BRENDLER CB, 1992, CA-CANCER J CLIN, V42, P212, DOI 10.3322/canjclin.42.4.212; Carter HB, 2002, J UROLOGY, V167, P1231, DOI 10.1016/S0022-5347(05)65271-8; CATALONA WJ, 1994, J UROLOGY, V152, P1837, DOI 10.1016/S0022-5347(17)32397-2; Catalona WJ, 1999, J UROLOGY, V162, P433, DOI 10.1016/S0022-5347(05)68578-3; Cavanagh W, 2000, Semin Urol Oncol, V18, P160; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CROOK JM, 1995, RADIOTHER ONCOL, V37, P35, DOI 10.1016/0167-8140(95)01613-L; D'Amico AV, 2000, JAMA-J AM MED ASSOC, V284, P1280, DOI 10.1001/jama.284.10.1280; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; D'Amico AV, 1999, J CLIN ONCOL, V17, P168, DOI 10.1200/JCO.1999.17.1.168; Dalesio O, 2000, LANCET, V355, P1491; DAmico AV, 1997, INT J RADIAT ONCOL, V37, P1053, DOI 10.1016/S0360-3016(96)00633-5; DAMICO AV, 1994, INT J RADIAT ONCOL, V30, P293, DOI 10.1016/0360-3016(94)90007-8; EGAWA S, 1993, UROLOGY, V42, P520, DOI 10.1016/0090-4295(93)90261-8; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; Fowler FJ, 2000, JAMA-J AM MED ASSOC, V283, P3217, DOI 10.1001/jama.283.24.3217; FOWLER FJ, 1995, UROLOGY, V45, P1007, DOI 10.1016/S0090-4295(99)80122-8; FOWLER JE, 1995, J UROLOGY, V153, P1026, DOI 10.1016/S0022-5347(01)67627-4; GEORGE NJR, 1988, LANCET, V1, P494; Gerber GS, 1998, J UROLOGY, V159, P1243, DOI 10.1016/S0022-5347(01)63572-9; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; Gleave ME, 1996, UROLOGY, V47, P708, DOI 10.1016/S0090-4295(96)80016-1; Griebling T L, 1996, Semin Urol Oncol, V14, P156; Grimm PD, 2001, INT J RADIAT ONCOL, V51, P31, DOI 10.1016/S0360-3016(01)01601-7; Gronberg H, 1997, UROLOGY, V49, P374, DOI 10.1016/S0090-4295(96)00508-0; Guillonneau B, 2000, J UROLOGY, V163, P418, DOI 10.1016/S0022-5347(05)67890-1; Han M, 2001, UROL CLIN N AM, V28, P555, DOI 10.1016/S0094-0143(05)70163-4; HANKS GE, 1994, INT J RADIAT ONCOL, V30, P289, DOI 10.1016/0360-3016(94)90006-X; HANKS GE, 1995, INT J RADIAT ONCOL, V31, P25, DOI 10.1016/0360-3016(94)00366-S; Hanks GE, 1998, INT J RADIAT ONCOL, V41, P501, DOI 10.1016/S0360-3016(98)00089-3; Hanlon AL, 2000, UROLOGY, V55, P725, DOI 10.1016/S0090-4295(99)00605-6; Hinkle GH, 1998, CANCER, V83, P739, DOI 10.1002/(SICI)1097-0142(19980815)83:4<739::AID-CNCR16>3.0.CO;2-T; Hong JJ, 2001, ALIMENT PHARM THER, V15, P1253, DOI 10.1046/j.1365-2036.2001.01075.x; Hugosson J, 2000, BJU INT, V85, P1078, DOI 10.1046/j.1464-410x.2000.00679.x; Hugosson J, 1996, UROL CLIN N AM, V23, P557, DOI 10.1016/S0094-0143(05)70336-0; Hugosson J, 1996, EUR UROL, V29, P413; Hull GW, 2002, J UROLOGY, V167, P528, DOI 10.1016/S0022-5347(01)69079-7; Incrocci L, 2002, INT J RADIAT ONCOL, V52, P681, DOI 10.1016/S0360-3016(01)02727-4; Incrocci L, 2001, INT J RADIAT ONCOL, V51, P1190, DOI 10.1016/S0360-3016(01)01767-9; Jackson A, 2001, INT J RADIAT ONCOL, V49, P685, DOI 10.1016/S0360-3016(00)01414-0; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Klein E A, 2001, Curr Treat Options Oncol, V2, P403, DOI 10.1007/s11864-001-0045-1; KLEINBERG L, 1994, INT J RADIAT ONCOL, V28, P985, DOI 10.1016/0360-3016(94)90119-8; Klotz L, 2000, J UROLOGY, V164, P1573, DOI 10.1016/S0022-5347(05)67031-0; Kupelian PA, 1997, INT J RADIAT ONCOL, V37, P1043, DOI 10.1016/S0360-3016(96)00590-1; Laverdiere J, 1997, INT J RADIAT ONCOL, V37, P247, DOI 10.1016/S0360-3016(96)00513-5; LAWTON CA, 1991, INT J RADIAT ONCOL, V21, P935, DOI 10.1016/0360-3016(91)90732-J; Lawton CA, 2001, INT J RADIAT ONCOL, V49, P937, DOI 10.1016/S0360-3016(00)01516-9; LEIBEL SA, 1994, SEMIN ONCOL, V21, P580; Lepor H, 2001, UROL CLIN N AM, V28, P509, DOI 10.1016/S0094-0143(05)70159-2; LEVRAN Z, 1995, BRIT J UROL, V75, P778, DOI 10.1111/j.1464-410X.1995.tb07390.x; Locke J, 2002, INT J RADIAT ONCOL, V52, P712, DOI 10.1016/S0360-3016(01)02657-8; Manyak MJ, 1999, UROLOGY, V54, P1058, DOI 10.1016/S0090-4295(99)00314-3; Martinez AA, 2001, INT J RADIAT ONCOL, V49, P61, DOI 10.1016/S0360-3016(00)01463-2; McCullough AR, 2001, UROL CLIN N AM, V28, P613, DOI 10.1016/S0094-0143(05)70166-X; Merrick GS, 2000, INT J RADIAT ONCOL, V48, P667, DOI 10.1016/S0360-3016(00)00698-2; Merrick GS, 1999, UROLOGY, V53, P1112, DOI 10.1016/S0090-4295(99)00048-5; Merrick GS, 2001, INT J RADIAT ONCOL, V51, P41, DOI 10.1016/S0360-3016(01)01594-2; Merrick GS, 2002, INT J RADIAT ONCOL, V52, P461, DOI 10.1016/S0360-3016(01)01811-9; Millikan RE, 1999, SEMIN ONCOL, V26, P185; Mohan DS, 2000, INT J RADIAT ONCOL, V46, P575, DOI 10.1016/S0360-3016(99)00454-X; Mulcahy J J, 2000, Semin Urol Oncol, V18, P71; Neal D E, 2000, Lancet Oncol, V1, P17, DOI 10.1016/S1470-2045(00)00005-X; Oh WK, 1999, J CLIN ONCOL, V17, P3664, DOI 10.1200/JCO.1999.17.11.3664; Ohori M, 1999, J UROLOGY, V161, P500, DOI 10.1016/S0022-5347(01)61935-9; OHORI M, 1995, J UROLOGY, V154, P1818, DOI 10.1016/S0022-5347(01)66792-2; Onel E, 1998, UROLOGY, V51, P63, DOI 10.1016/S0090-4295(97)00494-9; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Partin AW, 2001, UROLOGY, V58, P843, DOI 10.1016/S0090-4295(01)01441-8; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; PAULSON D F, 1988, NCI (National Cancer Institute) Monographs, P127; PILEPICH MV, 1987, INT J RADIAT ONCOL, V13, P1007, DOI 10.1016/0360-3016(87)90038-1; Pilepich MV, 2001, INT J RADIAT ONCOL, V50, P1243, DOI 10.1016/S0360-3016(01)01579-6; Pollack A, 2000, J CLIN ONCOL, V18, P3904, DOI 10.1200/JCO.2000.18.23.3904; Porter MP, 1997, J UROLOGY, V158, P1466, DOI 10.1016/S0022-5347(01)64244-7; Potosky AL, 2001, EPIDEMIOL REV, V23, P181, DOI 10.1093/oxfordjournals.epirev.a000787; Potters L, 2001, INT J RADIAT ONCOL, V50, P1235, DOI 10.1016/S0360-3016(01)01578-4; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; QUINLAN DM, 1991, J UROLOGY, V145, P998, DOI 10.1016/S0022-5347(17)38512-9; Ragde H, 2001, Arch Esp Urol, V54, P739; Ragde H, 2000, CANCER, V89, P135, DOI 10.1002/1097-0142(20000701)89:1<135::AID-CNCR18>3.0.CO;2-#; Ray GR, 2002, J UROLOGY, V167, P990, DOI 10.1016/S0022-5347(02)80322-6; Schild SE, 1996, J UROLOGY, V156, P1725, DOI 10.1016/S0022-5347(01)65492-2; Schroder FH, 2000, WORLD J UROL, V18, P204, DOI 10.1007/s003459900103; Schroder FH, 2001, EUR J CANCER, V37, pS127; Schulam PG, 2000, WORLD J UROL, V18, P278, DOI 10.1007/PL00007077; Shipley WU, 1999, JAMA-J AM MED ASSOC, V281, P1598, DOI 10.1001/jama.281.17.1598; SHIPLEY WU, 1994, J UROLOGY, V152, P1799, DOI 10.1016/S0022-5347(17)32388-1; Sofer M, 2002, J CLIN ONCOL, V20, P1853, DOI 10.1200/JCO.2002.07.069; Sokoloff MH, 2001, UROL CLIN N AM, V28, P535, DOI 10.1016/S0094-0143(05)70161-0; SOLOWAY MS, 1995, J UROLOGY, V154, P424, DOI 10.1016/S0022-5347(01)67067-8; Stattin P, 1997, EUR UROL, V32, P404, DOI 10.1159/000480797; Sylvester J, 2000, MOL UROL, V4, P155; Talcott JA, 1997, J NATL CANCER I, V89, P1117, DOI 10.1093/jnci/89.15.1117; Teloken C, 2001, Cancer Control, V8, P540; Thompson IM, 1999, J UROLOGY, V162, P107, DOI 10.1097/00005392-199907000-00026; Tsuda K, 1999, J COMPUT ASSIST TOMO, V23, P74, DOI 10.1097/00004728-199901000-00016; Uchida T, 2002, UROLOGY, V59, P394, DOI 10.1016/S0090-4295(01)01624-7; van den Ouden D, 2000, WORLD J UROL, V18, P194, DOI 10.1007/s003459900102; VANPOPPEL H, 1995, J UROLOGY, V154, P429, DOI 10.1016/S0022-5347(01)67068-X; Wallner K, 1999, INT J RADIAT ONCOL, V43, P583, DOI 10.1016/S0360-3016(98)00459-3; WALSH PC, 1984, BRIT J UROL, V56, P694, DOI 10.1111/j.1464-410X.1984.tb06149.x; Walsh PC, 2000, J UROLOGY, V163, P1802, DOI 10.1016/S0022-5347(05)67547-7; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; Weldon VE, 1997, J UROLOGY, V158, P1470, DOI 10.1016/S0022-5347(01)64245-9; WHITMORE WF, 1972, J UROLOGY, V108, P918, DOI 10.1016/S0022-5347(17)60906-6; WOLF JS, 1995, J UROLOGY, V153, P993, DOI 10.1016/S0022-5347(01)67620-1; Zagars GK, 1997, CANCER, V79, P1370, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1370::AID-CNCR15>3.0.CO;2-X; Zelefsky MJ, 1999, INT J RADIAT ONCOL, V45, P567, DOI 10.1016/S0360-3016(99)00232-1; Zelefsky MJ, 2000, RADIOTHER ONCOL, V55, P241, DOI 10.1016/S0167-8140(99)00100-0; Zelefsky MJ, 1999, UROLOGY, V53, P775, DOI 10.1016/S0090-4295(98)00594-9; Zelefsky MJ, 2001, J UROLOGY, V166, P876, DOI 10.1016/S0022-5347(05)65855-7; Zelefsky MJ, 1998, INT J RADIAT ONCOL, V41, P491, DOI 10.1016/S0360-3016(98)00091-1; Zelefsky MJ, 1999, J CLIN ONCOL, V17, P517, DOI 10.1200/JCO.1999.17.2.517; Zelefsky MJ, 2000, INT J RADIAT ONCOL, V47, P1261, DOI 10.1016/S0360-3016(00)00550-2; Zietman AL, 2001, J UROLOGY, V166, P1702, DOI 10.1016/S0022-5347(05)65657-1; ZIETMAN AL, 1995, INT J RADIAT ONCOL, V32, P287, DOI 10.1016/0360-3016(95)00123-G; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6; ZINCKE H, 1994, J CLIN ONCOL, V12, P2254, DOI 10.1200/JCO.1994.12.11.2254; Zlotta AR, 2000, WORLD J UROL, V18, P179, DOI 10.1007/s003450000119	140	166	166	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	2003	361	9362					1045	1053		10.1016/S0140-6736(03)12833-4	http://dx.doi.org/10.1016/S0140-6736(03)12833-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660074				2022-12-28	WOS:000181699700026
J	Blankenburg, F; Taskin, B; Ruben, J; Moosmann, M; Ritter, P; Curio, G; Villringer, A				Blankenburg, F; Taskin, B; Ruben, J; Moosmann, M; Ritter, P; Curio, G; Villringer, A			Imperceptible stimuli and sensory processing impediment	SCIENCE			English	Article							SOMATOSENSORY CORTEX; BLOOD-FLOW		Humboldt Univ, Charite, Dept Neurol, D-10117 Berlin, Germany; Free Univ Berlin, Benjamin Franklin Hosp, Dept Neurol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Blankenburg, F (corresponding author), Humboldt Univ, Charite, Dept Neurol, Schumannstr 20-21, D-10117 Berlin, Germany.		Ritter, Petra/B-6953-2008	Ritter, Petra/0000-0002-4643-4782; Villringer, Arno/0000-0003-2604-2404; Curio, Gabriel/0000-0002-3377-7735				DREVETS WC, 1995, NATURE, V373, P249, DOI 10.1038/373249a0; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hernandez A, 2002, NEURON, V33, P959, DOI 10.1016/S0896-6273(02)00613-X; LIBET B, 1967, SCIENCE, V158, P1597, DOI 10.1126/science.158.3808.1597; Paus T, 1998, J NEUROPHYSIOL, V79, P1102, DOI 10.1152/jn.1998.79.2.1102; Swadlow HA, 2003, CEREB CORTEX, V13, P25, DOI 10.1093/cercor/13.1.25; Swadlow HA, 2000, J NEUROPHYSIOL, V83, P2802, DOI 10.1152/jn.2000.83.5.2802	8	77	77	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 21	2003	299	5614					1864	1864		10.1126/science.1080806	http://dx.doi.org/10.1126/science.1080806			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649475				2022-12-28	WOS:000181669700036
J	Campion, EW				Campion, EW			A death at Duke	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	28	28	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1083	1084		10.1056/NEJMp030033	http://dx.doi.org/10.1056/NEJMp030033			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646664				2022-12-28	WOS:000181628400003
J	Alexander, GC; Werner, RM; Fagerlin, A; Ubel, PA				Alexander, GC; Werner, RM; Fagerlin, A; Ubel, PA			Support for physician deception of insurance companies among a sample of Philadelphia residents	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGED-CARE; REIMBURSEMENT RULES; MEDICAL-CARE	Background: Some physicians seem to be willing to sanction deception of insurance companies. Little is known about public attitudes regarding this practice. Objective: To assess public attitudes regarding physician deception of insurance companies. Design: Cross-sectional survey using clinical vignettes. Setting: Philadelphia County Courthouse, Philadelphia, Pennsylvania. Participants: Convenience sample of 700 prospective jurors. Measurements: Participants were asked whether, in response to restriction of health care, a physician should 1) accept restriction, 2) appeal restriction, or 3) misrepresent a patient's condition to obtain the desired service. The proportion of respondents reporting that the physician should misrepresent a patient's condition was determined. Results: 26% of respondents sanctioned deception, 70% supported appealing, and 4% supported accepting the insurance company decision. Among the 27% of respondents believing physicians have inadequate time to appeal coverage decisions, 50% sanctioned deception. Conclusions: sanctioning of deception was substantial in this sample of prospective jurors. Preferences regarding insurance company deception are related to perceptions of physician workload and may further pressure physicians struggling to balance advocacy with honesty.	Univ Penn, Philadelphia, PA 19104 USA; Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI USA; Univ Michigan, Ann Arbor, MI 48109 USA	University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	Alexander, GC (corresponding author), Univ Chicago, Robert Wood Johnson Clin Scholars Program, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA.	calexand@medicine.bsd.uchicago.edu		Werner, Rachel/0000-0003-3435-4221				Armstrong K, 2002, MED DECIS MAKING, V22, P76, DOI 10.1177/02729890222062946; BLENDON RJ, 1994, J AM HEALTH POLICY, V4, P42; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; Freeman VG, 1999, ARCH INTERN MED, V159, P2263, DOI 10.1001/archinte.159.19.2263; GOODMAN E, 2000, BOSTON GLOBE     APR, pA27; GRUMET GW, 1989, NEW ENGL J MED, V321, P607, DOI 10.1056/NEJM198908313210909; Illingworth P, 2000, J MED PHILOS, V25, P62, DOI 10.1076/0360-5310(200002)25:1;1-V;FT062; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1151, DOI 10.1056/NEJM199410273311709; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; MORREIM EH, 1991, ARCH INTERN MED, V151, P443, DOI 10.1001/archinte.151.3.443; MORREIM EH, 1989, ARCH INTERN MED, V149, P1012, DOI 10.1001/archinte.149.5.1012; NOVACK DH, 1989, JAMA-J AM MED ASSOC, V261, P2980, DOI 10.1001/jama.261.20.2980; Robinson JC, 2001, JAMA-J AM MED ASSOC, V285, P2622, DOI 10.1001/jama.285.20.2622; Rothman DJ, 2000, NEW ENGL J MED, V342, P1284, DOI 10.1056/NEJM200004273421711; Ubel P.A., 2000, PRICING LIFE WHY ITS; Werner RM, 2002, ARCH INTERN MED, V162, P1134, DOI 10.1001/archinte.162.10.1134; Wilson IB, 2001, ARCH INTERN MED, V161, P256, DOI 10.1001/archinte.161.2.256; Wynia MK, 2000, JAMA-J AM MED ASSOC, V283, P1858, DOI 10.1001/jama.283.14.1858; Zemencuk JK, 1999, AM J MED QUAL, V14, P21, DOI 10.1177/106286069901400104	19	15	15	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					472	475		10.7326/0003-4819-138-6-200303180-00011	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639080				2022-12-28	WOS:000181562400005
J	Quinlivan, JA; Box, H; Evans, SF				Quinlivan, JA; Box, H; Evans, SF			Postnatal home visits in teenage mothers: a randomised controlled trial	LANCET			English	Article							ADOLESCENT PREGNANCY; MATERNAL AGE; PROGRAM; CHILDBEARING; PREVENTION; VISITATION; INFANCY; NURSES; RISK	Background Teenage pregnancies are associated with negative socioeconomic effects. Our aim was to ascertain whether a postnatal home-visiting service for teenage mothers younger than age 18 years could reduce the frequency of adverse neonatal outcomes and improve knowledge of contraception, breastfeeding, and infant vaccination schedules in this parent group. Methods We enrolled 139 adolescents, attending a teenage pregnancy clinic, in a randomised controlled trial. After completing an antenatal questionnaire designed to assess their knowledge of contraception, infant vaccination, and breastfeeding, we assigned participants to either receive five structured postnatal home visits by nurse-midwives (n=65) or not (n=71). Assessment interviews were done 6 months postpartum. Our primary endpoint was unadjusted difference in knowledge between groups, and incidence of predefined adverse neonatal outcomes. Analysis was by intention to treat. Findings Three women withdrew before randomisation because of late fetal loss, 11 mothers withdrew because of adverse neonatal outcomes (adverse neonatal outcome was a primary endpoint, but resulted in withdrawal from the study for knowledge outcomes), and one left voluntarily. Follow-up data were, therefore, available for 124 teenagers. Postnatal home visits were associated with a reduction in adverse neonatal outcomes (intervention: 2; control: 9; relative risk 0.24, 95% CI 0.05-1.08), and a significant increase in contraception knowledge (mean difference 0.92, 95% CI 0.32-1.52). However, there was no significant increase in knowledge with respect to breastfeeding or infant vaccination schedules associated with the home visits. Interpretation Postnatal home-visiting services by nurse-midwives reduce adverse neonatal events and improve contraception outcomes, but do not affect breastfeeding or infant vaccination knowledge or compliance.	Univ Melbourne, Dept Obstet & Gynaecol, Parkville, Vic 3052, Australia; King Edward Mem Hosp, Obstet Clin Care Unit, Perth, WA, Australia; Univ Western Australia, Dept Obstet & Gynaecol, Nedlands, WA 6009, Australia; Univ Western Australia, Womens & Infants Res Fdn, Nedlands, WA 6009, Australia	University of Melbourne; King Edward Memorial Hospital; University of Western Australia; University of Western Australia; University of Western Australia	Quinlivan, JA (corresponding author), Univ Melbourne, Royal Womens Hosp, Univ Dept Obstet & Gynaecol, Carlton, Vic 3053, Australia.	julieq@unimelb.edu.au		Quinlivan, Julie/0000-0003-4706-2412				Alexander GR, 1996, PUBLIC HEALTH REP, V111, P408; [Anonymous], 1973, OB GYN NEWS, V8, P1; BABSON SG, 1983, J PEDIATR-US, V103, P391, DOI 10.1016/S0022-3476(83)80409-0; Chase-Lansdale PL, 2002, FUTURE CHILD, V12, P167; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; FURSTENBERG FF, 1989, AM PSYCHOL, V44, P313, DOI 10.1037/0003-066X.44.2.313; Gueorguieva RV, 2001, AM J EPIDEMIOL, V154, P212, DOI 10.1093/aje/154.3.212; Guyatt GH, 2000, J CLIN EPIDEMIOL, V53, P167, DOI 10.1016/S0895-4356(99)00160-2; Hippisley-Cox J, 2000, BRIT MED J, V320, P842, DOI 10.1136/bmj.320.7238.842; HOBBS CJ, 1999, CHILD ABUSE NEGLECT; Kitzman H, 1997, JAMA-J AM MED ASSOC, V278, P644, DOI 10.1001/jama.278.8.644; Korfmacher J, 1999, AM J PUBLIC HEALTH, V89, P1847, DOI 10.2105/AJPH.89.12.1847; Magann EF, 1996, AM J OBSTET GYNECOL, V175, P182, DOI 10.1016/S0002-9378(96)70272-7; MCANARNEY ER, 1987, AM J DIS CHILD, V141, P1053, DOI 10.1001/archpedi.1987.04460100031017; Miller F C, 2000, J Pediatr Adolesc Gynecol, V13, P5, DOI 10.1016/S1083-3188(99)00035-2; Morrell CJ, 2000, BRIT MED J, V321, P593, DOI 10.1136/bmj.321.7261.593; Nair P, 1997, CHILD ABUSE NEGLECT, V21, P1039, DOI 10.1016/S0145-2134(97)00064-1; OLDS DL, 1986, PEDIATRICS, V78, P65; Pierre Natalie, 1997, Current Opinion in Pediatrics, V9, P310, DOI 10.1097/00008480-199708000-00003; POLIT DF, 1986, AM J PUBLIC HEALTH, V76, P167, DOI 10.2105/AJPH.76.2.167; Quinlivan J A, 2001, J Pediatr Adolesc Gynecol, V14, P17, DOI 10.1016/S1083-3188(00)00078-4; Quinlivan JA, 1999, AUST NZ J PSYCHIAT, V33, P864, DOI 10.1046/j.1440-1614.1999.00592.x; Social Exclusion Unit, 1999, TEEN PREGN REP PARL; Stevens-Simon C, 1998, ARCH PEDIAT ADOL MED, V152, P893; Stevens-Simon C, 2001, CHILD ABUSE NEGLECT, V25, P753, DOI 10.1016/S0145-2134(01)00237-X; StevensSimon C, 1997, JAMA-J AM MED ASSOC, V277, P977, DOI 10.1001/jama.277.12.977; WILLIAMS S, 1987, BRIT MED J, V294, P20, DOI 10.1136/bmj.294.6563.20-a; 1989, HOME VISITING OPENIN	28	83	83	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	2003	361	9361					893	900		10.1016/S0140-6736(03)12770-5	http://dx.doi.org/10.1016/S0140-6736(03)12770-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	658VP	12648967				2022-12-28	WOS:000181741600006
J	Yoon, TP; Jacobsen, EN				Yoon, TP; Jacobsen, EN			Privileged chiral catalysts	SCIENCE			English	Article							RING-OPENING REACTIONS; ASYMMETRIC-SYNTHESIS; ENANTIOSELECTIVE SYNTHESIS; CINCHONA ALKALOIDS; DERIVATIVES; COMPLEXES; MECHANISM; EPOXIDES; ACID	One of the most active current areas of chemical research is centered on how to synthesize handed (chiral) compounds in a selective manner, rather than as mixtures of mirror-image forms (enantiomers) with different three-dimensional structures (stereochemistries). Nature points the way in this endeavor: different enantiomers of a given biomolecule can exhibit dramatically different biological activities, and enzymes have therefore evolved to catalyze reactions with exquisite selectivity for the formation of one enantiomeric form over the other. Drawing inspiration from these natural catalysts, chemists have developed a variety of synthetic small-molecule catalysts that can achieve levels of selectivity approaching, and in some cases matching, those observed in enzymatic reactions.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Jacobsen, EN (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.							BLASER HU, 1991, TETRAHEDRON-ASYMMETR, V2, P843, DOI 10.1016/S0957-4166(00)82195-3; Chen YG, 2000, J AM CHEM SOC, V122, P9542, DOI 10.1021/ja001765+; Corey EJ, 1997, J AM CHEM SOC, V119, P12414, DOI 10.1021/ja973174y; DOLLING UH, 1984, J AM CHEM SOC, V106, P446, DOI 10.1021/ja00314a045; EVANS BE, 1988, J MED CHEM, V31, P2235, DOI 10.1021/jm00120a002; GARLAND M, 1990, J AM CHEM SOC, V112, P7048, DOI 10.1021/ja00175a042; Hansen KB, 1996, J AM CHEM SOC, V118, P10924, DOI 10.1021/ja962600x; Jacobsen E. N., 1999, COMPREHENSIVE ASYMME, V1-3; JACOBSEN EN, 1991, J AM CHEM SOC, V113, P7063, DOI 10.1021/ja00018a068; Jacobsen EN, 2000, ACCOUNTS CHEM RES, V33, P421, DOI 10.1021/ar960061v; Josephsohn NS, 2001, J AM CHEM SOC, V123, P11594, DOI 10.1021/ja011875w; Kacprzak K, 2001, SYNTHESIS-STUTTGART, P961; Katsuki T, 2003, SYNLETT, P281, DOI 10.1055/s-2003-37101; Knowles WS, 2002, ANGEW CHEM INT EDIT, V41, P1999; KOLB HC, 1994, CHEM REV, V94, P2483, DOI 10.1021/cr00032a009; Myers JK, 1999, J AM CHEM SOC, V121, P8959, DOI 10.1021/ja991621z; Ready JM, 2002, ANGEW CHEM INT EDIT, V41, P1374, DOI 10.1002/1521-3773(20020415)41:8<1374::AID-ANIE1374>3.0.CO;2-8; Ruck RT, 2002, J AM CHEM SOC, V124, P2882, DOI 10.1021/ja025588j; SHARPLESS KB, 1998, TRANSITION METAL ORG, V2, P243; Taggi AE, 2000, J AM CHEM SOC, V122, P7831, DOI 10.1021/ja001754g; Tokunaga M, 1997, SCIENCE, V277, P936, DOI 10.1126/science.277.5328.936; Wenzel AG, 2002, J AM CHEM SOC, V124, P12964, DOI 10.1021/ja028353g; WYNBERG H, 1982, J AM CHEM SOC, V104, P166, DOI 10.1021/ja00365a030	23	1116	1135	9	271	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1691	1693		10.1126/science.1083622	http://dx.doi.org/10.1126/science.1083622			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637734				2022-12-28	WOS:000181519500033
J	O'Brien, SG; Guilhot, F; Larson, RA; Gathmann, I; Baccarani, M; Cervantes, F; Cornelissen, JJ; Fischer, T; Hochhaus, A; Hughes, T; Lechner, K; Nielsen, JL; Rousselot, P; Reiffers, J; Saglio, G; Shepherd, J; Simonsson, B; Gratwohl, A; Goldman, JM; Kantarjian, H; Taylor, K; Verhoef, G; Bolton, AE; Capdeville, R; Druker, BJ; Durrant, S; Schwarer, A; Joske, D; Seymour, J; Grigg, A; Ma, D; Arthur, C; Bradstock, K; Joshua, D; Louwagie, A; Martiat, P; Straetmans, N; Bosly, A; Shustik, C; Lipton, J; Forrest, D; Walker, I; Roy, DC; Rubinger, M; Bence-Bruckler, I; Kovacs, M; Turner, AR; Birgens, H; Bjerrum, O; Facon, T; Harousseau, JL; Tulliez, M; Guerci, A; Blaise, D; Maloisel, F; Michallet, M; Hossfeld, D; Mertelsmann, R; Andreesen, R; Nerl, C; Freund, M; Gattermann, N; Hoeffken, K; Ehninger, G; Deininger, M; Ottmann, O; Peschel, C; Fruehauf, S; Neubauer, A; Le Coutre, P; Aulitzky, W; Fanin, R; Rosti, G; Mandelli, F; Morra, E; Carella, A; Lazzarino, M; Petrini, M; Ferrini, PR; Nobile, F; Liso, V; Ferrara, F; Rizzoli, V; Fioritoni, G; Martinelli, G; Ossenkoppele, G; Browett, P; Gedde-Dahl, T; Tangen, JM; Dahl, I; Odriozola, J; Boluda, JCH; Steegmann, JL; Canizo, C; Sureda, A; Diaz, J; Granena, A; Fernandez, MN; Stenke, L; Paul, C; Bjoreman, M; Malm, C; Wadenvik, H; Nilsson, PG; Turesson, I; Hess, U; Solenthaler, M; Russel, N; Mufti, G; Cavenagh, J; Clark, RE; Green, AR; Holyoake, TL; Lucas, GS; Smith, G; Milligan, DW; Rule, SJ; Burnett, AK; Moroose, R; Wetzler, M; Bearden, J; Brown, R; Lobell, M; Cataland, S; Rabinowitz, I; Meisenberg, B; Gabrilove, J; Thompson, K; Graziano, S; Emanuel, P; Gross, H; Cobb, P; Bhatia, R; Dakhil, S; Irwin, D; Issell, B; Pavletic, S; Kuebler, P; Layhe, E; Butera, P; Glass, J; Moore, J; Grant, B; Niell, H; Herzig, R; Burris, H; Peterson, B; Powell, B; Kalaycio, M; Stirewalt, D; Samlowski, W; Berman, E; Limentani, S; Seay, T; Shea, T; Akard, L; Smith, G; Becker, P; DeVine, S; Hart, R; Veith, R; Wade, J; Brunvand, M; Silver, R; Kalman, L; Strickland, D; Shurafa, M; Bashey, A; Shadduck, R; Cooper, S; Safah, H; Rubenstein, M; Collins, R; Keller, A; Stone, R; Tallman, M; Stevens, D; Pecora, A; Agha, M; Holmes, H; Druker, BJ; Guilhot, F; Larson, RA; O'Brien, SG; Rowe, J; Schiffer, CA; Buyse, M; Baccarani, M; Cervantes, F; Cornelissen, J; Fischer, T; Hochhaus, A; Hughes, T; Kantarjian, H; Lechner, K; Nielsen, JL; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Simonsson, B; Gratwohl, A; Goldman, JM; Taylor, K; Verhoef, G				O'Brien, SG; Guilhot, F; Larson, RA; Gathmann, I; Baccarani, M; Cervantes, F; Cornelissen, JJ; Fischer, T; Hochhaus, A; Hughes, T; Lechner, K; Nielsen, JL; Rousselot, P; Reiffers, J; Saglio, G; Shepherd, J; Simonsson, B; Gratwohl, A; Goldman, JM; Kantarjian, H; Taylor, K; Verhoef, G; Bolton, AE; Capdeville, R; Druker, BJ; Durrant, S; Schwarer, A; Joske, D; Seymour, J; Grigg, A; Ma, D; Arthur, C; Bradstock, K; Joshua, D; Louwagie, A; Martiat, P; Straetmans, N; Bosly, A; Shustik, C; Lipton, J; Forrest, D; Walker, I; Roy, DC; Rubinger, M; Bence-Bruckler, I; Kovacs, M; Turner, AR; Birgens, H; Bjerrum, O; Facon, T; Harousseau, JL; Tulliez, M; Guerci, A; Blaise, D; Maloisel, F; Michallet, M; Hossfeld, D; Mertelsmann, R; Andreesen, R; Nerl, C; Freund, M; Gattermann, N; Hoeffken, K; Ehninger, G; Deininger, M; Ottmann, O; Peschel, C; Fruehauf, S; Neubauer, A; Le Coutre, P; Aulitzky, W; Fanin, R; Rosti, G; Mandelli, F; Morra, E; Carella, A; Lazzarino, M; Petrini, M; Ferrini, PR; Nobile, F; Liso, V; Ferrara, F; Rizzoli, V; Fioritoni, G; Martinelli, G; Ossenkoppele, G; Browett, P; Gedde-Dahl, T; Tangen, JM; Dahl, I; Odriozola, J; Boluda, JCH; Steegmann, JL; Canizo, C; Sureda, A; Diaz, J; Granena, A; Fernandez, MN; Stenke, L; Paul, C; Bjoreman, M; Malm, C; Wadenvik, H; Nilsson, PG; Turesson, I; Hess, U; Solenthaler, M; Russel, N; Mufti, G; Cavenagh, J; Clark, RE; Green, AR; Holyoake, TL; Lucas, GS; Smith, G; Milligan, DW; Rule, SJ; Burnett, AK; Moroose, R; Wetzler, M; Bearden, J; Brown, R; Lobell, M; Cataland, S; Rabinowitz, I; Meisenberg, B; Gabrilove, J; Thompson, K; Graziano, S; Emanuel, P; Gross, H; Cobb, P; Bhatia, R; Dakhil, S; Irwin, D; Issell, B; Pavletic, S; Kuebler, P; Layhe, E; Butera, P; Glass, J; Moore, J; Grant, B; Niell, H; Herzig, R; Burris, H; Peterson, B; Powell, B; Kalaycio, M; Stirewalt, D; Samlowski, W; Berman, E; Limentani, S; Seay, T; Shea, T; Akard, L; Smith, G; Becker, P; DeVine, S; Hart, R; Veith, R; Wade, J; Brunvand, M; Silver, R; Kalman, L; Strickland, D; Shurafa, M; Bashey, A; Shadduck, R; Cooper, S; Safah, H; Rubenstein, M; Collins, R; Keller, A; Stone, R; Tallman, M; Stevens, D; Pecora, A; Agha, M; Holmes, H; Druker, BJ; Guilhot, F; Larson, RA; O'Brien, SG; Rowe, J; Schiffer, CA; Buyse, M; Baccarani, M; Cervantes, F; Cornelissen, J; Fischer, T; Hochhaus, A; Hughes, T; Kantarjian, H; Lechner, K; Nielsen, JL; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Simonsson, B; Gratwohl, A; Goldman, JM; Taylor, K; Verhoef, G		IRIS Investigators	Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; BCR-ABL; CYTOGENETIC RESPONSES; IN-VITRO; C-KIT; INHIBITION; BUSULFAN; GROWTH; ALPHA	Background: Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML. Methods: We randomly assigned 1106 patients to receive imatinib (553 patients) or interferon alfa plus low-dose cytarabine (553 patients). Crossover to the alternative group was allowed if stringent criteria defining treatment failure or intolerance were met. Patients were evaluated for hematologic and cytogenetic responses, toxic effects, and rates of progression. Results: After a median follow-up of 19 months, the estimated rate of a major cytogenetic response (0 to 35 percent of cells in metaphase positive for the Philadelphia chromosome) at 18 months was 87.1 percent (95 percent confidence interval, 84.1 to 90.0) in the imatinib group and 34.7 percent (95 percent confidence interval, 29.3 to 40.0) in the group given interferon alfa plus cytarabine (P<0.001). The estimated rates of complete cytogenetic response were 76.2 percent (95 percent confidence interval, 72.5 to 79.9) and 14.5 percent (95 percent confidence interval, 10.5 to 18.5), respectively (P<0.001). At 18 months, the estimated rate of freedom from progression to accelerated-phase or blast-crisis CML was 96.7 percent in the imatinib group and 91.5 percent in the combination-therapy group (P<0.001). Imatinib was better tolerated than combination therapy. Conclusions: In terms of hematologic and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML.	Univ Newcastle, Newcastle, NSW 2308, Australia; CHU Poitiers, Poitiers, France; Univ Chicago, Chicago, IL 60637 USA; Novartis, Basel, Switzerland; St Orsola Marcello Malpighi Hosp, Bologna, Italy; Hosp Clin Barcelona, Barcelona, Spain; Erasmus MC, Dr Daniel Den Hoed Canc Ctr, Rotterdam, Netherlands; Johannes Gutenberg Univ Mainz, D-6500 Mainz, Germany; Heidelberg Univ, Klinikum Mannheim, Mannheim, Germany; Royal Adelaide Hosp, Adelaide, SA 5000, Australia; Univ Vienna, Innere Med Klin 1, Vienna, Austria; Aarhus Kommune Hosp, DK-8000 Aarhus, Denmark; Hop St Louis, Paris, France; CHU Bordeaux, Pessac, France; Azienda Osped S Luigi Gonzaga, Orbassano, Italy; Vancouver Hosp, Vancouver, BC, Canada; Uppsala Univ, Akad Sjukhuset, Uppsala, Sweden; Kantonsspital Basel, Basel, Switzerland; Hammersmith Hosp, London, England; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Mater Misericordiae Publ Hosp, Brisbane, Qld, Australia; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Oregon Hlth & Sci Univ, Inst Canc, Portland, OR USA	University of Newcastle; CHU Poitiers; Universite de Poitiers; University of Chicago; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Barcelona; Hospital Clinic de Barcelona; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Johannes Gutenberg University of Mainz; Ruprecht Karls University Heidelberg; Royal Adelaide Hospital; University of Vienna; Aarhus University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; University of British Columbia; Uppsala University; Uppsala University Hospital; Imperial College London; University of Texas System; UTMD Anderson Cancer Center; KU Leuven; University Hospital Leuven; Oregon Health & Science University	O'Brien, SG (corresponding author), Univ Newcastle, Newcastle, NSW 2308, Australia.		Devine, Steven/AAS-7644-2021; Kovacs, Michael/G-3315-2011; Fernandez, Manuel/M-9168-2013; Seymour, John/K-7326-2019; Larson, Richard A./AAE-7223-2019; Yang, Chen/G-1379-2010; Agha, Mounzer/AAC-2520-2022; Blaise, Didier/R-2483-2016; Bjerrum, Ole Weis/AAF-9999-2019; Arthur, Chris/ABG-7286-2022	Seymour, John/0000-0003-2188-6835; Larson, Richard A./0000-0001-9168-3203; Blaise, Didier/0000-0002-5684-9447; Arthur, Chris/0000-0002-9147-9090; Hochhaus, Andreas/0000-0003-0626-0834; Saglio, Giuseppe/0000-0002-1046-3514; Guilhot, Francois/0000-0001-7222-487X; Druker, Brian/0000-0001-8331-8206				ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Baccarani M, 2002, BLOOD, V99, P1527, DOI 10.1182/blood.V99.5.1527; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Delannoy A, 1997, J NATL CANCER I, V89, P1616; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; Gratwohl A, 2002, LANCET, V359, P712, DOI 10.1016/S0140-6736(02)07831-5; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hasford J, 1998, JNCI-J NATL CANCER I, V90, P850, DOI 10.1093/jnci/90.11.850; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLIHER M, 1990, P NATL ACAD SCI USA, V87, P9072; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Kluin-Nelemans JC, 1998, BLOOD, V91, P2713; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; NOWELL PC, 1960, SCIENCE, V132, P1497; OHNISHI K, 1995, BLOOD, V86, P906; Okuda K, 2001, BLOOD, V97, P2440, DOI 10.1182/blood.V97.8.2440; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Silver RT, 1999, BLOOD, V94, P1517; SOKAL JE, 1988, SEMIN HEMATOL, V25, P49; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; TURA S, 1994, NEW ENGL J MED, V330, P820	37	2627	2729	8	163	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					994	1004		10.1056/NEJMoa022457	http://dx.doi.org/10.1056/NEJMoa022457			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653YT	12637609				2022-12-28	WOS:000181465200004
J	Colhoun, HM; McKeigue, PM; Smith, GD				Colhoun, HM; McKeigue, PM; Smith, GD			Problems of reporting genetic associations with complex outcomes	LANCET			English	Review							ALPHA-ADDUCIN GENE; CONVERTING ENZYME GENE; LINKAGE DISEQUILIBRIUM; ESSENTIAL-HYPERTENSION; BLOOD-PRESSURE; POPULATION STRATIFICATION; MYOCARDIAL-INFARCTION; JAPANESE POPULATION; COMMON DISEASE; HEART-DISEASE	Inability to replicate many results has led to increasing scepticism about the value of simple association study designs for detection of genetic variants contributing to common complex traits. Much attention has been drawn to the problems that might, in theory, bedevil this approach, including confounding from population structure, misclassification of outcome, and allelic heterogeneity. Other researchers have argued that absence of replication may indicate true heterogeneity in gene-disease associations. We suggest that the most important factors underlying inability to replicate these associations are publication bias, failure to attribute results to chance, and inadequate sample sizes, problems that are all rectifiable. Without changes to present practice, we risk wastage of scientific effort and rejection of a potentially useful research strategy.	UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; London Sch Hyg & Trop Med, London WC1, England; Univ Bristol, Bristol BS8 1TH, Avon, England	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; University of Bristol	Colhoun, HM (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	h.colhoun@public-health.ucl.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Colhoun, Helen/0000-0002-8345-3288				Agerholm-Larsen B, 2000, ARTERIOSCL THROM VAS, V20, P484, DOI 10.1161/01.ATV.20.2.484; Altshuler D, 1998, NEW ENGL J MED, V338, P1626, DOI 10.1056/NEJM199805283382214; Ardlie KG, 2002, NAT REV GENET, V3, P299, DOI 10.1038/nrg777; BARNARDO JM, 2000, BAYESIAN THEORY, P67; Bianchi G, 2000, AM J HYPERTENS, V13, P739, DOI 10.1016/S0895-7061(00)00241-7; Boerwinkle E, 2000, AM J HYPERTENS, V13, P734, DOI 10.1016/S0895-7061(00)00243-0; Bray MS, 2000, AM J HYPERTENS, V13, P699, DOI 10.1016/S0895-7061(00)00242-9; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; CASARI G, 1995, HYPERTENSION, V25, P320, DOI 10.1161/01.HYP.25.3.320; Castellano M, 1997, J HYPERTENS, V15, P1707, DOI 10.1097/00004872-199715120-00076; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Collins A, 1996, P NATL ACAD SCI USA, V93, P9177, DOI 10.1073/pnas.93.17.9177; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Cusi D, 1997, LANCET, V349, P1353, DOI 10.1016/S0140-6736(97)01029-5; Dahlman I, 2002, NAT GENET, V30, P149, DOI 10.1038/ng825; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Egger M, 2002, INT J EPIDEMIOL, V31, P1, DOI 10.1093/ije/31.1.1; Elston RC, 1997, AM J HUM GENET, V60, P255; Gambaro G, 2000, LANCET, V355, P308, DOI 10.1016/S0140-6736(99)07202-5; GOODMAN SN, 1993, AM J EPIDEMIOL, V137, P485, DOI 10.1093/oxfordjournals.aje.a116700; Goring HHH, 2001, AM J HUM GENET, V69, P1357, DOI 10.1086/324471; Holtzman NA, 2001, INT J HEALTH SERV, V31, P445, DOI 10.2190/JPFC-A4NW-KWT6-Y2H7; *HUM GEN EP NETW, 2002, HUGE NET; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Ishikawa K, 1998, AM J HYPERTENS, V11, P502, DOI 10.1016/S0895-7061(97)00486-X; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Kamitani A, 1998, HYPERTENSION, V32, P138, DOI 10.1161/01.HYP.32.1.138; Kato N, 1998, HYPERTENSION, V31, P730, DOI 10.1161/01.HYP.31.3.730; Keavney B, 2000, LANCET, V355, P434; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Little J, 2002, AM J EPIDEMIOL, V156, P300, DOI 10.1093/oxfordjournals.aje.a000179; Morton NE, 1998, P NATL ACAD SCI USA, V95, P11389, DOI 10.1073/pnas.95.19.11389; *NAT CTR BIOT INF, 2002, OMIM ONL MEND INH MA; Oakes M, 1986, STAT INFERENCE; Paris PL, 1999, CANCER EPIDEM BIOMAR, V8, P901; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Ranade K, 2000, AM J HYPERTENS, V13, P704, DOI 10.1016/S0895-7061(00)00238-7; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Rosenberg N, 2002, AM J HUM GENET, V70, P758, DOI 10.1086/338932; Samani NJ, 1996, CIRCULATION, V94, P708, DOI 10.1161/01.CIR.94.4.708; Schork NJ, 2000, AM J HYPERTENS, V13, P693, DOI 10.1016/S0895-7061(00)00237-5; Staessen JA, 1997, J HYPERTENS, V15, P1579, DOI 10.1097/00004872-199715120-00059; Sterne JAC, 2001, BMJ-BRIT MED J, V322, P226, DOI 10.1136/bmj.322.7280.226; Strohman R, 2002, SCIENCE, V296, P701, DOI 10.1126/science.1070534; Terwilliger JD, 1998, CURR OPIN BIOTECH, V9, P578, DOI 10.1016/S0958-1669(98)80135-3; Thomas DC, 2002, CANCER EPIDEM BIOMAR, V11, P505; Tishkoff SA, 1996, SCIENCE, V271, P1380, DOI 10.1126/science.271.5254.1380; Vieland VJ, 2001, NAT GENET, V29, P244, DOI 10.1038/ng1101-244; Wacholder S, 2000, J NATL CANCER I, V92, P1151, DOI 10.1093/jnci/92.14.1151; Wacholder S, 2002, CANCER EPIDEM BIOMAR, V11, P513; Witte JS, 2000, STAT MED, V19, P369, DOI 10.1002/(SICI)1097-0258(20000215)19:3<369::AID-SIM335>3.0.CO;2-N; 1999, NAT GENET, V22, P1	57	943	966	0	33	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					865	872		10.1016/S0140-6736(03)12715-8	http://dx.doi.org/10.1016/S0140-6736(03)12715-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642066				2022-12-28	WOS:000181466600027
J	Hakin-Smith, V; Jellinek, DA; Levy, D; Carroll, T; Teo, M; Timperley, WR; McKay, MJ; Reddel, RR; Royds, JA				Hakin-Smith, V; Jellinek, DA; Levy, D; Carroll, T; Teo, M; Timperley, WR; McKay, MJ; Reddel, RR; Royds, JA			Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme	LANCET			English	Article							MECHANISM	Despite advances In the molecular pathogenesis of giloblastoma multiforme, no reliable prognostic markers have been Identified. We analysed telomerase activity and telomere lengths In giloblastoma multiformes from 77 patients. 19 patients (25%) had tumours with the alternative-lengthening-of-telomere (ALT) phenotype. Median survival for patients with this phenotype was 542 days (95% CI 114-970) compared with 247 days (224-270) for glioblastoma multiformes with normal telomeres (p=0.0003). Cox's regression analysis showed that this association is independent of age. In patients with non-ALT tumours, telomerase activity did not affect survival (median 287 [199-375] vs 236 [230-242] days, p=0.275). We conclude that ALT Is a prognostic Indicator for patients with glioblastoma multiforme.	Univ Sheffield, Sch Med, Inst Canc Studies, Sheffield, S Yorkshire, England; Royal Hallamshire Hosp, Dept Neuropathol, Sheffield S10 2JF, S Yorkshire, England; Royal Hallamshire Hosp, Dept Neurosurg, Sheffield S10 2JF, S Yorkshire, England; Weston Pk Hosp, Sheffield, S Yorkshire, England; Peter MacCallum Canc Inst, Div Res, Melbourne, Vic 3000, Australia; Childrens Med Res Inst, Sydney, NSW, Australia	University of Sheffield; University of Sheffield; University of Sheffield; Weston Park Hospital; Peter Maccallum Cancer Center; Children's Medical Research Institute - Australia; University of Sydney	Royds, JA (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, POB 913, Dunedin, New Zealand.		Reddel, Roger R/A-6635-2014; Teo, Mario/AAE-5804-2020; McKay, Michael/ABA-9029-2021	Reddel, Roger R/0000-0002-6302-6107; Teo, Mario/0000-0002-0051-3303; 				Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bryant JE, 1997, BIOTECHNIQUES, V23, P476, DOI 10.2144/97233st05; Carroll T, 1999, J PATHOL, V188, P395; Latif AZB, 1998, J NEUROL NEUROSUR PS, V64, P747, DOI 10.1136/jnnp.64.6.747; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599	5	213	223	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					836	838		10.1016/S0140-6736(03)12681-5	http://dx.doi.org/10.1016/S0140-6736(03)12681-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642053				2022-12-28	WOS:000181466600015
J	Lippincott-Schwartz, J; Patterson, GH				Lippincott-Schwartz, J; Patterson, GH			Development and use of fluorescent protein markers in living cells	SCIENCE			English	Review							IN-VIVO; CORRELATION SPECTROSCOPY; PHOTOBLEACHING RECOVERY; ENDOPLASMIC-RETICULUM; MEMBRANE-TRANSPORT; PLASMA-MEMBRANE; LIVE CELLS; DYNAMICS; GFP; MICROSCOPY	The ability to visualize, track, and quantify molecules and events in living cells with high spatial and temporal resolution is essential for understanding biological systems. Only recently has it become feasible to carry out these tasks due to the advent of fluorescent protein technology. Here, we trace the development of highly visible and minimally perturbing fluorescent proteins that, together with updated fluorescent imaging techniques, are providing unprecedented insights into the movement of proteins and their interactions with cellular components in living cells.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Lippincott-Schwartz, J (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	jlippin@helix.nih.gov	Patterson, George/ABI-4751-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001609] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001609] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ando R, 2002, P NATL ACAD SCI USA, V99, P12651, DOI 10.1073/pnas.202320599; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Bergsma CBJ, 2001, CYTOMETRY, V43, P261, DOI 10.1002/1097-0320(20010401)43:4<261::AID-CYTO1058>3.0.CO;2-D; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Bornfleth H, 1999, BIOPHYS J, V77, P2871, DOI 10.1016/S0006-3495(99)77119-5; Brock R, 1999, P NATL ACAD SCI USA, V96, P10123, DOI 10.1073/pnas.96.18.10123; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chudakov DM, 2003, NAT BIOTECHNOL, V21, P191, DOI 10.1038/nbt778; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1997, GREEN FLUORESCENT PR, V58, P19; Dayel MJ, 1999, BIOPHYS J, V76, P2843, DOI 10.1016/S0006-3495(99)77438-2; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; Denk Winfried, 1995, P445; Dyba M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.163901; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; Ellenberg J, 1998, BIOTECHNIQUES, V25, P838, DOI 10.2144/98255bt01; Gerlich D, 2001, NAT CELL BIOL, V3, P852, DOI 10.1038/ncb0901-852; Gurskaya NG, 2001, FEBS LETT, V507, P16, DOI 10.1016/S0014-5793(01)02930-1; Hammond AT, 2000, TRAFFIC, V1, P935, DOI 10.1034/j.1600-0854.2000.011203.x; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; Labas YA, 2002, P NATL ACAD SCI USA, V99, P4256, DOI 10.1073/pnas.062552299; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Lippincott-Schwartz J, 2000, ANNU REV CELL DEV BI, V16, P557, DOI 10.1146/annurev.cellbio.16.1.557; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Lukyanov KA, 2000, J BIOL CHEM, V275, P25879, DOI 10.1074/jbc.C000338200; Marchant JS, 2001, NAT BIOTECHNOL, V19, P645, DOI 10.1038/90249; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Moraru II, 2002, ANN NY ACAD SCI, V971, P595, DOI 10.1111/j.1749-6632.2002.tb04535.x; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nikonov AV, 2002, J CELL BIOL, V158, P497, DOI 10.1083/jcb.200201116; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Phair RD, 2001, NAT REV MOL CELL BIO, V2, P898, DOI 10.1038/35103000; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Piston DW, 1999, METHOD CELL BIOL, V58, P31; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Presley JF, 2002, NATURE, V417, P187, DOI 10.1038/417187a; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; Schwille P, 1999, BIOPHYS J, V77, P2251, DOI 10.1016/S0006-3495(99)77065-7; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Terskikh A, 2000, SCIENCE, V290, P1585, DOI 10.1126/science.290.5496.1585; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tvarusko W, 1999, P NATL ACAD SCI USA, V96, P7950, DOI 10.1073/pnas.96.14.7950; Van Craenenbroeck  E, 2000, J MOL RECOGNIT, V13, P93, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<93::AID-JMR492>3.0.CO;2-6; van Roessel P, 2002, NAT CELL BIOL, V4, pE15, DOI 10.1038/ncb0102-e15; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	59	738	801	5	267	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					87	91		10.1126/science.1082520	http://dx.doi.org/10.1126/science.1082520			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677058	Green Published			2022-12-28	WOS:000181988900036
J	Nussbaum, RL; Ellis, CE				Nussbaum, RL; Ellis, CE			Genomic medicine: Alzheimer's disease and Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RECESSIVE JUVENILE PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; AMYLOID PRECURSOR PROTEIN; ALPHA-SYNUCLEIN; LEWY BODIES; APOLIPOPROTEIN-E; F-18 DOPA; PRESENILIN-1 MUTATIONS; CLINICAL-DIAGNOSIS; TRANSGENIC MICE		NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Nussbaum, RL (corresponding author), NHGRI, Genet Dis Res Branch, NIH, 49 Convent Dr,Rm 4A72, Bethesda, MD 20892 USA.	rlnuss@nhgri.nih.gov	soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000117] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; ARONSON MK, 1991, ARCH INTERN MED, V151, P989, DOI 10.1001/archinte.1991.00400050129024; Birmingham K, 2002, NAT MED, V8, P199, DOI 10.1038/nm0302-199b; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BURN DJ, 1992, NEUROLOGY, V42, P1894, DOI 10.1212/WNL.42.10.1894; Campion D, 1999, AM J HUM GENET, V65, P664, DOI 10.1086/302553; Chapman PF, 2001, TRENDS GENET, V17, P254, DOI 10.1016/S0168-9525(01)02285-5; Check E, 2002, NATURE, V415, P462, DOI 10.1038/415462a; Citron M, 2002, J NEUROSCI RES, V70, P373, DOI 10.1002/jnr.10393; Clark C. M., 1998, BLUE BOOK PRACT NEUR, V19; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; De Strooper B, 2001, NATURE, V414, P159, DOI 10.1038/35102656; DUVOISIN RC, 1992, BRAIN PATHOL, V2, P309, DOI 10.1111/j.1750-3639.1992.tb00708.x; Duvoisin RC, 1996, ADV NEUROL, V69, P33; Eckman CB, 1997, HUM MOL GENET, V6, P2087, DOI 10.1093/hmg/6.12.2087; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Farrer M, 1999, HUM MOL GENET, V8, P81, DOI 10.1093/hmg/8.1.81; Farrer M, 2001, HUM MOL GENET, V10, P1847, DOI 10.1093/hmg/10.17.1847; Farrer M, 2001, ANN NEUROL, V50, P293, DOI 10.1002/ana.1132; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Galvin JE, 2001, ARCH NEUROL-CHICAGO, V58, P186, DOI 10.1001/archneur.58.2.186; Garrod A, 1928, LANCET, V1, P1055; Gasser T, 1998, NAT GENET, V18, P262, DOI 10.1038/ng0398-262; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Helmer C, 2001, AM J EPIDEMIOL, V154, P642, DOI 10.1093/aje/154.7.642; Helmuth L, 2000, SCIENCE, V289, P375; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Hicks AA, 2002, ANN NEUROL, V52, P549, DOI 10.1002/ana.10324; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Hutton M, 1998, ESSAYS BIOCHEM, V33, P117, DOI 10.1042/bse0330117; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Hy LX, 2000, NEUROLOGY, V55, P198, DOI 10.1212/WNL.55.2.198; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Izumi Y, 2001, NEUROSCI LETT, V300, P125, DOI 10.1016/S0304-3940(01)01557-9; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kosaka K, 1996, CURR OPIN NEUROL, V9, P271, DOI 10.1097/00019052-199608000-00005; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kruger R, 1999, ANN NEUROL, V45, P611, DOI 10.1002/1531-8249(199905)45:5<611::AID-ANA9>3.0.CO;2-X; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Louis ED, 1996, ADV NEUROL, V69, P311; Lucking CB, 1998, LANCET, V352, P1355, DOI 10.1016/S0140-6736(05)60746-5; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; LYNCH T, 1994, NEUROLOGY, V44, P1878, DOI 10.1212/WNL.44.10.1878; Marder K, 1996, NEUROLOGY, V47, P155, DOI 10.1212/WNL.47.1.155; Martin JB, 1999, NEW ENGL J MED, V341, P1407; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; Matsumine H, 1997, AM J HUM GENET, V60, P588; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta ND, 1998, ANN NEUROL, V43, P256, DOI 10.1002/ana.410430217; Meyer MR, 1998, NAT GENET, V19, P321, DOI 10.1038/1206; Mezey E, 1999, MOL PSYCHIATR, V4, P197, DOI 10.1038/sj.mp.4000524; Moechars D, 1996, EMBO J, V15, P1265, DOI 10.1002/j.1460-2075.1996.tb00468.x; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Morgan D, 2001, NATURE, V412, P660, DOI 10.1038/35088102; Morrish PK, 1998, J NEUROL NEUROSUR PS, V64, P314, DOI 10.1136/jnnp.64.3.314; Murayama O, 1999, NEUROSCI LETT, V265, P61, DOI 10.1016/S0304-3940(99)00187-1; Myers AJ, 2001, CURR OPIN NEUROL, V14, P433, DOI 10.1097/00019052-200108000-00002; Pankratz N, 2002, AM J HUM GENET, V71, P124, DOI 10.1086/341282; PAYAMI H, 1994, ANN NEUROL, V36, P659, DOI 10.1002/ana.410360417; Piccini P, 1997, ANN NEUROL, V41, P222, DOI 10.1002/ana.410410213; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Scott WK, 2001, JAMA-J AM MED ASSOC, V286, P2239, DOI 10.1001/jama.286.18.2239; SESHADRI S, 1995, ARCH NEUROL-CHICAGO, V52, P1074, DOI 10.1001/archneur.1995.00540350068018; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; Sveinbjornsdottir S, 2000, NEW ENGL J MED, V343, P1765, DOI 10.1056/NEJM200012143432404; Tan EK, 2000, NEUROLOGY, V54, P1195, DOI 10.1212/WNL.54.5.1195; Tanner CM, 1996, NEUROL CLIN, V14, P317, DOI 10.1016/S0733-8619(05)70259-0; Tanner CM, 1999, JAMA-J AM MED ASSOC, V281, P341, DOI 10.1001/jama.281.4.341; Valente EM, 2001, AM J HUM GENET, V68, P895, DOI 10.1086/319522; van Duijn C. M., 2001, American Journal of Human Genetics, V69, P629, DOI 10.1086/322996; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	84	880	916	1	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1356	1364		10.1056/NEJM2003ra020003	http://dx.doi.org/10.1056/NEJM2003ra020003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672864				2022-12-28	WOS:000181949100008
J	Dunder, K; Lind, L; Zethelius, B; Berglund, L; Lithell, H				Dunder, K; Lind, L; Zethelius, B; Berglund, L; Lithell, H			Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							DEPENDENT DIABETES-MELLITUS; CORONARY-HEART-DISEASE; INSULIN-RESISTANCE; ESSENTIAL-HYPERTENSION; TREATED HYPERTENSION; RISK-FACTORS; FOLLOW-UP; VASODILATION; SENSITIVITY; TOLERANCE	Objective To investigate the impact of an increase in blood glucose on the risk of developing myocardial infarction, with particular emphasis on people taking antihypertensive drugs. Design Prospective population based cohort study. Setting Uppsala, Sweden. Participants 1860 men who had participated in 1970-3 at age 50 in a health survey aimed at identifying risk factors for cardiovascular disease and were re-examined at age 60 and then followed for 17.4 years. Main outcome measure Myocardial infarction after age 60. Results The incidence of myocardial infarction was significantly higher in men treated for hypertension than in those without such treatment (23% v 13.5%, P < 0.0001). Participants who developed,myocardial infarction after the age of 60 (n=253) showed a significantly larger increase in blood glucose between age 50 and 60 than did those without myocardial infarction. In multivariate Cox proportional hazard models increase in blood glucose was an independent risk factor for myocardial infarction (P=0.0001) in men receiving antihypertensive treatment at age 60 (n=291, mainly &beta; blockers and thiazide diuretics) but not in those without such treatment. The impact of increase in blood glucose declined after inclusion of serum proinsulin concentrations at baseline but was still significant. A significant interaction existed between proinsulin concentration (a marker of insulin resistance) at baseline and antihypertensive treatment on increase in blood glucose. Conclusions Increase in blood glucose between the ages of 50 and 60 and baseline proinsulin concentration were important risk factors for myocardial infarction in men receiving antihypertensive treatment, indicating that both an insulin resistant state and the metabolic impact of P blockers and diuretics increase the risk of myocardial infarction.	Uppsala Univ, Dept Publ Hlth & Caring Sci Geriatr, SE-75125 Uppsala, Sweden; Uppsala Univ, Dept Med Sci, Akad Sjukhuset, SE-75185 Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University Hospital	Dunder, K (corresponding author), Uppsala Univ, Dept Publ Hlth & Caring Sci Geriatr, POB 609, SE-75125 Uppsala, Sweden.	kristina.dunder@pubcare.uu.se	Berglund, Lars/AAD-3856-2019; Berglund, Lars/AAA-3188-2019	Berglund, Lars/0000-0002-7437-9047; 				Andersson OK, 1998, BMJ-BRIT MED J, V317, P167, DOI 10.1136/bmj.317.7152.167; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FULLER JH, 1980, LANCET, V1, P1373; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; Haffner SM, 1999, AM J CARDIOL, V84, p11J; HARPER R, 1994, BRIT MED J, V309, P226, DOI 10.1136/bmj.309.6949.226; Hedstrand H, 1975, Ups J Med Sci Suppl, V19, P1; LUNDGREN H, 1988, BRIT MED J, V297, P1512, DOI 10.1136/bmj.297.6662.1512; MCVEIGH GE, 1992, DIABETOLOGIA, V35, P771; MYKKANEN L, 1994, J HYPERTENS, V12, P1425; Mykkanen L, 1999, DIABETOLOGIA, V42, P1060, DOI 10.1007/s001250051271; PHILLIPS DIW, 1994, DIABETIC MED, V11, P286, DOI 10.1111/j.1464-5491.1994.tb00273.x; POLLARE T, 1990, METABOLISM, V39, P167, DOI 10.1016/0026-0495(90)90071-J; POLLARE T, 1989, BRIT MED J, V298, P1152, DOI 10.1136/bmj.298.6681.1152; POLLARE T, 1988, DIABETOLOGIA, V31, P415, DOI 10.1007/BF00271585; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; RAMSAY LE, 1992, EUR HEART J, V13, P68, DOI 10.1093/eurheartj/13.suppl_G.68; REAVEN GM, 1991, DIABETES CARE, V14, P33, DOI 10.2337/diacare.14.4.33; Samuelsson O, 1996, BMJ-BRIT MED J, V313, P660; Sarabi M, 1999, J INTERN MED, V246, P265, DOI 10.1046/j.1365-2796.1999.00542.x; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; SOWERS JR, 1991, AM HEART J, V122, P932, DOI 10.1016/0002-8703(91)90814-X; Williams SB, 1996, J AM COLL CARDIOL, V27, P567, DOI 10.1016/0735-1097(95)00522-6; Williams SB, 1998, CIRCULATION, V97, P1695, DOI 10.1161/01.CIR.97.17.1695	26	89	95	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 29	2003	326	7391					681	684		10.1136/bmj.326.7391.681	http://dx.doi.org/10.1136/bmj.326.7391.681			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663WL	12663403	Green Published, Bronze			2022-12-28	WOS:000182029500014
J	Prchal, JT				Prchal, JT			Delivery on demand - A new era of gene therapy?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HYPOXIA; OXYGEN		Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Prchal, JT (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066333] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL66333-02, R01HL5007-09] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Binley K, 2002, BLOOD, V100, P2406, DOI 10.1182/blood-2002-02-0605; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Zhu H, 2001, SCIENCE, V292, P449, DOI 10.1126/science.1060849	4	11	13	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2003	348	13					1282	1283		10.1056/NEJMcibr035011	http://dx.doi.org/10.1056/NEJMcibr035011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659RG	12660394				2022-12-28	WOS:000181790800012
J	Schwartz, RS				Schwartz, RS			The hypereosinophilic syndrome and the biology of cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		NOWELL PC, 1960, SCIENCE, V132, P1497	1	18	21	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2003	348	13					1199	1200		10.1056/NEJMp030019	http://dx.doi.org/10.1056/NEJMp030019			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659RG	12660383				2022-12-28	WOS:000181790800001
J	Araya, R; Rojas, G; Fritsch, R; Gaete, J; Rojas, M; Simon, G; Peters, TJ				Araya, R; Rojas, G; Fritsch, R; Gaete, J; Rojas, M; Simon, G; Peters, TJ			Treating depression in primary care in low-income women in Santiago, Chile: a randomised controlled trial	LANCET			English	Article							PROBLEM-SOLVING TREATMENT; COMMON MENTAL-DISORDERS; MAJOR DEPRESSION; IMPROVE TREATMENT; PREVALENCE; MANAGEMENT; DISABILITY; TELEPHONE	Background Depression in women is one of the commonest problems encountered in primary care. We aimed to compare the effectiveness of a stepped-care programme with usual care in primary-care management of depression in low-income women in Santiago, Chile. Methods In a randomised controlled trial, in three primary-care clinics in Chile, 240 adult female primary-care patients with major depression were allocated stepped care or usual care. Stepped care was a 3-month, multicomponent intervention led by a non-medical health worker, which included a psychoeducational group intervention, structured and systematic follow-up, and drug treatment for patients with severe depression. Data were analysed on an intention-to-treat basis. The primary outcome measure was the Hamilton depression rating scale (HDRS) administered at baseline and at 3 and 6 months after randomisation. Findings About 90% of randomised patients completed outcome assessments. There was a substantial between-group difference in all outcome measures in favour of the stepped-care programme. The adjusted difference in mean HDRS score between the groups was -8.89 (95% CI -11.15 to -6.76; p<0.0001). At 6-months' follow-up, 70% (60-79) of the stepped-care compared with 30% (21-40) of the usual-care group had recovered (HDRS score <8). Interpretation Despite few resources and marked deprivation, women with major depression responded well to a structured, stepped-care treatment programme, which is being introduced across Chile. Socially disadvantaged patients might gain the most from systematic improvements in treatment of depression.	Univ Bristol, Div Psychiat, Bristol BS6 6UJ, Avon, England; Univ Bristol, Div Primary Hlth Care, Bristol, Avon, England; Univ Chile, Fac Med, Hosp Clin, Santiago 7, Chile; Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA	University of Bristol; University of Bristol; Universidad de Chile; Group Health Cooperative	Araya, R (corresponding author), Univ Bristol, Div Psychiat, Cotham House,Cotham Hill, Bristol BS6 6UJ, Avon, England.		Montero, Rosemarie Fritsch/C-3519-2009; Rojas, Graciela/G-2971-2012; Gaete, Jorge/C-7471-2014	Montero, Rosemarie Fritsch/0000-0001-7694-1470; Gaete, Jorge/0000-0002-6650-6018; Araya, Ricardo/0000-0002-0420-5148; Peters, Tim/0000-0003-2881-4180				Araya R, 2001, BRIT J PSYCHIAT, V178, P228, DOI 10.1192/bjp.178.3.228; Araya R, 2001, BRIT MED J, V322, P79, DOI 10.1136/bmj.322.7278.79; ARAYA R, 2000, THESIS U LONDON; Armitage P., 2002, STAT METHODS MED RES; Chilvers C, 2001, BMJ-BRIT MED J, V322, P772, DOI 10.1136/bmj.322.7289.772; Dowrick C, 2000, BMJ-BRIT MED J, V321, P1450, DOI 10.1136/bmj.321.7274.1450; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Jenkins R, 1997, PSYCHOL MED, V27, P775, DOI 10.1017/S0033291797005308; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Malt UF, 1999, BRIT MED J, V318, P1180; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Mynors-Wallis LM, 2000, BMJ-BRIT MED J, V320, P26, DOI 10.1136/bmj.320.7226.26; MynorsWallis L, 1997, BRIT J PSYCHIAT, V170, P113, DOI 10.1192/bjp.170.2.113; Patel V, 1999, SOC SCI MED, V49, P1461, DOI 10.1016/S0277-9536(99)00208-7; RAMOSBRIEVA JA, 1988, J PSYCHIATR RES, V22, P21, DOI 10.1016/0022-3956(88)90024-6; Schulberg HC, 1997, ARCH FAM MED, V6, P334, DOI 10.1001/archfami.6.4.334; Sheehan D.V., 1994, MINI INT NEUROPSYCHI; Sherbourne CD, 2001, ARCH GEN PSYCHIAT, V58, P696, DOI 10.1001/archpsyc.58.7.696; SIMON GE, 1993, J PSYCHIAT RES, V27, P247, DOI 10.1016/0022-3956(93)90035-Z; SIMON GE, 1995, ARCH GEN PSYCHIAT, V52, P850; Simon GE, 2000, BRIT MED J, V320, P550, DOI 10.1136/bmj.320.7234.550; TYLEE A, 1989, DEPRESSION INTEGRATI, P216; Ustun BT, 1995, MENTAL ILLNESS GEN H; Ward E, 2000, BRIT MED J, V321, P1383, DOI 10.1136/bmj.321.7273.1383; WARE JE, 1993, SF 36 PHYSICAL MENTA; WILLIAMS JW, 1995, J GEN INTERN MED, V10, P7, DOI 10.1007/BF02599568	27	301	308	1	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					995	1000		10.1016/S0140-6736(03)12825-5	http://dx.doi.org/10.1016/S0140-6736(03)12825-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660056				2022-12-28	WOS:000181699700009
J	Thomas, H				Thomas, H			Clinical networks for doctors and managers	BRITISH MEDICAL JOURNAL			English	Article									Royal Surrey Cty Hosp, St Lukes Canc Ctr, Guildford GU2 5XX, Surrey, England; Surrey W Sussex & Hampshire Network, Surrey, England	Royal Surrey County Hospital	Thomas, H (corresponding author), Royal Surrey Cty Hosp, St Lukes Canc Ctr, Guildford GU2 5XX, Surrey, England.	hilary.thomas@surrey.ac.uk						Baxter C, 2002, J HEALTHC MANAG, V47, P376; Edwards N, 2002, BRIT MED J, V324, P63, DOI 10.1136/bmj.324.7329.63	2	9	9	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 22	2003	326	7390					655	655						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649250	Green Published			2022-12-28	WOS:000181870800029
J	Clarke, J				Clarke, J			Physics: Flux qubit completes the hat trick	SCIENCE			English	Editorial Material							MACROSCOPIC QUANTUM STATES; JOSEPHSON-JUNCTION; SUPERPOSITION; OSCILLATIONS		Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Mat Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Clarke, J (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.							Chiorescu I, 2003, SCIENCE, V299, P1869, DOI 10.1126/science.1081045; Einstein A, 1935, PHYS REV, V47, P0777, DOI 10.1103/PhysRev.47.777; Friedman JR, 2000, NATURE, V406, P43, DOI 10.1038/35017505; Leggett A J, 1980, PROG THEOR PHYS SUPP, V69, P80; LEGGETT AJ, 1985, PHYS REV LETT, V54, P857, DOI 10.1103/PhysRevLett.54.857; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Pashkin YA, 2003, NATURE, V421, P823, DOI 10.1038/nature01365; van der Wal CH, 2000, SCIENCE, V290, P773, DOI 10.1126/science.290.5492.773; Vion D, 2002, SCIENCE, V296, P886, DOI 10.1126/science.1069372; Yu Y, 2002, SCIENCE, V296, P889, DOI 10.1126/science.1069452	12	7	9	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 21	2003	299	5614					1850	1851		10.1126/science.1083001	http://dx.doi.org/10.1126/science.1083001			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649468				2022-12-28	WOS:000181669700029
J	Leng, RP; Lin, YP; Ma, WL; Wu, H; Lemmers, B; Chung, S; Parant, JM; Lozano, G; Hakem, R; Benchimol, S				Leng, RP; Lin, YP; Ma, WL; Wu, H; Lemmers, B; Chung, S; Parant, JM; Lozano, G; Hakem, R; Benchimol, S			Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; EMBRYONIC LETHALITY; MONOCLONAL-ANTIBODIES; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; DNA-BINDING; IDENTIFICATION; ACTIVATION; COMPLEX; DOMAIN	The p53 tumor suppressor exerts anti-proliferative effects in response to various types of stress including DNA damage and abnormal proliferative signals. Tight regulation of p53 is essential for maintaining normal cell growth and this occurs primarily through post-translational modifications of p53. Here, we describe Pirh2, a gene regulated by p53 that encodes a RING-H2 domain-containing protein with intrinsic ubiquitin-protein ligase activity. Pirh2 physically interacts with p53 and promotes ubiquitination of p53 independently of Mdm2. Expression of Pirh2 decreases the level of p53 protein and abrogation of endogenous Pirh2 expression increases the level of p53. Furthermore, Pirh2 represses p53 functions including p53-dependent transactivation and growth inhibition. We propose that Pirh2 is involved in the negative regulation of p53 function through physical interaction and ubiquitin-mediated proteolysis. Hence, Pirh2, like Mdm2, participates in an autoregulatory feedback loop that controls p53 function.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Univ Hlth Network, Adv Med Discovery Inst, Toronto, ON M5G 2C1, Canada; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Texas System; UTMD Anderson Cancer Center	Benchimol, S (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	benchimo@uhnres.utoronto.ca		Hakem, Razqallah/0000-0001-5948-7931; Leng, Roger/0000-0001-9652-4703; Benchimol, Samuel/0000-0003-3433-890X				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Beitel LK, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290041; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LUNA RMD, 1995, NATURE, V378, P203; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	42	561	589	2	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2003	112	6					779	791		10.1016/S0092-8674(03)00193-4	http://dx.doi.org/10.1016/S0092-8674(03)00193-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	660DL	12654245	Bronze			2022-12-28	WOS:000181818500006
J	Powell, MD; Vickery, PJ; Reinhold, TA				Powell, MD; Vickery, PJ; Reinhold, TA			Reduced drag coefficient for high wind speeds in tropical cyclones	NATURE			English	Article							SEA-SURFACE ROUGHNESS; HURRICANE; STRESS; DEPENDENCE; MOMENTUM; MODELS; FLUX	The transfer of momentum between the atmosphere and the ocean is described in terms of the variation of wind speed with height and a drag coefficient that increases with sea surface roughness and wind speed. But direct measurements have only been available for weak winds; momentum transfer under extreme wind conditions has therefore been extrapolated from these field measurements. Global Positioning System sondes have been used since 1997 to measure the profiles of the strong winds in the marine boundary layer associated with tropical cyclones. Here we present an analysis of these data, which show a logarithmic increase in mean wind speed with height in the lowest 200 m, maximum wind speed at 500 m and a gradual weakening up to a height of 3 km. By determining surface stress, roughness length and neutral stability drag coefficient, we find that surface momentum flux levels off as the wind speeds increase above hurricane force. This behaviour is contrary to surface flux parameterizations that are currently used in a variety of modelling applications, including hurricane risk assessment and prediction of storm motion, intensity, waves and storm surges.	NOAA, Atlantic Oceanog & Meteorol Lab, Hurricane Res Div, Miami, FL 33149 USA; Univ Western Ontario, London, ON N6A 5B9, Canada; Clemson Univ, Dept Civil Engn, Clemson, SC 29634 USA	National Oceanic Atmospheric Admin (NOAA) - USA; Atlantic Oceanographic & Meteorological Laboratory (AOML); Western University (University of Western Ontario); Clemson University	Powell, MD (corresponding author), NOAA, Atlantic Oceanog & Meteorol Lab, Hurricane Res Div, Miami, FL 33149 USA.	Mark.Powell@noaa.gov	Vickery, Peter/AAH-1799-2019; Vickery, Peter/D-2708-2012; Powell, Mark D/I-4963-2013	Powell, Mark D/0000-0002-4890-8945				Alamaro M, 2002, 25 C HURR TROP MET S, P667; AMOROCHO J, 1980, J GEOPHYS RES-OCEANS, V85, P433, DOI 10.1029/JC085iC01p00433; Anctil F, 1996, J PHYS OCEANOGR, V26, P1344, DOI 10.1175/1520-0485(1996)026<1344:AMFOOS>2.0.CO;2; BENDER MA, 1993, J GEOPHYS RES-ATMOS, V98, P23245, DOI 10.1029/93JD02370; BLAIN CA, 1994, J GEOPHYS RES-OCEANS, V99, P18467, DOI 10.1029/94JC01348; Bradbury W., 1994, METEOROL APPL, V1, P365; CHARNOCK H, 1955, Q J ROY METEOR SOC, V81, P634, DOI 10.1002/qj.49708135022; DONELAN MA, 1993, J PHYS OCEANOGR, V23, P2143, DOI 10.1175/1520-0485(1993)023<2143:OTDOSS>2.0.CO;2; DONELAN MA, 1990, SURFACE WAVES FLUXES; Donnelly WJ, 1999, J GEOPHYS RES-OCEANS, V104, P11485, DOI 10.1029/1998JC900030; GARRATT JR, 1977, MON WEATHER REV, V104, P418; GEERNAERT GL, 1986, J GEOPHYS RES-OCEANS, V91, P7667, DOI 10.1029/JC091iC06p07667; Haurwitz B, 1935, MON WEA REV, V63, P45, DOI [10.1175/1520-0493(1935)63<45:THOTCA>2.0.CO;2, DOI 10.1175/1520-0493(1935)63<45:THOTCA>2.0.CO;2]; HAWKINS HF, 1968, MON WEATHER REV, V96, P617, DOI 10.1175/1520-0493(1968)096<0617:HH>2.0.CO;2; Hock TF, 1999, B AM METEOROL SOC, V80, P407, DOI 10.1175/1520-0477(1999)080<0407:TNGD>2.0.CO;2; Houston B, 2000, J MORAL EDUC, V29, P339, DOI 10.1080/03057240050137382; JANSSEN PAEM, 1989, J PHYS OCEANOGR, V19, P745, DOI 10.1175/1520-0485(1989)019<0745:WISATD>2.0.CO;2; Jelesnianski C., 1992, SLOSH SEA LAKE OVERL; JORGENSEN DP, 1984, J ATMOS SCI, V41, P1287, DOI 10.1175/1520-0469(1984)041<1287:MACSCO>2.0.CO;2; KAPLAN J, 1993, MON WEATHER REV, V121, P3, DOI 10.1175/1520-0493(1993)121<0003:TLSILS>2.0.CO;2; Katsaros KB, 2002, J OCEANOGR, V58, P137, DOI 10.1023/A:1015884903180; KEPERT JD, 1998, AIR SEA FLUXES MOMEN, P363; KRAYER WR, 1992, B AM METEOROL SOC, V73, P613, DOI 10.1175/1520-0477(1992)073<0613:GFATHW>2.0.CO;2; Krugermeyer L., 1978, Boundary-Layer Meteorology, V14, P403, DOI 10.1007/BF00121049; LARGE WG, 1981, J PHYS OCEANOGR, V11, P324, DOI 10.1175/1520-0485(1981)011<0324:OOMFMI>2.0.CO;2; LARGE WG, 1995, J PHYS OCEANOGR, V25, P2959, DOI 10.1175/1520-0485(1995)025<2959:AFSWDO>2.0.CO;2; LUNDQUIST J, 1999, LIMN OC NAV NEXT CEN; Miller BI, 1964, MON WEATHER REV, V92, P389, DOI [2.3.CO;2, DOI 10.1175/1520-0493(1964)0922.3.CO;2]; NEWELL AC, 1992, PHYS REV LETT, V69, P1149, DOI 10.1103/PhysRevLett.69.1149; PALMEN E, 1957, J METEOROL, V14, P150, DOI 10.1175/1520-0469(1957)014<0150:BOAMAE>2.0.CO;2; Paulson C.A., 1970, J APPL METEOROL, V9, P857, DOI [10.1175/1520-0450(1970)0092.0.co;2, DOI 10.1175/1520-0450(1970)009<0857:TMROWS>2.0.CO;2, 10.1175/1520-0450(1970)009, DOI 10.1175/1520-0450(1970)009]; POWELL MD, 1991, WEATHER FORECAST, V6, P379, DOI 10.1175/1520-0434(1991)006<0379:TLOHHI>2.0.CO;2; POWELL MD, 1980, MON WEATHER REV, V108, P757, DOI 10.1175/1520-0493(1980)108<0757:EODMBL>2.0.CO;2; Powell MD, 1999, WIND ENGINEERING INTO THE 21ST CENTURY, VOLS 1-3, P307; POWELL MD, 1990, J WIND ENG IND AEROD, V36, P381; SHAW N, 1922, GEOPHYS MEM, V2, P213; SHAY LK, 1999, 99003 RSMAS U MIAM; SMITH SD, 1988, J GEOPHYS RES-OCEANS, V93, P15467, DOI 10.1029/JC093iC12p15467; SMITH SD, 1992, BOUND-LAY METEOROL, V60, P109, DOI 10.1007/BF00122064; TANNENHILL IR, 1944, HURRICANES; Taylor PK, 2001, J PHYS OCEANOGR, V31, P572, DOI 10.1175/1520-0485(2001)031<0572:TDOSSR>2.0.CO;2; Tolman HL, 2002, WEATHER FORECAST, V17, P311, DOI 10.1175/1520-0434(2002)017<0311:DAIOWG>2.0.CO;2; Vickery PJ, 2000, J STRUCT ENG-ASCE, V126, P1203, DOI 10.1061/(ASCE)0733-9445(2000)126:10(1203); Vickery PJ, 2000, J STRUCT ENG, V126, P545, DOI 10.1061/(ASCE)0733-9445(2000)126:4(545); VICKERY PJ, UNPUB J STRUCT ENG; WILLOUGHBY HE, 1990, J ATMOS SCI, V47, P265, DOI 10.1175/1520-0469(1990)047<0265:GBITC>2.0.CO;2; Wright CW, 2001, J PHYS OCEANOGR, V31, P2472, DOI 10.1175/1520-0485(2001)031<2472:HDWSSV>2.0.CO;2; WROE DR, 2003, IN PRESS MON WEATH R, V131	48	1001	1081	4	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 20	2003	422	6929					279	283		10.1038/nature01481	http://dx.doi.org/10.1038/nature01481			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646913				2022-12-28	WOS:000181637300031
J	Colonna, M				Colonna, M			Inhibitory receptors: friend or foe?	LANCET			English	Editorial Material							CLASS-I MOLECULES; CELLS; EXPRESSION		Washington Univ, Sch Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Colonna, M (corresponding author), Washington Univ, Sch Med, St Louis, MO 63110 USA.	mcolonna@pathbox.wustl.edu		Colonna, Marco/0000-0001-5222-4987				Bertone S, 1999, EUR J IMMUNOL, V29, P23, DOI 10.1002/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO;2-Y; Chapman TL, 1999, IMMUNITY, V11, P603, DOI 10.1016/S1074-7613(00)80135-1; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; Held W, 1996, EUR J IMMUNOL, V26, P2286, DOI 10.1002/eji.1830261003; Lodolce J, 2002, MOL IMMUNOL, V39, P537, DOI 10.1016/S0161-5890(02)00211-0; OlssonAlheim MY, 1997, J IMMUNOL, V159, P3189; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Salcedo M, 1997, J IMMUNOL, V158, P3174; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861	10	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 29	2003	361	9363					1067	1068		10.1016/S0140-6736(03)12900-5	http://dx.doi.org/10.1016/S0140-6736(03)12900-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672305				2022-12-28	WOS:000181865200003
J	Andrews, L; Wang, XF				Andrews, L; Wang, XF			The infrared spectrum of Al2H6 in solid hydrogen	SCIENCE			English	Article							DENSITY-FUNCTIONAL THEORY; IR MATRIX-ISOLATION; AB-INITIO; ALUMINUM-HYDRIDE; VIBRATIONAL FREQUENCIES; MOLECULES; GALLIUM; DIALANE; ALH3; DIGALLANE(6)	Although many volatile binary boron hydride compounds are known, binary aluminum hydride chemistry is limited to the polymeric (AlH3)(n) solid. The reaction of laser-ablated aluminum atoms and pure H-2 during codeposition at 3.5 kelvin, followed by ultraviolet irradiation and annealing to 6.5 kelvin, allows dinnerization of the intermediate AlH3 photolysis product to form Al2H6. The Al2H6 molecule is identified by seven new infrared absorptions that are accurately predicted by quantum chemical calculations for dibridged Al2H6, a molecule that is isostructural with diborane.	Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA	University of Virginia	Andrews, L (corresponding author), Univ Virginia, Dept Chem, POB 400319, Charlottesville, VA 22904 USA.							ALMENNINGEN A, 1972, ACTA CHEM SCAND, V26, P2315, DOI 10.3891/acta.chem.scand.26-2315; Andrews L, 2002, CHEM REV, V102, P885, DOI 10.1021/cr0000729; BARONE V, 1994, J PHYS CHEM-US, V98, P13185, DOI 10.1021/j100101a016; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; BOCK CW, 1991, J PHYS CHEM-US, V95, P2339, DOI 10.1021/j100159a041; Breisacher P, 1964, J AM CHEM SOC, V86, P5053; BROWER FM, 1976, J AM CHEM SOC, V98, P2450, DOI 10.1021/ja00425a011; CHERTIHIN GV, 1993, J PHYS CHEM-US, V97, P10295, DOI 10.1021/j100142a007; Cotton F. A., 1999, ADV INORGANIC CHEM; DOWNS AJ, 1994, CHEM SOC REV, V23, P175, DOI 10.1039/cs9942300175; DOWNS AJ, 1989, J AM CHEM SOC, V111, P1936, DOI 10.1021/ja00187a090; DUKE BJ, 1991, J AM CHEM SOC, V113, P2884, DOI 10.1021/ja00008a015; Frisch M.J., 2016, GAUSSIAN 16 REVISION; FRISCH MJ, 1984, J CHEM PHYS, V80, P3265, DOI 10.1063/1.447079; GRADY AS, 1991, SPECTROCHIM ACTA A, V47, P47, DOI 10.1016/0584-8539(91)80177-K; HARA M, 1991, J PHYS CHEM-US, V95, P6, DOI 10.1021/j100154a003; Huber K.P., 1979, MOL SPECTRA MOL STRU, DOI DOI 10.1007/978-1-4757-0961-2; KOHDOH H, 1993, SURF SCI, V287, P74; KURTH FA, 1993, J CHEM SOC CHEM COMM, P1302, DOI 10.1039/c39930001302; LAMMERTSMA K, 1990, J PHYS CHEM-US, V94, P2806, DOI 10.1021/j100370a016; LAMMERTSMA K, 1989, INORG CHEM, V28, P313, DOI 10.1021/ic00301a032; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; LIANG CX, 1989, CHEM PHYS LETT, V159, P393, DOI 10.1016/0009-2614(89)87506-2; Lipscomb W. N., 1963, BORON HYDRIDES; MAGERS DH, 1994, INT J QUANTUM CHEM Q, V28, P579; MATZEK WE, 1975, CHEM ABSTR 45418, V83; MATZEK WE, 1975, Patent No. 3883644; PRICE WC, 1948, J CHEM PHYS, V16, P894, DOI 10.1063/1.1747028; PRICE WC, 1947, J CHEM PHYS, V15, P614, DOI 10.1063/1.1746611; PULHAM CR, 1991, J AM CHEM SOC, V113, P5149, DOI 10.1021/ja00014a003; PULLUMBI P, 1994, CHEM PHYS, V185, P25, DOI 10.1016/0301-0104(94)00111-1; PULLUMBI P, 1994, CHEM PHYS, V185, P13, DOI 10.1016/0301-0104(94)00110-3; PULLUMBI P, 1994, J CHEM PHYS, V101, P3610, DOI 10.1063/1.467546; Rao BK, 2001, PHYS REV LETT, V86, P692, DOI 10.1103/PhysRevLett.86.692; Schulz S, 2001, COORDIN CHEM REV, V215, P1, DOI 10.1016/S0010-8545(00)00401-X; Scott AP, 1996, J PHYS CHEM-US, V100, P16502, DOI 10.1021/jp960976r; SHEN MZ, 1992, J CHEM PHYS, V96, P2868, DOI 10.1063/1.461983; SIEGEL B, 1960, J AM CHEM SOC, V82, P1535, DOI 10.1021/ja01492a004; Stock A., 1933, HYDRIDES BORON SILIC; Tam S, 2000, J CHEM PHYS, V113, P9067, DOI 10.1063/1.1312268; TURLEY JW, 1969, INORG CHEM, V8, P18, DOI 10.1021/ic50071a005; WANG X, UNPUB; Wang XF, 2003, J PHYS CHEM A, V107, P570, DOI 10.1021/jp026930h; WELTNER W, 1995, J PHYS CHEM-US, V99, P6277, DOI 10.1021/j100017a005; Willis BG, 1998, J PHYS CHEM A, V102, P2613, DOI 10.1021/jp9800012	45	124	129	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2003	299	5615					2049	2052		10.1126/science.1082456	http://dx.doi.org/10.1126/science.1082456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663923				2022-12-28	WOS:000181834200049
J	Frame, JD; Steyn, MD				Frame, JD; Steyn, MD			Catastrophic burns in children: prediction of mortality	LANCET			English	Editorial Material									Springfield Hosp, Chelmsford CM1 7GU, Essex, England		Frame, JD (corresponding author), Springfield Hosp, Chelmsford CM1 7GU, Essex, England.		Steyn, Michael P/G-5963-2010					Blakeney P, 1998, J TRAUMA, V44, P625, DOI 10.1097/00005373-199804000-00011; *BRIT ASS PLAST SU, 2001, NAT BURN CAR REV; Rashid A, 2001, BURNS, V27, P723, DOI 10.1016/S0305-4179(01)00034-1; Slator R, 1996, EUR J PLAST SURG, V19, P207	4	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					980	981		10.1016/S0140-6736(03)12840-1	http://dx.doi.org/10.1016/S0140-6736(03)12840-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660051				2022-12-28	WOS:000181699700004
J	Osterhaus, A; Fouchier, R				Osterhaus, A; Fouchier, R			Human metapneumovirus in the community	LANCET			English	Editorial Material							CHILDREN		Erasmus MC, Dept Virol, NL-3015 GE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Osterhaus, A (corresponding author), Erasmus MC, Dept Virol, NL-3015 GE Rotterdam, Netherlands.		Fouchier, Ron A/A-1911-2014	Fouchier, Ron A/0000-0001-8095-2869				Boivin G, 2002, J INFECT DIS, V186, P1330, DOI 10.1086/344319; Jartti T, 2002, LANCET, V360, P1393, DOI 10.1016/S0140-6736(02)11391-2; Nissen MD, 2002, MED J AUSTRALIA, V176, P188, DOI 10.5694/j.1326-5377.2002.tb04354.x; Pelletier G, 2002, EMERG INFECT DIS, V8, P976, DOI 10.3201/eid0809.020238; Peret TCT, 2002, J INFECT DIS, V185, P1660, DOI 10.1086/340518; Stockton J, 2002, EMERG INFECT DIS, V8, P897, DOI 10.3201/eid0809.020084; van den Hoogen BG, 2002, VIROLOGY, V295, P119, DOI 10.1006/viro.2001.1355; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098	8	90	98	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 15	2003	361	9361					890	891		10.1016/S0140-6736(03)12785-7	http://dx.doi.org/10.1016/S0140-6736(03)12785-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648965				2022-12-28	WOS:000181741600004
J	Williams, BF; French, JK; White, HD				Williams, BF; French, JK; White, HD		HERO-2 Consent Substudy Investigat	Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIALS; COMPETENCE	Background Anxiety, fear, pain, and treatment with morphine might compromise the ability of patients to comprehend information about, and give informed consent for, participation in clinical trials. We aimed to assess whether patients with acute myocardial infarction could understand written and verbal information and whether they were competent to give autonomous informed consent to participate in a clinical trial. Methods We prospectively studied 399 patients with acute myocardial infarction in 16 hospitals in New Zealand and Australia who were eligible for participation in the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. We assessed readability of patient information sheets, patients' educational status, their views of the consent process, comprehension of verbal and written information, and competence to give consent. Findings The patient information sheet needed a year 13 (age 18) educational level for comprehension, although only 75 of 345 patients (22%) had been educated beyond secondary school. Only 63 of 346 (18%) read the patient. information sheet before giving or refusing consent to participate. Patients who gave consent were more likely to report good or partial comprehension of the information provided than were those who refused consent (272 [89%] vs 14 [70%], respectively; p=0.009). In an assessment of competence to make an autonomous decision, 75 of 145 (52%) were ranked at the lowest grade and 26 (18%) were not competent to consent. Interpretation Although the consent process for HERO-2 met regulatory requirements for clinical trials, it was inappropriate for the needs of most patients. The patients' comprehension of the information provided and their competence to autonomously give consent was less than optimum.	Green Lane Hosp, Cardiovasc Res Unit, Auckland 1030, New Zealand		Williams, BF (corresponding author), Green Lane Hosp, Cardiovasc Res Unit, CCU Res Suite,Private Bag 92189, Auckland 1030, New Zealand.	barbaraw@adhb.govt.nz						Agard A, 2001, HEART, V86, P632, DOI 10.1136/heart.86.6.632; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1986, HIST THEORY INFORM C; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Colaizzi PF., 1978, EXISTENTIAL PHENOMEN, P48; DeLuca S A, 1995, J Cardiovasc Nurs, V9, P54; *EUR PARL, 2001, OFFICIAL J L, V121, P34; Flesch R., 1974, ART READABLE WRITING; Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532; HOLMBERG S, 1990, AM J CARDIOL, V65, P401; Kucia AM, 2000, AM HEART J, V140, P94, DOI 10.1067/mhj.2000.106625; KUTNER JS, 1991, CHEST, V100, P1404, DOI 10.1378/chest.100.5.1404; Marson DC, 1996, NEUROLOGY, V46, P666, DOI 10.1212/WNL.46.3.666; Mason SA, 2000, LANCET, V356, P2045, DOI 10.1016/S0140-6736(00)03401-2; OCKENE IS, 1991, CLIN RES, V39, P13; Schaeffer MH, 1996, AM J MED, V100, P261, DOI 10.1016/S0002-9343(97)89483-1; Seedhouse D, 1998, ETHICS HEART HLTH CA; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; US Dept of Health and Human Services (HHS) Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM), ICH HARM TRIP GUID G; VEHEGGEN FW, 1998, PATIENT EDUC COUNS, V35, P111; White HD, 2001, LANCET, V358, P1855; Williams BF, 1997, NEW ZEAL MED J, V110, P298; Williams C, 1992, INTRO NEW TREATMENTS, P49; WILLIAMS CJ, 1994, EUR J CANCER, V30A, P907, DOI 10.1016/0959-8049(94)90111-2; *WORLD MED ASS DEC, 2000, P 52 WORLD MED ASS G; 1949, NUREMBERG CODE TRIAL, P181	28	97	98	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	2003	361	9361					918	922		10.1016/S0140-6736(03)12773-0	http://dx.doi.org/10.1016/S0140-6736(03)12773-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648970				2022-12-28	WOS:000181741600009
J	Cui, HM; Cruz-Correa, M; Giardiello, FM; Hutcheon, DF; Kafonek, DR; Brandenburg, S; Wu, YQ; He, XB; Powe, NR; Feinberg, AP				Cui, HM; Cruz-Correa, M; Giardiello, FM; Hutcheon, DF; Kafonek, DR; Brandenburg, S; Wu, YQ; He, XB; Powe, NR; Feinberg, AP			Loss of IGF2 imprinting: A potential marker of colorectal cancer risk	SCIENCE			English	Article							GROWTH-FACTOR-II; CELL-LINE; STIMULATION	Loss of imprinting (LOI), an epigenetic alteration affecting the insulin-like growth factor II gene (IGF2), is found in normal colonic mucosa of about 30% of colorectal cancer (CRC) patients, but it is found in only 10% of healthy individuals. In a pilot study to investigate the utility of LOI as a marker of CRC risk, we evaluated 172 patients at a colonoscopy clinic. The adjusted odds ratio for LOI in lymphocytes was 5.15 for patients with a positive family history [95% confidence interval (95% CI), 1.70 to 16.96; probability P = 0.002], 3.46 for patients with adenomas (95% CI, 1.14 to 11.37; P = 0.026), and 21.7 for patients with CRC (95% CI, 3.48 to 153.6; P = 0.0005). LOI can be assayed with a DNA-based blood test, and it may be a valuable predictive marker of an individual's risk for CRC.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Feinberg, AP (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 1064 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Feinberg, Andrew/AAY-7666-2020; Cui, Hengmi/A-2598-2008	Feinberg, Andrew/0000-0002-8364-1991	NATIONAL CANCER INSTITUTE [K07CA092445, R01CA065145] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA65145, K07 CA092445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2002, CANCER RES, V62, P6442; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 2002, METABOLIC MOL BASES, pCH18; GELATO MC, 1990, J CLIN ENDOCR METAB, V71, P1168, DOI 10.1210/jcem-71-5-1168; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Khoury MJ, 2003, NEW ENGL J MED, V348, P50, DOI 10.1056/NEJMra013182; LAHM H, 1992, BRIT J CANCER, V65, P341, DOI 10.1038/bjc.1992.69; LAMONERIE T, 1995, INT J CANCER, V61, P587, DOI 10.1002/ijc.2910610425; Markey Kristina, 2002, Curr Gastroenterol Rep, V4, P404, DOI 10.1007/s11894-002-0011-5; Percesepe A, 2001, J CLIN ONCOL, V19, P3944, DOI 10.1200/JCO.2001.19.19.3944; POMMIER GJ, 1992, CANCER RES, V52, P3182; Ravenel JD, 2001, JNCI-J NATL CANCER I, V93, P1698, DOI 10.1093/jnci/93.22.1698; Sakatani T, 2001, BIOCHEM BIOPH RES CO, V283, P1124, DOI 10.1006/bbrc.2001.4916; Samowitz WS, 2001, GASTROENTEROLOGY, V121, P830, DOI 10.1053/gast.2001.27996; YEE D, 1988, CANCER RES, V48, P6691	17	580	627	2	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1753	1755		10.1126/science.1080902	http://dx.doi.org/10.1126/science.1080902			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637750				2022-12-28	WOS:000181519500052
J	Lack, G; Fox, D; Northstone, K; Golding, J				Lack, G; Fox, D; Northstone, K; Golding, J		Avon Longitudinal Study Parents Ch	Factors associated with the development of peanut allergy in childhood	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATOPIC-DERMATITIS; FOOD HYPERSENSITIVITY; CHILDREN; SENSITIZATION; SKIN; FORMULAS; INFANTS; PROTEIN; ANTIGEN; SOY	Background: The prevalence of peanut allergy appears to have increased in recent decades. Other than a family history of peanut allergy and the presence of atopy, there are no known risk factors. Methods: We used data from the Avon Longitudinal Study of Parents and Children, a geographically defined cohort study of 13,971 preschool children, to identify those with a convincing history of peanut allergy and the subgroup that reacted to a double-blind peanut challenge. We first prospectively collected data on the whole cohort and then collected detailed information retrospectively by interview from the parents of children with peanut reactions and of children from two groups of controls (a random sample from the cohort and a group of children whose mothers had a history of eczema and who had had eczema themselves in the first six months of life). Results: Forty-nine children had a history of peanut allergy; peanut allergy was confirmed by peanut challenge in 23 of 36 children tested. There was no evidence of prenatal sensitization from the maternal diet, and peanut-specific IgE was not detectable in the cord blood. Peanut allergy was independently associated with intake of soy milk or soy formula (odds ratio, 2.6; 95 percent confidence interval, 1.3 to 5.2), rash over joints and skin creases (odds ratio, 2.6; 95 percent confidence interval, 1.4 to 5.0), and oozing, crusted rash (odds ratio, 5.2; 95 percent confidence interval, 2.7 to 10.2). Analysis of interview data showed a significant independent relation of peanut allergy with the use of skin preparations containing peanut oil (odds ratio, 6.8; 95 percent confidence interval, 1.4 to 32.9). Conclusions: Sensitization to peanut protein may occur in children through the application of peanut oil to inflamed skin. The association with soy protein could arise from cross-sensitization through common epitopes. Confirmation of these risk factors in future studies could lead to new strategies to prevent sensitization in infants who are at risk for subsequent peanut allergy.	Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Paediat Allergy & Immunol, London W2 1NY, England; Univ Bristol, Unit Paediat & Perinatal Epidemiol, Bristol, Avon, England	Imperial College London; University of Bristol	Lack, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Paediat Allergy & Immunol, Ground Floor,Salton House,Praed St, London W2 1NY, England.		Northstone, Kate/A-8165-2011	Northstone, Kate/0000-0002-0602-1983; Golding, Jean/0000-0003-2826-3307; Lack, Gideon/0000-0001-7350-4021				ASSEM ESK, 1990, BRIT MED J, V300, P1377, DOI 10.1136/bmj.300.6736.1377; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BURKS AW, 1989, ALLERGY PROC, V10, P265, DOI 10.2500/108854189778960045; CARSWELL F, 1986, LANCET, V2, P13, DOI 10.1016/S0140-6736(86)92560-2; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; DEKRUYFF RH, 1992, J IMMUNOL, V149, P3468; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1996, BRIT MED J, V313, P1046; Legendre C, 1997, NEW ENGL J MED, V337, P822, DOI 10.1056/NEJM199709183371204; Lever LR, 1996, BRIT MED J, V313, P299, DOI 10.1136/bmj.313.7052.299; Moneret-Vautrin D A, 1994, Pediatr Allergy Immunol, V5, P184, DOI 10.1111/j.1399-3038.1994.tb00236.x; Moneret-Vautrin DA, 1998, CLIN EXP ALLERGY, V28, P1113, DOI 10.1046/j.1365-2222.1998.00370.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4, DOI 10.1136/adc.77.1.4; Olszewski A, 1998, CLIN EXP ALLERGY, V28, P850, DOI 10.1046/j.1365-2222.1998.00325.x; RENZ H, 1993, J IMMUNOL, V151, P7206; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65, DOI 10.1164/ajrccm.149.1.8111600; Sampson HA, 1998, J ALLERGY CLIN IMMUN, V101, pS240; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2000, ALLERGY, V55, P515, DOI 10.1034/j.1398-9995.2000.00119.x; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; *U BRIST, 2003, ALSPAC; van Reijsen FC, 1998, J ALLERGY CLIN IMMUN, V101, P207, DOI 10.1016/S0091-6749(98)70410-5; ZIMMERMAN B, 1989, J ALLERGY CLIN IMMUN, V83, P764, DOI 10.1016/0091-6749(89)90012-2	29	648	661	2	68	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					977	985		10.1056/NEJMoa013536	http://dx.doi.org/10.1056/NEJMoa013536			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653YT	12637607				2022-12-28	WOS:000181465200002
J	Badro, J; Fiquet, G; Guyot, F; Rueff, JP; Struzhkin, VV; Vanko, G; Monaco, G				Badro, J; Fiquet, G; Guyot, F; Rueff, JP; Struzhkin, VV; Vanko, G; Monaco, G			Iron partitioning in Earth's mantle: Toward a deep lower mantle discontinuity	SCIENCE			English	Article							X-RAY-EMISSION; SILICATE PEROVSKITE; HIGH-PRESSURE; TRANSITION; SPIN; TEMPERATURE; (MG,FE)SIO3-PEROVSKITE; MAGNESIOWUSTITE; ABSORPTION; STABILITY	We measured the spin state of iron in ferropericlase (Mg0.83Fe0.17)O at high pressure and found a high-spin to low-spin transition occurring in the 60- to 70-gigapascal pressure range, corresponding to depths of 2000 kilometers in Earth's lower mantle. This transition implies that the partition coefficient of iron between ferropericlase and magnesium silicate perovskite, the two main constituents of the lower mantle, may increase by several orders of magnitude, depleting the perovskite phase of its iron. The lower mantle may then be composed of two different layers. The upper layer would consist of a phase mixture with about equal partitioning of iron between magnesium silicate perovskite and ferropericlase, whereas the lower layer would consist of almost iron-free perovskite and iron-rich ferropericlase. This strati. cation is likely to have profound implications for the transport properties of Earth's lowermost mantle.	Univ Paris 07, Univ Paris 06, Lab Mineral Cristallog Paris, CNRS,IPGP, F-75252 Paris 05, France; Univ Paris 06, Lab Chim Phys Mat & Rayonnement, UMR 7614, F-75231 Paris 05, France; Carnegie Inst Sci, Geophys Lab, Washington, DC 20015 USA; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Sorbonne Universite; Carnegie Institution for Science; European Synchrotron Radiation Facility (ESRF)	Badro, J (corresponding author), Univ Paris 07, Univ Paris 06, Lab Mineral Cristallog Paris, CNRS,IPGP, 4 Pl Jussieu, F-75252 Paris 05, France.		GUYOT, François J/C-3824-2016; Monaco, Giulio/AAW-4387-2020; Fiquet, Guillaume M/H-1219-2011; Monaco, Giulio/AAU-2947-2021; Badro, James/A-6003-2011; Vankó, György/B-8176-2012; Fiquet, Guillaume/O-7077-2019; Fiquet, Guillaume/M-6934-2014; Rueff, Jean-Pascal/D-8938-2016; Struzhkin, Viktor V/J-9847-2013	GUYOT, François J/0000-0003-4622-2218; Monaco, Giulio/0000-0003-2497-6422; Badro, James/0000-0001-9337-4789; Vankó, György/0000-0002-3095-6551; Fiquet, Guillaume/0000-0001-8961-3281; Rueff, Jean-Pascal/0000-0003-3594-918X; Struzhkin, Viktor V/0000-0002-3468-0548				Andrault D, 2001, J GEOPHYS RES-SOL EA, V106, P2079, DOI 10.1029/2000JB900362; Badro J, 1999, PHYS REV LETT, V83, P4101, DOI 10.1103/PhysRevLett.83.4101; BRODHOLT J, UNPUB; Cohen RE, 1997, SCIENCE, V275, P654, DOI 10.1126/science.275.5300.654; CORRIEU V, 1995, GEOPHYS J INT, V120, P516, DOI 10.1111/j.1365-246X.1995.tb01835.x; DEGROOT FMF, 1995, PHYS REV B, V51, P1045, DOI 10.1103/PhysRevB.51.1045; Dubrovinsky L, 2001, EUR J MINERAL, V13, P857, DOI 10.1127/0935-1221/2001/0013/0857; DURHAM WB, 1977, J GEOPHYS RES, V82, P5737, DOI 10.1029/JB082i036p05737; DURHAM WB, 1979, PHYS EARTH PLANET IN, V19, P263, DOI 10.1016/0031-9201(79)90027-X; Fiquet G, 2000, GEOPHYS RES LETT, V27, P21, DOI 10.1029/1999GL008397; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; Kesson SE, 1998, NATURE, V393, P252, DOI 10.1038/30466; KNITTLE E, 1987, SCIENCE, V235, P668, DOI 10.1126/science.235.4789.668; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; Malavergne V, 1997, EARTH PLANET SC LETT, V146, P499, DOI 10.1016/S0012-821X(96)00234-8; PENG G, 1994, APPL PHYS LETT, V65, P2527, DOI 10.1063/1.112625; Rueff JP, 1999, PHYS REV LETT, V82, P3284, DOI 10.1103/PhysRevLett.82.3284; Rueff JP, 1999, PHYS REV B, V60, P14510, DOI 10.1103/PhysRevB.60.14510; Serghiou G, 1998, SCIENCE, V280, P2093, DOI 10.1126/science.280.5372.2093; SETTE F, 1995, PHYS REV LETT, V75, P850, DOI 10.1103/PhysRevLett.75.850; SHERMAN DM, 1991, J GEOPHYS RES-SOLID, V96, P14299, DOI 10.1029/91JB01202; Shim SH, 2001, SCIENCE, V293, P2437, DOI 10.1126/science.1061235; VANKEKEN PE, 1995, J GEOPHYS RES-SOL EA, V100, P15233, DOI 10.1029/95JB00923; Wang X, 1997, PHYS REV B, V56, P4553, DOI 10.1103/PhysRevB.56.4553; WEERTMAN J, 1975, ANNU REV EARTH PL SC, V3, P293, DOI 10.1146/annurev.ea.03.050175.001453; ZERR A, 1993, SCIENCE, V262, P553, DOI 10.1126/science.262.5133.553	26	392	409	4	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 2	2003	300	5620					789	791		10.1126/science.1081311	http://dx.doi.org/10.1126/science.1081311			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12677070				2022-12-28	WOS:000182579800048
J	Palmer, MR; Pearson, PN				Palmer, MR; Pearson, PN			A 23,000-year record of surface water pH and PCO2 in the western equatorial Pacific Ocean	SCIENCE			English	Article							CARBON-CYCLE; EL-NINO; LAST DEGLACIATION; TROPICAL PACIFIC; CO2; ICE; DISTRIBUTIONS; ENSO; VARIABILITY	The oceans play a major role in de. ning atmospheric carbon dioxide (CO2) levels, and although the geographical distribution of CO2 uptake and release in the modern ocean is understood, little is known about past distributions. Boron isotope studies of planktonic foraminifera from the western equatorial Pacific show that this area was a strong source of CO2 to the atmosphere between approximately 13,800 and 15,600 years ago. This observation is most compatible with increased frequency of La Nina conditions during this interval. Hence, increased upwelling in the eastern equatorial Pacific may have played an important role in the rise in atmospheric CO2 during the last deglaciation.	Southampton Oceanog Ctr, Sch Ocean & Earth Sci, Southampton SO14 3ZH, Hants, England; Cardiff Univ, Dept Earth Sci, Cardiff CF10 3YE, S Glam, Wales	NERC National Oceanography Centre; University of Southampton; Cardiff University	Palmer, MR (corresponding author), Southampton Oceanog Ctr, Sch Ocean & Earth Sci, European Way, Southampton SO14 3ZH, Hants, England.	pmrp@soc.soton.ac.uk	Palmer, Martin R/I-6765-2012; Pearson, Paul N/B-2276-2009	Palmer, Martin R/0000-0003-1660-3714; Pearson, Paul N/0000-0003-4628-9818				Beaufort L, 2001, SCIENCE, V293, P2440, DOI 10.1126/science.293.5539.2440; BERGER WH, 1978, OCEANOL ACTA, V1, P203; BERGER WH, 1982, MAR GEOL, V45, P93, DOI 10.1016/0025-3227(82)90182-7; BLANCHON P, 1995, GEOLOGY, V23, P4, DOI 10.1130/0091-7613(1995)023<0004:RDDTLD>2.3.CO;2; BROECKER WS, 1982, PROG OCEANOGR, V11, P151, DOI 10.1016/0079-6611(82)90007-6; Brown SJ, 1996, PALEOCEANOGRAPHY, V11, P543, DOI 10.1029/96PA01491; Damste JSS, 2002, GEOCHIM COSMOCHIM AC, V66, P2737; Dekens PS, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000200; Farrell JW, 1989, PALEOCEANOGRAPHY, V4, P447, DOI 10.1029/PA004i004p00447; FEELY RA, 1995, DEEP-SEA RES PT II, V42, P365, DOI 10.1016/0967-0645(95)00027-N; Feely RA, 2002, DEEP-SEA RES PT II, V49, P2443, DOI 10.1016/S0967-0645(02)00044-9; Grootes PM, 1997, J GEOPHYS RES-OCEANS, V102, P26455, DOI 10.1029/97JC00880; Indermuhle A, 1999, NATURE, V398, P121, DOI 10.1038/18158; INOUE HY, 1992, TELLUS B, V44, P1, DOI 10.1034/j.1600-0889.1992.00001.x; Koutavas A, 2002, SCIENCE, V297, P226, DOI 10.1126/science.1072376; Mackey DJ, 1997, DEEP-SEA RES PT II, V44, P1951, DOI 10.1016/S0967-0645(97)00033-7; Marcantonio F, 2001, EARTH PLANET SC LETT, V184, P505, DOI 10.1016/S0012-821X(00)00342-3; Palmer MR, 1998, SCIENCE, V282, P1468, DOI 10.1126/science.282.5393.1468; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; Radenac MH, 1996, DEEP-SEA RES PT II, V43, P725, DOI 10.1016/0967-0645(96)00025-2; Sanyal A, 1996, PALEOCEANOGRAPHY, V11, P513, DOI 10.1029/96PA01858; Sigman DM, 2000, NATURE, V407, P859, DOI 10.1038/35038000; Smith HJ, 1999, NATURE, V400, P248, DOI 10.1038/22291; Spero HJ, 2002, SCIENCE, V296, P522, DOI 10.1126/science.1069401; Stott L, 2002, SCIENCE, V297, P222, DOI 10.1126/science.1071627; Stuiver M, 1998, RADIOCARBON, V40, P1127, DOI 10.1017/S0033822200019172; Takahashi T, 2002, DEEP-SEA RES PT II, V49, P1601, DOI 10.1016/S0967-0645(02)00003-6; Visser K, 2003, NATURE, V421, P152, DOI 10.1038/nature01297; Zeebe R. E., 2001, CO2 SEAWATER EQUILIB	29	114	131	5	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 18	2003	300	5618					480	482		10.1126/science.1080796	http://dx.doi.org/10.1126/science.1080796			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12663815				2022-12-28	WOS:000182295900038
J	DeCoursey, TE; Morgan, D; Cherny, VV				DeCoursey, TE; Morgan, D; Cherny, VV			The voltage dependence of NADPH oxidase reveals why phagocytes need proton channels	NATURE			English	Article							HYDROGEN-ION CURRENTS; HUMAN-NEUTROPHILS; ELECTRON CURRENTS; HUMAN EOSINOPHILS; SNAIL NEURONS; HUMAN BLOOD; H+ CHANNEL; ACTIVATION; PH; MEMBRANE	The enzyme NADPH oxidase in phagocytes is important in the body's defence against microbes: it produces superoxide anions (O-2(-), precursors to bactericidal reactive oxygen species(1)). Electrons move from intracellular NADPH, across a chain comprising FAD ( flavin adenine dinucleotide) and two haems, to reduce extracellular O-2 to O-2(-). NADPH oxidase is electrogenic(2), generating electron current (I-e) that is measurable under voltage-clamp conditions(3,4). Here we report the complete current-voltage relationship of NADPH oxidase, the first such measurement of a plasma membrane electron transporter. We find that Ie is voltage-independent from -100 mV to >0 mV, but is steeply inhibited by further depolarization, and is abolished at about +190 mV. It was proposed that H+ efflux(2) mediated by voltage-gated proton channels(5,6) compensates I-e, because Zn2+ and Cd2+ inhibit both H+ currents(7-9) and O-2(-) production(10). Here we show that COS-7 cells transfected with four NADPH oxidase components(11), but lacking H+ channels(12), produce O-2(-) in the presence of Zn2+ concentrations that inhibit O-2(-) production in neutrophils and eosinophils. Zn2+ does not inhibit NADPH oxidase directly, but through effects on H+ channels. H+ channels optimize NADPH oxidase function by preventing membrane depolarization to inhibitory voltages.	Rush Presbyterian St Lukes Med Ctr, Dept Mol Biophys & Physiol, Chicago, IL 60612 USA	Rush University	DeCoursey, TE (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Mol Biophys & Physiol, 1750 W Harrison, Chicago, IL 60612 USA.	tdecours@rush.edu	DeCoursey, Thomas/A-6820-2009	DeCoursey, Thomas/0000-0002-4263-180X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061437] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL061437] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Banfi B, 1999, J EXP MED, V190, P183, DOI 10.1084/jem.190.2.183; Biberstine-Kinkade KJ, 2001, J BIOL CHEM, V276, P31105, DOI 10.1074/jbc.M103327200; BURTON K, 1953, BIOCHEM J, V54, P86, DOI 10.1042/bj0540086; BYERLY L, 1984, J PHYSIOL-LONDON, V351, P199, DOI 10.1113/jphysiol.1984.sp015241; Cherny VV, 2001, J PHYSIOL-LONDON, V535, P783, DOI 10.1111/j.1469-7793.2001.00783.x; Cherny VV, 1999, J GEN PHYSIOL, V114, P819, DOI 10.1085/jgp.114.6.819; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DeCoursey TE, 2000, P NATL ACAD SCI USA, V97, P6885, DOI 10.1073/pnas.100047297; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DeCoursey TE, 2001, J PHYSIOL-LONDON, V535, P767, DOI 10.1111/j.1469-7793.2001.00767.x; Gordienko DV, 1996, J PHYSIOL-LONDON, V496, P299, DOI 10.1113/jphysiol.1996.sp021686; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1988, BIOCHEM J, V255, P285; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; Jankowski A, 1999, J BIOL CHEM, V274, P26098, DOI 10.1074/jbc.274.37.26098; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; Koshkin V, 1997, BBA-BIOENERGETICS, V1319, P139, DOI 10.1016/S0005-2728(96)00154-5; Lauger P., 1991, ELECTROGENIC ION PUM; Lowenthal A, 1999, J BIOL CHEM, V274, P21603, DOI 10.1074/jbc.274.31.21603; MAHAUTSMITH MP, 1989, J EXP BIOL, V145, P455; MARTIN MA, 1988, J IMMUNOL, V140, P3928; Morgan D, 2002, J GEN PHYSIOL, V119, P571, DOI 10.1085/jgp.20018544; MUIRWOOD P, 1974, FEBS LETT, V44, P22, DOI 10.1016/0014-5793(74)80297-8; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Schrenzel J, 1998, NATURE, V392, P734, DOI 10.1038/33725; Tare M, 1998, J PHYSIOL-LONDON, V506, P303, DOI 10.1111/j.1469-7793.1998.303bw.x; THOMAS RC, 1982, NATURE, V299, P826, DOI 10.1038/299826a0	30	247	251	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2003	422	6931					531	534		10.1038/nature01523	http://dx.doi.org/10.1038/nature01523			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673252				2022-12-28	WOS:000181965400040
J	Steinman, MA; Gonzales, R; Linder, JA; Landefeld, CS				Steinman, MA; Gonzales, R; Linder, JA; Landefeld, CS			Changing use of antibiotics in community-based outpatient practice, 1991-1999	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; RESPIRATORY-TRACT INFECTIONS; ACUTE OTITIS-MEDIA; ANTIMICROBIAL RESISTANCE; JUDICIOUS USE; PHARMACEUTICAL-INDUSTRY; UNITED-STATES; PRIMARY-CARE; INCREASING PREVALENCE; PHYSICIANS BEHAVIOR	Background: Judicious use of antibiotics can slow the spread of antimicrobial resistance. However, overall patterns of antibiotic use among ambulatory patients are not well understood. Objective: To study patterns of outpatient antibiotic use in the United States, focusing on broad-spectrum antibiotics. Design: Cross-sectional survey in three 2-year periods (1991-1992, 1994-1995, and 1998-1999). Setting: The National Ambulatory Medical Care Survey, a nationally representative sample of community-based outpatient visits. Patients: Patients visiting community-based outpatient clinics. Measurements: Rates of overall antibiotic use and use of broad-spectrum antibiotics (azithromycin and clarithromycin, quinolones, amoxicillin-clavulanate, and second- and third-generation cephalosporins). All comparisons were made between the first study period (1991-1992) and the final study period (1998-1999). Results: Between 1991-1992 and 1998-1999, antibiotics were used less frequently to treat acute respiratory tract infections, such as the common cold and pharyngitis. However, use of broad-spectrum agents increased from 24% to 48% of antibiotic prescriptions in adults (P < 0.001) and from 23% to 40% in children (P < 0.001). Use of broad-spectrum antibiotics increased across many conditions, increasing two- to threefold as a percentage of total antibiotic use for a variety of diagnoses in both adults and children. By 1998-1999, 22% of adult and 14% of pediatric prescriptions for broad-spectrum antibiotics were for the common cold, unspecified upper respiratory tract infections, and acute bronchitis, conditions that are primarily viral. Conclusions: Antibiotic use in ambulatory patients is decreasing in the United States. However, physicians are increasingly turning to expensive, broad-spectrum agents, even when there is little clinical rationale for their use.	Univ Calif San Francisco, Vet Adm Med Ctr, Div Geriatr, San Francisco, CA 94121 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Steinman, MA (corresponding author), Univ Calif San Francisco, Vet Adm Med Ctr, Div Geriatr, Box 18-G,4150 Clement St, San Francisco, CA 94121 USA.	mstein@itsa.ucsf.edu	Linder, Jeffrey/AAF-3424-2021	Linder, Jeffrey/0000-0003-2217-184X	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE011001] Funding Source: NIH RePORTER; BHP HRSA HHS [5T32PE11001-12] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); BHP HRSA HHS		Appelbaum PC, 2000, CLIN INFECT DIS, V31, pS29, DOI 10.1086/314057; Austin DJ, 1999, P NATL ACAD SCI USA, V96, P1152, DOI 10.1073/pnas.96.3.1152; Avorn J, 2000, ANN INTERN MED, V133, P128, DOI 10.7326/0003-4819-133-2-200007180-00012; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; Bell RA, 1999, J GEN INTERN MED, V14, P651, DOI 10.1046/j.1525-1497.1999.01049.x; Bloom BS, 2001, BMJ-BRIT MED J, V323, P647, DOI 10.1136/bmj.323.7314.647; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P800; Chen DK, 1999, NEW ENGL J MED, V341, P233, DOI 10.1056/NEJM199907223410403; Chew LD, 2000, J GEN INTERN MED, V15, P478, DOI 10.1046/j.1525-1497.2000.08014.x; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; ClavoSanchez AJ, 1997, CLIN INFECT DIS, V24, P1052, DOI 10.1086/513628; Doern GV, 2001, CLIN INFECT DIS, V33, pS187, DOI 10.1086/321847; Donskey CJ, 2000, NEW ENGL J MED, V343, P1925, DOI 10.1056/NEJM200012283432604; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P1, DOI 10.1097/00006454-199901000-00002; Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; Gonzales R, 1999, J GEN INTERN MED, V14, P151, DOI 10.1046/j.1525-1497.1999.00306.x; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; Gupta K, 2001, ANN INTERN MED, V135, P41, DOI 10.7326/0003-4819-135-1-200107030-00012; Gupta K, 2001, CLIN INFECT DIS, V33, P89, DOI 10.1086/320880; Hamm RM, 1996, J FAM PRACTICE, V43, P56; HEMMINKI E, 1975, SOC SCI MED, V9, P111, DOI 10.1016/0037-7856(75)90103-1; Huang ES, 2002, ARCH INTERN MED, V162, P41, DOI 10.1001/archinte.162.1.41; Hyde TB, 2001, JAMA-J AM MED ASSOC, V286, P1857, DOI 10.1001/jama.286.15.1857; Ioannidis JPA, 2001, J ANTIMICROB CHEMOTH, V48, P677, DOI 10.1093/jac/48.5.677; Jain A, 1999, BRIT MED J, V318, P1596, DOI 10.1136/bmj.318.7198.1596; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; Linder JA, 2001, JAMA-J AM MED ASSOC, V286, P1181, DOI 10.1001/jama.286.10.1181; Low DE, 2001, CLIN INFECT DIS, V33, pS206, DOI 10.1086/321849; LURIE N, 1990, J GEN INTERN MED, V5, P240, DOI 10.1007/BF02600542; Marshall WF, 1999, MAYO CLIN PROC, V74, P187, DOI 10.4065/74.2.187; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; *MED EC, 1999, DRUG TOP RED BOOK; *NAT CTR HLTH STAT, 2001, PUBL US MICR FIL DOC; *NAT CTR HLTH STAT, 1994, PUBL US DAT TAP DOC; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; O'Brien KL, 1998, PEDIATRICS, V101, P178; O'Brien KL, 1998, PEDIATRICS, V101, P174; Piccirillo JF, 2001, JAMA-J AM MED ASSOC, V286, P1849, DOI 10.1001/jama.286.15.1849; *PRACT MAN INF, 1998, INT CLASS DIS; Rosenstein N, 1998, PEDIATRICS, V101, P181; SABLE CA, 1993, GERIATRICS, V48, P41; Sargent J, 2001, Eff Clin Pract, V4, P136; Schwartz B, 1998, PEDIATRICS, V101, P171; SENSAKOVIC JW, 1995, MED CLIN N AM, V79, P695, DOI 10.1016/S0025-7125(16)30033-5; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Snow V, 2001, ANN INTERN MED, V134, P518, DOI 10.7326/0003-4819-134-6-200103200-00020; Snow V, 2001, ANN INTERN MED, V134, P506, DOI 10.7326/0003-4819-134-6-200103200-00018; Snow V, 2001, ANN INTERN MED, V134, P495, DOI 10.7326/0003-4819-134-6-200103200-00016; Snow V, 2001, ANN INTERN MED, V134, P487, DOI 10.7326/0003-4819-134-6-200103200-00014; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; *STAT CORP, 1999, OV SURV EST STAT US, P321; Steinman MA, 2003, JAMA-J AM MED ASSOC, V289, P719, DOI 10.1001/jama.289.6.719; Steinman MA, 2001, AM J MED, V110, P551, DOI 10.1016/S0002-9343(01)00660-X; Takata GS, 2001, PEDIATRICS, V108, P239, DOI 10.1542/peds.108.2.239; Walker S, 2000, CAN MED ASSOC J, V163, P273; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603; Wright AJ, 1999, MAYO CLIN PROC, V74, P290, DOI 10.4065/74.3.290; 2000, RESIDENT POPULATION	63	235	244	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					525	533		10.7326/0003-4819-138-7-200304010-00008	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667022				2022-12-28	WOS:000181872100001
J	Degeling, P; Maxwell, S; Kennedy, J; Coyle, B				Degeling, P; Maxwell, S; Kennedy, J; Coyle, B			Medicine, management, and modernisation: a "danse macabre"?	BRITISH MEDICAL JOURNAL			English	Article							GUIDELINES		Univ Durham, Wolfson Res Inst, Ctr Clin Management Dev, Stockton On Tees TS17 6BH, England	Durham University	Degeling, P (corresponding author), Univ Durham, Wolfson Res Inst, Ctr Clin Management Dev, Queens Campus, Stockton On Tees TS17 6BH, England.	p.j.degeling@durham.ac.uk						Degeling P, 2000, Nurs Inq, V7, P120, DOI 10.1046/j.1440-1800.2000.00056.x; Degeling P, 1999, Aust Health Rev, V22, P172; DEGELING P, 1998, PROFESSIONAL SUBCULT; DEGELING P, 2002, PROFESSIONAL SUBCULT, P48; *DEP HLTH, 2002, SHIFT BAL POW; *DEP HLTH, 2002, REF NHS FIN FLOWS IN; *DEP HLTH, 1998, 1ST CLASS SERV QUAL; *DEP HLTH, 1997, NEW NHS MOD DEP NAT; Edwards N, 2003, BRIT MED J, V326, P116, DOI 10.1136/bmj.326.7381.116; GRAY JAM, 1997, EVIDENCE BASED HEALT; HAM C, 1999, HLTH POLICY BRITAIN; HARRISON A, 2000, NHS FACING FUTURE; Harrison S, 1992, JUST MANAGING POWER; Holt P., 1996, CLIN PRACTICE GUIDEL; Leape L L, 1990, QRB Qual Rev Bull, V16, P42; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MCDONALD P, 2001, BMJ; POLLITT C, 1996, MANAGERIALISM PUBLIC; *PUBL HLTH DEV UN, 1999, PERF ASS FRAM QUAL P; RIVLIN A, 1971, OBSTACLES SOCIAL PRO; Swage T., 2000, CLIN GOVERNANCE HLTH; THOMSON R, 1995, BMJ-BRIT MED J, V311, P237, DOI 10.1136/bmj.311.6999.237	22	127	127	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 22	2003	326	7390					649	652		10.1136/bmj.326.7390.649	http://dx.doi.org/10.1136/bmj.326.7390.649			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649244	Green Accepted, Green Published			2022-12-28	WOS:000181870800024
J	Hantschel, O; Nagar, B; Guettler, S; Kretzschmar, J; Dorey, K; Kuriyan, J; Superti-Furga, G				Hantschel, O; Nagar, B; Guettler, S; Kretzschmar, J; Dorey, K; Kuriyan, J; Superti-Furga, G			A myristoyl/phosphotyrosine switch regulates c-Abl	CELL			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; SRC-FAMILY; SH3 DOMAINS; CRYSTAL-STRUCTURES; PROTEIN-KINASES; F-ACTIN; B-CELL; PHOSPHORYLATION; HCK	The c-Abl tyrosine kinase is inhibited by mechanisms that are poorly understood. Disruption of these mechanisms in the Bcr-Abl oncoprotein leads to several forms of human leukemia. We found that like Src kinases, c-Abl 1b is activated by phosphotyrosine ligands. Ligand-activated c-Abl is particularly sensitive to the anti-cancer drug STI-571/Gleevec/imatinib (STI-571). The SH2 domain-phosphorylated tail interaction in Src kinases is functionally replaced in c-Abl by an intramolecular engagement of the N-terminal myristoyl modification with the kinase domain. Functional studies coupled with structural analysis define a myristoyl/phosphotyrosine switch in c-Abl that regulates docking and accessibility of the SH2 domain. This mechanism offers an explanation for the observed cellular activation of c-Abl by tyrosine-phosphorylated proteins, the intracellular mobility of c-Abl, and it provides new insights into the mechanism of action of STI-571.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Dept Chem, Berkeley, CA 94720 USA; Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Cellzome AG, D-69117 Heidelberg, Germany; European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany	Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; GlaxoSmithKline; Cellzome GmbH; European Molecular Biology Laboratory (EMBL)	Superti-Furga, G (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Dept Chem, Berkeley, CA 94720 USA.	kuriyan@uclink.berkeley.edu; superti@embl-heidelberg.de	Hantschel, Oliver/M-7016-2019; Hantschel, Oliver D/H-4705-2013; Superti-Furga, Giulio/AAE-5681-2019; Superti-Furga, Giulio/F-4755-2015; Nagar, Bhushan/C-1297-2010	Hantschel, Oliver/0000-0001-8569-8169; Hantschel, Oliver D/0000-0001-8569-8169; Superti-Furga, Giulio/0000-0002-0570-1768; Guettler, Sebastian/0000-0002-3135-1546; Dorey, Karel/0000-0003-0846-5286				Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brasher BB, 2001, ONCOGENE, V20, P7744, DOI 10.1038/sj.onc.1204978; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; Dorey K, 2001, ONCOGENE, V20, P8075, DOI 10.1038/sj.onc.1205017; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; Hardin JD, 1996, ONCOGENE, V12, P2669; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 2002, CURR OPIN STRUC BIOL, V12, P735, DOI 10.1016/S0959-440X(02)00383-4; Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; LIU XQ, 1993, ONCOGENE, V8, P1119; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nagar B, 2002, CANCER RES, V62, P4236; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Sawyers CL, 2002, CANCER CELL, V1, P13, DOI 10.1016/S1535-6108(02)00022-3; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Smith JM, 2002, FRONT BIOSCI, V7, pD31; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Taniguchi H, 1999, BIOPHYS CHEM, V82, P129, DOI 10.1016/S0301-4622(99)00112-X; Taylor SS, 1997, CURR OPIN CHEM BIOL, V1, P219, DOI 10.1016/S1367-5931(97)80013-0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Yu HH, 2001, ONCOGENE, V20, P3995, DOI 10.1038/sj.onc.1204524; Zhou Songyang, 1995, Nature (London), V373, P536; ZHU GC, 1994, ONCOGENE, V9, P1379; Zipfel PA, 2000, J IMMUNOL, V165, P6872, DOI 10.4049/jimmunol.165.12.6872	63	323	333	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2003	112	6					845	857		10.1016/S0092-8674(03)00191-0	http://dx.doi.org/10.1016/S0092-8674(03)00191-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	660DL	12654250	Bronze			2022-12-28	WOS:000181818500011
J	Farooqi, IS; Keogh, JM; Yeo, GSH; Lank, EJ; Cheetham, T; O'Rahilly, S				Farooqi, IS; Keogh, JM; Yeo, GSH; Lank, EJ; Cheetham, T; O'Rahilly, S			Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGENITAL LEPTIN DEFICIENCY; BODY-WEIGHT REGULATION; EARLY-ONSET OBESITY; MORBID-OBESITY; ENERGY-EXPENDITURE; HUMANS; MICE; DYSFUNCTION; PROTEIN	Background: Melanocortin 4 receptor (MC4R) deficiency is the commonest monogenic form of obesity. However, the clinical spectrum and mode of inheritance have not been defined, pathophysiological mechanisms leading to obesity are poorly understood, and there is little information regarding genotype-phenotype correlations. Methods: We determined the nucleotide sequence of the MC4R gene in 500 probands with severe childhood obesity. Family studies were undertaken to examine cosegregation of identified mutations with obesity. Subjects with MC4R deficiency underwent metabolic and endocrine evaluation; the results were correlated with the signaling properties of mutant receptors. Results: Twenty-nine probands (5.8 percent) had mutations in MC4R; 23 were heterozygous, and 6 were homozygous. Mutation carriers had severe obesity, increased lean mass, increased linear growth, hyperphagia, and severe hyperinsulinemia; homozygotes were more severely affected than heterozygotes. Subjects with mutations retaining residual signaling capacity had a less severe phenotype. Conclusions: Mutations in MC4R result in a distinct obesity syndrome that is inherited in a codominant manner. Mutations leading to complete loss of function are associated with a more severe phenotype. The correlation between the signaling properties of these mutant receptors and energy intake emphasizes the key role of this receptor in the control of eating behavior in humans.	Addenbrookes Hosp, Cambridge Inst Med Res, Univ Dept Med, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Cambridge Inst Med Res, Genet Obes Collaborat Grp, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Cambridge Inst Med Res, Univ Dept Clin Biochem, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	O'Rahilly, S (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Univ Dept Med, Hills Rd, Cambridge CB2 2QQ, England.		O'Rahilly, Stephen/ABF-6509-2020; Farooqi, Ismaa Sadaf/AAZ-3046-2020	O'Rahilly, Stephen/0000-0003-2199-4449; Yeo, Giles See How/0000-0001-8823-3615; Farooqi, Sadaf/0000-0001-7609-3504	Wellcome Trust [068086] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; Butler AA, 2001, NAT NEUROSCI, V4, P605, DOI 10.1038/88423; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; CUNNINGHAM JJ, 1991, AM J CLIN NUTR, V54, P963, DOI 10.1093/ajcn/54.6.963; DeLany JP, 2002, AM J CLIN NUTR, V75, P705, DOI 10.1093/ajcn/75.4.705; Fan T, 2000, ENDOCRINOLOGY, V141, P3072; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Jacobson P, 2002, J CLIN ENDOCR METAB, V87, P4442, DOI 10.1210/jc.2002-020568; Katsanis N, 2001, HUM MOL GENET, V10, P2293, DOI 10.1093/hmg/10.20.2293; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Ohshiro Y, 1999, ANN HUM GENET, V63, P483, DOI 10.1017/S0003480099007782; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PERSANI L, 1993, J ENDOCRINOL INVEST, V16, P511, DOI 10.1007/BF03348894; Ste Marie L, 2000, P NATL ACAD SCI USA, V97, P12339, DOI 10.1073/pnas.220409497; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Van der Ploeg LHT, 2002, P NATL ACAD SCI USA, V99, P11381, DOI 10.1073/pnas.172378699; WAHNER HW, 1994, J BONE MINER RES, V9, P951; WILLIAMS DRR, 1995, DIABETIC MED, V12, P30, DOI 10.1111/j.1464-5491.1995.tb02058.x; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; Yeo GSH, 2000, QJM-INT J MED, V93, P7, DOI 10.1093/qjmed/93.1.7; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	35	1120	1166	1	65	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1085	1095		10.1056/NEJMoa022050	http://dx.doi.org/10.1056/NEJMoa022050			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646665				2022-12-28	WOS:000181628400004
J	Cross, AS; Opal, SM				Cross, AS; Opal, SM			A new paradigm for the treatment of sepsis: Is it time to consider combination therapy?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							SEPTIC SHOCK; PROTEIN-C; EFFICACY; TRIAL; IMMUNOTHERAPY; SAFETY	Despite the advances in supportive care and the availability of potent antimicrobial agents, mortality from sepsis, a leading cause of death in intensive care units, has not improved. Over the last decade, clinical trials with numerous adjunctive therapies, including antiendotoxin antibodies and inhibitors of the inflammatory response, have yielded disappointing results. Recently, treatment with recombinant human activated protein C reduced mortality 6% compared with controls. Given the likelihood that many processes in the complex pathophysiology of sepsis are simultneously activated, it is unlikely that therapy directed at any one of them, as has been done in the past, will dramatically improve survival. Rather, a combination of therapies directed at many arms of the septic process, much like the strategy used for cancer and HIV infection, is required. Given the likelihood that sepsis represents an excessive innate immune response to microbial products, vigorous attempts must be made to develop rapid assays that reflect the level of innate immune activation. Such assays could be used to identify patients who would benefit from therapy and to monitor their response so that overtreatment does not completely abrogate host defense mechanisms and render these patients susceptible to fatal infection. It is now time to test a new therapeutic paradigm based on an improved understanding of the pathophysiology of the septic process and the recognition that we may have reached the limits of adjunctive monotherapy.	Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Med, Baltimore, MD 21201 USA; Mem Hosp Rhode Isl, Pawtucket, RI USA	University System of Maryland; University of Maryland Baltimore	Cross, AS (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Med, 685 W Baltimore St,HSF 480, Baltimore, MD 21201 USA.	across@umm.edu			NIAID NIH HHS [R01 AI142181-01] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CROSS AS, 1993, J INFECT DIS, V167, P112, DOI 10.1093/infdis/167.1.112; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; Gendrel D, 1996, J PEDIATR-US, V128, P570, DOI 10.1016/S0022-3476(96)70374-8; Glauser MP, 2000, CRIT CARE MED, V28, pS4, DOI 10.1097/00003246-200009001-00002; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Levin M, 2000, LANCET, V356, P961, DOI 10.1016/S0140-6736(00)02712-4; Marshall J, 2000, CRIT CARE MED, V28, pA46; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Natanson C, 1998, CRIT CARE MED, V26, P1927, DOI 10.1097/00003246-199812000-00001; Opal SM, 1996, J INFECT DIS, V173, P1415, DOI 10.1093/infdis/173.6.1415; Opal SM, 1999, INFECT DIS CLIN N AM, V13, P285, DOI 10.1016/S0891-5520(05)70075-1; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869	20	47	49	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					502	505		10.7326/0003-4819-138-6-200303180-00016	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00016			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639085				2022-12-28	WOS:000181562400009
J	Brotman, DJ; Taege, A; Ruggieri, P; Kinkel, PR				Brotman, DJ; Taege, A; Ruggieri, P; Kinkel, PR			Acute ophthalmoplegia	LANCET			English	Article							RHINOCEREBRAL MUCORMYCOSIS		Cleveland Clin Fdn, Dept Gen Internal Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Infect Dis, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Radiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Brotman, DJ (corresponding author), Cleveland Clin Fdn, Dept Gen Internal Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Ruggieri, Pietro/AAR-5544-2021	Ruggieri, Pietro/0000-0001-9617-9882				Anand A, 1996, ARCH INTERN MED, V156, P2262, DOI 10.1001/archinte.1996.00440180126017; Keane JR, 1996, ARCH NEUROL-CHICAGO, V53, P967, DOI 10.1001/archneur.1996.00550100033012; NUSSBAUM ES, 1994, SURG NEUROL, V41, P152, DOI 10.1016/0090-3019(94)90114-7; Warwar Ronald E., 1998, Orbit, V17, P237, DOI 10.1076/orbi.17.4.237.2742	4	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 15	2003	361	9361					930	930		10.1016/S0140-6736(03)12776-6	http://dx.doi.org/10.1016/S0140-6736(03)12776-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648973				2022-12-28	WOS:000181741600012
J	Fahey, T; Montgomery, AA; Barnes, J; Protheroe, J				Fahey, T; Montgomery, AA; Barnes, J; Protheroe, J			Quality of care for elderly residents in nursing homes and elderly people living at home: controlled observational study	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; GENERAL-PRACTITIONERS; MYOCARDIAL-INFARCTION; HEALTH-CARE; PROJECT	Objectives To assess the quality of care given to elderly people and compare the care given to residents in nursing homes with those living in their own homes. Design Controlled observational study. Setting Primary care, Bristol. Subjects Elderly individuals (aged greater than or equal to 65 years) registered with three general practices, of whom 172 were residents in nursing homes (cases) and 526 lived at home (matched controls). Main outcome measures The quality of clinical care given to patients was measured against explicit standards. Quality indicators were derived from national sources and agreed with participating general practitioners. Results The overall standard of care was inadequate when judged against the quality indicators, irrespective of where patients lived. The overall prescribing of beneficial drugs for some conditions was deficient-for example, only 38% (11/29) (95% confidence interval 20% to 58%) of patients were prescribed beta blockers after myocardial infarction. The proportion of patients with heart disease or diabetes who had had their blood pressure measured in the past two years (heart disease) or past year (diabetes) was lower among those living in nursing homes: for heart disease, 74% (17/23) v 96% (122/127) (adjusted odds ratio 0.18, 0.04 to 0.75); for diabetes, 62% (8/13) v 96% (50/52) (adjusted odds ratio 0.05, 0.01 to 0.38). In terms of potentially harmful prescribing, significantly more patients in nursing homes were prescribed neuroleptic medication (28% (49/172) v 11% (56/526) (3.82, 2.37 to 6.17)) and laxatives (39% (67/172) v 16% (85/526) (2.79, 1.79 to 4.36)). Nursing home residents were less likely to have the appropriate diagnostic Read code linked to their prescribed neuroleptic drug (0.22, 0.07 to 0.71). Conclusions The quality of medical care that elderly patients receive in one UK city, particularly those in nursing homes, is inadequate. We suggest that better coordinated care for these patients would avoid the problems of overuse of unnecessary or harmful drugs, underuse of beneficial drugs, and poor monitoring of chronic disease.	Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland; Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England; Bradgate Surg, Bristol BS10 6SP, Avon, England; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 6PL, Lancs, England	University of Dundee; University of Bristol; University of Manchester	Fahey, T (corresponding author), Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland.		Fahey, Tom/C-9367-2012	Fahey, Tom/0000-0002-5896-5783; Montgomery, Alan/0000-0003-0450-1606				[Anonymous], 2001, IMPROVING QUALITY LO; Benbow SJ, 1997, BRIT MED J, V314, P1868, DOI 10.1136/bmj.314.7098.1868; Black D, 1997, BRIT MED J, V315, P441, DOI 10.1136/bmj.315.7106.441; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; *COMM SAF MED, 2000, THIOR RESTR IND NEW; Department of Health, 2001, NAT SERV FRAM OLD PE; *EXP GROUP HEALTHC, 2002, ADD LIF YEARS; Feder G, 1999, BRIT MED J, V318, P1522, DOI 10.1136/bmj.318.7197.1522; Gurvich T, 2000, AM FAM PHYSICIAN, V61, P1437; Gurwitz JH, 2002, ARCH INTERN MED, V162, P1670, DOI 10.1001/archinte.162.15.1670; Jolly K, 1999, BMJ-BRIT MED J, V318, P706; Kavanagh S, 1998, BRIT MED J, V317, P322, DOI 10.1136/bmj.317.7154.322; Kavanagh S, 1999, BRIT MED J, V318, P666, DOI 10.1136/bmj.318.7184.666; Kotseva K, 2001, LANCET, V357, P995, DOI 10.1016/S0140-6736(00)04235-5; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; MARSHALL MN, 2001, QUALITY INDICATORS G; McGrath AM, 1996, BRIT MED J, V312, P611; *NAT PRESCR CTR, 1999, MEREC B, P10; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Rochon PA, 2002, BMJ-BRIT MED J, V324, P1231, DOI 10.1136/bmj.324.7348.1231; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; Rochon PA, 1999, JAMA-J AM MED ASSOC, V282, P113, DOI 10.1001/jama.282.2.113; Roland M, 1999, BRIT J GEN PRACT, V49, P140; Wagner C, 2001, QUAL HEALTH CARE, V10, P211, DOI 10.1136/qhc.0100211..	25	131	132	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 15	2003	326	7389					580	583		10.1136/bmj.326.7389.580	http://dx.doi.org/10.1136/bmj.326.7389.580			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657ZF	12637404	Green Published, Bronze			2022-12-28	WOS:000181696600020
J	Brown, JKM				Brown, JKM			Little else but parasites	SCIENCE			English	Editorial Material							PLANT-DISEASE; RESISTANCE; ARABIDOPSIS; DISPERSAL; HOST		John Innes Ctr Plant Sci Res, Dept Dis & Stress Biol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Brown, JKM (corresponding author), John Innes Ctr Plant Sci Res, Dept Dis & Stress Biol, Norwich NR4 7UH, Norfolk, England.							Brown JKM, 2002, CURR OPIN PLANT BIOL, V5, P339, DOI 10.1016/S1369-5266(02)00270-4; Brown JKM, 2002, SCIENCE, V297, P537, DOI 10.1126/science.1072678; CRUTE IR, 1997, GENE GENE RELATIONSH; Damgaard C, 1999, J THEOR BIOL, V201, P1, DOI 10.1006/jtbi.1999.1007; Ellis J, 1997, ANNU REV PHYTOPATHOL, V35, P271, DOI 10.1146/annurev.phyto.35.1.271; Hill AVS, 2001, ANNU REV GENOM HUM G, V2, P373, DOI 10.1146/annurev.genom.2.1.373; Holub EB, 2001, NAT REV GENET, V2, P516, DOI 10.1038/35080508; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; Thrall PH, 2002, PLANT PATHOL, V51, P169, DOI 10.1046/j.1365-3059.2002.00683.x; Thrall PH, 2003, SCIENCE, V299, P1735, DOI 10.1126/science.1080070; van't Slot KAE, 2002, CRIT REV PLANT SCI, V21, P229, DOI 10.1080/0735-260291044223	11	18	20	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1680	1681		10.1126/science.1083033	http://dx.doi.org/10.1126/science.1083033			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637729				2022-12-28	WOS:000181519500028
J	Leung, DYM; Sampson, HA; Yunginger, JW; Burks, AW; Schneider, LC; Wortel, CH; Davis, FM; Hyun, JD; Shanahan, WR				Leung, DYM; Sampson, HA; Yunginger, JW; Burks, AW; Schneider, LC; Wortel, CH; Davis, FM; Hyun, JD; Shanahan, WR		TNX-901 Peanut Allergy Study Grp	Effect of Anti-IgE therapy in patients with peanut allergy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FC-EPSILON-RI; ANAPHYLACTIC REACTIONS; FOOD CHALLENGES; HUMAN BASOPHILS; CHILDREN; SAFETY; EXPRESSION; FORMULA; MOUSE	Background: Peanut-induced anaphylaxis is an IgE-mediated condition that is estimated to affect 1.5 million people and cause 50 to 100 deaths per year in the United States. TNX-901 is a humanized IgG1 monoclonal antibody against IgE that recognizes and masks an epitope in the CH3 region of IgE responsible for binding to the high-affinity Fc(epsilon) receptor on mast cells and basophils. Methods: We conducted a double-blind, randomized, dose-ranging trial in 84 patients with a history of immediate hypersensitivity to peanut. Hypersensitivity was confirmed and the threshold dose of encapsulated peanut flour established by a double-blind, placebo-controlled oral food challenge at screening. Patients were randomly assigned in a 3:1 ratio to receive either TNX-901 (150, 300, or 450 mg) or placebo subcutaneously every four weeks for four doses. The patients underwent a final oral food challenge within two to four weeks after the fourth dose. Results: From a mean base-line threshold of sensitivity of 178 to 436 mg of peanut flour in the various groups, the mean increases in the oral-food-challenge threshold were 710 mg in the placebo group, 913 mg in the group given 150 mg of TNX-901, 1650 mg in the group given 300 mg of TNX-901, and 2627 mg in the group given 450 mg of TNX-901 (P<0.001 for the comparison of the 450-mg dose with placebo, and P for trend with increasing dose <0.001). TNX-901 was well tolerated. Conclusions: A 450-mg dose of TNX-901 significantly and substantially increased the threshold of sensitivity to peanut on oral food challenge from a level equal to approximately half a peanut (178 mg) to one equal to almost nine peanuts (2805 mg), an effect that should translate into protection against most unintended ingestions of peanuts.	CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Mayo Clin, Rochester, MN USA; Arkansas Childrens Hosp, Little Rock, AR 72202 USA; Childrens Hosp, Boston, MA 02115 USA; ClinQuest, Marlborough, MA USA; Tanox, Houston, TX USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Jewish Health; Mayo Clinic; Arkansas Children's Hospital; Harvard University; Boston Children's Hospital	Sampson, HA (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	hugh.sampson@mssm.edu	Li, Yapeng/N-1042-2017	Li, Yapeng/0000-0002-5042-6881	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR-585, MO1 RR-00071] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AAAI Board of Directos, 1994, J ALLERGY CLIN IMMUN, V94, P666; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P417, DOI [10.1016/0091-6749(88)90910-4, 10.1016/0091-6749(88)90185-6]; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Corne J, 1997, J CLIN INVEST, V99, P879, DOI 10.1172/JCI119252; DAVIS FM, 1993, SPRINGER SEMIN IMMUN, V15, P51; Halken S, 1993, Pediatr Allergy Immunol, V4, P53, DOI 10.1111/j.1399-3038.1993.tb00067.x; Hallett R, 2002, NEW ENGL J MED, V346, P1833, DOI 10.1056/NEJM200206063462320; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P1240, DOI [10.1111/j.1365-2222.1997.tb01167.x, 10.1046/j.1365-2222.1997.1520954.x]; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; KOLBINGER F, 1993, PROTEIN ENG, V6, P971, DOI 10.1093/protein/6.8.971; Long A, 2002, NEW ENGL J MED, V346, P1320, DOI 10.1056/NEJM200204253461712; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1992, PEDIATRICS, V90, P463; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; SAMPSON HA, 1991, J PEDIATR-US, V118, P520, DOI 10.1016/S0022-3476(05)90001-2; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; van Neerven RJJ, 2001, INT ARCH ALLERGY IMM, V124, P400, DOI 10.1159/000053770; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	31	504	542	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					986	993		10.1056/NEJMoa022613	http://dx.doi.org/10.1056/NEJMoa022613			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653YT	12637608				2022-12-28	WOS:000181465200003
J	Cercek, B; Shah, PK; Noc, M; Zahger, D; Zeymer, U; Matetzky, S; Maurer, G; Mahrer, P				Cercek, B; Shah, PK; Noc, M; Zahger, D; Zeymer, U; Matetzky, S; Maurer, G; Mahrer, P		AZACS Investigators	Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial	LANCET			English	Article							SECONDARY PREVENTION TRIAL; CHLAMYDIA-PNEUMONIAE; MYOCARDIAL-INFARCTION; SEROLOGICAL EVIDENCE; ARTERY-DISEASE; ROXITHROMYCIN	Background There is serological and epidemiological evidence of an association between Chlamydia pneumoniae infection and coronary artery disease. Results of previous smaller studies have indicated a reduction of recurrent ischaemic events in patients with acute coronary syndrome when given macrolide antibiotics. We aimed to assess whether short-term treatment with the macrolide antibiotic azithromycin reduces recurrent ischaemic events in patients admitted for unstable angina or myocardial infarction. Methods We assessed the effect of azithromycin in a multicentre, double-blind randomised trial in 1439 patients with unstable angina or acute myocardial infarction. Patients were randomly allocated to receive 500 mg azithromycin on the first day after randomisation, followed by 250 mg daily for 4 days or placebo. Patients were followed up for 6 months. The primary endpoints were death, recurrent myocardial infarction, or recurrent ischaemia necessitating revascularisation. Analysis was done by intention to treat. Findings Treatment with azithromycin did not result in reduction of either individual endpoints or any of the primary endpoints. Of the 716 patients in the azithromycin group, 23 (3%) died, 17 (2%) developed myocardial infarction, 65 (9%) had recurrent ischaemia needing revascularisation, and 100 (14%) had one or more of these endpoints. In the placebo group (n=723) the corresponding numbers of patients were 24 (4%), 22 (3%), 59 (8%), and 106 (15%), respectively (p=0.664, 95% CI 0.72-1.24). 62 (9%) of patients in the azithromycin group and 59 (8%) in the placebo group reached the secondary endpoint of ischaemia or congestive heart failure necessitating admission (difference 0.5%, 95% CI 0.75-1.53; p=0.707). We recorded few side-effects. Interpretation Short-term treatment with azithromycin does not reduce development of recurrent events in patients with acute coronary syndrome.	Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA 90048 USA; Clin Ctr Ljubljana, Ljubljana, Slovenia; Mt Scopus Hosp, Hadassah Med Ctr, Jerusalem, Israel; Stadt Kliniken Kassel, Kassel, Germany; Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; Allgemeines Krankenhaus Wien, Vienna, Austria; Kaiser Permanente Med Ctr, Los Angeles, CA 90034 USA	Cedars Sinai Medical Center; University Medical Centre Ljubljana; Hebrew University of Jerusalem; Hadassah University Medical Center; Klinikum Kassel; Chaim Sheba Medical Center; Kaiser Permanente	Cercek, B (corresponding author), Cedars Sinai Med Ctr, Div Cardiol, Room 5314, Los Angeles, CA 90048 USA.	cercek@cshs.org		Maurer, Gerald/0000-0002-9043-7657	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00425] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anderson JL, 1999, CIRCULATION, V99, P1540, DOI 10.1161/01.CIR.99.12.1540; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Felker GM, 2002, J AM COLL CARDIOL, V40, P206, DOI 10.1016/S0735-1097(02)01919-8; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1999, EUR HEART J, V20, P121, DOI 10.1053/euhj.1998.1283; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; Muhlestein JB, 2000, CIRCULATION, V102, P1755; Neumann FJ, 2001, LANCET, V357, P2085, DOI 10.1016/S0140-6736(00)05181-3; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Sinisalo J, 2002, CIRCULATION, V105, P1555, DOI 10.1161/01.CIR.0000012544.07696.1F; Stone AFM, 2002, CIRCULATION, V106, P1219, DOI 10.1161/01.CIR.0000027820.66786.CF; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; WALLENTIN L, 1990, LANCET, V336, P827; WOOD S, 2002, HEARTWIRE NEWS; Zhu JH, 2001, CIRCULATION, V103, P45	18	111	118	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 8	2003	361	9360					809	813		10.1016/S0140-6736(03)12706-7	http://dx.doi.org/10.1016/S0140-6736(03)12706-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642046				2022-12-28	WOS:000181466600008
J	Carilli, CL; Lewis, GF; Djorgovski, SG; Mahabal, A; Cox, P; Bertoldi, F; Omont, A				Carilli, CL; Lewis, GF; Djorgovski, SG; Mahabal, A; Cox, P; Bertoldi, F; Omont, A			A molecular Einstein ring: Imaging a starburst disk surrounding a quasi-stellar object	SCIENCE			English	Article							STAR-FORMATION; BLACK-HOLES; GALAXIES; REDSHIFT; EMISSION; DUST; EVOLUTION; LENS; CO	Images of the molecular CO 2-1 line emission and the radio continuum emission from the redshift 4.12 gravitationally lensed quasi-stellar object (QSO) PSS J2322 + 1944 reveal an Einstein ring with a diameter of 1.5". These observations are modeled as a star-forming disk surrounding the QSO nucleus with a radius of 2 kiloparsecs. The implied massive star formation rate is 900 solar masses per year. At this rate, a substantial fraction of the stars in a large elliptical galaxy could form on a dynamical time scale of 10(8) years. The observation of active star formation in the host galaxy of a high-redshift QSO supports the hypothesis of coeval formation of supermassive black holes and stars in spheroidal galaxies.	Natl Radio Astron Observ, Socorro, NM 87801 USA; Univ Sydney, Sch Phys, Sydney, NSW 2006, Australia; CALTECH, Dept Astron, Pasadena, CA 91125 USA; Univ Paris 11, Inst Astrophys Spatiale, F-91405 Orsay, France; Max Planck Inst Radioastron, D-53121 Bonn, Germany; CNRS, Inst Astrophys Paris, F-75014 Paris, France	National Radio Astronomy Observatory (NRAO); University of Sydney; California Institute of Technology; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Carilli, CL (corresponding author), Natl Radio Astron Observ, POB O, Socorro, NM 87801 USA.		Lewis, Geraint/F-9069-2015	Lewis, Geraint/0000-0003-3081-9319				ADLER DS, 1991, ASTROPHYS J, V382, P475, DOI 10.1086/170734; BEGELMAN MC, 1984, REV MOD PHYS, V56, P255, DOI 10.1103/RevModPhys.56.255; Blain AW, 1999, MON NOT R ASTRON SOC, V309, P715, DOI 10.1046/j.1365-8711.1999.02879.x; Carilli CL, 2002, ASTROPHYS J, V575, P145, DOI 10.1086/341269; Carilli CL, 2001, ASTROPHYS J, V555, P625, DOI 10.1086/321519; Carilli CL, 2001, ASTRON J, V122, P1679, DOI 10.1086/323104; Cox P, 2002, ASTRON ASTROPHYS, V387, P406, DOI 10.1051/0004-6361:20020382; DJORGOVSKI S, IN PRESS ASTROPHYS J; Downes D, 1998, ASTROPHYS J, V507, P615, DOI 10.1086/306339; Ferrarese L, 2000, ASTROPHYS J, V539, pL9, DOI 10.1086/312838; Gebhardt K, 2000, ASTROPHYS J, V539, pL13, DOI 10.1086/312840; Kauffmann G, 2000, MON NOT R ASTRON SOC, V311, P576, DOI 10.1046/j.1365-8711.2000.03077.x; Kochanek CS, 2001, ASTROPHYS J, V547, P50, DOI 10.1086/318350; KOCHANEK CS, 1989, MON NOT R ASTRON SOC, V238, P43, DOI 10.1093/mnras/238.1.43; Maloney PR, 1999, ASTROPHYS SPACE SCI, V266, P207, DOI 10.1023/A:1002694926293; Omont A, 2001, ASTRON ASTROPHYS, V374, P371, DOI 10.1051/0004-6361:20010721; Page MJ, 2001, SCIENCE, V294, P2516, DOI 10.1126/science.1065880; Saha P, 2001, ASTRON J, V122, P585, DOI 10.1086/321151; SANDERS DB, 1989, ASTROPHYS J, V347, P29, DOI 10.1086/168094; Williams LLR, 1997, ASTRON GEOPHYS, V38, P10, DOI 10.1093/astrog/38.5.10	20	38	38	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 2	2003	300	5620					773	775		10.1126/science.1082600	http://dx.doi.org/10.1126/science.1082600			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KH	12677071	Green Accepted, Green Submitted			2022-12-28	WOS:000182579800042
J	Johnson, RW; Dworkin, RH				Johnson, RW; Dworkin, RH			Treatment of herpes zoster and postherpetic neuralgia	BMJ-BRITISH MEDICAL JOURNAL			English	Review							VARICELLA; PAIN; MANAGEMENT		Univ Bristol, Bristol Royal Infirm, Pain Management Clin, Bristol BS2 8HW, Avon, England; Univ Rochester, Med Ctr, New York, NY USA	Bristol Royal Infirmary; University of Bristol; University of Rochester	Johnson, RW (corresponding author), Univ Bristol, Bristol Royal Infirm, Pain Management Clin, Bristol BS2 8HW, Avon, England.							Bowsher D, 1996, J PAIN SYMPTOM MANAG, V12, P290, DOI 10.1016/S0885-3924(96)00180-7; Cunningham AL, 2000, BRIT MED J, V321, P778, DOI 10.1136/bmj.321.7264.778; Desmond RA, 2002, J PAIN SYMPTOM MANAG, V23, P510, DOI 10.1016/S0885-3924(02)00393-7; DWORKIN RH, 1994, LANCET, V343, P1648, DOI 10.1016/S0140-6736(94)93106-2; Dworkin RH, 2001, HERPES ZOSTER POSTHE, V11, P39, DOI DOI 10.1007/978-3-319-44348-5_; DWORKIN RH, 2003, IN PRESS CLIN INFECT; Gershon AA, 2001, INFECT DIS CLIN N AM, V15, P65, DOI 10.1016/S0891-5520(05)70268-3; Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674; Jackson JL, 1997, ARCH INTERN MED, V157, P909, DOI 10.1001/archinte.157.8.909; JOHNSON R, 1995, J INFECTION, V30, P193; Kanazi GE, 2000, DRUGS, V59, P1113, DOI 10.2165/00003495-200059050-00007; Kotani N, 2000, NEW ENGL J MED, V343, P1514, DOI 10.1056/NEJM200011233432102; Levin MJ, 2001, ARCH VIR S, V17, P151; Thomas SL, 2002, LANCET, V360, P678, DOI 10.1016/S0140-6736(02)09837-9; Wu CL, 2000, PAIN, V87, P121, DOI 10.1016/S0304-3959(00)00230-X	15	106	121	1	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2003	326	7392					748	750		10.1136/bmj.326.7392.748	http://dx.doi.org/10.1136/bmj.326.7392.748			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665LF	12676845	Green Published			2022-12-28	WOS:000182121600017
J	Watanabe, O; Jouzel, J; Johnsen, S; Parrenin, F; Shoji, H; Yoshida, N				Watanabe, O; Jouzel, J; Johnsen, S; Parrenin, F; Shoji, H; Yoshida, N			Homogeneous climate variability across East Antarctica over the past three glacial cycles	NATURE			English	Article							VOSTOK ICE CORE; TEMPERATURE-CHANGES; GREENLAND; RECORD; PRECIPITATION; DOME	Recent ice core studies have raised the disturbing possibility that glacial-interglacial climate changes may be non-uniform across Antarctica(1,2). These findings have been confined to records from the Ross Sea sector of the continent, but significant deviations in other areas would call into question the widely assumed validity of the climate record obtained from Vostok, East Antarctica, on large spatial scales(3). Here we present an isotopic profile from a core drilled at Dome Fuji(4,5), situated 1,500 km from Vostok in a different sector of East Antarctica. The two records show remarkable similarities over the past three glacial cycles ( the extent of the Dome Fuji record) in both large-amplitude changes, such as terminations, interglacials and interstadials and more subtle glacial events, even when the origin of precipitation is accounted for. Our results indicate that Antarctic climate is essentially homogeneous at the scale of the East Antarctic Plateau, possibly as a consequence of the symmetry of the plateau and the adjacent ocean.	Ctr Etud Saclay, IPSL, Lab Sci Climat & Environm, CEA,CNRS,UMR, F-91191 Gif Sur Yvette, France; Natl Inst Polar Res, Itabashi Ku, Tokyo 173, Japan; Univ Copenhagen, Dept Geophys, DK-2100 Copenhagen, Denmark; Univ Reykjavik, Inst Sci, IS-107 Reykjavik, Iceland; Lab Glaciol & Geophys Environm, CNRS, F-38402 St Martin Dheres, France; Kitami Inst Technol, New Energy Resources Res Ctr, Kitami, Hokkaido 0908507, Japan; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268502, Japan; Japan Sci & Technol Corp, SORST Project, Kawaguchi, Saitama 3320012, Japan	UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Research Organization of Information & Systems (ROIS); National Institute of Polar Research (NIPR) - Japan; University of Copenhagen; University of Iceland; Centre National de la Recherche Scientifique (CNRS); Kitami Institute of Technology; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Jouzel, J (corresponding author), Ctr Etud Saclay, IPSL, Lab Sci Climat & Environm, CEA,CNRS,UMR, F-91191 Gif Sur Yvette, France.	jouzel@lsce.saclay.cea.fr	Parrenin, Frédéric/H-3054-2014; Yoshida, Naohiro/A-8335-2010	Parrenin, Frédéric/0000-0002-9489-3991; Yoshida, Naohiro/0000-0003-0454-3849				Ageta Y, 1998, ANN GLACIOL, V27, P333; Aoki S, 1998, ANN GLACIOL-SER, V27, P338; BASSINOT FC, 1994, EARTH PLANET SC LETT, V126, P91, DOI 10.1016/0012-821X(94)90244-5; Bender ML, 1999, GEOPH MONOG SERIES, V112, P149; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Delaygue G, 2000, GEOPHYS RES LETT, V27, P2677, DOI 10.1029/2000GL011530; Delaygue G, 2000, TELLUS B, V52, P19, DOI 10.1034/j.1600-0889.2000.00951.x; DELMOTTE M, 1997, THESIS U J FOURIER G; *EPICA DOM C 2001, 2002, EOS, V83, P513; *EPICA DOM C 2001, 2002, EOS, V83, P517; Henderson GM, 2000, NATURE, V404, P61, DOI 10.1038/35003541; Hoffmann G, 2000, HYDROL PROCESS, V14, P1385, DOI [10.1002/1099-1085(20000615)14:8<1385::AID-HYP989>3.0.CO;2-1, 10.1002/1099-1085(20000615)14:8&lt;1385::AID-HYP989&gt;3.0.CO;2-1]; JOHNSEN SJ, 1972, NATURE, V235, P429, DOI 10.1038/235429a0; Jouzel J, 2001, GEOPHYS RES LETT, V28, P3199, DOI 10.1029/2000GL012243; JOUZEL J, IN PRESS J GEOPHYS R; Krinner G, 1997, GEOPHYS RES LETT, V24, P2825, DOI 10.1029/97GL52891; Landwehr JM, 2001, J GEOPHYS RES-ATMOS, V106, P31853, DOI 10.1029/2001JD900065; LORIUS C, 1985, NATURE, V316, P591, DOI 10.1038/316591a0; Masson V, 2000, QUATERNARY RES, V54, P348, DOI 10.1006/qres.2000.2172; Morgan V, 2002, SCIENCE, V297, P1862, DOI 10.1126/science.1074257; Parrenin F, 2001, J GEOPHYS RES-ATMOS, V106, P31837, DOI 10.1029/2001JD900245; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Severinghaus JP, 2003, GEOCHIM COSMOCHIM AC, V67, P325, DOI 10.1016/S0016-7037(02)00965-1; Steig EJ, 1998, SCIENCE, V282, P92, DOI 10.1126/science.282.5386.92; Stenni B, 2001, SCIENCE, V293, P2074, DOI 10.1126/science.1059702; Vimeux F, 2002, EARTH PLANET SC LETT, V203, P829, DOI 10.1016/S0012-821X(02)00950-0; Waelbroeck C, 2002, QUATERNARY SCI REV, V21, P295, DOI 10.1016/S0277-3791(01)00101-9; Watanabe O, 1999, ANN GLACIOL, V29, P176, DOI 10.3189/172756499781821553; Werner M, 2001, TELLUS B, V53, P53, DOI 10.1034/j.1600-0889.2001.01154.x; YOSHIDA N, 2001, INT S DOME FUJI ICE, V20	31	190	206	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2003	422	6931					509	512		10.1038/nature01525	http://dx.doi.org/10.1038/nature01525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673247				2022-12-28	WOS:000181965400034
J	Chung, DC; Rustgi, AK				Chung, DC; Rustgi, AK			The hereditary nonpolyposis colorectal cancer syndrome: Genetics and clinical implications	ANNALS OF INTERNAL MEDICINE			English	Review							DNA-MISMATCH-REPAIR; TUMOR MICROSATELLITE INSTABILITY; MSH6 GERMLINE MUTATIONS; COLON-CANCER; INSTITUTE WORKSHOP; TURCOTS-SYNDROME; LYNCH SYNDROME; CELL-DNA; FAMILIES; CARCINOMA	Basic studies of DNA replication and repair have provided surprising and pivotal insights into a novel pathway of tumorigenesis. Defects in the DNA mismatch repair process dramatically increase the risk for specific types of cancer because of instability in microsatellite DNA sequences. A germline mutation in either the hMSH2 or hMLH1 mismatch repair gene results in the hereditary nonpolyposis colorectal cancer (HNPCC), or Lynch, syndrome. The lifetime risk for colon cancer is 80% in affected persons, and an aggressive cancer surveillance program is essential not only for these individuals but also for at-risk family members. The diagnosis of HNPCC can be made by fulfillment of the Amsterdam clinical criteria or through genetic testing for germline mutations in hMSH2 or hMLH1. Genetic testing is particularly useful in families with atypical clinical features and also for cancer risk assessment within an established HNPCC kindred. Microsatellite instability (MSI) of DNA is a hallmark feature of HNPCC-associated tumors, and as many as 15% of cases of sporadic colorectal cancer also display MSI. The biological behavior of colorectal tumors with MSI is distinctive; the most intriguing feature is their favorable natural history. The study of HNPCC has provided an example of the powerful interplay between molecular genetics and clinical care.	Massachusetts Gen Hosp, Gastrointestinal Unit, GI Canc Genet Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Pennsylvania	Chung, DC (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, GI Canc Genet Serv, GRJ 825,50 Blossom St, Boston, MA 02114 USA.	dchung@partners.org			NCI NIH HHS [R01 CA92594] Funding Source: Medline; NIDDK NIH HHS [DK56645] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056645] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO;2-C; AMALDI F, 1973, EXP CELL RES, V80, P79, DOI 10.1016/0014-4827(73)90277-2; Bacon BR, 2001, GASTROENTEROLOGY, V120, P718, DOI 10.1053/gast.2001.21913; Boland CR, 1998, CANCER RES, V58, P5248; CAIRNS J, 1966, J MOL BIOL, V15, P372, DOI 10.1016/S0022-2836(66)80233-4; Cawkwell L, 1999, GUT, V45, P409, DOI 10.1136/gut.45.3.409; Church JM, 1996, ANN MED, V28, P479, DOI 10.3109/07853899608999111; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; De Rosa M, 2000, ONCOGENE, V19, P1719, DOI 10.1038/sj.onc.1203447; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Elsaleh H, 2001, CLIN CANCER RES, V7, P1343; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hankey, 1973, SEER CANC STAT REV; Hemminki A, 2000, GASTROENTEROLOGY, V119, P921, DOI 10.1053/gast.2000.18161; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; HENDRICKSON EA, 1987, NUCLEIC ACIDS RES, V15, P6369, DOI 10.1093/nar/15.16.6369; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jarvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5; Kolodner RD, 1999, CANCER RES, V59, P5068; Kornberg A., 1992, DNA REPLICATION; Kuraguchi M, 2001, CANCER RES, V61, P7934; Lamberti C, 1999, GUT, V44, P839, DOI 10.1136/gut.44.6.839; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; Lindor NM, 2002, J CLIN ONCOL, V20, P1043, DOI 10.1200/JCO.20.4.1043; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu T, 2000, GENE CHROMOSOME CANC, V27, P17, DOI 10.1002/(SICI)1098-2264(200001)27:1<17::AID-GCC3>3.0.CO;2-Y; Lynch HT, 1999, J MED GENET, V36, P801; LYNCH HT, 1988, GASTROENTEROL CLIN N, V17, P679; Lynch HT, 1996, DIS COLON RECTUM, V39, P109, DOI 10.1007/BF02048279; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; Marcus VA, 1999, AM J SURG PATHOL, V23, P1248, DOI 10.1097/00000478-199910000-00010; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reyes CM, 2002, CANCER, V95, P1848, DOI 10.1002/cncr.10910; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; RodriguezBigas MA, 1997, ANN SURG, V225, P202, DOI 10.1097/00000658-199702000-00008; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Samowitz WS, 2001, GASTROENTEROLOGY, V121, P830, DOI 10.1053/gast.2001.27996; Smyrk TC, 2001, CANCER, V91, P2417, DOI 10.1002/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.3.CO;2-L; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Syngal S, 1999, JAMA-J AM MED ASSOC, V282, P247, DOI 10.1001/jama.282.3.247; Terdiman JP, 2001, GASTROENTEROLOGY, V120, P21, DOI 10.1053/gast.2001.20874; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASEN HFA, 1995, LANCET, V345, P1183, DOI 10.1016/S0140-6736(95)91016-6; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Wijnen J, 1997, AM J HUM GENET, V61, P329, DOI 10.1086/514847; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Wu Y, 2001, NAT GENET, V29, P137, DOI 10.1038/ng1001-137; Wu Y, 2001, GASTROENTEROLOGY, V120, P1580, DOI 10.1053/gast.2001.25117; Wu Y, 1999, AM J HUM GENET, V65, P1291, DOI 10.1086/302612; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544	67	186	198	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					560	570		10.7326/0003-4819-138-7-200304010-00012	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00012			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667026				2022-12-28	WOS:000181872100005
J	Berg, L; Riise, GC; Cosman, D; Bergstrom, T; Olofsson, S; Karre, W; Carbone, E				Berg, L; Riise, GC; Cosman, D; Bergstrom, T; Olofsson, S; Karre, W; Carbone, E			LIR-1 expression on lymphocytes, and cytomegalovirus disease in lung-transplant recipients	LANCET			English	Article							INHIBITORY RECEPTOR; CELLS	Human cytomegalovirus infection is a major cause of morbidity after lung transplantation. LIR-1 (leucocyte immunoglobulin-like receptor-1) is an inhibitory cell surface receptor that has high affinity for an MHC class I homologue (UL18) encoded by human cytomegalovirus. We aimed to investigate whether reactivation of human cytomegalovirus affects the expression of LIR-1. We measured LIR-1 expression on peripheral blood lymphocytes from 13 lung-transplant recipients and established human cytomegalovirus load using PCR. Eight patients developed cytomegalovirus disease. The percentage of cells expressing LIR-1 increased in the patients who developed cytomegalovirus disease several weeks before viral DNA was detectable by PCR. Measurement of LIR-1 expression might allow early identification of cytomegalovirus disease in lung-transplant patients.	Karolinska Inst, Microbiol & Tumourbiol Ctr, S-17177 Stockholm, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Resp Med & Allergol, Gothenburg, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Virol, Gothenburg, Sweden; Amgen Corp, Mol Biol, Seattle, WA USA; Univ Catanzaro Magna Graecia, Dept Expt & Clin Med, Catanzaro, Italy	Karolinska Institutet; Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Magna Graecia University of Catanzaro	Carbone, E (corresponding author), Karolinska Inst, Microbiol & Tumourbiol Ctr, Box 280, S-17177 Stockholm, Sweden.	ennio.carbone@mtc.ki.se		carbone, ennio/0000-0002-2275-8803; Berg, Louise/0000-0001-6538-2837; Bergstrom, Tomas/0000-0002-9257-6757				Chang CC, 2002, NAT IMMUNOL, V3, P237, DOI 10.1038/ni760; Chapman TL, 1999, IMMUNITY, V11, P603, DOI 10.1016/S1074-7613(00)80135-1; LJUNGMAN P, 1993, BONE MARROW TRANSPL, V12, P399; Riise GC, 2000, CHEST, V118, P1653, DOI 10.1378/chest.118.6.1653; Wang LL, 2000, J IMMUNOL, V164, P5215, DOI 10.4049/jimmunol.164.10.5215	5	55	56	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 29	2003	361	9363					1099	1101		10.1016/S0140-6736(03)12855-3	http://dx.doi.org/10.1016/S0140-6736(03)12855-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672315				2022-12-28	WOS:000181865200013
J	Musher, DM				Musher, DM			Medical progress: How contagious are common respiratory tract infections?	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESISTANT STREPTOCOCCUS-PNEUMONIAE; HUMAN-IMMUNODEFICIENCY-VIRUS; C MENINGOCOCCAL DISEASE; HEALTH-CARE WORKERS; SYNCYTIAL-VIRUS; NEISSERIA-MENINGITIDIS; RHINOVIRUS COLDS; SEROGROUP-C; UNITED-STATES; MYCOBACTERIUM-TUBERCULOSIS		Vet Affairs Med Ctr, Med Serv, Infect Dis Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Baylor College of Medicine	Musher, DM (corresponding author), Vet Affairs Med Ctr, Med Serv, Infect Dis Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA.							Allos BM, 1996, ANN INTERN MED, V125, P114, DOI 10.7326/0003-4819-125-2-199607150-00007; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; APICELLA MA, 1979, PRINCIPLES PRACTICE, P1640; BATES JH, 1965, NEW ENGL J MED, V272, P714, DOI 10.1056/NEJM196504082721403; Briles DE, 2000, VACCINE, V18, P1707, DOI 10.1016/S0264-410X(99)00511-3; CATE TR, 1973, VIRAL MYCOPLASMAL IN, P141; Conyn-van Spaendonck MAE, 1999, J INFECTION, V39, P42, DOI 10.1016/S0163-4453(99)90101-9; COUCH RB, 1966, AM REV RESPIR DIS, V93, P529; COUCH RB, 1966, BACTERIOL REV, V30, P517, DOI 10.1128/MMBR.30.3.517-529.1966; DALESSIO DJ, 1976, J INFECT DIS, V133, P28, DOI 10.1093/infdis/133.1.28; DALESSIO DJ, 1984, J INFECT DIS, V150, P189, DOI 10.1093/infdis/150.2.189; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; Davies AL, 1996, EPIDEMIOL INFECT, V117, P259, DOI 10.1017/S0950268800001436; DICK EC, 1987, J INFECT DIS, V156, P442, DOI 10.1093/infdis/156.3.442; Dingle JH., 1964, STUDY 25000 ILLNESSE; Earhart KC, 2001, EMERG INFECT DIS, V7, P463, DOI 10.3201/eid0703.017320; ELKHOLY A, 1980, J INFECT DIS, V141, P759, DOI 10.1093/infdis/141.6.759; Falsey AR, 1997, J AM GERIATR SOC, V45, P706, DOI 10.1111/j.1532-5415.1997.tb01474.x; FEIGIN RD, 1982, NEW ENGL J MED, V307, P1255, DOI 10.1056/NEJM198211113072007; FOX JP, 1969, AM J EPIDEMIOL, V89, P25, DOI 10.1093/oxfordjournals.aje.a120913; FOY HM, 1976, J INFECT DIS, V134, P362, DOI 10.1093/infdis/134.4.362; FOY HM, 1971, J AMER MED ASSOC, V217, P1067, DOI 10.1001/jama.217.8.1067; GASTANADUY AS, 1980, LANCET, V2, P498; GAULD JR, 1965, AM J EPIDEMIOL, V82, P56, DOI 10.1093/oxfordjournals.aje.a120532; Gilmore A, 2000, LANCET, V356, P1654, DOI 10.1016/S0140-6736(00)03163-9; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923; Gray GC, 2000, CLIN INFECT DIS, V31, P663, DOI 10.1086/313999; GREENFIE.S, 1967, NEW ENGL J MED, V277, P497, DOI 10.1056/NEJM196709072771001; GREENFIELD S, 1971, J INFECT DIS, V123, P67, DOI 10.1093/infdis/123.1.67; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; GWALTNEY JM, 1978, ANN INTERN MED, V88, P463, DOI 10.7326/0003-4819-88-4-463; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; Gwaltney JM, 2002, AM J MED, V112, p13S; GWALTNEY JM, 1978, AM J EPIDEMIOL, V107, P357, DOI 10.1093/oxfordjournals.aje.a112555; HALL CB, 1981, INFECT IMMUN, V33, P779, DOI 10.1128/IAI.33.3.779-783.1981; HALL CB, 1980, J INFECT DIS, V141, P98, DOI 10.1093/infdis/141.1.98; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; HALL CB, 1981, J PEDIATR-US, V99, P100, DOI 10.1016/S0022-3476(81)80969-9; HAMBURGER M, 1945, J INFECT DIS, V77, P68, DOI 10.1093/infdis/77.1.68; Harley D, 2001, Commun Dis Intell, V25, P9; Hastings L, 1997, Commun Dis Rep CDR Rev, V7, pR195; Heffron R, 1979, PNEUMONIA SPECIAL RE; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; HENDLEY JO, 1969, AM J EPIDEMIOL, V89, P184, DOI 10.1093/oxfordjournals.aje.a120928; HENDLEY JO, 1973, NEW ENGL J MED, V288, P1361, DOI 10.1056/NEJM197306282882601; HENDLEY JO, 1972, J INFECT DIS, V125, P243, DOI 10.1093/infdis/125.3.243; HODGES RG, 1946, AM J HYG, V44, P193, DOI 10.1093/oxfordjournals.aje.a119089; HODGES RG, 1946, AM J HYG, V44, P183, DOI 10.1093/oxfordjournals.aje.a119088; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011; HUDSON PJ, 1986, PEDIATR INFECT DIS J, V5, P213, DOI 10.1097/00006454-198603000-00011; HUME SE, 1992, JAMA-J AM MED ASSOC, V267, P1833, DOI 10.1001/jama.267.13.1833; Imrey PB, 1996, AM J EPIDEMIOL, V143, P624, DOI 10.1093/oxfordjournals.aje.a008792; Iseman Michael D., 2000, CLIN GUIDE TUBERCULO; Jackson LA, 1996, PEDIATR INFECT DIS J, V15, P992, DOI 10.1097/00006454-199611000-00012; JENNINGS LC, 1978, J HYG-CAMBRIDGE, V81, P67, DOI 10.1017/S0022172400053778; Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501; Kim PE, 1996, CLIN INFECT DIS, V22, P100, DOI 10.1093/clinids/22.1.100; Kiska DL, 1997, J INFECT DIS, V176, P992, DOI 10.1086/516540; Knight V., 1973, Viral and mycoplasmal infections of the respiratory tract., P87; Knight V, 1973, VIRAL MYCOPLASMAL IN, P65; LEINO T, 2002, 3 INT S PNEUM PNEUM, P64; LONGINI IM, 1984, INT J EPIDEMIOL, V13, P99, DOI 10.1093/ije/13.1.99; MAHADY SC, 1961, AM REV RESPIR DIS, V84, P348; MCADAM JM, 1991, CHEST, V99, P792, DOI 10.1378/chest.99.3.792-c; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; McNeill KM, 2000, EMERG INFECT DIS, V6, P415, DOI 10.3201/eid0604.000419; McNeill KM, 1999, EMERG INFECT DIS, V5, P798; Meningococcal disease, 1976, JAMA-J AM MED ASSOC, V235, P261; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; Merz AJ, 2000, ANNU REV CELL DEV BI, V16, P423, DOI 10.1146/annurev.cellbio.16.1.423; MONTO AS, 1994, EPIDEMIOL REV, V16, P351, DOI 10.1093/oxfordjournals.epirev.a036158; MOORE PS, 1994, SCI AM, V271, P38, DOI 10.1038/scientificamerican1194-38; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; MUNFORD RS, 1974, LANCET, V1, P1275; Musher DM, 1997, CLIN INFECT DIS, V24, P441, DOI 10.1093/clinids/24.3.441; Musher DM, 2001, J INFECT DIS, V183, P827, DOI 10.1086/318833; Musher DM, 1997, J INVEST MED, V45, P57; MUSHER DM, 2000, MANDELL DOUGLAS BENN, V2, P2128; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; Nuorti JP, 1998, NEW ENGL J MED, V338, P1861, DOI 10.1056/NEJM199806253382601; OLCEN P, 1981, SCAND J INFECT DIS, V13, P105, DOI 10.3109/inf.1981.13.issue-2.05; Phair JJ, 1944, AM J HYG, V40, P318, DOI 10.1093/oxfordjournals.aje.a118996; Plikaytis B. B., 1999, Tubercle and Lung Disease, V79, P273, DOI 10.1054/tuld.1999.0197; Pollard AJ, 1999, BRIT MED J, V319, P1147, DOI 10.1136/bmj.319.7218.1147; RAMMELKAMP CH, 1964, ANN INTERN MED, V60, P753, DOI 10.7326/0003-4819-60-5-753; RAUCH AM, 1990, AM J DIS CHILD, V144, P923, DOI 10.1001/archpedi.1990.02150320087033; Richter SS, 2002, CLIN INFECT DIS, V34, P330, DOI 10.1086/338065; Riley, 1961, AIRBORNE INFECT TRAN; RONNE T, 1993, SCAND J INFECT DIS, V25, P331, DOI 10.3109/00365549309008507; Rosenstein NE, 1999, J INFECT DIS, V180, P1894, DOI 10.1086/315158; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; SCHIEBLE JH, 1970, P SOC EXP BIOL MED, V133, P329, DOI 10.3181/00379727-133-34468; SHAW JB, 1954, AM REV TUBERC PULM, V69, P724; SHEEHE PR, 1969, J INFECT DIS, V119, P172, DOI 10.1093/infdis/119.2.172; Smillie WG, 1938, AM J PUBLIC HEALTH N, V28, P293, DOI 10.2105/AJPH.28.3.293; Smith I, 1999, EPIDEMIOL INFECT, V123, P373, DOI 10.1017/S0950268899003143; SOARES S, 1993, J INFECT DIS, V168, P158, DOI 10.1093/infdis/168.1.158; STEAD WW, 1996, TUBERCULOSIS, P141; TYRRELL DAJ, 2002, AM J MED S6A, V112, pS4; Wannamaker L., 1954, STREPTOCOCCAL INFECT, P157; WEHRLE PF, 1972, COMMUNICABLE INFECTI, P401; Welliver R, 2001, JAMA-J AM MED ASSOC, V285, P748, DOI 10.1001/jama.285.6.748; Wells WF, 1955, AIR HYG ECOL STUDY D; Yaganehdoost A, 1999, J INFECT DIS, V180, P1245, DOI 10.1086/314991; Zangwill KM, 1997, JAMA-J AM MED ASSOC, V277, P389, DOI 10.1001/jama.277.5.389; 1992, MMWR MORB MORTAL WKL, V41, P342	109	190	198	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2003	348	13					1256	1266		10.1056/NEJMra021771	http://dx.doi.org/10.1056/NEJMra021771			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659RG	12660390				2022-12-28	WOS:000181790800008
J	Rowbotham, MC; Twilling, L; Davies, PS; Reisner, L; Taylor, K; Mohr, D				Rowbotham, MC; Twilling, L; Davies, PS; Reisner, L; Taylor, K; Mohr, D			Oral opioid therapy for chronic peripheral and central neuropathic pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RELIEVES POSTHERPETIC NEURALGIA; DIABETIC NEUROPATHY; RANDOMIZED TRIAL; DOUBLE-BLIND; MORPHINE; AMITRIPTYLINE; DESIPRAMINE; FENTANYL; EFFICACY	BACKGROUND: Although opioids are commonly used to treat chronic neuropathic pain, there are limited data to guide their use. Few controlled trials have been performed, and many types of neuropathic pain remain unstudied. METHODS: Adults with neuropathic pain that was refractory to treatment were randomly assigned to receive either high-strength (0.75-mg) or low-strength (0.15-mg) capsules of the potent (mu)-opioid agonist levorphanol for eight weeks under double-blind conditions. Intake was titrated by the patient to a maximum of 21 capsules of either strength per day. Outcome measures included the intensity of pain as recorded in a diary, the degree of pain relief, quality of life, psychological and cognitive function, the number of capsules taken daily, and blood levorphanol levels. RESULTS: Among the 81 patients exposed to the study drug, high-strength levorphanol capsules reduced pain by 36 percent, as compared with a 21 percent reduction in pain in the low-strength group (P=0.02). On average, patients in the high-strength group took 11.9 capsules per day (8.9 mg per day) and patients in the low-strength group took close to the 21 allowed (18.3 capsules per day; 2.7 mg per day). Affective distress and interference with functioning were reduced, and sleep was improved, but there were no differences between the high-strength group and the low-strength group in terms of these variables. Noncompletion of the study was primarily due to side effects of the opioid. Patients with central pain after stroke were the least likely to report benefit. CONCLUSIONS: The reduction in the intensity of neuropathic pain was significantly greater during treatment with higher doses of opioids than with lower doses. Higher doses produced more side effects without significant additional benefit in terms of other outcome measures.	Univ Calif San Francisco, Sch Med, Pain Clin, Res Ctr,Dept Neurol, San Francisco, CA 94115 USA; Univ Calif San Francisco, Sch Med, Dept Anesthesia, San Francisco, CA 94115 USA; Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rowbotham, MC (corresponding author), Univ Calif San Francisco, Sch Med, Pain Clin, Res Ctr,Dept Neurol, 1701 Divisadero St,Ste 480, San Francisco, CA 94115 USA.		Rowbotham, Michael/AAA-3606-2019	Mohr, David/0000-0002-5443-7596; Davies, Pamela S./0000-0002-2828-6755	NIDA NIH HHS [DA-01696] Funding Source: Medline; NINDS NIH HHS [NS07625, NS21445, K24-NS02164] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS021445, P01NS021445, F32NS007625, K24NS002164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA001696] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; ARNER S, 1991, PAIN, V47, P116, DOI 10.1016/0304-3959(91)90019-T; BANISTER EH, 1974, ANAESTHESIA, V29, P158, DOI 10.1111/j.1365-2044.1974.tb00614.x; Dellemijn P, 1999, PAIN, V80, P453, DOI 10.1016/S0304-3959(98)00256-5; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Dellemijn PLI, 1997, LANCET, V349, P753, DOI 10.1016/S0140-6736(96)09024-1; DIXON R, 1983, RES COMMUN CHEM PATH, V41, P3; DUBNER R, 1991, PAIN, V47, P1, DOI 10.1016/0304-3959(91)90002-F; Everhart ET, 1999, J CHROMATOGR B, V729, P173, DOI 10.1016/S0378-4347(99)00160-7; FIELDS HL, 1988, PAIN, V35, P365, DOI 10.1016/0304-3959(88)90148-0; First M.B., 2016, STRUCTURED CLIN INTE; FRANCE RD, 1984, SOC SCI MED, V19, P1379, DOI 10.1016/0277-9536(84)90027-3; Gilson AM, 2001, J PAIN SYMPTOM MANAG, V21, P227, DOI 10.1016/S0885-3924(00)00263-3; Joranson D E, 1998, Semin Oncol Nurs, V14, P158, DOI 10.1016/S0749-2081(98)80022-3; Joranson D E, 1990, J Pain Symptom Manage, V5, pS12; KERNS RD, 1985, PAIN, V23, P345, DOI 10.1016/0304-3959(85)90004-1; KISHOREKUMAR R, 1990, CLIN PHARMACOL THER, V47, P305, DOI 10.1038/clpt.1990.33; Littell RC, 2000, STAT MED, V19, P1793, DOI 10.1002/1097-0258(20000715)19:13<1793::AID-SIM482>3.3.CO;2-H; MARUTA T, 1979, MAYO CLIN PROC, V54, P241; MAX MB, 1988, NEUROLOGY, V38, P1427, DOI 10.1212/WNL.38.9.1427; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; MAX MB, 1987, NEUROLOGY, V37, P589, DOI 10.1212/WNL.37.4.589; McNair D.M., 1971, MANUAL PROFILES MOOD; McQuay HJ, 1997, ACTA ANAESTH SCAND, V41, P175, DOI 10.1111/j.1399-6576.1997.tb04634.x; Morgan D, 1999, ANESTH ANALG, V88, P407, DOI 10.1097/00000539-199902000-00035; MORRISON JD, 1971, BMJ-BRIT MED J, V3, P287, DOI 10.1136/bmj.3.5769.287; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; PORTER J, 1980, NEW ENGL J MED, V302, P123; PRESTON KL, 1987, J PHARMACOL EXP THER, V240, P900; Raja SN, 2002, NEUROLOGY, V59, P1015, DOI 10.1212/WNL.59.7.1015; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; ROWBOTHAM MC, 1991, NEUROLOGY, V41, P1024, DOI 10.1212/WNL.41.7.1024; Rowbotham MC, 1999, PROG PAIN RES MANAG, V14, P307; Smith A., 1991, SYMBOL DIGIT MODALIT; WALL PD, 1990, PAIN, V43, P267, DOI 10.1016/0304-3959(90)90023-7; WATSON CPN, 1988, PAIN, V35, P289, DOI 10.1016/0304-3959(88)90139-X; Watson CPN, 1998, NEUROLOGY, V50, P1837	38	325	342	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2003	348	13					1223	1232		10.1056/NEJMoa021420	http://dx.doi.org/10.1056/NEJMoa021420			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659RG	12660386				2022-12-28	WOS:000181790800004
J	Takasugi, N; Tomita, T; Hayashi, I; Tsuruoka, M; Niimura, M; Takahashi, Y; Thinakaran, G; Iwatsubo, T				Takasugi, N; Tomita, T; Hayashi, I; Tsuruoka, M; Niimura, M; Takahashi, Y; Thinakaran, G; Iwatsubo, T			The role of presenilin cofactors in the gamma-secretase complex	NATURE			English	Article							AMYLOID-BETA-PROTEIN; INTRAMEMBRANE PROTEOLYSIS; PRECURSOR PROTEIN; NICASTRIN; NOTCH; CLEAVAGE; CELLS; APH-1; APP; STABILIZATION	Mutations in presenilin genes account for the majority of the cases of the familial form of Alzheimer's disease (FAD). Presenilin is essential for gamma-secretase activity, a proteolytic activity involved in intramembrane cleavage of Notch and beta-amyloid precursor protein (betaAPP)(1,2). Cleavage of betaAPP by FAD mutant presenilin results in the overproduction of highly amyloidogenic amyloid beta42 peptides(3-6). gamma-Secretase activity requires the formation of a stable, high-molecular-mass protein complex(7-11) that, in addition to the endoproteolysed fragmented form of presenilin, contains essential cofactors including nicastrin(12-14), APH-1 (refs 15-18) and PEN-2 ( refs 16, 19). However, the role of each protein in complex formation and the generation of enzymatic activity is unclear. Here we show that Drosophila APH-1 (Aph-1) increases the stability of Drosophila presenilin (Psn) holoprotein in the complex. Depletion of PEN-2 by RNA interference prevents endoproteolysis of presenilin and promotes stabilization of the holoprotein in both Drosophila and mammalian cells, including primary neurons. Co-expression of Drosophila Pen-2 with Aph-1 and nicastrin increases the formation of Psn fragments as well as gamma-secretase activity. Thus, APH-1 stabilizes the presenilin holoprotein in the complex, whereas PEN-2 is required for endoproteolytic processing of presenilin and conferring gamma-secretase activity to the complex.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Tokyo; University of Chicago	Tomita, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Tomita, Taisuke/L-5427-2015	Tomita, Taisuke/0000-0002-0075-5943; TAKASUGI, NOBUMASA/0000-0002-6059-2082				Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Fukumoto H, 1999, NEUROREPORT, V10, P2965, DOI 10.1097/00001756-199909290-00017; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; UI K, 1994, IN VITRO CELL DEV-AN, V30A, P209; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	28	743	781	2	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					438	441		10.1038/nature01506	http://dx.doi.org/10.1038/nature01506			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660785				2022-12-28	WOS:000181801200046
J	Pich, J; Carne, X; Arnaiz, JA; Gomez, B; Trilla, A; Rodes, J				Pich, J; Carne, X; Arnaiz, JA; Gomez, B; Trilla, A; Rodes, J			Role of a research ethics committee in follow-up and publication of results	LANCET			English	Article								Follow-up of clinical trials is a commitment rarely fulfilled by research ethics committees (RECs). We assessed the output of clinical trials submitted in 1997 to our REC, and talked to principal investigators, sponsors, contract research organisations, or a combination of these. During 1997, our REC reviewed 166 clinical trials, and approved 158. The recruitment rate was lower than expected in 45% (64/143) of all initiated clinical trials; 64% (92/143) were finished in accordance with protocol. 3 years after, the results of only 21% (26/1.23) of finished clinical trials were published in peer-reviewed journals, rising to 31% (38/123) if in-press articles were included. RECs should devote more effort and resources to assess public dissemination of results of clinical trials.	Hosp Clin Barcelona, IDIBAPS, Clin Pharmacol Unit, Barcelona, Spain; Hosp Clin Barcelona, IDIBAPS, Assessment Support & Prevent Unit, Barcelona, Spain; Hosp Clin Barcelona, IDIBAPS, Res Direct, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Carne, X (corresponding author), Hosp Clin Barcelona, Farmacol Clin UASP, Villarroel 170, E-08036 Barcelona, Spain.		Trilla, Antoni/G-2446-2018					ALES JE, 2001, INVESTIGACION CLIN B, V39, P21; Mann H, 2002, LANCET, V360, P406, DOI 10.1016/S0140-6736(02)09613-7; World Medical Association, 2000, 52 WMA GEN ASS ED SC; 1993, BOE             0513, P14346	4	76	77	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					1015	1016		10.1016/S0140-6736(03)12799-7	http://dx.doi.org/10.1016/S0140-6736(03)12799-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660062				2022-12-28	WOS:000181699700015
J	Ploner, M; Schnitzler, A				Ploner, M; Schnitzler, A			Wernicke's encephalopathy	LANCET			English	Editorial Material									Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Ploner, M (corresponding author), Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany.		Schnitzler, Alfons/K-4625-2014; Schnitzler, Alfons/AAT-1054-2021; Schnitzler, Alfons/Q-5520-2019; Ploner, Markus/C-3281-2013	Schnitzler, Alfons/0000-0002-6414-7939; Schnitzler, Alfons/0000-0002-6414-7939; Ploner, Markus/0000-0002-7767-7170					0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					1000	1000		10.1016/S0140-6736(03)12826-7	http://dx.doi.org/10.1016/S0140-6736(03)12826-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660057	Bronze			2022-12-28	WOS:000181699700010
J	Fiorillo, CD; Tobler, PN; Schultz, W				Fiorillo, CD; Tobler, PN; Schultz, W			Discrete coding of reward probability and uncertainty by dopamine neurons	SCIENCE			English	Article							RESPONSES; STIMULI; SIGNAL	Uncertainty is critical in the measure of information and in assessing the accuracy of predictions. It is determined by probability P, being maximal. at P = 0.5 and decreasing at higher and lower probabilities. Using distinct stimuli to indicate the probability of reward, we found that the phasic activation of dopamine neurons varied monotonically across the full range of probabilities, supporting past claims that this response codes the discrepancy between predicted and actual reward. In contrast, a previously unobserved response co-varied with uncertainty and consisted of a gradual increase in activity until the potential time of reward. The coding of uncertainty suggests a possible role for dopamine signals in attention-based learning and risk-taking behavior.	Univ Fribourg, Inst Physiol, CH-1700 Fribourg, Switzerland; Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	University of Fribourg; University of Cambridge	Fiorillo, CD (corresponding author), Univ Fribourg, Inst Physiol, CH-1700 Fribourg, Switzerland.	cdf28@cam.ac.uk	Fiorillo, Christopher Dante/C-1718-2011	Fiorillo, Christopher/0000-0002-7232-9505; Tobler, Philippe/0000-0002-4915-9448	Wellcome Trust [095495] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Dayan P, 2000, NAT NEUROSCI, V3, P1218, DOI 10.1038/81504; Dickinson A., 1980, CONT ANIMAL LEARNING; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Fairhall AL, 2001, NATURE, V412, P787, DOI 10.1038/35090500; FIORILLO CD, UNPUB; Gallistel C. R., 1990, ORG LEARNING; Gallistel CR, 2000, PSYCHOL REV, V107, P289, DOI 10.1037/0033-295X.107.2.289; KAYE H, 1984, J EXP PSYCHOL ANIM B, V10, P90, DOI 10.1037/0097-7403.10.1.90; MACKINTOSH NJ, 1975, PSYCHOL REV, V82, P276, DOI 10.1037/h0076778; Mazur JE, 2001, PSYCHOL REV, V108, P96, DOI 10.1037/0033-295X.108.1.96; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; PEARCE JM, 1980, PSYCHOL REV, V87, P532, DOI 10.1037/0033-295X.87.6.532; PEARCE JM, 1987, INTRO ANIMAL COGNITI; Rao R. P., 2002, PROBABILISTIC MODELS; Rao RPN, 1999, NAT NEUROSCI, V2, P79, DOI 10.1038/4580; Redgrave P, 1999, TRENDS NEUROSCI, V22, P146, DOI 10.1016/S0166-2236(98)01373-3; Rescorla R.A., 1972, CLASSICAL CONDITION, P64, DOI DOI 10.1101/GR.110528.110; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; SCHULTZ W, 1993, J NEUROSCI, V13, P900; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Waelti P, 2001, NATURE, V412, P43, DOI 10.1038/35083500; Wolpert DM, 2000, NAT NEUROSCI, V3, P1212, DOI 10.1038/81497	23	1316	1336	3	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	2003	299	5614					1898	1902		10.1126/science.1077349	http://dx.doi.org/10.1126/science.1077349			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649484	Green Submitted			2022-12-28	WOS:000181669700048
J	Kalaria, RN				Kalaria, RN			Dementia comes of age in the developing world	LANCET			English	Editorial Material							ALZHEIMERS-DISEASE; 2 COMMUNITIES; PREVALENCE; INDIA; RISK		Newcastle Gen Hosp, Inst Ageing & Hlth, Wolfson Unit, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle General Hospital; Newcastle University - UK	Kalaria, RN (corresponding author), Newcastle Gen Hosp, Inst Ageing & Hlth, Wolfson Unit, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	r.n.kalaria@ncl.ac.uk	Kalaria, Raj/AAX-2630-2020					[Anonymous], 2002, Aging Male, V5, P1; BAXTER J, 2002, MAILS 125 YEAR OLD W; Bowirrat A, 2001, EUR J NEUROL, V8, P119, DOI 10.1046/j.1468-1331.2001.00183.x; Burmeister LA, 2001, THYROID, V11, P1177, DOI 10.1089/10507250152741037; Chandra V, 1998, NEUROLOGY, V51, P1000, DOI 10.1212/WNL.51.4.1000; Chandra V, 2001, NEUROLOGY, V57, P985, DOI 10.1212/WNL.57.6.985; Farrag AKF, 1998, DEMENT GERIATR COGN, V9, P323, DOI 10.1159/000017084; HENDRIE HC, 1995, AM J PSYCHIAT, V152, P1485; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Kalaria RN, 1997, BRAIN RES BULL, V44, P573, DOI 10.1016/S0361-9230(97)00310-9; KALARIA RN, 2002, VASCULAR COGNITIVE I, P145; OTT A, 1995, BRIT MED J, V310, P970, DOI 10.1136/bmj.310.6985.970; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; WHO, 2003, WHO PROC GLOB STRAT; Zhang MY, 1998, PSYCHIAT CLIN NEUROS, V52, pS291, DOI 10.1111/j.1440-1819.1998.tb03248.x	16	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	2003	361	9361					888	889		10.1016/S0140-6736(03)12783-3	http://dx.doi.org/10.1016/S0140-6736(03)12783-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648963				2022-12-28	WOS:000181741600002
J	Rehling, P; Model, K; Brandner, K; Kovermann, P; Sickmann, A; Meyer, HE; Kuhlbrandt, W; Wagner, R; Truscott, KN; Pfanner, N				Rehling, P; Model, K; Brandner, K; Kovermann, P; Sickmann, A; Meyer, HE; Kuhlbrandt, W; Wagner, R; Truscott, KN; Pfanner, N			Protein insertion into the mitochondrial inner membrane by a twin-pore translocase	SCIENCE			English	Article							OUTER-MEMBRANE; INTERMEMBRANE SPACE; IMPORT RECEPTORS; ADP/ATP CARRIER; COMPLEX; CHANNEL; PREPROTEINS; BIOGENESIS; MACHINERY; FAMILY	The mitochondrial inner membrane imports numerous proteins that span it multiple times using the membrane potential Deltapsi as the only external energy source. We purified the protein insertion complex (TIM22 complex), a twin-pore translocase that mediated the insertion of precursor proteins in a three-step process. After the precursor is tethered to the translocase without losing energy from the Deltapsi, two energy-requiring steps were needed. First, Deltapsi acted on the precursor protein and promoted its docking in the translocase complex. Then, Deltapsi and an internal signal peptide together induced rapid gating transitions in one pore and closing of the other pore and drove membrane insertion to completion. Thus, protein insertion was driven by the coordinated action of a twin-pore complex in two voltage-dependent steps.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Max Planck Inst Biophys, Abt Strukturbiol, D-60528 Frankfurt, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Univ Osnabruck, Fachbereich Biol Chem, D-49034 Osnabruck, Germany; Ruhr Univ Bochum, Med Proteom Ctr, D-44780 Bochum, Germany	University of Freiburg; Max Planck Society; University of Freiburg; University Osnabruck; Ruhr University Bochum	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Sickmann, Albert/A-1010-2011; Kovermann, Peter/AAF-4411-2020; Pfanner, Nikolaus/AAV-7878-2021; Truscott, Kaye/D-3362-2012	Sickmann, Albert/0000-0002-2388-5265; Kovermann, Peter/0000-0001-5296-4918; Truscott, Kaye/0000-0002-5352-9835; Kuhlbrandt, Werner/0000-0002-2013-4810				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Davis AJ, 1998, MOL BIOL CELL, V9, P2577, DOI 10.1091/mbc.9.9.2577; ElMoualij B, 1997, YEAST, V13, P573, DOI 10.1002/(SICI)1097-0061(199705)13:6<573::AID-YEA107>3.0.CO;2-I; Geissler A, 2000, MOL BIOL CELL, V11, P3977, DOI 10.1091/mbc.11.11.3977; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Jensen RE, 2001, NAT STRUCT BIOL, V8, P1008, DOI 10.1038/nsb1201-1008; Kaldi K, 1998, EMBO J, V17, P1569, DOI 10.1093/emboj/17.6.1569; Koehler CM, 1999, TRENDS BIOCHEM SCI, V24, P428, DOI 10.1016/S0968-0004(99)01462-0; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Kovermann P, 2002, MOL CELL, V9, P363, DOI 10.1016/S1097-2765(02)00446-X; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Model K, 2002, J MOL BIOL, V316, P657, DOI 10.1006/jmbi.2001.5365; Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Zara V, 2001, J MOL BIOL, V310, P965, DOI 10.1006/jmbi.2001.4833	23	232	244	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1747	1751		10.1126/science.1080945	http://dx.doi.org/10.1126/science.1080945			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637749				2022-12-28	WOS:000181519500050
J	Royer, S; Pare, D				Royer, S; Pare, D			Conservation of total synaptic weight through balanced synaptic depression and potentiation	NATURE			English	Article							LONG-TERM POTENTIATION; PYRAMIDAL CELLS; PLASTICITY; HIPPOCAMPUS; LTP; NEURONS; CALCIUM; STORES; EFFICACY; RELEASE	Memory is believed to depend on activity-dependent changes in the strength of synapses(1). In part, this view is based on evidence that the efficacy of synapses can be enhanced or depressed depending on the timing of pre- and postsynaptic activity(2-5). However, when such plastic synapses are incorporated into neural network models, stability problems may develop because the potentiation or depression of synapses increases the likelihood that they will be further strengthened or weakened(6). Here we report biological evidence for a homeostatic mechanism that reconciles the apparently opposite requirements of plasticity and stability. We show that, in intercalated neurons of the amygdala, activity-dependent potentiation or depression of particular glutamatergic inputs leads to opposite changes in the strength of inputs ending at other dendritic sites. As a result, little change in total synaptic weight occurs, even though the relative strength of inputs is modified. Furthermore, hetero- but not homosynaptic alterations are blocked by intracellular dialysis of drugs that prevent Ca2+ release from intracellular stores. Thus, in intercalated neurons at least, inverse heterosynaptic plasticity tends to compensate for homosynaptic long-term potentiation and depression, thus stabilizing total synaptic weight.	Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick	Pare, D (corresponding author), Rutgers State Univ, Ctr Mol & Behav Neurosci, 197 Univ Ave, Newark, NJ 07102 USA.	pare@axon.rutgers.edu						Abbott LF, 2000, NAT NEUROSCI, V3, P1178, DOI 10.1038/81453; ABRAHAM WC, 1991, BRAIN RES, V546, P336, DOI 10.1016/0006-8993(91)91498-P; Arbib MA, 1995, HDB BRAIN THEORY NEU; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Coussens CM, 1996, LEARN MEMORY, V3, P106, DOI 10.1101/lm.3.2-3.106; Debanne D, 1998, J PHYSIOL-LONDON, V507, P237, DOI 10.1111/j.1469-7793.1998.237bu.x; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; Emptage N, 1999, NEURON, V22, P115, DOI 10.1016/S0896-6273(00)80683-2; Feldman DE, 2000, NEURON, V27, P45, DOI 10.1016/S0896-6273(00)00008-8; HOLM S, 1979, SCAND J STAT, V6, P65; Liang Y, 2002, J NEUROPHYSIOL, V87, P1132, DOI 10.1152/jn.00661.2001; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; ODonovan MJ, 1997, TRENDS NEUROSCI, V20, P431, DOI 10.1016/S0166-2236(97)01124-7; Royer S, 2002, NEUROSCIENCE, V115, P455, DOI 10.1016/S0306-4522(02)00455-4; Scanziani M, 1996, NATURE, V380, P446, DOI 10.1038/380446a0; Segev C, 1989, METHODS NEURONAL MOD, P9; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Song S, 2000, NAT NEUROSCI, V3, P919, DOI 10.1038/78829; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; Winder DG, 2001, NAT REV NEUROSCI, V2, P461, DOI 10.1038/35081514; Xu L, 1999, J BIOL CHEM, V274, P32680, DOI 10.1074/jbc.274.46.32680	30	241	245	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2003	422	6931					518	522		10.1038/nature01530	http://dx.doi.org/10.1038/nature01530			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673250				2022-12-28	WOS:000181965400037
J	Mozaffarian, D; Kumanyika, SK; Lemaitre, RN; Olson, JL; Burke, GL; Siscovick, DS				Mozaffarian, D; Kumanyika, SK; Lemaitre, RN; Olson, JL; Burke, GL; Siscovick, DS			Cereal, fruit, and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the American-Heart-Associations-Epidemiology-Council	APR 24, 2002	HONOLULU, HI	Amer Heart Assoc Epidemiol Council			CORONARY-HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; DIETARY FIBER; MORTALITY; CANCER; REDUCE; DEATH; WOMEN; MEN	Context People older than 65 years are the fastest-growing segment of the population and account for the majority of cardiovascular disease (CVD) morbidity, mortality, and health care expenditures. Additionally, the influence of dietary habits on risk may be less pronounced in elderly persons, when atherosclerosis is more advanced. However, few data address the influence of diet on CVD risk in this population. Objective To determine whether fiber consumption from fruit, vegetable, and cereal sources (including whole grains and bran) is associated with incident CVD in elderly persons. Design Prospective cohort study conducted from 1989 to June 2000. Setting and Participants Population-based, multicenter study among 3588 men and women aged 65 years or older and free of known CVD at baseline in 1989-1990. Usual dietary fiber consumption was assessed at baseline (mean participant age, 72 years) using a 99-item food frequency questionnaire. Main Outcome Measure Incident CVD (combined stroke, ischemic heart disease death, and nonfatal myocardial infarction). Results During 8.6 years mean follow-up, there were 811 incident CVD events. After adjustment for age, sex, education, diabetes, ever smoking, pack-years of smoking, daily physical activity, exercise intensity, alcohol intake, and fruit and vegetable fiber consumption, cereal fiber consumption was inversely associated with incident CVD (P for trend=.02), with 21% lower risk (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.62-0.99) in the highest quintile of intake, compared with the lowest quintile. In similar analyses, neither fruit fiber intake (P for trend=.98) nor vegetable fiber intake (P for trend=.95) were associated with incident CVD. When CVD events were separately evaluated, higher cereal fiber intake was associated with lower risk of total stroke and ischemic stroke and a trend toward lower risk of ischemic heart disease death. In a post hoc analysis, dark breads such as wheat, rye, or pumpernickel were associated with a lower risk of incident CVD (HR, 0.76; 95% CI, 0.64-0.90) rather than cereal fiber from other sources. Conclusions Cereal fiber consumption late in life is associated with lower risk of incident CVD, supporting recommendations for elderly individuals to increase consumption of dietary cereal fiber.	Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA; Univ Washington, Div Cardiol, Seattle, WA 98101 USA; Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; NHLBI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Pennsylvania; Pennsylvania Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University	Mozaffarian, D (corresponding author), Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.	darymd@hotmail.com	Mozaffarian, Dariush/B-2276-2008		DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC015103, N01HC085086, N01HC035129, N01HC085079] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-35129, N01-HC-15103, N01-HC-85079, N01-HC-85086] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aldoori WH, 1998, J NUTR, V128, P714, DOI 10.1093/jn/128.4.714; *AM HEART ASS, 2001, 2002 HEART STROK STA; ANDERSON JW, 2002, CURR ATHEROSCLER REP, V2, P536; Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; Burke V, 2001, HYPERTENSION, V38, P821, DOI 10.1161/hy1001.092614; BURR ML, 1989, LANCET, V2, P757; CUSHMAN M, 1995, CLIN CHEM, V41, P264; FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; HUMBLE CG, 1993, AM J PREV MED, V9, P197, DOI 10.1016/S0749-3797(18)30715-3; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Jacobs DR, 1998, AM J CLIN NUTR, V68, P248, DOI 10.1093/ajcn/68.2.248; Jenkins DJA, 2000, BRIT J NUTR, V83, pS157; Katz DL, 2001, PREV MED, V33, P476, DOI 10.1006/pmed.2001.0918; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KROMHOUT D, 1982, LANCET, V2, P518; Kumanyika S, 1996, J AM DIET ASSOC, V96, P137, DOI 10.1016/S0002-8223(96)00042-9; Kumanyika Shiriki, 1994, Annals of Epidemiology, V4, P404; Kumanyika SK, 1997, AM J CLIN NUTR, V65, P1123; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; Liu SM, 1999, AM J CLIN NUTR, V70, P412; Liu SM, 2002, J AM COLL CARDIOL, V39, P49, DOI 10.1016/S0735-1097(01)01695-3; *PAN MICR SUBC UPP, 2002, DIET REF INT EN CARB; Panel on the Definition of Dietary Fiber, 2001, DIET REF INT PROP DE; Pereira M A, 2000, Curr Atheroscler Rep, V2, P494, DOI 10.1007/s11883-000-0049-5; Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720; Price T R, 1993, Ann Epidemiol, V3, P504; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; RAUTAHARJU PM, 1990, METHOD INFORM MED, V29, P362; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; SMUCKER R, 1989, AM J EPIDEMIOL, V129, P445, DOI 10.1093/oxfordjournals.aje.a115149; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; Terry P, 2001, GASTROENTEROLOGY, V120, P387, DOI 10.1053/gast.2001.21171; Todd S, 1999, AM J EPIDEMIOL, V150, P1073, DOI 10.1093/oxfordjournals.aje.a009931; *US CENS BUR, NAT POP PROJ; *USDA AGR RES SERV, 2002, 2002 USDA NUTR DAT S; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Wolk A, 1999, JAMA-J AM MED ASSOC, V281, P1998, DOI 10.1001/jama.281.21.1998	39	192	210	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1659	1666		10.1001/jama.289.13.1659	http://dx.doi.org/10.1001/jama.289.13.1659			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	662JX	12672734	Bronze			2022-12-28	WOS:000181944500029
J	Lalloo, F; Varley, J; Ellis, D; Moran, A; O'Dair, L; Pharoah, P; Evans, DGR				Lalloo, F; Varley, J; Ellis, D; Moran, A; O'Dair, L; Pharoah, P; Evans, DGR		Early Onset Breast Canc Study Grp	Prediction of pathogenic mutations in patients with early-onset breast cancer by family history	LANCET			English	Article								We aimed to assess frequency and penetrance of BRCA1, BRCA2, and TP53 mutations in women diagnosed with breast cancer aged 30 years or younger, and then correlate this frequency with family history. 17 of 36 familial cases had a BRCA1, BRCA2, or TP53 mutation, compared with three of 63 non-familial cases. The calculated population frequency of TP53 mutations was one In 5000, substantially greater than previous estimates. This finding underlines the importance of accurate elucidation of a family history from young women diagnosed with breast cancer. Establishment of family history could help with development of patient-specific management and tumour surveillance protocols.	St Marys Hosp, Dept Clin Genet, Manchester M13 0JH, Lancs, England; Christie NHS Trust, Canc Res UK Paterson Inst Canc Res, Manchester, Lancs, England; Guys Hosp, London SE1 9RT, England; Univ Manchester, Ctr Canc Epidemiol, Manchester M13 9PL, Lancs, England; Univ Cambridge, Dept Oncol, Strangeways Res Lab, Cambridge CB2 1TN, England	University of Manchester; Cancer Research UK; Christie NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of Manchester; University of Cambridge	Lalloo, F (corresponding author), St Marys Hosp, Dept Clin Genet, Manchester M13 0JH, Lancs, England.	Fiona.Lalloo@cmmc.nhs.uk	Pharoah, Paul/V-6658-2019; Evans, D Gareth/AAB-4308-2022; Mathew, Christopher G/G-3434-2015	Pharoah, Paul/0000-0001-8494-732X; Evans, D Gareth/0000-0002-8482-5784; Mathew, Christopher G/0000-0003-4178-1838; Howell, Anthony/0000-0002-6233-719X				BIRCH JM, 1994, CANCER RES, V54, P1298; EASTON DF, 1995, AM J HUM GENET, V56, P265; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301	4	130	132	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 29	2003	361	9363					1101	1102		10.1016/S0140-6736(03)12856-5	http://dx.doi.org/10.1016/S0140-6736(03)12856-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672316				2022-12-28	WOS:000181865200014
J	Smee, S				Smee, S			ABC of learning and teaching in medicine - Skill based assessment	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CHECKLISTS		Med Council Canada, Ottawa, ON, Canada		Smee, S (corresponding author), Med Council Canada, Ottawa, ON, Canada.							Gorter S, 2000, ACAD MED, V75, P1130, DOI 10.1097/00001888-200011000-00022; Hodges B, 1999, ACAD MED, V74, P1129, DOI 10.1097/00001888-199910000-00017; Kaufman DM, 2000, ACAD MED, V75, P267, DOI 10.1097/00001888-200003000-00018; Newble D, 1994, TEACH LEARN MED, V6, P213; Norcini JJ, 2002, BMJ-BRIT MED J, V324, P408, DOI 10.1136/bmj.324.7334.408; REZNICK RK, 1993, ACAD MED, V68, P513, DOI 10.1097/00001888-199307000-00001	6	59	67	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	2003	326	7391					703	706		10.1136/bmj.326.7391.703	http://dx.doi.org/10.1136/bmj.326.7391.703			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663WL	12663410	Green Published			2022-12-28	WOS:000182029500028
J	Gilmore, MS; Ferretti, JJ				Gilmore, MS; Ferretti, JJ			Microbiology: The thin line between gut commensal and pathogen	SCIENCE			English	Editorial Material							RESISTANT ENTEROCOCCUS-FAECALIS; VIRULENCE		Dept Ophthalmol, Oklahoma City, OK 73104 USA; Dept Microbiol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73104 USA; Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Gilmore, MS (corresponding author), Dept Ophthalmol, Oklahoma City, OK 73104 USA.							Hancock LE, 2000, GRAM-POSITIVE PATHOGENS, P251; Hooper LV, 1999, P NATL ACAD SCI USA, V96, P9833, DOI 10.1073/pnas.96.17.9833; Hooper LV, 2002, ANNU REV NUTR, V22, P283, DOI 10.1146/annurev.nutr.22.011602.092259; MOORE WEC, 1974, APPL MICROBIOL, V27, P961, DOI 10.1128/AEM.27.5.961-979.1974; Mundy LM, 2000, CLIN MICROBIOL REV, V13, P513, DOI 10.1128/CMR.13.4.513-522.2000; Paulsen IT, 2003, SCIENCE, V299, P2071, DOI 10.1126/science.1080613; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P1588, DOI 10.1128/AAC.33.9.1588; Shankar N, 2002, NATURE, V417, P746, DOI 10.1038/nature00802; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; WOSTMANN BS, 1983, LAB ANIM SCI, V33, P46; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029	11	120	126	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2003	299	5615					1999	+		10.1126/science.1083534	http://dx.doi.org/10.1126/science.1083534			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663906				2022-12-28	WOS:000181834200031
J	Lanoue, JL; Arkovitz, MS				Lanoue, JL; Arkovitz, MS			Trichobezoar in a four-year-old girl	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Lanoue, JL (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA.								0	6	6	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2003	348	13					1242	1242		10.1056/NEJMicm020348	http://dx.doi.org/10.1056/NEJMicm020348			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659RG	12660388				2022-12-28	WOS:000181790800006
J	Nishida, H; Pigg, KB; Rigby, JF				Nishida, H; Pigg, KB; Rigby, JF			Swimming sperm in an extinct Gondwanan plant	NATURE			English	Article									Chuo Univ, Fac Sci & Engn, Bunkyo Ku, Tokyo 1128551, Japan; Queensland Univ Technol, Sch Nat Resource Sci, Brisbane, Qld, Australia; Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA	Chuo University; Queensland University of Technology (QUT); Arizona State University; Arizona State University-Tempe	Nishida, H (corresponding author), Chuo Univ, Fac Sci & Engn, Bunkyo Ku, 1-13-27 Kasuga, Tokyo 1128551, Japan.							BLERHORST DW, 1971, MORPHOLOGY VASCULAR; CASS D, 1970, AM J BOT, V57, P2; CHAMBERLAIN CJ, 1935, GYMNOSPERMS; Gifford EM, 1989, MORPHOLOGY EVOLUTION; Gould RE, 1977, ALCHERINGA, V1, P387, DOI 10.1080/03115517708527774; Hirase S., 1896, BOT MAG TOKYO, V10, P325; Ikeno, 1896, BOT MAG TOKYO, V10, P367, DOI 10.15281/jplantres1887.10.115_61; LI Y, 1989, PROTOPLASMA, V149, P57, DOI 10.1007/BF01623983; NORSTOG KJ, 1986, BOT GAZ, V147, P40, DOI 10.1086/337566; Pigg KB, 1997, REV PALAEOBOT PALYNO, V97, P339, DOI 10.1016/S0034-6667(97)00007-9; RETALIACK G, 1988, PALEOBIOLOGY, V7, P54; ROTHWELL GW, 2001, BOT 2001, P25; STEWART WN, 1951, AM MIDL NAT, V46, P717, DOI 10.2307/2421812	13	29	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					396	397		10.1038/422396a	http://dx.doi.org/10.1038/422396a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660772				2022-12-28	WOS:000181801200033
J	Lochhead, J; Elston, JS				Lochhead, J; Elston, JS			Lesson of the week - Doxycycline induced intracranial hypertension	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PSEUDO-TUMOR CEREBRI; VISUAL-LOSS		Radcliffe Infirm, Oxford Eye Hosp, Dept Ophthalmol, Oxford OX2 6HE, England	Radcliffe Infirmary	Elston, JS (corresponding author), Radcliffe Infirm, Oxford Eye Hosp, Dept Ophthalmol, Oxford OX2 6HE, England.	mary.spearman@orh.nhs.uk						CORBETT JJ, 1982, ARCH NEUROL-CHICAGO, V39, P461, DOI 10.1001/archneur.1982.00510200003001; CORBETT JJ, 1983, CAN J NEUROL SCI, V10, P221, DOI 10.1017/S0317167100045042; Goulden V, 1996, BRIT J DERMATOL, V134, P693, DOI 10.1111/j.1365-2133.1996.tb06972.x; JOHNSTON I, 1974, BRAIN, V97, P301, DOI 10.1093/brain/97.1.301; Juckett G, 1999, AM FAM PHYSICIAN, V59, P2523; JUCKETT G, 1999, AM FAM PHYSICIAN, V2, P2535; Lander C M, 1989, Clin Exp Neurol, V26, P161; MONACO F, 1978, EUR NEUROL, V17, P48, DOI 10.1159/000114921; Nagarajan L, 2000, J PAEDIATR CHILD H, V36, P82, DOI 10.1046/j.1440-1754.2000.00430.x; ORCUTT JC, 1984, OPHTHALMOLOGY, V91, P1303; Rowe FJ, 1999, INT J OBESITY, V23, P54, DOI 10.1038/sj.ijo.0800758; STUART BH, 1978, J PEDIATR-US, V93, P901, DOI 10.1016/S0022-3476(78)81137-8	12	25	25	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	2003	326	7390					641	642		10.1136/bmj.326.7390.641	http://dx.doi.org/10.1136/bmj.326.7390.641			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649241	Green Published			2022-12-28	WOS:000181870800021
J	Johnston, SL; Unsworth, J; Gompels, MM				Johnston, SL; Unsworth, J; Gompels, MM			Lesson of the week - Adrenaline given outside the context of life threatening allergic reactions	BRITISH MEDICAL JOURNAL			English	Review							ANAPHYLAXIS; MANAGEMENT		Southmead Gen Hosp, Dept Immunol & Immunogenet, Bristol BS10 5NB, Avon, England	Southmead Hospital	Johnston, SL (corresponding author), Southmead Gen Hosp, Dept Immunol & Immunogenet, Bristol BS10 5NB, Avon, England.		Johnston, Sebastian Lennox/I-2423-2012	Johnston, Sebastian Lennox/0000-0003-3009-9200				*ASS AN GB IR BRIT, 1995, SUSP AN REACT ASS AN; *BRIT MED ASS ROYA, 2002, BRIT NAT FORM, P158; Chamberlain D, 1999, J ACCID EMERG MED, V16, P243; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Stewart AG, 1996, QJM-MON J ASSOC PHYS, V89, P859, DOI 10.1093/qjmed/89.11.859; Unsworth DJ, 2001, ARCH DIS CHILD, V84, P410, DOI 10.1136/adc.84.5.410	6	54	54	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 15	2003	326	7389					589	590		10.1136/bmj.326.7389.589	http://dx.doi.org/10.1136/bmj.326.7389.589			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657ZF	12637407	Green Published			2022-12-28	WOS:000181696600023
J	Bausch, AR; Bowick, MJ; Cacciuto, A; Dinsmore, AD; Hsu, MF; Nelson, DR; Nikolaides, MG; Travesset, A; Weitz, DA				Bausch, AR; Bowick, MJ; Cacciuto, A; Dinsmore, AD; Hsu, MF; Nelson, DR; Nikolaides, MG; Travesset, A; Weitz, DA			Grain boundary scars and spherical crystallography	SCIENCE			English	Article							CONFIGURATIONS; CHARGES	We describe experimental investigations of the structure of two-dimensional spherical crystals. The crystals, formed by beads self-assembled on water droplets in oil, serve as model systems for exploring very general theories about the minimum-energy configurations of particles with arbitrary repulsive interactions on curved surfaces. Above a critical system size we find that crystals develop distinctive high-angle grain boundaries, or scars, not found in planar crystals. The number of excess defects in a scar is shown to grow linearly with the dimensionless system size. The observed slope is expected to be universal, independent of the microscopic potential.	Tech Univ Munich, Dept Phys, D-85747 Munich, Germany; Syracuse Univ, Dept Phys, Syracuse, NY 13244 USA; FOM, Inst Atom & Mol Phys, NL-1098 SJ Amsterdam, Netherlands; Univ Massachusetts, Dept Phys, Amherst, MA 01003 USA; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA; Iowa State Univ, Dept Phys & Astron, Ames, IA 50011 USA; Ames Natl Lab, Ames, IA 50011 USA	Technical University of Munich; University of Munich; Syracuse University; AMOLF; University of Massachusetts System; University of Massachusetts Amherst; Harvard University; Harvard University; Iowa State University; United States Department of Energy (DOE); Ames National Laboratory	Bausch, AR (corresponding author), Tech Univ Munich, Dept Phys, E22, D-85747 Munich, Germany.	abausch@ph.tum.de; bowick@physics.syr.edu						Altschuler EL, 1997, PHYS REV LETT, V78, P2681, DOI 10.1103/PhysRevLett.78.2681; Anderson O., 1983, RADIOLARIA; BONSALL L, 1977, PHYS REV B, V15, P1959, DOI 10.1103/PhysRevB.15.1959; Bowick M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.185502; Bowick MJ, 2000, PHYS REV B, V62, P8738, DOI 10.1103/PhysRevB.62.8738; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Chaikin P.M., 1995, PRINCIPLES CONDENSED, V10, DOI DOI 10.1017/CBO9780511813467; Conway J. H., 1998, SPHERE PACKINGS LATT; Delaunay B, 1934, B ACAD SCI URSS, V6, P793; Dinsmore AD, 2002, SCIENCE, V298, P1006, DOI 10.1126/science.1074868; Dodgson MJW, 1997, PHYS REV B, V55, P3816, DOI 10.1103/PhysRevB.55.3816; Erber T, 1997, ADV CHEM PHYS, V98, P495, DOI 10.1002/9780470141571.ch5; EULER L, 1953, OPERA OMNIA 1, V26; Hilton P, 1996, AM MATH MON, V103, P121, DOI 10.2307/2975104; Jarrold MF, 2000, NATURE, V407, P26, DOI 10.1038/35024178; KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0; LEIDERER P, 1995, Z PHYS B CON MAT, V98, P303, DOI 10.1007/BF01338394; MARZEC CJ, 1993, BIOPHYS J, V65, P2559, DOI 10.1016/S0006-3495(93)81313-4; Nelson D. R., 2002, DEFECTS GEOMETRY CON; Perez-Garrido A, 1999, PHYS REV B, V60, P15628, DOI 10.1103/PhysRevB.60.15628; PUM D, 1991, J BACTERIOL, V173, P6865, DOI 10.1128/jb.173.21.6865-6873.1991; Reddy VS, 2001, J VIROL, V75, P11943, DOI 10.1128/JVI.75.24.11943-11947.2001; Sleytr UB, 2001, PROG SURF SCI, V68, P231, DOI 10.1016/S0079-6816(01)00008-9; SLOANE NJA, 1984, SCI AM, V250, P116, DOI 10.1038/scientificamerican0184-116; Smale S, 1998, MATH INTELL, V20, P7, DOI 10.1007/BF03025291; Thomson JJ, 1904, PHILOS MAG, V7, P237, DOI 10.1080/14786440409463107; TOOMRE A, COMMUNICATION	27	393	394	4	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	2003	299	5613					1716	1718		10.1126/science.1081160	http://dx.doi.org/10.1126/science.1081160			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637740	Green Submitted			2022-12-28	WOS:000181519500040
J	Carney, S; Cowen, P; Geddes, J; Goodwin, G; Rogers, R; Dearness, K; Tomlin, A; Eastaugh, J; Freemantle, N; Lester, H; Harvey, A; Scott, A				Carney, S; Cowen, P; Geddes, J; Goodwin, G; Rogers, R; Dearness, K; Tomlin, A; Eastaugh, J; Freemantle, N; Lester, H; Harvey, A; Scott, A		UK ECT Review Grp	Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis	LANCET			English	Review							ELECTRODE PLACEMENT; UNILATERAL ECT; STIMULUS-INTENSITY; COMPARATIVE TRIAL; BILATERAL ECT; SIMULATED ECT; BRIEF-PULSE; ANTIDEPRESSANT; MELANCHOLIA; TWICE	Background We aimed to review published work for the efficacy and safety of electroconvulsive therapy (ECT) with simulated ECT, ECT versus pharmacotherapy, and different forms of ECT for patients with depressive illness. Methods We designed a systematic overview and meta-analysis of randomised controlled trials and observational studies. We obtained data from the Cochrane Collaboration Depressive Anxiety and Neurosis and Schizophrenia Group Controlled trial registers, Cochrane Controlled Trials register, Biological Abstracts, CINAHL, EMBASE, LILACS, MEDLINE, PsycINFO, and SIGLE, reference lists, and specialist textbooks. Our main outcome measures were depressive symptoms, measures of cognitive function, and mortality. Findings Meta-analysis of data of short-term efficacy from randomised controlled trials was possible. Real ECT was significantly more effective than simulated ECT (six trials, 256 patients, standardised effect size [SES] -0.91, 95% CI-1.27 to -0.54). Treatment with ECT was significantly more effective than pharmacotherapy (18 trials, 1144 participants, SES -0.80, 95% CI-1.29 to -0.29). Bilateral ECT was more effective than unipolar ECT (22 trials, 1408 participants, SES -0.32, 95% CI-0.46 to -0.19). Interpretation ECT is an effective short-term treatment for depression, and is probably more effective than drug therapy. Bilateral ECT is moderately more effective than unilateral ECT, and high dose ECT is more effective than low dose.	Univ Oxford, Dept Psychiat, Ctr Evidence Based Mental Hlth, Oxford, England; Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham, W Midlands, England; Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; Royal Edinburgh & Associated Hosp, Edinburgh EH10 5HF, Midlothian, Scotland	University of Oxford; University of Birmingham; University of Oxford; Royal Infirmary of Edinburgh	Geddes, J (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	john.geddes@psych.ox.ac.uk	Goodwin, Guy/ABE-6084-2020	Freemantle, Nick/0000-0001-5807-5740; Cowen, Philip/0000-0001-5518-6138; Geddes, John/0000-0002-5281-5960				ABRAMS R, 1983, AM J PSYCHIAT, V140, P463; ABRAMS R, 1974, COMPR PSYCHIAT, V15, P233, DOI 10.1016/0010-440X(74)90021-2; ABRAMS R, 1969, DIS NERV SYST, V30, P262; ABRAMS R, 1991, ARCH GEN PSYCHIAT, V48, P746; ANDREWS P, 1988, CLADISTICS, V4, P297; [Anonymous], 1999, STAT MED, V18, P1905; AVERY D, 1976, ARCH GEN PSYCHIAT, V33, P1029; BABIGIAN HM, 1984, ARCH GEN PSYCHIAT, V41, P246; Bagadia V N, 1981, Indian J Psychiatry, V23, P324; BIDDER TG, 1970, AM J PSYCHIAT, V127, P737, DOI 10.1176/ajp.127.6.737; Black D.W., 1989, ANN CLIN PSYCHIATRY, V1, P165, DOI [10.3109/10401238909149975, DOI 10.3109/10401238909149975]; BRANDON S, 1984, BRIT MED J, V288, P22, DOI 10.1136/bmj.288.6410.22; BRUCE EM, 1960, AM J PSYCHIAT, V117, P76, DOI 10.1176/ajp.117.1.76; CALLOWAY SP, 1981, ACTA PSYCHIAT SCAND, V64, P442, DOI 10.1111/j.1600-0447.1981.tb00803.x; Carney M W, 1976, PDM, V7(9-12)8, P77; COSTELLO CG, 1970, BRIT J PSYCHIAT, V116, P69, DOI 10.1192/bjp.116.530.69; DANIEL WF, 1984, BRIT J PSYCHIAT, V145, P394, DOI 10.1192/bjp.145.4.394; DAVIDSON J, 1978, ARCH GEN PSYCHIAT, V35, P639; DELIA G, 1970, ACTA PSYCHIAT SCAND, P44; DELIA G, 1970, ACTA PSYCHIAT SCAND, P30; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DINAN TG, 1989, ACTA PSYCHIAT SCAND, V80, P97, DOI 10.1111/j.1600-0447.1989.tb01306.x; Duffett R, 1998, BRIT J PSYCHIAT, V172, P401, DOI 10.1192/bjp.172.5.401; Fink M, 2000, NATURE, V403, P826, DOI 10.1038/35002776; FLEMINGE.JJ, 1970, AM J PSYCHIAT, V127, P430, DOI 10.1176/ajp.127.4.430; Folkerts HW, 1997, ACTA PSYCHIAT SCAND, V96, P334, DOI 10.1111/j.1600-0447.1997.tb09926.x; FRASER RM, 1980, ACTA PSYCHIAT SCAND, V62, P13, DOI 10.1111/j.1600-0447.1980.tb00590.x; FREEMAN CPL, 1978, LANCET, V1, P738; Freemantle N, 2001, BRIT MED J, V322, P989, DOI 10.1136/bmj.322.7292.989; FROMHOLT P, 1973, ACTA PSYCHIAT SCAND, V49, P466, DOI 10.1111/j.1600-0447.1973.tb04439.x; GANGADHAR BN, 1982, BRIT J PSYCHIAT, V141, P367, DOI 10.1192/bjp.141.4.367; GANGADHAR BN, 1993, J AFFECT DISORDERS, V27, P273, DOI 10.1016/0165-0327(93)90051-K; GREENBLATT M, 1964, AM J PSYCHIAT, V120, P935, DOI 10.1176/ajp.120.10.935; GREGORY S, 1985, BRIT J PSYCHIAT, V146, P520, DOI 10.1192/bjp.146.5.520; HALLIDAY AM, 1968, BRIT J PSYCHIAT, V114, P997, DOI 10.1192/bjp.114.513.997; HEDGES LV, 1985, STAT METHODS META AN; HERMANN RC, 1995, AM J PSYCHIAT, V152, P869; HERRINGTON RN, 1974, LANCET, V2, P731; Heshe J, 1978, Acta Psychiatr Scand Suppl, P1; HICKIE I, 1995, BIOL PSYCHIAT, V37, P151, DOI 10.1016/0006-3223(94)00174-2; HORNE RL, 1985, ARCH GEN PSYCHIAT, V42, P1087; HUTCHINSON JT, 1963, BRIT J PSYCHIAT, V109, P536, DOI 10.1192/bjp.109.461.536; Janakiramaiah N, 2000, J AFFECT DISORDERS, V57, P255, DOI 10.1016/S0165-0327(99)00079-8; Janakiramaiah N, 1998, ACTA PSYCHIAT SCAND, V98, P316, DOI 10.1111/j.1600-0447.1998.tb10090.x; JOHNSTONE EC, 1980, LANCET, V2, P1317; KELLNER CH, 1992, CONVULSIVE THER, V8, P245; KENDRICK D C, 1965, Br J Soc Clin Psychol, V4, P63; KOLBEINSSON H, 1986, ACTA PSYCHIAT SCAND, V73, P28, DOI 10.1111/j.1600-0447.1986.tb02661.x; KRYSTAL AD, 1992, BIOL PSYCHIAT, V31, P617, DOI 10.1016/0006-3223(92)90249-Y; Krystal AD, 1996, CONVULSIVE THER, V12, P13; LAMBOURN J, 1978, BRIT J PSYCHIAT, V133, P514, DOI 10.1192/bjp.133.6.514; LERER B, 1995, AM J PSYCHIAT, V152, P564; LETEMENDIA FJJ, 1993, PSYCHOL MED, V23, P349, DOI 10.1017/S0033291700028452; LEVY R, 1968, BRIT J PSYCHIAT, V114, P459, DOI 10.1192/bjp.114.509.459; MACSWEENEY DA, 1975, LANCET, V2, P510; MALITZ S, 1986, ANN NY ACAD SCI, V462, P56, DOI 10.1111/j.1749-6632.1986.tb51239.x; MALITZ S, 1984, AM J SOCIAL PSYCHIAT, V4, P47; MARTIN WL, 1965, AM J PSYCHIAT, V121, P1087, DOI 10.1176/ajp.121.11.1087; McCall WV, 2000, ARCH GEN PSYCHIAT, V57, P438, DOI 10.1001/archpsyc.57.5.438; MCCALL WV, 1995, AM J GERIAT PSYCHIAT, V3, P317, DOI 10.1097/00019442-199503040-00006; MCDONALD IM, 1966, AM J PSYCHIAT, V122, P1427, DOI 10.1176/ajp.122.12.1427; *MED RES COUNC, 1965, BMJ-BRIT MED J, V1, P881; PAPAKOSTAS Y, 1984, AM J PSYCHIAT, V141, P1623; PHILIBERT RA, 1995, J CLIN PSYCHIAT, V56, P390; PIPPARD J, 1992, BRIT J PSYCHIAT, V160, P621, DOI 10.1192/bjp.160.5.621; ROBIN AA, 1962, J MENT SCI, V108, P217, DOI 10.1192/bjp.108.453.217; SACKEIM HA, 1987, AM J PSYCHIAT, V144, P1449; SACKEIM HA, 1993, NEW ENGL J MED, V328, P839, DOI 10.1056/NEJM199303253281204; Sackeim HA, 2001, JAMA-J AM MED ASSOC, V285, P1299, DOI 10.1001/jama.285.10.1299; SACKEIM HA, 1986, ANN NY ACAD SCI, V462, P326, DOI 10.1111/j.1749-6632.1986.tb51267.x; Sackeim HA, 2000, ARCH GEN PSYCHIAT, V57, P425, DOI 10.1001/archpsyc.57.5.425; SCOTT AIF, 1992, BRIT J PSYCHIAT, V160, P360, DOI 10.1192/bjp.160.3.360; Shapira B, 1998, BRIT J PSYCHIAT, V172, P44, DOI 10.1192/bjp.172.1.44; Shawcross Reinout Vieweg Charles R, 1998, J Ment Health, V7, P403, DOI 10.1080/09638239818003; Smith TC, 1995, STAT MED, V14, P2685, DOI 10.1002/sim.4780142408; STANLEY W, 1962, BRIT J PSYCHIAT, V108, P708; STEINER M, 1978, CURR THER RES CLIN E, V23, P655; Sterling P, 2000, NATURE, V403, P242, DOI 10.1038/35002188; Stromgren L S, 1973, Acta Psychiatr Scand Suppl, V240, P8; TAYLOR MA, 1985, BRIT J PSYCHIAT, V146, P308, DOI 10.1192/bjp.146.3.308; VALENTINE M, 1968, BRIT J PSYCHIAT, V114, P989, DOI 10.1192/bjp.114.513.989; WARREN EW, 1984, BRIT J PSYCHIAT, V144, P370, DOI 10.1192/bjp.144.4.370; WEAVER LA, 1977, BIOL PSYCHIAT, V12, P525; WEINER RD, 1986, ANN NY ACAD SCI, V462, P315, DOI 10.1111/j.1749-6632.1986.tb51266.x; WELCH C A, 1982, Psychopharmacology Bulletin, V18, P31; WEST ED, 1981, BRIT MED J, V282, P355, DOI 10.1136/bmj.282.6261.355; WILSON IC, 1963, J NEUROPSYCHIATRY, V4, P331	87	1041	1059	6	189	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 8	2003	361	9360					799	808						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642045				2022-12-28	WOS:000181466600007
J	Verheyen, E; Salzburger, W; Snoeks, J; Meyer, A				Verheyen, E; Salzburger, W; Snoeks, J; Meyer, A			Origin of the superflock of cichlid fishes from Lake Victoria, East Africa	SCIENCE			English	Article							LATE PLEISTOCENE DESICCATION; HAPLOCHROMINE FISHES; SPECIES FLOCK; EVOLUTION; TANGANYIKA; PHYLOGENY; LINEAGE; HISTORY; AGE	Lake Victoria harbors a unique species-rich flock of more than 500 endemic haplochromine cichlid fishes. The origin, age, and mechanism of diversification of this extraordinary radiation are still debated. Geological evidence suggests that the lake dried out completely about 14,700 years ago. On the basis of phylogenetic analyses of almost 300 DNA sequences of the mitochondrial control region of East African cichlids, we find that the Lake Victoria cichlid flock is derived from the geologically older Lake Kivu. We suggest that the two seeding lineages may have already been lake-adapted when they colonized Lake Victoria. A haplotype analysis further shows that the most recent desiccation of Lake Victoria did not lead to a complete extinction of its endemic cichlid fauna and that the major lineage diversification took place about 100,000 years ago.	Univ Konstanz, Dept Biol, Lehrstuhl Zool & Evolut Biol, D-78457 Constance, Germany; Royal Belgian Inst Nat Sci, Vertebrate Dept, B-1000 Brussels, Belgium; Royal Museum Cent Africa, Vertebrate Sect, B-3080 Tervuren, Belgium	University of Konstanz; Royal Belgian Institute of Natural Sciences; Royal Museum for Central Africa	Meyer, A (corresponding author), Univ Konstanz, Dept Biol, Lehrstuhl Zool & Evolut Biol, Univ Str 10, D-78457 Constance, Germany.	axel.meyer@uni-konstanz.de	Meyer, Axel/C-9826-2009; VERHEYEN, ERIK K/E-5550-2013; Salzburger, Walter/G-1598-2011	Meyer, Axel/0000-0002-0888-8193; VERHEYEN, ERIK K/0000-0001-7157-1474; Salzburger, Walter/0000-0002-9988-1674				[Anonymous], 2013, INS PESTS POT GLOB, DOI DOI 10.1016/B978-0-12-386895-4.00005-3; Beadle L.C., 1974, INLAND WATERS TROPIC, DOI [10.4319/lo.1977.22.5.0972b, DOI 10.4319/LO.1977.22.5.0972B]; Booton GC, 1999, MOL PHYLOGENET EVOL, V11, P273, DOI 10.1006/mpev.1998.0576; Clement M, 2000, MOL ECOL, V9, P1657, DOI 10.1046/j.1365-294x.2000.01020.x; EBINGER CJ, 1989, GEOL SOC AM BULL, V101, P885, DOI 10.1130/0016-7606(1989)101<0885:TDOTWB>2.3.CO;2; Fryer G, 1997, HYDROBIOLOGIA, V354, P177, DOI 10.1023/A:1003183432203; Fryer G, 2001, P ROY SOC B-BIOL SCI, V268, P1147, DOI 10.1098/rspb.2001.1601; Greenwood P.H., 1980, Bulletin of the British Museum (Natural History) Zoology, V39, P1; GREENWOOD P H, 1973, Bulletin of the British Museum (Natural History) Zoology, V25, P139; Greenwood P. H., 1981, HAPLOCHROMINE FISHES; Johnson TC, 2000, AMBIO, V29, P2, DOI 10.1639/0044-7447(2000)029[0002:THHOLV]2.0.CO;2; Johnson TC, 1996, SCIENCE, V273, P1091, DOI 10.1126/science.273.5278.1091; Kaufman LS, 1997, ENDEAVOUR, V21, P23, DOI 10.1016/S0160-9327(96)10034-X; LEE WJ, 1995, J MOL EVOL, V41, P54; Lippitsch E, 1997, J FISH BIOL, V51, P284; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; Meyer Axel, 1999, P141; MOEYERSONS J, 1979, MUS R AFR CENTR TERV, P127; Nagl S, 2000, P ROY SOC B-BIOL SCI, V267, P1049, DOI 10.1098/rspb.2000.1109; POUCLET A, 1978, MUS R AFR CENTR DEP, P145; Salzburger W, 2002, SYST BIOL, V51, P113, DOI 10.1080/106351502753475907; Schmidt U, 2001, PALAEOECO A, V27, P51; Seehausen O, 2002, P ROY SOC B-BIOL SCI, V269, P491, DOI 10.1098/rspb.2001.1906; Seehausen O, 2003, P ROY SOC B-BIOL SCI, V270, P129, DOI 10.1098/rspb.2002.2153; Snoeks J, 1997, S AFR J SCI, V93, P579; Snoeks Jos, 2001, Journal of Aquariculture & Aquatic Sciences, V9, P150; Stiassny Melanie L. J., 1994, V50, P235; Stiassny MLJ, 1999, SCI AM, V280, P64, DOI 10.1038/scientificamerican0299-64; STIASSNY MLJ, 1992, NETH J ZOOL, V42, P260, DOI 10.1163/156854291X00324; Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815; STURMBAUER C, 1994, MOL BIOL EVOL, V11, P691; Sturmbauer C, 2001, MOL BIOL EVOL, V18, P144, DOI 10.1093/oxfordjournals.molbev.a003788; STURMBAUER C, 1992, NATURE, V358, P578, DOI 10.1038/358578a0; SWOFFORD DL, 2000, PAUP STAR PHYLOGENET; 1953, ANN REPORT E AFRICAN, V41	35	311	331	2	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 11	2003	300	5617					325	329		10.1126/science.1080699	http://dx.doi.org/10.1126/science.1080699			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665RQ	12649486	Green Submitted			2022-12-28	WOS:000182135400056
J	Takada, S; Kelkar, A; Theurkauf, WE				Takada, S; Kelkar, A; Theurkauf, WE			Drosophila checkpoint kinase 2 couples centrosome function and spindle assembly to genomic integrity	CELL			English	Article							TOPOISOMERASE-II; DNA-DAMAGE; MITOTIC CATASTROPHE; GAMMA-TUBULIN; CLEAVAGE; CELLS; GENE; CHK2; ATM; INHIBITION	In syncytial Drosophila embryos, damaged or incompletely replicated DNA triggers centrosome disruption in mitosis, leading to defects in spindle assembly and anaphase chromosome segregation. The damaged nuclei drop from the cortex and are not incorporated into the cells that form the embryo proper. A null mutation in the Drosophila checkpoint kinase 2 tumor suppressor homolog [DmChk2) blocks this mitotic response to DNA lesions and also prevents loss of defective nuclei from the cortex. In addition, DNA damage leads to increased DmChk2 localization to the centrosome and spindle microtubules. DmChk2 is therefore essential for a "mitotic catastrophe" signal that disrupts centrosome function in response to genotoxic stress and ensures that mutant and aneuploid nuclei are eliminated from the embryonic precursor pool.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Cell Dynam, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Theurkauf, WE (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	william.theurkauf@umassmed.edu		Theurkauf, William/0000-0001-7342-1912; Kelkar, Anju/0000-0001-7956-8210	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050898] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50898] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdu U, 2002, CURR BIOL, V12, P1645, DOI 10.1016/S0960-9822(02)01165-X; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Andreassen PR, 2001, CANCER RES, V61, P7660; Brodsky MH, 2000, GENE DEV, V14, P666; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; Clarkson M, 1999, DNA CELL BIOL, V18, P457, DOI 10.1089/104454999315178; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Foe Victoria E., 1993, P149; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; HUT HMJ, 2003, IN PRESS MOL BIOL CE; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; KROSS J, 1982, BIOCHEMISTRY-US, V21, P4310, DOI 10.1021/bi00261a021; LONG BH, 1985, CANCER RES, V45, P3106; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; Oishi I, 1998, MECH DEVELOP, V71, P49, DOI 10.1016/S0925-4773(97)00200-1; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; RAFF JW, 1989, CELL, V57, P611, DOI 10.1016/0092-8674(89)90130-X; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; Robinson JT, 1999, J CELL BIOL, V146, P597, DOI 10.1083/jcb.146.3.597; Rong YKS, 2002, GENE DEV, V16, P1568, DOI 10.1101/gad.986602; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Sibon OCM, 1999, CURR BIOL, V9, P302, DOI 10.1016/S0960-9822(99)80138-9; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; Takai H, 2000, GENE DEV, V14, P1439; TANABE K, 1991, CANCER RES, V51, P4903; THEURKAUF WE, 1994, DROSOPHILA MELANOGAS; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, CANCER RES, V61, P5718; Xu JH, 2001, FEBS LETT, V508, P394, DOI 10.1016/S0014-5793(01)03103-9; Yu KR, 2000, NAT CELL BIOL, V2, P609, DOI 10.1038/35023555; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	41	168	170	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	2003	113	1					87	99		10.1016/S0092-8674(03)00202-2	http://dx.doi.org/10.1016/S0092-8674(03)00202-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679037	Bronze			2022-12-28	WOS:000182282900009
J	Kaplan, MJ; McCune, WJ				Kaplan, MJ; McCune, WJ			New evidence for vascular disease in patients with early rheumatoid arthritis	LANCET			English	Editorial Material							IMPROVES ENDOTHELIAL FUNCTION; ATHEROSCLEROSIS; MORTALITY; INFLAMMATION		Univ Michigan, Sch Med, Dept Internal Med, Div Rheumatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kaplan, MJ (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Rheumatol, Ann Arbor, MI 48109 USA.	makaplan@med.umich.edu						Bergholm R, 2002, ARTERIOSCL THROM VAS, V22, P1637, DOI 10.1161/01.ATV.0000033516.73864.4E; Buffon A, 2002, NEW ENGL J MED, V347, P5, DOI 10.1056/NEJMoa012295; del Rincon I, 2001, ARTHRITIS RHEUM-US, V44, P2737, DOI 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#; Goodson NJ, 2002, ARTHRITIS RHEUM-US, V46, P2010, DOI 10.1002/art.10419; Greaves DR, 2002, TRENDS IMMUNOL, V23, P535, DOI 10.1016/S1471-4906(02)02331-1; Hurlimann D, 2002, CIRCULATION, V106, P2184, DOI 10.1161/01.CIR.0000037521.71373.44; Kumeda Y, 2002, ARTHRITIS RHEUM-US, V46, P1489, DOI 10.1002/art.10269; Liuzzo G, 2000, CIRCULATION, V101, P2883, DOI 10.1161/01.CIR.101.25.2883; Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615; ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126; Park YB, 2002, ARTHRITIS RHEUM, V46, P1714, DOI 10.1002/art.10359; Pasceri V, 1999, CIRCULATION, V100, P2124, DOI 10.1161/01.CIR.100.21.2124; Sanada M, 2002, J CLIN ENDOCR METAB, V87, P4634, DOI 10.1210/jc.2001-011223; Symmons DPM, 1998, J RHEUMATOL, V25, P1072; Wallberg-Jonsson S, 2002, J RHEUMATOL, V29, P875; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408; Woo KS, 2002, AM J MED, V112, P535, DOI 10.1016/S0002-9343(02)01075-6	17	27	29	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 29	2003	361	9363					1068	1069		10.1016/S0140-6736(03)12901-7	http://dx.doi.org/10.1016/S0140-6736(03)12901-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672306				2022-12-28	WOS:000181865200004
J	Smith, PEM; Shah, P; Sharpe, J; Todd, A; Goringe, AP				Smith, PEM; Shah, P; Sharpe, J; Todd, A; Goringe, AP			Palinopsia	LANCET			English	Editorial Material									Univ Wales Hosp, Epillepsy Unit, Cardiff CF14 4XW, S Glam, Wales; Univ Wales Hosp, Dept Media Resources, Cardiff CF14 4XW, S Glam, Wales; Univ Wales Hosp, Dept Haematol, Cardiff CF14 4XW, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University	Smith, PEM (corresponding author), Univ Wales Hosp, Epillepsy Unit, Cardiff CF14 4XW, S Glam, Wales.	SmithPE@cardiff.ac.uk						CUMMINGS JL, 1982, NEUROLOGY, V32, P444, DOI 10.1212/WNL.32.4.444; Hayashi R, 2002, ACTA NEUROL SCAND, V105, P228, DOI 10.1034/j.1600-0404.2002.1c217.x; MEADOWS JC, 1977, J NEUROL NEUROSUR PS, V40, P5, DOI 10.1136/jnnp.40.1.5; Norton JW, 2000, SEMIN NEUROL, V20, P111, DOI 10.1055/s-2000-6837; Santhouse AM, 2002, BRAIN, V125, P1782, DOI 10.1093/brain/awf174	5	8	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 29	2003	361	9363					1098	1098		10.1016/S0140-6736(03)12896-6	http://dx.doi.org/10.1016/S0140-6736(03)12896-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672314				2022-12-28	WOS:000181865200012
J	Zhang, HL; Yang, ZR; Shen, Y; Tong, L				Zhang, HL; Yang, ZR; Shen, Y; Tong, L			Crystal structure of the carboxyltransferase domain of acetyl-coenzyme a carboxylase	SCIENCE			English	Article							COA CARBOXYLASE; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; ARYLOXYPHENOXYPROPIONATE; INHIBITORS	Acetyl-coenzyme A carboxylases (ACCs) are required for the biosynthesis and oxidation of long-chain fatty acids. They are targets for therapeutics against obesity and diabetes, and several herbicides function by inhibiting their carboxyltransferase (CT) domain. We determined the crystal structure of the free enzyme and the coenzyme A complex of yeast CT at 2.7 angstrom resolution and found that it comprises two domains, both belonging to the crotonase/ClpP superfamily. The active site is at the interface of a dimer. Mutagenesis and kinetic studies reveal the functional roles of conserved residues here. The herbicides target the active site of CT, providing a lead for inhibitor development against human ACCs.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			Tong, Liang/0000-0002-0563-6468				Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; ALBERTS AW, 1972, ENZYMES, V6, P37; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; Benning MM, 2000, BIOCHEMISTRY-US, V39, P4630, DOI 10.1021/bi9928896; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Jelenska J, 2002, J BIOL CHEM, V277, P23208, DOI 10.1074/jbc.M200455200; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; Lenhard JM, 2002, ADV DRUG DELIVER REV, V54, P1199, DOI 10.1016/S0169-409X(02)00092-3; Levert KL, 2002, J BIOL CHEM, V277, P16347, DOI 10.1074/jbc.C200113200; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Mursula AM, 2001, J MOL BIOL, V309, P845, DOI 10.1006/jmbi.2001.4671; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; Weaver LH, 2001, PROTEIN SCI, V10, P2618, DOI 10.1110/ps.ps.32701; Zagnitko O, 2001, P NATL ACAD SCI USA, V98, P6617, DOI 10.1073/pnas.121172798	22	150	170	5	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2003	299	5615					2064	2067		10.1126/science.1081366	http://dx.doi.org/10.1126/science.1081366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663926				2022-12-28	WOS:000181834200054
J	Ji, Y; Chung, YC; Sprinzak, D; Heiblum, M; Mahalu, D; Shtrikman, H				Ji, Y; Chung, YC; Sprinzak, D; Heiblum, M; Mahalu, D; Shtrikman, H			An electronic Mach-Zehnder interferometer	NATURE			English	Article							SLIT INTERFERENCE EXPERIMENT; PHASE	Double-slit electron interferometers fabricated in high mobility two-dimensional electron gases are powerful tools for studying coherent wave-like phenomena in mesoscopic systems(1-6). However, they suffer from low visibility of the interference patterns due to the many channels present in each slit, and from poor sensitivity to small currents due to their open geometry(3-5,7). Moreover, these interferometers do not function in high magnetic fields-such as those required to enter the quantum Hall effect regime(8)-as the field destroys the symmetry between left and right slits. Here we report the fabrication and operation of a single-channel, two-path electron interferometer that functions in a high magnetic field. This device is the first electronic analogue of the optical Mach-Zehnder interferometer(9), and opens the way to measuring interference of quasiparticles with fractional charges. On the basis of measurements of single edge state and closed geometry transport in the quantum Hall effect regime, we find that the interferometer is highly sensitive and exhibits very high visibility (62%). However, the interference pattern decays precipitously with increasing electron temperature or energy. Although the origin of this dephasing is unclear, we show, via shot-noise measurements, that it is not a decoherence process that results from inelastic scattering events.	Weizmann Inst Sci, Dept Condensed Matter Phys, Braun Ctr Submicron Res, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Heiblum, M (corresponding author), Weizmann Inst Sci, Dept Condensed Matter Phys, Braun Ctr Submicron Res, IL-76100 Rehovot, Israel.		heiblum, moty/Q-1193-2019; Ji, Yang/H-7065-2012	Ji, Yang/0000-0003-1671-9266; Sprinzak, David/0000-0001-6776-6957				AHARONOV Y, 1959, PHYS REV, V115, P485, DOI 10.1103/PhysRev.115.485; [Anonymous], 1987, QUANTUM HALL EFFECT; ARONOV AG, 1987, REV MOD PHYS, V59, P755, DOI 10.1103/RevModPhys.59.755; Born M., 1999, PRINCIPLES OPTICS, P348; Buks E, 1998, NATURE, V391, P871, DOI 10.1038/36057; BUTTIKER M, 1986, PHYS REV LETT, V57, P1761, DOI 10.1103/PhysRevLett.57.1761; CHKLOVSKII DB, 1992, PHYS REV B, V46, P4026, DOI 10.1103/PhysRevB.46.4026; dePicciotto R, 1997, NATURE, V389, P162, DOI 10.1038/38241; Ji Y, 2000, SCIENCE, V290, P779, DOI 10.1126/science.290.5492.779; KANE CL, 2002, CONDMAT0210621; Reznikov M, 1998, SUPERLATTICE MICROST, V23, P901, DOI 10.1006/spmi.1997.0559; Schuster R, 1997, NATURE, V385, P417, DOI 10.1038/385417a0; van der Wiel WG, 2000, SCIENCE, V289, P2105, DOI 10.1126/science.289.5487.2105; YACOBY A, 1994, PHYS REV LETT, V73, P3149, DOI 10.1103/PhysRevLett.73.3149; YACOBY A, 1995, PHYS REV LETT, V74, P4047, DOI 10.1103/PhysRevLett.74.4047	15	580	587	6	135	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					415	418		10.1038/nature01503	http://dx.doi.org/10.1038/nature01503			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660779	Green Submitted			2022-12-28	WOS:000181801200040
J	Pearson, H				Pearson, H			Mystery virus slow to yield its identity as patient numbers rise	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					364	364		10.1038/422364b	http://dx.doi.org/10.1038/422364b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660744	Green Published, Bronze			2022-12-28	WOS:000181801200009
J	Seiffert, ER; Simons, EL; Attia, Y				Seiffert, ER; Simons, EL; Attia, Y			Fossil evidence for an ancient divergence of lorises and galagos	NATURE			English	Article							OLIGOCENE; DISCOVERY; EVOLUTION; PRIMATES; AGE	Morphological, molecular, and biogeographic data bearing on early primate evolution suggest that the clade containing extant (or 'crown') strepsirrhine primates (lemurs, lorises and galagos) arose in Afro-Arabia during the early Palaeogene(1), but over a century of palaeontological exploration on that landmass has failed to uncover any conclusive support for that hypothesis(2). Here we describe the first demonstrable crown strepsirrhines from the Afro-Arabian Palaeogene-a galagid and a possible lorisid from the late middle Eocene of Egypt, the latter of which provides the earliest fossil evidence for the distinctive strepsirrhine toothcomb. These discoveries approximately double the previous temporal range of undoubted lorisiforms and lend the first strong palaeontological support to the hypothesis of an ancient Afro-Arabian origin for crown Strepsirrhini and an Eocene divergence of extant lorisiform families(1,3).	Duke Univ, Dept Biol Anthropol & Anat, Durham, NC 27705 USA; Duke Primate Ctr, Div Fossil Primates, Durham, NC 27705 USA; Egyptian Geol Museum, Cairo, Egypt	Duke University; Duke University	Seiffert, ER (corresponding author), Duke Univ, Dept Biol Anthropol & Anat, 1013 Broad St, Durham, NC 27705 USA.	erik.seiffert@duke.edu						Beadnell HJL, 1905, TOPOGRAPHY GEOLOGY F; Bown T.M., 1988, US GEOL SURV PROF PA, V1452, P1; CHARLESD.P, 1970, NATURE, V227, P257, DOI 10.1038/227257a0; CONROY GC, 1987, INT J PRIMATOL, V8, P115, DOI 10.1007/BF02735160; GHEERBRANT E, 1995, CR ACAD SCI II A, V321, P425; GINGERICH PD, 1992, U MICHIGAN PAPERS PA, V30, P1; Godinot Marc, 1994, P235; Holroyd Patricia A., 1996, Palaeovertebrata (Montpellier), V25, P175; KAPPELMAN J, 1992, J GEOL, V100, P647, DOI 10.1086/629619; MacLatchy L, 2002, AM J PHYS ANTHROPOL, P104; Maier W., 1980, Abhandlungen der Senckenbergischen Naturforschenden Gesellschaft, P1; Marivaux L, 2001, SCIENCE, V294, P587, DOI 10.1126/science.1065257; Martin R.D., 1990, PRIMATE ORIGINS EVOL; Martin RD, 2000, INT J PRIMATOL, V21, P1021, DOI 10.1023/A:1005563113546; McCall RA, 1997, P ROY SOC B-BIOL SCI, V264, P663, DOI 10.1098/rspb.1997.0094; Phillips EM, 2002, CAM S BIO EVOL ANTHR, V33, P83; Porter CA, 1997, INT J PRIMATOL, V18, P261, DOI 10.1023/A:1026328804319; Rambaut A, 1998, MOL BIOL EVOL, V15, P442, DOI 10.1093/oxfordjournals.molbev.a025940; Rasmussen DT, 1998, FOLIA PRIMATOL, V69, P250; ROSE KD, 1981, NATURE, V289, P583, DOI 10.1038/289583a0; Rose Kenneth D., 1994, P1; Simons EL, 1997, P NATL ACAD SCI USA, V94, P180, DOI 10.1073/pnas.94.1.180; SIMONS EL, 1986, J HUM EVOL, V15, P431, DOI 10.1016/S0047-2484(86)80026-4; Simons Elwyn L., 1994, P179; SIMPSON G G, 1967, Bulletin of the Museum of Comparative Zoology, V136, P39; Swofford D. L., 1998, PAUP PHYLOGENETIC AN; Tavare S, 2002, NATURE, V416, P726, DOI 10.1038/416726a; Yoder AD, 1997, EVOL ANTHROPOL, V6, P11, DOI 10.1002/(SICI)1520-6505(1997)6:1<11::AID-EVAN6>3.0.CO;2-Z; Yoder AD, 2001, SYST BIOL, V50, P408, DOI 10.1080/10635150116801; Yoder AD, 1996, P NATL ACAD SCI USA, V93, P5122, DOI 10.1073/pnas.93.10.5122	30	131	138	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 27	2003	422	6930					421	424		10.1038/nature01489	http://dx.doi.org/10.1038/nature01489			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660781	Green Published			2022-12-28	WOS:000181801200042
J	Williams, PM; Fowler, SB; Best, RB; Toca-Herrera, JL; Scott, KA; Steward, A; Clarke, J				Williams, PM; Fowler, SB; Best, RB; Toca-Herrera, JL; Scott, KA; Steward, A; Clarke, J			Hidden complexity in the mechanical properties of titin	NATURE			English	Article							MOLECULAR-DYNAMICS SIMULATION; ATOMIC-FORCE MICROSCOPY; MUSCLE PROTEIN TITIN; IMMUNOGLOBULIN DOMAINS; I-BAND; ELASTICITY; MODULES; EXTENSIBILITY; PATHWAY; DETAIL	Individual molecules of the giant protein titin span the A-bands and I-bands that make up striated muscle. The I-band region of titin is responsible for passive elasticity in such muscle(1-4), and contains tandem arrays of immunoglobulin domains. One such domain (I27) has been investigated extensively, using dynamic force spectroscopy and simulation(5-12). However, the relevance of these studies to the behaviour of the protein under physiological conditions was not established. Force studies reveal a lengthening of I27 without complete unfolding, forming a stable intermediate that has been suggested to be an important component of titin elasticity(6). To develop a more complete picture of the forced unfolding pathway, we use mutant titins-certain mutations allow the role of the partly unfolded intermediate to be investigated in more depth. Here we show that, under physiological forces, the partly unfolded intermediate does not contribute to mechanical strength. We also propose a unified forced unfolding model of all I27 analogues studied, and conclude that I27 can withstand higher forces in muscle than was predicted previously.	Univ Cambridge, Chem Lab, MRC, Ctr Prot Engn, Cambridge CB2 1EW, England; Univ Nottingham, Sch Pharmaceut Sci, Lab Biophys & Surface Anal, Nottingham NG7 2RD, England	University of Cambridge; University of Nottingham	Clarke, J (corresponding author), Univ Cambridge, Chem Lab, MRC, Ctr Prot Engn, Lensfield Rd, Cambridge CB2 1EW, England.		Best, Robert/H-7588-2016; Williams, Philip M/C-6947-2009; Toca-Herrera, Jose L./AAX-7366-2021	Best, Robert/0000-0002-7893-3543; Williams, Philip M/0000-0002-1822-2133; Toca-Herrera, Jose L./0000-0001-8951-2616; Scott, Kathryn/0000-0003-3395-9210				Best RB, 2002, P NATL ACAD SCI USA, V99, P12143, DOI 10.1073/pnas.192351899; Best RB, 2001, BIOPHYS J, V81, P2344, DOI 10.1016/S0006-3495(01)75881-X; Brockwell DJ, 2002, BIOPHYS J, V83, P458, DOI 10.1016/S0006-3495(02)75182-5; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; Evans E, 2001, ANNU REV BIOPH BIOM, V30, P105, DOI 10.1146/annurev.biophys.30.1.105; Fowler SB, 2001, STRUCTURE, V9, P355, DOI 10.1016/S0969-2126(01)00596-2; Fowler SB, 2002, J MOL BIOL, V322, P841, DOI 10.1016/S0022-2836(02)00805-7; FURST DO, 1988, J CELL BIOL, V106, P1563, DOI 10.1083/jcb.106.5.1563; Gautel M, 1996, J MUSCLE RES CELL M, V17, P449, DOI 10.1007/BF00123361; Improta S, 1996, STRUCTURE, V4, P323, DOI 10.1016/S0969-2126(96)00036-6; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Li HB, 2000, NAT STRUCT BIOL, V7, P1117; Li HB, 2002, NATURE, V418, P998, DOI 10.1038/nature00938; Linke WA, 1998, J CELL SCI, V111, P1567; Linke WA, 1998, BIOPHYS J, V75, P2613, DOI 10.1016/S0006-3495(98)77706-9; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; Lu H, 2000, BIOPHYS J, V79, P51, DOI 10.1016/S0006-3495(00)76273-4; Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3; Ma K, 2001, BIOCHEMISTRY-US, V40, P3427, DOI 10.1021/bi0022792; Marszalek PE, 1999, NATURE, V402, P100, DOI 10.1038/47083; Minajeva A, 2001, BIOPHYS J, V80, P1442, DOI 10.1016/S0006-3495(01)76116-4; PRESS WH, 1992, NUMERICAL RECIPES; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Steward A, 2002, PROTEIN SCI, V11, P2179, DOI 10.1110/ps.0212702; Trinick J, 1996, CURR BIOL, V6, P258, DOI 10.1016/S0960-9822(02)00472-4; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0; Tskhovrebova L, 1997, J MOL BIOL, V265, P100, DOI 10.1006/jmbi.1996.0717; Tskhovrebova L, 2001, J MOL BIOL, V310, P755, DOI 10.1006/jmbi.2001.4700	30	225	230	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					446	449		10.1038/nature01517	http://dx.doi.org/10.1038/nature01517			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660787				2022-12-28	WOS:000181801200048
J	Antes, G; Chalmers, I				Antes, G; Chalmers, I			Under-reporting of clinical trials is unethical	LANCET			English	Editorial Material							RESEARCH ETHICS COMMITTEES		Univ Freiburg, German Cochrane Ctr, Inst Med Biometrie & Med Informat, D-79104 Freiburg, Germany; UK Cochrane ctr, UK RCT Registrat Project, Oxford, England	University of Freiburg; Cochrane Centre	Antes, G (corresponding author), Univ Freiburg, German Cochrane Ctr, Inst Med Biometrie & Med Informat, D-79104 Freiburg, Germany.							Chalmers I, 2002, LANCET, V359, P174; Chalmers I., 2001, SYSTEMATIC REV HLTH, P429, DOI DOI 10.1002/9780470693926.CH24; *CURR CONTR TRIAL, FEAT MET CONTR TRIAL; Dickey ID, 2001, CURR ORTHOPAED, V15, P1, DOI 10.1054/cuor.2001.0135; EGGER M, 2003, HLTH TECHNOL ASSES, V7; *EUR SCI FDN POL B, 2001, CONTR CLIN TRIALS; Goldbeck-Wood S, 1998, BRIT MED J, V316, P1189; LOCK S, 1996, FRAUD MISCONDUCT MED, pR11; MANHEIMER E, 1996, BRIT MED J, V325, P528; Mann H, 2002, LANCET, V360, P406, DOI 10.1016/S0140-6736(02)09613-7; Savulescu J, 1996, BMJ-BRIT MED J, V313, P1390, DOI 10.1136/bmj.313.7069.1390; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; Sykes R, 1998, BRIT MED J, V317, P1172, DOI 10.1136/bmj.317.7167.1172; Tonks A, 2002, BRIT MED J, V325, P1314, DOI 10.1136/bmj.325.7376.1314; *TRIALSC, YOUR SOURC ONL CLIN; LINKING PATIENTS MED	16	89	90	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					978	979		10.1016/S0140-6736(03)12838-3	http://dx.doi.org/10.1016/S0140-6736(03)12838-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660049				2022-12-28	WOS:000181699700002
J	Holdcroft, A; Power, I				Holdcroft, A; Power, I			Recent developments - Management of pain	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NEUROPATHIC PAIN; NEUROBIOLOGY		Chelsea & Westminster Hosp, Imperial Coll London, Magill Dept Anaesthesia, London SW10 9JP, England; Univ Edinburgh, Royal Infirm, Edinburgh EH16 4SA, Midlothian, Scotland	Imperial College London; Royal Infirmary of Edinburgh; University of Edinburgh	Holdcroft, A (corresponding author), Chelsea & Westminster Hosp, Imperial Coll London, Magill Dept Anaesthesia, London SW10 9JP, England.	aholdcro@ic.ac.uk						Casey K L, 2000, Prog Brain Res, V129, P277; *COLL PHYS SURG ON, 2000, EV BAS REC MED MAN C; DeLeo JA, 2001, PAIN, V90, P1, DOI 10.1016/S0304-3959(00)00490-5; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Dickenson AH, 2002, EUR J PAIN, V6, P51, DOI 10.1053/eujp.2001.0323; Dubner R, 1999, P NATL ACAD SCI USA, V96, P7627, DOI 10.1073/pnas.96.14.7627; Fields H. L., 1999, PAIN S, P61; FILLINGIM RB, 2002, EUR J ANAESTHESI S26, V19, P6; Gear RW, 1999, PAIN, V83, P339, DOI 10.1016/S0304-3959(99)00119-0; Hofbauer RK, 2001, J NEUROPHYSIOL, V86, P402, DOI 10.1152/jn.2001.86.1.402; Kolk AM, 2000, CHILD CARE HLTH DEV, V26, P251, DOI 10.1046/j.1365-2214.2000.00145.x; LeResche L, 2000, PROGR PAIN RES MANAG, V17; Merskey H., 1994, CLASSIFICATION CHRON, V2nd ed; Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3; *NHS CTR REV DISS, 2000, EFFECTIVE HLTH CARE, V6; Petrovic P, 2002, PAIN, V95, P1, DOI 10.1016/S0304-3959(01)00467-5; Schmidt WK, 2001, AM J SURG, V182, p27S, DOI 10.1016/S0002-9610(01)00784-X; Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0; Watkins LR, 1999, P NATL ACAD SCI USA, V96, P7710, DOI 10.1073/pnas.96.14.7710; Woolf CJ, 1998, PAIN, V77, P227, DOI 10.1016/S0304-3959(98)00099-2; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Woolf CJ, 1999, PAIN, pS141, DOI 10.1016/S0304-3959(99)00148-7	22	38	42	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	2003	326	7390					635	639		10.1136/bmj.326.7390.635	http://dx.doi.org/10.1136/bmj.326.7390.635			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649239	Green Published			2022-12-28	WOS:000181870800019
J	Stutzmann, N; Friend, RH; Sirringhaus, H				Stutzmann, N; Friend, RH; Sirringhaus, H			Self-aligned, vertical-channel, polymer field-effect transistors	SCIENCE			English	Article							ORGANIC TRANSISTORS; IMPRINT	The manufacture of high-performance, conjugated polymer transistor circuits on flexible plastic substrates requires patterning techniques that are capable of defining critical features with submicrometer resolution. We used solid-state embossing to produce polymer field-effect transistors with submicrometer critical features in planar and vertical configurations. Embossing is used for the controlled microcutting of vertical sidewalls into polymer multilayer structures without smearing. Vertical-channel polymer field-effect transistors on flexible poly(ethylene terephthatate) substrates were fabricated, in which the critical channel length of 0.7 to 0.9 micrometers was defined by the thickness of a spin-coated insulator layer. Gate electrodes were self-aligned to minimize overlap capacitance by inkjet printing that used the embossed grooves to define a surface-energy pattern.	Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England	University of Cambridge	Sirringhaus, H (corresponding author), Univ Cambridge, Cavendish Lab, Madingley Rd, Cambridge CB3 0HE, England.	hs220@phy.cam.ac.uk	Sirringhaus, Henning/ABD-1555-2021; Stingelin, Natalie/D-6745-2016	Sirringhaus, Henning/0000-0001-9827-6061; Stingelin, Natalie/0000-0002-1414-4545; Friend, Richard Henry/0000-0001-6565-6308				BACHER W, 1995, IEEE T IND ELECTRON, V42, P431, DOI 10.1109/41.464604; Bao ZN, 1997, CHEM MATER, V9, P1299, DOI 10.1021/cm9701163; BARDEEN J, 1948, PHYS REV, V74, P230, DOI 10.1103/PhysRev.74.230; Burgi L, 2002, APPL PHYS LETT, V80, P2913, DOI 10.1063/1.1470702; Chou SY, 2002, NATURE, V417, P835, DOI 10.1038/nature00792; Chou SY, 1996, SCIENCE, V272, P85, DOI 10.1126/science.272.5258.85; Drury CJ, 1998, APPL PHYS LETT, V73, P108, DOI 10.1063/1.121783; GALE MT, 1997, MICROOPTICS ELEMENTS, P153; Garnier F, 1998, APPL PHYS LETT, V73, P1721, DOI 10.1063/1.122257; Rogers JA, 1999, APPL PHYS LETT, V75, P1010, DOI 10.1063/1.124581; Rogers JA, 1999, ADV MATER, V11, P741, DOI 10.1002/(SICI)1521-4095(199906)11:9<741::AID-ADMA741>3.0.CO;2-L; Rogers JA, 1998, APPL PHYS LETT, V72, P2716, DOI 10.1063/1.121109; Sirringhaus H, 2000, APPL PHYS LETT, V77, P406, DOI 10.1063/1.126991; Sirringhaus H, 1999, NATURE, V401, P685, DOI 10.1038/44359; Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741; Sirringhaus H, 2000, SCIENCE, V290, P2123, DOI 10.1126/science.290.5499.2123; SIRRINGHAUS H, 1999, ADV SOLID STATE PHYS, V39, P101; Stutzmann N, 2002, ADV FUNCT MATER, V12, P105, DOI 10.1002/1616-3028(20020201)12:2<105::AID-ADFM105>3.0.CO;2-I; Stutzmann N, 2000, ADV MATER, V12, P557, DOI 10.1002/(SICI)1521-4095(200004)12:8<557::AID-ADMA557>3.0.CO;2-W; Stutzmann N, 2000, NATURE, V407, P613, DOI 10.1038/35036545; SZE SM, 1981, PHYSICS SEMICONDUCTO; van Woudenbergh T, 2001, APPL PHYS LETT, V79, P1697, DOI 10.1063/1.1395515	22	475	500	10	232	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	2003	299	5614					1881	1884		10.1126/science.1081279	http://dx.doi.org/10.1126/science.1081279			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649478				2022-12-28	WOS:000181669700042
J	Abbott, A				Abbott, A			Chicken flu races through Dutch poultry farms	NATURE			English	News Item																		2003, NATURE, V422, P6	1	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					247	247		10.1038/422247b	http://dx.doi.org/10.1038/422247b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646883	Bronze			2022-12-28	WOS:000181637300006
J	Branson, R; Potoczna, N; Kral, JG; Lentes, K; Hoehe, MR; Horber, FF				Branson, R; Potoczna, N; Kral, JG; Lentes, K; Hoehe, MR; Horber, FF			Binge eating as a major phenotype of melanocortin 4 receptor gene mutations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-FAT DISTRIBUTION; EARLY-ONSET OBESITY; MORBID-OBESITY; FRAMESHIFT MUTATION; MISSENSE MUTATION; LEPTIN RECEPTOR; WEIGHT-LOSS; DISORDER; HUMANS; MC4R	Background: Obesity, a multifactorial disease caused by the interaction of genetic factors with the environment, is largely polygenic. A few mutations in these genes, such as in the leptin receptor (LEPR) gene and melanocortin 4 receptor (MC4R) gene, have been identified as causes of monogenic obesity. Methods: We sequenced the complete MC4R coding region, the region of the proopiomelanocortin gene (POMC) encoding the alpha melanocyte-stimulating hormone, and the leptin-binding domain of LEPR in 469 severely obese white subjects (370 women and 99 men; mean [+/-SE] age, 41.0+/-0.5 years; body-mass index [the weight in kilograms divided by the square of the height in meters], 44.1+/-2.0). Fifteen women and 10 men without a history of dieting or a family history of obesity served as normal-weight controls (age, 47.7+/-2.0 years; body-mass index, 21.6+/-0.4). Detailed phenotypic data, including information on body fat, resting energy expenditure, diet-induced thermogenesis, serum concentrations of leptin, and eating behavior, were collected. Results: Twenty-four obese subjects (5.1 percent) and one control subject (4 percent) had MC4R mutations, including five novel variants. Twenty of the 24 obese subjects with an MC4R mutation were matched for age, sex, and body-mass index with 120 of the 445 obese subjects without an MC4R mutation. All mutation carriers reported binge eating, as compared with 14.2 percent of obese subjects without mutations (P<0.001) and 0 percent of the normal-weight subjects without mutations. The prevalence of binge eating was similar among carriers of mutations in the leptin-binding domain of LEPR and noncarriers. No mutations were found in the region of POMC encoding (alpha) melanocyte-stimulating hormone. Conclusions: Binge eating is a major phenotypic characteristic of subjects with a mutation in MC4R, a candidate gene for the control of eating behavior.	Klin Hirslanden, CH-8008 Zurich, Switzerland; SUNY Downstate Med Ctr, Brooklyn, NY 11203 USA; Bioscientia, Ingelheim, Germany; Max Planck Inst Mol Genet, Berlin, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Max Planck Society	Horber, FF (corresponding author), Klin Hirslanden, Witellikerstr 40, CH-8008 Zurich, Switzerland.		horber, Fritz/AAL-5419-2020	Lentes, Klaus-Ulrich/0000-0002-1605-4332				*AM PSYCH ASS, 1994, DSM 4 CRIT SETS AX P, P703; Chen DL, 1999, J LIPID RES, V40, P1735; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Comuzzie AG, 1998, SCIENCE, V280, P1374, DOI 10.1126/science.280.5368.1374; DEVLIN MJ, 1992, INT J EAT DISORDER, V11, P333, DOI 10.1002/1098-108X(199205)11:4&lt;333::AID-EAT2260110407&gt;3.0.CO;2-K; Dubern B, 2001, J PEDIATR-US, V139, P204, DOI 10.1067/mpd.2001.116284; Eriksson J, 1999, HORM METAB RES, V31, P616, DOI 10.1055/s-2007-978807; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Farooqi IS, 2001, NATURE, V414, P34, DOI 10.1038/35102112; Gu W, 1999, DIABETES, V48, P635, DOI 10.2337/diabetes.48.3.635; Guss JL, 2002, OBES RES, V10, P1021, DOI 10.1038/oby.2002.139; Hamilton BS, 2002, OBES RES, V10, P182, DOI 10.1038/oby.2002.28; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; Horber FF, 1997, NUTRITION, V13, P524, DOI 10.1016/S0899-9007(97)00031-2; Hsu LKG, 2002, INT J OBESITY, V26, P1398, DOI 10.1038/sj.ijo.0802081; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; JACOBSEN P, 2002, J CLIN ENDOCR METAB, V84, P4442; Kalarchian MA, 2002, OBES SURG, V12, P270, DOI 10.1381/096089202762552494; Kobayashi H, 2002, DIABETES, V51, P243, DOI 10.2337/diabetes.51.1.243; Kral JG, 2001, SURG CLIN N AM, V81, P1039, DOI 10.1016/S0039-6109(05)70183-3; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Laederach-Hofmann K, 1999, INT J EAT DISORDER, V26, P231, DOI 10.1002/(SICI)1098-108X(199911)26:3&lt;231::AID-EAT1&gt;3.0.CO;2-6; Lahlou N, 2000, DIABETES, V49, P1347, DOI 10.2337/diabetes.49.8.1347; Lahlou N, 2002, DIABETES, V51, P1980, DOI 10.2337/diabetes.51.6.1980; Mergen M, 2001, J CLIN ENDOCR METAB, V86, P3448, DOI 10.1210/jc.86.7.3448; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Rankinen T, 2002, OBES RES, V10, P196, DOI 10.1038/oby.2002.30; Rosmond R, 2001, DIABETOLOGIA, V44, P1335, DOI 10.1007/s001250100649; Sina M, 1999, AM J HUM GENET, V65, P1501, DOI 10.1086/302660; SPITZER RL, 1993, INT J EAT DISORDER, V13, P137, DOI 10.1002/1098-108X(199303)13:2&lt;161::AID-EAT2260130204&gt;3.0.CO;2-R; SPITZER RL, 1992, INT J EAT DISORDER, V11, P191, DOI 10.1002/1098-108X(199204)11:3&lt;191::AID-EAT2260110302&gt;3.0.CO;2-S; Ste Marie L, 2000, P NATL ACAD SCI USA, V97, P12339, DOI 10.1073/pnas.220409497; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; Tabor HK, 2002, NAT REV GENET, V3, P391, DOI 10.1038/nrg796; TATARANNI PA, 1995, AM J CLIN NUTR, V62, P730, DOI 10.1093/ajcn/62.4.730; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Wauters M, 1998, Eat Weight Disord, V3, P124; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; 1999, WHO TECH REP SER, V894, P1	43	246	260	0	13	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1096	1103		10.1056/NEJMoa021971	http://dx.doi.org/10.1056/NEJMoa021971			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	656UY	12646666	Bronze			2022-12-28	WOS:000181628400005
J	Friedmann, AM; Oliva, E; Zietman, AL; Aquino, SL; Scully, RE; Harris, NL; O'Connor, PG				Friedmann, AM; Oliva, E; Zietman, AL; Aquino, SL; Scully, RE; Harris, NL; O'Connor, PG			An 18-year-old man with back and leg pain and a nondiagnostic biopsy specimen - Mediastinal germinoma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GERM-CELL TUMORS; NEEDLE-BIOPSY; SEMINOMAS; CHILDHOOD; CHILDREN		Massachusetts Gen Hosp, Dept Pediat Hematol Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Friedmann, AM (corresponding author), Massachusetts Gen Hosp, Dept Pediat Hematol Oncol, Boston, MA 02114 USA.							De Vita VT, 2001, CANC PRINCIPLES PRAC; Einhorn LH, 1998, J UROLOGY, V160, P1964, DOI 10.1016/S0022-5347(01)62213-4; HAINSWORTH JD, 1992, SEMIN ONCOL, V19, P119; HEILO A, 1993, RADIOLOGY, V189, P143, DOI 10.1148/radiology.189.1.8372184; HERKOWITZ HN, 1999, ROTHMANSIMEONE SPINE; HERMAN SJ, 1991, RADIOLOGY, V180, P167, DOI 10.1148/radiology.180.1.1647039; Hujala KT, 2001, ACTA ONCOL, V40, P79; KING HA, 1984, PEDIATR CLIN N AM, V31, P1083; King HA, 1999, ORTHOP CLIN N AM, V30, P467, DOI 10.1016/S0030-5898(05)70099-7; LEWIS JE, 1987, CANCER, V60, P2727, DOI 10.1002/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO;2-D; LUNA MA, 1976, AM J CLIN PATHOL, V65, P450; Moran C A, 1998, Adv Anat Pathol, V5, P1, DOI 10.1097/00125480-199801000-00001; MORAN CA, 1995, AM J SURG PATHOL, V19, P1047, DOI 10.1097/00000478-199509000-00008; Moran CA, 1997, CANCER-AM CANCER SOC, V80, P691, DOI 10.1002/(SICI)1097-0142(19970815)80:4<691::AID-CNCR7>3.0.CO;2-Q; Rosai J., 1995, INT J SURG PATHOL, V2, P73; SCHANTZ A, 1972, CANCER, V30, P1189, DOI 10.1002/1097-0142(197211)30:5<1189::AID-CNCR2820300508>3.0.CO;2-9; Schneider DT, 2001, KLIN PADIATR, V213, P204, DOI 10.1055/s-2001-16852; Suster S, 1998, HUM PATHOL, V29, P737, DOI 10.1016/S0046-8177(98)90284-2; TURNER PG, 1989, SPINE, V14, P812, DOI 10.1097/00007632-198908000-00007; Weidner N, 1999, SEMIN DIAGN PATHOL, V16, P42; WOOLNER LB, 1955, NEW ENGL J MED, V252, P653, DOI 10.1056/NEJM195504212521602	21	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1150	1158		10.1056/NEJMcpc030002	http://dx.doi.org/10.1056/NEJMcpc030002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646672				2022-12-28	WOS:000181628400011
J	Gillett, NP; Zwiers, FW; Weaver, AJ; Stott, PA				Gillett, NP; Zwiers, FW; Weaver, AJ; Stott, PA			Detection of human influence on sea-level pressure	NATURE			English	Article							ANTHROPOGENIC CLIMATE-CHANGE; MODEL	Greenhouse gases and tropospheric sulphate aerosols-the main human influences on climate-have been shown to have had a detectable effect on surface air temperature(1-3), the temperature of the free troposphere and stratosphere(2,4) and ocean temperature(5,6) Nevertheless, the question remains as to whether human influence is detectable in any variable other than temperature. Here we detect an influence of anthropogenic greenhouse gases and sulphate aerosols in observations of winter sea-level pressure (December to February), using combined simulations from four climate models. We find increases in sea-level pressure over the subtropical North Atlantic Ocean, southern Europe and North Africa, and decreases in the polar regions and the North Pacific Ocean, in response to human influence. Our analysis also indicates that the climate models substantially underestimate the magnitude of the sea-level pressure response. This discrepancy suggests that the upward trend in the North Atlantic Oscillation index(7) (corresponding to strengthened westerlies in the North Atlantic region), as simulated in a number of global warming scenarios(8-10), may be too small, leading to an underestimation of the impacts of anthropogenic climate change on European climate.	Univ Victoria, Sch Earth & Ocean Sci, Victoria, BC V8W 3P6, Canada; Meteorol Serv Canada, Canadian Ctr Climate Modelling & Anal, Victoria, BC V8W 2Y2, Canada; Hadley Ctr Climate Predict & Res, Met Off, Bracknell RG12 2SY, Berks, England	University of Victoria; Environment & Climate Change Canada; Canadian Centre for Climate Modelling & Analysis (CCCma); Meteorological Service of Canada; Met Office - UK; Hadley Centre	Gillett, NP (corresponding author), Univ Victoria, Sch Earth & Ocean Sci, POB 3055, Victoria, BC V8W 3P6, Canada.		Weaver, Andrew J/E-7590-2011; Scott, Peter/GYA-5335-2022; Stott, Peter/N-1228-2016	Weaver, Andrew J/0000-0001-8919-3598; Stott, Peter/0000-0003-4853-7686				Allen MR, 1999, CLIM DYNAM, V15, P419, DOI 10.1007/s003820050291; ALLEN MR, IN PRESS SURV GEOPHY; Barnett TP, 2001, SCIENCE, V292, P270, DOI 10.1126/science.1058304; Fyfe JC, 1999, GEOPHYS RES LETT, V26, P1601, DOI 10.1029/1999GL900317; Gillett NP, 2000, GEOPHYS RES LETT, V27, P993, DOI 10.1029/1999GL010981; Gillett NP, 2002, GEOPHYS RES LETT; GILLETT NP, 2002, J GEOPHYS RES; GILLETT NP, 2003, N ATLANTIC OSCILLATI, pCH9; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Krishnamurti TN, 1999, SCIENCE, V285, P1548, DOI 10.1126/science.285.5433.1548; Lambert SJ, 2001, CLIM DYNAM, V17, P83, DOI 10.1007/PL00013736; MITCHELL JFB, 2001, CLIMATE CHANGE 2001, pCH12; Osborn TJ, 1999, CLIM DYNAM, V15, P685, DOI 10.1007/s003820050310; REICHERT BK, 2002, GEOPHYS RES LETT; Shindell DT, 1999, NATURE, V399, P452, DOI 10.1038/20905; Tett SFB, 1999, NATURE, V399, P569, DOI 10.1038/21164; Tett SFB, 1996, SCIENCE, V274, P1170, DOI 10.1126/science.274.5290.1170; Thomas JM, 2000, TOP CATAL, V11, P1; Thompson DWJ, 2001, SCIENCE, V293, P85, DOI 10.1126/science.1058958; TRENBERTH KE, 1980, MON WEATHER REV, V108, P855, DOI 10.1175/1520-0493(1980)108<0855:TNHSLP>2.0.CO;2; [No title captured]	21	168	174	2	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					292	294		10.1038/nature01487	http://dx.doi.org/10.1038/nature01487			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646917				2022-12-28	WOS:000181637300035
J	Sokolowski-Tinten, K; Blome, C; Blums, J; Cavalleri, A; Dietrich, C; Tarasevitch, A; Uschmann, I; Forster, E; Kammler, M; Horn-von-Hoegen, M; von der Linde, D				Sokolowski-Tinten, K; Blome, C; Blums, J; Cavalleri, A; Dietrich, C; Tarasevitch, A; Uschmann, I; Forster, E; Kammler, M; Horn-von-Hoegen, M; von der Linde, D			Femtosecond X-ray measurement of coherent lattice vibrations near the Lindemann stability limit	NATURE			English	Article							STRUCTURAL DYNAMICS; PHASE-TRANSITION; PHONONS; DIFFRACTION; BISMUTH; PULSES	The study of phase-transition dynamics in solids beyond a time-averaged kinetic description requires direct measurement of the changes in the atomic configuration along the physical pathways leading to the new phase. The timescale of interest is in the range 10(-14) to 10(-12) s. Until recently, only optical techniques were capable of providing adequate time resolution(1), albeit with indirect sensitivity to structural arrangement. Ultrafast laser-induced changes of long-range order have recently been directly established for some materials using time-resolved X-ray diffraction(2-8). However, the measurement of the atomic displacements within the unit cell, as well as their relationship with the stability limit of a structural phase(9-11), has to date remained obscure. Here we report time-resolved X-ray diffraction measurements of the coherent atomic displacement of the lattice atoms in photoexcited bismuth close to a phase transition. Excitation of large-amplitude coherent optical phonons gives rise to a periodic modulation of the X-ray diffraction efficiency. Stronger excitation corresponding to atomic displacements exceeding 10 per cent of the nearest-neighbour distance-near the Lindemann limit-leads to a subsequent loss of long-range order, which is most probably due to melting of the material.	Univ Essen Gesamthsch, Inst Laser & Plasmaphys, D-45117 Essen, Germany; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Jena, Inst Opt & Quantenelektron, Forschungsgrp Rontgenopt, D-07743 Jena, Germany; Univ Hannover, Inst Halbleitertechnol, D-30167 Hannover, Germany	University of Duisburg Essen; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Friedrich Schiller University of Jena; Leibniz University Hannover	Sokolowski-Tinten, K (corresponding author), Univ Essen Gesamthsch, Inst Laser & Plasmaphys, D-45117 Essen, Germany.		Sokolowski-Tinten, Klaus/A-5415-2015; von Hoegen, Michael Horn/E-4969-2012	von Hoegen, Michael Horn/0000-0003-0324-3457; Blums, Juris/0000-0002-7087-6062; Kammler, Martin/0000-0002-9600-9768				Bloembergen N, 1999, REV MOD PHYS, V71, pS283, DOI 10.1103/RevModPhys.71.S283; Born M, 1939, J CHEM PHYS, V7, P591, DOI 10.1063/1.1750497; Cavalleri A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.237401; Chin AH, 1999, PHYS REV LETT, V83, P336, DOI 10.1103/PhysRevLett.83.336; DeCamp MF, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.092301; Feurer T, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.016412; Garrett GA, 1996, PHYS REV LETT, V77, P3661, DOI 10.1103/PhysRevLett.77.3661; Hase M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.067401; Hase M, 1998, PHYS REV B, V58, P5448, DOI 10.1103/PhysRevB.58.5448; HUNSCHE S, 1995, PHYS REV LETT, V75, P1815, DOI 10.1103/PhysRevLett.75.1815; Lindemann FA, 1910, PHYS Z, V11, P609; Lindenberg AM, 2000, PHYS REV LETT, V84, P111, DOI 10.1103/PhysRevLett.84.111; MADELUNG O, 1983, SEMICONDUCTORS PHY A, V17; Peierls R., 1991, MORE SURPRISES THEOR; Rousse A, 2001, NATURE, V410, P65, DOI 10.1038/35065045; Shick AB, 1999, PHYS REV B, V60, P15484, DOI 10.1103/PhysRevB.60.15484; Siders CW, 1999, SCIENCE, V286, P1340, DOI 10.1126/science.286.5443.1340; SOKOLOWSKITINTE.K, 2001, PHYS REV LETT, V87; TALLON JL, 1989, NATURE, V342, P658, DOI 10.1038/342658a0; von der Linde D, 2001, Z PHYS CHEM, V215, P1527, DOI 10.1524/zpch.2001.215.12.1527; ZEIGER HJ, 1992, PHYS REV B, V45, P768, DOI 10.1103/PhysRevB.45.768	21	498	502	1	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					287	289		10.1038/nature01490	http://dx.doi.org/10.1038/nature01490			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646915				2022-12-28	WOS:000181637300033
J	Knight, EL; Stampfer, MJ; Hankinson, SE; Spiegelman, D; Curhan, GC				Knight, EL; Stampfer, MJ; Hankinson, SE; Spiegelman, D; Curhan, GC			The impact of protein intake on renal function decline in women with normal renal function or mild renal insufficiency	ANNALS OF INTERNAL MEDICINE			English	Article							GLOMERULAR-FILTRATION-RATE; FOOD FREQUENCY QUESTIONNAIRE; CREATININE CLEARANCE; DIETARY-PROTEIN; MEASUREMENT ERROR; HEALTHY-SUBJECTS; CONFIDENCE-INTERVALS; PHOSPHORUS INTAKE; SERUM CREATININE; BLOOD-PRESSURE	Background: In individuals with moderate to severe renal insufficiency, low protein intake may slow renal function decline. However, the long-term impact of protein intake on renal function in persons with normal renal function or mild renal insufficiency is unknown. Objective: To determine whether protein intake influences the rate of renal function change in women over an 11-year period. Design: Prospective cohort study. Setting: Nurses' Health Study. Participants: 1624 women enrolled in the Nurses' Health Study who were 42 to 68 years of age in 1989 and gave blood samples in 1989 and 2000. Ninety-eight percent of women were white, and 1% were African American. Measurements: Protein intake was measured in 1990 and 1994 by using a semi-quantitative food-frequency questionnaire. Creatinine concentration was used to estimate glomerular filtration rate (GFR) and creatinine clearance. Results: In multivariate linear regression analyses, high protein intake was not significantly associated with change in estimated GFR in women with normal renal function (defined as an estimated GFR greater than or equal to 80 mL/min per 1.73 m(2)). Change in estimated GFR in this subgroup over the 11-year period was 0.25 mL/min per 1.73 m(2) (95% Cl, -0.78 to 1.28 mL/min per 1.73 m(2)) per 10-g increase in protein intake; the change in estimated GFR was 1.14 mL/min per 1.73 m(2) (Cl, -3.63 to 5.92 mL/min per 1.73 m(2)) after measurement-error adjustment for protein intake. In women with mild renal insufficiency (defined as an estimated GFR > 55 mL/min per 1.73 m(2) but <80 mL/min per 1.73 m(2)), protein intake was significantly associated with a change in estimated GFR of -1.69 mL/min per 1.73 m(2) (Cl, -2.93 to -0.45 mL/min per 1.73 m 2) per 10-g increase in protein intake. After measurement-error adjustment, the change in estimated GFR was -7.72 mL/min per 1.73 m(2) (Cl, -15.52 to 0.08 mL/min per 1.73 m(2)) per 10-g increase in protein intake, an association of borderline statistical significance. High intake of nondairy animal protein in women with mild renal insufficiency was associated with a significantly greater change in estimated GFR (-1.21 mL/min per 1.73 M2 [Cl, -2.34 to -0.33 mL/min per 1.73 m(2)] per 10-g increase in nondairy animal protein intake). Conclusions: High protein intake was not associated with renal function decline in women with normal renal function. However, high total protein intake, particularly high intake of nondairy animal protein, may accelerate renal function decline in women with mild renal insufficiency.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts General Hospital	Knight, EL (corresponding author), Channing Labs, Nurses Hlth Study, 3rd Floor,181 Longwood Ave, Boston, MA 02115 USA.	elknight@partners.org			NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052866, T32DK007791] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG BG, 1989, STAT MED, V8, P1151, DOI 10.1002/sim.4780080916; Barsotti G, 1996, NEPHRON, V74, P390, DOI 10.1159/000189341; BARSOTTI G, 1984, CLIN NEPHROL, V21, P54; Blackburn GL, 2001, CLEV CLIN J MED, V68, P761, DOI 10.3949/ccjm.68.9.761; Brandle E, 1996, EUR J CLIN NUTR, V50, P734; BROWN SA, 1991, J AM SOC NEPHROL, V1, P1169; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; DAMICO G, 1994, NEPHROL DIAL TRANSPL, V9, P1590; Dworkin LD, 2001, CURR OPIN NEPHROL HY, V10, P551, DOI 10.1097/00041552-200109000-00001; FOUQUE D, 2000, COCHRANE DATABASE SY; Fuiano G, 1996, NEPHRON, V73, P430; GENTILE MG, 1993, CLIN NEPHROL, V40, P315; Grimm M, 2001, EUR J CLIN NUTR, V55, P153, DOI 10.1038/sj.ejcn.1601131; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; JIBANI MM, 1991, DIABETIC MED, V8, P949, DOI 10.1111/j.1464-5491.1991.tb01535.x; JONES MG, 1987, CLIN NEPHROL, V27, P71; Kasiske BL, 1998, AM J KIDNEY DIS, V31, P954, DOI 10.1053/ajkd.1998.v31.pm9631839; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; KONTESSIS PS, 1995, DIABETES CARE, V18, P1233, DOI 10.2337/diacare.18.9.1233; Krauss RM, 2000, STROKE, V31, P2751, DOI 10.1161/01.STR.31.11.2751; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; LEW SQ, 1991, J AM SOC NEPHROL, V2, P856; LINDEMAN RD, 1985, J AM GERIATR SOC, V33, P278, DOI 10.1111/j.1532-5415.1985.tb07117.x; LOCATELLI F, 1991, LANCET, V337, P1299, DOI 10.1016/0140-6736(91)92977-A; Manjunath G, 2001, CURR OPIN NEPHROL HY, V10, P785, DOI 10.1097/00041552-200111000-00009; McDowell M A, 1994, Adv Data, P1; NICOLL SR, 1991, NEPHRON, V59, P621, DOI 10.1159/000186654; Ravid M, 1998, ARCH INTERN MED, V158, P998, DOI 10.1001/archinte.158.9.998; Rodriguez-Porcel M, 2001, HYPERTENSION, V37, P774, DOI 10.1161/01.HYP.37.2.774; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; ROSNER B, 1989, STAT MED, V8, P1051, DOI 10.1002/sim.4780080905; SALAZAR DE, 1988, AM J MED, V84, P1053, DOI 10.1016/0002-9343(88)90310-5; SOKOLL LJ, 1994, CLIN CHEM, V40, P2276; Soroka N, 1998, NEPHRON, V79, P173, DOI 10.1159/000045021; Spiegelman D, 1997, AM J CLIN NUTR, V65, P1179; Stein K, 2000, J AM DIET ASSOC, V100, P760, DOI 10.1016/S0002-8223(00)00219-4; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 2012, NUTR EPIDEMIOLOGY; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 2002, AM J KIDNEY DIS S2, V39, pS1	44	258	269	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					460	467		10.7326/0003-4819-138-6-200303180-00009	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639078	Green Published			2022-12-28	WOS:000181562400003
J	Thrall, PH; Burdon, JJ				Thrall, PH; Burdon, JJ			Evolution of virulence in a plant host-pathogen metapopulation	SCIENCE			English	Article							MELAMPSORA-LINI; INFECTIOUS-DISEASES; LOCAL ADAPTATION; PARASITE COEVOLUTION; RACIAL STRUCTURE; RESISTANCE; MARGINALE; POPULATION; SELECTION; MIGRATION	In a wild plant-pathogen system, host resistance and pathogen virulence varied markedly among local populations. Broadly virulent pathogens occurred more frequently in highly resistant host populations, whereas avirulent pathogens dominated susceptible populations. Experimental inoculations indicated a negative trade-off between spore production and virulence. The nonrandom spatial distribution of pathogens, maintained through time despite high pathogen mobility, implies that selection favors virulent strains of Melampsora lini in resistant Linum marginale populations and avirulent strains in susceptible populations. These results are consistent with gene-for-gene models of host-pathogen coevolution that require trade-offs to prevent pathogen virulence increasing until host resistance becomes selectively neutral.	CSIRO Plant Ind, Ctr Plant Biodivers Res, Canberra, ACT 2601, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Thrall, PH (corresponding author), CSIRO Plant Ind, Ctr Plant Biodivers Res, Gen POB 1600, Canberra, ACT 2601, Australia.		Burdon, Jeremy J/B-9913-2009					BLACK FL, 1995, EXP CLIN IMMUNOGENET, V12, P206; BURDON JJ, 1994, EVOLUTION, V48, P1564, DOI 10.1111/j.1558-5646.1994.tb02196.x; BURDON JJ, 1992, PLANT PATHOL, V41, P165, DOI 10.1111/j.1365-3059.1992.tb02335.x; Burdon JJ, 1999, EVOLUTION, V53, P704, DOI [10.1111/j.1558-5646.1999.tb05365.x, 10.2307/2640711]; CHIN KM, 1984, PLANT PATHOL, V33, P535, DOI 10.1111/j.1365-3059.1984.tb02878.x; Coltman DW, 1999, EVOLUTION, V53, P1259, DOI [10.2307/2640828, 10.1111/j.1558-5646.1999.tb04538.x]; FLOR HH, 1956, ADV GENET, V8, P29, DOI 10.1016/S0065-2660(08)60498-8; Gandon S, 2002, ECOL LETT, V5, P246, DOI 10.1046/j.1461-0248.2002.00305.x; Gandon S, 2002, J EVOLUTION BIOL, V15, P451, DOI 10.1046/j.1420-9101.2002.00402.x; Heyndrickx L, 2000, AIDS, V14, P1862, DOI 10.1097/00002030-200008180-00028; Hill AVS, 1999, BRIT MED BULL, V55, P401, DOI 10.1258/0007142991902457; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; JAROSZ AM, 1991, EVOLUTION, V45, P1618, DOI [10.2307/2409783, 10.1111/j.1558-5646.1991.tb02667.x]; Jeffery KJM, 2000, MICROBES INFECT, V2, P1335, DOI 10.1016/S1286-4579(00)01287-9; LIPSITCH M, 1995, EVOLUTION, V49, P743, DOI 10.1111/j.1558-5646.1995.tb02310.x; Lively CM, 1999, AM NAT, V153, pS34, DOI 10.1086/303210; Lively CM, 2002, EVOL ECOL RES, V4, P219; Meagher S, 1999, EVOLUTION, V53, P1318, DOI 10.1111/j.1558-5646.1999.tb04547.x; Messenger SL, 1999, P ROY SOC B-BIOL SCI, V266, P397, DOI 10.1098/rspb.1999.0651; Musser JM, 1996, EMERG INFECT DIS, V2, P1, DOI 10.3201/eid0201.960101; Parrish CR, 1999, VET MICROBIOL, V69, P29, DOI 10.1016/S0378-1135(99)00084-X; THOMPSON JN, 1992, NATURE, V360, P121, DOI 10.1038/360121a0; Thrall PH, 2002, PLANT PATHOL, V51, P169, DOI 10.1046/j.1365-3059.2002.00683.x; Thrall PH, 2002, EVOLUTION, V56, P1340; Thrall PH, 2000, PLANT PATHOL, V49, P767, DOI 10.1046/j.1365-3059.2000.00523.x; Thrall PH, 2001, J ECOL, V89, P736, DOI 10.1046/j.0022-0477.2001.00597.x; THRALL PH, IN PRESS PLANT PATHO	27	311	322	3	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1735	1737		10.1126/science.1080070	http://dx.doi.org/10.1126/science.1080070			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637745				2022-12-28	WOS:000181519500046
J	Check, E				Check, E			BSE in human tissue fires debate on patient disclosure	NATURE			English	News Item																		Hilton DA, 2002, BRIT MED J, V325, P633, DOI 10.1136/bmj.325.7365.633; 2000, NATURE, V405, P7	2	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					326	326		10.1038/419326a	http://dx.doi.org/10.1038/419326a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12645536	Bronze			2022-12-28	WOS:000178195400005
J	Grady, D				Grady, D			Postmenopausal hormones - Therapy for symptoms only	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							QUALITY-OF-LIFE; ESTROGEN/PROGESTIN REPLACEMENT; HEART; TRIAL; WOMEN		Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; San Francisco Vet Affairs Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Grady, D (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.							Grady D, 2002, AM J MED, V113, P543, DOI 10.1016/S0002-9343(02)01270-6; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; MacLennan A, 2001, Climacteric, V4, P58, DOI 10.1080/713605036; WIKLUND I, 1993, AM J OBSTET GYNECOL, V168, P824, DOI 10.1016/S0002-9378(12)90828-5	5	72	76	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2003	348	19					1835	1837		10.1056/NEJMp030038	http://dx.doi.org/10.1056/NEJMp030038			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	675FY	12642636				2022-12-28	WOS:000182684100001
J	Weijer, CJ				Weijer, CJ			Visualizing signals moving in cells	SCIENCE			English	Review							STAT PROTEIN; BINDING DOMAIN; CYCLIC-AMP; ACTIVATION; DYNAMICS; MORPHOGENESIS; OSCILLATIONS; MODEL; WAVES; EGG	Cells display a highly complex spatiotemporal organization, required to exert a wide variety of different functions, for example, detection, processing, and propagation of nerve impulses by neurons; contraction and relaxation by muscle cells; movement by leukocytes; and adsorption and secretion of nutrients and metabolites by epithelial cells lining the gut. Successful execution of these complex processes requires highly dynamic information transfer between different regions and compartments within cells. Through the development of fluorescent sensors for intracellular signaling molecules coupled with improved microscopic imaging techniques, it has now become possible to investigate signal propagation in cells with high spatial and temporal resolution.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Dundee	Weijer, CJ (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.	c.j.weijer@dundee.ac.uk	weijer, cornelis j/I-4538-2012	Weijer, Cornelis/0000-0003-2192-8150				Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Araki T, 1998, EMBO J, V17, P4018, DOI 10.1093/emboj/17.14.4018; Balla T., 2002, SCI STKE, V2002, p3pl; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Bootman MD, 2002, CURR BIOL, V12, pR563, DOI 10.1016/S0960-9822(02)01055-2; Castiglione F, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.031905; Dormann D, 2002, CELL MOTIL CYTOSKEL, V52, P221, DOI 10.1002/cm.10048; Dormann D, 2002, CURR BIOL, V12, P1178, DOI 10.1016/S0960-9822(02)00950-8; Dormann D, 2001, DEVELOPMENT, V128, P1081; Dowler S., 2002, SCI STKE, V2002, P16; Dumollard R, 2002, J CELL SCI, V115, P3557, DOI 10.1242/jcs.00056; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Firtel RA, 2000, BIOESSAYS, V22, P603, DOI 10.1002/1521-1878(200007)22:7<603::AID-BIES3>3.0.CO;2-#; GAITS F, 2003, SCI STKE; Gardiner EM, 2002, CURR BIOL, V12, P2029, DOI 10.1016/S0960-9822(02)01334-9; GILKEY JC, 1978, J CELL BIOL, V76, P448, DOI 10.1083/jcb.76.2.448; Gilman AG, 2002, NATURE, V420, P703, DOI 10.1038/nature01304; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Harada Y, 1998, METHOD CELL BIOL, V55, P117; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Honda A, 2001, P NATL ACAD SCI USA, V98, P2437, DOI 10.1073/pnas.051631298; Hou SX, 2002, DEV CELL, V3, P765, DOI 10.1016/S1534-5807(02)00376-3; IGLESIAS PA, 2002, SCI STKE; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Jaffe LF, 2002, CELL CALCIUM, V32, P217, DOI 10.1016/S0143416002001574; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Kindzelskii AL, 2003, J IMMUNOL, V170, P64, DOI 10.4049/jimmunol.170.1.64; Kindzelskii AL, 2002, P NATL ACAD SCI USA, V99, P9207, DOI 10.1073/pnas.132630999; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; Meinhardt H, 2000, BIOESSAYS, V22, P1048, DOI 10.1002/1521-1878(200011)22:11<1048::AID-BIES13>3.0.CO;2-S; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Neves SR, 2002, BIOESSAYS, V24, P1110, DOI 10.1002/bies.1154; Olsen LF, 2003, BIOPHYS J, V84, P69, DOI 10.1016/S0006-3495(03)74833-4; Pang KM, 1997, MOL BIOL CELL, V8, P964; Pang KM, 1998, CURR BIOL, V8, P405, DOI 10.1016/S0960-9822(98)70159-9; Phair RD, 2001, NAT REV MOL CELL BIO, V2, P898, DOI 10.1038/35103000; Rich TC, 2002, ANN BIOMED ENG, V30, P1088, DOI 10.1114/1.1511242; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Schuster S, 2002, EUR J BIOCHEM, V269, P1333, DOI 10.1046/j.0014-2956.2001.02720.x; Shih WM, 2000, CELL, V102, P683, DOI 10.1016/S0092-8674(00)00090-8; SHIMOZONO S, 2002, SCI STKE; Small JV, 2003, CURR OPIN CELL BIOL, V15, P40, DOI 10.1016/S0955-0674(02)00008-X; Toomre D, 2001, TRENDS CELL BIOL, V11, P298, DOI 10.1016/S0962-8924(01)02027-X; Vicker MG, 2002, FEBS LETT, V510, P5, DOI 10.1016/S0014-5793(01)03207-0; Wallace W, 2001, BIOTECHNIQUES, V31, P1076, DOI 10.2144/01315bi01; Wallingford JB, 2000, MOL BIOL CELL, V11, p148A; Watanabe N, 2002, SCIENCE, V295, P1083, DOI 10.1126/science.1067470; Waterman-Storer CM, 2002, CURR BIOL, V12, pR633, DOI 10.1016/S0960-9822(02)01139-9; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Zaccolo M, 2001, NOVART FDN SYMP, V239, P85; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	56	90	93	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					96	100		10.1126/science.1082830	http://dx.doi.org/10.1126/science.1082830			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677060				2022-12-28	WOS:000181988900038
J	Pitt, B; Remme, W; Zannad, F; Neaton, J; Martinez, F; Roniker, B; Bittman, R; Hurley, S; Kleiman, J; Gatlin, M				Pitt, B; Remme, W; Zannad, F; Neaton, J; Martinez, F; Roniker, B; Bittman, R; Hurley, S; Kleiman, J; Gatlin, M		Eplerenone Post-Acute Myocardial Inf	Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEART-RATE-VARIABILITY; RECEPTOR ANTAGONISM; SPIRONOLACTONE; FAILURE; INFLAMMATION; INHIBITION; MORBIDITY; MORTALITY; TRIALS	BACKGROUND: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS: Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3313 patients) or placebo (3319 patients) in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia. RESULTS: During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P<0.001). CONCLUSIONS: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.	Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA; Cardiovasc Res Fdn, STICARES, Rotterdam, Netherlands; Ctr Invest Clin Nancy, Nancy, France; Univ Minnesota, Minneapolis, MN USA; Fdn Rusculleda, Cordoba, Argentina; Pharmacia, Skokie, IL USA	University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities; Pfizer	Pitt, B (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, 3910 Taubman,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	bpitt@umich.edu	Zannad, Faiez/K-4649-2019					Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; Aronson D, 1997, ANN INTERN MED, V126, P296, DOI 10.7326/0003-4819-126-4-199702150-00006; BARR CS, 1995, AM J CARDIOL, V76, P1259, DOI 10.1016/S0002-9149(99)80353-1; Bauersachs J, 2002, J AM COLL CARDIOL, V39, P351, DOI 10.1016/S0735-1097(01)01729-6; Cleland John G F, 2002, Heart Fail Rev, V7, P229, DOI 10.1023/A:1020024122726; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Dargie HJ, 2001, LANCET, V357, P1385, DOI 10.1016/s0140-6736(00)04560-8; DEGASPARO M, 1987, J PHARMACOL EXP THER, V240, P650; Delyani JA, 2001, AM J PHYSIOL-HEART C, V281, pH647, DOI 10.1152/ajpheart.2001.281.2.H647; Dickstein K, 2002, LANCET, V360, P752, DOI 10.1016/S0140-6736(02)09895-1; Farquharson CAJ, 2000, CIRCULATION, V101, P594, DOI 10.1161/01.CIR.101.6.594; Korkmaz ME, 2000, AM J CARDIOL, V86, P649, DOI 10.1016/S0002-9149(00)01046-8; MacFadyen RJ, 1997, CARDIOVASC RES, V35, P30, DOI 10.1016/S0008-6363(97)00091-6; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pitt B, 2002, AM J HYPERTENS, V15, p22S, DOI 10.1016/S0895-7061(01)02275-0; Pitt B, 2001, CARDIOVASC DRUG THER, V15, P79, DOI 10.1023/A:1011119003788; Rajagopalan S, 2002, CIRCULATION, V105, P2212, DOI 10.1161/01.CIR.0000015854.60710.10; Rocha R, 2002, ENDOCRINOLOGY, V143, P4828, DOI 10.1210/en.2002-220120; Rocha R, 2002, AM J PHYSIOL-HEART C, V283, pH1802, DOI 10.1152/ajpheart.01096.2001; Rodriguez JA, 1997, REV MED CHILE, V125, P643; Schaefer A, 2002, EUR HEART J, V23, P401; Shih JH, 1995, CONTROL CLIN TRIALS, V16, P395, DOI 10.1016/S0197-2456(95)00132-8; Sun Y, 2002, AM J PATHOL, V161, P1773, DOI 10.1016/S0002-9440(10)64454-9; Suzuki G, 2002, CIRCULATION, V106, P2967, DOI 10.1161/01.CIR.0000039104.56479.42; WANG W, 1994, HYPERTENSION, V24, P571, DOI 10.1161/01.HYP.24.5.571; Yee KM, 2001, J AM COLL CARDIOL, V37, P1800, DOI 10.1016/S0735-1097(01)01243-8; Zhang ZH, 2002, AM J PHYSIOL-HEART C, V283, pH423, DOI 10.1152/ajpheart.00685.2001	27	3364	3493	6	72	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1309	1321		10.1056/NEJMoa030207	http://dx.doi.org/10.1056/NEJMoa030207			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12668699				2022-12-28	WOS:000181949100002
J	Srivastava, IK; Liu, MA				Srivastava, IK; Liu, MA			Gene vaccines	ANNALS OF INTERNAL MEDICINE			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; HERPES-SIMPLEX-VIRUS; HEPATITIS-B-VIRUS; CYTOTOXIC T-LYMPHOCYTES; DNA-BASED IMMUNIZATION; MUCOSAL IMMUNE-RESPONSES; NUCLEIC-ACID VACCINATION; PLASMID DNA; PROTECTIVE IMMUNITY; NONHUMAN-PRIMATES	Gene vaccines are a new approach to immunization and immunotherapy in which, rather than a live or inactivated organism (or a subunit thereof), one or more genes that encode proteins of the pathogen are delivered. The goal of this approach is to generate immunity against diseases for which traditional vaccines and treatments have not worked, to improve vaccines, and to treat chronic diseases. Gene vaccines make use of advances in immunology and molecular biology to more specifically tailor immune responses (cellular or humoral, or both) against selected antigens. They are still under development in research and clinical trials. The mechanisms for inducing cellular (as opposed to humoral) responses against a particular antigen have been elucidated. Gene vaccines provide a means to generate specific cellular responses while still generating antibodies, if desired. In addition, by delivering only the genes that encode the particular proteins against which a protective or therapeutic immune response is desired, the potential limitations and risks of certain other approaches can be avoided. This article describes the rationale for, immunologic mechanisms involved in, and design of gene vaccines under development. Preclinical and clinical studies of these vaccines are discussed for various clinical applications, focusing on infectious diseases.	Chiron Corp, Emeryville, CA 94608 USA; Transgene SA, Strasbourg, France	Novartis; Transgene SA	Liu, MA (corresponding author), 11 Rue Molsheim, F-67082 Strasbourg, France.	liu@transgene.fr						Allen TM, 2000, J IMMUNOL, V164, P4968, DOI 10.4049/jimmunol.164.9.4968; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Baba TW, 1999, NAT MED, V5, P194, DOI 10.1038/5557; Barnet SW, 2001, J VIROL, V75, P5526, DOI 10.1128/JVI.75.12.5526-5540.2001; Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barouch DH, 2001, J VIROL, V75, P2462, DOI 10.1128/JVI.75.5.2462-2467.2001; Biragyn A, 1999, NAT BIOTECHNOL, V17, P253, DOI 10.1038/6995; Bourne N, 1996, J INFECT DIS, V173, P800, DOI 10.1093/infdis/173.4.800; Boyer J D, 1998, Dev Biol Stand, V95, P147; Boyer JD, 2000, J INFECT DIS, V181, P476, DOI 10.1086/315229; Boyle JS, 1998, NATURE, V392, P408, DOI 10.1038/32932; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; Calarota S, 1998, LANCET, V351, P1320, DOI 10.1016/S0140-6736(97)09440-3; Calarota SA, 2001, HUM GENE THER, V12, P1623, DOI 10.1089/10430340152528129; Cherpelis S, 2001, J VIROL, V75, P1547, DOI 10.1128/JVI.75.3.1547-1550.2001; Cohen J, 2001, SCIENCE, V292, P24, DOI 10.1126/science.292.5514.24; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; Dietrich Guido, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P177; Donnelly JJ, 1996, J INFECT DIS, V173, P314, DOI 10.1093/infdis/173.2.314; DONNELLY JJ, 1995, NAT MED, V1, P583, DOI 10.1038/nm0695-583; Donnelly JJ, 2000, AM J RESP CRIT CARE, V162, pS190, DOI 10.1164/ajrccm.162.supplement_3.15tac10; Donnelly JJ, 1995, ANN NY ACAD SCI, V772, P40, DOI 10.1111/j.1749-6632.1995.tb44730.x; Feltquate DM, 1997, J IMMUNOL, V158, P2278; Fennelly GJ, 1999, J IMMUNOL, V162, P1603; Flo J, 2000, VACCINE, V18, P3242, DOI 10.1016/S0264-410X(00)00132-8; FRANKEL FR, 1995, J IMMUNOL, V155, P4775; Fu TM, 1997, MOL MED, V3, P362, DOI 10.1007/BF03401683; FULLER DH, 1994, AIDS RES HUM RETROV, V10, P1433, DOI 10.1089/aid.1994.10.1433; Fuller DH, 1997, IMMUNOL CELL BIOL, V75, P389, DOI 10.1038/icb.1997.61; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GHIASI H, 1995, ANTIVIR RES, V28, P147, DOI 10.1016/0166-3542(95)00045-N; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Haigwood NL, 1999, IMMUNOL LETT, V66, P183, DOI 10.1016/S0165-2478(98)00156-4; HOFFMAN SL, 1994, VACCINE, V12, P1529, DOI 10.1016/0264-410X(94)90078-7; HONE DM, 1994, DEV BIOL STAND, V82, P159; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; Iwasaki A, 1997, J IMMUNOL, V158, P4591; Johnson RP, 1999, NAT MED, V5, P154, DOI 10.1038/5515; Jones DH, 1997, VACCINE, V15, P814, DOI 10.1016/S0264-410X(96)00266-6; Kim JJ, 2000, J INTERF CYTOK RES, V20, P487, DOI 10.1089/10799900050023906; Kim JJ, 1997, NAT BIOTECHNOL, V15, P641; Klinman DM, 1997, J IMMUNOL, V158, P3635; Krieg AM, 1996, TRENDS MICROBIOL, V4, P73, DOI 10.1016/0966-842X(96)81515-0; Krieg AM, 1996, J LAB CLIN MED, V128, P128, DOI 10.1016/S0022-2143(96)90004-9; Kuhober A, 1996, J IMMUNOL, V156, P3687; Kuhrober A, 1997, INT IMMUNOL, V9, P1203, DOI 10.1093/intimm/9.8.1203; LAGGING LM, 1995, J VIROL, V69, P5859, DOI 10.1128/JVI.69.9.5859-5863.1995; LAI WC, 1995, DNA CELL BIOL, V14, P643, DOI 10.1089/dna.1995.14.643; Le TP, 2000, VACCINE, V18, P1893, DOI 10.1016/S0264-410X(99)00407-7; Letvin NL, 1997, P NATL ACAD SCI USA, V94, P9378, DOI 10.1073/pnas.94.17.9378; Liu MA, 1996, ANTIBIOT CHEMOTHER, V48, P100; Lodmell DL, 1998, NAT MED, V4, P949, DOI 10.1038/nm0898-949; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; MacGregor RR, 2000, J INFECT DIS, V181, P406, DOI 10.1086/315199; MAJOR ME, 1995, J VIROL, V69, P5798, DOI 10.1128/JVI.69.9.5798-5805.1995; Manickan E, 1995, VIRAL IMMUNOL, V8, P53, DOI 10.1089/vim.1995.8.53; MANICKAN E, 1995, J IMMUNOL, V155, P259; MARTINS LP, 1995, J VIROL, V69, P2574, DOI 10.1128/JVI.69.4.2574-2582.1995; McClements WL, 1996, P NATL ACAD SCI USA, V93, P11414, DOI 10.1073/pnas.93.21.11414; McDonnell WM, 1996, NEW ENGL J MED, V334, P42, DOI 10.1056/NEJM199601043340110; Medina E, 2001, VACCINE, V19, P1573, DOI 10.1016/S0264-410X(00)00354-6; Mendoza RB, 1997, J IMMUNOL, V159, P5777; Mitchell WM, 1995, IMMUNOTECHNOLOGY, V1, P211, DOI 10.1016/1380-2933(95)00022-4; Mittal SK, 2000, VACCINE, V19, P253, DOI 10.1016/S0264-410X(00)00170-5; Noriega FR, 1996, INFECT IMMUN, V64, P3055, DOI 10.1128/IAI.64.8.3055-3061.1996; O'Hagan D, 2001, J VIROL, V75, P9037, DOI 10.1128/JVI.75.19.9037-9043.2001; Orson FM, 2000, J IMMUNOL, V164, P6313, DOI 10.4049/jimmunol.164.12.6313; Ourmanov I, 2000, J VIROL, V74, P2960, DOI 10.1128/JVI.74.6.2960-2965.2000; Pertmer TM, 1996, J VIROL, V70, P6119, DOI 10.1128/JVI.70.9.6119-6125.1996; Prince AM, 1997, VACCINE, V15, P916, DOI 10.1016/S0264-410X(96)00248-4; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; Richmond JFL, 1998, J VIROL, V72, P9092, DOI 10.1128/JVI.72.11.9092-9100.1998; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9; Santra S, 2000, J IMMUNOL, V165, P6791, DOI 10.4049/jimmunol.165.12.6791; Sasaki S, 1998, ANTICANCER RES, V18, P3907; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; SCHIRMBECK R, 1995, J VIROL, V69, P5929, DOI 10.1128/JVI.69.10.5929-5934.1995; Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397; Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; Sedegah M, 2000, J IMMUNOL, V164, P5905, DOI 10.4049/jimmunol.164.11.5905; Shiver JW, 1995, ANN NY ACAD SCI, V772, P198, DOI 10.1111/j.1749-6632.1995.tb44745.x; Shiver JW, 1997, VACCINE, V15, P884, DOI 10.1016/S0264-410X(96)00251-4; Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811; SIZEMORE DR, 1995, SCIENCE, V270, P299, DOI 10.1126/science.270.5234.299; Stevens EJ, 1998, J IMMUNOL METHODS, V215, P59, DOI 10.1016/S0022-1759(98)00059-3; Sundaram P, 1996, NUCLEIC ACIDS RES, V24, P1375, DOI 10.1093/nar/24.7.1375; Tacket CO, 2000, INFECT IMMUN, V68, P1196, DOI 10.1128/IAI.68.3.1196-1201.2000; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; Thomson SA, 1998, J IMMUNOL, V160, P1717; TITE JP, 1990, IMMUNOLOGY, V70, P540; Ulmer JB, 1997, VACCINE, V15, P792, DOI 10.1016/S0264-410X(96)00255-1; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Wang B, 1995, AIDS, V9 Suppl A, pS159; WANG B, 1993, DNA CELL BIOL, V12, P799, DOI 10.1089/dna.1993.12.799; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; Wang SW, 2000, J VIROL, V74, P10514, DOI 10.1128/JVI.74.22.10514-10522.2000; WEBSTER RG, 1994, VACCINE, V12, P1495, DOI 10.1016/0264-410X(94)90071-X; Widera G, 2000, J IMMUNOL, V164, P4635, DOI 10.4049/jimmunol.164.9.4635; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; XU D, 1995, IMMUNOLOGY, V84, P173; YANG W, 1995, BIOCHEM BIOPH RES CO, V212, P1029, DOI 10.1006/bbrc.1995.2073; YANKAUCKAS MA, 1993, DNA CELL BIOL, V12, P771, DOI 10.1089/dna.1993.12.771; YOKOYAMA M, 1995, J VIROL, V69, P2684, DOI 10.1128/JVI.69.4.2684-2688.1995; Zucchelli S, 2000, J VIROL, V74, P11598, DOI 10.1128/JVI.74.24.11598-11607.2000; zur Megede J, 2000, J VIROL, V74, P2628, DOI 10.1128/JVI.74.6.2628-2635.2000	110	94	115	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	2003	138	7					550	559		10.7326/0003-4819-138-7-200304010-00011	http://dx.doi.org/10.7326/0003-4819-138-7-200304010-00011			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BV	12667025				2022-12-28	WOS:000181872100004
J	Pauwels, RA; Pedersen, S; Busse, WW; Tan, WC; Chen, YZ; Ohlsson, SV; Ullman, A; Lamm, CJ; O'Byrne, PM				Pauwels, RA; Pedersen, S; Busse, WW; Tan, WC; Chen, YZ; Ohlsson, SV; Ullman, A; Lamm, CJ; O'Byrne, PM		START Investigators Grp	Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial	LANCET			English	Article							LONG-TERM TREATMENT; INHALED CORTICOSTEROIDS; BECLOMETHASONE DIPROPIONATE; AIRWAY RESPONSIVENESS; MUCOSAL INFLAMMATION; LUNG-FUNCTION; CHILDREN; GROWTH; THERAPY; DISEASE	Background Although inhaled glucocorticosteroids are recommended for persistent asthma, their long-term effect on recent onset, mild, persistent asthma has yet to be established. Methods We did a randomised, double-blind clinical trial in 7241 patients in 32 countries to assess the effects of budesonide in patients who had had mild persistent asthma for less than 2 years and who had not had previous regular treatment with glucocorticosteroids. Patients aged 5-66 years received either budesonide or placebo once daily for 3 years in addition to their usual asthma medications. The daily budesonide dose was 400 mug, or 200 mug for children younger than 11 years. The primary outcome was time to first severe asthma-related event, and analysis was by intention. to treat. Findings 198 of 3568 patients on placebo and 117,of 3597 on budesonide had at least one severe asthma exacerbation; hazard ratio 0.56 (95% Cl 0.45-0.71, p<0.0001). Patients on budesonide had fewer courses of systemic corticosteroids and more symptom-free days than did those on placebo. Compared with placebo, budesonide increased postbronchodilator forced expiratory volume in 1 s (FEV1) from baseline by 1.48% (p<0.0001) after 1 year and by 0.88% (p=0.0005) after 3 years (expressed as percent of the predicted value). The corresponding increase in prebronchodilator FEV1 was 2.24% after 1 year and 1.71% after 3 years (p<0.0001 at both timepoints). The effect of treatment on all outcome variables was independent of the baseline lung function (prebronchodilator or postbronchodilator) or baseline medication. In children younger than 11 years, 3-year growth was reduced in the budesonide group by 1.34 cm. The reduction was greatest in the first year of treatment (0.58 cm) than years 2 and 3 (0.43 cm and 0.33 cm, respectively) Interpretation Long-term, once-daily treatment with low-dose budesonide decreases the risk of severe exacerbations and improves asthma control in patients with mild persistent asthma of recent onset.	Ghent Univ Hosp, Dept Resp Dis, B-9000 Ghent, Belgium; Odense Univ, Dept Pediat, Kolding Hosp, Kolding, Denmark; Univ Wisconsin, Madison, WI USA; Natl Univ Singapore, Singapore 117548, Singapore; Capital Inst Paediat, Beijing, Peoples R China; AstraZeneca Res & Dev, Lund, Sweden; McMaster Univ, Dept Med, Hamilton, ON, Canada	Ghent University; Ghent University Hospital; Kolding Hospital; University of Southern Denmark; University of Wisconsin System; University of Wisconsin Madison; National University of Singapore; AstraZeneca; McMaster University	Pauwels, RA (corresponding author), Ghent Univ Hosp, Dept Resp Dis, De Pintelaan 185, B-9000 Ghent, Belgium.	romain.pauwels@rug.ac.be	Wong, Dennis A/AAH-2958-2020; Panzner, Petr/I-7034-2017	Panzner, Petr/0000-0002-1291-450X; O'Byrne, Paul/0000-0003-0979-281X; Jacobs, Robert/0000-0002-2831-9086; Liam, Chong-Kin/0000-0002-3639-9231; Rossi, Andrea/0000-0001-7095-7121; Visitsunthorn, Nualanong/0000-0002-4342-5100; Pirozynski, Michal/0000-0003-3611-4328; Alm, Bernt/0000-0002-3557-2995; Hollingsworth, Helen/0000-0001-9007-9012; Teper, Alejandro/0000-0002-7835-9713; Jee, Young-Koo/0000-0001-5800-8038				Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Allen DB, 1998, J PEDIATR-US, V132, P472, DOI 10.1016/S0022-3476(98)70023-X; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; Brown H., 1999, APPL MIXED MODELS ME; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; *NAT HEART LUNG BL, 1997, NAT ASTHM ED PREV PR; *NAT HEART LUNG BL, 1998, PUBL NAT HEART LUNG; *NAT HEART LUNG BL, 1995, PUBL NAT HEART LUNG; O'Byrne P, 1996, CAN RESPIR J, V3, P169; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2001, CONTROL CLIN TRIALS, V22, P405, DOI 10.1016/S0197-2456(01)00144-1; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Roorda RJ, 1996, THORAX, V51, pS7, DOI 10.1136/thx.51.Suppl_1.S7; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; STEWART AG, 1993, TRENDS PHARMACOL SCI, V14, P275, DOI 10.1016/0165-6147(93)90130-C; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Szefler S, 2000, NEW ENGL J MED, V343, P1054; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	30	549	586	0	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 29	2003	361	9363					1071	1076		10.1016/S0140-6736(03)12891-7	http://dx.doi.org/10.1016/S0140-6736(03)12891-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672309				2022-12-28	WOS:000181865200007
J	Gao, KQ; Shubin, NH				Gao, KQ; Shubin, NH			Earliest known crown-group salamanders	NATURE			English	Article								Salamanders are a model system for studying the rates and patterns of the evolution of new anatomical structures(1-4). Recent discoveries of abundant Late Jurassic and Early Cretaceous salamanders are helping to address these issues(5-8). Here we report the discovery of well-preserved Middle Jurassic salamanders from China, which constitutes the earliest known record of crown-group urodeles (living salamanders and their closest relatives). The new specimens are from the volcanic deposits of the Jiulongshan Formation (Bathonian)(9-13), Inner Mongolia, China, and represent basal members of the Cryptobranchidae, a family that includes the endangered Asian giant salamander (Andrias) and the North American hellbender (Cryptobranchus). These fossils document a Mesozoic record of the Cryptobranchidae, predating the previous record of the group by some 100 million years(14-17). This discovery provides evidence to support the hypothesis that the divergence of the Cryptobranchidae from the Hynobiidae had taken place in Asia before the Middle Jurassic period.	Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Peking Univ, Sch Earth & Space Sci, Beijing 100871, Peoples R China	University of Chicago; Peking University	Shubin, NH (corresponding author), Univ Chicago, Dept Organismal Biol & Anat, 1027 E 57th St, Chicago, IL 60637 USA.							Dong Zhiming, 1998, Vertebrata Palasiatica, V36, P159; Duellman W. E., 1986, BIOL AMPHIBIANS; Estes R., 1981, HDB PALAOHERPETOLO 2; Evans SE, 1996, PHILOS T R SOC B, V351, P627, DOI 10.1098/rstb.1996.0061; EVANS SE, 1988, GEOBIOS-LYON, V21, P539, DOI 10.1016/S0016-6995(88)80069-X; GAO K, 1998, GEOL CHINA, V248, P40; Gao KQ, 2001, NATURE, V410, P574, DOI 10.1038/35069051; GUBIN YM, 1991, PALEONTOLOG J, P91; HARLAND BW, 1990, GEOLOGIC TIME SCALE; Ivachnenko M, 1978, PALEONTOL J, V1978, P362; [季强 Ji Qiang], 2002, [地质论评, Geological Review], V48, P221; KRZEMISKI W, 2002, POL PIS ENTOMOL, V71, P127; Larson Allan, 1993, Herpetological Monographs, V7, P77, DOI 10.2307/1466953; Milner A. R., 1983, EVOLUTION TIME SPACE, P431; Milner Andrew R., 2000, Amphibian Biology, V4, P1412; NAYLOR BG, 1981, COPEIA, P76, DOI 10.2307/1444042; NESSOV L A, 1988, Acta Zoologica Cracoviensia, V31, P475; Nessov LA, 1996, VESTNIK SANKT PETERS, V7, P3; REN D, 2002, STUTTGART BEIT NAT B, V33, P1; [任东 Ren Dong], 2002, [地质通报, Geological Bulletin of China], V21, P584; SCOTESE C. R., 2001, ATLAS EARTH HIST, V1; SHUBIN N, 1995, EVOLUTION, V49, P874, DOI 10.1111/j.1558-5646.1995.tb02323.x; Shubin N, 1996, AM ZOOL, V36, P51; VENCZEL M, 1987, 3 WORLD C HERP, P218; WAKE DB, 1987, SCIENCE, V238, P42, DOI 10.1126/science.238.4823.42; WAKE DB, 1991, AM NAT, V138, P543, DOI 10.1086/285234; WAKE DB, 1983, J THEOR BIOL, V101, P211, DOI 10.1016/0022-5193(83)90335-1; Wang S. E., 2000, STRATIGRAPHICAL LEXI; Wang Yuan, 2000, Vertebrata Palasiatica, V38, P100	29	237	276	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					424	428		10.1038/nature01491	http://dx.doi.org/10.1038/nature01491			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660782	Green Published			2022-12-28	WOS:000181801200043
J	Schmidt-Kaler, F; Haffner, H; Riebe, M; Gulde, S; Lancaster, GPT; Deuschle, T; Becher, C; Roos, CF; Eschner, J; Blatt, R				Schmidt-Kaler, F; Haffner, H; Riebe, M; Gulde, S; Lancaster, GPT; Deuschle, T; Becher, C; Roos, CF; Eschner, J; Blatt, R			Realization of the Cirac-Zoller controlled-NOT quantum gate	NATURE			English	Article							COLD TRAPPED IONS; ENTANGLEMENT; IMPLEMENTATION; COMPUTATION; UNIVERSAL; ALGORITHM	Quantum computers have the potential to perform certain computational tasks more efficiently than their classical counterparts. The Cirac-Zoller proposal(1) for a scalable quantum computer is based on a string of trapped ions whose electronic states represent the quantum bits of information (or qubits). In this scheme, quantum logical gates involving any subset of ions are realized by coupling the ions through their collective quantized motion. The main experimental step towards realizing the scheme is to implement the controlled-NOT (CNOT) gate operation between two individual ions. The CNOT quantum logical gate corresponds to the XOR gate operation of classical logic that flips the state of a target bit conditioned on the state of a control bit. Here we implement a CNOT quantum gate according to the Cirac-Zoller proposal(1). In our experiment, two (40)Ca(+) ions are held in a linear Paul trap and are individually addressed using focused laser beams(2); the qubits(3) are represented by superpositions of two long-lived electronic states. Our work relies on recently developed precise control of atomic phases(4) and the application of composite pulse sequences adapted from nuclear magnetic resonance techniques(5,6).	Univ Innsbruck, Inst Expt Phys, A-6020 Innsbruck, Austria	University of Innsbruck	Blatt, R (corresponding author), Univ Innsbruck, Inst Expt Phys, Technikerstr 25, A-6020 Innsbruck, Austria.	Rainer.Blatt@uibk.ac.at	Blatt, Rainer/H-9527-2014; Roos, Christian F/D-8475-2011; Eschner, Jürgen/N-1073-2013; Haeffner, Hartmut/D-8046-2012; Schmidt-Kaler, Ferdinand/E-2151-2017; Becker, Jonas/GZG-4234-2022; Becher, Christoph/AAE-8756-2020	Roos, Christian F/0000-0001-7121-8259; Eschner, Jürgen/0000-0002-8393-7258; Haeffner, Hartmut/0000-0002-5113-9622; Becher, Christoph/0000-0003-4645-6882; Schmidt-Kaler, Ferdinand/0000-0002-5697-2568				Childs AM, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.012306; CIRAC JI, 1995, PHYS REV LETT, V74, P4091, DOI 10.1103/PhysRevLett.74.4091; DEHMELT H, 1975, B AM PHYS SOC, V20, P60; DEVIVIERIEDLE R, 2001, CHEM PHYS, V267; DiVincenzo DP, 2000, FORTSCHR PHYS, V48, P771, DOI 10.1002/1521-3978(200009)48:9/11<771::AID-PROP771>3.0.CO;2-E; DIVINCENZO DP, 1995, PHYS REV A, V51, P1015, DOI 10.1103/PhysRevA.51.1015; Duan LM, 2001, NATURE, V414, P413, DOI 10.1038/35106500; Gulde S, 2003, NATURE, V421, P48, DOI 10.1038/nature01336; HAFFNER H, 2002, IN PRESS PHYS REV LE; Jones JA, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.012317; LEVITT MH, 1986, PROG NUCL MAG RES SP, V18, P61, DOI 10.1016/0079-6565(86)80005-X; Meekhof DM, 1996, PHYS REV LETT, V76, P1796, DOI 10.1103/PhysRevLett.76.1796; Nagerl HC, 1999, PHYS REV A, V60, P145, DOI 10.1103/PhysRevA.60.145; Nagerl HC, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.023405; Rohde H, 2001, J OPT B-QUANTUM S O, V3, pS34, DOI 10.1088/1464-4266/3/1/357; Roos C, 1999, PHYS REV LETT, V83, P4713, DOI 10.1103/PhysRevLett.83.4713; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Sasura M, 2002, J MOD OPTIC, V49, P1593, DOI 10.1080/09500340110115497; Shor P. W., 1994, Proceedings. 35th Annual Symposium on Foundations of Computer Science (Cat. No.94CH35717), P124, DOI 10.1109/SFCS.1994.365700; SLEATOR T, 1995, PHYS REV LETT, V74, P4087, DOI 10.1103/PhysRevLett.74.4087; Steane AM, 1999, NATURE, V399, P124, DOI 10.1038/20127; Turchette QA, 1998, PHYS REV LETT, V81, P3631, DOI 10.1103/PhysRevLett.81.3631; Vandersypen LMK, 2001, NATURE, V414, P883, DOI 10.1038/414883a	25	705	714	1	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					408	411		10.1038/nature01494	http://dx.doi.org/10.1038/nature01494			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660777				2022-12-28	WOS:000181801200038
J	Warrell, DA				Warrell, DA			Taking the sting out of ant stings: venom immunotherapy to prevent anaphylaxis	LANCET			English	Editorial Material							FATAL ANAPHYLAXIS; TASMANIA		John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	University of Oxford	Warrell, DA (corresponding author), John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.							Brown SGA, 2001, MED J AUSTRALIA, V175, P644, DOI 10.5694/j.1326-5377.2001.tb143761.x; CLARKE PS, 1986, MED J AUSTRALIA, V145, P564, DOI 10.5694/j.1326-5377.1986.tb139498.x; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; MUELLER ER, 1990, INSECT STING ALLERGY; Prahlow JA, 1998, AM J FOREN MED PATH, V19, P137, DOI 10.1097/00000433-199806000-00007; SOUTHCOTT RV, 1988, MED J AUSTRALIA, V149, P656, DOI 10.5694/j.1326-5377.1988.tb120814.x; Sutherland S, 2001, AUSTR ANIMAL TOXINS; SUTHERLAND SK, 1998, VENOMOUS LIFE, P313	9	0	0	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 22	2003	361	9362					979	980		10.1016/S0140-6736(03)12839-5	http://dx.doi.org/10.1016/S0140-6736(03)12839-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660050				2022-12-28	WOS:000181699700003
J	Oppo, DW; McManus, JF; Cullen, JL				Oppo, DW; McManus, JF; Cullen, JL			Palaeo-oceanography: Deepwater variability in the Holocene epoch	NATURE			English	Article							NORTH-ATLANTIC CLIMATE; CIRCULATION		Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02540 USA; Salem State Coll, Dept Geol Sci, Salem, MA 01970 USA	Woods Hole Oceanographic Institution; Massachusetts System of Public Higher Education; Salem State University	Oppo, DW (corresponding author), Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02540 USA.	doppo@whoi.edu						Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; Bianchi GG, 1999, NATURE, V397, P515, DOI 10.1038/17362; Bond G, 2001, SCIENCE, V294, P2130, DOI 10.1126/science.1065680; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Broecker WS, 1990, PALEOCEANOGRAPHY, V5, P469, DOI 10.1029/PA005i004p00469; Chapman MR, 2000, HOLOCENE, V10, P287, DOI 10.1191/095968300671253196; Curry WB, 1988, PALEOCEANOGRAPHY, V3, P317, DOI 10.1029/PA003i003p00317; Duplessy JC, 1988, PALEOCEANOGRAPHY, V3, P343, DOI 10.1029/PA003i003p00343; Keigwin LD, 2000, P NATL ACAD SCI USA, V97, P1343, DOI 10.1073/pnas.97.4.1343; KROOPNICK PM, 1985, DEEP-SEA RES, V32, P57, DOI 10.1016/0198-0149(85)90017-2; McManus JF, 1999, SCIENCE, V283, P971, DOI 10.1126/science.283.5404.971; OBRIEN SR, 1995, SCIENCE, V270, P1962, DOI 10.1126/science.270.5244.1962; STUIVER M, 1993, RADIOCARBON, V35, P137	13	197	204	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 20	2003	422	6929					277	278		10.1038/422277b	http://dx.doi.org/10.1038/422277b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	656XX	12646912				2022-12-28	WOS:000181637300030
J	Ford, N; Cantau, N; Jeanmart, H				Ford, N; Cantau, N; Jeanmart, H			Homelessness and hardship in Moscow	LANCET			English	Editorial Material									Med Sans Frontieres, London EC1R 5DJ, England; Med Sans Frontieres, Moscow 12310, Russia	Doctors Without Borders; Doctors Without Borders	Cantau, N (corresponding author), Med Sans Frontieres, Shmitovskij Proezd Dom 3, Moscow 12310, Russia.							WHO, 2002, GLOB TUB CONTR	1	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					875	875		10.1016/S0140-6736(03)12717-1	http://dx.doi.org/10.1016/S0140-6736(03)12717-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642069				2022-12-28	WOS:000181466600030
J	Tomasz, A				Tomasz, A			"Intelligence coup" for drug designers: crystal structure of Staphylococcus aureus beta-lactam resistance protein PBP2A	LANCET			English	Editorial Material							BINDING		Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA	Rockefeller University	Tomasz, A (corresponding author), Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA.	tomasz@mail.rockefeller.edu	Tomasz, Alexander/B-9939-2011	Tomasz, Alexander/0000-0003-1520-1983				Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P565; Crisostomo MI, 2001, P NATL ACAD SCI USA, V98, P9865, DOI 10.1073/pnas.161272898; Dufour P, 2002, CLIN INFECT DIS, V35, P819, DOI 10.1086/342576; Enright MC, 2002, P NATL ACAD SCI USA, V99, P7687, DOI 10.1073/pnas.122108599; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; Ito T, 2001, ANTIMICROB AGENTS CH, V45, P1323, DOI 10.1128/AAC.45.5.1323-1336.2001; Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858; Oliveira DC, 2002, LANCET INFECT DIS, V2, P180, DOI 10.1016/S1473-3099(02)00227-X; Pinho MG, 2001, P NATL ACAD SCI USA, V98, P10886, DOI 10.1073/pnas.191260798; *PUBL HLTH DISP, 2002, MMWR-MORBID MORTAL W, V51, P902; Sieradzki K, 1999, NEW ENGL J MED, V340, P517, DOI 10.1056/NEJM199902183400704; Toney JH, 1998, ANAL BIOCHEM, V255, P113, DOI 10.1006/abio.1997.2458; Wu SW, 2001, J BACTERIOL, V183, P2417, DOI 10.1128/JB.183.8.2417-2424.2001	13	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 8	2003	361	9360					795	796		10.1016/S0140-6736(03)12719-5	http://dx.doi.org/10.1016/S0140-6736(03)12719-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642041				2022-12-28	WOS:000181466600003
J	Allan, DW; St Pierre, SE; Miguel-Aliaga, I; Thor, S				Allan, DW; St Pierre, SE; Miguel-Aliaga, I; Thor, S			Specification of neuropeptide cell identity by the integration of retrograde BMP signaling and a combinatorial transcription factor code	CELL			English	Article							BONE MORPHOGENETIC PROTEINS; GROWTH CONE GUIDANCE; ZINC-FINGER PROTEIN; DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; SYMPATHETIC NEURONS; PATHWAY SELECTION; NERVOUS-SYSTEM; GENE; EXPRESSION	Individual neurons express only one or a few of the many identified neurotransmitters; and neuropeptides, but the molecular mechanisms controlling their selection are poorly understood. In the Drosophila ventral nerve cord, the six Tv neurons express the neuropeptide gene FMRFamide. Each Tv neuron resides within a neuronal cell group specified by the LIM-homeodomain gene apterous. We find that the zinc-finger gene squeeze acts in Tv cells to promote their unique axon pathfinding to a peripheral target. There, the BMP ligand Glass bottom boat activates the Wishful thinking receptor, initiating a retrograde BMP signal in the Tv neuron. This signal acts together with apterous and squeeze to activate FMRFamide expression. Reconstituting this "code," by combined BMP activation and apterous/squeeze misexpression, triggers ectopic FMRFamide expression in peptidergic neurons. Thus, an intrinsic transcription factor code integrates with an extrinsic retrograde signal to select a specific neuropeptide identity within peptidergic cells.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Thor, S (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.		Thor, Stefan/Y-5804-2019	Thor, Stefan/0000-0001-5095-541X; Miguel-Aliaga, Irene/0000-0002-1082-5108	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH020017] Funding Source: NIH RePORTER; NIMH NIH HHS [TG T32MH20017] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aberle H, 2002, NEURON, V33, P545, DOI 10.1016/S0896-6273(02)00589-5; Ai XB, 1999, MOL CELL NEUROSCI, V14, P506, DOI 10.1006/mcne.1999.0798; Allen MJ, 1999, J NEUROSCI, V19, P9374; Barolo S, 2002, GENE DEV, V16, P1167, DOI 10.1101/gad.976502; Benveniste RJ, 1998, DEVELOPMENT, V125, P4757; CHIN AC, 1990, DNA CELL BIOL, V9, P263, DOI 10.1089/dna.1990.9.263; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; Dorfman R, 2001, DEVELOPMENT, V128, P965; Duggan Anne, 1995, Current Opinion in Neurobiology, V5, P6, DOI 10.1016/0959-4388(95)80080-8; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Ernsberger U, 1999, CELL TISSUE RES, V297, P339, DOI 10.1007/s004410051363; Finley KD, 1998, NEURON, V21, P1363, DOI 10.1016/S0896-6273(00)80655-8; GORCZYCA MG, 1994, DEVELOPMENT, V120, P2143; Haerry TE, 1998, DEVELOPMENT, V125, P3977; Hall AK, 2002, J NEUROBIOL, V52, P52, DOI 10.1002/neu.10068; Hewes RS, 2003, DEVELOPMENT, V130, P1771, DOI 10.1242/dev.00404; Hokfelt T, 2000, NEUROPHARMACOLOGY, V39, P1337, DOI 10.1016/S0028-3908(00)00010-1; Jarecki J, 1995, J NEUROSCI, V15, P8177; Kaufmann N, 1998, DEVELOPMENT, V125, P453; Keleman K, 2001, NEURON, V32, P605, DOI 10.1016/S0896-6273(01)00505-0; Khalsa O, 1998, DEVELOPMENT, V125, P2723; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; Koo SJ, 2002, NEURON, V35, P823, DOI 10.1016/S0896-6273(02)00870-X; Landis SC, 1996, PERSPECT DEV NEUROBI, V4, P53; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; Massague J, 2000, GENE DEV, V14, P627; Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649-1658.2000; Nassel DR, 1996, CURR OPIN NEUROBIOL, V6, P842, DOI 10.1016/S0959-4388(96)80036-5; Nassel DR, 1996, PROG NEUROBIOL, V48, P325, DOI 10.1016/0301-0082(95)00048-8; NASSEL DR, 1988, J COMP NEUROL, V267, P343, DOI 10.1002/cne.902670305; O'Brien MA, 1998, J EXP BIOL, V201, P193; O'Keefe DD, 1998, DEVELOPMENT, V125, P3915; OLSON PF, 1990, EMBO J, V9, P1219, DOI 10.1002/j.1460-2075.1990.tb08229.x; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PEARSE AGE, 1980, CLIN ENDOCRINOL META, V9, P211, DOI 10.1016/S0300-595X(80)80030-2; Perrimon N, 1996, GENETICS, V144, P1681; Raftery LA, 1999, DEV BIOL, V210, P251, DOI 10.1006/dbio.1999.9282; ROUGVIE AE, 1995, DEVELOPMENT, V121, P2491; SCHNEIDER LE, 1993, J COMP NEUROL, V337, P446, DOI 10.1002/cne.903370308; SCHNEIDER LE, 1993, NEURON, V10, P279, DOI 10.1016/0896-6273(93)90318-L; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Skeath JB, 2003, CURR OPIN NEUROBIOL, V13, P8, DOI 10.1016/S0959-4388(03)00007-2; Spradling AC, 1999, GENETICS, V153, P135; St Pierre SE, 2002, DEVELOPMENT, V129, P1273; Taghert PH, 1999, MICROSC RES TECHNIQ, V45, P80, DOI 10.1002/(SICI)1097-0029(19990415)45:2<80::AID-JEMT3>3.0.CO;2-X; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; Torroja L, 1999, CURR BIOL, V9, P489, DOI 10.1016/S0960-9822(99)80215-2; Zhao HJ, 2000, DEVELOPMENT, V127, P1253	52	131	135	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 4	2003	113	1					73	86		10.1016/S0092-8674(03)00204-6	http://dx.doi.org/10.1016/S0092-8674(03)00204-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679036	Bronze			2022-12-28	WOS:000182282900008
J	Friedlander, RM				Friedlander, RM			Mechanisms of disease: Apoptosis and caspases in neurodegenerative diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TRANSGENIC MOUSE MODEL; INTERLEUKIN-1-BETA CONVERTING-ENZYME; AMYOTROPHIC-LATERAL-SCLEROSIS; PROGRAMMED CELL-DEATH; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; DNA FRAGMENTATION; CYTOCHROME-C; NEURONAL APOPTOSIS; GLOBAL-ISCHEMIA		Brigham & Womens Hosp, Dept Neurosurg, Div Cerebrovasc Surg, Neuroapoptosis Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Friedlander, RM (corresponding author), Brigham & Womens Hosp, Dept Neurosurg, Div Cerebrovasc Surg, Neuroapoptosis Lab, 75 Francis St, Boston, MA 02115 USA.	rfriedlander@rics.bwh.harvard.edu	Friedlander, Robert M/A-2845-2016	Friedlander, Robert M/0000-0003-4423-9219				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; CharriautMarlangue C, 1996, J CEREBR BLOOD F MET, V16, P186, DOI 10.1097/00004647-199603000-00002; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Crowe MJ, 1997, NAT MED, V3, P240; Deveraux Quinn L., 2001, Cardiology Clinics, V19, P57; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Enari M, 1998, NATURE, V393, P396, DOI 10.1038/30782; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 1998, NATURE, V392, P560; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; Garden GA, 2002, J NEUROSCI, V22, P4015, DOI 10.1523/JNEUROSCI.22-10-04015.2002; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guegn C, 2001, J NEUROSCI, V21, P6569, DOI 10.1523/JNEUROSCI.21-17-06569.2001; GURNEY ME, 1995, SCIENCE, V269, P149, DOI 10.1126/science.269.5221.149-a; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harper PS, 1991, HUNTINGTONS DIS; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Horvitz HR, 1999, CANCER RES, V59, p1701S; Kanduc D, 2002, INT J ONCOL, V21, P165; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kiechle T, 2002, NEUROMOL MED, V1, P183; Klevenyi P, 1999, NEUROREPORT, V10, P635, DOI 10.1097/00001756-199902250-00035; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Kuhn HG, 2001, EUR ARCH PSY CLIN N, V251, P152, DOI 10.1007/s004060170035; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li SH, 2000, HUM MOL GENET, V9, P2859, DOI 10.1093/hmg/9.19.2859; LI Y, 1995, MOL BRAIN RES, V28, P164, DOI 10.1016/0169-328X(94)00220-9; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Liu JL, 1998, J NEUROSCI, V18, P7768; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu XZ, 1997, J NEUROSCI, V17, P5395; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; LODDICK SA, 1999, NEUROREPORT, V10; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martin JB, 1999, NEW ENGL J MED, V341, P1407; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; Martin LJ, 2001, INT J MOL MED, V7, P455; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Reddy PH, 1998, NAT GENET, V20, P198, DOI 10.1038/2510; Rigamonti D, 2001, J BIOL CHEM, V276, P14545, DOI 10.1074/jbc.C100044200; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; RINK A, 1995, AM J PATHOL, V147, P1575; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Rossi F, 2002, NAT REV NEUROSCI, V3, P401, DOI 10.1038/nrn809; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Sun W, 2002, J NEUROSCI, V22, P6537; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Troost D, 1995, NEUROPATH APPL NEURO, V21, P498, DOI 10.1111/j.1365-2990.1995.tb01096.x; Troy CM, 2002, J NEUROSCI RES, V69, P145, DOI 10.1002/jnr.10294; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Wang XD, 2001, GENE DEV, V15, P2922; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Xu DG, 1999, J NEUROSCI, V19, P5026; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	100	669	723	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1365	1375		10.1056/NEJMra022366	http://dx.doi.org/10.1056/NEJMra022366			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672865				2022-12-28	WOS:000181949100009
J	Nichol, KL; Nordin, J; Mullooly, J; Lask, R; Fillbrandt, K; Iwane, M				Nichol, KL; Nordin, J; Mullooly, J; Lask, R; Fillbrandt, K; Iwane, M			Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXCESS MORTALITY; RISK-FACTOR; PREVENTING HOSPITALIZATION; PRECEDING INFECTION; COST-EFFECTIVENESS; BRAIN INFARCTION; REDUCED RISK; ASSOCIATION; EPIDEMIC; ADMISSIONS	BACKGROUND: Upper respiratory tract illnesses have been associated with an increased risk of ischemic heart disease and stroke. During two influenza seasons, we assessed the influence of vaccination against influenza on the risk of hospitalization for heart disease and stroke, hospitalization for pneumonia and influenza, and death from all causes. METHODS: Cohorts of community-dwelling members of three large managed-care organizations who were at least 65 years old were studied during the 1998-1999 and 1999-2000 influenza seasons. Administrative and clinical data were used to evaluate outcomes, with multivariable logistic regression to control for base-line demographic and health characteristics of the subjects. RESULTS: There were 140,055 subjects in the 1998-1999 cohort and 146,328 in the 1999-2000 cohort, of which 55.5 percent and 59.7 percent, respectively, were immunized. At base line, vaccinated subjects were on average sicker, having higher rates of most coexisting conditions, outpatient care, and prior hospitalization for pneumonia than unvaccinated subjects. Unvaccinated subjects, however, were more likely to have been given a prior diagnosis of dementia or stroke. Vaccination against influenza was associated with a reduction in the risk of hospitalization for cardiac disease (reduction of 19 percent during both seasons [P<0.001]), cerebrovascular disease (reduction of 16 percent during the 1998-1999 season [P<0.018] and 23 percent during the 1999-2000 season [P<0.001]), and pneumonia or influenza (reduction of 32 percent during the 1998-1999 season [P<0.001] and 29 percent during the 1999-2000 season [P<0.001]) and a reduction in the risk of death from all causes (reduction of 48 percent during the 1998-1999 season [P<0.001] and 50 percent during the 1999-2000 season [P<0.001]). In analyses according to age, the presence or absence of major medical conditions at base line, and study site, the findings were consistent across all subgroups. CONCLUSIONS: In the elderly, vaccination against influenza is associated with reductions in the risk of hospitalization for heart disease, cerebrovascular disease, and pneumonia or influenza as well as the risk of death from all causes during influenza seasons. These findings highlight the benefits of vaccination and support efforts to increase the rates of vaccination among the elderly.	Vet Affairs Med Ctr, Minneapolis, MN 55417 USA; Univ Minnesota, Minneapolis, MN USA; HealthPartners Res Fdn, Minneapolis, MN USA; Kaiser Permanente NW, Portland, OR USA; Oxford Hlth Plan, New York, NY USA; Ctr Dis Control & Prevent, Atlanta, GA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; HealthPartners Institute for Education & Research; Kaiser Permanente; UnitedHealth Group Incorporated; Centers for Disease Control & Prevention - USA	Nichol, KL (corresponding author), Vet Affairs Med Ctr, 1 Vet Dr, Minneapolis, MN 55417 USA.	nicho014@umn.edu		Nordin, James/0000-0002-3359-5843				*ADV COMM IMM PRAC, 2002, MMWR-MORBID MORTAL W, V51, P1; AHMED AEH, 1995, LANCET, V346, P591, DOI 10.1016/S0140-6736(95)91434-X; Ahmed AH, 1997, EPIDEMIOL INFECT, V118, P27, DOI 10.1017/S0950268896007121; ALLING DW, 1981, AM J EPIDEMIOL, V113, P30, DOI 10.1093/oxfordjournals.aje.a113063; [Anonymous], 1997, MMWR MORB MORT WKLY, V46, P1; BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; Becher H, 2000, J Epidemiol Biostat, V5, P277; Bova IY, 1996, STROKE, V27, P2204, DOI 10.1161/01.STR.27.12.2204; *CDCP, 2002, EARL REL SEL EST NAT; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P374; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P375; COLLINS S. D., 1932, Public Health Reports, V47, P2159, DOI 10.2307/4580606; COOK RJ, 1995, BRIT MED J, V310, P1056; Crocetti E, 2001, EUR J EPIDEMIOL, V17, P163, DOI 10.1023/A:1017978420601; *DEP HLTH HUM SERV, 2000, HLTH PEOPL 2010, V1; EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005; EPSEIN SE, 1999, CIRCULATION, V100, pE20; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V271, P1578; Fleming DM, 1995, EPIDEMIOL INFECT, V115, P581, DOI 10.1017/S095026880005874X; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; Gurfinkel EP, 2002, CIRCULATION, V105, P2143, DOI 10.1161/01.CIR.0000016182.85461.F4; Hak E, 2002, CLIN INFECT DIS, V35, P370, DOI 10.1086/341403; HOUSWORTH J, 1974, AM J EPIDEMIOL, V100, P40, DOI 10.1093/oxfordjournals.aje.a112007; Jackson LA, 2002, AM J EPIDEMIOL, V156, P634, DOI 10.1093/aje/kwf073; Jakovljevic D, 1996, STROKE, V27, P1774, DOI 10.1161/01.STR.27.10.1774; Lavallee P, 2002, STROKE, V33, P1172; Lavallee P, 2002, STROKE, V33, P513, DOI 10.1161/hs0202.102328; Mac Donald R, 1999, AM J PREV MED, V16, P173, DOI 10.1016/S0749-3797(98)00159-7; Macko RF, 1996, STROKE, V27, P1999, DOI 10.1161/01.STR.27.11.1999; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; Meier CR, 1998, LANCET, V351, P1467, DOI 10.1016/S0140-6736(97)11084-4; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; Naghavi M, 2000, CIRCULATION, V102, P3039; Nichol KL, 2001, ARCH INTERN MED, V161, P2702, DOI 10.1001/archinte.161.22.2702; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; NICHOL KL, 1998, TXB INFLUENZA, P358; Nordin J, 2001, J INFECT DIS, V184, P665, DOI 10.1086/323085; Ohmit SE, 1995, INT J EPIDEMIOL, V24, P1240, DOI 10.1093/ije/24.6.1240; PuigBarbera J, 1997, J EPIDEMIOL COMMUN H, V51, P526, DOI 10.1136/jech.51.5.526; Siscovick DS, 2000, AM J EPIDEMIOL, V152, P674, DOI 10.1093/aje/152.7.674; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; Stamboulian D, 1999, VACCINE, V17, pS53, DOI 10.1016/S0264-410X(99)00106-1; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; VALTONEN VV, 1991, ANN MED, V23, P539, DOI 10.3109/07853899109150515; Vu T, 2002, VACCINE, V20, P1831, DOI 10.1016/S0264-410X(02)00041-5	47	562	596	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1322	1332		10.1056/NEJMoa025028	http://dx.doi.org/10.1056/NEJMoa025028			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662LW	12672859				2022-12-28	WOS:000181949100003
J	Haight, RO				Haight, RO			Fragile corners	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2003	289	12					1477	1477		10.1001/jama.289.12.1477	http://dx.doi.org/10.1001/jama.289.12.1477			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659XE	12672745				2022-12-28	WOS:000181803100001
J	Shekelle, PG; Hardy, ML; Morton, SC; Maglione, M; Mojica, WA; Suttorp, MJ; Rhodes, SL; Jungvig, L; Gagne, J				Shekelle, PG; Hardy, ML; Morton, SC; Maglione, M; Mojica, WA; Suttorp, MJ; Rhodes, SL; Jungvig, L; Gagne, J			Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							DOUBLE-BLIND; CONTROLLED TRIAL; ENERGY-EXPENDITURE; COMBINED CAFFEINE; BODY-COMPOSITION; CLINICAL-TRIALS; OBESE PATIENTS; SIBUTRAMINE; ORLISTAT; INGESTION	Context Ephedra and ephedrine sometimes are used for weight loss or enhanced athletic performance, but the efficacy and safety of these compounds are uncertain. Objective To assess the efficacy and safety of ephedra and ephedrine used for weight loss and enhanced athletic performance. Data Sources We searched 9 databases using the terms ephedra, ephedrine, adverse effect, side effect, efficacy, effective, and toxic. We included unpublished trials and non-English-language documents. Adverse events reported to the US Food and Drug Administration MedWatch program were assessed. Study Selection Eligible studies were controlled trials of ephedra or ephedrine used for weight loss or athletic performance and case reports of adverse events associated with such use. Eligible studies for weight loss were human studies with at least 8 weeks of follow-up; and for athletic performance, those having no minimum follow-up. Eligible case reports documented that ephedra or ephedrine was consumed within 24 hours prior to an adverse event or that ephedrine or an associated product was found in blood or urine, and that other potential causes had been excluded. Of the 530 articles screened, 52 controlled trials and 65 case reports were included in the adverse events analysis. Of more than 18000 other case reports screened, 284 underwent detailed review. Data Extraction Two reviewers independently identified trials of efficacy and safety of ephedra and ephedrine on weight loss or athletic performance; disagreements were resolved by consensus. Case reports were reviewed with explicit and implicit methods. Data Synthesis No weight loss trials assessed duration of treatment greater than 6 months. Pooled results. for trials comparing placebo with ephedrine (n=5), ephedrine and caffeine (n=12), ephedra (n=1), and ephedra and herbs containing caffeine (n=4) yielded estimates of weight loss (more than placebo) of 0.6 (95% confidence interval, 0.2-1.0), 1.0 (0.7-1.3), 0:8 (0.4-1.2), and 1.0 (0.6-1.3) kg/mo, respectively. Sensitivity analyses did not substantially alter the latter 3 results. No trials of ephedra and athletic performance were found; 7 trials of ephedrine were too heterogeneous to synthesize. Safety data from 50 trials yielded estimates of 2.2- to 3.6-fold increases in odds of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations. Data are insufficient to draw conclusions about adverse events occurring at a rate less than 1.0 per thousand. The majority of case reports are insufficiently documented to allow meaningful assessment. Conclusions Ephedrine and ephedra promote modest short-term weight loss (approximate to0.9 kg/mo more than placebo) in clinical trials. There are no data regarding long-term weight loss, and evidence to support use of ephedra for athletic performance is insufficient. Use of ephedra or ephedrine and caffeine is associated with increased risk of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations.	RAND Corp, So Calif Evidence Based Practice Ctr, Santa Monica, CA 90407 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA; Univ So Calif, Dept Family Med, Los Angeles, CA USA	RAND Corporation; Cedars Sinai Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of Southern California	Shekelle, PG (corresponding author), RAND Corp, So Calif Evidence Based Practice Ctr, 1700 Main St,POB 2138, Santa Monica, CA 90407 USA.				PHS HHS [290-97-0001] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHAMSON A, 2001, LOS ANGELES TIM 0811, pD1; ABRAHAMSON A, 2001, LOS ANGELES TIM 0811, pD9; ASTRUP A, 1992, METABOLISM, V41, P686, DOI 10.1016/0026-0495(92)90304-S; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bell DG, 1999, AVIAT SPACE ENVIR MD, V70, P325; Bell DG, 2001, MED SCI SPORT EXER, V33, P1399, DOI 10.1097/00005768-200108000-00024; Bell DG, 1998, EUR J APPL PHYSIOL O, V77, P427, DOI 10.1007/s004210050355; Bell DG, 2000, AVIAT SPACE ENVIR MD, V71, P415; Bell DG, 1999, AVIAT SPACE ENVIR MD, V70, P583; BENT S, RELATIVE SAFETY EPHE; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; Boozer CN, 2001, INT J OBESITY, V25, P316, DOI 10.1038/sj.ijo.0801539; Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023; Bray GA, 1995, OBES RES, V3, pS425, DOI 10.1002/j.1550-8528.1995.tb00209.x; BREUM L, 1994, INT J OBESITY, V18, P99; BUEMANN B, 1994, INT J OBESITY, V18, P329; CAREY B, 2001, LOS ANGELES TIM 0827, pD13; CAREY B, 2001, LOS ANGELES TIM 0827, pD11; COLKER CM, 2001, J AM COLL NUTR, V20, P98; DALY PA, 1993, INT J OBESITY, V17, pS73; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fujioka K, 2000, DIABETES OBES METAB, V2, P175, DOI 10.1046/j.1463-1326.2000.00081.x; Gokcel A, 2001, DIABETES CARE, V24, P1957, DOI 10.2337/diacare.24.11.1957; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; Hill JO, 1999, AM J CLIN NUTR, V69, P1108; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jensen K B, 1980, Ugeskr Laeger, V142, P1499; Kalman DS, 2000, CURR THER RES CLIN E, V61, P199, DOI 10.1016/S0011-393X(00)89034-7; Karhunen L, 2000, INT J OBESITY, V24, P1567, DOI 10.1038/sj.ijo.0801443; Kettle R., 1998, International Journal of Obesity, V22, pS264; Lumholtz I B, 1980, Ugeskr Laeger, V142, P1487; MALCHOWMOLLER A, 1981, INT J OBESITY, V5, P183; MARSA L, 2002, LOS ANGELES TIM 0902, pD12; MARSA L, 2002, LOS ANGELES TIM 0902, pD10; Micic D, 1999, Med Pregl, V52, P323; Moheb M. Aghakhan, 1998, International Journal of Obesity, V22, pS264; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Molnar D, 2000, INT J OBESITY, V24, P1573, DOI 10.1038/sj.ijo.0801433; Morgenstern LB, 2003, NEUROLOGY, V60, P132, DOI 10.1212/01.WNL.0000042092.20411.5B; Muls E, 2001, INT J OBESITY, V25, P1713, DOI 10.1038/sj.ijo.0801814; MUNRO JF, 1968, BRIT MED J, V1, P352, DOI 10.1136/bmj.1.5588.352; Oksbjerg N, 1986, Ugeskr Laeger, V148, P2021; PASQUALI R, 1985, INT J OBESITY, V9, P93; PASTERNAK H, 1999, CAN J APPL PHYSIOL, V24, P471; *PUBL CIT, 2001, PUBL CIT CALLS FDA B; Quaade F, 1992, Ugeskr Laeger, V154, P1258; Roed P, 1980, Ugeskr Laeger, V142, P1491; SIDNEY KH, 1977, MED SCI SPORT EXER, V9, P95; Smith IG, 2001, J FAM PRACTICE, V50, P505; *STAT CORP, 2001, STAT COMP PROGR REL; Toubro S, 1997, BRIT MED J, V314, P29, DOI 10.1136/bmj.314.7073.29; Van Gaal LF, 1998, EUR J CLIN PHARMACOL, V54, P125, DOI 10.1007/s002280050433; Van Mil E., 2000, International Journal of Obesity, V24, pS184; Wirth A, 2001, JAMA-J AM MED ASSOC, V286, P1331, DOI 10.1001/jama.286.11.1331; 2002, HHS NEWS        0614	56	317	339	2	84	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2003	289	12					1537	1545		10.1001/jama.289.12.1537	http://dx.doi.org/10.1001/jama.289.12.1537			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659XE	12672771	Green Published			2022-12-28	WOS:000181803100032
J	McCarthy, HD; Ellis, SM; Cole, TJ				McCarthy, HD; Ellis, SM; Cole, TJ			Central overweight and obesity in British youth aged 11-16 years: cross sectional surveys of waist circumference	BRITISH MEDICAL JOURNAL			English	Article							BODY-MASS INDEX; FAT DISTRIBUTION; CHILDREN; ADOLESCENTS; PREVALENCE	Objective To compare changes over time in waist circumference (a measure of central fatness) and body mass index (a measure of overall obesity) in British youth. Design Representative cross sectional surveys in 1977, 1987, and 1997. Setting Great Britain. Participants Young people aged 11-16 years Surveyed in 1977 (boys) and 1987 (girls) for the British Standards Institute (n=3784) and in 1997 (both sexes) for the national diet and nutrition survey (n=776). Main outcome measures Waist Circumference, expressed as a standard deviation score using the first survey as reference, and body mass index (weight(kg)/height(m)(2)), expressed as a standard deviation score against the British 1990 revised reference. Overweight and obesity were defined as the measurement exceeding the 91st and 98th centile, respectively. Results Waist circumference increased sharply over the period between surveys (mean increases for boys and girls, 6.9 and 6.2 cm, or 0.84 and 1.02 SD score units, P <0.0001). In centile terms, waist circumference increased more in girls than in boys. Increases in body mass index were smaller and similar by sex (means 1.5 and 1.6, or 0.47 and 0.53 SD score units, P < 0.0001). Waist circumference in 1997 exceeded the 91st centile in 28% (n=110) of boys and 38% (n=147) of girls (against 9% for both sexes in 1977-87, P < 0.0001), whereas 14% (n=54) and 17% (n=68), respectively, exceeded the 98th centile (3% in 1977-87, P < 0.0001). The corresponding rates for body mass index in 1997 were 21% (n=80) of boys and 17% (n=67) of girls exceeding the 91st centile (8% and 6% in 1977-87) and 10% (n=39) and 8% (n=32) exceeding the 98th centile (3% and 2% in 1977-87). Conclusions Trends in waist circumference during the past 10-20 years have greatly exceeded those in body mass index, particularly in girls, showing that body mass index is a poor proxy for central fatness. Body mass index has therefore systematically underestimated the prevalence of obesity in young people.	London Metropolitan Univ, Dept Hlth & Human Sci, London N7 8DB, England; Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England	London Metropolitan University; University of London; University College London	McCarthy, HD (corresponding author), London Metropolitan Univ, Dept Hlth & Human Sci, London N7 8DB, England.	d.mccarthy@londonmet.ac.uk	Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200	MRC [G9827821] Funding Source: UKRI; Medical Research Council [G9827821, G9827821(62595)] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bates CJ, 2000, NATL DIET NUTR SURVE; BRAMBILLA P, 1994, INT J OBESITY, V18, P795; *BRIT STAND I, 1990, BS7321; *BRIT STAND I, 1990, BOD MEAS BOYS GIRLS; Bundred P, 2001, BMJ-BRIT MED J, V322, P326, DOI 10.1136/bmj.322.7282.326; Caprio S, 1996, AM J CLIN NUTR, V64, P12, DOI 10.1093/ajcn/64.1.12; Chinn S, 2001, BRIT MED J, V322, P24, DOI 10.1136/bmj.322.7277.24; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Daniels SR, 2000, AM J EPIDEMIOL, V152, P1179, DOI 10.1093/aje/152.12.1179; FLODMARK CE, 1994, ACTA PAEDIATR, V83, P941, DOI 10.1111/j.1651-2227.1994.tb13177.x; Freedman DS, 1999, AM J CLIN NUTR, V69, P308; Gregory JR, 1995, NATL DIET NUTR SURVE; Maynard LM, 2001, PEDIATRICS, V107, P344, DOI 10.1542/peds.107.2.344; McCarthy HD, 2001, EUR J CLIN NUTR, V55, P902, DOI 10.1038/sj.ejcn.1601240; Moreno LA, 1998, J PEDIATR GASTR NUTR, V27, P176, DOI 10.1097/00005176-199808000-00009; Moreno LA, 2001, INT J OBESITY, V25, P1656, DOI 10.1038/sj.ijo.0801803; Taylor RW, 2000, AM J CLIN NUTR, V72, P490; Ulijaszek SJ, 1999, BRIT J NUTR, V82, P165, DOI 10.1017/S0007114599001348; Wells JCK, 2002, INT J OBESITY, V26, P1323, DOI 10.1038/sj.ijo.0802077; World Health Organization, 1995, PHYS STAT US INT ANT	21	308	336	0	20	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 22	2003	326	7390					624	626		10.1136/bmj.326.7390.624	http://dx.doi.org/10.1136/bmj.326.7390.624			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649234	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000181870800014
J	Bent, S; Tiedt, TN; Odden, MC; Shlipak, MG				Bent, S; Tiedt, TN; Odden, MC; Shlipak, MG			The relative safety of ephedra compared with other herbal products	ANNALS OF INTERNAL MEDICINE			English	Article							MA-HUANG; SUPPLEMENTS; TOXICITY; SYSTEM	Background: Ephedra is widely used in dietary supplements that are marketed to promote weight loss or increase energy; however, the safety of this product has been questioned because of numerous case reports of adverse events. Objective: To compare the risk for adverse events attributable to ephedra and other herbal products. Design: Comparative case series. Setting: American Association of Poison Control Centers Toxic Event Surveillance System Database Annual Report, 2001. Measurements: The relative risk and 95% confidence interval for experiencing an adverse reaction after ephedra. use compared with other herbs. This risk was defined as the ratio of adverse reactions to ephedra. versus other products, divided by the ratio of their relative use in the United States. Results: Products containing ephedra accounted for 64% of all adverse reactions to herbs in the United States, yet these products represented only 0.82% of herbal product sales. The relative risks for an adverse reaction in persons using ephedra compared with other herbs were extremely high, ranging from 100 (95% Cl, 83 to 140) for kava to 720 (Cl, 520 to 1100) for Ginkgo biloba. Conclusions: Ephedra use is associated with a greatly increased risk for adverse reactions compared with other herbs, and its use should be restricted.	San Francisco VA Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA; Med Tox Grp, Longboat Key, FL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco	Bent, S (corresponding author), San Francisco VA Med Ctr, 111-A1,4150 Clement St, San Francisco, CA 94121 USA.	bent@itsa.ucsf.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K08AT001338] Funding Source: NIH RePORTER; NCCIH NIH HHS [1 K08 AT01338-01] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Bloedorn WA, 1928, ARCH INTERN MED, V42, P322, DOI 10.1001/archinte.1928.00020020010002; Boozer CN, 2001, INT J OBESITY, V25, P316, DOI 10.1038/sj.ijo.0801539; Chen KK, 1930, MEDICINE, V9, P1, DOI 10.1097/00005792-193002000-00001; Foster S., 1999, TYLERS HONEST HERBAL; Gilman A.G., 2001, GOODMAN GILMANS PHAR; Gurley BJ, 1998, J PHARM SCI, V87, P1547, DOI 10.1021/js9801844; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; KIMMEL SE, 2003, SUMMARY INCIDENCE SE; Litovitz TL, 2002, AM J EMERG MED, V20, P391, DOI 10.1053/ajem.2002.34955; RICHMAN A, 2001, 7 ANN HERB SALES SUR, P23; Rotblatt M, 2002, EVIDENCE BASED HERBA; Samenuk D, 2002, MAYO CLIN PROC, V77, P12, DOI 10.4065/77.1.12; Theoharides TC, 1997, J CLIN PSYCHOPHARM, V17, P437, DOI 10.1097/00004714-199710000-00025; TubertBitter P, 1996, J CLIN EPIDEMIOL, V49, P121, DOI 10.1016/0895-4356(95)00537-4; US Department of Health and Human Services Office of Inspector General, 2001, OEI010000180 US DEP; Vahedi K, 2000, J NEUROL NEUROSUR PS, V68, P112, DOI 10.1136/jnnp.68.1.112	16	94	102	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					468	471		10.7326/0003-4819-138-6-200303180-00010	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639079				2022-12-28	WOS:000181562400004
J	Bloor, K; Freemantle, N; Khadjesari, Z; Maynard, A				Bloor, K; Freemantle, N; Khadjesari, Z; Maynard, A			Impact of NICE guidance on laparoscopic surgery for inguinal hernias: analysis of interrupted time series	BRITISH MEDICAL JOURNAL			English	Article									Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of York - UK; University of Birmingham	Bloor, K (corresponding author), Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.			Khadjesari, Zarnie/0000-0002-2958-9555; Freemantle, Nick/0000-0001-5807-5740; Bloor, Karen/0000-0003-4852-9854				DEVLIN HB, 1998, MANAGEMENT ABDOMINAL; Motson RW, 2002, BRIT MED J, V324, P1092, DOI 10.1136/bmj.324.7345.1092; National Institute for Clinical Excellence, 2001, GUID US LAP SURG ING	3	36	36	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 15	2003	326	7389					578	578		10.1136/bmj.326.7389.578	http://dx.doi.org/10.1136/bmj.326.7389.578			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	657ZF	12637402	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000181696600018
J	Caillon, N; Severinghaus, JP; Jouzel, J; Barnola, JM; Kang, JC; Lipenkov, VY				Caillon, N; Severinghaus, JP; Jouzel, J; Barnola, JM; Kang, JC; Lipenkov, VY			Timing of atmospheric CO2 and Antarctic temperature changes across termination III	SCIENCE			English	Article							ABRUPT CLIMATE-CHANGE; VOSTOK ICE CORE; CARBON-DIOXIDE; TRAPPED AIR; POLAR ICE; RECORD; FIRN; GREENLAND; CYCLE; END	The analysis of air bubbles from ice cores has yielded a precise record of atmospheric greenhouse gas concentrations, but the timing of changes in these gases with respect to temperature is not accurately known because of uncertainty in the gas age-ice age difference. We have measured the isotopic composition of argon in air bubbles in the Vostok core during Termination III (similar to240,000 years before the present). This record most likely reflects the temperature and accumulation change, although the mechanism remains unclear. The sequence of events during Termination III suggests that the CO2 increase tagged Antarctic deglacial warming by 800 +/- 200 years and preceded the Northern Hemisphere deglaciation.	CEA Saclay, CNRS, Inst Pierre Simon Laplace, Lab Climat & Environm, F-91191 Gif Sur Yvette, France; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; CNRS, Lab Glaciol & Geophys Environm, F-38402 St Martin Dheres, France; Polar Res Inst China, Shanghai 200129, Peoples R China; Arctic & Antarctic Res Inst, St Petersburg 199397, Russia	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; University of California System; University of California San Diego; Scripps Institution of Oceanography; Centre National de la Recherche Scientifique (CNRS); Polar Research Institute of China; Arctic & Antarctic Research Institute	Caillon, N (corresponding author), CEA Saclay, CNRS, Inst Pierre Simon Laplace, Lab Climat & Environm, F-91191 Gif Sur Yvette, France.	ncaillon@ucsd.edu	Caillon, Nicolas/B-7127-2019; Lipenkov, Vladimir Y/Q-8262-2016	Caillon, Nicolas/0000-0002-6318-6194; Lipenkov, Vladimir Y/0000-0003-4221-5440				Arnaud L., 2000, PHYS ICE CORE RECORD, P285; BARNOLA JM, 1987, NATURE, V329, P408, DOI 10.1038/329408a0; Battle M, 1996, NATURE, V383, P231, DOI 10.1038/383231a0; Blunier T, 1997, GEOPHYS RES LETT, V24, P2683, DOI 10.1029/97GL02658; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P352, DOI 10.1029/98PA00920; Caillon N, 2001, J GEOPHYS RES-ATMOS, V106, P31893, DOI 10.1029/2001JD900145; CAILLON N, UNPUB; CAILLON N, 2001, THESIS U PARIS 6 FRA; Fischer H, 1999, SCIENCE, V283, P1712, DOI 10.1126/science.283.5408.1712; GENTHON C, 1987, NATURE, V329, P414, DOI 10.1038/329414a0; GOUJON C, COMMUNICATION; Grachev AM, 2003, GEOCHIM COSMOCHIM AC, V67, P345, DOI 10.1016/S0016-7037(02)01115-8; Jouzel J, 2002, QUATERNARY SCI REV, V21, P307, DOI 10.1016/S0277-3791(01)00106-8; JOUZEL J, IN PRESS J GEOPHYS R; Kump LR, 2002, NATURE, V419, P188, DOI 10.1038/nature01087; Lang C, 1999, SCIENCE, V286, P934, DOI 10.1126/science.286.5441.934; Leuenberger MC, 1999, J GEOPHYS RES-ATMOS, V104, P22163, DOI 10.1029/1999JD900436; LORIUS C, 1990, NATURE, V347, P139, DOI 10.1038/347139a0; LORIUS C, 1985, NATURE, V316, P591, DOI 10.1038/316591a0; MARTIN JH, 1990, NATURE, V345, P156, DOI 10.1038/345156a0; Monnin E, 2001, SCIENCE, V291, P112, DOI 10.1126/science.291.5501.112; NEFTEL A, 1988, NATURE, V331, P609, DOI 10.1038/331609a0; Pepin L, 2001, J GEOPHYS RES-ATMOS, V106, P31885, DOI 10.1029/2001JD900117; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; RAYNAUD D, 1993, SCIENCE, V259, P926, DOI 10.1126/science.259.5097.926; SCHWANDER J, COMMUNICATION; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Severinghaus JP, 1999, SCIENCE, V286, P930, DOI 10.1126/science.286.5441.930; Severinghaus JP, 2003, GEOCHIM COSMOCHIM AC, V67, P325, DOI 10.1016/S0016-7037(02)00965-1; Severinghaus JP, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2000GC000146; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; Sigman DM, 2000, NATURE, V407, P859, DOI 10.1038/35038000; Smith HJ, 1999, NATURE, V400, P248, DOI 10.1038/22291; SOWERS T, 1992, J GEOPHYS RES-ATMOS, V97, P15683, DOI 10.1029/92JD01297; Sowers T, 1991, PALEOCEANOGRAPHY, V6, P679, DOI 10.1029/91PA02023; Stephens BB, 2000, NATURE, V404, P171, DOI 10.1038/35004556; Toggweiler JR, 1999, PALEOCEANOGRAPHY, V14, P571, DOI 10.1029/1999PA900033; WATANABE O, IN PRESS NATURE	38	137	144	4	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	2003	299	5613					1728	1731		10.1126/science.1078758	http://dx.doi.org/10.1126/science.1078758			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637743				2022-12-28	WOS:000181519500044
J	Boelaert, K; Franklyn, JA				Boelaert, K; Franklyn, JA			Sodium iodide symporter: a novel strategy to target breast, prostate, and other cancers?	LANCET			English	Editorial Material							EXPRESSION; GENE; THERAPY; TRANSPORTER; CLONING		Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Franklyn, JA (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England.							Boland A, 2000, CANCER RES, V60, P3484; Cho JY, 2000, GENE THER, V7, P740, DOI 10.1038/sj.gt.3301170; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; ESKIN BA, 1970, T NEW YORK ACAD SCI, V32, P911, DOI 10.1111/j.2164-0947.1970.tb02988.x; Kogai T, 2000, P NATL ACAD SCI USA, V97, P8519, DOI 10.1073/pnas.140217197; Mandell RB, 1999, CANCER RES, V59, P661; Smanik PA, 1996, BIOCHEM BIOPH RES CO, V226, P339, DOI 10.1006/bbrc.1996.1358; Spitzweg C, 2000, CANCER RES, V60, P6526; Spitzweg C, 1999, CANCER RES, V59, P2136; Spitzweg C, 2001, J CLIN ENDOCR METAB, V86, P3327, DOI 10.1210/jc.86.7.3327; SPITZWEG C, 2002, P 74 ANN M AM THYR A, P128; Tazebay UH, 2000, NAT MED, V6, P871, DOI 10.1038/78630	12	28	33	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					796	797		10.1016/S0140-6736(03)12720-1	http://dx.doi.org/10.1016/S0140-6736(03)12720-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642042				2022-12-28	WOS:000181466600004
J	Davies, R				Davies, R			Children locked away from human rights in the UK	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Davies, R (corresponding author), Lancet, London NW1 7BY, England.							*CHILDR RIGHTS ALL, 2002, RETH CHILD IMPR; *HOW LEAG PEN REF, 2002, CHILDR PRIS BARR RIG	2	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					873	873		10.1016/S0140-6736(03)12714-6	http://dx.doi.org/10.1016/S0140-6736(03)12714-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642067				2022-12-28	WOS:000181466600028
J	Lee, BH; Amon, A				Lee, BH; Amon, A			Role of Polo-like kinase CDC5 in programming meiosis I chromosome segregation	SCIENCE			English	Article							SISTER-CHROMATID SEPARATION; SINGLE-DIVISION MEIOSIS; COHESIN SUBUNIT SCC1; SACCHAROMYCES-CEREVISIAE; PRECOCIOUS SEPARATION; BUDDING YEAST; CELL-CYCLE; ANAPHASE; CENTROMERES; CLEAVAGE	Meiosis is a specialized cell division in which two chromosome segregation phases follow a single DNA replication phase. The budding yeast Polo-like kinase Cdc5 was found to be instrumental in establishing the meiosis I chromosome segregation program. Cdc5 was required to phosphorylate and remove meiotic cohesin from chromosomes. Furthermore, in the absence of CDC5 kinetochores were bioriented during meiosis I, and Mam1, a protein essential for coorientation, failed to associate with kinetochores. Thus, sister-kinetochore coorientation and chromosome segregation during meiosis I are coupled through their dependence on CDC5.	MIT, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Amon, A (corresponding author), MIT, Ctr Canc Res, Howard Hughes Med Inst, E17-233,40 Ames St, Cambridge, MA 02139 USA.			Amon, Angelika/0000-0001-9837-0314; Lee, Brian/0000-0003-2497-5139	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062207] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62207] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BUONOMO SB, IN PRESS DEV CELL; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chase D, 2000, GENESIS, V26, P26, DOI 10.1002/(SICI)1526-968X(200001)26:1<26::AID-GENE6>3.0.CO;2-O; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Goshima G, 2001, GENES CELLS, V6, P765, DOI 10.1046/j.1365-2443.2001.00464.x; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; Herrmann S, 1998, CHROMOSOMA, V107, P440, DOI 10.1007/PL00013778; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Lee B, 2001, CURR OPIN CELL BIOL, V13, P770, DOI 10.1016/S0955-0674(00)00282-9; Lee B.H., UNPUB; Lee BH, 2002, GENE DEV, V16, P1672, DOI 10.1101/gad.989302; Lee JY, 2001, ANNU REV CELL DEV BI, V17, P753, DOI 10.1146/annurev.cellbio.17.1.753; MARSTON A, IN PRESS DEV CELL; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; SHARON G, 1990, GENETICS, V125, P487; SHARON G, 1990, GENETICS, V125, P475; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Shonn MA, 2002, GENE DEV, V16, P1659, DOI 10.1101/gad.975802; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831	32	186	192	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 18	2003	300	5618					482	486		10.1126/science.1081846	http://dx.doi.org/10.1126/science.1081846			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668LR	12663816				2022-12-28	WOS:000182295900039
J	Harris, LH; Paltrow, L				Harris, LH; Paltrow, L			The status of pregnant women and fetuses in US criminal law	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL COCAINE EXPOSURE; PERINATAL ETHICS		Univ Michigan, Ann Arbor, MI 48109 USA; Natl Advocates Pregnant Women, New York, NY USA	University of Michigan System; University of Michigan	Harris, LH (corresponding author), Univ Michigan, Ann Arbor, MI 48109 USA.							*AM MED ASS, 2002, MOT AM MED ASS LEAV; ANNAS GJ, 1990, HASTINGS CENT REP, V20, P27, DOI 10.2307/3562763; Chavkin W, 2001, JAMA-J AM MED ASSOC, V285, P1626, DOI 10.1001/jama.285.12.1626; CHERVENAK FA, 1985, OBSTET GYNECOL, V66, P442; Frank DA, 2001, JAMA-J AM MED ASSOC, V285, P1613, DOI 10.1001/jama.285.12.1613; Harris LH, 2000, OBSTET GYNECOL, V96, P786, DOI 10.1016/S0029-7844(00)01021-8; HODGE JG, 1999, AM LAW REPORTS, V70, P461; Humphries Drew, 1999, CRACK MOTHERS PREGNA; Marwick C, 1998, JAMA-J AM MED ASSOC, V279, P1149, DOI 10.1001/jama.279.15.1149; NELSON IJ, 1998, ETHICAL LEGAL ANAL 3; PALTROW L, 2000, GOVT RESPONSES PREGN; POLAND ML, 1993, DRUG ALCOHOL DEPEN, V31, P199, DOI 10.1016/0376-8716(93)90001-7; Rose-Jacobs R, 2002, J DEV BEHAV PEDIATR, V23, P340, DOI 10.1097/00004703-200210000-00007; *US DEP HHS, 1993, US DEP HHS PUBL; 2002, FED REG, V67, P61955	15	19	19	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1697	1699		10.1001/jama.289.13.1697	http://dx.doi.org/10.1001/jama.289.13.1697			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	662JX	12672741	Bronze			2022-12-28	WOS:000181944500036
J	Babcock, DF				Babcock, DF			Development: Smelling the roses?	SCIENCE			English	Editorial Material							SOLUBLE ADENYLYL-CYCLASE; ODORANT RECEPTORS; MAMMALIAN SPERM; EVOLUTION; PROTEINS		Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Babcock, DF (corresponding author), Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.			Babcock, Donner/0000-0002-4461-4544				Branscomb A, 2000, GENETICS, V156, P785; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; COOK SP, 1994, DEV BIOL, V165, P10, DOI 10.1006/dbio.1994.1229; Jaiswal BS, 2001, J BIOL CHEM, V276, P31698, DOI 10.1074/jbc.M011698200; Kaupp UB, 2003, NAT CELL BIOL, V5, P109, DOI 10.1038/ncb915; Spehr M, 2003, SCIENCE, V299, P2054, DOI 10.1126/science.1080376; Vacquier VD, 1998, SCIENCE, V281, P1995, DOI 10.1126/science.281.5385.1995; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; WALENSKY LD, 1995, MOL MED, V1, P130, DOI 10.1007/BF03401561; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Wiesner B, 1998, J CELL BIOL, V142, P473, DOI 10.1083/jcb.142.2.473; Yanagimachi R., 1981, FERTILIZATION EMBRYO, P81; Yoshida M, 2002, P NATL ACAD SCI USA, V99, P14831, DOI 10.1073/pnas.242470599	13	10	10	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2003	299	5615					1993	1994		10.1126/science.1083059	http://dx.doi.org/10.1126/science.1083059			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663902				2022-12-28	WOS:000181834200027
J	Li, YY; Cunin, F; Link, JR; Gao, T; Betts, RE; Reiver, SH; Chin, V; Bhatia, SN; Sailor, MJ				Li, YY; Cunin, F; Link, JR; Gao, T; Betts, RE; Reiver, SH; Chin, V; Bhatia, SN; Sailor, MJ			Polymer replicas of photonic porous silicon for sensing and drug delivery applications	SCIENCE			English	Article							OPTICAL-PROPERTIES; FILTERS	Elaborate one-dimensional photonic crystals are constructed from a variety of organic and biopolymers, which can be dissolved or melted, by templating the solution-cast or injection-molded materials in porous silicon or porous silicon dioxide multilayer (rugate dielectric mirror) structures. After the removal of the template by chemical dissolution, the polymer castings replicate the photonic features and the nanostructure of the master. We demonstrate that these castings can be used as vapor sensors, as deformable and tunable optical filters, and as self-reporting, bioresorbable materials.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Li, YY (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr,Dept 0358, La Jolla, CA 92093 USA.		Sailor, Michael J/H-9044-2017; Li, Yang Yang/J-9243-2012	Sailor, Michael J/0000-0002-4809-9826; LI, Yang Yang/0000-0003-4153-9558				Allcock P, 2001, J APPL PHYS, V90, P5052, DOI 10.1063/1.1412268; Berger MG, 1997, THIN SOLID FILMS, V297, P237, DOI 10.1016/S0040-6090(96)09361-3; Cunin F, 2002, NAT MATER, V1, P39, DOI 10.1038/nmat702; Gao J, 2002, LANGMUIR, V18, P2229, DOI 10.1021/la015568f; HALIMAOUI A, 1997, PROPERTIES POROUS SI, P12; Haynes CL, 2001, J PHYS CHEM B, V105, P5599, DOI 10.1021/jp010657m; Hulteen JC, 1997, J MATER CHEM, V7, P1075, DOI 10.1039/a700027h; Lehmann V, 2001, APPL PHYS LETT, V78, P589, DOI 10.1063/1.1334943; Matthias S, 2002, ADV MATER, V14, P1618, DOI 10.1002/1521-4095(20021118)14:22<1618::AID-ADMA1618>3.0.CO;2-A; Moller K, 1998, CHEM MATER, V10, P2950, DOI 10.1021/cm980243e; Pavesi L, 1997, SEMICOND SCI TECH, V12, P570, DOI 10.1088/0268-1242/12/5/009; Polarz S, 2002, CHEM COMMUN, P2593, DOI 10.1039/b205708p; Reese CE, 2001, ANAL CHEM, V73, P5038, DOI 10.1021/ac010667j; Schmedake TA, 2002, ADV MATER, V14, P1270, DOI 10.1002/1521-4095(20020916)14:18<1270::AID-ADMA1270>3.0.CO;2-R; Snow PA, 1999, J APPL PHYS, V86, P1781, DOI 10.1063/1.370968; Thonissen M., 1997, PROPERTIES POROUS SI, V18, P30; Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u; VINCENT G, 1994, APPL PHYS LETT, V64, P2367, DOI 10.1063/1.111982; Wirtz M, 2002, CHEM-EUR J, V8, P3573; Xu XL, 2002, J AM CHEM SOC, V124, P13864, DOI 10.1021/ja026901k; Zangooie S, 1997, SENSOR ACTUAT B-CHEM, V43, P168, DOI 10.1016/S0925-4005(97)00148-2	21	341	395	4	162	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					2045	2047		10.1126/science.1081298	http://dx.doi.org/10.1126/science.1081298			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663921				2022-12-28	WOS:000181834200047
J	Gruber, S; Haering, CH; Nasmyth, K				Gruber, S; Haering, CH; Nasmyth, K			Chromosomal cohesin forms a ring	CELL			English	Article							SISTER-CHROMATID COHESION; DNA-REPLICATION; BUDDING YEAST; COILED COILS; ABC-ATPASE; PROTEINS; ANAPHASE; COMPLEX; CLEAVAGE; SMC	The cohesin complex is essential for sister chromatid cohesion during mitosis. Its Smc1 and Smc3 subunits are rod-shaped molecules with globular ABC-like ATPases at one end and dimerization domains at the other connected by long coiled coils. Smc1 and Smc3 associate to form V-shaped heterodimers. Their ATPase heads are thought to be bridged by a third subunit, Scc1, creating a huge triangular ring that could trap sister DNA molecules. We address here whether cohesin forms such rings in vivo. Proteolytic cleavage of Scc1 by separase at the onset of anaphase triggers its dissociation from chromosomes. We show that N- and C-terminal Scc1 cleavage fragments remain connected due to their association with different heads of a single Smc1/Smc3 heterodimer. Cleavage of the Smc3 coiled coil is sufficient to trigger cohesin release from chromosomes and loss of sister cohesion, consistent with a topological association with chromatin.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	nasmyth@nt.imp.univie.ac.at	Gruber, Stephan/AFC-4848-2022; Gruber, Stephan/G-5686-2012	Gruber, Stephan/0000-0002-0150-0395; Haering, Christian/0000-0001-8301-1722; Nasmyth, Kim/0000-0001-7030-4403				Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Lowe J, 2001, J MOL BIOL, V306, P25, DOI 10.1006/jmbi.2000.4379; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; SCHLEIFFER A, 2003, IN PRESS MOL CELL; Severin F, 2001, J CELL BIOL, V155, P711, DOI 10.1083/jcb.200104096; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	28	437	443	0	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2003	112	6					765	777		10.1016/S0092-8674(03)00162-4	http://dx.doi.org/10.1016/S0092-8674(03)00162-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	660DL	12654244	Bronze			2022-12-28	WOS:000181818500005
J	Mezzenga, R; Ruokolainen, J; Fredrickson, GH; Kramer, EJ; Moses, D; Heeger, AJ; Ikkala, O				Mezzenga, R; Ruokolainen, J; Fredrickson, GH; Kramer, EJ; Moses, D; Heeger, AJ; Ikkala, O			Templating organic semiconductors via self-assembly of polymer colloids	SCIENCE			English	Article							POLY(METHYL METHACRYLATE); PERCOLATION-THRESHOLD; CARBON-BLACK; BLENDS; POLYANILINE; TRANSISTORS; MISCIBILITY; COMPOSITES; MORPHOLOGY; CIRCUITS	A route for producing semiconducting polymer blends is demonstrated in which a doped pi-conjugated polymer is forced into a three-dimensionally continuous minor phase by the self-assembly of colloidal particles and block copolymers. The resulting cellular morphology can be viewed as a high-internal phase polymeric emulsion. Compared with traditional blending procedures, this process reduces the percolation threshold for electrical conductivity by a factor of 10, increases the conductivity by several orders of magnitude, and simultaneously improves thermal stability. Following this route, new applications can be envisaged for semiconducting polymer blends that require only minimal concentrations of doped pi-conjugated polymer.	Univ Calif Santa Barbara, Mat Res Lab, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Polymers & Organ Solids, Santa Barbara, CA 93106 USA; Helsinki Univ Technol, Dept Engn Math & Phys, FIN-02015 Espoo, Finland; Helsinki Univ Technol, Ctr New Mat, FIN-02015 Espoo, Finland	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Aalto University; Aalto University	Kramer, EJ (corresponding author), Univ Calif Santa Barbara, Mat Res Lab, Santa Barbara, CA 93106 USA.		Ruokolainen, Janne T/F-6369-2010; Ikkala, Olli T./K-7447-2012	Ikkala, Olli T./0000-0002-0470-1889; Ruokolainen, Janne Tapio/0000-0003-2214-0621				Crone B, 2000, NATURE, V403, P521, DOI 10.1038/35000530; Fraysse J, 2000, MOL CRYST LIQ CRYST, V354, P1099; Fraysse J, 2001, MACROMOLECULES, V34, P8143, DOI 10.1021/ma0104377; Goh SH, 1998, J APPL POLYM SCI, V68, P1839; Goh SH, 1996, POLYMER, V37, P2675, DOI 10.1016/0032-3861(96)87627-0; GRANSTROM M, 1995, SCIENCE, V267, P1479, DOI 10.1126/science.267.5203.1479; GUBBELS F, 1994, MACROMOLECULES, V27, P1972, DOI 10.1021/ma00085a049; Ho PKH, 1999, SCIENCE, V285, P233, DOI 10.1126/science.285.5425.233; Kang ET, 1999, SYNTHETIC MET, V101, P696, DOI 10.1016/S0379-6779(98)01005-4; LEVON K, 1993, MACROMOLECULES, V26, P4061, DOI 10.1021/ma00067a054; LI SL, 1993, SCIENCE, V259, P957, DOI 10.1126/science.259.5097.957; Olinga TE, 2000, MACROMOLECULES, V33, P2107, DOI 10.1021/ma991525i; Ong CH, 1997, POLYMER, V38, P1065, DOI 10.1016/S0032-3861(96)00618-0; REGHU M, 1993, MACROMOLECULES, V26, P7245, DOI 10.1021/ma00078a020; Rutgers MA, 1996, PHYS REV B, V53, P5043, DOI 10.1103/PhysRevB.53.5043; Sirringhaus H, 2000, SCIENCE, V290, P2123, DOI 10.1126/science.290.5499.2123; Stauffer D., 1994, INTRO PERCOLATION TH; Thongruang W, 2002, POLYMER, V43, P3717, DOI 10.1016/S0032-3861(02)00180-5; Vikki T, 1997, MACROMOLECULES, V30, P4064, DOI 10.1021/ma9615056; YANG CY, 1993, SYNTHETIC MET, V53, P293, DOI 10.1016/0379-6779(93)91098-M; YANG Y, 1994, NATURE, V372, P344, DOI 10.1038/372344a0; Yu G, 1999, POLYM ENG SCI, V39, P1678, DOI 10.1002/pen.11562	22	159	164	2	138	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 21	2003	299	5614					1872	1874		10.1126/science.1081334	http://dx.doi.org/10.1126/science.1081334			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649476				2022-12-28	WOS:000181669700039
J	Stringfellow, GJ; Francis, IC				Stringfellow, GJ; Francis, IC			Appearance of intraocular silicone oil on computed tomography	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Prince Wales Hosp, Sydney, NSW 2031, Australia; Univ New S Wales, Sydney, NSW 2031, Australia	University of New South Wales Sydney	Stringfellow, GJ (corresponding author), Prince Wales Hosp, Sydney, NSW 2031, Australia.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1122	1122		10.1056/NEJMicm020276	http://dx.doi.org/10.1056/NEJMicm020276			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646669				2022-12-28	WOS:000181628400008
J	Iizuka, N; Oka, M; Yamada-Okabe, H; Nishida, M; Maeda, Y; Mori, N; Takao, T; Tamesa, T; Tangoku, A; Tabuchi, H; Hamada, K; Nakayama, H; Ishitsuka, H; Miyamoto, T; Hirabayashi, A; Uchimura, S; Hamamoto, Y				Iizuka, N; Oka, M; Yamada-Okabe, H; Nishida, M; Maeda, Y; Mori, N; Takao, T; Tamesa, T; Tangoku, A; Tabuchi, H; Hamada, K; Nakayama, H; Ishitsuka, H; Miyamoto, T; Hirabayashi, A; Uchimura, S; Hamamoto, Y			Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection	LANCET			English	Article							GENE-EXPRESSION PATTERNS; CDNA MICROARRAY; CANCER; CLASSIFICATION; IDENTIFICATION	Background Hepatocellular carcinoma has a poor prognosis because of the high intrahepatic recurrence rate. There are technological limitations to traditional methods such as TNM staging for accurate prediction of recurrence, suggesting that new techniques are needed. Methods We investigated mRNA expression profiles in tissue specimens from a training set, comprising 33 patients with hepatocellular carcinoma, with high-density oligonucleotide microarrays representing about 6000 genes. We used this training set in a supervised learning manner to construct a predictive system, consisting of 12 genes, with the Fisher linear classifier. We then compared the predictive performance of our system with that of a predictive system with a support vector machine (SVM-based system) on a blinded set of samples from 27 newly enrolled patients. Findings Early intrahepatic recurrence within 1 year after curative surgery occurred in 12 (36%) and eight (30%) patients in the training and blinded sets, respectively. Our system correctly predicted early intrahepatic recurrence or non-recurrence in 25 (93%) of 27 samples in the blinded set and had a positive predictive value of 88% and a negative predictive value of 95%. By contrast, the SVM-based system predicted early intrahepatic recurrence or non-recurrence correctly in only 16 (60%) individuals in the blinded set, and the result yielded a positive predictive value of only 38% and a negative predictive value of 79%. Interpretation Our system predicted early intrahepatic recurrence or non-recurrence for patients with hepatocellular carcinoma much more accurately than the SVM-based system, suggesting that our system could serve as a new method for characterising the metastatic potential of hepatocellular carcinoma.	Yamaguchi Univ, Sch Med, Dept Surg 2, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Bioregulatory Funct, Yamaguchi 7558505, Japan; Yamaguchi Univ, Fac Engn, Dept Comp Sci & Syst Engn, Yamaguchi 7558505, Japan; Nippon Roche Res Ctr, Dept Oncol, Kanagawa, Japan	Yamaguchi University; Yamaguchi University; Yamaguchi University; Roche Holding	Oka, M (corresponding author), Yamaguchi Univ, Sch Med, Dept Surg 2, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.							Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Brazma A, 2000, FEBS LETT, V480, P17, DOI 10.1016/S0014-5793(00)01772-5; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; CABRERA T, 1995, SCAND J IMMUNOL, V41, P398, DOI 10.1111/j.1365-3083.1995.tb03584.x; DeRisi J, 1996, NAT GENET, V14, P457; Duda R. O., 2001, PATTERN CLASSIFICATI, P1; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evron E, 2001, CANCER RES, V61, P2782; Furey TS, 2000, BIOINFORMATICS, V16, P906, DOI 10.1093/bioinformatics/16.10.906; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; HSU HC, 1993, CANCER RES, V53, P4691; IIZUKA N, 1995, CANCER RES, V55, P652; Iizuka N, 2002, CANCER RES, V62, P3939; IZUMI R, 1994, GASTROENTEROLOGY, V106, P720, DOI 10.1016/0016-5085(94)90707-2; Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819; Kell DB, 2000, TRENDS BIOTECHNOL, V18, P93, DOI 10.1016/S0167-7799(99)01407-9; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Luo J, 2001, CANCER RES, V61, P4683; Mathew J, 1996, J PATHOL, V179, P74; Okabe H, 2001, CANCER RES, V61, P2129; Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6; Poon RTP, 2000, CANCER, V89, P500, DOI 10.1002/1097-0142(20000801)89:3<500::AID-CNCR4>3.3.CO;2-F; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Sobin L, 2002, TNM CLASSIFICATION M, P81; Takayama T, 2000, LANCET, V356, P802, DOI 10.1016/S0140-6736(00)02654-4; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; Xu L, 2001, CANCER RES, V61, P3176	31	413	448	1	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 15	2003	361	9361					923	929		10.1016/S0140-6736(03)12775-4	http://dx.doi.org/10.1016/S0140-6736(03)12775-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648972				2022-12-28	WOS:000181741600011
J	Acharya, U; Patel, S; Koundakjian, E; Nagashima, K; Han, X; Acharya, JK				Acharya, U; Patel, S; Koundakjian, E; Nagashima, K; Han, X; Acharya, JK			Modulating sphingolipid biosynthetic pathway rescues photoreceptor degeneration	SCIENCE			English	Article							VISUAL-SYSTEM; DROSOPHILA; ARRESTIN; PROTEIN; ENDOCYTOSIS; RHODOPSIN; TRANSDUCTION; APOPTOSIS; DYNAMIN; ROLES	Mutations in proteins of the Drosophila phototransduction cascade, a prototypic guanine nucleotide-binding protein-coupled receptor signaling system, lead to retinal degeneration and have been used as models to understand human degenerative disorders. Here, modulating the sphingolipid biosynthetic pathway rescued retinal degeneration in Drosophila mutants. Targeted expression of Drosophila neutral ceramidase rescued retinal degeneration in arrestin and phospholipase C mutants. Decreasing flux through the de novo sphingolipid biosynthetic pathway also suppressed degeneration in these mutants. Both genetic backgrounds modulated the endocytic machinery because they suppressed defects in a dynamin mutant. Suppression of degeneration in arrestin mutant flies expressing ceramidase correlated with a decrease in ceramide levels. Thus, enzymes of sphingolipid metabolism may be suitable targets in the therapeutic management of retinal degeneration.	NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Sci Applicat Int Corp, Electron Microscopy Facil Image Anal Lab, Frederick, MD 21702 USA; Washington Univ, Sch Med, Dept Med, Div Bioorgan Chem & Mol Pharmacol, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; University of California System; University of California San Diego; Science Applications International Corporation (SAIC); Washington University (WUSTL)	Acharya, JK (corresponding author), NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA.			Acharya, Jairaj/0000-0001-7366-4228	NATIONAL CANCER INSTITUTE [Z01BC010331, ZIABC010331] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P7276; Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; D'Hondt K, 2000, ANNU REV GENET, V34, P255, DOI 10.1146/annurev.genet.34.1.255; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Dubnau J, 2001, NATURE, V411, P476, DOI 10.1038/35078077; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Han XL, 2002, ANAL BIOCHEM, V302, P199, DOI 10.1006/abio.2001.5536; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Nikolova-Karakashian M, 2000, METHOD ENZYMOL, V311, P194; Orem NR, 2002, VISION RES, V42, P497, DOI 10.1016/S0042-6989(01)00229-2; OTOUSA JE, 1997, PROGR RETINAL EYE RE, P691; POODRY CA, 1990, DEV BIOL, V138, P464, DOI 10.1016/0012-1606(90)90212-2; Sever S, 2000, TRAFFIC, V1, P385, DOI 10.1034/j.1600-0854.2000.010503.x; SMITH DP, 1991, ANNU REV CELL BIOL, V7, P161; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Wang Q, 2001, Ophthalmic Genet, V22, P133, DOI 10.1076/opge.22.3.133.2224; ZERR DM, 1990, J NEUROSCI, V10, P2749	23	110	112	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 14	2003	299	5613					1740	1743		10.1126/science.1080549	http://dx.doi.org/10.1126/science.1080549			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637747				2022-12-28	WOS:000181519500048
J	Brennecke, J; Hipfner, DR; Stark, A; Russell, RB; Cohen, SM				Brennecke, J; Hipfner, DR; Stark, A; Russell, RB; Cohen, SM			bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila	CELL			English	Article							SMALL RNAS; WINGLESS; GROWTH; EXPRESSION; SURVIVAL; ELEGANS; MYC; IDENTIFICATION; INITIATION; APOPTOSIS	Cell proliferation, cell death, and pattern formation are coordinated in animal development. Although many proteins that control cell proliferation and apoptosis have been identified, the means by which these effectors are linked to the patterning machinery remain poorly understood. Here, we report that the bantam gene of Drosophila encodes a 21 nucleotide microRNA that promotes tissue growth. bantam expression is temporally and spatially regulated in response to patterning cues. bantam microRNA simultaneously stimulates cell proliferation and prevents apoptosis. We identify the pro-apoptotic gene hid as a target for regulation by bantam miRNA, providing an explanation for bantam's anti-apoptotic activity.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Cohen, SM (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	cohen@embl.de	Brennecke, Julius/C-1626-2015; Russell, Robert/GWU-6389-2022; Russell, Rob/AAH-9145-2019; Stark, Alexander/D-1473-2012; Brennecke, Julius/T-5883-2019; Cohen, Stephen M/G-9930-2011	Brennecke, Julius/0000-0002-5141-0814; Russell, Robert/0000-0002-7213-1398; Russell, Rob/0000-0002-1905-4717; Stark, Alexander/0000-0003-2611-0841; Brennecke, Julius/0000-0002-5141-0814; Cohen, Stephen M/0000-0003-2858-9163				Ambros V, 2000, CURR OPIN GENET DEV, V10, P428, DOI 10.1016/S0959-437X(00)00108-8; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Baonza A, 2000, P NATL ACAD SCI USA, V97, P2609, DOI 10.1073/pnas.040576497; Baulcombe D, 2002, SCIENCE, V297, P2002, DOI 10.1126/science.1077906; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Chen CM, 1999, DEVELOPMENT, V126, P5441; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; DURMANSCHEEL M, 2002, NATURE, V417, P299; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; Go MJ, 1998, DEVELOPMENT, V125, P2031; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hipfner DR, 2002, GENETICS, V161, P1527; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; Johnston LA, 2002, BIOESSAYS, V24, P54, DOI 10.1002/bies.10021; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Martin-Castellanos C, 2002, DEVELOPMENT, V129, P1003; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Moreno E, 2002, NATURE, V416, P755, DOI 10.1038/416755a; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Neumann CJ, 1996, DEVELOPMENT, V122, P1781; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Pasquinelli AE, 2002, ANNU REV CELL DEV BI, V18, P495, DOI 10.1146/annurev.cellbio.18.012502.105832; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; Prober DA, 2001, CURR OPIN GENET DEV, V11, P19, DOI 10.1016/S0959-437X(00)00151-9; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinscheid RK, 2000, PEPTIDES, V21, P901, DOI 10.1016/S0196-9781(00)00226-6; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Ruvkun G, 2001, SCIENCE, V294, P797, DOI 10.1126/science.1066315; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Teleman AA, 2001, CELL, V105, P559, DOI 10.1016/S0092-8674(01)00377-4; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Yu SY, 2002, DEVELOPMENT, V129, P3269; Zeng WL, 2000, NATURE, V403, P789, DOI 10.1038/35001615; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zhang J, 1998, DEVELOPMENT, V125, P3075	66	1613	1812	4	118	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 4	2003	113	1					25	36		10.1016/S0092-8674(03)00231-9	http://dx.doi.org/10.1016/S0092-8674(03)00231-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679032	Bronze			2022-12-28	WOS:000182282900004
J	Wilf, P; Cuneo, NR; Johnson, KR; Hicks, JF; Wing, SL; Obradovich, JD				Wilf, P; Cuneo, NR; Johnson, KR; Hicks, JF; Wing, SL; Obradovich, JD			High plant diversity in Eocene South America: Evidence from Patagonia	SCIENCE			English	Article							RAIN-FOREST; CLIMATE; VEGETATION; HISTORY; HYPOTHESIS; SPECIATION; EVOLUTION; TAPHONOMY; AMAZONIA; TERTIARY	Tropical South America has the highest plant diversity of any region today, but this richness is usually characterized as a geologically recent development (Neogene or Pleistocene). From caldera-lake beds exposed at Laguna del Hunco in Patagonia, Argentina, paleolatitude similar to47degreesS, we report 102 leaf species. Radioisotopic and paleomagnetic analyses indicate that the. ora was deposited 52 million years ago, the time of the early Eocene climatic optimum, when tropical plant taxa and warm, equable climates reached middle latitudes of both hemispheres. Adjusted for sample size, observed richness exceeds that of any other Eocene leaf. ora, supporting an ancient history of high plant diversity in warm areas of South America.	Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Univ Michigan, Museum Paleontol, Ann Arbor, MI 48109 USA; Univ Penn, Dept Earth & Environm Sci, Philadelphia, PA 19104 USA; Museo Paleontol Egidio Feruglio, RA-9100 Trelew, Chubut, Argentina; Denver Museum Nat & Sci, Dept Earth Sci, Denver, CO 80205 USA; Smithsonian Inst, Dept Paleobiol, Washington, DC 20560 USA; US Geol Survey, Lakewood, CO 80225 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Michigan System; University of Michigan; University of Pennsylvania; Smithsonian Institution; Smithsonian National Museum of Natural History; United States Department of the Interior; United States Geological Survey	Wilf, P (corresponding author), Penn State Univ, Dept Geosci, University Pk, PA 16802 USA.	pwilf@geosc.psu.edu		Wilf, Peter/0000-0001-6813-1937; Wing, Scott/0000-0002-2954-8905				[Anonymous], 1994, PALAEOCLIMATES; [Anonymous], 1925, J HOPKINS U STUD GEO; [Anonymous], 1978, COURIER FORSCHUNGSIN; ARAGON E., 1997, REV ASOC GEOL ARGENT, V52, P243; ARAUJO D.S.D., 1997, CENTRES PLANT DIVERS, V3, P373; ARCHANGELSKY S, 1974, AMEGHINIANA, V11, P413; Behrensmeyer AK, 2000, PALEOBIOLOGY, V26, P103, DOI 10.1666/0094-8373(2000)26[103:TAP]2.0.CO;2; Berry E.W., 1938, GEOLOGICAL SOC AM SP, V12, P1, DOI DOI 10.1130/SPE12-P1; Burnham RJ, 1999, ANN MO BOT GARD, V86, P546, DOI 10.2307/2666185; BURNHAM RJ, 1994, US GEOLOGICAL SURVEY, V2085, P1; Burry EW, 1925, P NATL ACAD SCI USA, V11, P404, DOI 10.1073/pnas.11.7.404; BUSH MB, 1994, J BIOGEOGR, V21, P5, DOI 10.2307/2845600; CHRISTOPHEL DC, 1980, AUST J BOT, V28, P249, DOI 10.1071/BT9800249; Colinvaux PA, 2001, PALAEOGEOGR PALAEOCL, V166, P51, DOI 10.1016/S0031-0182(00)00201-7; Colinvaux PA, 2001, AMAZONIANA, V16, P609; Cowling SA, 2001, QUATERNARY RES, V55, P140, DOI 10.1006/qres.2000.2197; Davies-Vollum KS, 1998, PALAIOS, V13, P28, DOI 10.2307/3515279; DUTTONG AL, 2002, PALEOCEANOGRAPHY, V17, DOI DOI 10.1029/2000PA000503; Evanoff E., 2001, P DENVER MUSEUM NA 4, V1, P1; FISHER R, 1953, PROC R SOC LON SER-A, V217, P295, DOI 10.1098/rspa.1953.0064; GENTRY AH, 1988, P NATL ACAD SCI USA, V85, P156, DOI 10.1073/pnas.85.1.156; GREENWOOD DR, 1995, GEOLOGY, V23, P1044, DOI 10.1130/0091-7613(1995)023<1044:ECCALT>2.3.CO;2; GREENWOOD DR, IN PRESS GEOL SOC, V369; Haberle SG, 1999, QUATERNARY RES, V51, P27, DOI 10.1006/qres.1998.2020; HAFFER J, 1969, SCIENCE, V165, P131, DOI 10.1126/science.165.3889.131; Haffer J, 2001, AMAZONIANA, V16, P579; Hay WW, 1999, GEOL S AM S, P1; Herendeen PS, 2000, AM J BOT, V87, P1358, DOI 10.2307/2656727; Hill R. S., 1994, HIST AUSTR VEGETATIO, P390; Hill RS, 1999, AUST J BOT, V47, P639, DOI 10.1071/BT98093; HOORN C, 1994, PALAEOGEOGR PALAEOCL, V109, P1, DOI 10.1016/0031-0182(94)90117-1; Jaramillo CA, 2002, PALEOBIOLOGY, V28, P222, DOI 10.1666/0094-8373(2002)028<0222:ROTVTP>2.0.CO;2; Johnson KR, 2002, SCIENCE, V296, P2379, DOI 10.1126/science.1072102; Kershaw P, 2001, ANNU REV ECOL SYST, V32, P397, DOI 10.1146/annurev.ecolsys.32.081501.114059; KIRSCHVINK JL, 1980, GEOPHYS J ROY ASTR S, V62, P699, DOI 10.1111/j.1365-246X.1980.tb02601.x; MacGinitie H.D., 1969, U CALIF PUBLS GEOL S, V83, P1; MacGINITIE HARRY D., 1953, CARNEGIE INST WASHINGTON PUBL, V599, P1; MacGinitie HD., 1941, CARNEGIE I WASHINGTO, V534, P1; Manchester S. R., 2001, PROC DENVER MUS NAT, V4, P137; Marshall L.G., 1990, Revista Geologica de Chile, V17, P57; Mazzoni M. M., 1991, REV ASOC GEOL ARGENT, V46, P150; Melchor RN, 2002, PALAIOS, V17, P16, DOI 10.1669/0883-1351(2002)017<0016:ISAPOE>2.0.CO;2; Morley R.J., 2000, ORIGIN EVOLUTION TRO; Nores M, 1999, J BIOGEOGR, V26, P475, DOI 10.1046/j.1365-2699.1999.t01-1-00311.x; PASSMORE SM, 2002, GEOLOGICAL SOC AM AB, V34, P556; Petersen C.S., 1946, B DIRECCION GEN MINA, V59, P1; RAMOS VA, 2000, TECTONIC EVOLUTION S, P561; Remy R.R., 1992, US GEOL SURV B, VB1787BB, P1; Richardson JE, 2001, SCIENCE, V293, P2242, DOI 10.1126/science.1061421; ROMERO EJ, 1986, ANN MO BOT GARD, V73, P449, DOI 10.2307/2399123; ROMERO EJ, 1993, BIOLOGICAL RELATIONSHIPS BETWEEN AFRICA AND SOUTH AMERICA, P62; ROMERO EJ, 1976, B TORREY BOT CLUB, V103, P126, DOI 10.2307/2484888; Rull V, 1999, REV PALAEOBOT PALYNO, V107, P83, DOI 10.1016/S0034-6667(99)00014-7; SPICER RA, 1987, PALEOBIOLOGY, V13, P227; van der Hammen T, 2000, QUATERNARY SCI REV, V19, P725, DOI 10.1016/S0277-3791(99)00024-4; Villagran C, 1997, REV CHIL HIST NAT, V70, P241; Wilde V, 1998, REV PALAEOBOT PALYNO, V101, P7, DOI 10.1016/S0034-6667(97)00067-5; Wilf P, 1997, PALEOBIOLOGY, V23, P373, DOI 10.1017/S0094837300019746; Wilf P, 2000, GEOL SOC AM BULL, V112, P292, DOI 10.1130/0016-7606(2000)112<0292:LPEECC>2.3.CO;2; Wilf P, 1998, GEOLOGY, V26, P203, DOI 10.1130/0091-7613(1998)026<0203:UFLAPI>2.3.CO;2; Wilf P, 2001, P NATL ACAD SCI USA, V98, P6221, DOI 10.1073/pnas.111069498; Wing S.L., 2000, WARM CLIMATES EARTH, P197; WING SL, 1993, PHILOS T ROY SOC B, V341, P243, DOI 10.1098/rstb.1993.0109; Wolfe J.A., 1987, S GEO SURV B, V1597, P1; Wolfe JA, 1998, GEOL SOC AM BULL, V110, P664, DOI 10.1130/0016-7606(1998)110<0664:PEOEAO>2.3.CO;2; WOLFE JA, 1989, PALEOBIOLOGY, V15, P180, DOI 10.1017/S0094837300009350; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412; ZACHOS JC, 1994, PALEOCEANOGRAPHY, V9, P353, DOI 10.1029/93PA03266	68	215	229	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					122	125		10.1126/science.1080475	http://dx.doi.org/10.1126/science.1080475			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677065				2022-12-28	WOS:000181988900046
J	Zicha, D; Dobbie, IM; Holt, MR; Monypenny, J; Soong, DYH; Gray, C; Dunn, GA				Zicha, D; Dobbie, IM; Holt, MR; Monypenny, J; Soong, DYH; Gray, C; Dunn, GA			Rapid actin transport during cell protrusion	SCIENCE			English	Article							FILAMENT TURNOVER; DIFFUSION; DYNAMICS	Transformed rat fibroblasts expressing two variants of green fluorescent protein, each fused to beta-actin, were used to study actin dynamics during cell protrusion. The recently developed FLAP (fluorescence localization after photobleaching) method permits the tracking of one fluorophore after localized photobleaching by using the other as a colocalized reference. Here, by visualizing the ratio of bleached to total molecules, we found that actin was delivered to protruding zones of the leading edge of the cell at speeds that exceeded 5 micrometers per second. Monte Carlo modeling confirmed that this flow cannot be explained by diffusion and may involve active transport.	Kings Coll London, Randall Ctr, London SE1 1UL, England; Canc Res UK, Light Microscopy, Lincolns Inn Fields Labs, London WC2A 3PX, England; Natl Univ Ireland, Dept Biochem, Genome Stabil Lab, Galway, Ireland	University of London; King's College London; Cancer Research UK; Ollscoil na Gaillimhe-University of Galway	Dunn, GA (corresponding author), Kings Coll London, Randall Ctr, New Hunts House,Guys Campus, London SE1 1UL, England.	graham.a.dunn@kcl.ac.uk	Zicha, Daniel/H-9310-2016	Holt, Mark/0000-0001-7775-8539; Dobbie, Ian/0000-0002-5531-5865; Zicha, Daniel/0000-0002-8808-8064	Medical Research Council [G0100152(56891), G0100152] Funding Source: Medline; MRC [G0100152] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Dunn GA, 2002, J MICROSC-OXFORD, V205, P109, DOI 10.1046/j.0022-2720.2001.001007.x; DUNN GA, 1995, J CELL SCI, V108, P1239; McGrath JL, 1998, BIOPHYS J, V75, P2070, DOI 10.1016/S0006-3495(98)77649-0; Olveczky BP, 1998, BIOPHYS J, V74, P2722, DOI 10.1016/S0006-3495(98)77978-0; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Watanabe N, 2002, SCIENCE, V295, P1083, DOI 10.1126/science.1067470; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048	9	134	139	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 4	2003	300	5616					142	145		10.1126/science.1082026	http://dx.doi.org/10.1126/science.1082026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677069				2022-12-28	WOS:000181988900052
J	McCall, BJ; Huneycutt, AJ; Saykally, RJ; Geballe, TR; Djuric, N; Dunn, GH; Semaniak, J; Novotny, O; Al-Khalili, A; Ehlerding, A; Hellberg, F; Kalhori, S; Neau, A; Thomas, R; Osterdahl, F; Larsson, M				McCall, BJ; Huneycutt, AJ; Saykally, RJ; Geballe, TR; Djuric, N; Dunn, GH; Semaniak, J; Novotny, O; Al-Khalili, A; Ehlerding, A; Hellberg, F; Kalhori, S; Neau, A; Thomas, R; Osterdahl, F; Larsson, M			An enhanced cosmic-ray flux towards zeta Persei inferred from a laboratory study of the H-3(+)-e(-) recombination rate	NATURE			English	Article							DIFFUSE INTERSTELLAR-MEDIUM; DISSOCIATIVE RECOMBINATION; ELECTRONS; CLOUDS; SPECTROSCOPY; DESTRUCTION; MOLECULES; IONS	The H-3(+) molecular ion plays a fundamental role in interstellar chemistry, as it initiates a network of chemical reactions that produce many molecules(1,2). In dense interstellar clouds, the H-3(+) abundance is understood using a simple chemical model, from which observations of H-3(+) yield valuable estimates of cloud path length, density and temperature(3,4). But observations of diffuse clouds have suggested that H-3(+) is considerably more abundant than expected from the chemical models(5-7). Models of diffuse clouds have, however, been hampered by the uncertain values of three key parameters: the rate of H-3(+) destruction by electrons (e(-)), the electron fraction, and the cosmic-ray ionization rate. Here we report a direct experimental measurement of the H-3(+) destruction rate under nearly interstellar conditions. We also report the observation of H-3(+) in a diffuse cloud ( towards zeta Persei) where the electron fraction is already known. From these, we find that the cosmic-ray ionization rate along this line of sight is 40 times faster than previously assumed. If such a high cosmic-ray flux is ubiquitous in diffuse clouds, the discrepancy between chemical models and the previous observations(5-7) of H-3(+) can be resolved.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Gemini Observ, Hilo, HI 96720 USA; Univ Colorado, Joint Inst Lab Astrophys, Boulder, CO 80309 USA; Natl Inst Stand & Technol, Boulder, CO 80309 USA; Jan Kochanowski Univ Humanities & Sci, Inst Phys, PL-25406 Kielce, Poland; Charles Univ Prague, Fac Math & Phys, Dept Elect & Vacuum Phys, Prague 8, Czech Republic; Stockholm Univ, SCFAB, Dept Phys, S-10691 Stockholm, Sweden; Stockholm Univ, Manne Siegbahn Lab, S-10405 Stockholm, Sweden	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Colorado System; University of Colorado Boulder; National Institute of Standards & Technology (NIST) - USA; Jan Kochanowski University; Charles University Prague; Stockholm University; Stockholm University	McCall, BJ (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	bjmccall@astro.berkeley.edu	Novotny, Oldrich/K-6691-2013; McCall, Benjamin J/A-3136-2008	Novotny, Oldrich/0000-0003-2520-343X; Semaniak, Jacek/0000-0001-6953-6215; McCall, Benjamin/0000-0003-1022-7295; SAYKALLY, RICHARD/0000-0001-8942-3656				BOHLIN RC, 1978, ASTROPHYS J, V224, P132, DOI 10.1086/156357; Geballe TR, 1999, ASTROPHYS J, V510, P251, DOI 10.1086/306580; Geballe TR, 1996, NATURE, V384, P334, DOI 10.1038/384334a0; GUBERMAN SL, 1994, PHYS REV A, V49, pR4277, DOI 10.1103/PhysRevA.49.R4277; HEILES C, IN PRESS ASTROPHYS J; HEILES C, 2002, ASTROPH0207105; HERBST E, 1973, ASTROPHYS J, V185, P505, DOI 10.1086/152436; Jensen MJ, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.052701; Kokoouline V, 2001, NATURE, V412, P891, DOI 10.1038/35091025; KOKOULINE V, IN PRESS PHYS REV LE; Kreckel H, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.052509; Larsson M, 2000, PHILOS T ROY SOC A, V358, P2433, DOI 10.1098/rsta.2000.0658; LARSSON M, IN PRESS DISSOCIATIV; Lepp S., 1992, IAU S, V150, P471; Lindsay CM, 2001, J MOL SPECTROSC, V210, P60, DOI 10.1006/jmsp.2001.8444; McCall BJ, 1999, ASTROPHYS J, V522, P338, DOI 10.1086/307637; McCall BJ, 2002, ASTROPHYS J, V567, P391, DOI 10.1086/338380; McCall BJ, 1998, SCIENCE, V279, P1910, DOI 10.1126/science.279.5358.1910; OKA T, DISSOCIATIVE RECOMBI; Orel AE, 2000, PHILOS T R SOC A, V358, P2445, DOI 10.1098/rsta.2000.0659; Paul JB, 1997, J PHYS CHEM A, V101, P5211, DOI 10.1021/jp971216z; Plasil R, 2002, INT J MASS SPECTROM, V218, P105, DOI 10.1016/S1387-3806(02)00714-5; SAVAGE BD, 1977, ASTROPHYS J, V216, P291, DOI 10.1086/155471; Schneider IF, 2000, PHYS REV LETT, V85, P3785, DOI 10.1103/PhysRevLett.85.3785; Strasser D, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.032719; SUNDSTROM G, 1994, SCIENCE, V263, P785, DOI 10.1126/science.263.5148.785; TANABE T, 2000, DISSOCIATIVE RECOMBI, V4, P170; VANDISHOECK EF, 1986, ASTROPHYS J SUPPL S, V62, P109, DOI 10.1086/191135; WATSON WD, 1973, ASTROPHYS J, V183, pL17, DOI 10.1086/181242	30	298	299	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2003	422	6931					500	502		10.1038/nature01498	http://dx.doi.org/10.1038/nature01498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673244				2022-12-28	WOS:000181965400031
J	Rogers, RR; Krause, DW; Rogers, KC				Rogers, RR; Krause, DW; Rogers, KC			Cannibalism in the Madagascan dinosaur Majungatholus atopus	NATURE			English	Article							DYNAMICS	Many lines of evidence have been brought to bear on the question of theropod feeding ecology, including functional and physiological considerations, morphological constraints, taphonomic associations, and telling - although rare - indications of direct ingestion(1-7). Tooth marks of theropods, although rarely described and generally left unassigned to a particular taxon, can provide unique clues into predator - prey interaction(8), and can also yield insights into the extent of carcass utilization(9,10). Here we describe a sample of tooth-marked dinosaur bone recovered from three well-documented localities in the Upper Cretaceous Maevarano Formation of Madagascar that provides insights into the feeding ecology of the abelisaurid theropod Majungatholus atopus(11). Intensely tooth-marked elements from multiple individuals show that Majungatholus defleshed dinosaur carcasses. Furthermore, Majungatholus clearly fed upon the remains of not only sauropods, but also conspecifics, and thus was a cannibal. Cannibalism is a common ecological strategy among extant carnivores, but until now the evidence in relation to carnivorous dinosaurs has been sparse and anecdotal.	Macalester Coll, Dept Geol, St Paul, MN 55105 USA; SUNY Stony Brook, Dept Anat Sci, Stony Brook, NY 11794 USA; Sci Museum Minnesota, Dept Paleontol, St Paul, MN 55102 USA	Macalester College; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Rogers, RR (corresponding author), Macalester Coll, Dept Geol, 1600 Grand Ave, St Paul, MN 55105 USA.	rogers@macalester.edu						AUFFENBERG W, 1981, BEHAV ECOLOGY KOMODO, V406; BERTRAM BCR, 1975, J ZOOL, V177, P463; Buckley GA, 1999, SPEC PAP PALAEONTOL, P149; Buffetaut E., 1979, Bulletin de la Societe Geologique de France, V21, P183; Carrano MT, 2002, J VERTEBR PALEONTOL, V22, P510, DOI 10.1671/0272-4634(2002)022[0510:TOOMKA]2.0.CO;2; Chin K, 1998, NATURE, V393, P680, DOI 10.1038/31461; Colbert E. H, 1989, MUSEUM NO ARIZONA B, V57, P1; COLBERT EH, 1995, LITTLE DINOSAURS GHO, V250; COOPER M R, 1981, Occasional Papers of the National Museums and Monuments of Rhodesia Series B Natural Sciences, V6, P689; Erickson GM, 1996, NATURE, V382, P706, DOI 10.1038/382706a0; Farlow J.O., 1991, Modern Geology, V16, P161; FARLOW JO, 1976, ECOLOGY, V57, P841, DOI 10.2307/1941052; FIORILLO AR, 1991, PALAEOGEOGR PALAEOCL, V88, P157, DOI 10.1016/0031-0182(91)90062-V; FOX LR, 1975, ANNU REV ECOL SYST, V6, P87, DOI 10.1146/annurev.es.06.110175.000511; Gay Robert J., 2002, Journal of Vertebrate Paleontology, V22, p57A; Hunt Adrian P., 1994, Gaia, V10, P225; Jacobsen Aase Roland, 1998, Historical Biology, V13, P17; KRAUSE DW, 1999, GSA TODAY, V9, P1; Maxwell WD, 1995, J VERTEBR PALEONTOL, V15, P707, DOI 10.1080/02724634.1995.10011256; POLIS GA, 1984, MAMMAL REV, V14, P187, DOI 10.1111/j.1365-2907.1984.tb00345.x; POLIS GA, 1981, ANNU REV ECOL SYST, V12, P225, DOI 10.1146/annurev.es.12.110181.001301; Rayfield EJ, 2001, NATURE, V409, P1033, DOI 10.1038/35059070; Rogers KC, 2001, NATURE, V412, P530, DOI 10.1038/35087566; Rogers RR, 2000, J GEOL, V108, P275, DOI 10.1086/314403; Sampson SD, 1998, SCIENCE, V280, P1048, DOI 10.1126/science.280.5366.1048; Varricchio DJ, 2001, J PALEONTOL, V75, P401, DOI 10.1666/0022-3360(2001)075<0401:GCFACT>2.0.CO;2	26	74	77	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 3	2003	422	6931					515	518		10.1038/nature01532	http://dx.doi.org/10.1038/nature01532			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673249				2022-12-28	WOS:000181965400036
J	Singhal, A; Fewtrell, M; Cole, TJ; Lucas, A				Singhal, A; Fewtrell, M; Cole, TJ; Lucas, A			Low nutrient intake and early growth for later insulin resistance in adolescents born preterm	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; FOR-GESTATIONAL-AGE; LOW-BIRTH-WEIGHT; CATCH-UP; INFANTS; RISK; CHOLESTEROL; MULTICENTER; GLUCOSE; COHORT	Background In animals, acceleration of neonatal growth is thought to increase the later propensity to insulin resistance and non-insulin-dependent diabetes, whereas slow growth as a consequence of undernutrition is thought to have a beneficial effect. To test this hypothesis in people, we measured fasting concentrations of 32-33 split proinsulin, a marker of insulin resistance, in adolescents born preterm who had participated in randomised intervention trials of neonatal nutrition, and in adolescents born at term. Methods We determined fasting 32-33 split proinsulin concentration in participants aged 13-16 years born preterm and randomised to receive a nutrient-enriched or lower nutrient diet (n=216) or in a reference group born at term (n=61). Findings Fasting 32-33 split proinsulin concentration was greater in children given a nutrient-enriched diet (geometric mean 7.2 pmol/L, 95% Cl 6.4-8.1) than in those given the lower-nutrient diet (5.9 pmol/L [5.2-6.4]; mean difference 20.6% [5.0-36.3]; p=0.01). Healthy babies born at term had similar fasting 32-33 split proinsulin concentrations (6.9 pmol/L; 6.0-8.2) to the nutrient-enriched group. In non-randomised analyses, fasting 32-33 split proinsulin concentration was associated with greater weight gain in the first 2 weeks of life (13.2% [5.4-20.9] change per 100 g weight increase; p=0.001) independent of birthweight, gestation, neonatal morbidity, and demographic, anthropometric, and socioeconomic factors. Interpretation Our results suggest that relative undernutrition early in life in children born preterm may have beneficial effects on insulin resistance.	Inst Child Hlth, MRC, Childhood Nutr Res Ctr, London WC1N 1EH, England; Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London, England	University of London; University College London; University of London; University College London	Singhal, A (corresponding author), Inst Child Hlth, MRC, Childhood Nutr Res Ctr, 30 Guilford St, London WC1N 1EH, England.	a.singhal@ich.ucl.ac.uk	Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200	MRC [G9827821] Funding Source: UKRI; Medical Research Council [G9827821(62595), G9827821] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Cianfarani S, 1999, ARCH DIS CHILD-FETAL, V81, pF71, DOI 10.1136/fn.81.1.F71; Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F; COLLE E, 1976, PEDIATRICS, V57, P363; DEIBER M, 1989, J CLIN ENDOCR METAB, V68, P232, DOI 10.1210/jcem-68-1-232; Eriksson JG, 2001, BRIT MED J, V322, P949, DOI 10.1136/bmj.322.7292.949; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; Fewtrell MS, 2000, DIABETOLOGIA, V43, P714, DOI 10.1007/s001250051368; GELDING SV, 1995, CLIN ENDOCRINOL, V42, P255, DOI 10.1111/j.1365-2265.1995.tb01873.x; HAHN P, 1984, J NUTR, V114, P1231, DOI 10.1093/jn/114.7.1231; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HOKKENKOELEGA ACS, 1995, PEDIATR RES, V38, P267, DOI 10.1203/00006450-199508000-00022; KARLBERG J, 1995, PEDIATR RES, V38, P733, DOI 10.1203/00006450-199511000-00017; KRAMER MS, 1990, PEDIATRICS, V86, P707; Law CM, 2002, ARCH DIS CHILD-FETAL, V86, pF7, DOI 10.1136/fn.86.1.F7; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; LUCAS A, 1980, LANCET, V1, P1267; Lucas A, 1998, BRIT MED J, V317, P1481, DOI 10.1136/bmj.317.7171.1481; LUCAS A, 1984, ARCH DIS CHILD, V59, P722, DOI 10.1136/adc.59.8.722; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Metcalfe NB, 2001, TRENDS ECOL EVOL, V16, P254, DOI 10.1016/S0169-5347(01)02124-3; MYKKANEN L, 1995, DIABETOLOGIA, V38, P1176, DOI 10.1007/BF00422366; Pettitt DJ, 1997, LANCET, V350, P166, DOI 10.1016/S0140-6736(96)12103-6; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PLAGEMANN A, 1992, EXP CLIN ENDOCRINOL, V99, P154, DOI 10.1055/s-0029-1211159; Plagemann A, 1999, BRAIN RES, V836, P146, DOI 10.1016/S0006-8993(99)01662-5; Roth GS, 2000, EUR J CLIN NUTR, V54, pS15, DOI 10.1038/sj.ejcn.1601020; Singhal A, 2001, LANCET, V358, P1159, DOI 10.1016/S0140-6736(01)06276-6; Singhal A, 2001, LANCET, V357, P413, DOI 10.1016/S0140-6736(00)04004-6; Stettler N, 2002, PEDIATRICS, V109, P194, DOI 10.1542/peds.109.2.194; Wareham NJ, 1999, DIABETES CARE, V22, P262, DOI 10.2337/diacare.22.2.262	30	391	406	0	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 29	2003	361	9363					1089	1097		10.1016/S0140-6736(03)12895-4	http://dx.doi.org/10.1016/S0140-6736(03)12895-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	660ZD	12672313				2022-12-28	WOS:000181865200011
J	Farquhar, GD; Roderick, ML				Farquhar, GD; Roderick, ML			Atmospheric science: Pinatubo, diffuse light, and the carbon cycle	SCIENCE			English	Editorial Material							DIOXIDE; FOREST		Australian Natl Univ, Inst Adv Studies, Res Sch Biol Sci, Cooperat Res Ctr Greenhouse Accounting, Canberra, ACT 0200, Australia	Australian National University	Farquhar, GD (corresponding author), Australian Natl Univ, Inst Adv Studies, Res Sch Biol Sci, Cooperat Res Ctr Greenhouse Accounting, Canberra, ACT 0200, Australia.	farquhar@rsbs.anu.edu.au; roderick@anu.edu.au	Roderick, Michael/C-9621-2009; FARQUHAR, GRAHAM D/A-3722-2008	Roderick, Michael/0000-0002-3630-7739; Farquhar, Graham/0000-0002-7065-1971				Budyko MI., 1974, CLIMATE LIFE; Gu LH, 2003, SCIENCE, V299, P2035, DOI 10.1126/science.1078366; HOLLINGER DY, 1994, ECOLOGY, V75, P134, DOI 10.2307/1939390; HORN H S, 1971, P144; Jones CD, 2001, GLOBAL BIOGEOCHEM CY, V15, P453, DOI 10.1029/2000GB001281; Lucht W, 2002, SCIENCE, V296, P1687, DOI 10.1126/science.1071828; Munoz O, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000983; Nakazawa T, 1997, J GEOPHYS RES-ATMOS, V102, P1271, DOI 10.1029/96JD02720; NORMAN JM, 1971, AGRON J, V63, P743, DOI 10.2134/agronj1971.00021962006300050026x; NORMAN JM, 1983, AGRON J, V75, P481, DOI 10.2134/agronj1983.00021962007500030016x; Roderick ML, 2002, SCIENCE, V298, P1410; Roderick ML, 2001, OECOLOGIA, V129, P21, DOI 10.1007/s004420100760; Stanhill G, 2001, AGR FOREST METEOROL, V107, P255, DOI 10.1016/S0168-1923(00)00241-0	13	138	157	6	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					1997	1998		10.1126/science.1080681	http://dx.doi.org/10.1126/science.1080681			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663904				2022-12-28	WOS:000181834200029
J	Sinn, H; Glorieux, B; Hennet, L; Alatas, A; Hu, M; Alp, EE; Bermejo, FJ; Price, DL; Saboungi, ML				Sinn, H; Glorieux, B; Hennet, L; Alatas, A; Hu, M; Alp, EE; Bermejo, FJ; Price, DL; Saboungi, ML			Microscopic dynamics of liquid aluminum oxide	SCIENCE			English	Article							SPECTROSCOPY; RELAXATION	Collective excitations have been observed in liquid aluminum oxide at high temperatures by combining a containerless sample environment with inelastic x-ray scattering. The excitation spectra show a well-defined triplet peak structure at lower wave vectors Q (1 to 6 nanometers(-1)) and a single quasi-elastic peak at higher Q. The high-Q spectra are well described by kinetic theory. The low-Q spectra require a frequency-dependent viscosity and provide previously unknown experimental constraints on the behavior of liquids at the interface between atomistic and continuum theory.	Univ Orleans, CNRS, Ctr Rech Mat Divisee, F-45071 Orleans 2, France; Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA; Inst Sci Genie Mat & Proc, F-66100 Perpignan, France; CNRS, Ctr Rech Mat Hauts Temp, F-45071 Orleans, France; Univ Basque Country, CSIC, Dept Elect & Elect, Bilbao 48080, Spain	Centre National de la Recherche Scientifique (CNRS); Universite de Orleans; United States Department of Energy (DOE); Argonne National Laboratory; Centre National de la Recherche Scientifique (CNRS); Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country	Saboungi, ML (corresponding author), Univ Orleans, CNRS, Ctr Rech Mat Divisee, F-45071 Orleans 2, France.	mls@cnrs-orleans.fr	HENNET, Louis/C-1711-2008; Saboungi, Marie-Louise/C-5920-2013; Price, David Long/A-8468-2013; Alatas, Ahmet/AAY-4125-2021; Hu, Michael Y./C-7571-2013	HENNET, Louis/0000-0002-2992-4800; Saboungi, Marie-Louise/0000-0002-0607-4815; Alatas, Ahmet/0000-0001-6521-856X; Hu, Michael Y./0000-0002-3718-7169; Glorieux, Benoit/0000-0002-0620-777X				ANISIMOV YS, 1977, IAN SSSR NEORG MATER, V13, P1442; Ansell S, 1997, PHYS REV LETT, V78, P464, DOI 10.1103/PhysRevLett.78.464; Boon J.-P., 1980, MOL HYDRODYNAMICS; Burkel E, 2000, REP PROG PHYS, V63, P171, DOI 10.1088/0034-4885/63/2/203; Castanet R., 1984, High Temperatures - High Pressures, V16, P449; Chong SH, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.051201; COHEN EGD, 1987, PHYS REV LETT, V59, P2872, DOI 10.1103/PhysRevLett.59.2872; DINGWELL DB, 1989, PHYS CHEM MINER, V16, P508; Egelstaff P.A., 1992, INTRO LIQUID STATE; Enderby JE, 1997, APPL PHYS LETT, V71, P116, DOI 10.1063/1.119445; GLORIEUX B, COMMUNICATION; Glyde H. R., 1994, EXCITATIONS LIQUID S; GUREVICH VL, 1986, MODERN PROBLEMS COND, V18, P274; GUREVICH VL, 1986, MODERN PROBLEMS CO S, V18, P370; Hennet L, 2002, REV SCI INSTRUM, V73, P124, DOI 10.1063/1.1426228; KRISHNAN S, 1991, J AM CERAM SOC, V74, P881, DOI 10.1111/j.1151-2916.1991.tb06947.x; Landron C, 2001, PHYS REV LETT, V86, P4839, DOI 10.1103/PhysRevLett.86.4839; Lovesey S W, 1984, THEORY NEUTRON SCATT; MARIS HJ, 1977, REV MOD PHYS, V49, P341, DOI 10.1103/RevModPhys.49.341; MOUNTAIN RD, 1966, J RES NBS A PHYS CH, VA 70, P207, DOI 10.6028/jres.070A.017; Powell R.L., 1972, AM I PHYS HDB, V3rd, P4; Saboungi ML, 2002, J NON-CRYST SOLIDS, V312-14, P294, DOI 10.1016/S0022-3093(02)01689-7; SCHOBER H, 1993, Z PHYS B CON MAT, V92, P273, DOI 10.1007/BF01308745; SETTE F, 1995, PHYS REV LETT, V75, P850, DOI 10.1103/PhysRevLett.75.850; Shukla RC, 2000, PHYS REV B, V62, P3232, DOI 10.1103/PhysRevB.62.3232; Sinn H, 2001, J PHYS-CONDENS MAT, V13, P7525, DOI 10.1088/0953-8984/13/34/305; URBAIN G, 1982, REV INT HAUTES TEMP, V19, P55; Zoppi M., 1994, DYNAMICS LIQUID STAT	28	65	66	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					2047	2049		10.1126/science.1080950	http://dx.doi.org/10.1126/science.1080950			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12663922				2022-12-28	WOS:000181834200048
J	Ferguson, NM; Galvani, AP; Bush, RM				Ferguson, NM; Galvani, AP; Bush, RM			Ecological and immunological determinants of influenza evolution	NATURE			English	Article							A VIRUSES; CELLULAR-IMMUNITY; HEMAGGLUTININ; INFECTION; VACCINE; FLU	In pandemic and epidemic forms, influenza causes substantial, sometimes catastrophic, morbidity and mortality. Intense selection from the host immune system drives antigenic change in influenza A and B, resulting in continuous replacement of circulating strains with new variants able to re-infect hosts immune to earlier types. This 'antigenic drift'(1) often requires a new vaccine to be formulated before each annual epidemic. However, given the high transmissibility and mutation rate of influenza, the constancy of genetic diversity within lineages over time is paradoxical. Another enigma is the replacement of existing strains during a global pandemic caused by 'antigenic shift'-the introduction of a new avian influenza A subtype into the human population(1). Here we explore ecological and immunological factors underlying these patterns using a mathematical model capturing both realistic epidemiological dynamics and viral evolution at the sequence level. By matching model output to phylogenetic patterns seen in sequence data collected through global surveillance(2), we find that short-lived strain-transcending immunity is essential to restrict viral diversity in the host population and thus to explain key aspects of drift and shift dynamics.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London W2 1PG, England; Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA	Imperial College London; University of California System; University of California Berkeley; University of California System; University of California Irvine	Ferguson, NM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, St Marys Campus,Norfolk Pl, London W2 1PG, England.		Ferguson, Neil/B-8578-2008	Ferguson, Neil/0000-0002-1154-8093				Benenson A.S., 1975, CONTROL COMMUNICABLE; Bush RM, 1999, MOL BIOL EVOL, V16, P1457, DOI 10.1093/oxfordjournals.molbev.a026057; Bush RM, 1999, SCIENCE, V286, P1921, DOI 10.1126/science.286.5446.1921; *CDCP, 1986, MORB MORT WEEKL REP; COX N, 1993, OPTIONS CONTROL INFL, V2, P223; COX NJ, 1996, OPTIONS CONTROL INFL, V3, P591; DALY JM, 1998, TXB INFLUENZA, P168; Earn DJD, 2002, TRENDS ECOL EVOL, V17, P334, DOI 10.1016/S0169-5347(02)02502-8; Fitch WM, 1997, P NATL ACAD SCI USA, V94, P7712, DOI 10.1073/pnas.94.15.7712; FRANK AL, 1987, AM J EPIDEMIOL, V125, P576, DOI 10.1093/oxfordjournals.aje.a114571; FRANK AL, 1983, J MED VIROL, V12, P17, DOI 10.1002/jmv.1890120103; GILL PW, 1977, MED J AUSTRALIA, V2, P761, DOI 10.5694/j.1326-5377.1977.tb99276.x; GLEZEN WP, 1997, VIRAL INFECT HUMANS, P473; HOSKINS TW, 1979, LANCET, V1, P33; Layne SP, 2001, SCIENCE, V293, P1729, DOI 10.1126/science.293.5536.1729; Lindstrom SE, 1999, J VIROL, V73, P4413, DOI 10.1128/JVI.73.5.4413-4426.1999; MCELHANEY JE, 1995, VACCINE, V13, P6, DOI 10.1016/0264-410X(95)80003-V; MOSER MR, 1979, AM J EPIDEMIOL, V110, P1; Nicholson KG, 1998, TXB INFLUENZA, P219; Sambhara S, 2001, CELL IMMUNOL, V211, P143, DOI 10.1006/cimm.2001.1835; Seo SH, 2002, J VIROL, V76, P4886, DOI 10.1128/JVI.76.10.4886-4890.2002; Skoner DP, 1996, CLIN IMMUNOL IMMUNOP, V79, P294, DOI 10.1006/clin.1996.0082; Smith CB, 2002, J INFECT DIS, V185, P980, DOI 10.1086/339416; SONOGUCHI T, 1985, J INFECT DIS, V151, P81, DOI 10.1093/infdis/151.1.81; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.iy.08.040190.003513; YETTER RA, 1980, INFECT IMMUN, V29, P654; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785	29	489	524	4	155	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					428	433		10.1038/nature01509	http://dx.doi.org/10.1038/nature01509			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660783				2022-12-28	WOS:000181801200044
J	Kaneko, Y; Floras, JS; Usui, K; Plante, J; Tkacova, R; Kubo, T; Ando, S; Bradley, TD				Kaneko, Y; Floras, JS; Usui, K; Plante, J; Tkacova, R; Kubo, T; Ando, S; Bradley, TD			Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEYNE-STOKES RESPIRATION; FAILING HUMAN HEART; DILATED CARDIOMYOPATHY; SYMPATHETIC ACTIVITY; DOWN-REGULATION; HYPOXIA; HYPERTENSION; ASSOCIATION; RESPONSES; DISEASE	BACKGROUND: Obstructive sleep apnea subjects the failing heart to adverse hemodynamic and adrenergic loads and may thereby contribute to the progression of heart failure. We hypothesized that treatment of obstructive sleep apnea by continuous positive airway pressure in patients with heart failure would improve left ventricular systolic function. METHODS: Twenty-four patients with a depressed left ventricular ejection fraction (45 percent or less) and obstructive sleep apnea who were receiving optimal medical treatment for heart failure underwent polysomnography. On the following morning, their blood pressure and heart rate were measured by digital photoplethysmography, and left ventricular dimensions and left ventricular ejection fraction were assessed by echocardiography. The subjects were then randomly assigned to receive medical therapy either alone (12 patients) or with the addition of continuous positive airway pressure (12 patients) for one month. The assessment protocol was then repeated. RESULTS: In the control group of patients who received only medical therapy, there were no significant changes in the severity of obstructive sleep apnea, daytime blood pressure, heart rate, left ventricular end-systolic dimension, or left ventricular ejection fraction during the study. In contrast, continuous positive airway pressure markedly reduced obstructive sleep apnea, reduced the daytime systolic blood pressure from a mean (+/-SE) of 126+/-6 mm Hg to 116+/-5 mm Hg (P=0.02), reduced the heart rate from 68+/-3 to 64+/-3 beats per minute (P=0.007), reduced the left ventricular end-systolic dimension from 54.5+/-1.8 to 51.7+/-1.2 mm (P=0.009), and improved the left ventricular ejection fraction from 25.0+/-2.8 to 33.8+/-2.4 percent (P<0.001). CONCLUSIONS: In medically treated patients with heart failure, treatment of coexisting obstructive sleep apnea by continuous positive airway pressure reduces systolic blood pressure and improves left ventricular systolic function. Obstructive sleep apnea may thus have an adverse effect in heart failure that can be addressed by targeted therapy.	Toronto Gen Hosp Univ Hlth Network, Toronto, ON M5G 2C4, Canada; Toronto Rehabil Inst, Sleep Res Labs, Toronto, ON, Canada; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Ctr Sleep Med & Ciradian Biol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of Toronto	Bradley, TD (corresponding author), Toronto Gen Hosp Univ Hlth Network, NU 9-112,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.		Floras, John S./D-4042-2015					American Heart Association, 2000, 2001 HEART STROK STA; Bradley TD, 2003, CLIN SCI, V104, P231, DOI 10.1042/CS20020157; Bradley TD, 2001, CHEST, V119, P1827, DOI 10.1378/chest.119.6.1827; Brooks D, 1997, J CLIN INVEST, V99, P106, DOI 10.1172/JCI119120; DALY PA, 1990, CIRCULATION, V82, P35; Faccenda JF, 2001, AM J RESP CRIT CARE, V163, P344, DOI 10.1164/ajrccm.163.2.2005037; FLORAS JS, 1993, J AM COLL CARDIOL, V22, pA72, DOI 10.1016/0735-1097(93)90466-E; FRANKLIN KA, 1995, LANCET, V345, P1085, DOI 10.1016/S0140-6736(95)90820-X; Hall MJ, 1998, J APPL PHYSIOL, V85, P1476, DOI 10.1152/jappl.1998.85.4.1476; HORNER RL, 1995, J APPL PHYSIOL, V79, P151, DOI 10.1152/jappl.1995.79.1.151; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Javaheri S, 1998, CIRCULATION, V97, P2154, DOI 10.1161/01.CIR.97.21.2154; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Jong P, 2002, ARCH INTERN MED, V162, P1689, DOI 10.1001/archinte.162.15.1689; Kraiczi H, 2000, AM J RESP CRIT CARE, V161, P1423, DOI 10.1164/ajrccm.161.5.9909024; KUSUOKA H, 1986, CIRC RES, V59, P270, DOI 10.1161/01.RES.59.3.270; Leung RST, 2001, AM J RESP CRIT CARE, V164, P2147, DOI 10.1164/ajrccm.164.12.2107045; MALONE S, 1991, LANCET, V338, P1480; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V152, P473, DOI 10.1164/ajrccm.152.2.7633695; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V151, P92, DOI 10.1164/ajrccm.151.1.7812579; Ogletree-Hughes ML, 2001, CIRCULATION, V104, P881, DOI 10.1161/hc3301.094911; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Parker JD, 1999, AM J RESP CRIT CARE, V160, P1888, DOI 10.1164/ajrccm.160.6.9807074; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Pepperell JCT, 2002, LANCET, V359, P204, DOI 10.1016/S0140-6736(02)07445-7; Razeghi P, 2002, CARDIOLOGY, V97, P203, DOI 10.1159/000063122; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Schneider H, 2000, J APPL PHYSIOL, V88, P1093, DOI 10.1152/jappl.2000.88.3.1093; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; SHIOMI T, 1991, CHEST, V100, P894, DOI 10.1378/chest.100.4.894; Sin DD, 1999, AM J RESP CRIT CARE, V160, P1101, DOI 10.1164/ajrccm.160.4.9903020; Sin DD, 2000, CIRCULATION, V102, P61, DOI 10.1161/01.CIR.102.1.61; SIN DD, IN PRESS CHEST; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; SOMERS VK, 1989, J APPL PHYSIOL, V67, P2101, DOI 10.1152/jappl.1989.67.5.2101; Tkacova R, 1998, CIRCULATION, V98, P2269, DOI 10.1161/01.CIR.98.21.2269; TOLLE FA, 1983, J APPL PHYSIOL, V55, P1718, DOI 10.1152/jappl.1983.55.6.1718; Waravdekar NV, 1996, AM J RESP CRIT CARE, V153, P1333, DOI 10.1164/ajrccm.153.4.8616563; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	41	694	727	1	44	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2003	348	13					1233	1241		10.1056/NEJMoa022479	http://dx.doi.org/10.1056/NEJMoa022479			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	659RG	12660387				2022-12-28	WOS:000181790800005
J	Martin, M; Turco, JH; Zegans, ME; Facklam, RR; Sodha, S; Elliott, JA; Pryor, JH; Beall, B; Erdman, DD; Baumgartner, YY; Sanchez, PA; Schwartzman, JD; Montero, J; Schuchat, A; Whitney, CG				Martin, M; Turco, JH; Zegans, ME; Facklam, RR; Sodha, S; Elliott, JA; Pryor, JH; Beall, B; Erdman, DD; Baumgartner, YY; Sanchez, PA; Schwartzman, JD; Montero, J; Schuchat, A; Whitney, CG			An outbreak of conjunctivitis due to atypical streptococcus pneumoniae	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPIDEMIC KERATOCONJUNCTIVITIS; CARE; IDENTIFICATION; INFECTION; SEQUENCE	Background: In February 2002, clinicians at the Dartmouth College Health Service recognized an outbreak of conjunctivitis; cultures of conjunctival swabs implicated Streptococcus pneumoniae. An investigation was begun to determine the extent of the outbreak, confirm the cause, identify modes of transmission, and implement control measures. Methods: Investigators reviewed the health service's data base for diagnoses of conjunctivitis. Viral and bacterial cultures were obtained from ill students. Bile-soluble isolates that were susceptible to ethylhydrocupreine (optochin) and therefore were presumed to be pneumococci underwent serotyping, capsular staining, pulsed-field gel electrophoresis, a DNA probe, and multilocus sequence typing. A cohort study of risk factors was conducted with the use of the Internet. Control measures included distribution of alcohol-based hand gel and messages about prevention. Results: Among 5060 students, 698 (13.8 percent) received a diagnosis of conjunctivitis from January 1, 2002, through April 12, 2002, including 22 percent of first-year students. Presumed pneumococci were isolated from 43.3 percent of conjunctival swabs (110 of 254); viral cultures performed on 85 specimens were negative. DNA probes and multilocus sequence typing confirmed that the organisms were pneumococci, although the bacteria did not have the characteristic capsule. On pulsed-field gel electrophoresis, strains were found to be identical to pneumococci that caused outbreaks of conjunctivitis in other parts of the country in 1980. Analysis of survey data from 1832 students indicated that close contact with a student with conjunctivitis, wearing contact lenses, membership on a sports team, and attending parties at or living in a fraternity or sorority house were associated with conjunctivitis. The rate of diagnosis of conjunctivitis declined after the implementation of control measures and after spring break. Conclusions: This large outbreak of conjunctivitis on a college campus was caused by an atypical, unencapsulated strain of S. pneumoniae that was identical to strains that had caused outbreaks two decades earlier.	Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Dartmouth Coll, Hlth Serv, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Hanover, NH USA; Dartmouth Coll Sch Med, Hanover, NH 03756 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; New Hampshire Dept Hlth & Human Serv, Off Community & Publ Hlth, Concord, NH 03301 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Dartmouth College; Dartmouth College; Dartmouth College; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Whitney, CG (corresponding author), Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, 1600 Clifton Rd NE,MS C23, Atlanta, GA 30333 USA.	cwhitney@cdc.gov			NATIONAL EYE INSTITUTE [K08EY013977] Funding Source: NIH RePORTER; NEI NIH HHS [1 K08 EY13977-01] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AUSTRIAN R, 1994, HARRISONS PRINCIPLES, V1, P607; Bischoff WE, 2000, ARCH INTERN MED, V160, P1017, DOI 10.1001/archinte.160.7.1017; BLUESTONE CD, 1992, PEDIATR INFECT DIS J, V11, pS7, DOI 10.1097/00006454-199208001-00002; BUEHLER JW, 1983, SOUTHERN MED J, V76, P587, DOI 10.1097/00007611-198305000-00014; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P553; Chapin Kimberle, 1995, P33; Elliott JA, 1998, J CLIN MICROBIOL, V36, P2115, DOI 10.1128/JCM.36.7.2115-2116.1998; Enright MC, 1998, MICROBIOL-UK, V144, P3049, DOI 10.1099/00221287-144-11-3049; Ertugrul N, 1997, J INFECT DIS, V176, P1401, DOI 10.1086/517331; Geslin P, 1997, ADV EXP MED BIOL, V418, P383; Gwaltney JM, 1996, CLIN INFECT DIS, V23, P1209, DOI 10.1093/clinids/23.6.1209; *IMP COLL, 2003, MULT LOC SEQ TYP HOM; JERNIGAN JA, 1993, J INFECT DIS, V167, P1307, DOI 10.1093/infdis/167.6.1307; Leibowitz HM, 2000, NEW ENGL J MED, V343, P345, DOI 10.1056/NEJM200008033430507; Loeffler JM, 2001, SCIENCE, V294, P2170, DOI 10.1126/science.1066869; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; MCDANIEL LS, 1991, INFECT IMMUN, V59, P222, DOI 10.1128/IAI.59.1.222-228.1991; MCMINN PC, 1991, J INFECT DIS, V164, P1113, DOI 10.1093/infdis/164.6.1113; National Committee for Clinical Laboratory Standards NCCLS, 2000, M7A5 NCCLS; O'Brien KL, 2001, J CLIN MICROBIOL, V39, P1021, DOI 10.1128/JCM.39.3.1021-1024.2001; OBRIEN TP, 2000, MANDELL DOUGLAS BENN, V1, P1251; PAPARELLO SF, 1991, MIL MED, V156, P256, DOI 10.1093/milmed/156.5.256; Parienti JJ, 2002, JAMA-J AM MED ASSOC, V288, P722, DOI 10.1001/jama.288.6.722; Parienti JJ, 2002, JAMA-J AM MED ASSOC, V288, P2688, DOI 10.1001/jama.288.21.2688-JLT1204-5-2; Pryor JH, 2002, J AM COLL HEALTH, V50, P267, DOI 10.1080/07448480209603444; Sampson JS, 1997, INFECT IMMUN, V65, P1967, DOI 10.1128/IAI.65.5.1967-1971.1997; Schinsky MF, 2000, INT J SYST EVOL MICR, V50, P575, DOI 10.1099/00207713-50-2-575; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SCHWARTZ B, 1989, American Journal of Ophthalmology, V107, P341; SEAL DV, 1982, BRIT J OPHTHALMOL, V66, P357, DOI 10.1136/bjo.66.6.357; SHAYEGANI M, 1982, J CLIN MICROBIOL, V16, P8, DOI 10.1128/JCM.16.1.8-14.1982; Stackebrandt E, 2002, INT J SYST EVOL MICR, V52, P1043, DOI [10.1099/ijs.0.02360-0, 10.1099/00207713-52-3-1043]; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; TROTTIER S, 1991, PEDIATR INFECT DIS J, V10, P578, DOI 10.1097/00006454-199108000-00006; 2002, MMWR MORB MORTAL WKL, V51, P205; 1990, MMWR MORB MORTAL WKL, V39, P598; 2000, 50 MOST WIRED U	37	105	107	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1112	1121		10.1056/NEJMoa022521	http://dx.doi.org/10.1056/NEJMoa022521			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646668	Bronze			2022-12-28	WOS:000181628400007
J	Mukamal, KJ; Kuller, LH; Fitzpatrick, AL; Longstreth, WT; Mittleman, MA; Siscovick, DS				Mukamal, KJ; Kuller, LH; Fitzpatrick, AL; Longstreth, WT; Mittleman, MA; Siscovick, DS			Prospective-study of alcohol consumption and risk of dementia in older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; TOBACCO CONSUMPTION; VASCULAR DEMENTIA; SMOKING; DRINKING; PERFORMANCE; IMPAIRMENT; BRAIN; QUESTIONNAIRE	Context Alcohol consumption has been associated with complex changes in cerebral vasculature and structure in older adults. How alcohol consumption affects the incidence of dementia is less clear. Objective To determine the prospective relationship of alcohol consumption and risk of dementia among older adults. Design, Setting, and Participants Nested case-control study of 373 cases with incident dementia and 373 controls who were among 5888 adults aged 65 years and older who participated in the Cardiovascular Health Study, a prospective, population-based cohort study in 4 US communities. The controls were frequency-matched on age, death before 1999, and their attendance of a 1998-1999 clinic. Participants in this study underwent magnetic resonance imaging (MRI) of the brain and cognitive testing between 1992 and 1994 and were followed up until 1999. Main Outcome Measures Odds of incident dementia, ascertained by detailed neurological and neuropsychological examinations according to average alcohol consumption, assessed by self-reported intake of beer, wine, and liquor at 2 visits prior to the date of the MRI. Result's Compared with abstention, the adjusted odds for dementia among those whose weekly alcohol consumption was less than 1 drink were 0.65 (95% confidence interval [CI], 0.41-1.02); 1 to 6 drinks, 0.46 (95% CI, 0.27-0.77); 7 to 13 drinks, 0.69 (95% CI, 0.37-1.31); and 14 or more drinks, 1.22 (95% CI, 0.60-2.49; P for quadratic term=.001). A trend toward greater odds of dementia associated with heavier alcohol consumption was most apparent among men and participants with an apolipoprotein E epsilon4 allele. We found generally similar relationships of alcohol use with Alzheimer disease and vascular dementia. Conclusions Compared with abstention, consumption of 1 to 6 drinks weekly is associated with a lower risk of incident dementia among older adults.	Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Harvard T.H. Chan School of Public Health	Mukamal, KJ (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,RO-114, Boston, MA 02215 USA.	kmukamal@caregroup.harvard.edu	Mukamal, Kenneth/GVR-7978-2022	Mittleman, Murray/0000-0001-9788-7274	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085086, N01HC085085, N01HC085082, N01HC085081, N01HC085083, N01HC085080, N01HC015103, N01HC085084, N01HC085079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K23AA000299] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85084, N01HC85085, N01HC85086, N01HC15103] Funding Source: Medline; NIAAA NIH HHS [K23AA00299] Funding Source: Medline; NIA NIH HHS [R01AG015928] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams WL, 1996, J AM GERIATR SOC, V44, P1082, DOI 10.1111/j.1532-5415.1996.tb02943.x; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BAUMBAICKER C, 1985, DRUG ALCOHOL DEPEN, V15, P305, DOI 10.1016/0376-8716(85)90008-0; Broe GA, 1998, AUST NZ J PUBL HEAL, V22, P621, DOI 10.1111/j.1467-842X.1998.tb01449.x; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Bryan RN, 1997, RADIOLOGY, V202, P47, DOI 10.1148/radiology.202.1.8988191; Cervilla JA, 2000, J NEUROL NEUROSUR PS, V68, P622, DOI 10.1136/jnnp.68.5.622; Cervilla JA, 2000, BRIT J PSYCHIAT, V177, P66, DOI 10.1192/bjp.177.1.66; CHRISTIAN JC, 1995, J STUD ALCOHOL, V56, P414, DOI 10.15288/jsa.1995.56.414; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; Conigrave KM, 2001, DIABETES, V50, P2390, DOI 10.2337/diabetes.50.10.2390; Dufouil C, 1997, AM J EPIDEMIOL, V146, P405, DOI 10.1093/oxfordjournals.aje.a009293; Dufouil C, 2000, EPIDEMIOLOGY, V11, P280, DOI 10.1097/00001648-200005000-00009; Edelstein SL, 1998, J WOMENS HEALTH, V7, P1271, DOI 10.1089/jwh.1998.7.1271; Elias PK, 1999, AM J EPIDEMIOL, V150, P580; Elwood PC, 1999, J EPIDEMIOL COMMUN H, V53, P9, DOI 10.1136/jech.53.1.9; Fadda F, 1998, PROG NEUROBIOL, V56, P385, DOI 10.1016/S0301-0082(98)00032-X; Fagrell B, 1999, J INTERN MED, V246, P331, DOI 10.1046/j.1365-2796.1999.00576.x; Fahn S., 1987, RECENT DEV PARKINSON, P153; Fitzpatrick AL, 2002, AM J EPIDEMIOL, V155, ps53; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; GILL JS, 1991, AM J MED, V90, P489, DOI 10.1016/0002-9343(91)80090-9; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; Goodwin N, 2001, J SOUTHWEST, V43, P1; GRAVES AB, 1991, INT J EPIDEMIOL, V20, pS48, DOI 10.1093/ije/20.Supplement_2.S48; Green RC, 2002, JAMA-J AM MED ASSOC, V287, P329, DOI 10.1001/jama.287.3.329; Haan MN, 1999, JAMA-J AM MED ASSOC, V282, P40, DOI 10.1001/jama.282.1.40; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HEBERT LE, 1992, AM J EPIDEMIOL, V135, P347, DOI 10.1093/oxfordjournals.aje.a116296; HEBERT LE, 1993, AM J EPIDEMIOL, V137, P881, DOI 10.1093/oxfordjournals.aje.a116749; Hendrie HC, 1996, J AM GERIATR SOC, V44, P1158, DOI 10.1111/j.1532-5415.1996.tb01364.x; HERZOG AR, 1998, NIH PUBLICATION; Jagust W, 2001, LANCET, V358, P2097, DOI 10.1016/S0140-6736(01)07230-0; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; Leibovici D, 1999, INT J EPIDEMIOL, V28, P77, DOI 10.1093/ije/28.1.77; Leon J, 1998, HEALTH AFFAIR, V17, P206, DOI 10.1377/hlthaff.17.6.206; LOOMIS TA, 1958, Q J STUD ALCOHOL, V19, P30; Lopez OL, 2003, NEUROEPIDEMIOLOGY, V22, P1, DOI 10.1159/000067110; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; McDowell I, 2000, NEUROLOGY, V55, P66; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mukamal KJ, 2001, STROKE, V32, P1939, DOI 10.1161/hs0901.095723; NIXON SJ, 1998, NIH PUBLICATION; Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P94; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; SCHERR PA, 1992, J AM GERIATR SOC, V40, P651, DOI 10.1111/j.1532-5415.1992.tb01954.x; Stampfer MJ, 2001, AM J EPIDEMIOL, V153, pS28; Sturmer T, 2001, EPIDEMIOLOGY, V12, P101; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P307, DOI 10.1093/ije/17.2.307; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Yue NC, 1997, RADIOLOGY, V202, P33, DOI 10.1148/radiology.202.1.8988189	57	312	324	1	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	2003	289	11					1405	1413		10.1001/jama.289.11.1405	http://dx.doi.org/10.1001/jama.289.11.1405			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	656PM	12636463	Bronze			2022-12-28	WOS:000181616200032
J	Ezekowitz, JA; Armstrong, PW; McAlister, FA				Ezekowitz, JA; Armstrong, PW; McAlister, FA			Implantable cardioverter defibrillators in primary and secondary prevention: A systematic review of randomized, controlled trials	ANNALS OF INTERNAL MEDICINE			English	Review							SUDDEN CARDIAC DEATH; QUALITY-OF-LIFE; COST-EFFECTIVENESS; MYOCARDIAL-INFARCTION; VENTRICULAR-ARRHYTHMIAS; PROPHYLACTIC USE; HIGH-RISK; THERAPY; AMIODARONE; CIDS	Background: Sudden cardiac death is common in persons with cardiovascular disease. Purpose: To assess the efficacy of implantable cardioverter defibrillators (ICDs) in persons at increased risk for sudden cardiac death. Data Sources: MEDLINE (1980-2002), EMBASE (1980-2002), Cochrane Controlled Clinical Trial Registry (2002, Volume 3), other databases, and conference proceedings. Primary study authors and device manufacturers were contacted, and bibliographies of relevant papers were hand searched. Study Selection: Randomized, controlled clinical trials evaluating ICDs versus usual care were selected. Data Extraction: Two reviewers extracted data independently. Data Synthesis: Eight trials were included in the final analysis (4909 patients, 1154 deaths). Compared with usual care (most commonly amiodarone therapy), ICDs significantly reduced sudden cardiac death (relative risk [RR], 0.43 [95% Cl, 0.35 to 0.53]) and all-cause mortality (RR, 0.74 [Cl, 0.67 to 0.82]). The included trials were divided a priori into two categories: secondary prevention (involving patients resuscitated after cardiac arrest or unstable ventricular tachycardia or ventricular fibrillation [n = 1963]) and primary prevention (involving patients at increased risk for sudden cardiac death but without documented cardiac arrest, ventricular fibrillation, or ventricular tachycardia [n = 2946]). Regardless of baseline risk, ICDs were equally efficacious in preventing sudden cardiac death in both types of trials (RR, 0.50 [Cl, 0.38 to 0.66] for secondary prevention vs. 0.37 [Cl, 0.27 to 0.50] for primary prevention). However, the magnitude of benefit in total mortality varied within the primary prevention trials depending on baseline risk for sudden cardiac death. Conclusions: implantable cardioverter defibrillators prevent sudden cardiac death regardless of baseline risk. However, their impact on total mortality is sensitive to baseline risk for arrhythmic death. Decisions about resource allocation for ICDs depend on accurate stratification of patients according to risk.	Univ Alberta, Edmonton, AB, Canada	University of Alberta	McAlister, FA (corresponding author), Walter Mackenzie Ctr, 2E3-24,8440 112th St, Edmonton, AB T6G 2B7, Canada.	finlay.mcalister@ualberta.ca	McAlister, Finlay/C-4151-2013; Ezekowitz, Justin A/C-4579-2013	McAlister, Finlay/0000-0001-7435-3341; Ezekowitz, Justin A/0000-0002-2724-4086; Armstrong, Paul/0000-0002-0460-3445				AKHTAR M, 1992, CIRCULATION, V85, P1; American Heart Association, 2002, HEART STROK STAT UPD; Bansch D, 2002, CIRCULATION, V105, P1453, DOI 10.1161/01.CIR.0000012350.99718.AD; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; Bigger JT, 2002, NEW ENGL J MED, V346, P931, DOI 10.1056/NEJMe020011; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; Connolly SJ, 2000, EUR HEART J, V21, P2071, DOI 10.1053/euhj.2000.2476; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; Domanski MJ, 1997, CIRCULATION, V95, P2694, DOI 10.1161/01.CIR.95.12.2694; Exner DV, 2002, AM HEART J, V144, P208, DOI 10.1067/mhj.2002.124051; Gregoratos G, 1998, CIRCULATION, V97, P1325, DOI 10.1161/01.CIR.97.13.1325; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; Irvine J, 2002, AM HEART J, V144, P282, DOI 10.1067/mhj.2002.124049; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kadish A, 2002, J AM COLL CARDIOL, V39, P788, DOI 10.1016/S0735-1097(01)01820-4; Kuck KH, 2000, CIRCULATION, V102, P748, DOI 10.1161/01.CIR.102.7.748; KUPPERMANN M, 1990, CIRCULATION, V81, P91, DOI 10.1161/01.CIR.81.1.91; Larsen G, 2002, CIRCULATION, V105, P2049, DOI 10.1161/01.CIR.0000015504.57641.D0; LARSEN GC, 1992, J AM COLL CARDIOL, V19, P1323, DOI 10.1016/0735-1097(92)90341-J; McAlister FA, 2002, INT J EPIDEMIOL, V31, P76, DOI 10.1093/ije/31.1.76; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Mushlin AI, 1998, CIRCULATION, V97, P2129, DOI 10.1161/01.CIR.97.21.2129; Nisam S, 2002, EUR HEART J, V23, P700, DOI 10.1053/euhj.2001.2843; O'Brien BJ, 2001, CIRCULATION, V103, P1416, DOI 10.1161/01.CIR.103.10.1416; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; Parkes J, 2002, HEART, V87, P438, DOI 10.1136/heart.87.5.438; Sanders GD, 2001, ANN INTERN MED, V135, P870, DOI 10.7326/0003-4819-135-10-200111200-00007; Schron EB, 2002, CIRCULATION, V105, P589, DOI 10.1161/hc0502.103330; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sheldon R, 2001, CIRCULATION, V104, P1622, DOI 10.1161/hc3901.096720; STRICKBERGER SA, 2003, IN PRESS J AM COLL C; WEVER EFD, 1995, CIRCULATION, V91, P2195, DOI 10.1161/01.CIR.91.8.2195; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334; Zipes DP, 2001, CIRCULATION, V103, P1372, DOI 10.1161/01.CIR.103.10.1372	38	197	204	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					445	452		10.7326/0003-4819-138-6-200303180-00007	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639076				2022-12-28	WOS:000181562400001
J	Norcini, JJ; Blank, LL; Duffy, FD; Fortna, GS				Norcini, JJ; Blank, LL; Duffy, FD; Fortna, GS			The Mini-CEX: A method for assessing clinical skills	ANNALS OF INTERNAL MEDICINE			English	Article							EVALUATION EXERCISE; RESIDENTS	Objective: To evaluate the mini-clinical evaluation exercise (mini-CEX), which assesses the clinical skills of residents. Design: Observational study and psychometric assessment of the mini-CEX. Setting: 21 internal medicine training programs. Participants: Data from 1228 mini-CEX encounters involving 421 residents and 316 evaluators. Intervention: The encounters were assessed for the type of visit, sex and complexity of the patient, when the encounter occurred, length of the encounter, ratings provided, and the satisfaction of the examiners. Using this information, we determined the overall average ratings for residents in all categories, the reliability of the mini-CEX scores, and the effects of the characteristics of the patients and encounters. Measurements: Interviewing skills, physical examination, professionalism, clinical judgment, counseling, organization and efficiency, and overall competence were evaluated. Results: Residents were assessed in various clinical settings with a diverse set of patient problems. Residents received the lowest ratings in the physical examination and the highest ratings in professionalism. Comparisons over the first year of training showed statistically significant improvement in all aspects of competence, and the method generated reliable ratings. Conclusions: The measurement characteristics of the mini-CEX are similar to those of other performance assessments, such as standardized patients. Unlike these assessments, the difficulty of the examination will vary with the patients that a resident encounters. This effect is mitigated to a degree by the examiners, who slightly overcompensate for patient difficulty, and by the fact that each resident interacts with several patients. Furthermore, the mini-CEX has higher fidelity than these formats, permits evaluation based on a much broader set of clinical settings and patient problems, and is administered on site.	Fdn Advancement Int Med Educ & Res, Philadelphia, PA 19104 USA; Amer Board Internal Med, Philadelphia, PA USA	American Board of Internal Medicine	Norcini, JJ (corresponding author), Fdn Advancement Int Med Educ & Res, 3624 Market St,4th Floor, Philadelphia, PA 19104 USA.	jnorcini@faimer.org		Norcini, John/0000-0002-8464-4115				*AM BOARD INT MED, 1994, GUID EV RES INT MED; BRENNAN RL, 1983, ELEMENTS GENERALIZAB; Crocker L, 1986, INTRO CLASSICAL MODE; Cronbach L.J., 1972, MENTAL TESTS CULTURA; DAY SC, 1990, J GEN INTERN MED, V5, P421, DOI 10.1007/BF02599432; Elstein AS, 1978, MED PROBLEM SOLVING; KROBOTH FJ, 1992, J GEN INTERN MED, V7, P174, DOI 10.1007/BF02598008; MAATSCH JL, 1986, NEWER DEV ASSESSING; NOEL GL, 1992, ANN INTERN MED, V117, P757, DOI 10.7326/0003-4819-117-9-757; NORCINI JJ, 1995, ANN INTERN MED, V123, P795, DOI 10.7326/0003-4819-123-10-199511150-00008; Norcini JJ, 1997, ADV HEALTH SCI EDUC, V2, P27, DOI 10.1023/A:1009734723651; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; WOOLLISCROFT JO, 1984, J MED EDUC, V59, P799	13	413	435	2	40	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 18	2003	138	6					476	481		10.7326/0003-4819-138-6-200303180-00012	http://dx.doi.org/10.7326/0003-4819-138-6-200303180-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655PV	12639081				2022-12-28	WOS:000181562400006
J	DeMarzo, AM; Nelson, WG; Isaacs, WB; Epstein, JI				DeMarzo, AM; Nelson, WG; Isaacs, WB; Epstein, JI			Pathological and molecular aspects of prostate cancer	LANCET			English	Review							SYSTEMATIC SEXTANT BIOPSIES; PROLIFERATIVE INFLAMMATORY ATROPHY; METASTASIS SUPPRESSOR GENE; FATTY-ACID SYNTHASE; HIGH GLEASON SCORE; CELL ANTIGEN PSCA; RADICAL PROSTATECTOMY; NEEDLE-BIOPSY; INTRAEPITHELIAL NEOPLASIA; HIGH-GRADE	This review focuses on new findings and controversial issues in the the pathology and molecular biology of adenocarcinoma of the prostate. Since management of high-grade prostatic intraepithelial neoplasia on needle biopsy-the most common precursor lesion to prostate cancer-is the crucial issue with this lesion, we discuss the risk of cancer subsequent to this histological diagnosis and the issue of whether such neoplasia should be regarded as carcinoma-in-situ. We also look at prostate cancer itself, starting with its diagnosis, reporting on needle biopsy, and reviewing how the most frequently used grading system, the Gleason grading system, affects treatment. The molecular basis of prostate cancer includes inheritable and somatic genetic changes (tumour suppressor genes, loss of heterozygosity, gene targets and regions of chromosomal gain, CpG island promoter methylation, invasion and metastasis suppressor genes, telomere shortening, and genetic instability). Changed gene expression (eg, proliferation-related genes, changes in the androgen receptor, apoptosis and stress-response genes) have potential as biomarkers and therapeutic targets in prostate cancer.	Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Dept Urol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Dept Pathol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Dept Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Dept Med, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Epstein, JI (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Hosp, Dept Urol, Room 2242,401 N Broadway St, Baltimore, MD 21231 USA.	jepstein@jhmi.edu			NATIONAL CANCER INSTITUTE [K08CA078588, R01CA084997, U01CA089600, R01CA070196, P50CA058236] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70196, P50 CA58236, CA89600, CA84997, CA78588] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN DA, 1993, J UROLOGY, V150, P1845, DOI 10.1016/S0022-5347(17)35912-8; Alexander EE, 1996, UROLOGY, V47, P693, DOI 10.1016/S0090-4295(96)00004-0; ALLAN RW, IN PRESS J UROL; Allsbrook WC, 2001, HUM PATHOL, V32, P74, DOI 10.1053/hupa.2001.21134; Allsbrook WC, 2001, HUM PATHOL, V32, P81, DOI 10.1053/hupa.2001.21135; Anderson PR, 1998, INT J RADIAT ONCOL, V41, P1087, DOI 10.1016/S0360-3016(98)00167-9; Badalament RA, 1996, J UROLOGY, V156, P1375, DOI 10.1016/S0022-5347(01)65590-3; Baisden BL, 1999, AM J SURG PATHOL, V23, P918, DOI 10.1097/00000478-199908000-00009; BASTACKY SI, 1993, AM J SURG PATHOL, V17, P336, DOI 10.1097/00000478-199304000-00003; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Bookstein R, 2001, CONT CANC RES, P61; Bostwick DG, 1996, PROSTATE, V29, P117; Bowen C, 2000, CANCER RES, V60, P6111; BRAWER MK, 1985, CANCER RES, V45, P3663; BRAWN PN, 1983, CANCER, V52, P246, DOI 10.1002/1097-0142(19830715)52:2<246::AID-CNCR2820520210>3.0.CO;2-Q; Brinker DA, 1999, J UROLOGY, V162, P2036, DOI 10.1016/S0022-5347(05)68094-9; Bruce RG, 1996, UROLOGY, V48, P75; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Casey G, 2002, NAT GENET, V32, P582, DOI 10.1038/ng1021; Chan TY, 2002, LAB INVEST, V82, p157A; Chandran B, 2000, J ACQ IMMUN DEF SYND, V23, pA35; Chung L. W. K., 2001, PROSTATE CANC BIOL G; Conrad S, 1998, J UROLOGY, V159, P2023, DOI 10.1016/S0022-5347(01)63234-8; Cote RJ, 1998, J NATL CANCER I, V90, P916, DOI 10.1093/jnci/90.12.916; CUMMING JA, 1990, BRIT J UROL, V65, P271, DOI 10.1111/j.1464-410X.1990.tb14725.x; CUPP MR, 1995, J UROLOGY, V153, P1543, DOI 10.1016/S0022-5347(01)67458-5; DAVIDSON D, 1995, J UROLOGY, V154, P1295, DOI 10.1016/S0022-5347(01)66840-X; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; De Marzo AM, 1998, AM J PATHOL, V153, P911, DOI 10.1016/S0002-9440(10)65632-5; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; DIETRICK DD, 1995, UROLOGY, V45, P987, DOI 10.1016/S0090-4295(99)80119-8; DiPaola RS, 2001, HEMATOL ONCOL CLIN N, V15, P509, DOI 10.1016/S0889-8588(05)70229-X; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Epstein JI, 1996, AM J SURG PATHOL, V20, P851, DOI 10.1097/00000478-199607000-00008; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; EPSTEIN JI, 1995, HUM PATHOL, V26, P223, DOI 10.1016/0046-8177(95)90041-1; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Epstein JI, 2001, J UROLOGY, V166, P1688, DOI 10.1016/S0022-5347(05)65654-6; Epstein JI, 2001, UROL CLIN N AM, V28, P567, DOI 10.1016/S0094-0143(05)70164-6; EPSTEIN JI, 2002, INTERPRETATION PROST; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Gao AC, 2002, MOLECULAR BASIS OF HUMAN CANCER, P365; Gao AC, 1997, CANCER RES, V57, P846; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Goldstein NS, 1999, AM J CLIN PATHOL, V112, P69; Green GA, 1998, CANCER-AM CANCER SOC, V83, P971, DOI 10.1002/(SICI)1097-0142(19980901)83:5<971::AID-CNCR24>3.0.CO;2-R; Gronberg H, 2003, LANCET, V361, P859, DOI 10.1016/S0140-6736(03)12713-4; GROSSFELD GD, 2001, PROSTATE CANC, P149; Gu Z, 2000, ONCOGENE, V19, P1288, DOI 10.1038/sj.onc.1203426; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Haggman MJ, 1997, J UROLOGY, V158, P12, DOI 10.1097/00005392-199707000-00004; HAMPER UM, 1991, RADIOLOGY, V180, P101, DOI 10.1148/radiology.180.1.2052673; HEDRICK L, 1989, AM J SURG PATHOL, V13, P389, DOI 10.1097/00000478-198905000-00006; Hsing AW, 2001, EPIDEMIOL REV, V23, P42, DOI 10.1093/oxfordjournals.epirev.a000795; Huland H, 1996, J UROLOGY, V155, P1344, DOI 10.1016/S0022-5347(01)66262-1; HUMPHREY PA, 1995, CANCER, V75, P1842, DOI 10.1002/1097-0142(19950401)75:7+<1842::AID-CNCR2820751614>3.0.CO;2-2; Isaacs WB, 2001, CONT CANC RES, P13; Ishiguro T, 2001, AM J PATHOL, V158, P179, DOI 10.1016/S0002-9440(10)63956-9; Jaeger EB, 2001, CANCER METAST REV, V20, P279, DOI 10.1023/A:1015587411668; Jiang Z, 2001, AM J SURG PATHOL, V25, P1397, DOI 10.1097/00000478-200111000-00007; Kamoi K, 2000, J UROLOGY, V163, P819, DOI 10.1016/S0022-5347(05)67811-1; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kolonel LN, 2001, EPIDEMIOL REV, V23, P72, DOI 10.1093/oxfordjournals.epirev.a000798; Krajewska M, 1996, AM J PATHOL, V148, P1567; Kronz JD, 2000, CANCER, V89, P1818, DOI 10.1002/1097-0142(20001015)89:8<1818::AID-CNCR23>3.3.CO;2-A; Kronz JD, 2001, AM J SURG PATHOL, V25, P1079, DOI 10.1097/00000478-200108000-00014; Langer JE, 1996, J UROLOGY, V155, P228, DOI 10.1016/S0022-5347(01)66601-1; Li LC, 2000, CANCER RES, V60, P702; LOEB LA, 1991, CANCER RES, V51, P3075; Lou W, 1999, CANCER RES, V59, P2329; Luo J, 2002, CANCER RES, V62, P2220; Makridakis NM, 2001, EPIDEMIOL REV, V23, P24, DOI 10.1093/oxfordjournals.epirev.a000791; McMenamin ME, 1999, CANCER RES, V59, P4291; MCNEAL JE, 1991, HUM PATHOL, V22, P644, DOI 10.1016/0046-8177(91)90286-X; MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X; MCNEAL JE, 1969, CANCER, V23, P24, DOI 10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO;2-1; MCNEAL JE, 1986, HUM PATHOL, V17, P64, DOI 10.1016/S0046-8177(86)80156-3; Meeker AK, 2002, CANCER RES, V62, P6405; MENG MV, 2002, PROSTATE CANC, P42; NAGLE RB, 1987, CANCER RES, V47, P281; NAGLE RB, 1995, AM J PATHOL, V146, P1498; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Nelson JB, 1997, CANCER RES, V57, P35; Nelson WG, 2001, ANN NY ACAD SCI, V952, P135, DOI 10.1111/j.1749-6632.2001.tb02734.x; Noguchi M, 2001, J UROLOGY, V166, P104, DOI 10.1016/S0022-5347(05)66086-7; O'Dowd GJ, 2000, UROLOGY, V55, P553, DOI 10.1016/S0090-4295(00)00447-7; OMALLEY FP, 1990, VIRCHOWS ARCH A, V417, P191, DOI 10.1007/BF01600133; PARTIN AW, 1990, J UROLOGY, V143, P747, DOI 10.1016/S0022-5347(17)40079-6; Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445; PELLER PA, 1995, CANCER, V75, P530, DOI 10.1002/1097-0142(19950115)75:2<530::AID-CNCR2820750216>3.0.CO;2-Y; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Platz EA, 2001, EPIDEMIOL REV, V23, P93, DOI 10.1093/oxfordjournals.epirev.a000801; Pollak M, 2001, EPIDEMIOL REV, V23, P59, DOI 10.1093/oxfordjournals.epirev.a000796; Porkka K, 2002, LAB INVEST, V82, P629, DOI 10.1038/labinvest.3780457; Presti JC, 1998, UROLOGY, V52, P1079, DOI 10.1016/S0090-4295(98)00373-2; Ramos CG, 1999, J UROLOGY, V162, P1587, DOI 10.1016/S0022-5347(05)68172-4; RAVERY V, 1994, UROLOGY, V44, P371, DOI 10.1016/S0090-4295(94)80095-2; Rebbeck TR, 2000, AM J HUM GENET, V67, P1014, DOI 10.1086/303096; Reiter RE, 2000, GENE CHROMOSOME CANC, V27, P95, DOI 10.1002/(SICI)1098-2264(200001)27:1<95::AID-GCC12>3.0.CO;2-3; Rennert H, 2002, AM J HUM GENET, V71, P981, DOI 10.1086/342775; Rhodes DR, 2002, CANCER RES, V62, P4427; Roberts RO, 2002, MAYO CLIN PROC, V77, P219, DOI 10.4065/77.3.219; Rokman A, 2002, AM J HUM GENET, V70, P1299, DOI 10.1086/340450; Rokman A, 2001, CANCER RES, V61, P6038; RONNETT BM, 1993, J UROLOGY, V150, P386, DOI 10.1016/S0022-5347(17)35488-5; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Saramaki O, 2001, AM J PATHOL, V159, P2089, DOI 10.1016/S0002-9440(10)63060-X; Sasaki M, 2002, J NATL CANCER I, V94, P384; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Savinainen KJ, 2002, AM J PATHOL, V160, P339, DOI 10.1016/S0002-9440(10)64377-5; Sebo TJ, 2000, J UROLOGY, V163, P174, DOI 10.1016/S0022-5347(05)67998-0; Sebo TJ, 2002, AM J SURG PATHOL, V26, P431, DOI 10.1097/00000478-200204000-00004; SHAH IA, 1991, MODERN PATHOL, V4, P220; Shepherd D, 1996, J UROLOGY, V156, P460, DOI 10.1016/S0022-5347(01)65881-6; SHURBAJI MS, 1992, AM J CLIN PATHOL, V97, P686, DOI 10.1093/ajcp/97.5.686; Smith C J, 1987, Prog Clin Biol Res, V239, P317; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Sommerfeld HJ, 1996, CANCER RES, V56, P218; Steinberg DM, 1997, AM J SURG PATHOL, V21, P566, DOI 10.1097/00000478-199705000-00010; Suarez BK, 2001, CANCER RES, V61, P4982; Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; TERRIS MK, 1995, UROLOGY, V45, P75, DOI 10.1016/S0090-4295(95)96858-X; Tigrani VS, 1999, UROLOGY, V54, P689, DOI 10.1016/S0090-4295(99)00211-3; UMBAS R, 1994, CANCER RES, V54, P3929; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visakorpi T, 2001, CONT CANC RES, P29; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang L, 2002, AM J HUM GENET, V71, P116, DOI 10.1086/341281; Wang L, 2001, CANCER RES, V61, P6494; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang XD, 1997, J UROLOGY, V158, P1431, DOI 10.1016/S0022-5347(01)64233-2; Waskewich C, 2002, CANCER RES, V62, P2029; WELDON VE, 1995, J UROLOGY, V154, P1074, DOI 10.1016/S0022-5347(01)66980-5; Wills ML, 1998, UROLOGY, V51, P759, DOI 10.1016/S0090-4295(98)00011-9; Wills ML, 1997, UROLOGY, V49, P367, DOI 10.1016/S0090-4295(96)00622-X; WOJNO KJ, 1995, AM J SURG PATHOL, V19, P251, DOI 10.1097/00000478-199503000-00002; Xu JF, 2002, NAT GENET, V32, P321, DOI 10.1038/ng994; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zha S, 2001, CANCER RES, V61, P8617	142	333	354	2	44	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	2003	361	9361					955	964		10.1016/S0140-6736(03)12779-1	http://dx.doi.org/10.1016/S0140-6736(03)12779-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648986				2022-12-28	WOS:000181741600024
J	Merz, B				Merz, B			Behind the research: Studying peanut anaphylaxis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	3	3	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 13	2003	348	11					975	976		10.1056/NEJMp030008	http://dx.doi.org/10.1056/NEJMp030008			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653YT	12637606				2022-12-28	WOS:000181465200001
J	Wald, NJ; Huttly, WJ; Hackshaw, AK				Wald, NJ; Huttly, WJ; Hackshaw, AK			Antenatal screening for Down's syndrome with the quadruple test	LANCET			English	Article								Second trimester screening for Down's syndrome is widely practised throughout the world. We assessed the performance of antenatal serum screening for Down's syndrome with the quadruple test In 46 193 pregnancies from 14 hospitals over 5 years. Women who screened positive (risk greater than or equal to1 in 300) were offered diagnostic amniocentesis or chorionic villus sampling. Of 88 observed Down's syndrome pregnancies, 71 (81%) had a positive screening result (81% detection rate, 95% CI 72-89), and of 46 105 unaffected pregnancies, 3200 tested positive (7% false-positive rate). These results show that the quadruple test is a better method of screening for Down's syndrome than use of maternal age alone (51% detection rate, 14% false-positive rate) and is more effective than other second trimester screening tests. Therefore, we conclude that the quadruple test should be the test of choice in second trimester screening for Down's syndrome.	Barts & London Queen Mary Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Wald, NJ (corresponding author), Barts & London Queen Mary Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					Morris JK, 1999, PRENATAL DIAG, V19, P142, DOI 10.1002/(SICI)1097-0223(199902)19:2<142::AID-PD486>3.3.CO;2-Z; Wald N J, 1997, J Med Screen, V4, P181; Wald NJ, 1996, PRENATAL DIAG, V16, P143, DOI 10.1002/(SICI)1097-0223(199602)16:2<143::AID-PD825>3.0.CO;2-F; Wald NJ, 1997, PRENATAL DIAG, V17, P285, DOI 10.1002/(SICI)1097-0223(199703)17:3<285::AID-PD71>3.0.CO;2-A; Wellesley D, 2002, BRIT MED J, V325, P15, DOI 10.1136/bmj.325.7354.15	5	91	99	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					835	836		10.1016/S0140-6736(03)12680-3	http://dx.doi.org/10.1016/S0140-6736(03)12680-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642052				2022-12-28	WOS:000181466600014
J	Goldfield, N; Gnani, S; Majeed, A				Goldfield, N; Gnani, S; Majeed, A			Primary care in the United States - Profiling performance in primary care in the United States	BRITISH MEDICAL JOURNAL			English	Article							MEASURING QUALITY; GENERAL-PRACTICE; PUBLIC RELEASE; INFORMATION; INDICATORS; PHYSICIANS; BIAS		UCL, Primary Care Res Unit, Sch Publ Policy, London WC1H 9QU, England; 3M Hlth Informat Syst, Wallingford, CT 06492 USA	University of London; University College London; 3M	Majeed, A (corresponding author), UCL, Primary Care Res Unit, Sch Publ Policy, London WC1H 9QU, England.	a.majeed@ucl.ac.uk		Majeed, Azeem/0000-0002-2357-9858				Bindman AB, 1999, JAMA-J AM MED ASSOC, V281, P2142, DOI 10.1001/jama.281.22.2142; Carroll K, 2003, J PUBLIC HEALTH MED, V25, P29, DOI 10.1093/pubmed/fdg007; Davies HTO, 2002, J HEALTH POLIT POLIC, V27, P379, DOI 10.1215/03616878-27-3-379; Eisenberg JM, 2002, ANN INTERN MED, V136, P153, DOI 10.7326/0003-4819-136-2-200201150-00013; Giuffrida A, 1999, BRIT MED J, V319, P94, DOI 10.1136/bmj.319.7202.94; GOLDFIELD N, 1999, PHYSICIAN PROFILING, P67; GOLDFIELD N, 1999, JOINT COMM J QUAL IM, V25, P422; Goldstein E, 2001, HEALTH SERV RES, V36, P477; Greenfield S, 2002, ANN INTERN MED, V136, P111, DOI 10.7326/0003-4819-136-2-200201150-00008; Hannan EL, 1997, MED CARE, V35, P49, DOI 10.1097/00005650-199701000-00004; Hibbard JH, 2002, MED CARE RES REV, V59, P104, DOI 10.1177/1077558702059001006; Kluge EHW, 2000, J EVAL CLIN PRACT, V6, P235; MAJEED FA, 1995, BRIT MED J, V311, P209, DOI 10.1136/bmj.311.6999.209; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Marshall MN, 2002, BRIT MED J, V325, P1278, DOI 10.1136/bmj.325.7375.1278; *MASS MED SOC, 1999, PRINC PROF PHYS PER; Naylor CD, 2002, JAMA-J AM MED ASSOC, V287, P1323, DOI 10.1001/jama.287.10.1323; Schneiter E J, 1998, Jt Comm J Qual Improv, V24, P579; Shekelle PG, 1998, LANCET, V352, P163, DOI 10.1016/S0140-6736(05)77801-6; Spranca M, 2000, HEALTH SERV RES, V35, P933; Weiner Jonathan, 2002, J Health Serv Res Policy, V7, P43, DOI 10.1258/1355819021927665	21	16	18	2	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 5	2003	326	7392					744	747		10.1136/bmj.326.7392.744	http://dx.doi.org/10.1136/bmj.326.7392.744			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665LF	12676844	Bronze, Green Published			2022-12-28	WOS:000182121600016
J	Tu, YZ; Wu, S; Shi, XH; Chen, K; Wu, CY				Tu, YZ; Wu, S; Shi, XH; Chen, K; Wu, CY			Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation	CELL			English	Article							ONLY PROTEIN PINCH; CAENORHABDITIS-ELEGANS; INTEGRIN ADHESION; BINDING PROTEIN; TRANSMEMBRANE LINKAGE; EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; TARGETS FILAMIN; PLASMA-MEMBRANE; ADAPTER PROTEIN	Cell-extracellular matrix adhesion is an important determinant of cell morphology. We show here that migfilin, a LIM-containing protein, localizes to cell-matrix adhesions, associates with actin filaments, and is essential for cell shape modulation. Migfilin interacts with the cell-matrix adhesion protein Mig-2 (mitogen inducible gene-2), a mammalian homolog of UNC-112, and the actin binding protein filamin through its C- and N-terminal domains, respectively. Loss of Mig-2 or migfilin impairs cell shape modulation. Mig-2 recruits migfilin to cell-matrix adhesions, while the interaction with filamin mediates the association of migfilin with actin filaments. Migfilin therefore functions as an important scaffold at cell-matrix adhesions. Together, Mig-2, migfilin and filamin define a connection between cell matrix adhesions and the actin cytoskeleton and participate in the orchestration of actin assembly and cell shape modulation.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA.				NIDDK NIH HHS [DK54639] Funding Source: Medline; NIGMS NIH HHS [GM65188] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Brown NH, 2000, MATRIX BIOL, V19, P191, DOI 10.1016/S0945-053X(00)00064-0; Brown NH, 2000, DEV BIOL, V223, P1, DOI 10.1006/dbio.2000.9711; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Calderwood DA, 2001, NAT CELL BIOL, V3, P1060, DOI 10.1038/ncb1201-1060; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hudson DF, 2002, TRENDS CELL BIOL, V12, P281, DOI 10.1016/S0962-8924(02)02281-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; Li FG, 1999, J CELL SCI, V112, P4589; Liu SC, 2000, J CELL SCI, V113, P3563; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Nakamura F, 2002, J BIOL CHEM, V277, P9148, DOI 10.1074/jbc.M111297200; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Olski TM, 2001, J CELL SCI, V114, P525; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Rogalski TM, 2000, J CELL BIOL, V150, P253, DOI 10.1083/jcb.150.1.253; SHARMA CP, 1995, J IMMUNOL, V154, P3461; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; van der Flier A, 2002, J CELL BIOL, V156, P361, DOI 10.1083/jcb.200103037; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; WICK M, 1994, J CELL SCI, V107, P227; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zamir E, 2001, J CELL SCI, V114, P3583; Zervas CG, 2002, CURR BIOL, V12, pR350, DOI 10.1016/S0960-9822(02)00856-4; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	50	295	311	0	26	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 4	2003	113	1					37	47		10.1016/S0092-8674(03)00163-6	http://dx.doi.org/10.1016/S0092-8674(03)00163-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	668GX	12679033	Bronze			2022-12-28	WOS:000182282900005
J	Abbott, A				Abbott, A			Axeing of website article sparks row at Max Planck	NATURE			English	News Item																		Gura T, 2002, NATURE, V416, P250, DOI 10.1038/416250a	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2003	422	6931					460	460		10.1038/422460b	http://dx.doi.org/10.1038/422460b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673216	Bronze			2022-12-28	WOS:000181965400007
J	Gregg, MC; Sanford, TB; Winkel, DP				Gregg, MC; Sanford, TB; Winkel, DP			Reduced mixing from the breaking of internal waves in equatorial waters	NATURE			English	Article							TURBULENT DISSIPATION; ABYSSAL OCEAN; THERMOCLINE; SHEAR; ENERGY; SCALE	In the oceans, heat, salt and nutrients are redistributed much more easily within water masses of uniform density than across surfaces separating waters of different densities. But the magnitude and distribution of mixing across density surfaces are also important for the Earth's climate as well as the concentrations of organisms(1). Most of this mixing occurs where internal waves break, overturning the density stratification of the ocean and creating patches of turbulence. Predictions of the rate at which internal waves dissipate(2,3) were confirmed earlier at midlatitudes(4,5). Here we present observations of temperature and velocity fluctuations in the Pacific and Atlantic oceans between 42degreesN and 2degreesS to extend that result to equatorial regions. We find a strong latitude dependence of dissipation in accordance with the predictions(3). In our observations, dissipation rates and accompanying mixing across density surfaces near the Equator are less than 10% of those at mid-latitudes for a similar background of internal waves. Reduced mixing close to the Equator will have to be taken into account in numerical simulations of ocean dynamics-for example, in climate change experiments.	Univ Washington, Coll Ocean & Fishery Sci, Appl Phys Lab, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle	Gregg, MC (corresponding author), Univ Washington, Coll Ocean & Fishery Sci, Appl Phys Lab, Seattle, WA 98105 USA.	gregg@apl.washington.edu						DAVIS RE, 1994, J PHYS OCEANOGR, V24, P2560, DOI 10.1175/1520-0485(1994)024<2560:DMITOT>2.0.CO;2; GARRETT C, 1975, J GEOPHYS RES, V80, P291, DOI 10.1029/JC080i003p00291; GREGG MC, 1988, J GEOPHYS RES-OCEANS, V93, P12381, DOI 10.1029/JC093iC10p12381; GREGG MC, 1977, J PHYS OCEANOGR, V7, P436, DOI 10.1175/1520-0485(1977)007<0436:VITIOS>2.0.CO;2; GREGG MC, 1987, DEEP-SEA RES, V34, P1689, DOI 10.1016/0198-0149(87)90017-3; GREGG MC, 1989, J GEOPHYS RES-OCEANS, V94, P9686, DOI 10.1029/JC094iC07p09686; Gregg MC, 1996, DYNAM ATMOS OCEANS, V24, P1, DOI 10.1016/0377-0265(95)00406-8; HENYEY FS, 1986, J GEOPHYS RES-OCEANS, V91, P8487, DOI 10.1029/JC091iC07p08487; HENYEY HF, 1991, DYNAMICS INTERNAL GR, P233; Ledwell JR, 2000, NATURE, V403, P179, DOI 10.1038/35003164; LEDWELL JR, 1993, NATURE, V364, P701, DOI 10.1038/364701a0; MCCOMAS CH, 1981, J PHYS OCEANOGR, V11, P970, DOI 10.1175/1520-0485(1981)011<0970:TDBOIW>2.0.CO;2; Munk W.H., 1981, EVOLUTION PHYS OCEAN, P264, DOI DOI 10.1121/1.3425741; Nagasawa M, 2000, J GEOPHYS RES-OCEANS, V105, P13933, DOI 10.1029/2000JC900019; *NAT SCI FDN, 2001, OC SCI NEW MILL; OSBORN TR, 1980, J PHYS OCEANOGR, V10, P83, DOI 10.1175/1520-0485(1980)010<0083:EOTLRO>2.0.CO;2; PETERS H, 1991, J GEOPHYS RES-OCEANS, V96, P16913, DOI 10.1029/91JC01317; POLZIN KL, 1995, J PHYS OCEANOGR, V25, P306, DOI 10.1175/1520-0485(1995)025<0306:FPOTD>2.0.CO;2; SCHMITT RW, 1987, DEEP-SEA RES, V34, P1655, DOI 10.1016/0198-0149(87)90014-8; Sun HL, 1999, J PHYS OCEANOGR, V29, P2905, DOI 10.1175/1520-0485(1999)029<2905:IWWIPI>2.0.CO;2; TOOLE JM, 1994, SCIENCE, V264, P1120, DOI 10.1126/science.264.5162.1120; Winkel DP, 2002, J PHYS OCEANOGR, V32, P3269, DOI 10.1175/1520-0485(2002)032<3269:POSATA>2.0.CO;2; Winkel DP, 1996, J ATMOS OCEAN TECH, V13, P1046, DOI 10.1175/1520-0426(1996)013<1046:ROSAVW>2.0.CO;2	24	272	286	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 3	2003	422	6931					513	515		10.1038/nature01507	http://dx.doi.org/10.1038/nature01507			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662TW	12673248				2022-12-28	WOS:000181965400035
J	Lahiri, SD; Zhang, GF; Dunaway-Mariano, D; Allen, KN				Lahiri, SD; Zhang, GF; Dunaway-Mariano, D; Allen, KN			The pentacovalent phosphorus intermediate of a phosphoryl transfer reaction	SCIENCE			English	Article							CRYSTAL-STRUCTURE; ENZYME; PHOSPHOGLUCOMUTASE; MECHANISM; PHOSPHATE; COVALENT; STATE; CATALYSIS; PATHWAY; LACTIS	Enzymes provide enormous rate enhancements, unmatched by any other type of catalyst. The stabilization of high-energy states along the reaction coordinate is the crux of the catalytic power of enzymes. We report the atomic-resolution structure of a high-energy reaction intermediate stabilized in the active site of an enzyme. Crystallization of phosphorylated beta-phosphoglucomutase in the presence of the Mg(II) cofactor and either of the substrates glucose 1-phosphate or glucose 6-phosphate produced crystals of the enzyme-Mg(II)-glucose 1,6(bis)phosphate complex, which diffracted x-rays to 1.2 and 1.4 angstroms, respectively. The structure reveals a stabilized pentacovatent phosphorane formed in the phosphoryl transfer from the C(1)O of glucose 1,6-(bis)phosphate to the nucleophilic Asp8 carboxylate.	Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	University of New Mexico; Boston University	Dunaway-Mariano, D (corresponding author), Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA.	dd39@unm.edu; allen@med-xtal.bu.edu	Allen, Karen N./J-7045-2019	Allen, Karen N./0000-0001-7296-0551	NCRR NIH HHS [RR07707] Funding Source: Medline; NIGMS NIH HHS [GM16099] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard J, 2001, P NATL ACAD SCI USA, V98, P3679, DOI 10.1073/pnas.071380898; Allison RD, 2002, METHOD ENZYMOL, V354, P455; Brubaker MJ, 1996, BIOCHEMISTRY-US, V35, P2854, DOI 10.1021/bi951105v; Bruice TC, 2002, ACCOUNTS CHEM RES, V35, P139, DOI 10.1021/ar0001665; Bruice TC, 1999, ACCOUNTS CHEM RES, V32, P127, DOI 10.1021/ar960131y; Bruice TC, 2000, BIOCHEMISTRY-US, V39, P6267, DOI 10.1021/bi0003689; CLELAND WW, 1995, METHOD ENZYMOL, V249, P341; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; Corbridge D. E. C., 1974, STRUCTURAL CHEM PHOS; DAI JB, 1992, J BIOL CHEM, V267, P6322; Dunaway-Mariano D, 1999, METHOD ENZYMOL, V308, P149; Gross JW, 2002, METHOD ENZYMOL, V354, P27; Hanes RE, 2002, ORG LETT, V4, P201, DOI 10.1021/ol016941d; Heine A, 2001, SCIENCE, V294, P369, DOI 10.1126/science.1063601; Hu QY, 2002, J AM CHEM SOC, V124, P14858, DOI 10.1021/ja027976r; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; Kack H, 1998, P NATL ACAD SCI USA, V95, P5495, DOI 10.1073/pnas.95.10.5495; KEMP G, 1976, TETRAHEDRON LETT, P4381; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; Li YF, 1998, J BIOL CHEM, V273, P15035, DOI 10.1074/jbc.273.24.15035; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Muller S, 2002, J MOL BIOL, V315, P141, DOI 10.1006/jmbi.2001.5168; Naught LE, 2001, ARCH BIOCHEM BIOPHYS, V396, P111, DOI 10.1006/abbi.2001.2618; Pauling L, 1960, NATURE CHEM BOND, V3rd, P255; Petsko GA, 2000, CURR OPIN CHEM BIOL, V4, P89, DOI 10.1016/S1367-5931(99)00057-5; Qian N, 1997, MICROBIOL-SGM, V143, P855, DOI 10.1099/00221287-143-3-855; QIAN N, 1994, J BACTERIOL, V176, P5304, DOI 10.1128/JB.176.17.5304-5311.1994; Rajagopalan PTR, 2002, CHEM REC, V2, P24, DOI 10.1002/tcr.10009; RAMIREZ F, 1979, J AM CHEM SOC, V101, P1460, DOI 10.1021/ja00500a016; Regni C, 2002, STRUCTURE, V10, P269, DOI 10.1016/S0969-2126(02)00705-0; Ridder IS, 1999, J BIOL CHEM, V274, P30672, DOI 10.1074/jbc.274.43.30672; RUDNICK G, 1975, BIOCHEMISTRY-US, V14, P4515, DOI 10.1021/bi00691a028; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schramm VL, 2001, CURR OPIN STRUC BIOL, V11, P657, DOI 10.1016/S0959-440X(01)00269-X; Schramm VL, 2001, CURR OPIN CHEM BIOL, V5, P556, DOI 10.1016/S1367-5931(00)00246-5; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035; WESTHEIMER FH, 1968, ACCOUNTS CHEM RES, V1, P70, DOI 10.1021/ar50003a002; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; [No title captured]	44	290	295	0	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 28	2003	299	5615					2067	2071		10.1126/science.1082710	http://dx.doi.org/10.1126/science.1082710			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	660LG	12637673				2022-12-28	WOS:000181834200055
J	Stanley, SL				Stanley, SL			Amoebiasis	LANCET			English	Review							AMEBIC LIVER-ABSCESS; NONPATHOGENIC ENTAMOEBA-HISTOLYTICA; COMBINED IMMUNODEFICIENT MICE; ANTIGEN-CAPTURE ELISA; RIBOSOMAL-RNA GENES; HAMSTER OVARY CELLS; CYSTEINE PROTEINASES; INVASIVE AMEBIASIS; HEPATIC AMEBIASIS; ADHERENCE LECTIN	Amoebiasis is the second leading cause of death from parasitic disease worldwide. The causative protozoan parasite, Entamoeba histolytica, is a potent pathogen. Secreting proteinases that dissolve host tissues, killing host cells on contact, and engulfing red blood cells, E histolytica trophozoltes invade the intestinal mucosa, causing amoebic colitis. In some cases amoebas breach the mucosal barrier and travel through the portal circulation to the liver, where they cause abscesses consisting of a few E histolytica trophozoltes surrounding dead and dying hepatocytes and liquefied cellular debris. Amoebic liver abscesses grow inexorably and, at one time, were almost always fatal, but now even large abscesses can be cured by one dose of antibiotic. Evidence that what we thought was a single species based on morphology is, in fact, two genetically distinct species-now termed Entamoeba histolytica (the pathogen) and Entamoeba dispar (a commensal)-has turned conventional wisdom about the epidemiology and diagnosis of amoebiasis upside down. New models of disease have linked E histolytica induction of intestinal inflammation and hepatocyte programmed cell death to the pathogenesis of amoebic colitis and amoebic liver abscess.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Stanley, SL (corresponding author), Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	sstanley@im.wustl.edu			NIAID NIH HHS [AI51591, AI30084] Funding Source: Medline; NIDDK NIH HHS [DK52574] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abd-Alla MD, 2002, TROP MED INT HEALTH, V7, P365, DOI 10.1046/j.1365-3156.2002.00862.x; Abd-Alla MD, 2000, AM J TROP MED HYG, V62, P579, DOI 10.4269/ajtmh.2000.62.579; ABIOYE AA, 1973, J TROP MED HYG, V76, P97; ABUABARA SF, 1982, ARCH SURG-CHICAGO, V117, P239; Acuna-Soto R, 2000, AM J GASTROENTEROL, V95, P1277, DOI 10.1111/j.1572-0241.2000.01525.x; ADAMS EB, 1977, MEDICINE, V56, P315, DOI 10.1097/00005792-197707000-00003; ADAMS EB, 1977, MEDICINE, V56, P325, DOI 10.1097/00005792-197707000-00004; ADEYEMO AO, 1984, J ROY SOC MED, V77, P17; Akgun Y, 1999, WORLD J SURG, V23, P102, DOI 10.1007/s002689900573; ALLAN RJ, 1992, RADIOLOGY, V183, P827; ALLASONJONES E, 1986, NEW ENGL J MED, V315, P353, DOI 10.1056/NEJM198608073150603; Ankri S, 1999, INFECT IMMUN, V67, P421, DOI 10.1128/IAI.67.1.421-422.1999; Arellano J, 1996, PARASITE IMMUNOL, V18, P491, DOI 10.1046/j.1365-3024.1996.d01-16.x; ARELLANO J, 1992, ARCHIVES OF MEDICAL RESEARCH, VOL 23, NO 2, P269; ARISTIZABAL H, 1991, WORLD J SURG, V15, P216, DOI 10.1007/BF01659055; Ayeh-Kumi PF, 2001, EXP PARASITOL, V99, P80, DOI 10.1006/expr.2001.4652; BANK S, 1971, South African Medical Journal, V45, P219; BARNES PF, 1987, MEDICINE, V66, P472, DOI 10.1097/00005792-198711000-00005; Berninghausen O, 1997, INFECT IMMUN, V65, P3615, DOI 10.1128/IAI.65.9.3615-3621.1997; BHATTACHARYA A, 1992, MOL BIOCHEM PARASIT, V56, P161, DOI 10.1016/0166-6851(92)90163-E; Blessmann J, 2002, AM J TROP MED HYG, V66, P578, DOI 10.4269/ajtmh.2002.66.578; BLUMENCRANZ H, 1983, AM J GASTROENTEROL, V78, P15; Boonyapisit Sasiprapa, 1993, Journal of the Medical Association of Thailand, V76, P243; Braga LL, 1998, J CLIN MICROBIOL, V36, P3044, DOI 10.1128/JCM.36.10.3044-3045.1998; BRAGA LL, 1992, J CLIN INVEST, V90, P1131, DOI 10.1172/JCI115931; Bruchhaus I, 1996, MOL MICROBIOL, V22, P255, DOI 10.1046/j.1365-2958.1996.00111.x; BRUMPT ME, 1925, B ACAD MED PARIS, V94, P943; Bundesen HN, 1934, J AMER MED ASSOC, V102, P367, DOI 10.1001/jama.1934.62750050001011; BURCH DJ, 1991, J CLIN MICROBIOL, V29, P696, DOI 10.1128/JCM.29.4.696-701.1991; BURCHARD GD, 1993, PARASITOL RES, V79, P140, DOI 10.1007/BF00932260; CABALLEROSALCEDO A, 1994, AM J TROP MED HYG, V50, P412, DOI 10.4269/ajtmh.1994.50.412; CAMPBELL S, 1993, SEMIN NEUROL, V13, P153, DOI 10.1055/s-2008-1041120; CARDOSO JM, 1977, AM J ROENTGENOL, V128, P935, DOI 10.2214/ajr.128.6.935; CLARK CG, 1993, EXP PARASITOL, V77, P450, DOI 10.1006/expr.1993.1105; CLARK CG, 1995, P NATL ACAD SCI USA, V92, P6518, DOI 10.1073/pnas.92.14.6518; CLARK CG, 1991, MOL BIOCHEM PARASIT, V49, P297, DOI 10.1016/0166-6851(91)90073-F; COAR T, 1982, APHORISMS HIPPOCRATE; DEBAKEY ME, 1951, INT ABSTR SURG, V92, P209; DENIS M, 1989, INFECT IMMUN, V57, P1750, DOI 10.1128/IAI.57.6.1750-1756.1989; EGGLESTON FC, 1982, SURGERY, V91, P46; Eichinger D, 2001, J EUKARYOT MICROBIOL, V48, P17, DOI 10.1111/j.1550-7408.2001.tb00411.x; ELHENNAWY M, 1978, J TROP MED HYG, V81, P71; ELLYSON JH, 1986, AM J SURG, V152, P21, DOI 10.1016/0002-9610(86)90131-5; Elsdon-Dew R., 1968, Advances in Parasitology, V6, P1, DOI 10.1016/S0065-308X(08)60471-6; Evangelopoulos A, 2001, PARASITOL INT, V50, P185, DOI 10.1016/S1383-5769(01)00078-2; GATHIRAM V, 1987, S AFR MED J, V72, P669; GATTI S, 1995, T ROY SOC TROP MED H, V89, P403, DOI 10.1016/0035-9203(95)90029-2; GONZALEZRUIZ A, 1994, J CLIN PATHOL, V47, P236, DOI 10.1136/jcp.47.3.236; Haghighi A, 2002, J CLIN MICROBIOL, V40, P4081, DOI 10.1128/JCM.40.11.4081-4090.2002; Haque R, 2000, J CLIN MICROBIOL, V38, P3235, DOI 10.1128/JCM.38.9.3235-3239.2000; Haque R, 1999, AM J TROP MED HYG, V60, P1031, DOI 10.4269/ajtmh.1999.60.1031; Haque R, 2001, J INFECT DIS, V183, P1787, DOI 10.1086/320740; Haque R, 1997, J INFECT DIS, V175, P734, DOI 10.1093/infdis/175.3.734; HARRIS HF, 1898, AM J MED SCI, V115, P384; HEALY GR, 1971, B NEW YORK ACAD MED, V47, P478; HEINZ KPW, 1973, S AFR MED J, V47, P1795; Hellberg A, 2001, CELL MICROBIOL, V3, P13, DOI 10.1046/j.1462-5822.2001.00086.x; Hoffner RJ, 1999, ANN EMERG MED, V34, P351, DOI 10.1016/S0196-0644(99)70130-7; Huston CD, 2000, CELL MICROBIOL, V2, P617, DOI 10.1046/j.1462-5822.2000.00085.x; IBARRAPEREZ C, 1981, CHEST, V79, P672, DOI 10.1378/chest.79.6.672; ISTRE GR, 1982, NEW ENGL J MED, V307, P339, DOI 10.1056/NEJM198208053070603; JAMMAL MA, 1985, J PEDIATR GASTR NUTR, V4, P294, DOI 10.1097/00005176-198504000-00024; JARUMILINTA R, 1964, ANN TROP MED PARASIT, V58, P375, DOI 10.1080/00034983.1964.11686259; Jelinek T, 1996, EUR J CLIN MICROBIOL, V15, P752, DOI 10.1007/BF01691966; KANANI SR, 1969, BMJ-BRIT MED J, V2, P613, DOI 10.1136/bmj.2.5657.613; KATZENSTEIN D, 1982, MEDICINE, V61, P237, DOI 10.1097/00005792-198207000-00003; KELSALL BL, 1993, J INFECT DIS, V168, P1319, DOI 10.1093/infdis/168.5.1319; Kimura K, 1997, SEMIN ROENTGENOL, V32, P250, DOI 10.1016/S0037-198X(97)80021-1; Kirsh D, 1943, AM J MED SCI, V206, P372, DOI 10.1097/00000441-194320630-00014; KNOBLOCH J, 1983, AM J TROP MED HYG, V32, P727, DOI 10.4269/ajtmh.1983.32.727; KROGSTAD DJ, 1978, NEW ENGL J MED, V298, P262, DOI 10.1056/NEJM197802022980507; KRUPP IM, 1970, AM J TROP MED HYG, V19, P57, DOI 10.4269/ajtmh.1970.19.57; KUBITSCHEK KR, 1985, WESTERN J MED, V142, P203; LASSERRE R, 1983, AM J TROP MED HYG, V32, P723, DOI 10.4269/ajtmh.1983.32.723; Leippe M, 1997, PARASITOL TODAY, V13, P178, DOI 10.1016/S0169-4758(97)01038-7; Leippe M, 1995, PARASITOLOGY, V111, P569, DOI 10.1017/S0031182000077040; Leroy A, 2000, FASEB J, V14, P1139, DOI 10.1096/fasebj.14.9.1139; LEWIS EA, 1969, T ROY SOC TROP MED H, V63, P633, DOI 10.1016/0035-9203(69)90183-7; LI E, 1988, J EXP MED, V167, P1725, DOI 10.1084/jem.167.5.1725; LI E, 1994, INFECT IMMUN, V62, P5112, DOI 10.1128/IAI.62.11.5112-5119.1994; LI E, 1989, INFECT IMMUN, V57, P8, DOI 10.1128/IAI.57.1.8-12.1989; Losch F., 1875, Arch Pathol Anat, V65, P196, DOI 10.1007/BF02028799; Lowther SA, 2000, CLIN INFECT DIS, V30, P955, DOI 10.1086/313811; Mann BJ, 2002, INT REV CYTOL, V216, P59; Marinets A, 1997, J EXP MED, V186, P1557, DOI 10.1084/jem.186.9.1557; MARKELL EK, 1984, AM J TROP MED HYG, V33, P239, DOI 10.4269/ajtmh.1984.33.239; MENG XY, 1994, SOUTHERN MED J, V87, P985, DOI 10.1097/00007611-199410000-00004; MERRITT RJ, 1982, AM J DIS CHILD, V136, P785, DOI 10.1001/archpedi.1982.03970450027007; Meza I, 2000, PARASITOL TODAY, V16, P23, DOI 10.1016/S0169-4758(99)01586-0; Mirelman D, 1997, J CLIN MICROBIOL, V35, P2405, DOI 10.1128/JCM.35.9.2405-2407.1997; MONGA NK, 1976, AM J GASTROENTEROL, V66, P366; Moody-Haupt S, 2000, J MOL BIOL, V297, P409, DOI 10.1006/jmbi.2000.3577; NWAFO DC, 1981, ANN ROY COLL SURG, V63, P126; OLEARY RK, 1984, S AFR MED J, V65, P113; ORBISON JA, 1951, MEDICINE, V30, P247; *PAN AM HLTH ORG, 1998, HLTH AM, P357; PEHRSON PO, 1984, SCAND J INFECT DIS, V16, P195, DOI 10.3109/00365548409087141; PHAM VL, 1996, ANN CHIR, V50, P340; Pillai DR, 1999, CLIN INFECT DIS, V29, P1315, DOI 10.1086/313433; POWELL SJ, 1969, ANN TROP MED PARASIT, V63, P139, DOI 10.1080/00034983.1969.11686609; PRATHAP K, 1970, AM J PATHOL, V60, P229; Que XC, 2000, CLIN MICROBIOL REV, V13, P196, DOI 10.1128/CMR.13.2.196-206.2000; RADIN DR, 1988, AM J ROENTGENOL, V150, P1297, DOI 10.2214/ajr.150.6.1297; RAGLAND BD, 1994, EXP PARASITOL, V79, P460, DOI 10.1006/expr.1994.1107; RALLS PW, 1982, RADIOLOGY, V145, P123, DOI 10.1148/radiology.145.1.7122867; RAVDIN JI, 1980, J EXP MED, V152, P377, DOI 10.1084/jem.152.2.377; RAVDIN JI, 1989, INFECT IMMUN, V57, P2179, DOI 10.1128/IAI.57.7.2179-2186.1989; Reed S. L., 1988, Amebiasis: human infection by Entamoeba histolytica., P511; REED SL, 1989, J IMMUNOL, V143, P189; REED SL, 1991, AM J MED, V90, P269, DOI 10.1016/0002-9343(91)80173-J; REEVES RE, 1984, ADV PARASIT, V23, P105, DOI 10.1016/S0065-308X(08)60286-9; Rivera WL, 1998, AM J TROP MED HYG, V59, P916, DOI 10.4269/ajtmh.1998.59.916; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; SARGEAUNT PG, 1978, T ROY SOC TROP MED H, V72, P519, DOI 10.1016/0035-9203(78)90174-8; SCHMERIN MJ, 1977, JAMA-J AM MED ASSOC, V238, P1386, DOI 10.1001/jama.238.13.1386; Seydel KB, 1998, GASTROENTEROLOGY, V115, P1446, DOI 10.1016/S0016-5085(98)70023-X; Seydel KB, 1998, INFECT IMMUN, V66, P2980, DOI 10.1128/IAI.66.6.2980-2983.1998; Seydel KB, 1997, INFECT IMMUN, V65, P3951, DOI 10.1128/IAI.65.9.3951-3953.1997; Seydel KB, 1997, INFECT IMMUN, V65, P1631, DOI 10.1128/IAI.65.5.1631-1639.1997; Seydel KB, 2000, INFECT IMMUN, V68, P400, DOI 10.1128/IAI.68.1.400-402.2000; Shandera WX, 1998, SOUTH MED J, V91, P829, DOI 10.1097/00007611-199809000-00005; SPEELMAN P, 1984, J INFECT DIS, V150, P899, DOI 10.1093/infdis/150.6.899; STANLEY SL, 1992, MOL BIOCHEM PARASIT, V50, P127, DOI 10.1016/0166-6851(92)90250-N; STANLEY SL, 1995, INFECT IMMUN, V63, P1587, DOI 10.1128/IAI.63.4.1587-1590.1995; STANLEY SL, 2000, AMEBIASIS, P137; Stenson WF, 2001, INFECT IMMUN, V69, P3382, DOI 10.1128/IAI.69.5.3382-3388.2001; Takahashi T, 1997, DIS COLON RECTUM, V40, P1362, DOI 10.1007/BF02050824; TANNICH E, 1989, P NATL ACAD SCI USA, V86, P5118, DOI 10.1073/pnas.86.13.5118; THOMPSON JE, 1985, REV INFECT DIS, V7, P171; Tsutsumi V., 1988, Amebiasis: human infection by Entamoeba histolytica., P147; TUCKER PC, 1975, ARCH INTERN MED, V135, P681, DOI 10.1001/archinte.135.5.681; Valdez E, 1999, PARASITOL RES, V85, P833, DOI 10.1007/s004360050641; Velazquez C, 1998, PARASITE IMMUNOL, V20, P255, DOI 10.1046/j.1365-3024.1998.00128.x; Vreden SGS, 2000, CLIN INFECT DIS, V31, P1101, DOI 10.1086/318153; WALKER EL, 1913, J SCI B TROP MED, V8, P253; Walsh J.A., 1988, P93; WEINKE T, 1990, J INFECT DIS, V161, P1029, DOI 10.1093/infdis/161.5.1029; Weinke T, 2002, EUR J MED RES, V7, P25; WRUBLE LD, 1966, NEW ENGL J MED, V275, P926, DOI 10.1056/NEJM196610272751704; Yan L, 2001, INFECT IMMUN, V69, P7911, DOI 10.1128/IAI.69.12.7911-7914.2001; YANG WG, 1994, MOL BIOCHEM PARASIT, V64, P253, DOI 10.1016/0166-6851(93)00020-A; Zafar Arshad, 2002, J Ayub Med Coll Abbottabad, V14, P10; Zhang Z, 2000, MOL MICROBIOL, V37, P542, DOI 10.1046/j.1365-2958.2000.02037.x; 1994, MMWR MORB MORTAL WKL, V42, P1	144	794	845	1	82	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 22	2003	361	9362					1025	1034		10.1016/S0140-6736(03)12830-9	http://dx.doi.org/10.1016/S0140-6736(03)12830-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658AP	12660071				2022-12-28	WOS:000181699700023
J	Thomas, RH				Thomas, RH			Evolution: Wingless insects and plucked chickens	SCIENCE			English	Editorial Material									Nat Hist Museum, Dept Zool, London SW7 5BD, England	Natural History Museum London	Thomas, RH (corresponding author), Nat Hist Museum, Dept Zool, Cromwell Rd, London SW7 5BD, England.							FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FORTEY RA, 1997, ARTHR RELATIONSHIPS; Haas F, 2003, ORG DIVERS EVOL, V3, P39, DOI 10.1078/1439-6092-00057; Klass KD, 2001, ANN SOC ENTOMOL FR, V37, P265; Lankester ER, 1904, Q J MICROSC SCI, V47, P523; Nardi F, 2003, SCIENCE, V299, P1887, DOI 10.1126/science.1078607; WHALLEY P, 1981, NATURE, V291, P317, DOI 10.1038/291317a0	7	7	8	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 21	2003	299	5614					1854	1855		10.1126/science.1083465	http://dx.doi.org/10.1126/science.1083465			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649471				2022-12-28	WOS:000181669700032
J	Phimister, EG				Phimister, EG			Medicine and the racial divide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	58	60	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1081	1082		10.1056/NEJMp030028	http://dx.doi.org/10.1056/NEJMp030028			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646663				2022-12-28	WOS:000181628400002
J	Yung, L; Linch, D				Yung, L; Linch, D			Hodgkin's lymphoma	LANCET			English	Review							BONE-MARROW-TRANSPLANTATION; EPSTEIN-BARR-VIRUS; STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; POSITRON-EMISSION-TOMOGRAPHY; KAPPA-B; COMBINATION CHEMOTHERAPY; BISPECIFIC ANTIBODIES; DISEASE PATIENTS; 2ND MALIGNANCY	Hodgkin's lymphoma was first described in 1832, but the nature of the pathognomic Reed-Sternberg cell, on which diagnosis of the disease is based, has only been elucidated in the past few years. Radiotherapy has been used to treat localised disease since the 1940s, and in the 1960s, effective combination chemotherapy regimens were introduced for anatomically advanced disease. The past three decades have witnessed continued, improvement in outcome to such an extent that Hodgkin's lymphoma is now one of the most curable of all non-cutaneous malignancies. With improved survival and extended follow-up, relevance of treatment-induced late effects has become apparent, and modern therapeutic strategies must fully account for these effects. We review the pathology of Hodgkin's lymphoma, and its clinical presentation, investigation, present management, and natural history, including late effects of treatment.	UCL, Royal Free & Univ Coll Med Sch, Dept Haematol, London WC1E 6HX, England	University of London; University College London	Linch, D (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Haematol, 98 Chenies Mews, London WC1E 6HX, England.	d.linch@ucl.ac.uk						Akpek G, 2001, J CLIN ONCOL, V19, P4314, DOI 10.1200/JCO.2001.19.23.4314; Alexander FE, 2000, BRIT J CANCER, V82, P1117, DOI 10.1054/bjoc.1999.1049; ANDERSON JE, 1993, J CLIN ONCOL, V11, P2342, DOI 10.1200/JCO.1993.11.12.2342; ANDERSON JR, 1995, ANN ONCOL, V6, P167; Annunziata CM, 2000, BLOOD, V96, P2841; Barth S, 2000, BLOOD, V95, P3909; Bauer S, 1999, CANCER RES, V59, P1961; BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7; Bonfante V, 1997, J CLIN ONCOL, V15, P528, DOI 10.1200/JCO.1997.15.2.528; BORCHMANN P, 2001, LEUK LYMPHOMA S2, V42, P88; Brierley JD, 1998, BRIT J CANCER, V77, P1300, DOI 10.1038/bjc.1998.217; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; CARELLA AM, 1988, J CLIN ONCOL, V6, P1411, DOI 10.1200/JCO.1988.6.9.1411; Cartwright R, 1999, EUR J CANCER, V35, P627, DOI 10.1016/S0959-8049(98)00401-8; Chapman ALN, 2001, CANCER RES, V61, P6219; Chen CI, 2001, BONE MARROW TRANSPL, V27, P177, DOI 10.1038/sj.bmt.1702771; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Chisesi T, 2002, ANN ONCOL, V13, P102, DOI 10.1093/annonc/13.S1.102; CHOPRA R, 1993, BLOOD, V81, P1137; Coiffier B, 2001, Curr Oncol Rep, V3, P266, DOI 10.1007/s11912-001-0060-1; Connors JM, 1997, J CLIN ONCOL, V15, P1638, DOI 10.1200/JCO.1997.15.4.1638; da Costa L, 2000, CANCER CHEMOTH PHARM, V46, pS33, DOI 10.1007/PL00014047; de Wit M, 2001, ANN ONCOL, V12, P29, DOI 10.1023/A:1008357126404; DEVITA VT, 1970, ANN INTERN MED, V73, P881, DOI 10.7326/0003-4819-73-6-881; Diehl V, 1999, J CLIN ONCOL, V17, P776, DOI 10.1200/JCO.1999.17.3.776; Diehl V, 2001, BLOOD, V98, p769A; Dolcetti R, 2001, EUR J CANCER, V37, P1276, DOI 10.1016/S0959-8049(01)00105-8; DUGGAN D, 1997, P AN M AM SOC CLIN, V16, P12; EKSTRAND B, 2002, P AN M AM SOC CLIN, V21, P264; ENGERT A, 1995, INT J CANCER, V63, P304, DOI 10.1002/ijc.2910630226; *EORTC LYMPH COOP, 1999, TRIAL H9 PROT PROSP; FEDERICO M, 2002, P AN M AM SOC CLIN, V21, P263; FEI C, 2001, AM J PATHOL, V159, P387; Ferme C, 2000, BLOOD, V95, P2246; FRIEDBERG JW, 2001, LEUK LYMPHOMA S2, V42, P64; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Glaser SL, 1996, BAILLIERE CLIN HAEM, V9, P401, DOI 10.1016/S0950-3536(96)80018-7; Hagenbeek A, 2000, BLOOD, V96, p575A; Hagenbeek A, 1997, BLOOD, V90, P2603; Hancock, 1996, Semin Radiat Oncol, V6, P225, DOI 10.1016/S1053-4296(96)80018-X; HANCOCK BW, 1991, BRIT J CANCER, V63, P579, DOI 10.1038/bjc.1991.134; Hancock BW, 2001, BRIT J CANCER, V84, P1293, DOI 10.1054/bjoc.2001.1778; HANCOCK BW, 1986, RADIOTHER ONCOL, V7, P215, DOI 10.1016/S0167-8140(86)80032-9; HANCOCK SL, 1993, JAMA-J AM MED ASSOC, V270, P1949, DOI 10.1001/jama.270.16.1949; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; HAYBITTLE JL, 1985, LANCET, V1, P967; Horning SJ, 1997, J CLIN ONCOL, V15, P1736, DOI 10.1200/JCO.1997.15.5.1736; Horning SJ, 2002, J CLIN ONCOL, V20, P630, DOI 10.1200/JCO.20.3.630; HOSKIN PJ, 2002, ANN ONCOL, V13, P65; Hueltenschmidt B, 2001, CANCER-AM CANCER SOC, V91, P302, DOI 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4; Huhn M, 2001, CANCER RES, V61, P8737; Jaffe E.S., 2001, PATHOLOGY GENETICS T, VVolume 3; Jarrett AF, 1996, ANN ONCOL, V7, P5; Jarrett RF, 1999, SEMIN HEMATOL, V36, P260; Jerusalem G, 2001, HAEMATOLOGICA, V86, P266; JONES RJ, 1990, J CLIN ONCOL, V8, P527, DOI 10.1200/JCO.1990.8.3.527; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Keller SA, 2000, BLOOD, V96, P2537; Klimka A, 1999, BRIT J CANCER, V80, P1214, DOI 10.1038/sj.bjc.6690488; KNECHT H, 1993, BLOOD, V82, P2937; Kottaridis PD, 2001, BLOOD, V98, p416A; Kulkarni SS, 1997, AM J CLIN ONCOL-CANC, V20, P354, DOI 10.1097/00000421-199708000-00006; Kuppers R, 1998, ANNU REV IMMUNOL, V16, P471, DOI 10.1146/annurev.immunol.16.1.471; Kuppers R, 1996, ANN ONCOL, V7, P27; Kuppers R, 1998, ANN ONCOL, V9, P17, DOI 10.1023/A:1008449822185; Linch David C., 2000, Hematology Am Soc Hematol Educ Program, P205; LINCH DC, 1993, LANCET, V341, P1051, DOI 10.1016/0140-6736(93)92411-L; Linch DC, 1999, BRIT J HAEMATOL, V107, P685, DOI 10.1046/j.1365-2141.1999.01570.x; LINCH DC, 2001, LEUKAEMIA LYMPHOM S2, V42, P80; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; Loeffler M, 1998, J CLIN ONCOL, V16, P818, DOI 10.1200/JCO.1998.16.3.818; LONGO DL, 1986, J CLIN ONCOL, V4, P1295, DOI 10.1200/JCO.1986.4.9.1295; Lucas JB, 1999, J CLIN ONCOL, V17, P2627; Majolino I, 1997, J CLIN ONCOL, V15, P509, DOI 10.1200/JCO.1997.15.2.509; Matthey B, 2000, INT J MOL MED, V6, P509; Meraw SJ, 1998, J AM DENT ASSOC, V129, P201, DOI 10.14219/jada.archive.1998.0178; Milpied N, 1996, J CLIN ONCOL, V14, P1291, DOI 10.1200/JCO.1996.14.4.1291; NADEMANEE A, 1995, BLOOD, V85, P1381, DOI 10.1182/blood.V85.5.1381.bloodjournal8551381; Ng AK, 2002, J CLIN ONCOL, V20, P2101, DOI 10.1200/JCO.2002.08.021; PFREUNDSCHUH MG, 1994, J CLIN ONCOL, V12, P580, DOI 10.1200/JCO.1994.12.3.580; Pittrof RU, 1996, J ASSIST REPROD GEN, V13, P310, DOI 10.1007/BF02070144; Raemaekers JMM, 2001, BLOOD, V98, p768A; Renner C, 1996, BLOOD, V87, P2930, DOI 10.1182/blood.V87.7.2930.bloodjournal8772930; RUEFFER JU, 2001, LEUK LYMPHOMA S2, V42, P54; Salloum E, 1997, J CLIN ONCOL, V15, P518, DOI 10.1200/JCO.1997.15.2.518; Santoro A, 2000, J CLIN ONCOL, V18, P2615, DOI 10.1200/JCO.2000.18.13.2615; Scheffold A, 1998, EUR CYTOKINE NETW, V9, P5; Schellong G, 1999, J CLIN ONCOL, V17, P3736, DOI 10.1200/JCO.1999.17.12.3736; Schmitz N, 1996, LANCET, V347, P353, DOI 10.1016/S0140-6736(96)90536-X; Schmitz N, 2002, LANCET, V359, P2065, DOI 10.1016/S0140-6736(02)08938-9; Schnell R, 2002, ANN ONCOL, V13, P57, DOI 10.1093/annonc/13.S1.57; Schnell R, 2001, BLOOD, V98, p610A; Sieber M, 2000, ANN ONCOL, V11, P81, DOI 10.1023/A:1008317426152; Specht L, 1998, J CLIN ONCOL, V16, P830, DOI 10.1200/JCO.1998.16.3.830; Stein H, 2001, BLOOD, V97, P496, DOI 10.1182/blood.V97.2.496; Su Z, 2001, EUR J IMMUNOL, V31, P947, DOI 10.1002/1521-4141(200103)31:3<947::AID-IMMU947>3.0.CO;2-M; Swerdlow AJ, 2000, J CLIN ONCOL, V18, P498, DOI 10.1200/JCO.2000.18.3.498; SWERDLOW AJ, 1992, BRIT MED J, V304, P1137, DOI 10.1136/bmj.304.6835.1137; Swerdlow AJ, 2001, J CLIN ONCOL, V19, P1610, DOI 10.1200/JCO.2001.19.6.1610; Theil J, 2001, BLOOD, V97, P3191, DOI 10.1182/blood.V97.10.3191; Thomas RK, 2002, ANN ONCOL, V13, P147, DOI 10.1093/annonc/mdf652; TROUNSON A, 1983, NATURE, V305, P707, DOI 10.1038/305707a0; van Leeuwen FE, 2000, J CLIN ONCOL, V18, P487, DOI 10.1200/JCO.2000.18.3.487; Van Leeuwenl F.E., 2002, ANN ONCOL         S2, V13, P25; VAUGHAN HB, 1994, ANN ONCOL         S2, V5, pS65; Viviani S, 1996, J CLIN ONCOL, V14, P1421, DOI 10.1200/JCO.1996.14.5.1421; VOSE JM, 1991, J CLIN ONCOL, V9, P1421, DOI 10.1200/JCO.1991.9.8.1421; Weidmann E, 1999, LEUKEMIA LYMPHOMA, V34, P545, DOI 10.3109/10428199909058482	108	86	95	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 15	2003	361	9361					943	951		10.1016/S0140-6736(03)12777-8	http://dx.doi.org/10.1016/S0140-6736(03)12777-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658VP	12648984				2022-12-28	WOS:000181741600022
J	Gaffikin, L; Blumenthal, PD; Emerson, M; Limpaphayom, K; Lumbiganon, P; Ringers, P; Srisupundit, S; Warakamin, S; Lewis, R; Chumworathayee, B; Kanavacharakul, S				Gaffikin, L; Blumenthal, PD; Emerson, M; Limpaphayom, K; Lumbiganon, P; Ringers, P; Srisupundit, S; Warakamin, S; Lewis, R; Chumworathayee, B; Kanavacharakul, S		RTCOG; JHPIEGO Corp Cervical Canc Grp	Safety, acceptability, and feasibility of a single-visit approach to cervical-cancer prevention in rural Thailand: a demonstration project	LANCET			English	Article							SQUAMOUS INTRAEPITHELIAL LESIONS; ACETIC-ACID; DEVELOPING-COUNTRIES; VISUAL INSPECTION; NEOPLASIA; MANAGEMENT; PRECURSORS; CARCINOMA; TRIAL	Background To increase screening and treatment coverage, innovative approaches to cervical-cancer prevention are being investigated in rural Thailand. We assessed the value of a single-visit approach combining visual inspection of the cervix with acetic acid wash (VIA) and cryotherapy. Methods 12 trained nurses provided services in mobile (village health centre-based) and static (hospital-based) teams in four districts of Roi-et Province, Thailand. Over 7 months, 5999 women were tested by VIA. If they tested positive, after counselling about the benefits, potential risks, and probable side-effects they were offered cryotherapy. Data measuring safety, acceptability, feasibility, and effort to implement the programme were gathered. Findings The VIA test-positive rate was 13.3% (798/5999), and 98.5% (609/618) of those eligible accepted immediate treatment. Overall, 756 women received cryotherapy, 629 (83.2%) of whom returned for their first follow-up visit. No major complications were recorded, and 33 (4.4%) of those treated returned for a perceived problem. Only 17 (2.2%) of the treated women needed clinical management other than reassurance about side-effects. Both VIA and cryotherapy were highly acceptable to the patients (over 95% expressed satisfaction with their experience). At their 1-year visit, the squamocolumnar junction was visible to the nurses, and the VIA test-negative rate was 94.3%. Interpretation A single-visit approach with VIA and cryotherapy seems to be safe, acceptable, and feasible in rural Thailand, and is a potentially efficient method of cervical-cancer prevention in such settings.	JHPIEGO Corp, Cerv Canc Prevent Programme, Baltimore, MD 21231 USA	Jhpiego	Gaffikin, L (corresponding author), JHPIEGO Corp, Cerv Canc Prevent Programme, 1615 Thames St,Suite 200, Baltimore, MD 21231 USA.		Chumworathayi, Bandit/J-9927-2019	Chumworathayi, Bandit/0000-0003-1214-1962				ABWAO S, 1998, P REG M NAIR KEN 199; ANDERSEN ES, 1992, GYNECOL ONCOL, V45, P240, DOI 10.1016/0090-8258(92)90297-V; Belinson JL, 2001, OBSTET GYNECOL, V98, P441, DOI 10.1016/S0029-7844(01)01454-5; Blumenthal P D, 2001, Medscape Womens Health, V6, P1; CECCHINI S, 1993, TUMORI, V79, P22, DOI 10.1177/030089169307900104; Cox JT, 1999, LANCET, V353, P857, DOI 10.1016/S0140-6736(98)00392-4; CULLINS VE, 1999, REPROD HEALTH MATTER, V1, P134; Gaffikin L, 1999, LANCET, V353, P869; GAFFIKIN L, 1997, WORKSH P ALT CERV CA; Goldie SJ, 2001, JAMA-J AM MED ASSOC, V285, P3107, DOI 10.1001/jama.285.24.3107; Holschneider CH, 1999, CANCER-AM CANCER SOC, V86, P2659, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2659::AID-CNCR10>3.0.CO;2-S; Kitchener HC, 1999, LANCET, V353, P856, DOI 10.1016/S0140-6736(98)00417-6; LIMPAPHAYOM K, 1997, BRIT J OBSTET GYNAEC, V23, P3107; Londhe M., 1997, Indian Journal of Cancer, V34, P88; MANDELBLATT JS, 2002, J NATL CANCER I, V94, P1; Megevand E, 1996, OBSTET GYNECOL, V88, P383, DOI 10.1016/0029-7844(96)00189-5; Mitchell MF, 1998, OBSTET GYNECOL, V92, P737, DOI 10.1097/00006250-199811000-00001; MORRIS DL, 1996, NURSE PRACTITIONER, V23, P101; Nuovo J, 2000, INT J GYNECOL OBSTET, V68, P25, DOI 10.1016/S0020-7292(99)00162-9; *REPR HLTH OUTL, 2003, CERV CANC PREV; Sankaranarayanan R, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P411; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sankaranarayanan R, 1998, CANCER-AM CANCER SOC, V83, P2150, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2150::AID-CNCR13>3.3.CO;2-S; Sankaranarayanan R, 1999, INT J CANCER, V80, P161, DOI 10.1002/(SICI)1097-0215(19990105)80:1<161::AID-IJC28>3.3.CO;2-#; Santos C, 1996, GYNECOL ONCOL, V61, P11, DOI 10.1006/gyno.1996.0088; Soler, 2000, Prim Care Update Ob Gyns, V7, P118, DOI 10.1016/S1068-607X(00)00032-9; *UNFPA, UPD 1998 1999 MATERN; [No title captured]	28	181	185	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					814	820						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642047				2022-12-28	WOS:000181466600009
J	Ketteler, M; Bongartz, P; Westenfeld, R; Wildberger, JE; Mahnken, AH; Bohm, R; Metzger, T; Wanner, C; Jahnen-Dechent, W; Floege, J				Ketteler, M; Bongartz, P; Westenfeld, R; Wildberger, JE; Mahnken, AH; Bohm, R; Metzger, T; Wanner, C; Jahnen-Dechent, W; Floege, J			Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study	LANCET			English	Article							STAGE RENAL-DISEASE; C-REACTIVE PROTEIN; MATRIX GLA PROTEIN; HEMODIALYSIS-PATIENTS; PERITONEAL-DIALYSIS; CALCIFICATION; INFLAMMATION; CALCIUM; GENE; RISK	Background Vascular calcification is the most prominent underlying pathological finding in patients with uraemia, and is a predictor. of mortality in this population. Fetuin-A (alpha(2)-Heremans Schmid glycoprotein; AHSG) is an important circulating inhibitor of calcification in vivo, and is downregulated during the acute-phase response. We aimed to investigate the hypothesis that AHSG deficiency is directly related to uraemic vascular calcification. Methods We did a cross-sectional study in 312 stable patients on haemodialysis to analyse the inter-relation of AHSG and C-reactive protein (CRP) and their predictive effect on all-cause and cardiovascular mortality, over a period of 32 months. Subsequently, we tested the capacity of serum to inhibit CaxPO(4) precipitation in patients on long-term dialysis (n=17) with apparent soft-tissue calcifications, and in those on short-term dialysis (n=8) without evidence of calcifications and cardiovascular disease. Findings AHSG concentrations in serum were significantly lower in patients on haemodialysis (mean 0.66 g/L [SD 0.28]) than in healthy controls (0.72 [0.19]). Low concentrations of the glycoprotein were associated with raised amounts of CRP and with enhanced cardiovascular (p=0.031) and all-cause mortality (p=0.0013). Sera from patients on long-term dialysis with low AHSG concentrations showed impaired ex-vivo capacity to inhibit CaxPO(4) precipitation (mean IC50: 9.0 muL serum [SD 3.1] vs 7.5 [0.8] in short-term patients and 6.4 [2.6] in controls). Reconstitution of sera with purified AHSG returned this impairment to normal. Interpretation AHSG deficiency is associated with inflammation and links vascular calcification to mortality in patients on dialysis. Activated acute-phase response and AHSG deficiency might account for accelerated atherosclerosis in uraemia.	Univ Hosp Aachen, Dept Nephrol & Immunol, Aachen, Germany; Univ Hosp Aachen, Dept Diagnost Radiol, Aachen, Germany; Univ Hosp Aachen, IZKF BioMAT, Aachen, Germany; Univ Hosp Wurzburg, Div Nephrol, Wurzburg, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; University of Wurzburg	Ketteler, M (corresponding author), Univ Hosp Aachen, Dept Nephrol, Pauwelsstr 30, D-52057 Aachen, Germany.		Mahnken, Andreas H/H-4644-2011; Jahnen-Dechent, Willi/A-7608-2011	Mahnken, Andreas H./0000-0001-8077-9306; Jahnen-Dechent, Willi/0000-0003-1315-4407				Banine F, 2000, EUR J BIOCHEM, V267, P1214, DOI 10.1046/j.1432-1327.2000.01119.x; Blacher J, 2001, HYPERTENSION, V38, P938, DOI 10.1161/hy1001.096358; Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176; Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003; HAUCK WW, 1991, STAT MED, V10, P711, DOI 10.1002/sim.4780100505; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; JahnenDechent W, 1997, J BIOL CHEM, V272, P31496, DOI 10.1074/jbc.272.50.31496; Kalabay L, 2002, EUR J GASTROEN HEPAT, V14, P389, DOI 10.1097/00042737-200204000-00009; Kaysen GA, 2000, KIDNEY INT, V58, P346, DOI 10.1046/j.1523-1755.2000.00172.x; Lagrand WK, 1999, CIRCULATION, V100, P96, DOI 10.1161/01.CIR.100.1.96; LEBRETON JP, 1979, J CLIN INVEST, V64, P1118, DOI 10.1172/JCI109551; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Malatino LS, 2000, AM J KIDNEY DIS, V36, P945, DOI 10.1053/ajkd.2000.19087; Mathews ST, 2002, DIABETES, V51, P2450, DOI 10.2337/diabetes.51.8.2450; Ohnesorge B, 2000, RADIOLOGY, V217, P564, DOI 10.1148/radiology.217.2.r00nv30564; Osawa M, 2001, ANN HUM GENET, V65, P27, DOI 10.1046/j.1469-1809.2001.6510027.x; Parhami F, 2001, CIRC RES, V88, P954, DOI 10.1161/hh0901.090975; Price PA, 2002, J BIOL CHEM, V277, P3926, DOI 10.1074/jbc.M106366200; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Rumberger JA, 1999, MAYO CLIN PROC, V74, P243, DOI 10.4065/74.3.243; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; Schwedler SB, 2002, KIDNEY INT, V62, P301, DOI 10.1046/j.1523-1755.2002.00423.x; Stenvinkel P, 2000, J AM SOC NEPHROL, V11, P1303, DOI 10.1681/ASN.V1171303; Szweras M, 2002, J BIOL CHEM, V277, P19991, DOI 10.1074/jbc.M112234200; TOLLESHAUG H, 1984, BIOCHIM BIOPHYS ACTA, V803, P182, DOI 10.1016/0167-4889(84)90008-9; US Renal Data System, 1999, USRDS 1998 ANN DAT R, P63; Wang AYM, 2001, J AM SOC NEPHROL, V12, P1927, DOI 10.1681/ASN.V1291927; Wang TJ, 2002, CIRCULATION, V106, P1189, DOI 10.1161/01.CIR.0000032135.98011.C4; Zimmermann J, 1999, KIDNEY INT, V55, P648, DOI 10.1046/j.1523-1755.1999.00273.x; Zoccali C, 2001, LANCET, V358, P2113, DOI 10.1016/S0140-6736(01)07217-8	30	732	764	1	38	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					827	833		10.1016/S0140-6736(03)12710-9	http://dx.doi.org/10.1016/S0140-6736(03)12710-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642050				2022-12-28	WOS:000181466600012
J	Solomon, T; Dung, NM; Wills, B; Kneen, R; Gainsborough, M; Diet, TV; Thuy, TTN; Loan, HT; Khanh, VC; Vaughn, DW; White, NJ; Farrar, JJ				Solomon, T; Dung, NM; Wills, B; Kneen, R; Gainsborough, M; Diet, TV; Thuy, TTN; Loan, HT; Khanh, VC; Vaughn, DW; White, NJ; Farrar, JJ			Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial	LANCET			English	Article							CEREBROSPINAL-FLUID; DENGUE; RIBAVIRIN; VIRUS; WEST	Background Japanese encephalitis virus (JEV), although confined to Asia, causes about 35 000-50 000 cases and 10 000 deaths every year, and is the most important cause of encephalitis worldwide. There is no known antiviral treatment for any flavivirus. Results from in-vitro studies and work in animals have shown inteferon alfa has antiviral activity on Japanese encephalitis and other flaviviruses; therefore, we aimed to assess the efficacy of inteferon alfa-2a in Japanese encephalitis. Methods We did a randomised double-blind placebo-controlled trial of interferon alfa-2a (10 million units/m(2), daily for 7 days) in 112 Vietnamese children with suspected Japanese encephalitis, 87 of whom had serologically confirmed infections. Our primary endpoints were hospital death or severe sequelae at discharge. Analysis was by intention to treat. Findings Overall, 21 children (19%) died, and 17 (15%) had severe sequelae. Outcome at discharge and 3 months did not differ between the two treatment groups; 20 children in the interferon group had a poor outcome (death or severe sequelae), compared with 18 in the placebo group (p=0.85, difference 0.1%, 95% CI-17.5 to 17.6%), there were no long-term side effects of interferon. Interpretation The doses of interferon alfa-2a given in this regimen did not improve the outcome of patients with Japanese encephalitis.	Univ Liverpool, Walton Ctr Neurol & Neurosurg, Dept Neurol Sci, Liverpool L9 7LJ, Merseyside, England; Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England; Royal Liverpool Childrens NHS Trust, Roald Dahl EEG Unit, Liverpool, Merseyside, England; Hosp Trop Dis, Univ Oxford Wellcome Trust Clin Res Unit, Ho Chi Minh City, Vietnam; Armed Forces Res Inst Med Sci, US Army Med Component, Dept Virol, Bangkok 10400, Thailand; Mahidol Univ, Fac Trop Med, Wellcome Trust Mahidol Univ Oxford Trop Med Res P, Bangkok, Thailand	University of Liverpool; Walton Centre; University of Oxford; Alder Hey Children's NHS Foundation Trust; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); Mahidol University	Solomon, T (corresponding author), Univ Liverpool, Walton Ctr Neurol & Neurosurg, Dept Neurol Sci, Lower Lane, Liverpool L9 7LJ, Merseyside, England.	tsolomon@liv.ac.uk	Farrar, Jeremy J./HGA-7610-2022; White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; Farrar, Jeremy/0000-0002-2700-623X; Wills, Bridget/0000-0001-9086-8804; Solomon, Tom/0000-0001-7266-6547				Anderson JF, 2002, EMERG INFECT DIS, V8, P107, DOI 10.3201/eid0801.010252; BURKE DS, 1987, J INFECT DIS, V155, P797, DOI 10.1093/infdis/155.4.797; *CDCP, 2002, W NIL VIR UPD CURR C; FRANKENBERG WK, 1968, DENVER DEV SCREENING; HARINASUTA C, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P656; HARINASUTA C, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P332; HARINASUTA C, 1984, Southeast Asian Journal of Tropical Medicine and Public Health, V15, P564; HARRINGTON DG, 1977, AM J TROP MED HYG, V26, P1191, DOI 10.4269/ajtmh.1977.26.1191; HOKE CH, 1992, J INFECT DIS, V165, P631, DOI 10.1093/infdis/165.4.631; HOPKINS A, 1991, BRIT MED J, V303, P634; HOUGLUM JE, 1983, CLIN PHARMACY, V2, P20; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; MOLYNEUX ME, 1989, Q J MED, V71, P441; PHU NH, 1995, T ROY SOC TROP MED H, V89, P200, DOI 10.1016/0035-9203(95)90496-4; SMITH RA, 1985, CLIN PHARMACOL THER, V37, P85, DOI 10.1038/clpt.1985.16; Solomon T, 1998, J CLIN MICROBIOL, V36, P2030, DOI 10.1128/JCM.36.7.2030-2034.1998; Solomon T, 2000, LANCET, V355, P1053, DOI 10.1016/S0140-6736(00)02036-5; Solomon T, 2002, J CHILD NEUROL, V17, P703, DOI 10.1177/088307380201700911; Solomon T, 2001, J INFECTION, V42, P104, DOI 10.1053/jinf.2001.0802; Solomon T, 2000, BRIT MED J, V321, P1484, DOI 10.1136/bmj.321.7275.1484; Solomon T, 2002, CURR TOP MICROBIOL, V267, P171; Solomon T, 2002, BRAIN, V125, P1084, DOI 10.1093/brain/awf116; Solomon T, 2000, J NEUROL NEUROSUR PS, V68, P405, DOI 10.1136/jnnp.68.4.405; Solomon T, 1998, LANCET, V351, P1094, DOI 10.1016/S0140-6736(97)07509-0; Solomon T, 1996, 7 INT C INF DIS, P132; TEASDALE G, 1974, LANCET, V2, P81; Tsai Theodore F., 2000, Vaccine, V18, P1, DOI 10.1016/S0264-410X(00)00037-2; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VITHANOMSAT S, 1984, Southeast Asian Journal of Tropical Medicine and Public Health, V15, P27; WARRELL MJ, 1989, BMJ-BRIT MED J, V299, P830, DOI 10.1136/bmj.299.6703.830; *WHO, 1981, CANC TREATM WHO REC	31	118	140	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 8	2003	361	9360					821	826		10.1016/S0140-6736(03)12709-2	http://dx.doi.org/10.1016/S0140-6736(03)12709-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642049				2022-12-28	WOS:000181466600011
J	Poutanen, SM; Low, DE; Henry, B; Finkelstein, S; Rose, D; Green, K; Tellier, R; Draker, R; Adachi, D; Ayers, M; Chan, AK; Skowronski, DM; Salit, I; Simor, AE; Slutsky, AS; Doyle, PW; Krajden, M; Petric, M; Brunham, RC; McGeer, AJ				Poutanen, SM; Low, DE; Henry, B; Finkelstein, S; Rose, D; Green, K; Tellier, R; Draker, R; Adachi, D; Ayers, M; Chan, AK; Skowronski, DM; Salit, I; Simor, AE; Slutsky, AS; Doyle, PW; Krajden, M; Petric, M; Brunham, RC; McGeer, AJ		Natl Microbiology Lab Canada; Canadian Severe Acute Respiratory	Identification of severe acute respiratory syndrome in Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN METAPNEUMOVIRUS; MECHANICAL VENTILATION; CORONAVIRUS; INFECTIONS; RIBAVIRIN; CHILDREN; TRIAL	BACKGROUND Severe acute respiratory syndrome (SARS) is a condition of unknown cause that has recently been recognized in patients in Asia, North America, and Europe. This report summarizes the initial epidemiologic findings, clinical description, and diagnostic findings that followed the identification of SARS in Canada. METHODS SARS was first identified in Canada in early March 2003. We collected epidemiologic, clinical, and diagnostic data from each of the first 10 cases prospectively as they were identified. Specimens from all cases were sent to local, provincial, national, and international laboratories for studies to identify an etiologic agent. RESULTS The patients ranged from 24 to 78 years old; 60 percent were men. Transmission occurred only after close contact. The most common presenting symptoms were fever (in 100 percent of cases) and malaise (in 70 percent), followed by nonproductive cough (in 100 percent) and dyspnea (in 80 percent) associated with infiltrates on chest radiography (in 100 percent). Lymphopenia (in 89 percent of those for whom data were available), elevated lactate dehydrogenase levels (in 80 percent), elevated aspartate aminotransferase levels (in 78 percent), and elevated creatinine kinase levels (in 56 percent) were common. Empirical therapy most commonly included antibiotics, oseltamivir, and intravenous ribavirin. Mechanical ventilation was required in five patients. Three patients died, and five have had clinical improvement. The results of laboratory investigations were negative or not clinically significant except for the amplification of human metapneumovirus from respiratory specimens from five of nine patients and the isolation and amplification of a novel coronavirus from five of nine patients. In four cases both pathogens were isolated. CONCLUSIONS SARS is a condition associated with substantial morbidity and mortality. It appears to be of viral origin, with patterns suggesting droplet or contact transmission. The role of human metapneumovirus, a novel coronavirus, or both requires further investigation.	Toronto Med Labs, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Toronto, Dept Med, Div Infect Dis, Toronto, ON, Canada; Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; City Toronto Publ Hlth Dept, Toronto, ON, Canada; Scarborough Gen Hosp, Toronto, ON, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; British Columbia Ctr Dis Control, Epidemiol Serv, Vancouver, BC, Canada; British Columbia Ctr Dis Control, Lab Serv, Vancouver, BC, Canada; Univ Hlth Network, Toronto, ON, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; St Michaels Hosp, Toronto, ON M5B 1W8, Canada; Vancouver Hosp & Hlth Sci Ctr, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Ctr Dis Control, Vancouver, BC V5Z 1M9, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; Scarborough Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of British Columbia; University of British Columbia	McGeer, AJ (corresponding author), Toronto Med Labs, 600 Univ Ave,Rm 1460, Toronto, ON M5G 1X5, Canada.		Draker, Ryan/GQP-7335-2022; Low, Donald/B-1726-2012; Poutanen, Susan M/F-9640-2012; Poutanen, Susan M./N-8066-2019; Slutsky, Arthur S/A-6013-2008; Slutsky, Arthur/M-3325-2019; McGeer, Allison/AAB-6885-2020; mcgeer, allison/H-7747-2014	Poutanen, Susan M/0000-0003-4747-2550; Poutanen, Susan M./0000-0003-4747-2550; Slutsky, Arthur S/0000-0002-6063-3876; McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137				[Anonymous], 2003, WKLY EPIDEMIOL REC, V78, P81; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Boivin G, 2002, J INFECT DIS, V186, P1330, DOI 10.1086/344319; Borio L, 2002, JAMA-J AM MED ASSOC, V287, P2391, DOI 10.1001/jama.287.18.2391; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Crotty S, 2001, NAT MED, V7, P255; Falsey AR, 1997, J AM GERIATR SOC, V45, P706, DOI 10.1111/j.1532-5415.1997.tb01474.x; Farr BM, 2000, RESP MED, V94, P954, DOI 10.1053/rmed.2000.0865; Greensill J, 2003, EMERG INFECT DIS, V9, P372, DOI 10.3201/eid0903.020289; Heymann D L, 2001, Lancet Infect Dis, V1, P345, DOI 10.1016/S1473-3099(01)00148-7; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Nissen MD, 2002, MED J AUSTRALIA, V176, P188, DOI 10.5694/j.1326-5377.2002.tb04354.x; Peret TCT, 2002, J INFECT DIS, V185, P1660, DOI 10.1086/340518; SIDWELL RW, 1987, ANTIMICROB AGENTS CH, V31, P1130, DOI 10.1128/AAC.31.7.1130; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; SMITH DW, 1991, NEW ENGL J MED, V325, P24, DOI 10.1056/NEJM199107043250105; Stockton J, 2002, EMERG INFECT DIS, V8, P897, DOI 10.3201/eid0809.020084; TRUYEN U, 1995, VET MICROBIOL, V43, P103, DOI 10.1016/0378-1135(95)92531-F; Vabret A, 1998, PRESSE MED, V27, P1813; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; WEISS RC, 1989, VET MICROBIOL, V20, P255, DOI 10.1016/0378-1135(89)90049-7; 2003, MMWR MORB MORTAL WKL, V52, P241	23	784	924	0	54	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 15	2003	348	20					1995	2005		10.1056/NEJMoa030634	http://dx.doi.org/10.1056/NEJMoa030634			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677TJ	12671061	Green Published, Bronze			2022-12-28	WOS:000182823400008
J	Ovretveit, J; Gustafson, D				Ovretveit, J; Gustafson, D			Improving the quality of health care - Using research to inform quality programmes	BRITISH MEDICAL JOURNAL			English	Article							IMPROVEMENT; MANAGEMENT; PROJECT		Karolinska Inst, Med Management Ctr, S-40242 Stockholm, Sweden; Univ Wisconsin, Madison, WI 53705 USA	Karolinska Institutet; University of Wisconsin System; University of Wisconsin Madison	Ovretveit, J (corresponding author), Karolinska Inst, Med Management Ctr, S-40242 Stockholm, Sweden.			ovretveit, john/0000-0002-5177-6613				BIGELOW B, 1995, HEALTH CARE MANAGE R, V20, P15; Blumenthal D, 1998, MILBANK Q, V76, P625, DOI 10.1111/1468-0009.00108; *CLEV HLTH QUAL CH, 1995, QUAL MANAGE HLTH CAR, V3, P78; Cook T.C., 1979, QUASIEXPERIMENTATION; *EUR FDN QUAL MAN, 1992, EUR QUAL AW 1992; Hertz H S, 1994, Qual Manag Health Care, V2, P63; Motwani J, 1996, HEALTH CARE MANAGE R, V21, P73; *NAT I STAND TECHN, 1990, MALC BALDR NAT QUAL; Ovretveit J, 2001, J Manag Med, V15, P125, DOI 10.1108/02689230110394543; Ovretveit J, 2001, INT J HEALTH PLAN M, V16, P229, DOI 10.1002/hpm.629; OVRETVEIT J, 2002, INT J HLTH CARE QUAL, V15, P33; Ovretveit J., 1997, EVALUATION, V3, P451; OVRETVEIT J, 2002, ACTION EVALUATION HL; *PENNS HLTH CAR CO, 1992, HOSP EFF REP; PLSEK P, BMJ, V323, P746; ROSENTHAL G, 1994, J QUALITY IMPROVEMEN, V2, P425; Shaw C, 2001, BRIT MED J, V322, P851, DOI 10.1136/bmj.322.7290.851; Shaw CD, 2000, INT J QUAL HEALTH C, V12, P169, DOI 10.1093/intqhc/12.3.169; Shortell SM, 1998, MILBANK Q, V76, P593, DOI 10.1111/1468-0009.00107; Sweeney J, 2000, INT J QUAL HEALTH C, V12, P203, DOI 10.1093/intqhc/12.3.203; Thomson RG, 1997, QUAL HEALTH CARE, V6, P49, DOI 10.1136/qshc.6.1.49; Wensing M, 1994, Int J Qual Health Care, V6, P115; West E, 2001, QUAL HEALTH CARE, V10, P40, DOI 10.1136/qhc.10.1.40	23	79	80	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 5	2003	326	7392					759	761		10.1136/bmj.326.7392.759	http://dx.doi.org/10.1136/bmj.326.7392.759			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665LF	12676849	Green Published			2022-12-28	WOS:000182121600021
J	Liu, QL; D'Silva, P; Walter, W; Marszalek, J; Craig, EA				Liu, QL; D'Silva, P; Walter, W; Marszalek, J; Craig, EA			Regulated cycling of mitochondrial Hsp70 at the protein import channel	SCIENCE			English	Article							MATRIX; MOTOR; ATP; DISSOCIATION; SSC1	Hsp70 of the mitochondrial matrix (mtHsp70) provides a critical driving force for the import of proteins into mitochondria. Tim44, a peripheral inner-membrane protein, tethers it to the import channel. Here, regulated interactions were found to maximize occupancy of the active, adenosine 5'-triphosphate (ATP)-bound mtHsp70 at the channel through its intrinsic high affinity for Tim44, as well as through release of adenosine diphosphate (ADP)-bound mtHsp70 from Tim44 by the cofactor Mge1. A model peptide substrate rapidly released mtHsp70 from Tim44, even in the absence of ATP hydrolysis. In vivo, the analogous interaction of translocating polypeptide would release mtHsp70 from the channel. Consistent with the ratchet model of translocation, subsequent hydrolysis of ATP would trap the polypeptide, driving import by preventing its movement back toward the cytosol.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Grad Program Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Craig, EA (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	ecraig@wisc.edu	D'Silva, Patrick/L-6653-2019	Marszalek, Jaroslaw/0000-0002-6978-1189	NIGMS NIH HHS [R01GM27870] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Dekker PJT, 1997, J MOL BIOL, V270, P321, DOI 10.1006/jmbi.1997.1131; Horst M, 1996, PROTEIN SCI, V5, P759; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; Liu QL, 2001, J BIOL CHEM, V276, P6112, DOI 10.1074/jbc.M009519200; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Okamoto K, 2002, EMBO J, V21, P3659, DOI 10.1093/emboj/cdf358; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; VOISINE C, UNPUB; VONAHSEN O, 1995, J BIOL CHEM, V270, P29848; Weiss C, 1999, P NATL ACAD SCI USA, V96, P8890, DOI 10.1073/pnas.96.16.8890	20	138	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 4	2003	300	5616					139	141		10.1126/science.1083379	http://dx.doi.org/10.1126/science.1083379			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663CP	12677068				2022-12-28	WOS:000181988900051
J	Miller, FG; Rosenstein, DL				Miller, FG; Rosenstein, DL			The therapeutic orientation to clinical trials	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROFESSIONAL INTEGRITY; CONSENT; ETHICS		NIH, Dept Clin Bioeth, Ctr Clin, Bethesda, MD 20892 USA; NIH, Psychiat Consultat Liaison Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA	Miller, FG (corresponding author), NIH, Dept Clin Bioeth, Ctr Clin, Bldg 10,Rm 1C118, Bethesda, MD 20892 USA.	fmiller@nih.gov						*AND CANC CTR, 2003, CHOOS CLIN TRIAL; Appelbaum Paul S., 2002, American Journal of Bioethics, V2, P22, DOI 10.1162/152651602317533596; APPELBAUM PS, 1987, HASTINGS CENT REP, V17, P20, DOI 10.2307/3562038; Appelbaum PS, 1996, KENNEDY INST ETHIC J, V6, P283, DOI 10.1353/ken.1996.0019; Beauchamp T L, 2012, PRINCIPLES BIOMEDICA; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; CHALMERS TC, 1981, MILBANK FUND Q, V59, P324, DOI 10.2307/3349683; Dickert N, 1999, NEW ENGL J MED, V341, P198, DOI 10.1056/NEJM199907153410312; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freedman B, 1996, J LAW MED ETHICS, V24, P252, DOI 10.1111/j.1748-720X.1996.tb01860.x; Hochhauser Mark, 2002, IRB, V24, P11, DOI 10.2307/3564027; Joffe S, 2001, LANCET, V358, P1772, DOI 10.1016/S0140-6736(01)06805-2; Katz Jay, 1993, St Louis Univ Law J, V38, P7; LEVINE ROBERT J., 1988, ETHICS REGULATION CL, V2nd; Lidz CW, 2002, MED CARE, V40, P55, DOI 10.1097/01.MLR.0000023956.25813.18; Miller F G, 1999, IRB, V21, P1, DOI 10.2307/3563755; Miller FG, 1998, JAMA-J AM MED ASSOC, V280, P1449, DOI 10.1001/jama.280.16.1449; MILLER FG, 1995, HASTINGS CENT REP, V25, P8, DOI 10.2307/3562107; Miller Franklin G., 2002, American Journal of Bioethics, V2, P3, DOI 10.1162/152651602317533523; REISER SJ, 1978, ANN AM ACAD POLIT SS, V437, P8, DOI 10.1177/000271627843700102; Rettig RA, 2000, HEALTH AFFAIR, V19, P129, DOI 10.1377/hlthaff.19.2.129; Sugarman Jeremy, 1998, IRB, V20, P1, DOI 10.2307/3564262	24	175	176	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2003	348	14					1383	1386		10.1056/NEJMsb030228	http://dx.doi.org/10.1056/NEJMsb030228			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	662LW	12672867				2022-12-28	WOS:000181949100012
J	Steinberg, MH; Barton, F; Castro, S; Pegelow, CH; Ballas, SK; Kutlar, A; Orringer, E; Bellevue, R; Olivieri, N; Varma, M; Ramirez, G; Adler, B; Smith, W; Carlos, T; Ataga, K; DeCastro, L; Bigelow, C; Saunthararajah, Y; Teller, M; Vichinsky, E; Claster, S; Shurin, S; Bridges, K; Waclawiw, M; Bonds, D; Terrin, M				Steinberg, MH; Barton, F; Castro, S; Pegelow, CH; Ballas, SK; Kutlar, A; Orringer, E; Bellevue, R; Olivieri, N; Varma, M; Ramirez, G; Adler, B; Smith, W; Carlos, T; Ataga, K; DeCastro, L; Bigelow, C; Saunthararajah, Y; Teller, M; Vichinsky, E; Claster, S; Shurin, S; Bridges, K; Waclawiw, M; Bonds, D; Terrin, M			Effect of hydroxyurea on mortality. and morbidity in adult sickle cell anemia - Risks and benefits up to 9 years of treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CHEST SYNDROME; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; LEUKEMOGENIC RISK; ACUTE-LEUKEMIA; DISEASE; THERAPY; RATES	Context Hydroxyurea increases levels of fetal hemoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cell anemia (SCA). High HbF levels reduce morbidity and mortality. Objective To determine whether hydroxyurea attenuates mortality in patients with SCA. Design Long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), conducted in 1992-1995, to determine if hydroxyurea reduces vaso-occlusive events. In the MSH Patients' Followup, conducted in 1996-2001, patients could continue, stop, or start hydroxyurea. Data were collected during the trial and in the follow-up period. Setting Inpatients and outpatients in 21 sickle cell referral centers in the United States and Canada. Patients Two-hundred ninety-nine adult patients with frequent painful episodes enrolled in the follow-up. Follow-up data through May 2001 were complete for 233 patients. Intervention In the MSH, patients were randomly assigned to receive hydroxyurea (n = 152) or placebo (n = 147). Main Outcome Measures Mortality, HbF levels, painful episodes, acute chest syndrome, and blood cell counts. The randomized trial was not designed to detect specified differences in mortality. Results Seventy-five of the original 299 patients died, 28% from pulmonary disease. Patients with reticulocyte counts less than 250000/mm(3) and hemoglobin levels lower than 9 g/dL had increased mortality (P=.002). Cumulative mortality at 9 years was 28% when HbF levels were lower than 0.5 g/dL after the trial was completed compared with 15% when HbF levels were 0.5 g/dL or higher (P=.03). Individuals who had acute chest syndrome during the trial had 32% mortality compared with 18% of individuals without acute chest syndrome (P=.02). Patients with 3 or more painful episodes per year during the trial had 27% mortality compared with 17% of patients with less frequent episodes (P=.06). Taking hydroxyurea was associated with a 40% reduction in mortality (P=.04) in this observational follow-up with self-selected treatment. There were 3 cases of cancer, 1 fatal. Conclusions Adult patients taking hydroxyurea for frequent painful sickle cell episodes appear to have reduced mortality after 9 of years follow-up. Survival was related to HbF levels and frequency of vaso-occlusive events. Whether indications for hydroxyurea treatment should be expanded is unknown.	Boston Univ, Sch Med, Ctr Excellence Sickle Cell Dis, Boston Med Ctr, Boston, MA 02118 USA; Univ Mississippi, Sch Med, Jackson, MS 39216 USA; Maryland Med Res Inst, Baltimore, MD USA; Howard Univ, Sch Med, Ctr Sickle Cell Dis, Washington, DC 20059 USA; Univ Miami, Sch Med, Miami, FL USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Med Coll Georgia, Augusta, GA 30912 USA; Univ N Carolina, Chapel Hill, NC USA; New York Methodist Hosp, Brooklyn, NY USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Emory Univ, Sickle Cell Ctr, Atlanta, GA 30322 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Roosevelt Med Ctr, New York, NY USA; Univ Alabama Birmingham, Birmingham, AL USA; Virginia Commonwealth Univ, Richmond, VA USA; Univ Pittsburgh, Pittsburgh, PA USA; Duke Univ, Sch Med, Durham, NC USA; Univ Illinois, Chicago, IL USA; Michael Reese Med Ctr, Chicago, IL USA; Childrens Hosp & Res Ctr Oakland, Oakland, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; NHLBI, Bethesda, MD 20892 USA	Boston Medical Center; Boston University; University of Mississippi; Howard University; University of Miami; Jefferson University; University System of Georgia; Augusta University; University of North Carolina; University of North Carolina Chapel Hill; NewYork-Presbyterian Brooklyn Methodist Hospital; NewYork-Presbyterian Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Emory University; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Alabama System; University of Alabama Birmingham; Virginia Commonwealth University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Duke University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Michael Reese Hospital & Medical Center; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of California System; University of California San Francisco; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Harvard University; Brigham & Women's Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Steinberg, MH (corresponding author), Boston Univ, Sch Med, Ctr Excellence Sickle Cell Dis, Boston Med Ctr, 88 E Newton St, Boston, MA 02118 USA.	msteinberg@medicine.bu.edu	Olivieri, Nancy/AAI-2250-2020; Vichinsky, Elliott P/F-8541-2011; MAGALHÃES, PÉROLA O/P-2521-2017	Vichinsky, Elliott P/0000-0002-0500-9579; MAGALHÃES, PÉROLA O/0000-0001-8011-6940; Barton, Franca/0000-0002-6628-5745; Steinberg, Martin/0000-0001-8800-8020	DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB067129] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HB-67129] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Jam'a AH, 2002, SAUDI MED J, V23, P1411; ANSON JA, 1991, J NEUROSURG, V75, P552, DOI 10.3171/jns.1991.75.4.0552; Ballas SK, 1999, BRIT J HAEMATOL, V105, P491, DOI 10.1111/j.1365-2141.1999.01339.x; Barbui T, 1998, BLOOD, V92, p489A; Bridges KR, 1996, BLOOD, V88, P4701, DOI 10.1182/blood.V88.12.4701.bloodjournal88124701; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Charache S, 1996, MEDICINE, V75, P300, DOI 10.1097/00005792-199611000-00002; Charache S, 1995, CONTROL CLIN TRIALS, V16, P432, DOI 10.1016/S0197-2456(95)00098-4; Draper NR., 1998, APPL REGRESSION ANAL, DOI [10.1002/9781118625590, DOI 10.1002/9781118625590]; FEINBERG SE, 1980, ANAL CROSS CLASSIFIE; Fenaux P, 1998, BLOOD, V92, P1460; Ferster A, 2001, BLOOD, V97, P3628, DOI 10.1182/blood.V97.11.3628; FRIEDMAN GD, 1975, CIRCULATION, V52, P164; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOSTIS JB, 1984, AM J CARDIOL, V53, P997, DOI 10.1016/0002-9149(84)90624-6; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Liozon E, 1997, HEMATOL CELL THER, V39, P11, DOI 10.1007/s00282-997-0011-x; Najean Y, 1997, BLOOD, V89, P2319, DOI 10.1182/blood.V89.7.2319; Najean Y, 1997, BLOOD, V90, P3370, DOI 10.1182/blood.V90.9.3370; Nand S, 1996, AM J HEMATOL, V52, P42, DOI 10.1002/(SICI)1096-8652(199605)52:1<42::AID-AJH7>3.0.CO;2-6; Ohene-Frempong K, 1998, BLOOD, V91, P288; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; POWARS DR, 1991, ANN INTERN MED, V115, P614, DOI 10.7326/0003-4819-115-8-614; Rauch A, 1999, BLOOD, V94, p415A; Steinberg MH, 1997, BLOOD, V89, P1078, DOI 10.1182/blood.V89.3.1078; Steinberg MH, 1997, BRIT J HAEMATOL, V98, P838, DOI 10.1046/j.1365-2141.1997.3173132.x; Sterkers Y, 1998, BLOOD, V91, P616, DOI 10.1182/blood.V91.2.616.616_616_622; Vichinsky EP, 2000, NEW ENGL J MED, V342, P1855, DOI 10.1056/NEJM200006223422502; Vichinsky EP, 1997, BLOOD, V89, P1787, DOI 10.1182/blood.V89.5.1787.1787_1787_1792; WEINFELD A, 1994, EUR J HAEMATOL, V52, P134; Wilson S, 2000, ANN INTERN MED, V133, P925, DOI 10.7326/0003-4819-133-11-200012050-00029	33	587	623	0	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 2	2003	289	13					1645	1651		10.1001/jama.289.13.1645	http://dx.doi.org/10.1001/jama.289.13.1645			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662JX	12672732	Bronze			2022-12-28	WOS:000181944500027
J	Lutz, W; O'Neill, BC; Scherbov, S				Lutz, W; O'Neill, BC; Scherbov, S			Demographics: Europe's population at a turning point	SCIENCE			English	Editorial Material							FERTILITY; WORLD; GROWTH; END		Austrian Acad Sci, Vienna Inst Demog, A-1040 Vienna, Austria; Int Inst Appl Syst Anal, A-2361 Laxenburg, Austria; Brown Univ, Watson Inst Int Studies, Providence, RI 02912 USA	Austrian Academy of Sciences; International Institute for Applied Systems Analysis (IIASA); Brown University	Lutz, W (corresponding author), Austrian Acad Sci, Vienna Inst Demog, A-1040 Vienna, Austria.		Scherbov, Sergey/F-3158-2019; O'Neill, Brian C./E-6531-2013	Scherbov, Sergey/0000-0001-5902-3790; O'Neill, Brian C./0000-0001-7505-8897; Scherbov, Sergei/0000-0002-0881-1073; Lutz, Wolfgang/0000-0001-7975-8145				BAGAVOS C, 2001, ANN SEM SEV SPAIN 15; BONGAARTS J, 1994, SCIENCE, V263, P771, DOI 10.1126/science.8303293; Bongaarts J, 1998, POPUL DEV REV, V24, P271, DOI 10.2307/2807974; Bongaarts J, 2002, POPUL DEV REV, V28, P419, DOI 10.1111/j.1728-4457.2002.00419.x; Bongaarts J., 2000, 6 BILLION PROJECTING, V1st ed.; BUTTNER T, 1990, POPUL DEV REV, V16, P539, DOI 10.2307/1972835; FREJKA T, 1968, POP STUD-J DEMOG, V22, P379, DOI 10.1080/00324728.1968.10404946; Frejka T, 2001, POPUL DEV REV, V27, P103, DOI 10.1111/j.1728-4457.2001.00103.x; Gauthier AH, 1997, POP STUD-J DEMOG, V51, P295, DOI 10.1080/0032472031000150066; KEYFITZ N, 1971, DEMOGRAPHY, V8, P71, DOI 10.2307/2060339; Kohler HP, 2002, POPUL DEV REV, V28, P641, DOI 10.1111/j.1728-4457.2002.00641.x; Kohler HP, 2001, DEMOGRAPHY, V38, P1, DOI 10.1353/dem.2001.0004; Lutz W, 2001, NATURE, V412, P543, DOI 10.1038/35087589; Preston SH, 1986, POPUL DEV REV, V12, P176, DOI 10.2307/2807901; RYDER NB, 1964, DEMOGRAPHY, V1, P74, DOI 10.2307/2060032; Teitelbaum M. S., 1985, FEAR POPULATION DECL; Williams J., 1999, UNBENDING GENDER WHY	17	150	154	2	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 28	2003	299	5615					1991	1992		10.1126/science.1080316	http://dx.doi.org/10.1126/science.1080316			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	660LG	12663901	Green Accepted			2022-12-28	WOS:000181834200026
J	Smith, GF; Steenkamp, Y; Klopper, RR; Siebert, SJ; Arnold, TH				Smith, GF; Steenkamp, Y; Klopper, RR; Siebert, SJ; Arnold, TH			The price of collecting life - Overcoming the challenges involved in computerizing herbarium specimens.	NATURE			English	Editorial Material									Natl Bot Inst S Africa, ZA-0002 Pretoria, South Africa; SABONET Reg Off, ZA-0002 Pretoria, South Africa	National Research Foundation - South Africa	Smith, GF (corresponding author), Natl Bot Inst S Africa, Private Bag X101, ZA-0002 Pretoria, South Africa.		Klopper, Ronell R./H-9915-2013	Klopper, Ronell R./0000-0002-0948-5038; Siebert, Stefan/0000-0001-5135-6718; Smith, Gideon/0000-0002-5417-9208				ARNOLD T, 2002, SABONET NEWS, V7, P92; Arnold T. H., 1993, MEM BOT SURV S AFR, V62, P1; Edwards D., 1971, MITTEILUNGEN BOT STA, V10, P501; Godfray HCJ, 2002, NATURE, V417, P17, DOI 10.1038/417017a; Holmgren P.K., 1990, INDEX HERBARIORUM 1; SMITH GF, 2001, SABONET NEWS, V6, P214	6	10	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 27	2003	422	6930					375	376		10.1038/422375a	http://dx.doi.org/10.1038/422375a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	659WV	12660755				2022-12-28	WOS:000181801200018
J	Ducharme, FM				Ducharme, FM			Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FLUTICASONE PROPIONATE; PERSISTENT ASTHMA; ORAL MONTELUKAST; CONTROLLED TRIAL; CLINICAL-TRIALS; MILD ASTHMATICS; DOUBLE-BLIND; BECLOMETHASONE; THERAPY; ZAFIRLUKAST	Objective To compare the safety and efficacy of anti-leukotrienes and inhaled glucocorticoids as monotherapy in people with asthma. Design Systematic review of randomised controlled trials comparing anti-leukotrienes with inhaled glucocorticoids for 28 days or more in children and adults. Main outcome measure Rate of exacerbations that required treatment with systemic glucocorticoids. Results 13 trials (12 in adults, one in children) met the inclusion criteria; all were in people with mild and moderate asthma. Leukotriene receptor antagonists were compared with inhaled glucocorticoids at a daily dose equivalent to 400-450 mug beclometasone dipropionate. Patients treated with leukotriene receptor antagonists were 60% more likely to suffer an exacerbation requiring systemic glucocorticoids (relative risk 1.6, 95% confidence interval 1.2 to 2.2; number needed to treat 27,13 to 81). A 130 ml greater improvement (80 ml to 170 ml) in forced expiratory volume in one second and a 19 l/min greater increase (14 1 to 24 1) in morning peak expiratory flow rate were noted in favour of inhaled glucocorticoids. Differences in favour of inhaled glucocorticoids were also observed for nocturnal awakenings, use of rescue beta(2) agonists, and days without symptoms. Risk of side effects was no different between groups, but leukotriene receptor antagonists were associated a 2.5-fold increase risk of withdrawals due to poor asthma control (relative risk 2.5,1.8 to 3.5). Conclusions Inhaled glucocorticoids doses equivalent to 400 mug/day beclometasone are more effective than leukotriene receptor antagonists in the treatment of adults with mild or moderate asthma. There is insufficient evidence to conclude on the efficacy of anti-leukotrienes in children.	McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Dept Paediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Dept Epidemiol & Biostat, Montreal, PQ H3H 1P3, Canada	McGill University; McGill University	Ducharme, FM (corresponding author), McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Dept Paediat, Montreal, PQ H3H 1P3, Canada.	Francine.duchanne@muhc.mcgill.ca	Ducharme, Francine/N-8332-2013	Ducharme, Francine/0000-0001-5096-0614				Baumgarter RA, 1999, AM J RESP CRIT CARE, V159, pA640; Bleecker ER, 2000, J ALLERGY CLIN IMMUN, V105, P1123, DOI 10.1067/mai.2000.106043; Boulet L P, 2001, Can Respir J, V8 Suppl A, p5A; BOULET LP, 2001, CAN RESP J SA, V8, pS5; Busse W, 2001, J FAM PRACTICE, V50, P595; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; DEEKS JJ, 2001, SYSTEMATIC REV HLTH, V285, P312; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Ducharme FM, 2002, BMJ-BRIT MED J, V324, P1545, DOI 10.1136/bmj.324.7353.1545; Ducharme FM, 2000, COCHRANE DB SYST REV; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Gleser LJ, 1996, STAT MED, V15, P2493, DOI 10.1002/(SICI)1097-0258(19961215)15:23<2493::AID-SIM381>3.0.CO;2-C; Global Initiative for Asthma, 2002, NIH PUBL; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; Hughes GL, 1999, AM J RESP CRIT CARE, V159, pA641; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kim KT, 2000, ANN ALLERG ASTHMA IM, V85, P398, DOI 10.1016/S1081-1206(10)62555-0; Korenblat P, 1998, AM J RESP CRIT CARE, V157, pA411; LAITINEN LA, 1997, EUR RESPIR J, V10, P419; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Maspero JF, 2001, CURR MED RES OPIN, V17, P96, DOI 10.1185/0300799039117037; *NAT ASTHM ED PREV, 2002, NIH PUBL; Skalky CS, 1999, J ALLERGY CLIN IMMUN, V103, pS228; Spahn JD, 1996, ALLERGY ASTHMA PROC, V17, P341, DOI 10.2500/108854196778606365; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; Williams B, 2001, CLIN EXP ALLERGY, V31, P845, DOI 10.1046/j.1365-2222.2001.01085.x; Yamauchi K, 2001, J ASTHMA, V38, P51, DOI 10.1081/JAS-100000021; 1997, THORAX S, V52, pS1	30	58	60	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	2003	326	7390					621	623		10.1136/bmj.326.7390.621	http://dx.doi.org/10.1136/bmj.326.7390.621			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	661BF	12649233	Bronze, Green Published			2022-12-28	WOS:000181870800013
J	Harrison, SC				Harrison, SC			Variation on an Src-like theme	CELL			English	Review							CRYSTAL-STRUCTURES; KINASE DOMAIN; C-ABL; COMPLEX; MUTATION; STI-571; HCK	The modularity of protein architecture and the diversity of protein domains hint at a vast combinatorial richness. But evolution appears to have been relatively conservative about selecting new combinations. When a particular grouping of domains within a polypeptide chain can perform a concerted function, that combination tends to reappear in multiple genomic contexts. In other words, once a molecular solution to a functional problem has emerged, it is reused rather than reinvented.	Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst,Dept Biol Chem, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst,Dept Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst,Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Harrison, SC (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst,Dept Biol Chem, Boston, MA 02115 USA.	harrison@crystal.harvard.edu						Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Fushman D, 1999, BIOCHEMISTRY-US, V38, P10225, DOI 10.1021/bi990897g; HANTSCHEL O, 2003, CELL, V112, P123; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Nagar B, 2002, CANCER RES, V62, P4236; NAGAR B, 2003, CELL, V112, P123; Park SH, 2003, SCIENCE, V299, P1061, DOI 10.1126/science.1076979; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4	19	142	150	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 21	2003	112	6					737	740		10.1016/S0092-8674(03)00196-X	http://dx.doi.org/10.1016/S0092-8674(03)00196-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	660DL	12654240	Bronze			2022-12-28	WOS:000181818500001
J	Werlen, G; Hausmann, B; Naeher, D; Palmer, E				Werlen, G; Hausmann, B; Naeher, D; Palmer, E			Signaling life and death in the thymus: Timing is everything	SCIENCE			English	Review							T-CELL-RECEPTOR; THYMOCYTE POSITIVE SELECTION; CLASS-I MOLECULES; ALPHA-BETA; NEGATIVE SELECTION; APOPTOSIS; PEPTIDE; CD8; ACTIVATION; BINDING	T lymphocytes are generated in the thymus, where developing thymocytes must accept one of two fates: They either differentiate or they die. These fates are chiefly determined by signals that originate from the T cell receptor (TCR), a single receptor complex with a remarkable capacity to decide between distinct cell fates. This review explores TCR signaling in thymocytes and focuses on the kinetic aspects of ligand binding, coreceptor involvement, protein phosphorylation, and mitogen-activated protein kinase (MAPK) activation. Understanding the logic of TCR signaling may eventually explain how thymocytes and T cells distinguish self from nonself, a phenomenon that has fascinated immunologists for 50 years.	Univ Basel Hosp, Dept Res, Lab Transplantat Immunol & Nephrol, CH-4031 Basel, Switzerland	University of Basel	Werlen, G (corresponding author), Univ Basel Hosp, Dept Res, Lab Transplantat Immunol & Nephrol, CH-4031 Basel, Switzerland.	guy.werlen@unibas.ch; ed.palmer@unibas.ch						Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; Backstrom BT, 1998, SCIENCE, V281, P835, DOI 10.1126/science.281.5378.835; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; DOUCEY MA, 2002, J BIOL CHEM, V4, P4; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P212, DOI 10.1002/eji.1830230133; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; Haks MC, 2002, J EXP MED, V196, P1, DOI 10.1084/jem.20020268; Hayes SM, 2002, IMMUNITY, V16, P827, DOI 10.1016/S1074-7613(02)00320-5; Hernandez-Hoyos G, 2000, IMMUNITY, V12, P313, DOI 10.1016/S1074-7613(00)80184-3; HOGQUIST KA, 1995, IMMUNITY, V3, P79, DOI 10.1016/1074-7613(95)90160-4; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; JANEWAY CA, 1999, IMMUNOBIOLOGY IMMUNE, P4; Legname G, 2000, IMMUNITY, V12, P537, DOI 10.1016/S1074-7613(00)80205-8; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; Mariathasan S, 2001, J IMMUNOL, V167, P4966, DOI 10.4049/jimmunol.167.9.4966; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; Naeher D, 2002, J IMMUNOL, V169, P2964, DOI 10.4049/jimmunol.169.6.2964; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Paz PE, 2001, BIOCHEM J, V356, P461, DOI 10.1042/0264-6021:3560461; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Santori FR, 2002, IMMUNITY, V17, P131, DOI 10.1016/S1074-7613(02)00361-8; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; Singer A, 2002, CURR OPIN IMMUNOL, V14, P207, DOI 10.1016/S0952-7915(02)00323-0; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; Takagi T, 2001, NAT IMMUNOL, V2, P1048, DOI 10.1038/ni728; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1989, IMMUNOL TODAY, V10, P57, DOI 10.1016/0167-5699(89)90307-1; Werlen G, 2000, NATURE, V406, P422, DOI 10.1038/35019094; WINKLER DG, 1993, P NATL ACAD SCI USA, V90, P5176, DOI 10.1073/pnas.90.11.5176; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	59	191	197	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 21	2003	299	5614					1859	1863		10.1126/science.1067833	http://dx.doi.org/10.1126/science.1067833			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	657LY	12649474				2022-12-28	WOS:000181669700035
J	Taupenot, L; Harper, KL; O'Connor, DT				Taupenot, L; Harper, KL; O'Connor, DT			Mechanisms of disease - The chromogranin-secretogranin family.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TRANS-GOLGI NETWORK; PANCREASTATIN-LIKE IMMUNOREACTIVITY; INHIBITORY PEPTIDE CATESTATIN; SECRETORY GRANULE BIOGENESIS; ELEVATED SERUM CHROMOGRANIN; POSSIBLE DIAGNOSTIC-VALUE; BRAIN MICROGLIAL CELLS; CENTRAL-NERVOUS-SYSTEM; DISULFIDE-BONDED LOOP; CATECHOLAMINE RELEASE		Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	O'Connor, DT (corresponding author), Univ Calif San Diego, Dept Med 9111H, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	doconnor@ucsd.edu		Taupenot, Laurent/0000-0003-2316-3825	NHLBI NIH HHS [HL58120, HL69758] Funding Source: Medline; NIDDK NIH HHS [DK59628] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL069758, P01HL058120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059628] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; Angelsen A, 1997, PROSTATE, V30, P1; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BANKS P, 1965, BIOCHEM J, V97, pC40, DOI 10.1042/bj0970040C; BARGSTEN G, 1992, J HISTOCHEM CYTOCHEM, V40, P1147, DOI 10.1177/40.8.1352316; BOOMSMA F, 1995, CLIN CHIM ACTA, V239, P57, DOI 10.1016/0009-8981(95)06100-R; Cadman PE, 2002, ANN NY ACAD SCI, V971, P528, DOI 10.1111/j.1749-6632.2002.tb04518.x; CANALE MP, 1994, J CLIN ENDOCR METAB, V78, P1139, DOI 10.1210/jc.78.5.1139; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; Ciesielski-Treska J, 1998, J BIOL CHEM, V273, P14339, DOI 10.1074/jbc.273.23.14339; Ciesielski-Treska J, 2001, J BIOL CHEM, V276, P13113, DOI 10.1074/jbc.M009711200; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Corti A, 2000, ADV EXP MED BIOL, V482, P351; DEFTOS LJ, 1989, J CLIN ENDOCR METAB, V68, P869, DOI 10.1210/jcem-68-5-869; Deftos LJ, 1998, UROLOGY, V51, P141, DOI 10.1016/S0090-4295(98)00062-4; Degorce F, 1999, BRIT J CANCER, V79, P65, DOI 10.1038/sj.bjc.6690013; Desmoucelles C, 1999, MOL CELL ENDOCRINOL, V157, P55, DOI 10.1016/S0303-7207(99)00158-6; DESTEPHANO DB, 1984, AM J PATHOL, V116, P464; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; DIMSDALE JE, 1992, LIFE SCI, V51, P519, DOI 10.1016/0024-3205(92)90029-O; Eskeland NL, 1996, J CLIN INVEST, V98, P148, DOI 10.1172/JCI118760; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; Ferrari L, 1999, ANTICANCER RES, V19, P3415; FISCHERCOLBRIE R, 1995, PROG NEUROBIOL, V46, P49, DOI 10.1016/0301-0082(94)00060-U; GERDES HH, 1989, J BIOL CHEM, V264, P12009; Giovanella L, 2001, INT J BIOL MARKER, V16, P268, DOI 10.1177/172460080101600408; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; Granberg D, 1999, J CLIN ENDOCR METAB, V84, P2712, DOI 10.1210/jc.84.8.2712; GRIMES M, 1987, ANN NY ACAD SCI, V493, P351, DOI 10.1111/j.1749-6632.1987.tb27218.x; HALBAN PA, 1994, BIOCHEM J, V299, P1; HELLE KB, 1990, ACTA PHYSIOL SCAND, V138, P565, DOI 10.1111/j.1748-1716.1990.tb08885.x; Helle KB, 2000, ADV EXP MED BIOL, V482, P225; HELLE KB, 1966, MOL PHARMACOL, V2, P298; HSIAO RJ, 1991, MEDICINE, V70, P33, DOI 10.1097/00005792-199101000-00003; HSIAO RJ, 1990, AM J MED, V88, P607, DOI 10.1016/0002-9343(90)90526-J; HSIAO RJ, 1990, J CLIN INVEST, V85, P1555, DOI 10.1172/JCI114604; HSIAO RJ, 1990, KIDNEY INT, V37, P955, DOI 10.1038/ki.1990.71; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTNER WB, 1995, CURR BIOL, V5, P242, DOI 10.1016/S0960-9822(95)00049-2; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; IGUCHI H, 1991, HORM METAB RES, V23, P486, DOI 10.1055/s-2007-1003735; IGUCHI H, 1989, EUR J CANCER CLIN ON, V25, P1225, DOI 10.1016/0277-5379(89)90419-7; Ischia R, 1997, J BIOL CHEM, V272, P11657; Ischia R, 2000, J CLIN ENDOCR METAB, V85, P355, DOI 10.1210/jc.85.1.355; Jiang QJ, 2001, J BIOL CHEM, V276, P25022, DOI 10.1074/jbc.M101545200; KAILASAM MT, 1995, AM J HYPERTENS, V8, P651, DOI 10.1016/0895-7061(95)00076-2; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Kitao Y, 2000, PSYCHIAT GENET, V10, P139, DOI 10.1097/00041444-200010030-00006; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; Kong C, 1998, J NEUROIMMUNOL, V88, P91, DOI 10.1016/S0165-5728(98)00094-0; Krijnen JLM, 1997, J UROLOGY, V158, P171, DOI 10.1097/00005392-199707000-00054; KRISCH K, 1986, AM J PATHOL, V123, P100; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; Lamberts SWJ, 2001, FRONT NEUROENDOCRIN, V22, P309, DOI 10.1006/frne.2001.0218; Landen M, 1999, EUR NEUROPSYCHOPHARM, V9, P311, DOI 10.1016/S0924-977X(98)00042-X; Laslop A, 1998, J NEUROCHEM, V70, P374; LEE RWH, 1983, J BIOL CHEM, V258, P1326; Loh YP, 1997, TRENDS ENDOCRIN MET, V8, P130, DOI 10.1016/S1043-2760(97)00010-6; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Lugardon K, 2001, J BIOL CHEM, V276, P35875, DOI 10.1074/jbc.M104670200; Mahapatra NR, 2000, ENDOCRINOLOGY, V141, P3668, DOI 10.1210/en.141.10.3668; Mahata SK, 1999, NEUROSCIENCE, V88, P405, DOI 10.1016/S0306-4522(98)00225-5; Mahata SK, 1996, GENOMICS, V33, P135, DOI 10.1006/geno.1996.0171; Mahata SK, 1999, ENDOCRINOLOGY, V140, P739, DOI 10.1210/en.140.2.739; Mahata SK, 1999, J BIOL CHEM, V274, P2920, DOI 10.1074/jbc.274.5.2920; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; Mbikay M, 2001, BIOCHEM J, V357, P329, DOI 10.1042/0264-6021:3570329; MUNOZ DG, 1991, LAB INVEST, V64, P826; MUNOZ DG, 1990, NEUROSCIENCE, V34, P533, DOI 10.1016/0306-4522(90)90162-W; NANES MS, 1989, J CLIN ENDOCR METAB, V69, P950, DOI 10.1210/jcem-69-5-950; NATORI S, 1988, ENDOCRINOL JAPON, V35, P651; NEUMANN HPH, 1994, NEW ENGL J MED, V331, P1535; Nobels FRE, 1998, EUR J CLIN INVEST, V28, P431; Nolan EM, 1996, MOL CELL ENDOCRINOL, V124, P51, DOI 10.1016/S0303-7207(96)03927-5; O'Connor DT, 2002, J HYPERTENS, V20, P1335, DOI 10.1097/00004872-200207000-00020; OCONNOR DT, 1994, ANN NY ACAD SCI, V733, P36, DOI 10.1111/j.1749-6632.1994.tb17254.x; OCONNOR DT, 1983, LIFE SCI, V33, P1657, DOI 10.1016/0024-3205(83)90721-X; OCONNOR DT, 1984, J BIOL CHEM, V259, P3237; OCONNOR DT, 1986, NEW ENGL J MED, V314, P1145, DOI 10.1056/NEJM198605013141803; OCONNOR DT, 1983, REGUL PEPTIDES, V6, P263, DOI 10.1016/0167-0115(83)90145-3; OCONNOR DT, 1984, NEW ENGL J MED, V311, P764, DOI 10.1056/NEJM198409203111204; OCONNOR DT, 1989, CLIN CHEM, V35, P1631; OCONNOR DT, 1993, NEUROSCIENCE, V56, P999, DOI 10.1016/0306-4522(93)90146-7; OCONNOR DT, 1991, BRAIN RES, V567, P188, DOI 10.1016/0006-8993(91)90795-W; OHASHI M, 1990, HORM METAB RES, V22, P114, DOI 10.1055/s-2007-1004862; OTTIGER HP, 1990, J NEUROSCI, V10, P3135; Rao FW, 2000, HYPERTENSION, V36, P1045, DOI 10.1161/01.HYP.36.6.1045; Ratti S, 2000, J BIOL CHEM, V275, P29257, DOI 10.1074/jbc.M003796200; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; ROSA P, 1981, MOL CELL ENDOCRINOL, V24, P181, DOI 10.1016/0303-7207(81)90058-7; ROZANSKY DJ, 1994, J CLIN INVEST, V94, P2357, DOI 10.1172/JCI117601; RUSSELL J, 1994, ENDOCRINOLOGY, V135, P337, DOI 10.1210/en.135.1.337; Sanchez-Margalet V, 2000, ADV EXP MED BIOL, V482, P247; SanchezMargalet V, 1996, J MOL ENDOCRINOL, V16, P1, DOI 10.1677/jme.0.0160001; SANCHEZMARGALET V, 1995, J HYPERTENS, V13, P251; Sanduleanu S, 2001, EUR J CLIN INVEST, V31, P802, DOI 10.1046/j.1365-2362.2001.00890.x; SEKIYA K, 1989, J CLIN INVEST, V83, P1834, DOI 10.1172/JCI114089; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V262, P1; SIMONSSON M, 1988, SCAND J GASTROENTERO, V23, P1089, DOI 10.3109/00365528809090174; SOBOL RE, 1989, NEW ENGL J MED, V320, P444, DOI 10.1056/NEJM198902163200707; SOBOL RE, 1986, ANN INTERN MED, V105, P698, DOI 10.7326/0003-4819-105-5-698; SOMOGYI P, 1984, BRAIN RES REV, V8, P193, DOI 10.1016/0165-0173(84)90007-9; STABILE BE, 1990, ARCH SURG-CHICAGO, V125, P451; Stridsberg M, 1997, EUR J ENDOCRINOL, V136, P67, DOI 10.1530/eje.0.1360067; STRIDSBERG M, 1995, J ENDOCRINOL, V144, P49, DOI 10.1677/joe.0.1440049; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; SUZUKI H, 1986, J CLIN ENDOCR METAB, V63, P758, DOI 10.1210/jcem-63-3-758; SYVERSEN U, 1994, NEUROPEPTIDES, V26, P201, DOI 10.1016/0143-4179(94)90131-7; SYVERSEN U, 1995, EUR J GASTROEN HEPAT, V7, P667; SYVERSEN U, 1993, EUR J GASTROEN HEPAT, V5, P1043, DOI 10.1097/00042737-199312000-00009; TAKIYYUDDIN MA, 1995, HYPERTENSION, V26, P213, DOI 10.1161/01.HYP.26.1.213; TAKIYYUDDIN MA, 1990, CIRCULATION, V81, P185, DOI 10.1161/01.CIR.81.1.185; TAKIYYUDDIN MA, 1991, J CLIN ENDOCR METAB, V72, P616, DOI 10.1210/jcem-72-3-616; TAKIYYUDDIN MA, 1990, J CLIN ENDOCR METAB, V71, P360, DOI 10.1210/jcem-71-2-360; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Taupenot L, 2000, REGUL PEPTIDES, V95, P9, DOI 10.1016/S0167-0115(00)00135-X; Taupenot L, 1998, J CLIN INVEST, V101, P863, DOI 10.1172/JCI1129; Taupenot L, 1996, NEUROSCIENCE, V72, P377, DOI 10.1016/0306-4522(96)83172-1; Taupenot L, 1999, HYPERTENSION, V34, P1152, DOI 10.1161/01.HYP.34.5.1152; Thiele C, 1997, CURR BIOL, V7, pR496, DOI 10.1016/S0960-9822(06)00247-8; Thiele C, 1998, SEMIN CELL DEV BIOL, V9, P511, DOI 10.1006/scdb.1998.0259; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Tsao KC, 2001, CLIN CHIM ACTA, V313, P21, DOI 10.1016/S0009-8981(01)00645-3; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; VIEAU D, 1991, CLIN ENDOCRINOL, V35, P319, DOI 10.1111/j.1365-2265.1991.tb03543.x; WAND GS, 1991, ENDOCRINOLOGY, V128, P1345, DOI 10.1210/endo-128-3-1345; WATKINSON A, 1992, REGUL PEPTIDES, V40, P51, DOI 10.1016/0167-0115(92)90083-7; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Wiedermann CJ, 2000, PEPTIDES, V21, P1289, DOI 10.1016/S0196-9781(00)00271-0; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; Woulfe J, 1999, NEUROPEPTIDES, V33, P285, DOI 10.1054/npep.1999.0043; WU HJ, 1994, J CLIN INVEST, V94, P118, DOI 10.1172/JCI117297; WU HJ, 1995, J CLIN INVEST, V96, P568, DOI 10.1172/JCI118069; Wu JT, 2000, ANN CLIN LAB SCI, V30, P175; Wu TL, 1999, J CLIN LAB ANAL, V13, P312, DOI 10.1002/(SICI)1098-2825(1999)13:6<312::AID-JCLA11>3.0.CO;2-1; YASUDA D, 1993, HORM METAB RES, V25, P593, DOI 10.1055/s-2007-1002184; YASUHARA O, 1994, NEUROSCI LETT, V170, P13, DOI 10.1016/0304-3940(94)90227-5; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; Zhang BF, 2002, NEUROSCI LETT, V323, P229, DOI 10.1016/S0304-3940(02)00145-3	145	654	679	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 20	2003	348	12					1134	1149		10.1056/NEJMra021405	http://dx.doi.org/10.1056/NEJMra021405			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	656UY	12646671				2022-12-28	WOS:000181628400010
J	Donta, ST; Clauw, DJ; Engel, CC; Guarino, P; Peduzzi, P; Williams, DA; Skinner, JS; Barkhuizen, A; Taylor, T; Kazis, LE; Sogg, S; Hunt, SC; Dougherty, CM; Richardson, RD; Kunkel, C; Rodriguez, W; Alicea, E; Chiliade, P; Ryan, M; Gray, GC; Lutwick, L; Norwood, D; Smith, S; Everson, M; Blackburn, W; Martin, W; Griffiss, JM; Cooper, R; Renner, E; Schmitt, J; McMurtry, C; Thakore, M; Mori, D; Kerns, R; Park, M; Pullman-Mooar, S; Bernstein, J; Hershberger, P; Salisbury, DC; Feussner, JR				Donta, ST; Clauw, DJ; Engel, CC; Guarino, P; Peduzzi, P; Williams, DA; Skinner, JS; Barkhuizen, A; Taylor, T; Kazis, LE; Sogg, S; Hunt, SC; Dougherty, CM; Richardson, RD; Kunkel, C; Rodriguez, W; Alicea, E; Chiliade, P; Ryan, M; Gray, GC; Lutwick, L; Norwood, D; Smith, S; Everson, M; Blackburn, W; Martin, W; Griffiss, JM; Cooper, R; Renner, E; Schmitt, J; McMurtry, C; Thakore, M; Mori, D; Kerns, R; Park, M; Pullman-Mooar, S; Bernstein, J; Hershberger, P; Salisbury, DC; Feussner, JR		VA Cooperative Study 470 Study Grp	Cognitive behavioral therapy and aerobic exercise for Gulf War veterans' illnesses - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC-FATIGUE-SYNDROME; FIBROMYALGIA; ADHERENCE; MANAGEMENT; INFERENCE; OUTCOMES; AFFAIRS; MODELS; PAIN	Context Gulf War veterans' illnesses (GWVI), multisymptom illnesses characterized by persistent pain, fatigue, and cognitive symptoms, have been reported by many Gulf War veterans. There are currently no effective therapies available to treat GWVI. Objective To compare the effectiveness of cognitive behavioral therapy (CBT), exercise, and the combination of both for improving physical functioning and reducing the symptoms,of GWVI. Design, Setting, and Patients Randomized controlled 2 x 2 factorial trial conducted from April 1999 to September 2001 among 1092 Gulf War veterans who reported at least 2 of 3 symptom types (fatigue, pain, and cognitive) for more than 6 months and at the time of screening. Treatment assignment was unmasked except or a masked assessor of study outcomes at each clinical site (18 Department of Veterans Affairs [VA] and 2 Department of Defense [DOD] medical centers). Interventions Veterans were randomly assigned to receive usual care (n=271), consisting of any and all care received from inside or outside the VA or DOD health care systems; CBT plus usual care (n=286); exercise plus usual care (n=269); or CBT plus exercise plus usual care (n=266). Exercise sessions were 60 minutes and CBT sessions were 60 to 90 minutes; both met weekly for 12 weeks. Main Outcome Measures The primary end point was a 7-point or greater increase (improvement) on the Physical Component Summary scale of the Veterans Short Form 36-Item Health Survey at 12 months. Secondary outcomes were standardized measures of pain, fatigue, cognitive symptoms, distress, and mental health functioning. Participants were evaluated at baseline and at 3, 6, and 12 months. Results The percentage of veterans with improvement in physical function at 1 year was 11.5% for usual care, 11.7% for exercise alone, 18.4% for CBT plus exercise, and 18.5% for CBT alone. The adjusted odds ratios (OR) for improvement in exercise, CBT, and exercise plus CBT vs usual care were 1.07 (95% confidence interval [CI], 0.63-1.82), 1.72 (95% CI, 0.91-3.23), and 1.84 (95% CI, 0.95-3.55), respectively. OR for the overall (marginal) effect of receiving CBT (n=552) vs no CBT (n=535) was 1.71 (95% CI, 1.15-2.53) and for exercise (n=531) vs no exercise (n=556) was 1.07 (95% CI, 0.76-1.50). For secondary outcomes, exercise alone or in combination with CBT significantly improved fatigue, distress, cognitive symptoms, and mental health functioning, while CBT alone significantly improved cognitive symptoms and menial health functioning. Neither treatment had a significant impact on pain. Conclusion Our results suggest that CBT and/or exercise can provide modest relief for some of the symptoms of chronic multisymptom illnesses such as GWVI.	VA Connecticut Healthcare Syst, Cooperat Studies Program Coordinating Ctr 151A, West Haven, CT 06516 USA; VA Med Ctr, Boston, MA USA; Univ Michigan, Med Ctr, Ann Arbor, MI USA; Walter Reed Army Med Ctr, Bethesda, MD USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Indiana Univ, Bloomington, IN USA; Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR USA; VA Med & Reg Off Ctr, White River Jct, VT USA; VA Med Ctr, Bedford, MA USA; VA Puget Sound Healthcare Syst, Seattle Div, Seattle, WA USA; New Mexico VA Hlth Care Syst, Albuquerque, NM USA; San Juan VA Med Ctr, San Juan, PR USA; Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA; USN, Hlth Res Ctr, San Diego, CA 92152 USA; New York Harbor VA Healthcare Syst, New York, NY USA; Birmingham VA Med Ctr, Birmingham, AL USA; John Cochran VA Med Ctr, St Louis, MO USA; San Francisco VA Med Ctr, San Francisco, CA USA; Fargo VA Med & Reg Off Ctr, Fargo, ND USA; HH McGuire VA Med Ctr, Richmond, VA USA; VA New Jersey Hlth Care Syst, E Orange, NJ USA; Philadelphia VA Med Ctr, Philadelphia, PA USA; Dayton VA Med Ctr, Dayton, OH USA; Med Univ S Carolina, Charleston, SC 29425 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Michigan System; University of Michigan; United States Department of Defense; United States Army; Uniformed Services University of the Health Sciences - USA; Indiana University System; Indiana University Bloomington; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC); US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; Hunter Holmes McGuire Veterinary Affairs Medical Center; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Medical University of South Carolina	Peduzzi, P (corresponding author), VA Connecticut Healthcare Syst, Cooperat Studies Program Coordinating Ctr 151A, 950 Campbell Ave, West Haven, CT 06516 USA.	peterp5@mindspring.com	Gray, Gregory C./ABF-1298-2020; Williams, David A/A-1180-2007	Engel, Charles/0000-0002-9232-3389; Gray, Gregory/0000-0002-4628-5908; Kazis, Lewis/0000-0003-1800-5849				[Anonymous], 1994, JAMA, V272, P391; [Anonymous], 1996, FIN REP; BLUMENTHAL JA, 1991, J GERONTOL, V46, pP352, DOI 10.1093/geronj/46.6.P352; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brown R, 2001, PEDIATR PULM, P26; Clauw DJ, 1997, NEUROIMMUNOMODULAT, V4, P134, DOI 10.1159/000097332; Deale A, 1997, AM J PSYCHIAT, V154, P408; Dishman R.K., 1994, ADV EXERCISE ADHEREN; Doebbeling BN, 2000, AM J MED, V108, P695, DOI 10.1016/S0002-9343(00)00405-8; Dunbar-Jacob J, 2001, J CLIN EPIDEMIOL, V54, pS57, DOI 10.1016/S0895-4356(01)00457-7; Fukuda K, 1998, JAMA-J AM MED ASSOC, V280, P981, DOI 10.1001/jama.280.11.981; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; Gray GC, 1999, AM J TROP MED HYG, V60, P758, DOI 10.4269/ajtmh.1999.60.758; Guarino P, 2001, CONTROL CLIN TRIALS, V22, P310, DOI 10.1016/S0197-2456(00)00133-1; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Hyams KC, 1998, AM J EPIDEMIOL, V148, P339; KATZ JN, 1992, J RHEUMATOL, V19, P1938; Kazis L. E., 2000, MED OUTCOMES TRUST M, V5, P13; Kazis L. E., 2000, MED OUTCOMES TRUST M, V5, P1; Kazis LE, 1999, AM J MED QUAL, V14, P28, DOI 10.1177/106286069901400105; Kazis LE, 1998, ARCH INTERN MED, V158, P626, DOI 10.1001/archinte.158.6.626; Kazis LE., 2000, HLTH STATUS OUTCOMES; Keefe F. J., 1996, CLIN PSYCHOL, V49, P4; KIZIS LE, 1998, HLTH STATUS OUTCOMES; KROENKE K, 1998, J AM COLL CARDIOL, V40, P528; Lachin JM, 1999, CONTROL CLIN TRIALS, V20, P408, DOI 10.1016/S0197-2456(99)00022-7; Martin L, 1996, J RHEUMATOL, V23, P1050; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Morgan WP, 2001, QUEST, V53, P366, DOI 10.1080/00336297.2001.10491754; NIELSON WR, 1992, J RHEUMATOL, V19, P98; Ockene IS, 2002, J AM COLL CARDIOL, V40, P630, DOI 10.1016/S0735-1097(02)02078-8; Phillips R C, 1992, J Heart Valve Dis, V1, P42; RAND CS, 1993, AM J CARDIOL, V72, pD68, DOI 10.1016/0002-9149(93)90014-4; Rossy LA, 1999, ANN BEHAV MED, V21, P180, DOI 10.1007/BF02908299; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Turk D, 1983, PAIN BEHAV MED COGNI; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; WARE JE, 1994, SF36 PHYSICAL MENTAL; Wessely S, 1999, LANCET, V354, P936, DOI 10.1016/S0140-6736(98)08320-2; Whiting P, 2001, JAMA-J AM MED ASSOC, V286, P1360, DOI 10.1001/jama.286.11.1360; Wigers SH, 1996, SCAND J RHEUMATOL, V25, P77, DOI 10.3109/03009749609069212; Williams DA, 2002, J RHEUMATOL, V29, P1280; WOLFINGER R, 1993, J STAT COMPUT SIM, V48, P233, DOI 10.1080/00949659308811554	51	83	84	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 19	2003	289	11					1396	1404		10.1001/jama.289.11.1396	http://dx.doi.org/10.1001/jama.289.11.1396			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	656PM	12636462	Bronze			2022-12-28	WOS:000181616200031
J	Straight, AF; Cheung, A; Limouze, J; Chen, I; Westwood, NJ; Sellers, JR; Mitchison, TJ				Straight, AF; Cheung, A; Limouze, J; Chen, I; Westwood, NJ; Sellers, JR; Mitchison, TJ			Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor	SCIENCE			English	Article							CONTRACTILE RING; PROTEIN-KINASE; MAMMALIAN-CELLS; MITOTIC SPINDLE; CLEAVAGE; LOCALIZATION; MICROTUBULES; PROTEOLYSIS; ANTIBODY; MIDZONE	Completion of cell division during cytokinesis requires temporally and spatially regulated communication from the microtubule cytoskeleton to the actin cytoskeleton and the cell membrane. We identified a specific inhibitor of nonmuscle myosin II, blebbistatin, that inhibited contraction of the cleavage furrow without disrupting mitosis or contractile ring assembly. Using blebbistatin and other drugs, we showed that exit from the cytokinetic phase of the cell cycle depends on ubiquitin-mediated proteolysis. Continuous signals from microtubules are required to maintain the position of the cleavage furrow, and these signals control the localization of myosin II independently of other furrow components.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Boston, MA 02115 USA; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Univ St Andrews, Sch Chem, St Andrews KY16 9AJ, Fife, Scotland	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Massachusetts General Hospital; University of St Andrews	Straight, AF (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 250 Longwood Ave, Boston, MA 02115 USA.	aaron_straight@hms.harvard.edu		Westwood, Nicholas/0000-0003-0630-0138; Straight, Aaron/0000-0001-5885-7881; Chen, Irene/0000-0001-6040-7927	NIGMS NIH HHS [GM23928, GM62566] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL004234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023928, P01GM062566] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Canman JC, 2000, CURR BIOL, V10, P611, DOI 10.1016/S0960-9822(00)00490-5; Cheung A, 2002, NAT CELL BIOL, V4, P83, DOI 10.1038/ncb734; Cimini D, 1998, CHROMOSOMA, V107, P479, DOI 10.1007/s004120050332; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; Fabbro D, 1999, PHARMACOL THERAPEUT, V82, P293, DOI 10.1016/S0163-7258(99)00005-4; FIELD CM, 1995, J CELL BIOL, V131, P165, DOI 10.1083/jcb.131.1.165; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; Gatti M, 2000, MICROSC RES TECHNIQ, V49, P202, DOI 10.1002/(SICI)1097-0029(20000415)49:2<202::AID-JEMT13>3.0.CO;2-8; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; HENRI JF, 2001, Patent No. 0155116; HENRI JF, 2001, Patent No. 0121596; HIRANO A, 1974, EXP CELL RES, V89, P111, DOI 10.1016/0014-4827(74)90193-1; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; MARTINEAU SN, 1995, J CELL BIOL, V131, P191, DOI 10.1083/jcb.131.1.191; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; Murata-Hori M, 2002, J CELL BIOL, V159, P45, DOI 10.1083/jcb.200207014; Oegema K, 2000, J CELL BIOL, V150, P539, DOI 10.1083/jcb.150.3.539; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Peterson JR, 2002, CHEM BIOL, V9, P1275, DOI 10.1016/S1074-5521(02)00284-3; Rappaport R., 1996, DEV CELL BIOL SERIES, V32; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Shuster CB, 2002, CURR BIOL, V12, P854, DOI 10.1016/S0960-9822(02)00838-2; Straight AF, 2000, CURR BIOL, V10, pR760, DOI 10.1016/S0960-9822(00)00746-6; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wheatley SP, 1996, J CELL BIOL, V135, P981, DOI 10.1083/jcb.135.4.981	32	1085	1113	1	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 14	2003	299	5613					1743	1747		10.1126/science.1081412	http://dx.doi.org/10.1126/science.1081412			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	654WM	12637748				2022-12-28	WOS:000181519500049
J	Benn, P				Benn, P			Improved antenatal screening for Down's syndrome	LANCET			English	Editorial Material							MATERNAL SERUM		Univ Connecticut, Ctr Hlth, Dept Pediat, Div Human Genet, Farmington, CT 06030 USA	University of Connecticut	Benn, P (corresponding author), Univ Connecticut, Ctr Hlth, Dept Pediat, Div Human Genet, Farmington, CT 06030 USA.							BENN, 2002, OBSTET GYNECOL, V100, P1168; Benn PA, 2002, CLIN CHIM ACTA, V324, P1, DOI 10.1016/S0009-8981(02)00187-0; BENN PA, IN PRESS OBSTET GYNE; Bilardo CM, 2001, ULTRASOUND OBST GYN, V17, P99, DOI 10.1046/j.1469-0705.2001.00358.x; CHEN J, 2000, COMMUNITY GENET, V3, P24; Cuckle H, 1996, EARLY HUM DEV, V47, pS27, DOI 10.1016/S0378-3782(96)01814-2; Cuckle H, 2001, LANCET, V358, P1658, DOI 10.1016/S0140-6736(01)06724-1; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883	9	14	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 8	2003	361	9360					794	795		10.1016/S0140-6736(03)12718-3	http://dx.doi.org/10.1016/S0140-6736(03)12718-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653ZH	12642040				2022-12-28	WOS:000181466600002
